Clustering O 0 6.636955276917433e-06
of O 0 2.0944614789186744e-06
missense O 0 2.415887502138503e-05
mutations O 0 4.3266680904707755e-07
in O 0 8.487862857009532e-08
the O 0 4.666364930017153e-06
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999923706054688
telangiectasia I-Disease 1 0.999997615814209
gene O 0 1.269381300517125e-06
in O 0 9.148711654916042e-08
a O 0 3.5147704124938173e-07
sporadic B-Disease 0 0.0014160742284730077
T I-Disease 1 0.9999574422836304
- I-Disease 1 0.9995218515396118
cell I-Disease 1 0.9888849258422852
leukaemia I-Disease 1 0.9984847903251648
. O 0 1.188878741231747e-05

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.3692763149738312
A B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
T I-Disease 1 0.9999985694885254
) O 0 3.1496185215473815e-08
is O 0 2.974294810442757e-09
a O 0 8.858256350663396e-09
recessive B-Disease 0 8.513559350831201e-07
multi I-Disease 1 0.899359941482544
- I-Disease 1 0.9970014691352844
system I-Disease 0 0.32748815417289734
disorder I-Disease 1 0.9988555908203125
caused O 0 1.6650901102366333e-07
by O 0 1.7317105527325793e-09
mutations O 0 6.961975440589185e-09
in O 0 3.1891880247769677e-09
the O 0 1.1544290856591033e-08
ATM O 0 6.485134690592531e-06
gene O 0 7.022686787649945e-08
at O 0 7.790711151756113e-07
11q22 O 0 1.2826250895159319e-05
- O 0 3.728246156242676e-06
q23 O 0 6.936495992704295e-06
( O 0 9.83044188274107e-08
ref O 0 6.174796453706222e-06
. O 0 2.275853105970782e-08
3 O 0 4.3585737330431584e-07
) O 0 1.0024215413295678e-07
. O 0 5.883083531443845e-07

The O 0 5.690877742381417e-07
risk O 0 4.765839094034163e-06
of O 0 2.275765382364625e-06
cancer B-Disease 0 0.015130855143070221
, O 0 1.2833791629418556e-07
especially O 0 1.4904378531355178e-06
lymphoid B-Disease 0 0.00028496450977399945
neoplasias I-Disease 0 0.00011648789222817868
, O 0 1.3670878651339535e-08
is O 0 2.1668542515840272e-09
substantially O 0 9.873888018319121e-08
elevated O 0 2.2149363303469727e-06
in O 0 2.2686283074335734e-08
A B-Disease 1 0.9999943971633911
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
patients O 0 4.067509507876821e-06
and O 0 3.505861201347216e-08
has O 0 1.0705353936657502e-08
long O 0 7.839706661627588e-09
been O 0 1.9569215137238416e-09
associated O 0 1.3242235752386478e-08
with O 0 2.6907660100050634e-08
chromosomal O 1 1.0
instability O 1 1.0
. O 0 0.00045385793782770634

By O 0 3.0764383041059773e-07
analysing O 0 5.6670120102353394e-05
tumour B-Disease 1 0.9999786615371704
DNA O 0 3.708784333866788e-06
from O 0 1.5748017290206917e-07
patients O 0 4.3540861582869184e-08
with O 0 1.2433524432253762e-08
sporadic B-Disease 0 3.52984425262548e-05
T I-Disease 0 0.31817734241485596
- I-Disease 0 0.004548364784568548
cell I-Disease 0 0.000308628921629861
prolymphocytic I-Disease 0 0.3399258852005005
leukaemia I-Disease 1 0.9999186992645264
( O 0 2.580016598585644e-06
T B-Disease 0 0.44410377740859985
- I-Disease 0 0.0016194615745916963
PLL I-Disease 0 0.001637784531340003
) O 0 4.9699035997718966e-09
, O 0 8.829305619961758e-10
a O 0 1.0966557661973297e-09
rare O 0 8.146891161686654e-09
clonal B-Disease 0 1.4302173667601892e-06
malignancy I-Disease 0 3.660496531665558e-06
with O 0 2.44644349223222e-09
similarities O 0 1.6612842657082183e-08
to O 0 4.77316852709464e-09
a O 0 1.6919004508508806e-07
mature B-Disease 0 5.755320671596564e-06
T I-Disease 0 0.15881110727787018
- I-Disease 0 0.0012657925253733993
cell I-Disease 0 0.00031365471659228206
leukaemia I-Disease 0 0.0009094744455069304
seen O 0 1.7845096067503619e-07
in O 0 3.9118987160691177e-08
A B-Disease 1 0.998324453830719
- I-Disease 1 0.8849035501480103
T I-Disease 1 0.999370276927948
, O 0 1.6026223903509162e-08
we O 0 1.1046583647811303e-09
demonstrate O 0 2.2130164367695215e-09
a O 0 3.26562554775478e-10
high O 0 9.191030159172442e-10
frequency O 0 2.1952837325756036e-09
of O 0 2.7242381683834083e-09
ATM O 0 1.9746439647860825e-06
mutations O 0 3.7446834966203824e-08
in O 0 1.23277487773521e-07
T B-Disease 0 0.0016200738027691841
- I-Disease 0 0.0009459992870688438
PLL I-Disease 0 0.06435812264680862
. O 0 2.2609863663092256e-05

In O 0 4.2523160459495557e-07
marked O 0 2.3608330934621335e-07
contrast O 0 4.1383426463426076e-08
to O 0 2.1679706918575903e-09
the O 0 1.0495389446418812e-08
ATM O 0 4.2350852709205355e-06
mutation O 0 1.7591897716329186e-08
pattern O 0 6.466739677080113e-08
in O 0 5.2156739371866934e-08
A B-Disease 1 0.9999771118164062
- I-Disease 1 0.9999825954437256
T I-Disease 1 0.9999973773956299
, O 0 1.3669366083490786e-08
the O 0 1.6997715457378604e-09
most O 0 4.6316703250504077e-10
frequent O 0 7.178119765249846e-10
nucleotide O 0 4.678080145481545e-09
changes O 0 1.2018475104014215e-09
in O 0 1.1543580535899878e-09
this O 0 3.584565533287787e-09
leukaemia B-Disease 0 2.561138717283029e-05
were O 0 2.7370998623155174e-07
missense O 0 1.2701896594080608e-05
mutations O 0 2.6389291178929852e-06
. O 0 3.1852159736445174e-06

These O 0 2.9122136879777827e-07
clustered O 0 1.792337798178778e-06
in O 0 1.7985493983019296e-08
the O 0 7.589350481396195e-09
region O 0 1.7757352921421443e-08
corresponding O 0 2.9085114316984573e-09
to O 0 7.697106840787171e-10
the O 0 9.161229108656244e-09
kinase O 0 9.631886399574796e-08
domain O 0 6.347156045194424e-08
, O 0 4.595479996538643e-09
which O 0 6.30051955052835e-10
is O 0 3.928876390890679e-10
highly O 0 3.0339641909904458e-09
conserved O 0 1.0011008910737473e-08
in O 0 2.491219452949167e-09
ATM O 0 4.882841949438443e-06
- O 0 2.7667715585266706e-07
related O 0 2.37829134164258e-08
proteins O 0 2.5229420774763867e-09
in O 0 5.8803886204827904e-09
mouse O 0 6.133269181418655e-08
, O 0 2.813902533205237e-08
yeast O 0 1.122881030823919e-06
and O 0 1.0166451858140135e-07
Drosophila O 0 2.366175749557442e-06
. O 0 1.7231355968760909e-06

The O 0 2.3817671035430976e-07
resulting O 0 1.6949138625932392e-07
amino O 0 1.129985562897673e-07
- O 0 1.1124572552034806e-07
acid O 0 5.2428632102419215e-08
substitutions O 0 8.181744703961158e-08
are O 0 1.1654572862340729e-09
predicted O 0 4.0550503399572335e-08
to O 0 3.4420786221289745e-09
interfere O 0 8.32756654745026e-08
with O 0 1.0149998175279507e-08
ATP O 0 1.549131775391288e-05
binding O 0 1.1892045392869477e-07
or O 0 4.2453542903331254e-08
substrate O 0 4.0758749264568905e-07
recognition O 0 1.003153784040478e-06
. O 0 4.0706954678171314e-06

Two O 0 5.192209755477961e-07
of O 0 7.642401556040568e-07
seventeen O 0 3.3463261388533283e-06
mutated O 0 1.4385989288712153e-06
T B-Disease 0 2.410582783340942e-05
- I-Disease 0 4.960254500474548e-06
PLL I-Disease 0 3.2629744964651763e-05
samples O 0 8.948841667688612e-08
had O 0 3.396299419478055e-08
a O 0 1.317348630180959e-08
previously O 0 6.415265119130709e-08
reported O 0 1.0611740464128161e-07
A B-Disease 0 0.03141459450125694
- I-Disease 0 0.007498185615986586
T I-Disease 1 0.9283635020256042
allele O 0 2.2166013877722435e-06
. O 0 1.7142500610134448e-06

In O 0 2.9621253361256095e-07
contrast O 0 2.541788717280724e-07
, O 0 1.0748790302272937e-08
no O 0 1.0769763747475736e-08
mutations O 0 5.334511943289044e-09
were O 0 2.958667311148133e-09
detected O 0 2.669693976997678e-08
in O 0 5.160649130253603e-10
the O 0 1.5855947665954773e-09
p53 O 0 8.525826267202774e-09
gene O 0 1.2245828351353794e-08
, O 0 5.202357655775813e-09
suggesting O 0 2.0498438502158933e-08
that O 0 8.02394761745262e-10
this O 0 7.510451816017394e-09
tumour B-Disease 1 0.999997615814209
suppressor O 0 1.3675133232027292e-05
is O 0 1.1548012324169576e-08
not O 0 9.355143326672533e-10
frequently O 0 1.5595839064630468e-09
altered O 0 8.084078295667041e-09
in O 0 2.0574222325819846e-09
this O 0 1.3759192896145578e-08
leukaemia B-Disease 0 0.00021556716819759458
. O 0 1.415158749296097e-06

Occasional O 0 7.935759640531614e-06
missense O 0 1.4191445188771468e-05
mutations O 0 1.9564471642752324e-07
in O 0 2.65108166530581e-08
ATM O 0 2.6404461095808074e-05
were O 0 3.325860831182581e-08
also O 0 2.7740403307774386e-09
found O 0 2.3387580760925175e-09
in O 0 2.587974279322225e-09
tumour B-Disease 1 0.8974888324737549
DNA O 0 8.276152385633395e-08
from O 0 7.325719142414755e-09
patients O 0 3.2748086464806647e-09
with O 0 2.4949806665119922e-09
B B-Disease 0 0.006481215823441744
- I-Disease 0 6.173220026539639e-05
cell I-Disease 0 2.002585824811831e-05
non I-Disease 0 0.00046926899813115597
- I-Disease 1 0.9990901947021484
Hodgkins I-Disease 1 1.0
lymphomas I-Disease 1 0.9282270669937134
( O 0 2.50723104500139e-07
B B-Disease 0 0.00013234982907306403
- I-Disease 0 3.9473965784964093e-07
NHL I-Disease 0 1.0717775467128376e-06
) O 0 2.9567321924162115e-09
and O 0 3.1268834188580286e-09
a O 0 6.637947080889717e-08
B B-Disease 0 0.0006724816048517823
- I-Disease 0 1.0872094208025374e-05
NHL I-Disease 0 0.00029998962418176234
cell O 0 0.000306182075291872
line O 0 8.607027666585054e-06
. O 0 1.6393876194342738e-06

The O 0 2.797997353809478e-07
evidence O 0 2.1337828570722195e-07
of O 0 1.113293102150692e-08
a O 0 3.5834444300775203e-09
significant O 0 3.295310024853393e-09
proportion O 0 1.3366372897394285e-08
of O 0 1.3805563803259702e-08
loss O 0 8.222143605962628e-07
- O 0 7.900396781224117e-07
of O 0 1.23009385788464e-07
- O 0 4.5192035713625955e-07
function O 0 2.7059074980684272e-08
mutations O 0 5.5931441700352025e-09
and O 0 2.8621525149929994e-09
a O 0 6.733018587112838e-09
complete O 0 3.3012316436042966e-08
absence O 0 2.3828643236356584e-07
of O 0 1.7457393752806638e-08
the O 0 2.616798111532148e-09
normal O 0 6.433373389569397e-09
copy O 0 4.973450096201759e-09
of O 0 2.5483373189416625e-09
ATM O 0 6.206566354194365e-07
in O 0 1.4722086882912322e-09
the O 0 6.908781879921833e-10
majority O 0 1.7291295062449308e-09
of O 0 3.148873872760305e-08
mutated O 0 1.3672647583007347e-06
tumours B-Disease 1 0.9999691247940063
establishes O 0 3.935626409656834e-06
somatic O 0 2.1481582734850235e-06
inactivation O 0 4.92432582177571e-06
of O 0 2.3179577368637183e-08
this O 0 9.285741620068677e-10
gene O 0 2.8307178823183676e-09
in O 0 2.4661204189868613e-09
the O 0 1.4298784378752316e-08
pathogenesis O 0 0.00012009168858639896
of O 0 1.2258701644896064e-06
sporadic B-Disease 0 0.01738659292459488
T I-Disease 1 0.9845197200775146
- I-Disease 0 0.028274573385715485
PLL I-Disease 0 0.008428043685853481
and O 0 2.1564160235243435e-08
suggests O 0 2.0458635674458492e-08
that O 0 4.404734355034634e-10
ATM O 0 6.976153485993564e-07
acts O 0 4.323145574858245e-08
as O 0 4.494597050097582e-08
a O 0 1.9909284674213268e-06
tumour B-Disease 1 0.9999990463256836
suppressor O 0 0.0010731355287134647
. O 0 7.335701866395539e-06

As O 0 2.703406210002868e-07
constitutional O 0 2.414626123936614e-06
DNA O 0 3.570640672023728e-07
was O 0 7.033920468302313e-08
not O 0 5.487157395123177e-10
available O 0 1.8450987404605712e-09
, O 0 1.313188557894307e-09
a O 0 1.3618359773204247e-08
putative O 0 9.269430734093476e-07
hereditary O 1 0.9622527956962585
predisposition O 0 0.022132372483611107
to O 0 1.854620859376155e-05
T B-Disease 1 0.9999991655349731
- I-Disease 1 0.9994183778762817
PLL I-Disease 0 0.44111114740371704
will O 0 3.6623706733962536e-08
require O 0 3.729066833102479e-08
further O 0 1.8525861733564852e-08
investigation O 0 1.8048767458367365e-07
. O 0 4.63844713749495e-08
. O 0 5.968432787994971e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 0.00047207664465531707
kinase O 0 2.861668235709658e-06
is O 0 5.75785907841464e-09
involved O 0 7.043691407915276e-09
in O 0 6.736123880912714e-10
the O 0 1.3869850823411412e-09
modulation O 0 5.8641283828819724e-08
of O 0 9.152774538279118e-09
the O 0 1.3048127911474694e-08
Ca2 O 0 1.0154761866942863e-06
+ O 0 5.4760926104791e-06
homeostasis O 0 0.0010388507507741451
in O 0 2.7397190933697857e-06
skeletal O 1 0.9999122619628906
muscle O 0 0.15586574375629425
cells O 0 3.857915726257488e-05
. O 0 8.70998792379396e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9946573376655579
DM B-Disease 1 1.0
) O 0 2.043149379460374e-06
, O 0 1.7875374069831196e-08
the O 0 3.0874374168377017e-09
most O 0 1.9270904871859784e-08
prevalent O 0 0.0008864186820574105
muscular B-Disease 1 0.9994254112243652
disorder I-Disease 1 0.9999732971191406
in O 0 4.674702438478562e-07
adults O 0 5.885333393962355e-07
, O 0 1.624466783312073e-08
is O 0 3.2110885062053285e-09
caused O 0 2.4991591018874715e-08
by O 0 6.55580700836822e-09
( O 0 5.1166477277320155e-08
CTG O 0 5.7252524129580706e-05
) O 0 2.5783236878851312e-08
n O 0 5.231056547927437e-07
- O 0 1.3989047431550716e-07
repeat O 0 2.7911951860914996e-08
expansion O 0 2.311895563877897e-08
in O 0 9.999896466439395e-10
a O 0 1.3065678539092573e-09
gene O 0 1.981900865644093e-09
encoding O 0 4.600349612360333e-08
a O 0 1.6514675849066407e-07
protein O 0 1.3613292821901268e-06
kinase O 0 4.533298579190159e-06
( O 0 1.0024862149293767e-06
DM B-Disease 1 0.9999991655349731
protein O 0 1.6449739632662386e-05
kinase O 0 1.9406033970881253e-06
; O 0 3.609953580507863e-08
DMPK O 0 0.0002665363426785916
) O 0 1.0255315707752288e-08
and O 0 1.5902984484839067e-09
involves O 0 6.920641393293181e-09
changes O 0 2.7842390615262502e-09
in O 0 7.332890739064624e-09
cytoarchitecture O 0 1.2273383163119433e-06
and O 0 2.359297290865925e-08
ion O 0 0.0005343056982383132
homeostasis O 0 0.00472279591485858
. O 0 4.852407982980367e-06

To O 0 1.3623925099182088e-07
obtain O 0 4.4769120677301544e-07
clues O 0 3.0447750987150357e-07
to O 0 2.1326909127594718e-09
the O 0 6.504243810212529e-09
normal O 0 5.419544280016453e-08
biological O 0 8.932335049394169e-08
role O 0 2.9004525003983872e-08
of O 0 5.838659689061387e-08
DMPK O 0 0.00015530100790783763
in O 0 4.495668548543108e-08
cellular O 0 2.5061005999305053e-06
ion O 0 1.402564248564886e-05
homeostasis O 0 0.0006340798572637141
, O 0 2.172947688450222e-08
we O 0 3.830962214124156e-09
have O 0 3.6299316330534737e-10
compared O 0 2.6335467140370383e-09
the O 0 1.2616123701292281e-09
resting O 0 1.8199868634383165e-07
[ O 0 3.449283525469582e-08
Ca2 O 0 2.959820122327983e-08
+ O 0 1.0121294735654374e-07
] O 0 9.394740629886655e-08
i O 0 3.330329434447776e-08
, O 0 1.3278371735481187e-09
the O 0 1.075462940924865e-09
amplitude O 0 8.19754930603267e-09
and O 0 1.561849205522492e-09
shape O 0 3.2933890281583444e-08
of O 0 3.291844308250802e-08
depolarization O 0 3.579163774247718e-07
- O 0 6.295072125794832e-07
induced O 0 2.8048984290762746e-07
Ca2 O 0 3.256790250816266e-07
+ O 0 7.082370530042681e-07
transients O 0 2.0123770809732378e-06
, O 0 7.151939485083858e-09
and O 0 8.553772690156336e-10
the O 0 3.5320355529222525e-09
content O 0 2.9684816382768986e-08
of O 0 1.1950089806589403e-08
ATP O 0 7.967062629177235e-06
- O 0 3.9922289829519286e-07
driven O 0 4.3485918865826534e-08
ion O 0 2.5009719593072077e-06
pumps O 0 3.20580625157163e-07
in O 0 3.5944328402592873e-08
cultured O 0 7.309563443413936e-06
skeletal O 0 0.0037313213106244802
muscle O 0 3.293821464467328e-06
cells O 0 2.8036380328444466e-08
of O 0 3.96222574750027e-08
wild O 0 1.7042783184706423e-08
- O 0 3.279448179682731e-08
type O 0 3.1927015697874594e-08
and O 0 1.0004155726051067e-08
DMPK O 0 0.031248267740011215
[ O 0 8.52517314342549e-06
- O 0 0.00064125593053177
/ O 0 0.03261464461684227
- O 0 0.0009451564983464777
] O 0 2.3799308110028505e-05
knockout O 1 0.995292067527771
mice O 0 1.4715808902110439e-05
. O 0 2.3607435650774278e-06

In O 0 1.747537112350983e-06
vitro O 0 1.30931503008469e-05
- O 0 3.5549301173887216e-06
differentiated O 0 1.2647229823414818e-06
DMPK O 0 0.01170419529080391
[ O 0 1.0966020454361569e-05
- O 0 9.693906031316146e-05
/ O 0 9.396956738783047e-05
- O 0 5.133126251166686e-06
] O 0 2.538397154694394e-07
myotubes O 0 1.3181877420720411e-06
exhibit O 0 9.819513202558028e-09
a O 0 4.6470431946943336e-09
higher O 0 4.526290098283425e-08
resting O 0 4.6240003825914755e-07
[ O 0 5.407092373843625e-08
Ca2 O 0 1.2086910317066213e-07
+ O 0 2.785210710953834e-07
] O 0 1.9938421758070035e-07
i O 0 5.4196167553755004e-08
than O 0 2.4304349643955447e-09
do O 0 2.2931725407460135e-09
wild O 0 6.172228950163117e-09
- O 0 1.2784484582084588e-08
type O 0 2.174626878570507e-08
myotubes O 0 1.6659748780512018e-07
because O 0 6.870921054336065e-10
of O 0 4.842787837411322e-10
an O 0 9.956536983768416e-11
altered O 0 1.0266231198485798e-09
open O 0 2.39323383333101e-09
probability O 0 1.9666990258571104e-09
of O 0 3.999466535731244e-09
voltage O 0 7.118204621292534e-07
- O 0 7.464711870852625e-08
dependent O 0 3.1216409013268276e-08
l O 0 8.808238050050932e-08
- O 0 3.030530137948517e-08
type O 0 2.2546174704984878e-08
Ca2 O 0 7.850693606314962e-08
+ O 0 1.2745107369482866e-07
and O 0 3.660038316866121e-08
Na O 0 0.0003466324124019593
+ O 0 5.87354224990122e-06
channels O 0 4.509935024543665e-06
. O 0 1.2916098057758063e-06

The O 0 2.1171160824451363e-06
mutant O 0 8.856510248733684e-06
myotubes O 0 2.8198555810377002e-05
exhibit O 0 1.872687676041096e-07
smaller O 0 3.972789741624183e-08
and O 0 5.600830466079287e-09
slower O 0 1.3085568184578733e-07
Ca2 O 0 1.9446623866770096e-08
+ O 0 1.0875410794142226e-08
responses O 0 3.9634084902928635e-10
upon O 0 7.470187801672523e-10
triggering O 0 2.002155774505354e-09
by O 0 2.008343213955044e-10
acetylcholine O 0 2.215724848042555e-08
or O 0 5.223994126168918e-09
high O 0 1.7549061226418416e-07
external O 0 1.7875803450806416e-06
K O 0 8.749048902245704e-06
+ O 0 5.1065549087070394e-06
. O 0 9.456581437916611e-07

In O 0 4.144896195157344e-07
addition O 0 1.187524958368158e-07
, O 0 8.599007728093966e-09
we O 0 2.244713082077965e-09
observed O 0 1.819919437373585e-09
that O 0 8.313937732706833e-11
these O 0 2.709245883192324e-10
Ca2 O 0 2.5143970461272147e-08
+ O 0 1.0533598526762944e-07
transients O 0 4.116309355595149e-07
partially O 0 2.0353471796852318e-08
result O 0 2.7622135689853167e-09
from O 0 8.27057422547739e-10
an O 0 1.5732667946188883e-10
influx O 0 8.720156152719483e-09
of O 0 1.067275334776241e-08
extracellular O 0 1.5785020934799832e-07
Ca2 O 0 8.903266035531487e-08
+ O 0 4.763821337405716e-08
through O 0 2.412988919786585e-09
the O 0 5.601599628590748e-09
l O 0 1.335838817340118e-07
- O 0 7.321782646840802e-08
type O 0 8.334748713423323e-08
Ca2 O 0 1.9414903817960294e-07
+ O 0 1.7508033351987251e-06
channel O 0 4.458290732145542e-06
. O 0 1.1895883744728053e-06

Neither O 0 3.459893378021661e-06
the O 0 4.2983558046216785e-08
content O 0 8.911726467886183e-08
nor O 0 3.3972455071307195e-08
the O 0 1.3637717621861611e-09
activity O 0 8.481515045843935e-09
of O 0 3.409592252978655e-08
Na O 0 5.0409911636961624e-05
+ O 0 7.74962927607703e-07
/ O 0 1.6370318007830065e-06
K O 0 6.064168474040343e-07
+ O 0 2.7931133672609576e-07
ATPase O 0 5.11001530867361e-07
and O 0 1.3342354776568754e-08
sarcoplasmic O 0 1.3209173630457371e-06
reticulum O 0 1.1005557780663366e-06
Ca2 O 0 9.68100380305259e-07
+ O 0 1.8004170669883024e-06
- O 0 1.5472523955395445e-06
ATPase O 0 4.877750257037405e-07
are O 0 8.060393463793503e-10
affected O 0 3.4986586960883415e-09
by O 0 6.714730993451212e-09
DMPK O 0 0.00014544744044542313
absence O 0 2.1756115529569797e-05
. O 0 3.858776381093776e-06

In O 0 5.003022920391231e-07
conclusion O 0 4.0936072309705196e-07
, O 0 1.916668779244901e-08
our O 0 9.419857782688723e-09
data O 0 2.4973768830705012e-08
suggest O 0 1.4003886050772962e-08
that O 0 1.156842066585284e-09
DMPK O 0 1.7041495084413327e-05
is O 0 3.259578607028857e-09
involved O 0 2.5378699142208916e-09
in O 0 6.053340051437317e-10
modulating O 0 3.283077987248362e-08
the O 0 7.422367720444356e-10
initial O 0 9.119313082450731e-10
events O 0 6.837323485164859e-10
of O 0 3.6784144619161907e-09
excitation O 0 9.519922627987398e-07
- O 0 3.837487838609377e-06
contraction O 0 7.522424994022003e-07
coupling O 0 7.406528084175079e-07
in O 0 4.7452851958951214e-07
skeletal O 1 0.5077751278877258
muscle O 0 8.071009506238624e-05
. O 0 1.9309409253764898e-06
. O 0 8.74852321430808e-06

Constitutional O 0 0.0007121079252101481
RB1 O 1 0.9786499738693237
- O 0 6.718379881931469e-05
gene O 0 2.4262521947093774e-07
mutations O 0 1.0511580939009946e-07
in O 0 1.6184609208380607e-08
patients O 0 3.2563985286060415e-08
with O 0 1.8180294603098446e-08
isolated O 0 6.496728929050732e-06
unilateral B-Disease 0 1.150759453594219e-05
retinoblastoma I-Disease 1 0.6547383069992065
. O 0 1.708276067802217e-05

In O 0 3.7510744732571766e-07
most O 0 3.041613894083639e-08
patients O 0 6.601858615340461e-09
with O 0 1.4172060192052527e-09
isolated O 0 3.4758764400066866e-07
unilateral B-Disease 0 1.0214047279077931e-06
retinoblastoma I-Disease 1 0.8015156388282776
, O 0 1.6622453813397442e-07
tumor B-Disease 0 4.8836709538591094e-06
development O 0 8.78967654216467e-08
is O 0 7.731291162826892e-09
initiated O 0 1.7619536052393414e-08
by O 0 1.26433918890001e-09
somatic O 0 1.1448570091943111e-07
inactivation O 0 1.3866097106074449e-06
of O 0 1.9733356282358727e-08
both O 0 9.819456359139167e-09
alleles O 0 1.170068397726709e-08
of O 0 5.645557621392072e-08
the O 0 3.455823218700971e-07
RB1 O 0 0.0030831543263047934
gene O 0 4.517860361374915e-06
. O 0 5.739452262787381e-06

However O 0 9.175963100460649e-07
, O 0 2.4300653933551075e-08
some O 0 1.394031889923042e-09
of O 0 3.757968158879521e-09
these O 0 1.342349342792204e-09
patients O 0 1.5354114424326326e-08
can O 0 9.419282243072757e-09
transmit O 0 2.714670017667231e-06
retinoblastoma B-Disease 0 0.03465050831437111
predisposition O 0 1.3547572962124832e-05
to O 0 3.8617912423433154e-08
their O 0 1.6239748390489694e-07
offspring O 0 3.518499852361856e-06
. O 0 3.3198575692949817e-06

To O 0 1.153872588588456e-07
determine O 0 8.886284064146821e-08
the O 0 6.312503408878456e-09
frequency O 0 1.3205259996595942e-08
and O 0 5.079148768238895e-10
nature O 0 2.010467570201513e-09
of O 0 8.23311907538482e-09
constitutional O 0 3.637417648860719e-06
RB1 O 0 0.013430806808173656
- O 0 4.067866484547267e-06
gene O 0 6.119924478298344e-08
mutations O 0 1.9399944761744337e-08
in O 0 4.777723106030862e-09
patients O 0 6.805216834493422e-09
with O 0 2.616508565367326e-09
isolated O 0 7.657386618120654e-07
unilateral B-Disease 0 5.019841182729579e-07
retinoblastoma I-Disease 0 9.80217955657281e-05
, O 0 2.8244511174335685e-09
we O 0 1.1626686280408194e-09
analyzed O 0 8.956453356745442e-09
DNA O 0 1.6809567071618403e-08
from O 0 9.517852284091077e-09
peripheral O 0 9.268633220926858e-06
blood O 0 5.798694928671466e-07
and O 0 1.6321666862495476e-07
from O 0 7.873642971389927e-06
tumor B-Disease 1 0.9990522265434265
tissue O 0 0.003109137061983347
. O 0 2.634597876749467e-05

The O 0 3.519163840337569e-07
analysis O 0 2.5795318947530177e-07
of O 0 1.3232283890829422e-06
tumors B-Disease 1 0.9999915361404419
from O 0 8.255591978922894e-07
54 O 0 1.5544403595413314e-06
( O 0 3.332210596340701e-08
71 O 0 2.945263872788928e-07
% O 0 2.246513197690092e-08
) O 0 1.3998536774195713e-09
of O 0 1.2854218134350504e-08
76 O 0 7.601934726153559e-07
informative O 0 1.535050415668593e-07
patients O 0 3.553756044993861e-08
showed O 0 4.7180119366885265e-08
loss O 0 1.0275270767579059e-07
of O 0 2.9753442731816904e-07
constitutional O 0 0.00011753112630685791
heterozygosity O 1 0.9994586110115051
( O 0 0.00019777117995545268
LOH O 1 0.999998927116394
) O 0 5.676253636011097e-07
at O 0 6.640063475060742e-06
intragenic O 0 7.968622958287597e-05
loci O 0 4.3329796426405665e-06
. O 0 5.036542006564559e-06

Three O 0 4.077990070072701e-07
of O 0 3.070511525038455e-07
13 O 0 2.9222615012258757e-06
uninformative O 0 0.00028412463143467903
patients O 0 1.5897525145192049e-06
had O 0 3.061788902414264e-07
constitutional O 0 5.763548415416153e-06
deletions O 0 5.522416813619202e-06
. O 0 2.193913587689167e-06

For O 0 5.041387112214579e-07
39 O 0 1.629151029192144e-06
randomly O 0 6.538589047977439e-08
selected O 0 8.321610494022025e-07
tumors B-Disease 1 0.9999796152114868
, O 0 2.383262085459137e-07
SSCP O 0 0.1400550901889801
, O 0 7.052189516798535e-07
hetero O 0 0.00037818297278136015
- O 0 3.135583028779365e-06
duplex O 0 1.8535918115958339e-06
analysis O 0 9.815487089781527e-09
, O 0 1.1643952468887164e-09
sequencing O 0 6.196787971646245e-09
, O 0 1.5663330632520456e-09
and O 0 2.0193837713122775e-09
Southern O 0 3.813947557773645e-08
blot O 0 5.5406516707989795e-08
analysis O 0 6.694014675900917e-09
were O 0 2.4753521454812244e-09
used O 0 1.3611756166653777e-09
to O 0 1.415298989115854e-09
identify O 0 3.364587541909714e-07
mutations O 0 4.054203145642532e-06
. O 0 5.6170365496654995e-06

Mutations O 0 1.1278060583208571e-06
were O 0 6.116656692256583e-08
detected O 0 1.439788519519425e-07
in O 0 5.0929944706012975e-09
21 O 0 5.484798393240453e-08
( O 0 2.456548076068543e-09
91 O 0 3.445667218215931e-08
% O 0 1.1501366969923765e-08
) O 0 6.653612327767178e-09
of O 0 3.0032444442440465e-07
23 O 0 0.43614643812179565
tumors B-Disease 1 1.0
with O 0 0.001436897786334157
LOH O 1 1.0
. O 0 0.00033026793971657753

In O 0 1.1515227242853143e-06
6 O 0 2.084915649902541e-06
( O 0 2.25097380734951e-08
38 O 0 1.3148351740710496e-07
% O 0 6.428442222983222e-09
) O 0 3.1682345635886122e-09
of O 0 9.257172450816142e-08
16 O 0 0.003849730594083667
tumors B-Disease 1 1.0
without O 0 0.00614180788397789
LOH O 1 1.0
, O 0 1.867721621806595e-08
one O 0 2.018251565871765e-09
mutation O 0 1.5424553856391299e-09
was O 0 1.4355872046678542e-08
detected O 0 2.095530859946848e-08
, O 0 7.10955572191807e-10
and O 0 3.4186795061508235e-10
in O 0 3.0417863783327448e-09
9 O 0 6.101113569911831e-08
( O 0 2.8256632589318542e-09
56 O 0 1.9912191007165347e-08
% O 0 4.310356960246509e-09
) O 0 1.587434628191886e-09
of O 0 1.4104193368780216e-08
the O 0 4.7596071794941963e-07
tumors B-Disease 1 1.0
without O 0 0.11202573776245117
LOH O 1 1.0
, O 0 9.829110325654256e-08
both O 0 3.2067934085944216e-08
mutations O 0 5.323060037198957e-08
were O 0 8.58156141703148e-08
found O 0 2.2085717432673846e-07
. O 0 4.811631129086891e-07

Thus O 0 1.691737111286784e-06
, O 0 2.3273583948935084e-08
a O 0 4.621022675621589e-09
total O 0 5.401530334125937e-10
of O 0 2.4533546305605114e-09
45 O 0 1.7645902516960632e-08
mutations O 0 4.713134771350269e-09
were O 0 3.1413796008905592e-09
identified O 0 2.0790089649835863e-08
in O 0 3.472791121339469e-08
tumors B-Disease 1 0.9999943971633911
of O 0 2.5616682250984013e-06
36 O 0 0.0002698442549444735
patients O 0 2.1178764654905535e-05
. O 0 4.798035661224276e-06

Thirty O 0 5.0435930461389944e-05
- O 0 3.3111055017798208e-06
nine O 0 6.13956601114296e-08
of O 0 7.403383239790173e-09
the O 0 3.6801057756719047e-09
mutations O 0 2.7736117846899333e-09
- O 0 1.8192920947512903e-08
including O 0 2.7064273044885567e-09
34 O 0 3.540738546803368e-08
small O 0 8.531031880920636e-09
mutations O 0 1.0222565016704266e-08
, O 0 5.2558362106935874e-09
2 O 0 5.783783407764531e-08
large O 0 1.6710725248003655e-08
structural O 0 2.1138660031283507e-06
alterations O 0 2.497730520190089e-06
, O 0 1.7898299731200495e-08
and O 0 2.6587786194909313e-08
hypermethylation O 1 0.5074677467346191
in O 0 2.2511965198646067e-06
3 O 1 0.7881913781166077
tumors O 1 1.0
- O 0 2.4772864435362862e-06
were O 0 8.001348028585653e-09
not O 0 7.573194293897245e-10
detected O 0 1.0339120670721513e-08
in O 0 5.885648080017347e-10
the O 0 1.821579553862307e-09
corresponding O 0 9.546764090373472e-08
peripheral O 0 4.2688072426244617e-05
blood O 0 2.918307018262567e-06
DNA O 0 6.435820978367701e-06
. O 0 2.263050419060164e-06

In O 0 1.2856495459345751e-06
6 O 0 5.7511065278958995e-06
( O 0 5.570990424530464e-08
17 O 0 8.616168400976676e-08
% O 0 8.239465998371998e-09
) O 0 1.6286728632408654e-09
of O 0 7.664047174671396e-09
the O 0 1.955187656221824e-08
36 O 0 4.0636103904034826e-07
patients O 0 3.4031987894422855e-08
, O 0 1.5751292492538482e-09
a O 0 1.8337314999783416e-09
mutation O 0 1.976231178701937e-09
was O 0 1.537468641288342e-08
detected O 0 1.5222486382526768e-08
in O 0 7.512725996861036e-10
constitutional O 0 6.242223804520108e-08
DNA O 0 7.003438184938204e-08
, O 0 2.9744082752358736e-09
and O 0 8.356804137577001e-10
1 O 0 1.696501250592064e-08
of O 0 1.2131048388042132e-09
these O 0 1.8160002668299313e-10
mutations O 0 1.2508349911399819e-09
is O 0 8.449137500754489e-10
known O 0 1.3780879770664e-09
to O 0 1.1074304806513169e-09
be O 0 7.511741451082798e-09
associated O 0 1.276454639764779e-07
with O 0 4.852213919548376e-08
reduced O 0 8.808826351014432e-06
expressivity O 0 0.00025870793615467846
. O 0 7.041920071060304e-06

The O 0 2.037728847881226e-07
presence O 0 1.1326753934781664e-07
of O 0 2.2863519077986894e-08
a O 0 2.0268474898443856e-08
constitutional O 0 1.9804910778020712e-07
mutation O 0 1.0603764089012202e-08
was O 0 2.7818622072572907e-08
not O 0 2.8275759511586784e-10
associated O 0 1.4139578397021069e-09
with O 0 1.6492222865149841e-10
an O 0 6.67293942324676e-10
early O 0 6.39398507473743e-08
age O 0 9.226849329024844e-07
at O 0 5.648030310112517e-06
treatment O 0 1.3868761016055942e-05
. O 0 2.8360102533042664e-06

In O 0 1.1057761639676755e-06
1 O 0 4.547661774267908e-06
patient O 0 1.1667700619000243e-06
, O 0 7.843912896987604e-08
somatic O 0 7.134745374060003e-06
mosaicism O 0 0.0022644761484116316
was O 0 1.4014845817200694e-07
demonstrated O 0 7.30734051046511e-09
by O 0 1.4491732813759484e-10
molecular O 0 3.4861884490311468e-09
analysis O 0 7.266530155369821e-10
of O 0 1.169474406204074e-09
DNA O 0 1.82389570113628e-08
and O 0 5.2472022282756825e-09
RNA O 0 3.6463263768382603e-06
from O 0 4.1608652168179106e-07
peripheral O 0 0.0018620560877025127
blood O 0 1.1451881618995685e-05
. O 0 7.4207355282851495e-06

In O 0 1.7240313354704995e-06
2 O 0 2.7511739517649403e-06
patients O 0 2.648241270719609e-08
without O 0 5.325860197302745e-09
a O 0 2.869028126184503e-09
detectable O 0 3.0171906928444514e-07
mutation O 0 8.15335710058207e-09
in O 0 7.168655891121034e-09
peripheral O 0 1.4336752428789623e-05
blood O 0 1.6535414033569396e-06
, O 0 1.402961089524979e-07
mosaicism O 1 0.6955999135971069
was O 0 2.0479933482420165e-06
suggested O 0 8.754257407872501e-08
because O 0 2.4398403297709592e-09
1 O 0 3.564814932133231e-08
of O 0 4.71822581005199e-09
the O 0 2.0568895919836905e-08
patients O 0 1.6661574591125827e-06
showed O 0 0.0018874786328524351
multifocal O 1 1.0
tumors B-Disease 1 1.0
and O 0 5.051021503277298e-07
the O 0 9.8180557017713e-08
other O 0 1.4070686837897028e-08
later O 0 4.3057863763351634e-07
developed O 0 1.2612492810148979e-06
bilateral B-Disease 0 0.0008769742562435567
retinoblastoma I-Disease 0 0.1781035214662552
. O 0 5.862277703272412e-06

In O 0 6.213513756847533e-07
conclusion O 0 1.0314843166270293e-06
, O 0 3.523619795942068e-08
our O 0 1.00216501763839e-08
results O 0 6.1206226753540705e-09
emphasize O 0 2.550210709273415e-08
that O 0 6.344669234437106e-10
the O 0 3.6916636414474624e-09
manifestation O 0 4.1015007923306257e-07
and O 0 2.0879861395428634e-08
transmissibility O 0 0.0004618419916369021
of O 0 5.241888061391364e-07
retinoblastoma B-Disease 0 4.377397272037342e-05
depend O 0 8.420926178587251e-08
on O 0 2.2955804368507415e-08
the O 0 1.4606236220515711e-09
nature O 0 2.00233141178785e-09
of O 0 1.5219517868203525e-09
the O 0 8.643515903017374e-10
first O 0 1.340780930725316e-09
mutation O 0 6.010782427345873e-10
, O 0 1.758248824312858e-10
its O 0 9.394709316046246e-11
time O 0 1.0182920062717926e-09
in O 0 4.739129644271145e-10
development O 0 3.4845930585447604e-09
, O 0 5.765933286383529e-10
and O 0 2.0689829016706796e-10
the O 0 7.026633164208818e-10
number O 0 6.012582653980303e-10
and O 0 3.2018515616627496e-10
types O 0 1.1693768620091305e-08
of O 0 4.363730710110758e-08
cells O 0 1.1875562755392366e-08
that O 0 2.877620086660926e-10
are O 0 4.015715537875053e-10
affected O 0 5.299948924175624e-09
. O 0 6.354033299516004e-09
. O 0 1.7236814642274112e-07

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 0 0.0003827410109806806
the I-Disease 0 4.292491667001741e-06
fifth I-Disease 0 1.4245194506656844e-05
component I-Disease 0 8.42820736579597e-06
of I-Disease 0 2.4959632582977065e-07
complement I-Disease 0 1.2692214568232885e-06
in O 0 4.999402563043986e-07
man O 0 1.8052181985694915e-05
. O 0 4.369862836028915e-06

I O 0 0.00878703873604536
. O 0 0.00017037414363585413

Clinical O 0 0.0005253521958366036
, O 0 4.484262717596721e-06
immunochemical O 0 0.0013851710828021169
, O 0 5.535401328415901e-07
and O 0 1.7778407368496119e-07
family O 0 2.585420588729903e-07
studies O 0 1.0974106317007681e-06
. O 0 1.3368523923418252e-06

The O 0 2.1436281372189114e-07
first O 0 2.948067212571459e-08
recognized O 0 1.853461526479805e-07
human O 0 2.9042482196928177e-07
kindred O 0 6.195565219968557e-05
with O 0 1.0003498118749121e-06
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9107547998428345
the I-Disease 0 6.928892980795354e-05
fifth I-Disease 0 6.64013932691887e-05
component I-Disease 0 1.3472073078446556e-05
of I-Disease 0 1.6903630921660806e-06
complement I-Disease 0 2.6051960958284326e-05
( O 0 5.431581485026982e-06
C5 O 1 0.7041870355606079
) O 0 1.0503082847890255e-07
is O 0 5.239434130999143e-08
described O 0 4.8289751930497e-07
. O 0 7.227866376524616e-07

The O 0 1.3922237940278137e-06
proband O 0 5.1677234296221286e-05
, O 0 1.0988342324935729e-07
a O 0 7.364459264636025e-08
20 O 0 1.6882641773463547e-07
- O 0 1.4478810328455438e-07
year O 0 1.1496323004678288e-08
- O 0 6.608916010009125e-07
old O 0 5.682574624188419e-07
black O 0 4.3815955308446064e-08
female O 0 5.132981186761754e-07
with O 0 0.000382925703888759
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 1 0.9948569536209106
age O 1 0.9980231523513794
11 O 0 3.085705975536257e-05
, O 0 1.1098694585598423e-07
lacked O 0 1.787538712960668e-05
serum O 0 2.6845432330446783e-06
hemolytic O 0 0.00010000972542911768
complement O 0 3.390792073787452e-07
activity O 0 2.7459657303552376e-07
, O 0 1.1869086158355913e-08
even O 0 1.5745651893439572e-08
during O 0 6.513060384349956e-07
remission O 0 5.243020495981909e-06
. O 0 8.981439236777078e-07

C5 O 1 0.5368912816047668
was O 0 1.841234916355461e-05
undetectable O 0 8.100631384877488e-05
in O 0 3.130202586021369e-08
her O 0 9.021949409770968e-09
serum O 0 3.033468232160885e-08
by O 0 1.370251134780176e-09
both O 0 2.8179091060565042e-08
immunodiffusion O 0 6.763447890989482e-05
and O 0 8.166074394466705e-07
hemolytic O 1 0.9998226761817932
assays O 0 8.027487638173625e-05
. O 0 1.8401939087198116e-05

Other O 0 1.6326958984791418e-07
complement O 0 5.93944605498109e-07
components O 0 2.225692924184841e-06
were O 0 2.8668964091593807e-08
normal O 0 2.9682098556804704e-08
during O 0 2.8972676702210265e-08
remission O 0 1.6153188653333928e-07
of O 0 9.518200272395916e-08
lupus O 0 1.4856704183330294e-05
, O 0 6.333309698902667e-08
but O 0 9.7793872555485e-08
C1 O 1 0.5554507374763489
, O 0 1.5764998124723206e-06
C4 O 1 0.9997169375419617
, O 0 3.7975209465912485e-07
C2 O 0 0.0004940837388858199
, O 0 1.117113868076558e-07
and O 0 1.6119180656914978e-07
C3 O 1 0.5354825854301453
levels O 0 2.860739186871797e-05
fell O 0 0.0037679190281778574
during O 0 9.471345038036816e-06
exacerbations O 0 0.0008285772055387497
. O 0 8.034466191020329e-06

A O 0 7.940738578327e-05
younger O 0 2.4468252377118915e-05
half O 0 1.9263243302702904e-06
- O 0 9.844617125054356e-06
sister O 0 9.613713700673543e-07
, O 0 3.002396553597464e-08
who O 0 2.2979328662131593e-08
had O 0 1.0692500751474654e-07
no O 0 2.547693043197796e-07
underlying O 1 0.963007390499115
disease O 0 0.008180594071745872
, O 0 2.7105100386393133e-08
was O 0 3.2936566185526317e-07
also O 0 4.836235856231497e-09
found O 0 2.9899367426367007e-09
to O 0 3.6493155164407654e-09
lack O 0 1.4032060562385595e-06
immunochemically O 0 0.002918923506513238
detectable O 0 0.15334853529930115
C5 O 1 0.9423302412033081
. O 0 1.2985004104848485e-05

By O 0 9.39956805723341e-07
hemolytic O 0 0.2707569897174835
assay O 0 9.964251148630865e-06
, O 0 2.722157432799577e-07
she O 0 6.905797533818259e-08
exhibited O 0 6.356351036629349e-07
1 O 0 5.409082177720848e-07
- O 0 1.354659104890743e-07
2 O 0 3.6548065907027194e-08
% O 0 2.0182708837523933e-09
of O 0 3.882335342098031e-09
the O 0 6.54573639735645e-09
normal O 0 2.2552461587110884e-07
serum O 0 3.0153640295793593e-07
C5 O 0 1.8517578155297088e-06
level O 0 7.743646790459024e-08
and O 0 1.192335563615643e-09
normal O 0 1.004739225152207e-08
concentrations O 0 2.5806558667795798e-08
of O 0 2.5738264852748216e-09
other O 0 1.5800218911010688e-09
complement O 0 1.6290051974010566e-07
components O 0 5.907702870899811e-06
. O 0 1.3172817716622376e-06

C5 O 0 0.001956571824848652
levels O 0 2.8018262128171045e-06
of O 0 8.502347981220737e-08
other O 0 6.616482028931614e-09
family O 0 4.752057414236788e-09
members O 0 9.25575172061599e-10
were O 0 2.9235842635699782e-09
either O 0 6.452962608705093e-09
normal O 0 1.048686559812495e-08
or O 0 1.028437890404632e-09
approximately O 0 1.7717693978624993e-09
half O 0 8.7033402706993e-09
- O 0 1.2097506107977551e-08
normal O 0 4.845866374836305e-09
, O 0 2.8026833631678016e-10
consistent O 0 3.2529576809992022e-09
with O 0 1.5035463984958142e-09
autosomal O 0 1.809861487345188e-07
codominant O 0 1.4611533742936444e-06
inheritance O 0 1.783403860144972e-07
of O 0 3.378525192943016e-08
the O 0 4.512041940074596e-08
gene O 0 3.611741931308643e-06
determining O 0 0.01734238862991333
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.00031476758886128664

Normal O 0 0.0005270695546641946
hemolytic O 1 0.9738730192184448
titers O 0 0.0006149350665509701
were O 0 7.587528330077475e-07
restored O 0 1.042301278175728e-06
to O 0 1.712199093617528e-08
both O 0 1.2900508750135486e-07
homozygous O 0 5.157064879313111e-05
C5 B-Disease 1 1.0
- I-Disease 1 0.9999946355819702
deficient I-Disease 1 1.0
( O 0 3.921769530279562e-05
C5D B-Disease 1 1.0
) O 0 1.9084234281763202e-07
sera O 0 8.559816819797561e-07
by O 0 1.230498813953318e-09
addition O 0 4.076373461003868e-09
of O 0 2.2384803344266402e-08
highly O 0 9.122807114181342e-07
purified O 0 2.0572465473378543e-06
human O 0 2.283494040966616e-06
C5 O 0 0.003684206632897258
. O 0 7.833864401618484e-06

In O 0 5.169911219127243e-07
specific O 0 1.010828896141902e-06
C5 O 0 0.005362192168831825
titrations O 0 6.518873124150559e-05
, O 0 3.669558523711203e-08
however O 0 2.6172386924372404e-08
, O 0 2.8326354595265e-09
it O 0 5.109737077901855e-10
was O 0 1.2476213839818229e-08
noted O 0 4.46608661164305e-09
that O 0 9.642240478280328e-11
when O 0 4.1166417497073837e-10
limited O 0 7.602399820783035e-10
amounts O 0 3.6427993954646354e-09
of O 0 1.9864621947363048e-08
C5 O 0 9.565513209963683e-06
were O 0 1.539058835930973e-08
assayed O 0 1.0537074501826282e-07
in O 0 4.831973710039961e-10
the O 0 2.7593582974105857e-10
presence O 0 7.587001582542996e-10
of O 0 3.020096173145248e-09
low O 0 1.0255632076905385e-07
dilutions O 0 1.1601215419432265e-06
of O 0 4.25243733559455e-08
either O 0 4.676597598063381e-07
C5D B-Disease 1 0.9999996423721313
serum O 0 2.226720425824169e-06
, O 0 1.0472753331214335e-08
curving O 0 6.047748257742569e-08
rather O 0 3.748390042801475e-09
than O 0 4.075757509269806e-10
linear O 0 5.266814540050291e-09
dose O 0 7.42340802162289e-08
- O 0 4.16507450751169e-09
response O 0 3.7862704638236266e-10
plots O 0 1.5288180721384492e-09
were O 0 4.5505146872848456e-10
consistently O 0 1.2274468108586234e-09
obtained O 0 1.928166515341445e-09
, O 0 2.483371286388092e-10
suggesting O 0 2.014743927247764e-09
some O 0 4.013211429843011e-10
inhibitory O 0 1.7404639152118762e-07
effect O 0 4.602175067702774e-07
. O 0 5.107677338855865e-07

Further O 0 1.082686480913253e-06
studies O 0 2.5455219088144077e-07
suggested O 0 1.0879087142257049e-07
that O 0 1.7919707939739737e-09
low O 0 2.1793486837395903e-07
dilutions O 0 6.0199836298124865e-06
of O 0 2.9466627893270925e-07
C5D B-Disease 1 0.9999972581863403
serum O 0 3.8235225474636536e-07
contain O 0 5.928872059968171e-09
a O 0 4.368741812754706e-09
factor O 0 1.3988562308497876e-08
( O 0 6.619810810626348e-10
or O 0 1.1044435366258654e-09
factors O 0 9.355273000721809e-09
) O 0 1.8841403992553296e-09
interfering O 0 5.546742443129915e-08
at O 0 4.248343543622468e-08
some O 0 8.071008861243456e-10
step O 0 1.8824207970169482e-08
in O 0 1.4682658422415784e-09
the O 0 8.78730954667617e-09
hemolytic O 0 2.053054777206853e-05
assay O 0 7.255159175656445e-07
of O 0 3.1987410693545826e-06
C5 O 1 0.9758224487304688
, O 0 2.9024503689356607e-08
rather O 0 1.8043598615236078e-08
than O 0 2.146770983202373e-09
a O 0 1.488918499603642e-08
true O 0 1.9676591023198853e-07
C5 O 0 0.0004673004150390625
inhibitor O 0 7.013850790826837e-06
or O 0 2.2009453459759243e-07
inactivator O 0 6.785794539609924e-05
. O 0 3.949086476495722e-06

Of O 0 3.713342721312074e-06
clinical O 0 1.8827309759217314e-05
interest O 0 4.990642423763347e-07
are O 0 7.541802737875969e-09
( O 0 3.0884033108691256e-09
a O 0 3.013088223369209e-09
) O 0 3.559742778325159e-10
the O 0 6.926079154645493e-10
documentation O 0 1.0649189619016397e-07
of O 0 5.74285138554842e-07
membranous O 1 1.0
glomerulonephritis B-Disease 1 1.0
, O 1 0.940005362033844
vasculitis B-Disease 1 1.0
, O 0 1.0073595149151515e-05
and O 0 1.1570484275580384e-05
arthritis B-Disease 1 1.0
in O 0 1.7602781099412823e-07
an O 0 1.4997922903603467e-08
individual O 0 9.222734576042058e-08
lacking O 1 0.987170398235321
C5 O 1 0.9996981620788574
( O 0 2.272565247096736e-08
and O 0 1.6342490694043477e-09
its O 0 6.868327018239029e-10
biologic O 0 1.6220633369812276e-07
functions O 0 7.495454035222338e-09
) O 0 2.0962731550611124e-09
, O 0 1.9592707456439484e-09
and O 0 4.0752232699503566e-09
( O 0 8.137914342398744e-09
b O 0 3.722174426457059e-07
) O 0 2.5542108428311394e-09
a O 0 5.7469637937401785e-09
remarkable O 0 3.3970056989574005e-08
propensity O 0 6.289916996138345e-07
to O 0 1.923055634733828e-07
bacterial B-Disease 1 1.0
infections I-Disease 1 0.9999985694885254
in O 0 6.143361730437391e-08
the O 0 3.269954262918873e-08
proband O 0 6.5093054217868485e-06
, O 0 7.473355267961779e-09
even O 0 1.9219137392667562e-09
during O 0 4.1117784732591645e-09
periods O 0 1.7310904709688657e-08
of O 0 4.79997330771198e-09
low O 0 1.1936586474803335e-07
- O 0 2.850120139896717e-08
dose O 0 1.5010284570848853e-08
or O 0 9.29614329958639e-10
alternate O 0 1.0283344842321185e-08
- O 0 1.1605449401486112e-07
day O 0 9.193930594619815e-08
corticosteroid O 0 3.108901364612393e-05
therapy O 0 4.406265725265257e-05
. O 0 1.7077591110137291e-06

Other O 0 1.7477425728884555e-07
observations O 0 1.9286905228454998e-07
indicate O 0 7.891694053796527e-08
that O 0 1.461509802069827e-09
the O 0 1.5877807513220432e-08
C5D B-Disease 1 0.9998724460601807
state O 0 1.456821063783309e-08
is O 0 1.3465702997095264e-09
compatible O 0 1.8682097646660623e-08
with O 0 9.089514696469791e-10
normal O 0 3.4315135621909576e-08
coagulation O 0 1.222478260842763e-07
function O 0 1.5818319099025757e-08
and O 0 2.6030784194830403e-09
the O 0 8.240754745258982e-09
capacity O 0 6.567273658220074e-08
to O 0 1.1003312927471143e-08
mount O 0 3.002785661010421e-06
a O 0 1.3625982546727755e-06
neutrophilic O 1 0.9408943057060242
leukocytosis O 1 0.5108343958854675
during O 0 0.0002456016663927585
pyogenic B-Disease 1 0.993678867816925
infection I-Disease 0 7.984862168086693e-05
. O 0 2.0894707120078237e-07
. O 0 1.527821041236166e-06

Susceptibility O 0 0.012852810323238373
to O 0 0.00014747944078408182
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.0056242989376187325
twins O 0 2.245761606900487e-05
: O 0 6.190101764502742e-09
the O 0 3.845031848470626e-09
role O 0 3.898484379760703e-08
of O 0 5.670962721637807e-08
genes O 0 4.705834300011702e-08
, O 0 4.129023523091746e-08
HLA O 0 8.047046867432073e-05
, O 0 6.503216098963094e-08
and O 0 1.1981128089644244e-08
the O 0 5.5491337747071157e-08
environment O 0 7.846920198062435e-06
. O 0 3.888580522470875e-06

OBJECTIVE O 0 2.7019239496439695e-05
To O 0 7.713678229492871e-08
determine O 0 6.057225476752137e-08
the O 0 8.744239998748071e-09
relative O 0 1.2026993090330507e-07
effects O 0 4.040497856294678e-07
of O 0 3.1834222369298004e-08
genetic O 0 3.0595817435141726e-08
and O 0 1.8355231778954817e-09
environmental O 0 2.840855550800825e-08
factors O 0 1.6324181117965963e-08
in O 0 8.287758923586352e-09
susceptibility O 0 4.428209194884403e-06
to O 0 6.070664767321432e-06
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 1 0.991603434085846
AS B-Disease 1 0.9999995231628418
) O 0 3.336177542223595e-06
. O 0 6.353287972160615e-06

METHODS O 0 0.00023905557463876903
Twins O 0 9.00814302440267e-06
with O 0 7.666726276056579e-08
AS B-Disease 1 0.831626832485199
were O 0 2.012022193298435e-08
identified O 0 7.353507580631913e-09
from O 0 1.0202204636655665e-09
the O 0 2.6012618725701486e-09
Royal O 0 3.375438609509729e-06
National O 0 2.2759891180612613e-06
Hospital O 0 0.0003133841964881867
for O 0 2.080661261061323e-06
Rheumatic B-Disease 1 1.0
Diseases I-Disease 1 0.9999963045120239
database O 0 0.00012097958097001538
. O 0 4.140870078117587e-05

Clinical O 0 4.4116433855379e-05
and O 0 5.963522653473774e-08
radiographic O 0 5.287565272737993e-06
examinations O 0 2.147621444237302e-06
were O 0 1.9155578456775402e-08
performed O 0 1.4882739485244656e-08
to O 0 2.108101471165469e-09
establish O 0 3.14702191417382e-07
diagnoses O 0 1.5468654964934103e-05
, O 0 7.497459364458336e-08
and O 0 3.7566664445876086e-07
disease O 0 0.0005982956499792635
severity O 0 2.9566742796305334e-06
was O 0 1.9057407030231843e-07
assessed O 0 3.8206895425219045e-08
using O 0 4.3657761850113275e-09
a O 0 3.13358805570374e-09
combination O 0 1.2638528446018427e-08
of O 0 9.658336352913466e-09
validated O 0 2.4350282501472975e-07
scoring O 0 9.63872025749879e-07
systems O 0 4.382667975733057e-05
. O 0 4.242750037519727e-06

HLA O 0 0.0010174461640417576
typing O 0 3.6287714465288445e-05
for O 0 1.449132810193987e-06
HLA O 0 0.01743304915726185
- O 0 0.0005760017083957791
B27 O 0 6.504236807813868e-05
, O 0 1.9002273177193274e-07
HLA O 0 0.00021417772222775966
- O 0 2.1970980014884844e-05
B60 O 0 1.1852064744743984e-05
, O 0 4.4745643634769294e-08
and O 0 5.925596369138475e-08
HLA O 1 0.9833505749702454
- O 1 0.9591047167778015
DR1 O 1 0.9999200105667114
was O 0 5.28181715253595e-07
performed O 0 4.9162505177946514e-08
by O 0 3.249181590447847e-09
polymerase O 0 6.360074280564731e-07
chain O 0 2.508318530658471e-08
reaction O 0 3.2804035043909607e-09
with O 0 6.469941804532198e-10
sequence O 0 5.7836699873803354e-09
- O 0 8.888855873578905e-09
specific O 0 6.082691017539332e-10
primers O 0 3.60259377885086e-08
, O 0 1.1358199936140068e-09
and O 0 1.5201356839966707e-09
zygosity O 0 1.0062564115287387e-06
was O 0 6.46950368832222e-08
assessed O 0 8.37423570487772e-08
using O 0 6.416415487819904e-08
microsatellite O 0 4.896233349427348e-06
markers O 0 3.722291921803844e-06
. O 0 2.6153779799642507e-06

Genetic O 0 4.784665634360863e-06
and O 0 2.4935310705131997e-08
environmental O 0 3.1938892419702825e-08
variance O 0 1.2071414090542021e-08
components O 0 1.3317671232471184e-07
were O 0 7.159787429600328e-09
assessed O 0 1.627046763985618e-08
with O 0 5.728050811448782e-10
the O 0 1.8455491579416616e-09
program O 0 2.6751771908806177e-09
Mx O 0 5.260191215938903e-08
, O 0 1.5592975521894203e-10
using O 0 2.674237220556819e-10
data O 0 6.471644886651973e-10
from O 0 2.344527350039982e-10
this O 0 5.911081346621216e-11
and O 0 1.6238950462099666e-10
previous O 0 2.2312585112871375e-09
studies O 0 5.28760990547994e-09
of O 0 4.804555686632739e-08
twins O 0 4.800158990292402e-07
with O 0 7.60116023457158e-08
AS B-Disease 1 0.9998002648353577
. O 0 1.345658802165417e-05

RESULTS O 0 2.483635626049363e-06
Six O 0 7.162849442465813e-07
of O 0 7.493168823202723e-07
8 O 0 1.18498155643465e-05
monozygotic O 0 8.435781637672335e-05
( O 0 1.4191023183229845e-06
MZ O 1 0.5231542587280273
) O 0 2.3940737037264626e-07
twin O 0 1.5707310012658127e-06
pairs O 0 1.6975636185634357e-07
were O 0 3.153514285259007e-07
disease O 0 7.892429607636586e-07
concordant O 0 2.4578318402745936e-07
, O 0 1.2561858220294653e-09
compared O 0 2.709696911296078e-09
with O 0 1.0362628533044926e-09
4 O 0 2.8709017385608604e-08
of O 0 8.489607239425823e-09
15 O 0 4.0009794588513614e-08
B27 O 0 3.049640042718238e-07
- O 0 1.781162772829248e-08
positive O 0 3.3732243664985617e-09
dizygotic O 0 1.854872039075417e-06
( O 0 6.43032080915873e-08
DZ O 0 0.00010714154632296413
) O 0 3.272961990319345e-08
twin O 0 1.3925183850460598e-07
pairs O 0 4.016240495730017e-08
( O 0 7.1463759354628564e-09
27 O 0 9.684737989346104e-08
% O 0 5.52061640846091e-09
) O 0 9.336925677061458e-10
and O 0 1.146465367085625e-09
4 O 0 7.159380999155474e-08
of O 0 4.9657746359343946e-08
32 O 0 3.9185410969366785e-06
DZ O 0 0.0048008752055466175
twin O 0 5.502873250406992e-07
pairs O 0 3.458295338987227e-08
overall O 0 9.949469870207395e-08
( O 0 6.56549214994584e-09
12 O 0 1.8128874401668327e-08
. O 0 1.6810841607650673e-09
5 O 0 3.426412220619568e-08
% O 0 2.105301888377653e-08
) O 0 4.09307929771785e-08
. O 0 7.717900416537304e-07

Nonsignificant O 0 0.0004173513734713197
increases O 0 9.890453611660632e-07
in O 0 9.325930250270176e-09
similarity O 0 1.5019908872204724e-08
with O 0 9.807210599177552e-10
regard O 0 3.103202317333853e-08
to O 0 3.0967559627725905e-09
age O 0 2.4680543901922647e-06
at O 0 0.00028750713681802154
disease O 0 0.014952704310417175
onset O 0 1.0037020729214419e-05
and O 0 4.27534496694193e-09
all O 0 2.294231027377691e-09
of O 0 2.769658813406295e-08
the O 0 4.276407494785417e-08
disease O 0 2.1802425465011765e-07
severity O 0 3.852507290957874e-08
scores O 0 1.7612007852108036e-08
assessed O 0 2.5310407991696593e-08
were O 0 3.1415772205889425e-09
noted O 0 1.4883535293108707e-08
in O 0 1.3454209302210529e-08
disease O 0 1.7113805370172486e-05
- O 0 1.014677582134027e-05
concordant O 0 0.00013439016765914857
MZ O 1 0.9984503984451294
twins O 0 6.726360879838467e-06
compared O 0 8.36060451092635e-07
with O 0 2.3494254719480523e-07
concordant O 0 0.00801040232181549
DZ O 1 0.9997683167457581
twins O 0 0.0005677713779732585
. O 0 1.2430022252374329e-05

HLA O 1 0.9679694175720215
- O 0 0.0010486490791663527
B27 O 0 3.837188342004083e-05
and O 0 9.995843441856778e-08
B60 O 0 4.298772182664834e-06
were O 0 9.952806578894524e-09
associated O 0 8.660319572584285e-09
with O 0 7.88942911000845e-10
the O 0 2.867049531118937e-08
disease O 0 1.0490825843589846e-06
in O 0 6.431385646266108e-09
probands O 0 6.262172519200249e-06
, O 0 2.7297308857754388e-09
and O 0 5.584336326691641e-10
the O 0 1.8988490779747735e-09
rate O 0 6.310471434289866e-08
of O 0 2.3202048282655596e-08
disease O 0 5.944846748207055e-07
concordance O 0 6.142401076658643e-08
was O 0 1.832662377410088e-08
significantly O 0 1.354386025553822e-08
increased O 0 3.64072434422269e-08
among O 0 2.7651616107959853e-08
DZ O 0 0.002117319032549858
twin O 0 3.3438814739383815e-07
pairs O 0 1.6647765832544792e-08
in O 0 3.409772686424617e-09
which O 0 4.767234385028019e-10
the O 0 5.030702965314049e-09
co O 0 5.731133569497615e-06
- O 0 1.1326638968967018e-06
twin O 0 5.934441205113217e-08
was O 0 2.6531303376486903e-08
positive O 0 2.6667814623237973e-09
for O 0 1.907179303373141e-09
both O 0 3.096597822604963e-08
B27 O 0 1.2773360140272416e-05
and O 0 1.0523251603444805e-06
DR1 O 1 0.9936502575874329
. O 0 5.7074885262409225e-06

Additive O 0 3.95899633076624e-06
genetic O 0 1.359909674647497e-06
effects O 0 2.6990574042429216e-06
were O 0 3.122069713867859e-08
estimated O 0 3.5143890020350455e-09
to O 0 5.706350947320971e-10
contribute O 0 1.1191521487319278e-08
97 O 0 1.553122928044104e-07
% O 0 9.904194797627497e-09
of O 0 6.5595719966893284e-09
the O 0 3.866934328300431e-09
population O 0 7.863678597175294e-10
variance O 0 6.394582641178204e-08
. O 0 3.043796823476441e-07

CONCLUSION O 0 2.8769165510311723e-05
Susceptibility O 0 1.3107418453728314e-05
to O 0 1.1245083442190662e-07
AS B-Disease 1 0.9125280976295471
is O 0 3.369432377553494e-08
largely O 0 2.11505000180523e-08
genetically O 0 8.983725763300754e-09
determined O 0 6.81576484140578e-09
, O 0 5.48395606703167e-10
and O 0 1.4973411399665792e-10
the O 0 9.99026972259287e-10
environmental O 0 1.4084944766068475e-08
trigger O 0 1.1714194947387568e-08
for O 0 2.525609277270746e-09
the O 0 9.398648614933336e-08
disease O 0 1.5366735169664025e-05
is O 0 2.814127952888157e-08
probably O 0 5.302772478898987e-07
ubiquitous O 0 6.940882940398296e-06
. O 0 8.627873739897041e-07

HLA O 1 0.5156562328338623
- O 0 0.00015032669762149453
B27 O 0 9.137216693488881e-06
accounts O 0 1.7932539009279935e-08
for O 0 3.732224307384513e-09
a O 0 5.9665805629549595e-09
minority O 0 3.648688906565667e-09
of O 0 7.284865599643808e-09
the O 0 5.4413029637601085e-09
overall O 0 1.476239361863918e-07
genetic O 0 4.567249050069222e-07
susceptibility O 0 1.2194152532174485e-06
to O 0 1.413843193631692e-07
AS B-Disease 1 0.9999642372131348
. O 0 3.322661359561607e-05

Cell O 0 0.00016713606601115316
cycle O 0 2.3592738216393627e-06
- O 0 6.727526624672464e-07
dependent O 0 1.689739548282887e-07
colocalization O 0 3.4293721000722144e-06
of O 0 9.649281196288939e-08
BARD1 O 0 0.008819321170449257
and O 0 4.5234937573468414e-08
BRCA1 O 0 1.1304738478656873e-07
proteins O 0 4.423503341399737e-09
in O 0 5.24472065777104e-09
discrete O 0 4.3181063347219606e-07
nuclear O 0 8.26353789307177e-06
domains O 0 4.554176030069357e-06
. O 0 2.2210515453480184e-06

Germ O 1 0.9999784231185913
- O 0 0.00010481728531885892
line O 0 9.104164178097562e-07
mutations O 0 2.4923139108068426e-08
of O 0 1.515758718539928e-08
the O 0 2.488409300838157e-08
BRCA1 O 0 2.435170074477355e-07
gene O 0 9.301010095441598e-08
predispose O 0 6.444981863751309e-07
women O 0 9.881155449420476e-09
to O 0 4.658980312655103e-09
early O 0 2.066740853479132e-05
- O 1 0.9941655397415161
onset O 1 0.9999997615814209
breast B-Disease 1 1.0
and I-Disease 1 0.999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 6.239445156097645e-07
compromising O 0 7.720365101704374e-05
the O 0 2.0299142988733365e-07
genes O 0 2.518578412491479e-07
presumptive O 0 1.4257861039368436e-05
function O 0 1.945527401403524e-07
as O 0 1.674228400361244e-07
a O 0 1.391277464790619e-06
tumor B-Disease 0 0.0005388390272855759
suppressor O 0 0.000257120409514755
. O 0 1.0008660865423735e-05

Although O 0 2.9251791033857444e-07
the O 0 6.817847264528609e-08
biochemical O 0 7.351630415541877e-07
properties O 0 6.191096417751396e-07
of O 0 4.3183905518162646e-07
BRCA1 O 0 1.5363436887128046e-06
polypeptides O 0 1.865272878376345e-07
are O 0 2.263069509567117e-09
not O 0 1.5924930263366832e-09
understood O 0 1.5706628886391627e-08
, O 0 4.445992185519998e-10
their O 0 1.2361060786059141e-10
expression O 0 1.636079938194257e-09
pattern O 0 6.811345709678562e-09
and O 0 1.664772653064972e-09
subcellular O 0 1.0365836260461947e-06
localization O 0 1.335900492449582e-06
suggest O 0 2.507572460785923e-08
a O 0 5.98061777878911e-09
role O 0 3.366008627381234e-08
in O 0 2.3942989813008353e-08
cell O 0 4.373014689917909e-06
- O 0 9.720248499434092e-07
cycle O 0 1.8750215247109736e-07
regulation O 0 1.914069798658602e-06
. O 0 9.534368814456684e-07

When O 0 1.1404352335375734e-05
resting O 0 0.00020712097466457635
cells O 0 1.2646589198084257e-07
are O 0 2.5526134539433087e-09
induced O 0 3.44062982549076e-08
to O 0 1.680020011995964e-09
proliferate O 0 1.2308402119742823e-07
, O 0 2.4973472179112832e-09
the O 0 2.761033623954745e-09
steady O 0 2.0013099799598422e-07
- O 0 5.891716448047646e-09
state O 0 2.522546338479259e-10
levels O 0 2.7282058834288136e-09
of O 0 1.1009437805853395e-09
BRCA1 O 0 3.8228162857478765e-09
increase O 0 7.43125005975287e-10
in O 0 2.20960028052275e-09
late O 0 1.9911912829684297e-07
G1 O 0 3.5312669410814124e-07
and O 0 1.6406797032075815e-09
reach O 0 4.218079219242554e-09
a O 0 2.3379820301983045e-09
maximum O 0 8.24802004473213e-09
during O 0 3.842255225094959e-08
S O 0 8.266085842478788e-07
phase O 0 1.9370679638086585e-06
. O 0 5.970437086944003e-07

Moreover O 0 6.764984391338658e-06
, O 0 7.9885424497661e-08
in O 0 1.9243172388883067e-08
S O 0 1.550540446260129e-06
phase O 0 3.2104337606142508e-06
cells O 0 5.3466667537804824e-08
, O 0 1.0956652474192197e-08
BRCA1 O 0 5.352839949068766e-08
polypeptides O 0 3.97152497555453e-08
are O 0 2.5047983687187525e-09
hyperphosphorylated O 0 2.888401695599896e-07
and O 0 3.507371060251785e-09
accumulate O 0 4.692810406936587e-08
into O 0 1.26075674344861e-08
discrete O 0 3.334137375077262e-07
subnuclear O 0 4.880923825112404e-06
foci O 0 8.159129720297642e-06
termed O 0 1.2503630841820268e-06
" O 0 4.816354817194224e-07
BRCA1 O 0 3.4810191209544428e-06
nuclear O 0 1.095175502996426e-05
dots O 0 5.256848908175016e-06
. O 0 1.6775125004642177e-06

" O 0 0.00010891415149671957
BRCA1 O 0 0.00017139445117209107
associates O 0 4.0463208279106766e-05
in O 0 1.7689515630081587e-07
vivo O 0 3.1246365779225016e-06
with O 0 4.4750080974154116e-08
a O 0 3.070877596655919e-07
structurally O 0 3.5653058148454875e-05
related O 0 1.7853959661806584e-06
protein O 0 3.7500515190913575e-06
termed O 0 5.669379333994584e-06
BARD1 O 0 0.004349909257143736
. O 0 9.036640221893322e-06

Here O 0 3.4615998174558626e-06
we O 0 1.367071433833189e-07
show O 0 2.3132232129796648e-08
that O 0 2.8719723821346577e-10
the O 0 2.6767748018130533e-09
steady O 0 7.987216577021172e-08
- O 0 3.859168096198573e-09
state O 0 2.9568716919392557e-10
levels O 0 7.524044498552485e-09
of O 0 3.895449740554113e-09
BARD1 O 0 2.108286389557179e-05
, O 0 2.5564821370949176e-09
unlike O 0 2.0233856812268414e-09
those O 0 8.722846334130452e-10
of O 0 1.320236275859088e-08
BRCA1 O 0 8.470024681628274e-08
, O 0 4.4158237066938e-09
remain O 0 2.9179480165453242e-08
relatively O 0 5.8315450246482214e-09
constant O 0 2.0545682488659622e-08
during O 0 5.5847682034482204e-08
cell O 0 6.313686071734992e-07
cycle O 0 1.0351259760454923e-07
progression O 0 1.4198712960933335e-06
. O 0 7.027697961348167e-07

However O 0 3.664575842776685e-06
, O 0 4.528405952441972e-07
immunostaining O 0 3.1043451599543914e-05
revealed O 0 1.1411044624765054e-06
that O 0 1.4775401346867056e-08
BARD1 O 0 0.0002624386688694358
resides O 0 4.366500888863811e-06
within O 0 7.100820766936522e-07
BRCA1 O 0 1.508517243564711e-06
nuclear O 0 7.319029464269988e-06
dots O 0 1.25963097730164e-07
during O 0 3.4329797671261986e-08
S O 0 1.5778880424477393e-07
phase O 0 9.286847557632427e-08
of O 0 5.801967351004578e-09
the O 0 8.425307562731632e-09
cell O 0 2.102012217619631e-07
cycle O 0 7.341315555464689e-09
, O 0 8.487303637672028e-10
but O 0 6.712921885032586e-10
not O 0 5.831152782853621e-10
during O 0 1.8804792389914837e-08
the O 0 2.212114402766474e-08
G1 O 0 8.66379286890151e-06
phase O 0 3.877486051351298e-06
. O 0 9.165074743577861e-07

Nevertheless O 0 8.046171569731086e-05
, O 0 2.432584778944147e-06
BARD1 O 0 0.0007739912834949791
polypeptides O 0 1.578163391968701e-06
are O 0 3.966844630554078e-09
found O 0 2.9720887972928267e-09
exclusively O 0 3.0629025982165103e-09
in O 0 4.5941631054979837e-10
the O 0 1.0290344132357632e-09
nuclear O 0 5.1098595577059314e-08
fractions O 0 8.46541770016529e-09
of O 0 3.237965007230059e-09
both O 0 1.1112565090343196e-08
G1 O 0 4.287962838134263e-06
- O 0 2.660711970747798e-07
and O 0 1.364977464390904e-08
S O 0 1.0780546290334314e-05
- O 0 1.3904285651733517e-06
phase O 0 5.633205546473619e-06
cells O 0 4.80243045331008e-07
. O 0 2.830542200626951e-07

Therefore O 0 2.519806457712548e-06
, O 0 9.503924047749024e-08
progression O 0 4.6468153414025437e-07
to O 0 8.871022139089746e-09
S O 0 2.3666427750868024e-06
phase O 0 8.61952685227152e-07
is O 0 2.6478761405712703e-09
accompanied O 0 4.8396868734812415e-09
by O 0 7.417269576315277e-11
the O 0 3.8929667822706904e-10
aggregation O 0 9.13230291388345e-09
of O 0 1.8193928141840843e-08
nuclear O 0 4.53616166851134e-06
BARD1 O 0 4.79494447063189e-05
polypeptides O 0 4.89920466861804e-07
into O 0 2.1438366104575834e-07
BRCA1 O 0 2.7024830160371494e-06
nuclear O 0 1.2555904504552018e-05
dots O 0 3.847125299216714e-06
. O 0 1.5546819440714899e-06

This O 0 3.4590414088597754e-07
cell O 0 3.891648702847306e-06
cycle O 0 2.7474246167003e-07
- O 0 1.5264244268564653e-07
dependent O 0 3.3721583747592376e-08
colocalization O 0 1.7351120504827122e-06
of O 0 1.2615582534181158e-07
BARD1 O 0 0.002871390664950013
and O 0 4.4655099173951385e-08
BRCA1 O 0 1.3917231456161971e-07
indicates O 0 2.776820728911389e-08
a O 0 5.310361039789768e-09
role O 0 1.1682799616608008e-08
for O 0 9.44836031635532e-09
BARD1 O 0 0.003640551585704088
in O 0 5.582567723649845e-07
BRCA1 O 0 2.0962093913112767e-05
- O 0 0.000268508680164814
mediated O 0 0.0013520455686375499
tumor B-Disease 1 0.6011413931846619
suppression O 0 0.019900955259799957
. O 0 1.935081854753662e-05

Ethnic O 0 3.16508248943137e-06
differences O 0 2.808080353133846e-06
in O 0 1.1850123371459631e-07
the O 0 9.102065234856127e-08
HFE O 0 3.672034290502779e-05
codon O 0 1.2963780591235263e-06
282 O 0 9.509809387964197e-06
( O 0 4.396774784254376e-06
Cys O 1 0.9887645244598389
/ O 0 0.015535376034677029
Tyr O 0 0.000496219377964735
) O 0 2.5688116238598013e-06
polymorphism O 0 3.5203509469283745e-05
. O 0 5.254273219179595e-06

Recent O 0 6.88865497977531e-07
studies O 0 2.2914296948783885e-07
have O 0 5.765628863230177e-09
shown O 0 1.1605161631678129e-07
that O 0 4.657507872707356e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 1 0.9630143642425537
HH B-Disease 1 0.9999997615814209
) O 0 9.018664286486455e-07
is O 0 3.015072991274792e-08
likely O 0 1.1431469992828625e-08
to O 0 9.591983873846743e-10
be O 0 2.5015278737328117e-09
caused O 0 8.107239324317561e-09
by O 0 1.0927344584743537e-09
homozygosity O 0 3.030258994840551e-07
for O 0 4.4313481772917385e-09
a O 0 1.7784707040391368e-08
Cys282Tyr O 0 1.2198502190585714e-06
mutation O 0 7.939096491327291e-09
in O 0 5.910354872185053e-09
the O 0 5.9405792285360803e-08
HFE O 0 0.0002861220564227551
gene O 0 1.8916546196123818e-06
located O 0 1.675705675552308e-06
4 O 0 1.0933397788903676e-05
. O 0 4.60958563053282e-06

5 O 0 5.462541594170034e-05
Mb O 0 0.0004276340769138187
telomeric O 0 0.0001110723169404082
to O 0 1.8117194713340723e-06
HLA O 1 0.991391658782959
- O 0 0.003995009232312441
A O 0 5.5660690122749656e-05
. O 0 4.314732905186247e-06

Population O 0 3.0574817344586336e-08
studies O 0 2.3854603625750315e-08
of O 0 8.885364444211064e-09
this O 0 1.3047822822187527e-09
polymorphism O 0 2.994207193296461e-08
are O 0 3.9590944411749263e-10
facilitated O 0 8.100113468856307e-09
by O 0 6.765275006870297e-10
the O 0 1.7205528113350965e-09
fact O 0 3.2434910313128285e-09
that O 0 2.356722317298221e-10
the O 0 2.289898715090999e-09
Cys282Tyr O 0 4.742724399875442e-07
mutation O 0 7.517432010217817e-09
creates O 0 1.534237625833157e-08
a O 0 3.149462557416882e-08
Rsal O 0 2.893380269597401e-06
restriction O 0 2.9540936452576716e-07
site O 0 5.567547987084254e-07
. O 0 6.811334856138274e-07

We O 0 4.6845383394611417e-07
have O 0 4.289516741806665e-09
studied O 0 6.366919080846856e-08
the O 0 5.148794723908168e-09
codon O 0 6.313758404985492e-08
282 O 0 7.178119290074392e-07
( O 0 8.397250326197536e-07
Cys O 1 0.9601059556007385
/ O 0 0.0009141997434198856
Tyr O 0 2.313768709427677e-05
) O 0 2.17901963139866e-08
polymorphism O 0 6.969989385652298e-08
in O 0 2.198635939976157e-09
different O 0 1.6333142616176133e-09
ethnic O 0 3.403251014333364e-08
groups O 0 5.8918089962389786e-08
. O 0 6.83582300098351e-07

In O 0 3.102986454450729e-07
agreement O 0 2.9246854182929383e-07
with O 0 1.3551742839013059e-08
previous O 0 1.522707471224294e-08
observations O 0 2.073112881362249e-08
the O 0 1.0686727058839551e-08
Tyr O 0 4.76889852052409e-07
allele O 0 2.1748093104179134e-08
appeared O 0 5.220939058858676e-08
to O 0 2.162935830440915e-09
be O 0 4.924816554563449e-09
rare O 0 1.7248021677573888e-08
or O 0 1.5465449365592576e-08
absent O 0 7.946233040456718e-07
in O 0 2.1628377311344593e-08
Asiatic O 0 5.763113222201355e-07
( O 0 3.466283926556457e-09
Indian O 0 1.2563061702053346e-08
, O 0 5.393009594456544e-09
Chinese O 0 4.935576924935958e-08
) O 0 7.717883221403099e-09
populations O 0 8.471656798292315e-08
. O 0 4.747394655169046e-07

The O 0 1.7312349598341825e-07
highest O 0 2.0425228797193995e-07
allele O 0 1.1049918313688067e-08
frequency O 0 3.4017585193169e-08
( O 0 1.8680912372559533e-09
7 O 0 1.4883989152281174e-08
. O 0 4.413059639940542e-10
5 O 0 6.8949757014991064e-09
% O 0 1.2089657053238057e-09
) O 0 1.4177711227247869e-09
was O 0 5.469504316124585e-08
found O 0 6.971569543878786e-09
in O 0 1.0555415208557406e-08
Swedes O 0 4.595009613694856e-06
. O 0 1.594772697899316e-06

Saamis O 0 0.0007991109741851687
( O 0 7.075484518281883e-07
2 O 0 1.4592078514397144e-06
% O 0 3.068845444431645e-08
) O 0 4.476354842353203e-09
and O 0 7.845945226847562e-09
Mordvinians O 0 6.014818609401118e-06
( O 0 7.793280687451443e-09
1 O 0 3.176223017931079e-08
. O 0 6.068865965325188e-10
8 O 0 1.6203015817950472e-08
% O 0 3.1347537898795963e-09
) O 0 8.179490418314117e-10
had O 0 2.26931118341156e-09
significantly O 0 2.861966885703282e-09
lower O 0 1.250348979908722e-08
frequencies O 0 1.4414972326903808e-08
of O 0 5.284635840041574e-09
the O 0 2.8137149499229963e-08
Tyr O 0 5.456376584334066e-06
allele O 0 9.154949793810374e-07
. O 0 1.3475726063916227e-06

Comparisons O 0 5.681084758180077e-07
with O 0 1.4972627582210407e-08
allele O 0 1.9212842872207148e-08
frequencies O 0 4.366544814615736e-08
based O 0 6.649121253587964e-09
on O 0 8.183254962546016e-09
prevalence O 0 9.224969232946023e-08
estimates O 0 8.811578133816056e-09
of O 0 4.9583167793798566e-08
HH B-Disease 1 0.5082090497016907
showed O 0 1.370748123008525e-06
some O 0 5.46289102842934e-09
disagreements O 0 2.5057610741896497e-07
with O 0 2.4337054593814855e-09
the O 0 6.2800307176758e-09
RFLP O 0 2.1564453334121936e-07
data O 0 2.8942519492147767e-08
, O 0 7.2144148433039845e-09
particularly O 0 4.336416736805404e-08
in O 0 3.737126874625574e-08
Finns O 0 7.755234946671408e-06
. O 0 3.15477655021823e-06

The O 0 1.9435797184996773e-06
newly O 0 8.03420516604092e-06
described O 0 1.4469231928160298e-06
HFE O 0 6.898236460983753e-05
marker O 0 7.063968610054872e-07
provides O 0 4.6328857195021556e-08
a O 0 6.24739104893024e-09
new O 0 2.5156621230593146e-09
approach O 0 5.041240314085371e-09
to O 0 6.946571651234024e-10
the O 0 1.8044932215133258e-09
screening O 0 2.3933171888756988e-08
of O 0 2.6757195570326076e-08
HH B-Disease 0 0.002925422741100192
as O 0 2.940929100248013e-08
well O 0 3.689150540608921e-09
as O 0 3.0011750862257713e-09
studies O 0 4.3692001128192715e-09
of O 0 5.0315573929538004e-09
the O 0 7.304887805759108e-09
relationship O 0 1.6614878006748768e-07
between O 0 1.0007022410718491e-07
the O 0 4.3323492349145454e-08
HFE O 0 0.0006150203407742083
Tyr O 0 4.514729425864061e-06
allele O 0 1.0948509299169018e-07
and O 0 5.87002313423568e-09
different O 0 2.2737644655990152e-07
disorders O 1 0.9999841451644897
including O 0 0.0008700742619112134
cancer B-Disease 1 0.9999988079071045

Autosomal B-Disease 1 0.9995312690734863
dominant I-Disease 1 0.999998927116394
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9975317716598511
associated O 0 2.2918979993846733e-06
with O 0 3.899555167663493e-08
a O 0 1.8736058393642452e-07
missense O 0 6.720767942169914e-07
mutation O 0 1.85739423841369e-08
encoding O 0 6.591932901756081e-07
Gly23 O 0 0.00014849967556074262
- O 0 3.5114520869683474e-05
- O 0 1.5275416444637813e-05
> O 0 5.970282472844701e-06
Val O 0 1.0129324437002651e-05
in O 0 1.6604327868208202e-07
neurophysin O 0 0.0007964744581840932
II O 1 0.9999978542327881
. O 0 4.330697993282229e-05

Autosomal B-Disease 1 0.9988177418708801
dominant I-Disease 1 0.999998927116394
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999983310699463
( O 0 2.443893754389137e-05
ADNDI B-Disease 1 0.9999427795410156
) O 0 3.226038813863852e-07
is O 0 6.588828682652093e-08
an O 0 5.007610184293299e-07
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.00010337126877857372
by O 0 3.3903006624314003e-07
progressive O 1 0.9999986886978149
degeneration O 1 0.9999997615814209
of O 0 0.00019826095376629382
the O 0 4.788286241819151e-05
magnocellular O 1 0.9663639068603516
neurons O 0 3.4966369639732875e-06
of O 0 6.30634417575493e-07
the O 0 4.867290499532828e-07
hypothalamus O 0 3.572316700228839e-06
leading O 0 7.591755206703965e-07
to O 0 5.57152946001338e-09
decreased O 0 6.440625952564005e-07
ability O 0 1.512876224296633e-08
to O 0 2.427757106460149e-09
produce O 0 6.129092344764331e-09
the O 0 1.740904664870868e-08
hormone O 0 3.070508398650418e-07
arginine O 0 1.239725520463253e-06
vasopressin O 0 1.4920570720278192e-05
( O 0 1.4896791071805637e-06
AVP O 0 0.00034511712146922946
) O 0 2.141498271157616e-06
. O 0 7.031102541077416e-06

Affected O 0 1.0733485851233127e-06
individuals O 0 1.7423696263563215e-08
are O 0 2.6115725137998425e-09
not O 0 2.4156643352313267e-09
symptomatic O 0 6.708178830194811e-07
at O 0 1.1299112401275124e-07
birth O 0 2.6931331831292482e-08
, O 0 2.168797808010936e-09
but O 0 1.5082310955705225e-09
usually O 0 2.0430638514312705e-08
develop O 0 5.393667379394174e-06
diabetes B-Disease 1 0.9993614554405212
insipidus I-Disease 0 0.00038593518547713757
at O 0 1.4609018762712367e-05
1 O 0 3.140838089166209e-05
- O 0 1.1094690307800192e-05
6 O 0 5.702815087715862e-06
yr O 0 3.282656325609423e-05
of O 0 3.760462163882039e-07
age O 0 1.056015298672719e-05
. O 0 4.813527084479574e-06

The O 0 1.110948119276145e-06
genetic O 0 1.0162464150198502e-06
locus O 0 2.7447953243608936e-07
of O 0 1.4423888217152125e-07
the O 0 3.34939329604822e-07
disease O 0 6.628706614719704e-05
is O 0 1.7960880782652566e-08
the O 0 1.340861359722112e-07
AVP O 0 0.0393015593290329
- O 0 0.14318910241127014
neurophysin O 1 0.912086009979248
II O 1 1.0
( O 0 2.9507334602385527e-06
NPII O 0 0.009095264598727226
) O 0 1.463736776230462e-08
gene O 0 2.1235507574601797e-08
, O 0 2.0677688450376763e-09
and O 0 2.8295195075855872e-09
mutations O 0 1.7086691173062718e-08
that O 0 1.3278041999242873e-09
cause O 0 4.424484529863548e-07
ADNDI B-Disease 1 0.8755099773406982
have O 0 1.387001624664208e-08
been O 0 2.9847744276167987e-09
found O 0 4.832065858551005e-10
in O 0 2.080736694054508e-10
both O 0 2.8887561787094285e-10
the O 0 3.9936562390430197e-10
signal O 0 2.4709148505053236e-08
peptide O 0 7.185301686973844e-09
of O 0 5.9450422362772315e-09
the O 0 3.962150429970279e-08
prepro O 0 8.21302819531411e-05
- O 0 0.0002873478806577623
AVP O 0 0.002639027079567313
- O 0 0.0001778047881089151
NPII O 0 0.202513188123703
precursor O 0 6.785072855564067e-06
and O 0 4.4351896377747835e-08
within O 0 7.201672360679368e-07
NPII O 0 0.0496063269674778
itself O 0 5.497625352290925e-06
. O 0 2.779863280011341e-06

An O 0 8.563483220314083e-07
affected O 0 1.8701654198594042e-06
girl O 0 2.1615610421577003e-06
who O 0 2.882809013726728e-08
presented O 0 7.519513900433594e-08
at O 0 1.6048898032750003e-07
9 O 0 1.0772520653290485e-07
months O 0 1.0438870212681195e-08
of O 0 8.124668937625756e-09
age O 0 9.249971100189214e-08
and O 0 7.23486381914995e-09
her O 0 1.0007514816834373e-08
similarly O 0 3.3484823802609753e-08
affected O 0 2.6162702226883994e-08
younger O 0 3.779586279506475e-07
brother O 0 6.766848059669428e-07
and O 0 2.3528441417397516e-08
father O 0 2.745421170402551e-07
were O 0 1.9484271973624345e-08
all O 0 7.449613703691682e-10
found O 0 7.90860821275885e-10
to O 0 7.734040491369498e-11
have O 0 1.1240028352510478e-10
a O 0 8.908302429055936e-10
novel O 0 1.9897830050297216e-09
missense O 0 1.933717719282413e-08
mutation O 0 4.27516555490115e-09
( O 0 1.03668247319888e-08
G1758 O 0 2.5006595478771487e-06
- O 0 5.56214172320324e-06
- O 0 3.2330226531485096e-06
> O 0 1.000644715531962e-06
T O 0 2.3698605389199656e-07
) O 0 6.488825587958047e-10
encoding O 0 3.3960778633712607e-09
the O 0 9.817110457888134e-10
amino O 0 2.4638306950208744e-09
acid O 0 6.732017165944626e-09
substitution O 0 2.5465070052632655e-08
Gly23 O 0 6.096250217524357e-06
- O 0 6.42382656224072e-06
- O 0 4.421567155077355e-06
> O 0 5.163567493582377e-06
Val O 0 6.056104666640749e-06
within O 0 9.263968649975141e-07
NPII O 0 0.019847309216856956
. O 0 5.986948508507339e-06

The O 0 1.3069794704279047e-06
mutation O 0 4.290742197099462e-07
was O 0 2.274790631418e-07
confirmed O 0 2.1143440775972522e-08
by O 0 2.400878384989369e-09
restriction O 0 5.6585591323710105e-08
endonuclease O 0 3.132011443085503e-06
analysis O 0 8.2548831414897e-07
. O 0 1.745764734550903e-06

A O 0 9.550056711304933e-05
T1 O 0 0.0013142982497811317
- O 0 3.749661630081391e-07
weighted O 0 5.340826447763902e-08
magnetic O 0 6.295768173458782e-08
resonance O 0 1.8036378435226652e-07
imaging O 0 1.1675959967760718e-06
of O 0 5.4365546731105496e-08
the O 0 2.3348732725025911e-07
fathers O 0 4.301831268094247e-06
pituitary O 0 5.6129967560991645e-05
gland O 0 1.2757327567669563e-05
demonstrates O 0 2.5684219053800916e-06
an O 0 1.6739761576900491e-07
attenuated O 0 5.9634839999489486e-05
posterior O 0 0.00014202985039446503
pituitary O 0 0.04343454912304878
bright O 0 0.000227789263590239
spot O 0 0.00012555246939882636
. O 0 1.0432070666865911e-05

This O 0 9.131679234997137e-08
mutation O 0 1.3280738642151846e-07
may O 0 2.8723643907824226e-08
be O 0 3.5804383902160453e-09
valuable O 0 3.1550300150229305e-08
for O 0 2.3619617373071833e-09
developing O 0 5.056631380284671e-08
models O 0 1.701086027594556e-08
of O 0 3.1655005727770913e-07
dominantly B-Disease 1 0.9995500445365906
inherited I-Disease 1 1.0
neurodegeneration I-Disease 1 1.0
, O 0 6.780484795854136e-07
as O 0 1.771892144120102e-08
the O 0 2.6467148472875124e-09
early O 0 1.9144875906818015e-08
age O 0 9.897400587988159e-08
of O 0 9.839258297006381e-08
onset O 0 0.0488930270075798
of O 0 1.3397201655607205e-05
symptoms O 0 0.011998472735285759
suggests O 0 7.501664356368565e-08
that O 0 6.59385102075305e-10
this O 0 8.128277495522696e-10
mutation O 0 1.066534682792053e-08
may O 0 5.777925693450925e-09
be O 0 4.103207551509058e-09
particularly O 0 1.8440019289300835e-08
deleterious O 0 1.0690563811976972e-07
to O 0 5.133458547135206e-09
the O 0 1.0876866696207799e-07
magnocellular O 0 0.00016257338575087488
neuron O 0 5.678924480889691e-06
. O 0 3.1828852797843865e-07
. O 0 1.1019368457709788e-06

Frequent O 0 5.1393180910963565e-06
inactivation O 0 0.00023887651332188398
of O 0 2.6613402951625176e-05
PTEN O 1 0.9986300468444824
/ O 0 0.06400143355131149
MMAC1 O 1 0.9928950667381287
in O 0 1.9989438442280516e-06
primary O 1 0.9999178647994995
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0004154705675318837

Sporadic B-Disease 1 0.999997615814209
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 1.0016767646447988e-06
the O 0 3.469368436981313e-08
most O 0 1.2898770052061082e-08
common O 0 1.2706065888323792e-07
male B-Disease 0 6.7131718424207065e-06
cancer I-Disease 0 0.0003022694436367601
in O 0 3.266351455977201e-08
the O 0 7.696952764035814e-08
Western O 0 7.653429747733753e-07
world O 0 2.6360305938055717e-08
, O 0 1.2040501928822778e-09
yet O 0 7.92650334258127e-10
many O 0 1.1583163594952595e-10
of O 0 7.711375982211166e-10
the O 0 1.0460451393967674e-09
major O 0 1.627754464550435e-08
genetic O 0 5.6689701821710514e-09
events O 0 1.7312117295276153e-09
involved O 0 8.380624194614938e-09
in O 0 1.6262887703177853e-09
the O 0 7.622208642033002e-09
progression O 0 1.6464903751511883e-07
of O 0 1.1572266700454747e-08
this O 0 4.653074814342517e-09
often O 0 1.6933773849814315e-07
fatal O 0 0.0015124111669138074
cancer B-Disease 0 0.00022357446141541004
remain O 0 1.7902008266901248e-06
to O 0 2.8461164092163926e-08
be O 0 5.365345714380965e-07
elucidated O 0 0.000319781742291525
. O 0 5.256227723293705e-06

Numerous O 0 2.517058874218492e-06
cytogenetic O 0 0.00013045109517406672
and O 0 2.2394291931959742e-07
allelotype O 0 0.00023948014131747186
studies O 0 2.301550239280914e-07
have O 0 4.049359958457899e-09
reported O 0 7.80202569217181e-09
frequent O 0 5.594445351420063e-09
loss O 0 3.110384483306916e-08
of O 0 1.4796898994973162e-07
heterozygosity O 0 0.1231444850564003
on O 0 6.009933713357896e-06
chromosomal O 0 0.0005943725700490177
arm O 0 4.169630483374931e-05
10q O 0 0.00015795954095665365
in O 0 1.6910338445086381e-06
sporadic B-Disease 1 0.9999011754989624
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0005983111332170665

Deletion O 0 1.412710207659984e-05
mapping O 0 2.2279907625488704e-06
studies O 0 2.4601277459623816e-07
have O 0 1.1525918885979536e-08
unambiguously O 0 2.3386192538055184e-07
identified O 0 6.811556119146189e-08
a O 0 2.58720085355435e-08
region O 0 1.7131866059116874e-07
of O 0 9.522286603669272e-08
chromosome O 0 8.373946229767171e-07
10q23 O 0 1.0959892051687348e-06
to O 0 2.2041111158443982e-09
be O 0 2.281167033046927e-09
the O 0 1.9264536632590534e-09
minimal O 0 2.3991796638256346e-07
area O 0 1.3963843059627834e-07
of O 0 2.030638341921076e-07
loss O 0 1.1410248589527328e-05
. O 0 9.928226972988341e-06

A O 0 1.1304719919280615e-05
new O 0 5.470546966535039e-07
tumor B-Disease 0 2.310300260432996e-05
suppressor O 0 8.45693466544617e-06
gene O 0 1.0193708703809534e-06
, O 0 5.475191642290156e-07
PTEN O 1 0.7436143159866333
/ O 0 0.13819573819637299
MMAC1 O 1 0.9999656677246094
, O 0 2.582852687282866e-07
was O 0 1.1752910040740971e-06
isolated O 0 2.331508852648767e-07
recently O 0 2.9313973470834753e-08
at O 0 1.7111021932691983e-08
this O 0 4.0968556325182703e-10
region O 0 1.3571115786703558e-08
of O 0 1.9417120356024498e-08
chromosome O 0 3.8490847487082647e-07
10q23 O 0 6.737826083735854e-07
and O 0 2.9841766835403405e-09
found O 0 1.920312575620642e-09
to O 0 1.912252300950712e-10
be O 0 1.991422304836732e-10
inactivated O 0 3.939714332545918e-09
by O 0 8.855290806186744e-11
mutation O 0 6.611457492589068e-10
in O 0 3.1084610441212135e-09
three O 0 2.3624281766387867e-06
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9996368885040283
lines O 0 9.112768020713702e-05
. O 0 3.06543415717897e-06

We O 0 1.8465786979504628e-06
screened O 0 1.9098495613434352e-05
80 O 0 4.207689198665321e-05
prostate B-Disease 1 0.9998471736907959
tumors I-Disease 1 0.9999897480010986
by O 0 1.9882779866975397e-08
microsatellite O 0 2.2978861125011463e-06
analysis O 0 3.490967515062948e-08
and O 0 7.33728411361767e-09
found O 0 3.890654554083994e-08
chromosome O 0 2.6608873326949833e-07
10q23 O 0 7.387425284832716e-07
to O 0 5.4176911845615905e-09
be O 0 5.431897598384694e-09
deleted O 0 5.297010474691888e-08
in O 0 1.1321587223278584e-08
23 O 0 2.6948600861942396e-07
cases O 0 5.0777973825688605e-08
. O 0 3.674122126540169e-07

We O 0 7.194190061454719e-07
then O 0 7.051382766576353e-08
proceeded O 0 4.730518909923376e-08
with O 0 2.755707884105618e-10
sequence O 0 5.571207939425449e-10
analysis O 0 7.596065998427548e-10
of O 0 1.331395105275135e-09
the O 0 7.98672594726213e-09
entire O 0 1.7485873513578554e-06
PTEN O 0 0.003149273805320263
/ O 0 4.2164861952187493e-05
MMAC1 O 0 0.003290556138381362
coding O 0 1.0143669896933716e-05
region O 0 1.416091350847637e-07
and O 0 4.558048605218801e-09
tested O 0 1.0626968638405287e-08
for O 0 1.2873790922185435e-09
homozygous O 0 2.08601171891587e-08
deletion O 0 3.896878553177885e-08
with O 0 1.9184234201219397e-09
new O 0 1.9906002179936877e-08
intragenic O 0 6.151514753582887e-06
markers O 0 9.788120536313727e-08
in O 0 3.301576345648982e-09
these O 0 7.585757022532391e-10
23 O 0 2.3995884390615174e-08
cases O 0 1.0855178977919877e-09
with O 0 3.4116331981692838e-09
10q23 O 0 3.5482203202263918e-06
loss O 0 1.8992502646142384e-06
of O 0 7.445049504894996e-06
heterozygosity O 1 0.9912609457969666
. O 0 5.556766700465232e-05

The O 0 2.6808288566826377e-07
identification O 0 2.4452651814499404e-07
of O 0 4.1332782529934775e-08
the O 0 2.085546313423947e-08
second O 0 9.651710541902503e-08
mutational O 0 7.331998403969919e-07
event O 0 3.142777416087483e-08
in O 0 1.491960333055431e-08
10 O 0 4.383250384876192e-08
( O 0 7.759330067358405e-09
43 O 0 2.1982708631185233e-07
% O 0 4.2357419260952156e-07
) O 0 3.6731798900291324e-06
tumors B-Disease 1 1.0
establishes O 0 0.00704168900847435
PTEN O 1 0.9996762275695801
/ O 0 0.07875402271747589
MMAC1 O 0 0.19192031025886536
as O 0 1.1080060602353115e-07
a O 0 2.1351054257934265e-08
main O 0 3.1387042298547385e-08
inactivation O 0 1.4807034176556044e-07
target O 0 5.0296380393888285e-09
of O 0 6.6417951138930675e-09
10q O 0 2.122264731951873e-06
loss O 0 4.4751536165676953e-07
in O 0 1.4648630042302102e-07
sporadic B-Disease 1 0.9979281425476074
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.877597009704914e-06
. O 0 7.481368811568245e-06

Risk O 0 3.560140612535179e-05
reversals O 0 9.185776434605941e-06
in O 0 4.605793080258991e-08
predictive O 0 4.2662566102080746e-07
testing O 0 4.029980402719957e-07
for O 0 7.2240941335621756e-06
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.00012098500155843794

The O 0 1.064921093529847e-07
first O 0 3.000776160888563e-08
predictive O 0 1.8703994442148542e-07
testing O 0 2.0591433269601112e-07
for O 0 4.252038252161583e-06
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.6124420199048473e-06
HD B-Disease 0 0.3685443103313446
) O 0 1.813274685957822e-08
was O 0 3.335281562044656e-08
based O 0 3.036440543446872e-10
on O 0 6.38246455686442e-10
analysis O 0 5.905608224665571e-10
of O 0 2.1849324571832085e-09
linked O 0 4.584381230188228e-08
polymorphic O 0 6.235893579287222e-08
DNA O 0 8.95322926908193e-08
markers O 0 1.9807341544719748e-08
to O 0 7.196434559375575e-10
estimate O 0 3.845912033284549e-09
the O 0 2.9776436871742362e-09
likelihood O 0 4.35491713801639e-08
of O 0 2.2949368627678268e-08
inheriting O 0 2.2543731859059335e-07
the O 0 2.0213152041037574e-08
mutation O 0 2.3829775486206017e-08
for O 0 1.2566098916977353e-07
HD B-Disease 0 0.0012827066238969564
. O 0 9.497464816377033e-06

Limits O 0 1.8637720700098726e-07
to O 0 4.9516795108672795e-09
accuracy O 0 1.1051925241645222e-07
included O 0 8.657775829590264e-09
recombination O 0 2.3598644816047454e-08
between O 0 1.508099423119802e-08
the O 0 1.2629348233872406e-08
DNA O 0 5.895698862445897e-08
markers O 0 1.5951080456488853e-08
and O 0 1.439092733868108e-09
the O 0 6.165757238107972e-09
mutation O 0 8.266004769552637e-09
, O 0 4.335595882309917e-09
pedigree O 0 7.243538391321636e-08
structure O 0 4.4164875134811155e-07
, O 0 4.8222354998017636e-09
and O 0 7.105325772194249e-10
whether O 0 1.0710515807588195e-09
DNA O 0 2.4338864257344994e-09
samples O 0 5.612397768750554e-10
were O 0 8.379788529744303e-10
available O 0 4.612586312902067e-09
from O 0 1.1137370137248581e-08
family O 0 2.3657637626683936e-08
members O 0 2.431192136498339e-08
. O 0 7.763595135656942e-07

With O 0 1.2739457133648102e-07
direct O 0 5.964830762650308e-08
tests O 0 5.778840073134006e-09
for O 0 8.211456514750637e-10
the O 0 4.2190766436078775e-09
HD B-Disease 0 1.6223049897234887e-05
mutation O 0 1.940449578796688e-08
, O 0 1.071529642793223e-09
we O 0 7.278528890708458e-10
have O 0 9.538323603175414e-11
assessed O 0 2.4602289094843854e-09
the O 0 1.4861592512183108e-10
accuracy O 0 3.5145364396527157e-09
of O 0 5.024112792462176e-10
results O 0 3.067841536363858e-10
obtained O 0 1.1213866502046699e-09
by O 0 3.7015679410501434e-10
linkage O 0 4.439446499304722e-08
approaches O 0 2.5024741390211602e-08
when O 0 2.24157270523051e-09
requested O 0 8.079823032858258e-09
to O 0 1.1807033128974354e-09
do O 0 1.0197146460555473e-09
so O 0 6.958997822437141e-10
by O 0 5.248460555051793e-10
the O 0 3.105794288416064e-09
test O 0 1.1557840906561978e-08
individuals O 0 9.223470875951989e-09
. O 0 7.714089065302687e-07

For O 0 1.4162169748033193e-07
six O 0 1.433461171984618e-08
such O 0 1.4794767633219408e-09
individuals O 0 9.307498660682256e-10
, O 0 3.1948867995623687e-09
there O 0 3.0239810655530164e-09
was O 0 2.544967792061925e-08
significant O 0 1.4068513465304022e-08
disparity O 0 2.845986841748527e-07
between O 0 2.378187069496107e-08
the O 0 2.9534421130961164e-08
tests O 0 1.0635995550956068e-07
. O 0 2.290195340037826e-07

Three O 0 9.387178465658508e-07
went O 0 1.3166651342544355e-06
from O 0 3.943746307299989e-08
a O 0 1.8510709409724768e-08
decreased O 0 7.578085359227771e-08
risk O 0 5.859150498110921e-09
to O 0 1.3289030986740613e-10
an O 0 2.9788127520191665e-10
increased O 0 9.868705852511539e-09
risk O 0 2.9209379803774027e-08
, O 0 7.259686740646032e-10
while O 0 1.57829294078482e-09
in O 0 5.243247502839665e-10
another O 0 8.766881109956159e-10
three O 0 3.876739484987013e-10
the O 0 3.332107256781569e-09
risk O 0 1.4713762652718287e-07
was O 0 4.4825256395597535e-07
decreased O 0 4.288204308977583e-06
. O 0 1.447676936550124e-06

Knowledge O 0 2.8465065042837523e-05
of O 0 3.2053324616754253e-07
the O 0 4.323607072365121e-08
potential O 0 4.033590172980439e-08
reasons O 0 2.8493629677939225e-09
for O 0 3.024360206715926e-10
these O 0 4.473977091579151e-11
changes O 0 4.2004466571654575e-10
in O 0 1.6009342462819376e-10
results O 0 1.9376773796597746e-10
and O 0 1.1282019762859363e-10
impact O 0 2.8504121285521933e-09
of O 0 8.978856547159353e-10
these O 0 3.0291172348206885e-10
risk O 0 2.880522487203052e-08
reversals O 0 1.6783801015662903e-07
on O 0 2.2251862574762526e-08
both O 0 9.38112787451928e-09
patients O 0 1.3592720726762764e-08
and O 0 2.9047249050506707e-09
the O 0 2.011749700159271e-08
counseling O 0 7.613754604562928e-08
team O 0 6.614690128969869e-09
can O 0 5.380657031039959e-10
assist O 0 9.11879638465507e-09
in O 0 9.647046494976053e-10
the O 0 1.2182245212599696e-09
development O 0 3.647812274465423e-09
of O 0 3.775188606169877e-09
strategies O 0 6.984599565384997e-09
for O 0 9.197430594909406e-10
the O 0 5.066002728426611e-09
prevention O 0 6.061190447326226e-07
and O 0 1.2340383159781254e-09
, O 0 1.4278882520812886e-09
where O 0 2.390929898510308e-09
necessary O 0 3.9386797823226516e-08
, O 0 3.3872022964231974e-09
management O 0 2.7754705200777607e-08
of O 0 9.308923409889758e-09
a O 0 2.346641458927934e-08
risk O 0 4.3238628677499946e-08
reversal O 0 3.227779998837832e-08
in O 0 1.8257709788471743e-09
any O 0 1.985321018693753e-09
predictive O 0 2.716570612903979e-08
testing O 0 2.6693783183873165e-08
program O 0 3.153597916139006e-08
. O 0 1.4018744387556126e-08
. O 0 4.2925066168209014e-07

A O 0 1.0229927283944562e-05
novel O 0 4.216545335111732e-07
common O 0 1.277347223549441e-07
missense O 0 2.651615659488016e-06
mutation O 0 6.064890811785517e-08
G301C O 0 1.1001980055880267e-06
in O 0 5.185258888928956e-09
the O 0 1.7505476179735524e-08
N O 0 6.888438292662613e-06
- O 0 2.0291490727686323e-06
acetylgalactosamine O 0 1.0389429007773288e-05
- O 0 3.3287469705101103e-06
6 O 0 3.0013140985829523e-06
- O 0 1.9875933503499255e-06
sulfate O 0 3.28356532008911e-06
sulfatase O 0 2.768995000224095e-05
gene O 0 3.6394160929376085e-07
in O 0 3.88558987651777e-07
mucopolysaccharidosis B-Disease 0 0.003349417122080922
IVA I-Disease 1 0.9999951124191284
. O 0 0.0001022071301122196

Mucopolysaccharidosis B-Disease 1 0.9986135959625244
IVA I-Disease 1 0.9999994039535522
( O 0 0.0035512365866452456
MPS B-Disease 1 0.9999978542327881
IVA I-Disease 1 1.0
) O 0 5.927664687987999e-07
is O 0 2.198972559597223e-08
an O 0 2.7577719663440803e-08
autosomal B-Disease 1 0.911498486995697
recessive I-Disease 1 0.9999634027481079
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 7.816714060027152e-05
by O 0 2.5342481890788804e-08
a O 0 1.8949588138639228e-06
genetic B-Disease 1 0.9998867511749268
defect I-Disease 1 0.999950647354126
in O 0 6.434339070438e-07
N O 0 0.22097912430763245
- O 0 0.0035049605648964643
acetylgalactosamine O 0 0.001187046873383224
- O 0 7.902198558440432e-05
6 O 0 8.27555195428431e-05
- O 0 8.250818063970655e-05
sulfate O 0 0.00040779367554932833
sulfatase O 0 0.019721202552318573
( O 0 4.535322204901604e-06
GALNS O 0 0.07857092469930649
) O 0 1.9399335542402696e-06
. O 0 2.8863771603937494e-06

In O 0 9.089037433795966e-08
previous O 0 5.4113531433586104e-08
studies O 0 5.399722979859689e-08
, O 0 3.4454286090834785e-09
we O 0 1.0614847889556245e-09
have O 0 1.6335190144989298e-10
found O 0 2.720306202519396e-10
two O 0 7.196499646200394e-11
common O 0 1.1712334435642902e-09
mutations O 0 4.386978780246409e-09
in O 0 7.318694095204137e-09
Caucasians O 0 1.1370531893817315e-07
and O 0 9.543283496782351e-09
Japanese O 0 2.552209480199963e-06
, O 0 1.0846661524510637e-07
respectively O 0 1.7220135077877785e-06
. O 0 9.879819344860152e-07

To O 0 9.841413657341036e-07
characterize O 0 2.216841676272452e-05
the O 0 5.099782356410287e-07
mutational O 0 6.613137520616874e-05
spectrum O 0 2.4784135348454583e-06
in O 0 9.87222659176723e-09
various O 0 3.2256552984222253e-09
ethnic O 0 1.3001002940882245e-08
groups O 0 1.413752892531761e-09
, O 0 7.136129465123986e-10
mutations O 0 1.4735093145645806e-09
in O 0 6.771135874217293e-10
the O 0 5.920622658805996e-09
GALNS O 0 2.2845157218398526e-05
gene O 0 5.982799677894945e-08
in O 0 2.6864174884622116e-08
Colombian O 0 1.2439816600817721e-05
MPS B-Disease 1 0.9999990463256836
IVA I-Disease 1 1.0
patients O 0 0.00017823034431785345
were O 0 1.9306190779388999e-07
investigated O 0 1.329865085608617e-06
, O 0 4.59581306344603e-09
and O 0 3.0450777455115485e-09
genetic O 0 6.406119013036005e-08
backgrounds O 0 4.494717131819925e-08
were O 0 8.37146973964309e-09
extensively O 0 9.321111882343303e-09
analyzed O 0 2.8475592994681165e-09
to O 0 9.612161760985671e-11
identify O 0 9.93103266289097e-10
racial O 0 7.4333090793743395e-09
origin O 0 2.2381720921060833e-09
, O 0 5.120996404706091e-10
based O 0 5.112310574872936e-10
on O 0 4.600277048183443e-09
mitochondrial O 0 5.1385352861643696e-08
DNA O 0 9.837194170358998e-08
( O 0 1.5051913493380198e-08
mtDNA O 0 1.1686771017593856e-07
) O 0 1.981191957156625e-07
lineages O 0 2.8734987154166447e-06
. O 0 6.282624781306367e-06

Three O 0 6.460674057962024e-07
novel O 0 8.604340564488666e-07
missense O 0 6.557630968018202e-06
mutations O 0 2.1626030388688378e-07
never O 0 8.08209179581354e-08
identified O 0 4.089692495767849e-08
previously O 0 2.2324430304365706e-08
in O 0 1.0472068767697351e-09
other O 0 2.1221802093407405e-10
populations O 0 2.2814052036412846e-10
and O 0 2.660165698831207e-10
found O 0 1.1796407184405666e-09
in O 0 9.451599503051966e-10
16 O 0 1.279321715230708e-08
out O 0 7.236654608888671e-10
of O 0 8.775618454137657e-09
19 O 0 3.585921604098985e-07
Colombian O 0 2.152433808078058e-06
MPS B-Disease 1 0.9185250401496887
IVA I-Disease 1 0.9999998807907104
unrelated O 0 2.171074811485596e-06
alleles O 0 4.134461306648518e-08
account O 0 1.8393896183965808e-08
for O 0 4.458411950736263e-08
84 O 0 8.341589818883222e-06
. O 0 6.207843398442492e-06

2 O 0 4.053156226291321e-05
% O 0 5.089443106953695e-07
of O 0 7.942855972942198e-08
the O 0 1.521720349728639e-08
alleles O 0 7.61792051662269e-09
in O 0 3.783875435203754e-09
this O 0 3.044688945408325e-09
study O 0 6.933248641871614e-08
. O 0 4.346705964053399e-07

The O 0 2.2956432985665742e-06
G301C O 0 2.2791431547375396e-05
and O 0 7.435736648631064e-08
S162F O 0 3.469899183983216e-06
mutations O 0 3.406680093576142e-08
account O 0 2.387016806437714e-08
for O 0 5.295768090718411e-08
68 O 0 1.1296906450297683e-05
. O 0 5.4146435104485136e-06

4 O 0 1.5821486158529297e-05
% O 0 7.341576520047965e-07
and O 0 4.0950718016574683e-07
10 O 0 3.1130250590649666e-06
. O 0 1.810601816032431e-06

5 O 0 4.597280167217832e-06
% O 0 1.9694971342687495e-07
of O 0 7.643583899152873e-08
mutations O 0 5.8913709466423825e-08
, O 0 8.023782527288859e-09
respectively O 0 4.957257360160838e-08
, O 0 4.236826001147165e-09
whereas O 0 1.311714825646959e-08
the O 0 5.4755240341819444e-09
remaining O 0 4.142039529142494e-07
F69V O 0 3.96842006011866e-05
is O 0 2.745824678740405e-09
limited O 0 1.7684269604245628e-09
to O 0 8.357441960704648e-10
a O 0 7.150602776562209e-09
single O 0 2.082795447222452e-08
allele O 0 1.95231123711892e-07
. O 0 6.783809567423305e-07

The O 0 3.0565377073799027e-07
skewed O 0 4.963133051205659e-07
prevalence O 0 8.175518360076239e-07
of O 0 5.959554627565922e-08
G301C O 0 1.2147040706622647e-06
in O 0 6.9481522757541825e-09
only O 0 2.3015549466265384e-09
Colombian O 0 5.530156954591803e-08
patients O 0 8.238052018327835e-09
and O 0 1.3411927124451495e-09
haplotype O 0 3.810733417708434e-08
analysis O 0 2.652698949390242e-09
by O 0 4.677926379592634e-10
restriction O 0 5.863756147306276e-09
fragment O 0 1.6729156726569272e-08
length O 0 8.078774982323011e-09
polymorphisms O 0 3.81952389716389e-08
in O 0 3.83539289217083e-09
the O 0 1.6233547839306084e-08
GALNS O 0 6.248783756745979e-05
gene O 0 7.797164869316475e-08
suggest O 0 2.6052257240394283e-08
that O 0 2.9213320651422237e-09
G301C O 0 1.0235938816549606e-06
originated O 0 6.02062115717672e-08
from O 0 9.58196810785239e-09
a O 0 2.457224290708382e-08
common O 0 1.0915564274682765e-07
ancestor O 0 3.599696356104687e-06
. O 0 2.5698750505398493e-06

Investigation O 0 7.91340607975144e-06
of O 0 2.12577219826926e-07
the O 0 2.9474769291937264e-08
genetic O 0 2.4060412329163228e-08
background O 0 3.100865342275938e-08
by O 0 5.88059823058984e-10
means O 0 1.1672108612970078e-08
of O 0 1.4049340357757956e-08
mtDNA O 0 2.9324207062586538e-08
lineages O 0 1.2738432531023136e-08
indicate O 0 5.6539062320837274e-09
that O 0 2.339229920877983e-10
all O 0 6.715265565837569e-10
our O 0 1.0497652525032208e-08
patients O 0 1.3535906617789806e-08
are O 0 2.787043096308395e-10
probably O 0 7.614826991186874e-09
of O 0 7.040844351990927e-09
native O 0 7.108260291488477e-08
American O 0 1.6284117236864404e-06
descent O 0 0.0001930732250912115

Low O 0 1.7243536376554403e-06
frequency O 0 7.59920226300892e-07
of O 0 2.795420925849612e-07
BRCA1 O 0 1.0612160394884995e-06
germline O 0 1.2901385844088509e-06
mutations O 0 1.658308512730855e-08
in O 0 1.0808863137867775e-08
45 O 0 3.8491876352964027e-07
German O 1 0.9999873638153076
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.154091271222569e-05
. O 0 2.5965475288103335e-05

In O 0 1.560058393579311e-07
this O 0 7.485338571200373e-09
study O 0 9.804110412403588e-09
we O 0 3.2122768889308873e-09
investigated O 0 6.918598671745713e-08
45 O 0 1.9959691144322278e-07
German O 1 0.988477885723114
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.9220971359554824e-08
for O 0 6.812712882720007e-08
germline O 0 8.381285624636803e-06
mutations O 0 3.9409489005493015e-08
in O 0 8.346167312822672e-09
the O 0 1.0791316640279547e-07
BRCA1 O 0 4.171586624579504e-06
gene O 0 1.7124397118095658e-06
. O 0 3.0307730867207283e-06

We O 0 5.2233491487641e-07
identified O 0 4.075194794950221e-07
four O 0 4.334184211529646e-08
germline O 0 2.044991560978815e-06
mutations O 0 4.245321960638648e-08
in O 0 1.1523193954587896e-08
three O 0 1.538529801337063e-07
breast B-Disease 1 0.9777628779411316
cancer I-Disease 0 0.0008791214786469936
families O 0 9.49221257151578e-10
and O 0 4.344627324570638e-09
in O 0 2.2132413235453896e-08
one O 0 4.767657628690358e-06
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.0016539476346224546
. O 0 1.4938482451043456e-08
among O 0 1.3667822429397347e-09
these O 0 8.432120557344547e-10
were O 0 7.606523411141097e-09
one O 0 3.990718866475618e-09
frameshift O 0 4.0420704294774623e-07
mutation O 0 8.274365193017275e-09
, O 0 2.3889286104861185e-09
one O 0 2.7134052782429308e-09
nonsense O 0 4.1359331248713715e-07
mutation O 0 1.4673706694168231e-08
, O 0 3.3237919083717316e-09
one O 0 9.019261448806049e-10
novel O 0 5.6245959001444135e-09
splice O 0 5.8620369003392625e-08
site O 0 1.1172668124004304e-08
mutation O 0 5.292745797191856e-09
, O 0 4.8361621374226615e-09
and O 0 5.91273430217143e-09
one O 0 1.3663493803051097e-07
missense O 0 2.566765215306077e-05
mutation O 0 2.9083687422826188e-06
. O 0 4.199595878162654e-06

The O 0 1.6199498986679828e-06
missense O 0 1.7864140318124555e-05
mutation O 0 1.7765408699688123e-07
was O 0 5.092725245958718e-07
also O 0 1.220271617086155e-08
found O 0 1.249457426411027e-08
in O 0 2.3138937876865384e-08
2 O 0 3.0102060009085108e-06
. O 0 1.65929611739557e-06

8 O 0 8.842172064760234e-06
% O 0 1.7434973642593832e-07
of O 0 4.126645691826525e-08
the O 0 9.597735939337326e-09
general O 0 2.3951074012984463e-08
population O 0 5.526946122991205e-10
, O 0 1.0258929261652838e-09
suggesting O 0 4.052520097275192e-09
that O 0 1.1180523173948131e-10
it O 0 1.6674094049928812e-10
is O 0 6.29290564102547e-10
not O 0 3.4877714050196573e-09
disease O 0 8.060076197580202e-07
associated O 0 1.2682364740612684e-06
. O 0 1.7992103948927252e-06

The O 0 3.080777446484717e-07
average O 0 2.394544083017536e-07
age O 0 6.697490562146413e-07
of O 0 4.7607423425688467e-07
disease O 0 0.000888767302967608
onset O 0 2.016060534515418e-05
in O 0 1.3341769466990172e-08
those O 0 4.702709333059829e-09
families O 0 3.6627529897970135e-09
harbouring O 0 5.371348834160017e-06
causative O 0 4.344085027696565e-06
mutations O 0 3.749128723029571e-07
was O 0 2.1911325802648207e-06
between O 0 3.407841631997144e-06
32 O 0 4.1131592297460884e-05
. O 0 1.2777612028003205e-05

3 O 0 3.223177918698639e-05
and O 0 2.4256514734588563e-06
37 O 0 5.853932088939473e-05
. O 0 7.855507647036575e-06

4 O 0 1.8415808881400153e-05
years O 0 8.141525427163288e-07
, O 0 3.332566222979949e-08
whereas O 0 3.361055789241618e-08
the O 0 1.821094031129178e-08
family O 0 2.7226240817412872e-08
harbouring O 0 2.5478320822003298e-06
the O 0 1.8643831367626262e-08
missense O 0 9.861801117949653e-07
mutation O 0 4.0789345234770735e-08
had O 0 1.7844476118966668e-08
an O 0 1.65370872551307e-09
average O 0 3.5957270494435534e-09
age O 0 5.618209186764034e-08
of O 0 1.1523187026796222e-07
onset O 0 0.0001065254255081527
of O 0 6.879312877572374e-06
51 O 0 0.00014649076911155134
. O 0 1.3609627785626799e-05

2 O 0 0.0002803429961204529
years O 0 2.8643426048802212e-05
. O 0 1.9302122382214293e-05

These O 0 1.1346689632318885e-07
findings O 0 1.768276973734828e-07
show O 0 9.515495946743613e-08
that O 0 4.791685714877758e-09
BRCA1 O 0 2.552498585828289e-07
is O 0 8.630209435978031e-09
implicated O 0 5.2656723426025565e-08
in O 0 2.0942909628729467e-09
a O 0 2.4679884802480956e-09
small O 0 2.89407942055675e-09
fraction O 0 3.8836258653418554e-08
of O 0 2.2870117390993983e-06
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.492248161293901e-08
suggesting O 0 9.695310154711478e-08
the O 0 4.697240818529735e-09
involvement O 0 6.029584653788334e-08
of O 0 2.820936728653578e-08
another O 0 9.861353333917577e-08
susceptibility O 0 2.845079734470346e-06
gene O 0 2.260841483803233e-06
( O 0 1.0384516144767986e-06
s O 0 5.659499583998695e-05
) O 0 2.3731161491014063e-05

Paternal O 0 0.014529801905155182
transmission O 1 0.9997331500053406
of O 1 0.9999653100967407
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.9994961023330688

We O 0 6.233033786884334e-07
report O 0 3.644802859525953e-08
a O 0 7.4143207129395705e-09
rare O 0 2.883285832311344e-09
case O 0 5.8395479562989294e-09
of O 0 6.071372382621121e-08
paternally O 1 0.9997859597206116
transmitted O 1 0.9999998807907104
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999936819076538
DM B-Disease 1 1.0
) O 0 0.00013675661466550082
. O 0 2.1580763132078573e-05

The O 0 1.8159694263886195e-06
proband O 0 6.179628690006211e-05
is O 0 6.856605239136115e-08
a O 0 2.387508679646544e-08
23 O 0 5.969701533103944e-08
year O 0 5.7413216403290335e-09
old O 0 1.9818223790935008e-06
, O 0 1.069661607289163e-06
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 1 0.9667565822601318
who O 0 0.11220277845859528
suffers O 1 0.9999997615814209
severe O 1 1.0
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 1 0.5972331762313843

He O 0 2.5747615381988e-06
presented O 0 1.5367305650215712e-06
with O 0 4.593703692989948e-07
respiratory O 1 0.9999357461929321
and O 0 4.097751400422567e-07
feeding O 0 2.0170593870716402e-06
difficulties O 0 7.3100445661111735e-06
at O 0 1.0432338058308233e-05
birth O 0 3.940178430639207e-06
. O 0 1.7857229295259458e-06

His O 0 8.615083970653359e-06
two O 0 6.370761639118427e-06
sibs O 1 0.9973909854888916
suffer O 0 0.00011317899043206125
from O 0 7.448082214978058e-06
childhood O 1 0.9941741824150085
onset O 1 0.9999984502792358
DM B-Disease 1 1.0
. O 0 0.0008605471812188625

Their O 0 9.825006230812505e-08
late O 0 1.279015759791946e-05
father O 0 1.0706148714234587e-06
had O 0 2.2978408509288784e-08
the O 0 6.763278825872021e-09
adult O 0 1.7064316182313632e-08
type O 0 4.727244728996993e-08
of O 0 3.919199969004694e-07
DM B-Disease 1 1.0
, O 0 1.029314020684069e-07
with O 0 1.5508460293744974e-08
onset O 0 0.0003202710940968245
around O 0 1.6555058834910596e-07
30 O 0 7.092211831150053e-07
years O 0 2.2412773148516862e-07
. O 0 7.072536050145573e-07

Only O 0 1.4377729939951678e-07
six O 0 1.7719663958359888e-08
other O 0 5.966122595957302e-10
cases O 0 6.886192727151297e-10
of O 0 5.952371928685807e-09
paternal O 0 6.4669893617974594e-06
transmission O 1 0.8829760551452637
of O 1 0.9488879442214966
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 0.0001483756786910817
been O 0 1.3224058648120263e-06
reported O 0 2.8426558174032834e-07
recently O 0 6.563372494383657e-07
. O 0 6.248311024137365e-07

We O 0 1.8460717399193527e-07
review O 0 3.105677492953873e-08
the O 0 2.9311666427389582e-09
sex O 0 9.874825401823273e-09
related O 0 4.1114023296984215e-09
effects O 0 7.223339792972183e-08
on O 0 1.3583046154508338e-07
transmission O 0 3.8867121475050226e-05
of O 0 1.120985052693868e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9803984761238098

Decreased O 0 5.916463123867288e-05
fertility O 0 6.759638381481636e-06
of O 0 7.486598718742243e-08
males O 0 1.9708156884234995e-08
with O 0 2.6682686282697432e-08
adult O 0 6.250711521715857e-06
onset O 1 0.9730255603790283
DM B-Disease 1 1.0
and O 0 2.9620971986332734e-07
contraction O 0 8.835941116558388e-07
of O 0 5.0633875758876457e-08
the O 0 1.0843285380701673e-08
repeat O 0 4.1299607289602136e-08
upon O 0 9.46390699141375e-09
male O 0 4.616408588731247e-08
transmission O 0 9.895192221165416e-08
contribute O 0 2.5547077786569616e-09
to O 0 4.3669737270768394e-10
the O 0 1.694113960226673e-09
almost O 0 4.634226780098061e-09
absent O 0 9.626702990317426e-09
occurrence O 0 4.254471441811347e-09
of O 0 1.3722945446659196e-08
paternal O 0 1.5464381704077823e-06
transmission O 0 0.0003259537334088236
of O 0 0.00033675270969979465
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.987032413482666

Also O 0 8.544761271878087e-07
the O 0 1.2303237895139318e-07
fathers O 0 2.69030238086998e-07
of O 0 4.638712880478124e-08
the O 0 3.770174927808512e-08
reported O 0 6.683695801257272e-07
congenitally O 0 1.125329526985297e-05
affected O 0 3.245423485509491e-08
children O 0 5.851556128533275e-09
showed O 0 2.056254189142237e-08
, O 0 2.217004801963185e-09
on O 0 8.39116420792152e-09
average O 0 1.2387791237244983e-08
, O 0 6.59137766589879e-09
shorter O 0 2.7204316666029627e-07
CTG O 0 1.6074329323600978e-05
repeat O 0 2.804440839554445e-07
lengths O 0 5.145950581209036e-07
and O 0 2.136795185236906e-09
hence O 0 1.9990126887137194e-08
less O 0 3.825181238426012e-08
severe O 0 1.4991393300078926e-06
clinical O 0 1.4729881741004647e-06
symptoms O 0 4.862873765887343e-07
than O 0 2.0673625034106635e-09
the O 0 1.4556099436902059e-08
mothers O 0 3.750694688164913e-08
of O 0 2.7566990468130825e-08
children O 0 1.0406986916677852e-07
with O 0 1.834121394495014e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9987881779670715

We O 0 1.4494838751488714e-06
conclude O 0 4.0506242839910556e-06
that O 0 2.3336214738378658e-08
paternal O 0 4.591776814777404e-06
transmission O 0 0.012065129354596138
of O 0 0.07111550122499466
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 4.762095613841666e-06
rare O 0 1.089532588594011e-07
and O 0 3.549804672431378e-09
preferentially O 0 1.823356576835522e-08
occurs O 0 4.549692622646262e-09
with O 0 2.2538897415103065e-09
onset O 0 9.694414620753378e-05
of O 0 1.2101253560103942e-05
DM B-Disease 1 1.0
past O 0 1.8747941794572398e-06
30 O 0 3.9087632330847555e-07
years O 0 1.1764372587208527e-08
in O 0 2.3142014971000435e-09
the O 0 1.0192485078164282e-08
father O 0 7.254045897298056e-08
. O 0 2.9533349987787005e-08
. O 0 8.713815304872696e-07

The O 0 3.9203878259286284e-06
RB1 O 0 0.00037541246274486184
gene O 0 3.0215329616112285e-07
mutation O 0 7.161224147012035e-08
in O 0 1.3307155377617619e-08
a O 0 4.521009699942624e-08
child O 0 4.373342221697385e-07
with O 0 1.3246652770249057e-06
ectopic B-Disease 1 0.9999877214431763
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 0.9999984502792358
. O 0 0.0003505876229610294

The O 0 1.710364449536428e-05
RB1 O 0 0.0011429806472733617
gene O 0 7.637352155143162e-07
mutation O 0 1.9725159461358999e-07
was O 0 3.7728841562056914e-07
investigated O 0 6.184616268001264e-07
in O 0 1.599891952253074e-08
a O 0 5.168338290673091e-08
child O 0 1.4057427222269325e-07
with O 0 1.4494158051547856e-07
ectopic B-Disease 1 0.9953179359436035
intracranial I-Disease 1 0.9999969005584717
retinoblastoma I-Disease 0 0.00578678771853447
using O 0 6.926521223249438e-08
DNA O 0 7.913489241673233e-08
obtained O 0 2.399666421126767e-08
from O 0 4.2234247210615194e-09
both O 0 4.602901171324447e-09
the O 0 1.0097018332544394e-07
pineal B-Disease 0 0.005327430088073015
and I-Disease 0 3.991679477621801e-06
retinal I-Disease 1 0.9999985694885254
tumours I-Disease 1 1.0
of O 0 0.00033972092205658555
the O 0 2.830589801305905e-05
patient O 0 0.00036410277243703604
. O 0 1.1658216862997506e-05

A O 0 7.2626817200216465e-06
nonsense O 0 5.420326942839893e-06
mutation O 0 7.070480023685377e-08
in O 0 4.466105707479073e-08
exon O 0 2.580853333711275e-06
17 O 0 1.9192741262941126e-07
( O 0 9.753342133933529e-09
codon O 0 7.139512092635414e-08
556 O 0 5.4956050377086285e-08
) O 0 4.431855327169387e-09
of O 0 3.335071596666239e-08
the O 0 9.65804574093454e-08
RB1 O 0 0.0005336132016964257
gene O 0 3.121206759715278e-07
was O 0 6.246119141906092e-07
found O 0 7.599330054119946e-09
to O 0 4.194137814828025e-10
be O 0 9.650689136719848e-10
present O 0 8.218810521043451e-09
homozygously O 0 4.37196376879001e-06
in O 0 1.3363925965848011e-08
both O 0 6.44885300715714e-09
the O 0 2.3719897157548075e-08
retinal B-Disease 0 1.833047645050101e-05
and I-Disease 0 1.899477268807459e-07
the I-Disease 0 2.2123451344668865e-05
pineal I-Disease 1 0.9999454021453857
tumours I-Disease 1 1.0
. O 0 0.00019849171803798527

The O 0 2.8037803190272825e-07
same O 0 5.853009810152798e-08
mutation O 0 2.7758570553260142e-08
was O 0 3.6492476596095e-08
present O 0 1.499391899528746e-08
heterozygously O 0 1.0952849152090494e-06
in O 0 1.876909294651341e-09
the O 0 2.503451668189882e-09
DNA O 0 8.28459789659064e-09
from O 0 6.325033830023585e-10
the O 0 1.017620210319592e-09
constitutional O 0 1.1073426975372058e-07
cells O 0 3.408810345106872e-09
of O 0 2.4857182978621495e-09
the O 0 5.422322590931117e-09
patient O 0 3.6559079319431476e-08
, O 0 4.9087804931957635e-09
proving O 0 4.331506886501302e-07
it O 0 2.1853480136613257e-10
to O 0 4.391505492584713e-10
be O 0 2.8090318959783644e-09
of O 0 6.278236241996638e-08
germline O 0 4.983816324966028e-06
origin O 0 9.222556514032476e-07
. O 0 2.2133547190605896e-06

The O 0 1.49468107224493e-07
initial O 0 7.45869144225253e-08
mutation O 0 2.6953633991411152e-08
was O 0 1.2015689776490035e-07
shown O 0 9.177493431877792e-09
to O 0 1.4717930207908125e-09
have O 0 2.1946642281278628e-09
occurred O 0 4.489867322376995e-08
in O 0 1.727896492553782e-09
the O 0 7.800553092351947e-09
paternally O 0 8.889688842828036e-07
derived O 0 2.5859583274723263e-07
RB1 O 0 9.084916382562369e-05
allele O 0 5.397300355980406e-06
. O 0 5.327911821950693e-06

The O 0 3.413331342017045e-07
mutation O 0 4.2190791305074526e-08
is O 0 3.4123361913884764e-09
in O 0 1.1349905459923093e-09
an O 0 6.634524041260192e-10
area O 0 1.6141694203497536e-08
of O 0 1.0220595036969371e-08
the O 0 9.437265191536426e-09
gene O 0 7.678107927233668e-09
that O 0 4.068247128063973e-10
encodes O 0 2.710834223762504e-09
the O 0 3.969440331985652e-09
protein O 0 2.3857424480411282e-08
- O 0 1.24456720485e-08
binding O 0 8.191672229429514e-09
region O 0 5.597255636757836e-08
known O 0 1.4893161370821417e-08
as O 0 8.449092980811201e-09
the O 0 4.517647766988375e-08
pocket O 0 0.020849114283919334
region O 0 1.257621988770552e-06
and O 0 2.0002406841967968e-08
has O 0 2.4862163439109963e-09
been O 0 1.7969028487385685e-09
detected O 0 8.623349145864267e-09
in O 0 4.2200404282155546e-10
other O 0 2.5368862566210737e-10
cases O 0 5.179229489726822e-09
of O 0 1.0355505963843825e-07
retinoblastoma B-Disease 0 0.0002981497091241181
. O 0 3.496499516586482e-07
. O 0 3.487784624667256e-06

Low O 0 2.285816890434944e-06
levels O 0 3.0814976526016835e-07
of O 0 5.436989880536203e-08
beta O 0 6.092230364629359e-07
hexosaminidase O 0 5.418373348220484e-06
A O 0 9.905256348474722e-08
in O 0 4.988155666296734e-09
healthy O 0 1.4776556866991086e-08
individuals O 0 2.6606528091832615e-10
with O 0 1.6061260765809493e-08
apparent O 0 0.029953040182590485
deficiency O 1 0.9999728202819824
of O 0 6.732701422151877e-06
this O 0 4.025148427899694e-07
enzyme O 0 4.841535883315373e-06
. O 0 1.7902194713315112e-06

Appreciable O 0 0.00014316085434984416
beta O 0 3.87879554182291e-05
hexosaminidase O 0 0.00021689738787245005
A O 0 6.284086794039467e-06
( O 0 4.6994031777103373e-08
hex O 0 8.142728802340571e-07
A O 0 1.5701948541391175e-07
) O 0 6.632869808953501e-09
activity O 0 3.653182290008772e-08
has O 0 2.716393110446802e-09
been O 0 3.294832406908199e-09
detected O 0 3.681912019715128e-08
in O 0 8.577302423873334e-09
cultured O 0 2.8283554911467945e-06
skin O 0 4.146847459196579e-06
fibroblasts O 0 2.7058099476562347e-06
and O 0 9.458367458137218e-07
melanoma B-Disease 1 0.9999586343765259
tissue O 0 6.857762491563335e-05
from O 0 4.254839325312787e-07
healthy O 0 8.241730711233686e-07
individuals O 0 3.9563712306289744e-09
previously O 0 1.9339084644798277e-07
reported O 0 2.918170594057301e-08
as O 0 1.4470701081847892e-08
having O 0 4.925058760818501e-07
deficiency B-Disease 0 0.0003926552308257669
of I-Disease 0 1.8379348887265223e-07
hex I-Disease 0 6.400256893357437e-07
A I-Disease 0 4.59127704743878e-08
activity O 0 8.850048693886947e-09
indistinguishable O 0 1.5846401524299836e-08
from O 0 3.67021302238868e-10
that O 0 8.243229709936628e-11
of O 0 3.886462263125168e-09
patients O 0 4.024690980486412e-08
with O 0 2.4792461772449315e-05
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
( O 0 5.019668969907798e-05
TSD B-Disease 1 0.9998351335525513
) O 0 4.845286639465485e-06
. O 0 4.44343868366559e-06

Identification O 0 5.35402159584919e-06
and O 0 4.693361290719622e-07
quantitation O 0 0.0004841902118641883
of O 0 1.7854709994935547e-06
hex O 0 1.4653643120254856e-05
A O 0 1.91730327969708e-06
, O 0 2.1610151890172347e-08
amounting O 0 1.870169370477015e-07
to O 0 3.5090991445940745e-08
3 O 0 2.836356316038291e-06
. O 0 8.667088309266546e-07

5 O 0 3.751858093892224e-05
% O 0 1.0981227205775212e-05
- O 0 7.799157174304128e-05
6 O 0 2.8633812689804472e-05
. O 0 4.822716164198937e-06

9 O 0 9.028594831761438e-06
% O 0 8.82283330838618e-08
of O 0 2.92317317018842e-08
total O 0 1.1963271262516173e-08
beta O 0 3.299806223822088e-07
hexosaminidase O 0 8.52769801440445e-07
activity O 0 4.265540454184702e-08
, O 0 1.4773393619549324e-09
has O 0 4.738966996598037e-10
been O 0 2.3811849714228117e-10
obtained O 0 1.5771433048428207e-09
by O 0 2.022282119540364e-09
cellulose O 0 1.8831407260222477e-06
acetate O 0 8.67585470132326e-07
gel O 0 1.0461119927640539e-05
electrophoresis O 0 1.0272433428326622e-05
, O 0 5.11001530867361e-07
DEAE O 1 0.9017690420150757
- O 0 5.956310633337125e-05
cellulose O 0 3.1643634429201484e-05
ion O 0 1.4986938367655966e-05
- O 0 1.7792972357710823e-06
exchange O 0 2.547559915910824e-06
chromatography O 0 3.319235111121088e-05
, O 0 2.4706274359687086e-08
radial O 0 1.0505182217457332e-06
immunodiffusion O 0 1.2311727914493531e-05
, O 0 4.446268064839387e-08
and O 0 6.74253115562351e-08
radioimmunoassay O 0 0.00014272361295297742
. O 0 3.508187091938453e-06

Previous O 0 6.676447810605168e-06
family O 0 5.098318638374622e-07
studies O 0 1.558968278914108e-07
suggested O 0 4.542809506347112e-08
that O 0 1.541284044836999e-10
these O 0 1.9749565871585162e-10
individuals O 0 4.6294537647817435e-10
may O 0 5.7132254482894496e-09
be O 0 1.7712085131904587e-09
compound O 0 3.2321295861947874e-08
heterozygotes O 0 5.0330761780514877e-08
for O 0 1.2127995274724412e-09
the O 0 3.6334246722447006e-09
common O 0 2.208290972305349e-08
mutant O 0 7.938339763313706e-07
TSD B-Disease 0 5.5897075071698055e-05
gene O 0 5.059361996018197e-08
and O 0 3.9252157080227335e-09
a O 0 2.2297832913409366e-08
rare O 0 8.903045767283402e-08
( O 0 3.9677090057921305e-08
allelic O 0 1.956435653482913e-06
) O 0 2.11582104725494e-07
mutant O 0 3.23445669891953e-06
gene O 0 4.098000317753758e-06
. O 0 4.499856459005969e-06

Thus O 0 3.943711817555595e-06
, O 0 9.115964871853066e-08
the O 0 3.6843005091213854e-08
postulated O 0 4.4447335767472396e-07
rate O 0 6.189076628970724e-08
mutant O 0 1.7574459221236793e-08
gene O 0 9.293595226722573e-09
appears O 0 7.338431640135923e-09
to O 0 1.3579906643634843e-10
code O 0 7.268567414620009e-10
for O 0 5.345917042376414e-10
the O 0 1.0515140980160709e-09
expression O 0 3.892961508711323e-09
of O 0 4.401948139332035e-09
low O 0 3.345290622291941e-08
amounts O 0 1.482316314138643e-08
of O 0 5.0292761955006426e-08
hex O 0 3.7439945117512252e-06
A O 0 4.735385118692648e-06
. O 0 2.4801040581223788e-06

Heterozygotes O 0 4.895609527011402e-05
for O 0 1.0710075315500944e-07
the O 0 6.701503707517986e-08
rare O 0 2.3089788214747387e-07
mutant O 0 2.4079105287455604e-07
may O 0 1.5605339243052185e-08
be O 0 2.7991267081972637e-09
indistinguishable O 0 8.144502317009028e-08
from O 0 7.251055311741084e-09
heterozygotes O 0 1.909084232920577e-07
for O 0 3.7346312709019e-09
the O 0 1.890548873006992e-08
common O 0 3.8163420867931563e-07
TSD B-Disease 0 0.014902519062161446
mutant O 0 1.3835603567713406e-05
. O 0 3.8403291000577156e-06

However O 0 1.788412419045926e-06
, O 0 7.451667016766805e-08
direct O 0 8.364849435338328e-08
visualization O 0 2.3096115455700783e-06
and O 0 4.3779195380011515e-08
quantitation O 0 0.0026328733656555414
of O 0 1.1500180789880687e-06
hex O 0 4.863202320848359e-06
A O 0 6.924975082256424e-08
by O 0 3.6560227067994333e-10
the O 0 5.819075776791749e-10
methods O 0 1.1239310815369663e-08
described O 0 7.809410007553197e-09
may O 0 1.285955786300974e-09
prevent O 0 3.1935343258737703e-09
false O 0 5.824142057520021e-09
- O 0 1.8625099684754787e-08
positive O 0 2.430736278924428e-09
prenatal O 0 2.2203792582331516e-07
diagnosis O 0 4.315632224916044e-07
of O 0 2.2611318684084836e-07
TSD B-Disease 1 0.9759706258773804
in O 0 2.3327321230226516e-07
fetuses O 0 1.9143165275181673e-07
having O 0 2.533494303236239e-08
the O 0 6.191754664541804e-09
incomplete O 0 1.300808918358598e-07
hex B-Disease 0 4.906423782813363e-06
A I-Disease 0 1.6201729522435926e-05
deficiency I-Disease 1 0.7419642806053162
of O 0 2.736248916335171e-07
the O 0 6.36925108210562e-08
type O 0 6.131180271040648e-06
described O 0 4.685521304281792e-08
in O 0 4.443798662379095e-09
the O 0 1.1256087617539379e-08
four O 0 1.2432984419774584e-07
healthy O 0 2.059572807411314e-06
individuals O 0 1.0315619647371932e-06

The O 0 6.649936949543189e-06
tumor B-Disease 0 0.0010582196991890669
suppressor O 0 6.12140356679447e-05
gene O 0 2.2308056486508576e-06
Smad4 O 0 0.0003780042170546949
/ O 0 2.9451044611050747e-05
Dpc4 O 0 2.7267922632745467e-05
is O 0 6.227475868314514e-09
required O 0 3.5718303870169166e-09
for O 0 4.6631942751673705e-09
gastrulation O 0 1.2643973832382471e-06
and O 0 2.4244206642265453e-09
later O 0 1.6952494519273387e-08
for O 0 3.221541700071384e-09
anterior O 0 5.149278763383336e-07
development O 0 1.837293410744678e-07
of O 0 2.923062538684462e-07
the O 0 4.989904596186534e-07
mouse O 0 3.268609589213156e-06
embryo O 0 1.1293569741610554e-06
. O 0 1.5738332876935601e-06

Mutations O 0 3.3533865462231915e-06
in O 0 1.9888665292455698e-07
the O 0 5.139770564710489e-07
SMAD4 O 1 0.9997187256813049
/ O 1 0.9388838410377502
DPC4 O 1 0.999677300453186
tumor B-Disease 0 0.0020940995309501886
suppressor O 0 1.57696249516448e-05
gene O 0 1.5560540589376615e-07
, O 0 2.272409105330553e-08
a O 0 3.2713767694758644e-08
key O 0 1.212506049341755e-06
signal O 0 1.2484674698498566e-06
transducer O 0 8.252459338109475e-07
in O 0 9.328634753558163e-09
most O 0 1.3797982312269141e-08
TGFbeta O 0 6.505885266960831e-06
- O 0 2.9536232659665984e-07
related O 0 4.850798163147374e-08
pathways O 0 4.318274804404609e-08
, O 0 1.8574430882267734e-09
are O 0 8.113294064360232e-11
involved O 0 4.434601297287344e-10
in O 0 2.9140295731977517e-10
50 O 0 5.956847015653466e-09
% O 0 5.1586077631782246e-08
of O 0 9.598920769349206e-06
pancreatic B-Disease 1 1.0
cancers I-Disease 1 0.9999880790710449
. O 0 5.340702409739606e-05

Homozygous O 0 0.00021478961571119726
Smad4 O 0 0.0034656180068850517
mutant O 0 0.0001580416428623721
mice O 0 1.1472442565718666e-05
die O 0 1.9430144675425254e-06
before O 0 4.3797743387585797e-07
day O 0 3.794386032041075e-07
7 O 0 2.9267157515278086e-06
. O 0 1.8114827753379359e-06

5 O 0 2.3887512725195847e-05
of O 0 1.1471579455246683e-05
embryogenesis O 0 0.0004515087930485606
. O 0 2.2660680770059116e-05

Mutant O 0 1.385418090649182e-05
embryos O 0 1.708179553361333e-07
have O 0 4.827471311585896e-09
reduced O 0 3.291272676619883e-08
size O 0 1.0916518355941207e-08
, O 0 3.6550973359084082e-09
fail O 0 1.4407963710993954e-08
to O 0 1.911432789825085e-09
gastrulate O 0 2.4326359380211215e-06
or O 0 1.2905562840614948e-08
express O 0 6.4473892891214746e-09
a O 0 1.0669679362251827e-08
mesodermal O 0 5.294682523526717e-07
marker O 0 3.6214194665262767e-07
, O 0 3.285853367174241e-08
and O 0 2.517319508399396e-08
show O 0 7.504067980335094e-07
abnormal O 0 4.14714031649055e-06
visceral O 0 3.9713242586003616e-05
endoderm O 0 0.0003782915009651333
development O 0 1.4472321709035896e-05
. O 0 7.404003554256633e-06

Growth B-Disease 1 0.9999440908432007
retardation I-Disease 1 0.9999986886978149
of O 0 2.13485463973484e-06
the O 0 7.028166919553769e-07
Smad4 O 0 0.06931546330451965
- O 0 2.4818957172101364e-05
deficient O 0 2.2451631593867205e-06
embryos O 0 3.15366843750553e-09
results O 0 1.0678224970916972e-09
from O 0 1.5639508577081074e-09
reduced O 0 7.586299233253158e-08
cell O 0 3.108377200078394e-07
proliferation O 0 1.6494827548285684e-07
rather O 0 1.9359940317542623e-09
than O 0 1.1708537472898684e-09
increased O 0 7.077037622593707e-08
apoptosis O 0 4.6813461267447565e-06
. O 0 6.339714673231356e-07

Aggregation O 0 4.556526619126089e-06
of O 0 9.384547183799441e-07
mutant O 0 6.364980436046608e-06
Smad4 O 0 0.0007525620167143643
ES O 0 4.780954623129219e-05
cells O 0 3.506677259679236e-08
with O 0 5.47284084717603e-09
wild O 0 2.690447864495127e-08
- O 0 1.889915068886694e-07
type O 0 3.374919401721854e-07
tetraploid O 0 4.881682798441034e-06
morulae O 0 4.2636973375920206e-05
rescues O 0 6.798791218898259e-06
the O 0 7.828598427295219e-07
gastrulation B-Disease 0 0.001083260984160006
defect I-Disease 0 0.0009989974787458777
. O 0 2.6138815883314237e-05

These O 0 1.179232356207649e-07
results O 0 5.8396512514491405e-08
indicate O 0 5.062518226850443e-08
that O 0 2.8789666206563425e-09
Smad4 O 0 9.679416734797996e-07
is O 0 1.27486832202095e-09
initially O 0 1.941592664422842e-09
required O 0 6.825361942297548e-10
for O 0 3.389307168255584e-10
the O 0 9.736164097162714e-10
differentiation O 0 4.739080239346549e-08
of O 0 1.7369446325687932e-08
the O 0 3.614625043724118e-08
visceral O 0 1.6799876902950928e-06
endoderm O 0 8.820416951493826e-06
and O 0 5.683434167735868e-09
that O 0 5.387568169368251e-10
the O 0 6.986824452326346e-09
gastrulation B-Disease 0 5.7839979490381666e-06
defect I-Disease 0 3.994529151896131e-07
in O 0 7.341511398806233e-09
the O 0 3.370460532892139e-08
epiblast O 0 2.8048847525496967e-05
is O 0 4.461369940145232e-09
secondary O 0 1.0813424466959987e-07
and O 0 7.036494498180446e-09
non O 0 7.217263828351861e-06
- O 0 5.918917668168433e-05
cell O 0 1.0164509149035439e-05
autonomous O 0 1.2522914403234608e-06
. O 0 1.294791672989959e-06

Rescued O 0 0.0009123116033151746
embryos O 0 1.2728281035379041e-05
show O 0 4.497072040976491e-06
severe O 0 2.6521584004512988e-05
anterior O 0 4.7839508624747396e-05
truncations O 1 0.7450099587440491
, O 0 1.6066999819486227e-07
indicating O 0 3.381098281352024e-07
a O 0 1.9258374450714655e-08
second O 0 7.530331913585542e-09
important O 0 1.2953256245396005e-08
role O 0 5.5647994656737865e-08
for O 0 2.442127744473055e-08
Smad4 O 0 4.797071233042516e-05
in O 0 3.145878793020529e-07
anterior O 0 4.462741708266549e-05
patterning O 0 0.0006794102373532951
during O 0 0.00018085229385178536
embryogenesis O 0 0.0003570897097233683
. O 0 1.5343948689405806e-05

Prevalence O 0 4.676296521211043e-05
of O 0 1.035761442835792e-06
p16 O 0 8.000320121936966e-06
and O 0 1.0604739486552717e-07
CDK4 O 0 0.004163855221122503
germline O 0 1.1511029697430786e-05
mutations O 0 1.8107454025084735e-07
in O 0 6.930815743544372e-08
48 O 0 9.140145994024351e-05
melanoma B-Disease 1 0.9999997615814209
- O 0 0.42620959877967834
prone O 0 0.0002245713403681293
families O 0 2.1579385389713934e-08
in O 0 2.214267880162879e-07
France O 0 8.879963388608303e-06
. O 0 2.1166174519748893e-06

The O 0 2.242700020360644e-06
French O 0 0.0013184099225327373
Familial B-Disease 1 0.9997430443763733
Melanoma I-Disease 1 0.9999992847442627
Study O 0 4.39152381659369e-06
Group O 0 1.2795775319318636e-06
. O 0 2.5831188850133913e-06

Germline O 0 0.0003530201793182641
mutations O 0 1.0360241731177666e-06
in O 0 6.349202408273413e-08
the O 0 5.7718814616691816e-08
p16 O 0 2.5552856186550343e-06
and O 0 3.874917098301012e-08
CDK4 O 0 0.3435082733631134
genes O 0 4.835915845546879e-08
have O 0 1.0878724587826127e-09
been O 0 1.3140881716111608e-09
reported O 0 1.0405468708896137e-09
in O 0 1.608727456803294e-10
a O 0 8.861800182558e-10
subset O 0 2.278059341165317e-08
of O 0 1.1957470746892795e-07
melanoma B-Disease 0 0.1965971142053604
pedigrees O 0 4.325409577177197e-07
, O 0 2.7536077862322372e-09
but O 0 3.337741194542332e-10
their O 0 4.5138362492203044e-10
prevalence O 0 1.357855268224739e-07
is O 0 1.114822567593876e-09
not O 0 9.819040025504933e-10
well O 0 1.5905692762885337e-08
known O 0 1.8027435544354375e-07
. O 0 7.790756058057013e-07

We O 0 8.114852221297042e-07
searched O 0 1.0573751296760747e-06
for O 0 4.018422039564484e-09
such O 0 6.221966497577114e-09
germline O 0 7.623969509040762e-07
mutations O 0 2.988792147107233e-08
in O 0 2.0903133446381617e-08
48 O 0 2.7013647923013195e-06
French O 1 0.9874703288078308
melanoma B-Disease 1 0.9999998807907104
- O 0 0.03627392649650574
prone O 0 9.319172022514977e-06
families O 0 1.1612724115650508e-09
selected O 0 3.4391913761311343e-09
according O 0 6.388956586000916e-10
to O 0 1.4879263099398798e-10
two O 0 3.753754251878405e-10
major O 0 1.1244972064616832e-08
criteria O 0 1.629276447090433e-08
families O 0 2.1510242198541363e-10
with O 0 5.321237339650509e-10
at O 0 3.893059741244542e-08
least O 0 1.7002904639795702e-09
three O 0 6.376660866003192e-10
affected O 0 8.56853366038024e-10
members O 0 9.901527375788532e-10
( O 0 2.103193619262811e-09
n O 0 9.265580303008392e-08
= O 0 1.208768338756272e-07
20 O 0 7.693357417792868e-08
) O 0 2.490630368612301e-09
or O 0 2.845984781174593e-09
families O 0 5.352099874400551e-10
with O 0 7.240962274224216e-10
two O 0 2.692751577271224e-09
affected O 0 2.7469457819506715e-09
members O 0 7.615693631279896e-10
, O 0 5.791040980085427e-10
one O 0 3.4591096653713294e-10
of O 0 1.2523245773721214e-09
them O 0 5.566980210147676e-10
affected O 0 1.1475635997015843e-09
before O 0 1.277882022421295e-09
the O 0 3.894912448121346e-10
age O 0 3.8164125193418386e-09
of O 0 3.4952167826673985e-09
50 O 0 8.5958262729946e-09
( O 0 9.38309319131747e-10
n O 0 3.131647829945905e-08
= O 0 3.270833914825744e-08
28 O 0 1.0288056984109062e-07
) O 0 2.424966449865451e-09
, O 0 8.668594730920631e-10
and O 0 4.806090525555362e-10
one O 0 4.851996582289075e-10
additional O 0 4.647255913425852e-09
minor O 0 1.679615934335743e-06
criterion O 0 0.00014313410792965442
. O 0 5.017758212488843e-06

Sixteen O 0 7.388203812297434e-06
different O 0 3.612743739722646e-07
p16 O 0 2.2307367544271983e-05
germline O 0 1.3783503163722344e-05
mutations O 0 2.0976587222776288e-07
were O 0 4.8892349724383166e-08
found O 0 1.0603400824038545e-08
in O 0 4.286433430422676e-09
21 O 0 9.825492952586501e-08
families O 0 1.4192808039936722e-09
, O 0 1.8194509232571932e-09
while O 0 6.728025248037284e-09
one O 0 7.0430732357351644e-09
germline O 0 5.496395942827803e-07
mutation O 0 5.40906235357852e-08
, O 0 1.888084177892324e-08
Arg24His O 0 6.376913006533869e-06
, O 0 1.0729331201275727e-08
was O 0 7.142686087036054e-08
detected O 0 6.957305487276244e-08
in O 0 6.057859547325961e-09
the O 0 3.893223166073767e-08
CDK4 O 0 0.0002664430649019778
gene O 0 3.032377662748331e-06
. O 0 1.932525265146978e-06

The O 0 1.5074387249569554e-07
frequency O 0 6.595441846002359e-07
of O 0 1.0039752140755809e-07
p16 O 0 7.061570954647323e-07
gene O 0 5.2361276203782836e-08
mutation O 0 9.41728828252053e-09
in O 0 1.3043444102578405e-09
our O 0 1.8277185320769718e-09
sample O 0 2.958119971196993e-09
( O 0 1.4163601402827908e-09
44 O 0 2.0998477623379586e-08
% O 0 1.1371102281998446e-08
) O 0 3.821970295803112e-09
is O 0 1.0024053809232214e-09
among O 0 4.5428050210460924e-10
the O 0 6.213283221256916e-10
highest O 0 3.3581020630890634e-08
rates O 0 2.8638796223390273e-08
yet O 0 3.2478986167205903e-09
reported O 0 2.4082715821549527e-09
and O 0 1.7384541028953038e-10
the O 0 1.600089505338076e-09
CDK4 O 0 8.169086868292652e-06
mutation O 0 2.0294190772318643e-09
is O 0 3.069937082322838e-10
the O 0 4.429664413052592e-10
second O 0 3.013674643170816e-09
mutation O 0 2.272980026418736e-09
detected O 0 1.295765450493036e-08
in O 0 7.439290850008717e-10
this O 0 8.858183631055283e-10
gene O 0 4.19286259045748e-08
worldwide O 0 1.0253949511707106e-07
. O 0 1.3659914657182526e-06

In O 0 1.4535370382873225e-06
summary O 0 2.3259576664713677e-06
, O 0 1.575622832206136e-08
our O 0 1.0106224301864586e-08
results O 0 6.009685193930636e-09
show O 0 4.589471025440162e-09
frequent O 0 3.6929663771445576e-09
involvement O 0 4.022557575922292e-08
of O 0 1.9456937394579654e-08
the O 0 3.188617725413678e-08
p16 O 0 6.118208943917125e-07
gene O 0 7.551493297341949e-08
in O 0 1.0392447080675993e-07
familial B-Disease 0 0.14277195930480957
melanoma I-Disease 1 0.9999289512634277
and O 0 9.047266757988837e-08
confirm O 0 1.369131723549799e-07
the O 0 8.238020043904726e-09
role O 0 6.86695784679614e-08
of O 0 2.0011565737831916e-08
the O 0 2.058993509024276e-08
CDK4 O 0 7.38104063202627e-05
gene O 0 3.4872076781766737e-08
as O 0 2.1462602362021244e-08
a O 0 6.909426133461238e-07
melanoma B-Disease 1 0.9997784495353699
- O 0 0.0014481001999229193
predisposing O 0 6.349524483084679e-05
gene O 0 2.01057764570578e-06
. O 0 4.5229506895339e-07
. O 0 4.606848051480483e-06

Progression O 0 0.00017145265883300453
of O 0 9.200627573591191e-06
somatic O 0 7.04267222317867e-05
CTG O 0 0.0005638024304062128
repeat O 0 9.069300972441852e-07
length O 0 3.1999256577819324e-08
heterogeneity O 0 1.9461731426417828e-07
in O 0 3.5195810710320075e-09
the O 0 7.754507258539434e-09
blood O 0 2.4087856331789226e-07
cells O 0 7.790213203406893e-07
of O 0 0.0007460474735125899
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.8393257260322571
. O 0 5.276219599181786e-05

The O 0 5.624989967145666e-07
genetic O 0 1.3362139270611806e-06
basis O 0 5.4845963859406766e-06
of O 1 0.9996805191040039
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9972119927406311
DM B-Disease 1 1.0
) O 0 4.1973112274718005e-07
is O 0 4.65437066665686e-09
the O 0 1.5577228396068676e-09
expansion O 0 2.992014813685273e-08
of O 0 9.621526686487414e-09
an O 0 1.1706911884346027e-08
unstable O 0 5.557153781410307e-05
CTG O 0 0.0006433335947804153
repeat O 0 3.4371410606581776e-07
in O 0 1.4214949217716821e-08
the O 0 8.927561800931016e-09
34 O 0 2.629207358495478e-07
UTR O 0 3.694574115797877e-05
of O 0 1.512731273578538e-07
the O 0 4.489259595175099e-07
DM B-Disease 1 0.9999980926513672
protein O 0 2.9342643301788485e-06
kinase O 0 7.041752496661502e-07
gene O 0 6.112831840709987e-08
on O 0 2.750824990016554e-07
chromosome O 0 5.991597390675452e-06
19 O 0 7.732436642982066e-06
. O 0 4.205768163956236e-06

One O 0 4.062451637310005e-07
of O 0 1.3071223747829208e-07
the O 0 5.701700089844053e-08
principal O 0 1.3723254141950747e-06
features O 0 3.650027480261997e-08
of O 0 5.987651263694715e-08
the O 0 3.481831640783639e-07
DM B-Disease 1 0.9999998807907104
mutation O 0 5.957690873970023e-08
is O 0 3.922207003625999e-09
an O 0 1.7361950765959477e-09
extraordinarily O 0 1.8878542107358953e-07
high O 0 9.718267790503887e-08
level O 0 2.799518767915288e-07
of O 0 1.7705954746816133e-07
somatic O 0 1.8966403558806633e-06
mosaicism O 0 7.575659401481971e-05
, O 0 7.787886779908604e-09
due O 0 1.1767693486319786e-08
to O 0 5.934877034263764e-10
an O 0 5.821095827585054e-10
extremely O 0 1.3695933276380856e-08
high O 0 2.3255301684343976e-08
degree O 0 1.21769019756357e-07
of O 0 3.515631163963917e-08
somatic O 0 1.0245421435683966e-06
instability O 0 2.26247630052967e-06
both O 0 2.047436886698506e-08
within O 0 2.938310750266737e-08
and O 0 3.3560638712515356e-09
between O 0 5.52373720097421e-08
different O 0 2.393239739717501e-08
tissues O 0 9.26234349662991e-07
. O 0 6.312072287073534e-07

This O 0 8.97512904884934e-07
instability O 0 8.865381096256897e-05
appears O 0 1.8531152079503954e-07
to O 0 1.813145744655742e-09
be O 0 1.6450071305129654e-09
biased O 0 7.817085645456245e-09
towards O 0 3.101390033677376e-09
further O 0 3.5892928629266407e-09
expansion O 0 2.296828682801788e-08
and O 0 8.031542098052569e-10
continuous O 0 1.1574827318838743e-08
throughout O 0 2.083541339459316e-09
the O 0 5.760832921808401e-10
life O 0 8.134403706172577e-10
of O 0 5.844548178757236e-10
an O 0 8.754844765812564e-11
individual O 0 2.1124112181691856e-10
, O 0 1.2467333831978067e-09
features O 0 4.3773744629049816e-09
that O 0 4.3575548724916757e-10
could O 0 1.8343891960981296e-09
be O 0 9.7307983892847e-10
associated O 0 2.972502688436407e-09
with O 0 4.238537576473078e-10
the O 0 4.808495379649003e-09
progressive O 0 1.1924995533263427e-06
nature O 0 5.3530850863126034e-08
of O 0 2.2157762202823506e-07
the O 0 2.257560254292912e-06
disease O 0 0.011243500746786594
. O 0 1.8118074649464688e-06

Although O 0 2.8303153953856963e-07
increasing O 0 1.1129750987493026e-07
measured O 0 3.195729192384533e-08
allele O 0 1.2479117295072228e-08
size O 0 1.4722262520194818e-08
between O 0 3.9061653467342694e-08
patients O 0 3.49572495395023e-08
clearly O 0 1.3233827367287176e-08
correlates O 0 1.28096244722542e-08
with O 0 1.942213889716271e-10
an O 0 2.9551239233427395e-10
increased O 0 7.076440322606459e-09
severity O 0 1.726975540350395e-07
of O 0 4.1105732151436314e-08
symptoms O 0 1.680723471508827e-07
and O 0 1.2978201846536308e-09
an O 0 4.232575678830841e-10
earlier O 0 5.7156781529954515e-09
age O 0 5.2877940248663435e-08
of O 0 2.5461865504894376e-08
onset O 0 2.285657728862134e-06
, O 0 1.2498476698041827e-09
this O 0 2.0413244705697053e-10
correlation O 0 4.939888054167341e-09
is O 0 3.656796809803353e-10
not O 0 1.8571019722024573e-10
precise O 0 5.07746600320047e-09
and O 0 4.4672260335332226e-10
measured O 0 7.11760517191351e-09
allele O 0 4.2099128627626214e-09
length O 0 3.1913542919426163e-09
cannot O 0 2.742569282787599e-09
be O 0 4.906756112532662e-10
used O 0 3.825403604995614e-10
as O 0 3.607313892040054e-10
an O 0 1.6396559110454234e-10
accurate O 0 3.35299468190442e-08
predictor O 0 8.07815979442239e-07
of O 0 4.5466581610753565e-08
age O 0 2.10257462640584e-06
of O 0 3.9181486499728635e-06
onset O 1 0.6182678937911987
. O 0 2.230105019407347e-05

In O 0 3.2238736480394437e-07
order O 0 4.3352422096631926e-08
to O 0 5.2079069945421e-09
further O 0 1.17286145240314e-08
characterize O 0 2.698522223454347e-07
the O 0 4.7365499966645075e-08
dynamics O 0 3.0265355235314928e-05
of O 0 3.959177774959244e-05
DM B-Disease 1 1.0
CTG O 1 0.9999241828918457
repeat O 0 0.00012416117533575743
somatic O 0 6.913752440596e-05
instability O 0 5.344860255718231e-05
, O 0 4.26176676171508e-08
we O 0 6.175054689805393e-09
have O 0 8.264077755448795e-10
studied O 0 3.295072659170728e-08
repeat O 0 8.23545942552073e-09
length O 0 7.47777229026525e-10
changes O 0 3.66404406815235e-10
over O 0 1.821606199214898e-10
time O 0 1.6857271134540497e-09
in O 0 2.070714089086323e-08
111 O 0 0.010300295427441597
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 3.27114321407862e-07
with O 0 6.173076272375511e-09
varying O 0 1.0215649126621429e-07
clinical O 0 2.355530568820541e-06
severity O 0 3.2310897495335666e-06
and O 0 8.909432125392414e-08
CTG O 0 0.00014383859524969012
repeat O 0 2.1248986570299166e-07
size O 0 2.4767325967900433e-08
over O 0 5.48255751908755e-09
time O 0 5.554404047813932e-09
intervals O 0 8.934989637054969e-09
of O 0 8.894826208916129e-09
1 O 0 5.183848088563536e-07
- O 0 3.4475544907763833e-07
7 O 0 3.096979241945519e-07
years O 0 1.7764951110166294e-07
. O 0 6.949439921299927e-07

We O 0 8.356906278095266e-07
have O 0 1.501515356494565e-08
found O 0 2.4107533747042e-09
a O 0 1.4319355701175596e-09
direct O 0 3.887270061397885e-09
progression O 0 4.556398991439892e-08
of O 0 9.788564625523577e-09
the O 0 3.67758667962903e-09
size O 0 2.3226313317081804e-08
heterogeneity O 0 9.778455023479182e-08
over O 0 7.572822369183996e-09
time O 0 1.2428307272216443e-08
related O 0 1.4542252735338934e-08
to O 0 1.960975604120563e-09
initial O 0 6.986240919104603e-08
CTG O 0 3.273814945714548e-05
repeat O 0 2.7132028890264337e-07
size O 0 4.613978887846315e-08
and O 0 2.7051423323598556e-09
the O 0 2.4288455691134914e-09
time O 0 4.339012704690504e-09
interval O 0 4.5604245713093405e-08
and O 0 2.2816064593200736e-09
always O 0 9.65690016840881e-09
biased O 0 6.900343407778564e-09
towards O 0 4.9699035997718966e-09
further O 0 1.3471078474935894e-08
expansion O 0 5.290790454637317e-07
. O 0 5.752537504122301e-07

Attempts O 0 1.4554997278537485e-06
to O 0 6.301234378724985e-08
mathematically O 0 1.4207380445441231e-06
model O 0 1.168189029954192e-07
the O 0 5.183026985378092e-08
dynamics O 0 8.792057087703142e-06
have O 0 1.8018491587667995e-08
proved O 0 8.081596547526715e-07
only O 0 2.558589340395656e-09
partially O 0 2.0847387816047558e-08
successful O 0 1.4442299800521141e-08
suggesting O 0 7.162860526932491e-09
that O 0 6.457560181027944e-11
individual O 0 4.2425875312890327e-11
specific O 0 8.559468134272663e-10
genetic O 0 1.7438855692830657e-08
and O 0 6.028409327285544e-09
/ O 0 2.358666506552254e-06
or O 0 2.3801700166359296e-08
environmental O 0 8.71374226107946e-08
factors O 0 4.6926317054385436e-08
also O 0 3.006922266735046e-09
play O 0 3.4188786912636715e-08
a O 0 6.481234660071777e-09
role O 0 8.486114211336826e-08
in O 0 8.740025947417962e-08
somatic O 0 6.004754141031299e-06
mosaicism O 0 0.0008080759434960783
. O 0 5.465608410304412e-07
. O 0 6.23974028712837e-06

Aspartylglucosaminuria B-Disease 1 0.9996198415756226
among O 0 2.308358716618386e-06
Palestinian O 0 1.0899346307269298e-05
Arabs O 0 2.581011358415708e-05
. O 0 1.217255339724943e-05

Aspartylglucosaminuria B-Disease 1 1.0
( O 1 0.989257276058197
AGU B-Disease 1 1.0
) O 0 1.0106987247127108e-06
is O 0 3.963026884434839e-08
a O 0 3.2380469860981975e-08
rare O 0 6.726519359290251e-07
disorder B-Disease 1 0.9506276249885559
of I-Disease 0 7.950056897243485e-05
glycoprotein I-Disease 1 0.997965931892395
metabolism I-Disease 0 0.056478165090084076
caused O 0 6.848174507467775e-07
by O 0 1.2038625207821951e-08
the O 0 3.027711557024304e-07
deficiency B-Disease 1 0.9809104800224304
of I-Disease 0 1.2072077879565768e-06
the I-Disease 0 1.437167270523787e-06
lysosomal I-Disease 1 0.9633901715278625
enzyme I-Disease 0 3.2810862649057526e-06
aspartylglucosaminidase I-Disease 0 0.0004903434892185032
( O 0 1.3879856624043896e-06
AGA O 0 0.0011427652789279819
) O 0 1.4288256124928012e-06
. O 0 4.715259819931816e-06

AGU B-Disease 1 1.0
is O 0 1.7077793017961085e-05
inherited O 0 0.027727264910936356
as O 0 3.107698489657196e-07
an O 0 1.760964920549668e-07
autosomal O 0 0.30239230394363403
recessive O 0 0.0027302720118314028
trait O 0 5.390160822571488e-06
and O 0 6.22778770775767e-08
occurs O 0 1.7397860929690978e-08
with O 0 2.4302635459605426e-09
a O 0 7.677771307612602e-09
high O 0 4.114762219842305e-08
frequency O 0 2.1099449298844775e-08
in O 0 1.496979318282854e-09
Finland O 0 2.430858181412532e-08
because O 0 2.108121677224517e-09
of O 0 1.826907336521799e-08
a O 0 7.777455124369226e-08
founder O 0 1.4476727301371284e-06
effect O 0 2.0642371509893565e-06
. O 0 2.2294573227554793e-06

While O 0 1.1803997495007934e-06
very O 0 2.916210348757886e-07
few O 0 8.363891623730524e-08
patients O 0 9.710096549042646e-08
with O 0 1.0970499886298057e-07
AGU B-Disease 1 1.0
have O 0 3.255522784684217e-08
been O 0 6.198383584177236e-09
reported O 0 1.9822450347817266e-09
from O 0 6.035666411108309e-10
non O 0 1.4281286375705804e-08
- O 0 1.2328698062447074e-08
Finnish O 0 7.936069437164406e-07
origin O 0 2.5632212796722342e-08
, O 0 3.1443589953994433e-09
we O 0 1.0340993839008661e-08
diagnosed O 0 3.4293525459361263e-06
the O 0 1.0921766602223215e-08
disorder O 0 8.516259185853414e-06
in O 0 1.0983602471981158e-08
8 O 0 1.419783046685552e-07
patients O 0 5.175852191285912e-09
originating O 0 8.511041649228446e-09
from O 0 5.465059071951828e-09
3 O 0 5.4384003078666865e-08
unrelated O 0 2.7720528095187547e-08
families O 0 3.1834615499271024e-10
, O 0 5.352365217703436e-10
all O 0 1.7589331380296613e-10
Palestinian O 0 1.1743881422887625e-08
Arabs O 0 7.651587807799842e-09
from O 0 3.403807680157911e-09
the O 0 1.4488727995143336e-09
region O 0 1.176922026502325e-08
of O 0 1.1383167297651653e-08
Jerusalem O 0 1.3136673260305542e-06
. O 0 9.496101824879588e-07

The O 0 3.821575319307158e-06
clinical O 0 0.0010740590514615178
diagnosis O 1 0.9841242432594299
of O 0 0.4201422333717346
AGU B-Disease 1 1.0
is O 0 1.1512097444210667e-06
often O 0 1.4926776259471808e-08
difficult O 0 7.37695700081531e-08
, O 0 2.1065178490431435e-09
in O 0 3.8952843728345954e-10
particular O 0 1.575808261655709e-09
early O 0 4.82008388758004e-09
in O 0 1.0410888817702357e-09
the O 0 8.403204243556672e-10
course O 0 2.0588050375636158e-08
of O 0 6.6711738355706984e-09
the O 0 4.976972789449974e-08
disease O 0 8.324252121383324e-06
, O 0 1.8813215429958063e-09
and O 0 2.130779774844882e-09
most O 0 1.8984904759378196e-09
of O 0 1.2586927056190689e-08
the O 0 6.299660526565276e-08
patients O 0 2.589684982012841e-07
are O 0 5.6882276666669895e-09
diagnosed O 0 1.0701759265430155e-06
after O 0 8.031025622301513e-09
the O 0 4.681597332023557e-09
age O 0 1.7969796317629516e-07
of O 0 1.6967867111361556e-07
5 O 0 9.765806225914275e-07
years O 0 3.4068301602019346e-07
. O 0 9.543184660287807e-07

However O 0 1.7134558447651216e-06
, O 0 7.561654769006054e-08
since O 0 3.010636717704074e-08
these O 0 2.667081666629656e-09
patients O 0 9.17119358234686e-09
excrete O 0 7.478264052451777e-08
early O 0 1.1884536021966596e-08
large O 0 2.72263322997901e-09
amounts O 0 3.4233271772876606e-09
of O 0 4.284529175890839e-09
aspartylglucosamine O 0 6.413565074581129e-07
in O 0 3.6587310958680064e-09
urine O 0 5.491515686628645e-09
, O 0 1.1764388352375477e-09
biochemical O 0 5.240663369932008e-08
screening O 0 3.798013281652857e-08
is O 0 1.4972534323476339e-09
easy O 0 7.252936029544799e-09
by O 0 2.5199844433387852e-09
urine O 0 1.27044188502623e-07
chromatography O 0 3.3598716981941834e-05
. O 0 1.0628020845615538e-06
. O 0 3.8648017834930215e-06

Detection O 0 9.919330295815598e-06
of O 0 2.941227421615622e-07
heterozygous O 0 1.4879624643526768e-07
carriers O 0 3.182724128691916e-08
of O 0 2.2225776774575934e-08
the O 0 9.99968392534356e-07
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999973773956299
telangiectasia I-Disease 1 0.9999998807907104
( O 0 3.825119620159967e-06
ATM O 0 0.0006356650847010314
) O 0 1.8750352381857738e-08
gene O 0 9.334258699311704e-09
by O 0 4.499852934713999e-09
G2 O 0 0.00017983447469305247
phase O 0 0.00011198510765098035
chromosomal O 0 0.0030034531373530626
radiosensitivity O 0 0.0009984866483137012
of O 0 1.566879655001685e-05
peripheral O 1 0.9992581009864807
blood O 0 0.0001698145642876625
lymphocytes O 0 4.321369488025084e-05
. O 0 8.524985787516925e-06

In O 0 0.0006905437330715358
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 1 0.6539143919944763
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 4.820201411348535e-07
patients O 0 9.384800847556107e-08
, O 0 4.0976235737844036e-09
mutations O 0 2.9097100284758426e-09
in O 0 1.1013174816554283e-09
a O 0 1.516527237122034e-09
single O 0 1.2192566956059636e-09
gene O 0 5.234906286233354e-09
, O 0 2.0799360012091483e-09
ATM O 0 3.940103397326311e-06
, O 0 1.989289843962183e-09
result O 0 1.9434935882856053e-09
in O 0 1.4563339423290245e-09
an O 0 4.699609235103708e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 4.0781185361993266e-07
embraces O 0 7.670183777008788e-07
a O 0 3.31189617952532e-08
variety O 0 3.1458181837251686e-08
of O 0 4.033359601862685e-08
clinical O 0 3.8174670180524117e-07
features O 0 5.157899352070672e-08
and O 0 1.284735517970148e-08
manifests O 0 2.418450719687826e-07
extreme O 0 1.4185881127559696e-06
radiosensitivity O 0 2.132930421794299e-05
and O 0 1.077066791310699e-08
a O 0 4.069772074899447e-08
strong O 0 4.294512478963952e-08
pre O 0 9.839707672654185e-06
- O 0 3.364190888532903e-06
disposition O 0 3.5059697438555304e-06
to O 0 2.844779487531923e-07
malignancy B-Disease 1 0.8012505769729614
. O 0 6.779323030059459e-06

Heterozygotes O 0 1.7539787222631276e-05
for O 0 1.3968491430205177e-07
the O 0 1.5320027557663707e-07
ATM O 0 3.496482167975046e-05
gene O 0 6.370393634824723e-08
have O 0 1.469277255417012e-09
no O 0 1.914848057893437e-09
clinical O 0 8.894503800149778e-09
expression O 0 3.784337287981998e-09
of O 0 1.3949734523066581e-07
A B-Disease 1 0.9999982118606567
- I-Disease 1 0.9999849796295166
T I-Disease 1 0.9999977350234985
but O 0 5.6081663757368005e-08
may O 0 1.2112793967844482e-07
be O 0 5.520819712501179e-08
cancer B-Disease 0 2.53342750511365e-06
prone O 0 3.90552912676867e-07
with O 0 3.682619542644261e-09
a O 0 3.310519502974785e-08
moderate O 0 1.5284228993550641e-07
increase O 0 5.591170637586629e-09
in O 0 4.2536765221257156e-09
in O 0 1.567140728298e-08
vitro O 0 9.69543634710135e-07
radiosensitivity O 0 1.8733462638920173e-05
. O 0 1.1782964293161058e-06

We O 0 1.0318306067347294e-06
performed O 0 1.0602479960653e-06
a O 0 1.923494039601792e-07
blind O 0 7.81864571308688e-07
chromosomal O 0 1.7990629430642002e-06
analysis O 0 2.1636490998844238e-07
on O 0 3.0170582476785057e-07
G2 O 0 7.385278877336532e-05
- O 0 4.166483620338113e-07
phase O 0 2.9292493763932725e-07
lymphocytes O 0 1.691312334628492e-08
from O 0 1.2864176390792181e-08
7 O 0 1.2385609693410515e-07
unrelated O 0 3.8522208001268154e-07
A B-Disease 1 0.9938130378723145
- I-Disease 1 0.9998823404312134
T I-Disease 1 0.999996542930603
patients O 0 4.679180278799322e-07
, O 0 1.5131444541793826e-08
13 O 0 1.5926904950447351e-07
obligate O 0 3.681677185340959e-07
A B-Disease 1 0.9999499320983887
- I-Disease 1 0.9999278783798218
T I-Disease 1 0.9999977350234985
heterozygotes O 0 0.00010776577255455777
( O 0 2.0040594961301395e-08
parents O 0 1.1248226794435823e-09
of O 0 2.0016670543299142e-09
the O 0 7.016123682035413e-09
patients O 0 7.939641832876987e-09
) O 0 7.278833646928717e-10
, O 0 9.237197673428454e-10
and O 0 1.0604001010605657e-09
14 O 0 2.0000729961111574e-08
normal O 0 1.9262012429521747e-08
controls O 0 3.179465934977088e-08
following O 0 4.977397605188116e-09
X O 0 2.5837840667009004e-07
- O 0 7.81741675837111e-08
irradiation O 0 4.052776958474169e-08
with O 0 2.3043749131090863e-09
1 O 0 4.7468873276557133e-07
Gy O 0 8.699956879354431e-07
in O 0 7.963873449590153e-10
order O 0 5.300795358209598e-10
to O 0 2.560589795752577e-10
evaluate O 0 7.372325860899309e-09
this O 0 7.71676111899211e-10
cytogenetic O 0 2.7259036983195983e-07
method O 0 1.771341295864204e-08
as O 0 1.5470693615071696e-09
a O 0 1.938924354405458e-09
tool O 0 1.7691297315991505e-08
for O 0 1.6146982639853036e-09
detection O 0 3.45634418863483e-07
of O 0 2.630765152389358e-07
ATM O 0 0.0019892489071935415
carriers O 0 1.041622363118222e-05
. O 0 1.7223519535036758e-06

Both O 0 1.4001681847730651e-05
A B-Disease 1 0.999995231628418
- I-Disease 1 0.9999916553497314
T I-Disease 1 0.9999961853027344
homozygotes O 0 0.0002112559595843777
and O 0 5.518693058093049e-08
heterozygotes O 0 9.695232847661828e-07
showed O 0 1.5685223786476854e-08
significantly O 0 5.328999908016385e-09
increased O 0 1.8669266133031215e-09
levels O 0 7.96255683610525e-09
of O 0 9.448936744149705e-09
radiation O 0 7.249010377563536e-05
- O 0 3.0936103030398954e-06
induced O 0 4.621986590791494e-06
chromatid O 0 0.00010373939585406333
damage O 0 1.274841793019732e-06
relative O 0 2.800015295179037e-07
to O 0 2.0132226996594227e-09
that O 0 1.2355269030095428e-09
of O 0 3.139991733291936e-08
normal O 0 9.32112982354738e-07
controls O 0 6.027824383636471e-06
. O 0 1.169200459116837e-06

These O 0 5.619816434432323e-08
results O 0 3.845671869839862e-08
show O 0 1.9683511709445156e-08
that O 0 7.55201901014857e-10
the O 0 1.81483859051923e-08
G2 O 0 2.43918093474349e-05
- O 0 3.1297642522076785e-07
phase O 0 1.0574719908618135e-06
chromosomal O 0 1.8967922414958593e-06
radiosensitivity O 0 1.9999906726297922e-06
assay O 0 4.786134866208158e-08
can O 0 9.00420404903457e-10
be O 0 7.458542117255718e-10
used O 0 3.6713684870015584e-10
for O 0 9.280353568952293e-11
the O 0 5.607283526387619e-10
detection O 0 1.6749311271269107e-07
of O 0 2.452909768635436e-07
A B-Disease 1 0.999996542930603
- I-Disease 1 0.9999892711639404
T I-Disease 1 0.9999983310699463
heterozygotes O 0 0.0005973250954411924
. O 0 9.039200449478813e-06

In O 0 4.637907693449961e-07
combination O 0 9.432371825823793e-07
with O 0 1.6169858341186227e-08
molecular O 0 9.676297167970915e-07
genetic O 0 1.8289301806362346e-07
analyses O 0 5.670238323318699e-08
, O 0 1.3882555105482197e-09
this O 0 2.519728314887004e-10
test O 0 1.5520643659172606e-09
may O 0 3.910089751979484e-10
be O 0 9.941905632082637e-11
of O 0 2.4132362774764715e-10
value O 0 2.098481388657092e-09
in O 0 3.110618429502665e-10
studies O 0 1.0045566600780376e-09
of O 0 2.932659670662474e-09
familial B-Disease 0 1.883042415329328e-07
and I-Disease 0 6.666546426004061e-08
sporadic I-Disease 0 0.0006178907351568341
cancers I-Disease 0 0.00031170572037808597
aimed O 0 4.769362362821994e-07
at O 0 1.5505329997722583e-07
determination O 0 5.7058777258589544e-08
of O 0 2.2531558840910293e-08
the O 0 4.6673318543355435e-09
potential O 0 1.7016798636859676e-08
involvement O 0 3.785797275668301e-08
of O 0 1.636242963343193e-08
ATM O 0 3.2713029213482514e-05
mutations O 0 6.486307313480211e-08
in O 0 3.014980975990511e-08
tumor B-Disease 0 2.782946285151411e-05
risk O 0 6.389955728991481e-07
or O 0 1.665789817195673e-08
development O 0 2.261170521933309e-07
. O 0 8.281884333882772e-08
. O 0 1.4971077462178073e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999388456344604
telangiectasia I-Disease 1 0.9999836683273315
: O 0 6.97149218353843e-08
identification O 0 1.8013063041166788e-08
and O 0 3.314662544440239e-09
detection O 0 1.234250703419093e-06
of O 0 2.490038752966939e-07
founder O 0 1.1471874131530058e-05
- O 0 1.6941460216912674e-06
effect O 0 2.945971573353745e-07
mutations O 0 2.166487611532375e-08
in O 0 7.23667170632325e-09
the O 0 1.6346115572218878e-08
ATM O 0 2.2153517420520075e-05
gene O 0 7.781387267868922e-08
in O 0 1.290588258484604e-08
ethnic O 0 9.398719669206912e-08
populations O 0 3.084105344441923e-07
. O 0 1.1463650935183978e-06

To O 0 1.1417746037523102e-07
facilitate O 0 2.176322482227988e-07
the O 0 1.2485521949656686e-08
evaluation O 0 9.004933332334986e-08
of O 0 3.215398791667212e-08
ATM O 0 2.7615687940851785e-05
heterozygotes O 0 6.194167099238257e-07
for O 0 1.1351599660258671e-08
susceptibility O 0 1.936229949706103e-07
to O 0 1.6994150531246532e-09
other O 0 2.7686924752856612e-08
diseases O 0 0.0017717150039970875
, O 0 2.9676647805843004e-09
such O 0 7.2709975817986106e-09
as O 0 3.288971583970124e-06
breast B-Disease 1 0.9999852180480957
cancer I-Disease 1 0.9792455434799194
, O 0 1.53950296066796e-07
we O 0 3.385653712939529e-08
have O 0 1.8719756855745118e-09
attempted O 0 1.8189487249742342e-08
to O 0 4.035271283786557e-10
define O 0 1.8088428532792022e-08
the O 0 3.973720019700977e-09
most O 0 1.2028842366618164e-09
common O 0 1.3599352755022664e-09
mutations O 0 2.8480576230727195e-10
and O 0 5.3570911595635096e-11
their O 0 1.7674414709567543e-10
frequencies O 0 5.496045218933432e-08
in O 0 1.6654951195960166e-07
ataxia B-Disease 1 0.999995231628418
- I-Disease 1 0.9999527931213379
telangiectasia I-Disease 1 1.0
( O 0 5.8275036280974746e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999866485595703
T I-Disease 1 0.9999935626983643
) O 0 2.5605638143133547e-07
homozygotes O 0 1.1852540410473011e-05
from O 0 1.0564544083990768e-07
10 O 0 5.562698035532776e-08
ethnic O 0 3.8129144286358496e-08
populations O 0 1.344059370467221e-07
. O 0 6.865542445666506e-07

Both O 0 8.679371603648178e-07
genomic O 0 2.4244789074145956e-06
mutations O 0 6.245510775215735e-08
and O 0 5.174785933093062e-09
their O 0 1.640867552943348e-09
effects O 0 3.797904923885653e-07
on O 0 7.908781185506086e-08
cDNA O 0 7.232706593640614e-07
were O 0 7.440176830186829e-08
characterized O 0 7.00458656410774e-07
. O 0 9.804102774069179e-07

Protein O 0 9.85925453278469e-06
- O 0 5.560671638704662e-07
truncation O 0 9.34312936351489e-07
testing O 0 4.3742055311213335e-08
of O 0 5.7893654314966625e-09
the O 0 3.1313653892084403e-09
entire O 0 3.318130481488879e-08
ATM O 0 9.414460464540753e-07
cDNA O 0 7.97342636360554e-08
detected O 0 2.1359852553359815e-08
92 O 0 4.397788089249843e-08
( O 0 5.125865509825189e-09
66 O 0 7.123067291558982e-08
% O 0 1.460532406127868e-08
) O 0 4.283744470257034e-09
truncating O 0 1.6162357496796176e-07
mutations O 0 2.1772622815774412e-08
in O 0 8.727560896204523e-09
140 O 0 4.348575544099731e-08
mutant O 0 1.7850321398782398e-07
alleles O 0 1.7686782882719854e-07
screened O 0 3.4232389225508086e-06
. O 0 2.1006005681556417e-06

The O 0 1.3216960041972925e-06
haplotyping O 0 0.0005115459789521992
of O 0 8.880740551830968e-07
patients O 0 5.00965917638041e-08
with O 0 2.148622391118238e-09
identical O 0 6.805388608199792e-08
mutations O 0 1.1019863244143835e-08
indicates O 0 4.567708433711459e-09
that O 0 8.600556378191015e-11
almost O 0 1.896860724048821e-10
all O 0 5.296588515002476e-11
of O 0 1.6077766895605805e-10
these O 0 4.349431925732006e-11
represent O 0 4.990095003876149e-10
common O 0 9.975664738703927e-10
ancestry O 0 7.528030421255494e-10
and O 0 4.5606374232676217e-10
that O 0 2.0638039888165594e-10
very O 0 1.4807697290564192e-09
few O 0 3.066357168179934e-09
spontaneously O 0 5.36900621739278e-08
recurring O 0 1.4132273236100446e-06
ATM O 0 0.00014500290853902698
mutations O 0 6.199225026648492e-07
exist O 0 9.516201089354581e-07
. O 0 2.0513730305538047e-06

Assays O 0 2.3512413918069797e-06
requiring O 0 1.518431673730447e-07
minimal O 0 2.17872099028682e-07
amounts O 0 2.7222140985827536e-08
of O 0 1.5903387051707796e-08
genomic O 0 4.274735942999541e-08
DNA O 0 2.9492033704059395e-08
were O 0 2.32560015689387e-09
designed O 0 3.829975891989079e-09
to O 0 2.2823669343363662e-10
allow O 0 1.3867786918808633e-09
rapid O 0 8.115164007449494e-08
screening O 0 1.912910718715466e-08
for O 0 1.8226846698610188e-09
common O 0 1.0043885723121093e-08
ethnic O 0 9.97477940245517e-08
mutations O 0 5.9153597931072e-07
. O 0 1.546470571156533e-06

These O 0 4.756394744731551e-08
rapid O 0 4.782110636369907e-07
assays O 0 1.3320642722192133e-07
detected O 0 2.85795334065142e-08
mutations O 0 1.1841493341435694e-09
in O 0 1.0222930280079368e-09
76 O 0 3.5004354970169516e-08
% O 0 5.8215428033747685e-09
of O 0 2.702389778619363e-08
Costa O 0 1.1029515007976443e-06
Rican O 0 2.795218051687698e-06
patients O 0 3.5995310554426396e-07
( O 0 1.318346587453334e-08
3 O 0 2.291337253268466e-08
) O 0 4.263827901862527e-10
, O 0 2.5302560047180123e-10
50 O 0 1.4609523590891627e-09
% O 0 6.225785997848732e-10
of O 0 3.1180331649949267e-09
Norwegian O 0 1.3292437870404683e-06
patients O 0 3.065399667434576e-08
( O 0 2.7130482305182113e-09
1 O 0 4.8609678060529404e-08
) O 0 4.6002399112232695e-10
, O 0 5.019189508459476e-10
25 O 0 3.2015723405720564e-09
% O 0 1.9267916151477493e-09
of O 0 2.157329248575479e-08
Polish O 0 0.0002721987257245928
patients O 0 3.4841968954424374e-07
( O 0 8.592957456698969e-09
4 O 0 5.391438406832094e-08
) O 0 1.009169636745355e-09
, O 0 8.07978794981068e-10
and O 0 4.33358432472275e-10
14 O 0 1.4082285559879892e-08
% O 0 3.4824934047605893e-09
of O 0 3.683246774244253e-08
Italian O 0 0.0027682010550051928
patients O 0 5.499321673596569e-07
( O 0 6.3766520952412975e-09
1 O 0 1.0244331605235857e-07
) O 0 4.715380308439876e-10
, O 0 2.6036481304281267e-10
as O 0 5.534182556665712e-10
well O 0 7.037295746137318e-10
as O 0 9.373611886687172e-10
in O 0 1.2335323873458037e-09
patients O 0 4.414779208872233e-09
of O 0 8.4099312402941e-08
Amish O 0 2.8648617444559932e-05
/ O 0 0.00022544662351720035
Mennonite O 0 6.23399455434992e-06
and O 0 4.000254705260886e-08
Irish O 0 6.850775207567494e-06
English O 0 6.984507763263537e-06
backgrounds O 0 3.4529055028542643e-06
. O 0 3.263560756749939e-06

Additional O 0 5.206743480812293e-07
mutations O 0 1.1583599501818753e-07
were O 0 1.4493267919135633e-08
observed O 0 5.815040005074934e-09
in O 0 1.243484537560846e-09
Japanese O 0 5.305241046471565e-08
, O 0 4.108909212874323e-09
Utah O 0 2.9513145705095667e-07
Mormon O 0 4.730338432068493e-08
, O 0 2.2881219141623887e-09
and O 0 3.5703795475683364e-09
African O 0 1.6306108818753273e-07
American O 0 1.877986392173625e-06
patients O 0 9.184926057059783e-06
. O 0 2.394604052824434e-06

These O 0 3.709586238187512e-08
assays O 0 4.714674517458661e-08
should O 0 1.9815795671007663e-09
facilitate O 0 5.504435129921603e-09
screening O 0 2.879533589350558e-08
for O 0 2.0070356043788706e-08
A B-Disease 1 0.9996305704116821
- I-Disease 1 0.9996523857116699
T I-Disease 1 0.999941349029541
heterozygotes O 0 1.8351202015765011e-06
in O 0 4.249443463777425e-09
the O 0 1.9679522456073073e-09
populations O 0 4.747364723556302e-09
studied O 0 4.323013627072214e-07
. O 0 2.696546097524788e-08
. O 0 4.6424833044511615e-07

The O 0 9.405268428963609e-06
von B-Disease 1 0.9964463114738464
Hippel I-Disease 1 0.9998430013656616
- I-Disease 1 0.9999117851257324
Lindau I-Disease 1 0.9997938275337219
tumor I-Disease 0 0.005334474146366119
suppressor O 0 7.12288874638034e-06
gene O 0 1.0990710563874018e-07
is O 0 2.995376391368154e-09
required O 0 9.499969699788835e-09
for O 0 1.8906860077549936e-08
cell O 0 1.1235173360546469e-06
cycle O 0 6.387073625546691e-08
exit O 0 8.600799361602185e-08
upon O 0 8.88162361434297e-08
serum O 0 5.267530696073663e-07
withdrawal O 0 1.1859217465826077e-06
. O 0 2.740928948696819e-06

The O 0 8.974384400062263e-07
inactivation O 0 1.5402827557409182e-05
of O 0 3.1977421599549416e-07
the O 0 1.9199808320990996e-07
von B-Disease 1 0.7341135144233704
Hippel I-Disease 1 0.9991587400436401
- I-Disease 1 0.9997498393058777
Lindau I-Disease 1 0.9997560381889343
( I-Disease 0 4.864510628976859e-06
VHL I-Disease 1 0.9821099638938904
) I-Disease 0 1.55673524204758e-06
tumor I-Disease 0 0.11756370216608047
suppressor O 0 0.00040988755063153803
gene O 0 1.40665747494495e-06
predisposes O 0 3.0632045309175737e-06
affected O 0 5.033172456592183e-08
individuals O 0 1.8182331196214818e-09
to O 0 2.487947625695597e-09
the O 0 3.061695394990238e-07
human O 0 0.33017927408218384
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
and O 0 2.159116405664463e-07
is O 0 3.013020588582549e-08
associated O 0 1.0701620567488135e-07
with O 0 5.895968513414118e-08
sporadic B-Disease 1 0.9999827146530151
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 1 0.9915167093276978
RCC B-Disease 1 1.0
) O 0 5.260856596578378e-06
and O 0 6.726091214659391e-06
brain B-Disease 1 0.9991363883018494
hemangioblastomas I-Disease 1 0.6589685678482056
. O 0 1.4591324543289375e-05

VHL O 0 0.02301362343132496
- O 0 3.985908915637992e-05
negative O 0 1.3305298125487752e-06
786 O 0 0.00010539780487306416
- O 0 0.023521218448877335
0 O 0 1.7109972759499215e-05
RCC B-Disease 1 0.9988331198692322
cells O 0 1.837980505570158e-07
are O 0 7.002180169024541e-09
tumorigenic O 0 3.813118382822722e-06
in O 0 8.525521622004817e-08
nude O 0 1.3989135368319694e-05
mice O 0 2.533499809942441e-07
which O 0 1.4038913365155281e-09
is O 0 1.5933619978980573e-09
suppressed O 0 5.93106630475404e-09
by O 0 4.2849268577782595e-10
the O 0 8.360268033413831e-09
reintroduction O 0 4.182630846116808e-07
of O 0 7.12418113835156e-07
VHL B-Disease 0 0.25474271178245544
. O 0 1.4255562746257056e-05

Remarkably O 0 0.0001476833422202617
, O 0 5.951251580427197e-08
this O 0 1.7058744417042249e-09
occurs O 0 2.3010719996108264e-09
without O 0 2.316723257678177e-09
affecting O 0 1.6813022085671037e-09
the O 0 2.257489750689956e-10
growth O 0 2.297537271545025e-09
rate O 0 5.676370928853203e-09
and O 0 9.289566893500023e-10
cell O 0 5.811450520809558e-08
cycle O 0 2.8320681355609167e-09
profile O 0 1.971341090367673e-09
of O 0 2.025575041031402e-09
these O 0 7.602936613615441e-10
cells O 0 3.852842933582679e-09
in O 0 2.7725592932625887e-09
culture O 0 3.450350050115958e-07
. O 0 5.011379471397959e-07

The O 0 2.098820232276921e-06
786 O 0 7.021777128102258e-05
- O 0 0.00012080469605280086
0 O 0 1.507427214164636e-06
cell O 0 4.95511540066218e-06
line O 0 2.2673549437968177e-07
, O 0 5.440991213134794e-09
like O 0 7.505296828469454e-09
many O 0 8.886584801359732e-09
cancer B-Disease 0 4.058312333654612e-05
cells O 0 4.536056508186448e-08
, O 0 6.9116978806960105e-09
fails O 0 3.226819700330452e-08
to O 0 2.3637822810229636e-09
exit O 0 2.655870048329234e-07
the O 0 6.21947719992022e-08
cell O 0 2.9693035230593523e-07
cycle O 0 1.4297039996336025e-08
upon O 0 9.22083209786706e-09
serum O 0 1.7152528641872777e-07
withdrawal O 0 4.2974050984412315e-07
. O 0 1.4706482716064784e-06

Here O 0 3.961013135267422e-06
, O 0 3.094920941748569e-08
it O 0 1.3738049586820011e-09
is O 0 2.557387912549558e-10
shown O 0 2.6121491081276815e-10
that O 0 4.894153832202264e-11
reintroduction O 0 7.872808183151392e-09
of O 0 3.2556144446971302e-09
the O 0 7.681960845218327e-09
wild O 0 5.5084917960357416e-08
- O 0 5.59529098609346e-07
type O 0 1.7492444612798863e-06
VHL B-Disease 0 0.0004199516260996461
gene O 0 1.658166723927934e-07
restores O 0 3.067198690587247e-07
the O 0 8.468648005077739e-09
ability O 0 1.6862809815165747e-08
of O 0 5.976925763206964e-07
VHL O 1 0.9999442100524902
- O 1 0.7821224331855774
negative O 0 7.255233504110947e-05
RCC B-Disease 1 1.0
cancer I-Disease 0 0.17777679860591888
cells O 0 2.7723700668502715e-08
to O 0 3.844078833026288e-09
exit O 0 1.20175926099364e-07
the O 0 3.225570566200986e-08
cell O 0 7.504403924940561e-07
cycle O 0 1.3180749824925897e-08
and O 0 2.1258881321983836e-09
enter O 0 4.674127467296785e-07
G0 O 0 0.04309716448187828
/ O 0 3.251171438023448e-05
quiescence O 0 1.54659865074791e-05
in O 0 2.248001038651637e-07
low O 0 3.33465391122445e-06
serum O 0 3.7125673770788126e-06
. O 0 1.267771040147636e-06

Both O 0 2.25079547817586e-05
VHL O 1 0.7886940240859985
- O 0 2.942339597211685e-05
positive O 0 1.6988559536912362e-07
and O 0 1.444842183673245e-07
VHL O 1 0.9812905192375183
- O 0 0.00011821754742413759
negative O 0 1.121996888286958e-06
RCC B-Disease 1 0.999875545501709
cells O 0 1.0135261163668474e-07
exit O 0 1.0904494018859623e-07
the O 0 1.342657363068156e-08
cell O 0 4.8215753167824e-07
cycle O 0 1.2696951934287881e-08
by O 0 4.409679732475524e-09
contact O 0 8.497758017256274e-07
inhibition O 0 6.466952527262038e-06
. O 0 3.9092246879590675e-06

The O 0 5.051588686910691e-06
cyclin O 0 0.00012739301018882543
- O 0 6.535137345053954e-06
dependent O 0 8.988012041299953e-07
kinase O 0 2.0965437670383835e-06
inhibitor O 0 2.206806129834149e-06
, O 0 2.6316751444710462e-08
p27 O 0 5.702689577447018e-06
, O 0 1.0923016269259733e-08
accumulates O 0 7.711927452191958e-08
upon O 0 9.642801224174491e-09
serum O 0 4.8089930260175606e-08
withdrawal O 0 3.224863220907537e-08
, O 0 3.772244738797781e-09
only O 0 4.307888490373557e-10
in O 0 3.5916536411662037e-10
the O 0 6.705921928862324e-10
presence O 0 1.2131980753338212e-08
of O 0 1.1391089316248326e-07
VHL B-Disease 0 0.014793405309319496
, O 0 2.647776753406106e-08
as O 0 2.695737189029046e-09
a O 0 1.0242017234318723e-09
result O 0 1.1637824037791233e-09
of O 0 1.99882110862859e-09
the O 0 3.0239810655530164e-09
stabilization O 0 6.575576776413072e-07
of O 0 1.7700382670682302e-07
the O 0 4.937431867801934e-07
protein O 0 2.6078316750499653e-06
. O 0 1.6053841136454139e-06

We O 0 8.6049476522021e-07
propose O 0 8.356842045031954e-07
that O 0 6.056219081784775e-09
the O 0 1.6615567588473823e-08
loss O 0 2.1491528912065405e-07
of O 0 2.8231633564246295e-07
wild O 0 1.160615056505776e-06
- O 0 5.513770702236798e-06
type O 0 5.034304649598198e-06
VHL B-Disease 0 0.00036485862801782787
gene O 0 4.054787439145002e-08
results O 0 7.687119385479946e-09
in O 0 1.5486548710086367e-09
a O 0 2.020747569275727e-09
specific O 0 3.4821081573710444e-09
cellular O 0 3.829028628388187e-06
defect O 0 8.5059150478628e-07
in O 0 1.864528975659141e-08
serum O 0 3.5623892813418934e-07
- O 0 3.37396357963371e-07
dependent O 0 6.712646438700176e-08
growth O 0 8.837233167469094e-08
control O 0 1.3071489775029477e-06
, O 0 1.3527698961013357e-08
which O 0 1.5369343575599714e-09
may O 0 1.7717534106509447e-08
initiate O 0 2.2805858179708594e-07
tumor B-Disease 0 2.8927650419063866e-05
formation O 0 1.6025504010031e-05
. O 0 1.1723798706952948e-05

This O 0 2.3420697914389166e-07
is O 0 3.076657861811327e-08
corrected O 0 1.8579690674869198e-07
by O 0 1.5002262765406726e-09
the O 0 5.378391954025119e-09
reintroduction O 0 7.83249092251026e-08
of O 0 3.980473550768693e-08
wild O 0 1.9931482597712602e-07
- O 0 4.434083166415803e-06
type O 0 0.00013720436254516244
VHL B-Disease 1 0.9999886751174927
, O 0 9.918053365254309e-06
implicating O 1 0.9991782307624817
VHL B-Disease 1 0.9998103976249695
as O 0 5.363612558539899e-07
the O 0 9.986239035697508e-08
first O 0 1.0142319695205515e-07
tumor B-Disease 0 7.086065579642309e-06
suppressor O 0 1.687605504230305e-06
involved O 0 2.3596394171931934e-08
in O 0 3.111593205318286e-09
the O 0 5.222460242038096e-09
regulation O 0 2.5418273708055494e-07
of O 0 7.912885990890572e-08
cell O 0 3.434346808717237e-06
cycle O 0 1.182560254164855e-07
exit O 0 1.6483348019846744e-07
, O 0 6.328030099922444e-09
which O 0 6.856991641157606e-10
is O 0 5.706764505397643e-10
consistent O 0 5.804822844623914e-09
with O 0 4.289179011962574e-10
its O 0 1.5464322045133372e-09
gatekeeper O 0 4.6981170953586116e-07
function O 0 6.09443731036663e-08
in O 0 3.1682606760341514e-08
the O 0 3.727666353370296e-07
kidney O 0 0.03253844007849693
. O 0 8.618293918516429e-07
. O 0 5.437224899651483e-06

Piebaldism B-Disease 1 0.9999996423721313
with O 0 0.0002818357024807483
deafness B-Disease 1 1.0
: O 0 4.2646701103876694e-07
molecular O 0 4.5074099830344494e-07
evidence O 0 7.204214824696464e-08
for O 0 3.4158131878569975e-09
an O 0 1.4030167250211889e-08
expanded O 0 7.922192162368447e-05
syndrome O 1 0.9994496703147888
. O 0 1.2309815247135703e-05

In O 0 4.048146422519494e-07
a O 0 3.985138619100326e-07
South O 0 4.5995162167855597e-07
African O 0 1.837659766579236e-07
girl O 0 2.9236312570901646e-07
of O 0 8.318454547406873e-08
Xhosa O 0 0.00013462489005178213
stock O 0 2.4618597649350704e-07
with O 0 9.198803496701657e-09
severe O 0 1.7347401808365248e-05
piebaldism B-Disease 0 0.0004691175709012896
and O 0 1.2689056347880978e-06
profound O 1 0.9999972581863403
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 8.152732334565371e-05
identified O 0 5.167954100215866e-07
a O 0 2.990839576000326e-08
novel O 0 8.250096605877388e-09
missense O 0 5.042435091695552e-08
substitution O 0 2.663006526404388e-08
at O 0 3.8610327379728915e-08
a O 0 6.205327363062452e-09
highly O 0 2.3939017879115454e-08
conserved O 0 2.984889846402439e-08
residue O 0 2.388743070014243e-08
in O 0 8.340085289049171e-10
the O 0 3.2918927583835966e-09
intracellular O 0 9.951747870218242e-08
kinase O 0 7.74649819845763e-08
domain O 0 5.212521614339494e-08
of O 0 4.621227134293804e-08
the O 0 3.788514391089848e-07
KIT O 0 0.1273699253797531
proto O 0 0.35466107726097107
- O 0 0.041471440345048904
oncogene O 0 0.0006591128185391426
, O 0 2.9122379601176362e-06
R796G O 0 0.00015257515769917518
. O 0 6.293682417890523e-06

Though O 0 8.06038315204205e-06
auditory B-Disease 0 0.0015747530851513147
anomalies I-Disease 0 0.0006032989476807415
have O 0 3.4155675621150294e-08
been O 0 1.3250041952517222e-08
observed O 0 2.1233969249578877e-08
in O 0 7.601780538379899e-09
mice O 0 2.296154022474184e-08
with O 0 3.5157834421539746e-09
dominant O 0 0.0022990666329860687
white O 0 6.888747066113865e-06
spotting O 1 0.9770644307136536
( O 0 1.3023236533626914e-06
W O 0 0.06287490576505661
) O 0 3.98798727374583e-09
due O 0 1.7650581440875612e-08
to O 0 5.733792107776026e-09
KIT O 1 0.6272966861724854
mutations O 0 6.471369943028549e-06
, O 0 1.4482731785392389e-05
deafness B-Disease 1 1.0
is O 0 3.031354651739093e-07
not O 0 1.6617310194533275e-08
typical O 0 2.767088176369725e-07
in O 0 2.643114349609732e-08
human O 0 1.3316578417743585e-07
piebaldism B-Disease 0 3.284475315012969e-05
. O 0 3.26924259752559e-06

Thus O 0 1.1846648249047576e-06
, O 0 1.3271870713538192e-08
the O 0 4.468063696805302e-09
occurrence O 0 1.3488593708643748e-07
of O 0 8.631424861960113e-06
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 1.2441054195733159e-06
this O 0 1.1767334662238227e-08
patient O 0 8.228005299315555e-08
extends O 0 8.131428863578094e-09
considerably O 0 2.2891050832640758e-08
the O 0 1.1202344607497139e-09
phenotypic O 0 7.373524368858853e-08
range O 0 3.777459411935524e-08
of O 0 3.0645928461581207e-08
piebaldism B-Disease 0 1.6900842183531495e-06
due O 0 8.11977827197552e-08
to O 0 5.773067357495165e-09
KIT O 0 2.1135489078005776e-05
gene O 0 1.2384677461341198e-07
mutation O 0 4.5254960667762134e-08
in O 0 1.722191989017574e-08
humans O 0 3.369445167322738e-08
and O 0 6.92671608959472e-09
tightens O 0 1.0085238955070963e-07
the O 0 1.2573465824061714e-08
clinical O 0 1.4430176520363602e-07
similarity O 0 5.499862254509935e-08
between O 0 5.286755708766577e-07
piebaldism B-Disease 0 8.510185580234975e-06
and O 0 2.136566923383043e-09
the O 0 9.898128983110155e-10
various O 0 1.5963369515148429e-09
forms O 0 3.422558592092173e-08
of O 0 1.4127882423053961e-05
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 0.9999988079071045
. O 0 2.5976000870286953e-06
. O 0 8.21352114144247e-06

Cycloheximide O 0 9.832547948462889e-05
facilitates O 0 1.1078524266849854e-06
the O 0 4.2349135753738665e-08
identification O 0 1.506699902620312e-07
of O 0 1.2258124115760438e-07
aberrant O 0 3.382330362455832e-07
transcripts O 0 6.843761184427422e-07
resulting O 0 9.43366984529348e-08
from O 0 1.1307903946544684e-08
a O 0 1.2750488664892146e-08
novel O 0 1.4678690263281169e-08
splice O 0 2.29439706345147e-07
- O 0 3.5884049509604665e-08
site O 0 1.3706282331327202e-08
mutation O 0 3.2491502821585527e-09
in O 0 7.666152157526085e-09
COL17A1 O 0 0.00014450382150243968
in O 0 4.752078197611809e-08
a O 0 5.1689298175006115e-08
patient O 0 1.1606146443909893e-07
with O 0 5.342844033862093e-08
generalized O 0 0.0007004503859207034
atrophic B-Disease 1 0.9999995231628418
benign I-Disease 1 0.9999996423721313
epidermolysis I-Disease 1 0.9999988079071045
bullosa I-Disease 1 0.999889612197876
. O 0 0.00017825768736656755

Patients O 0 1.3648724234371912e-05
with O 0 1.2994106555197504e-06
generalized O 0 0.09968528896570206
atrophic B-Disease 1 0.9999998807907104
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999765157699585
often O 0 6.073295253372635e-07
show O 0 1.2193939369353757e-07
decreased O 0 4.162889410963544e-07
expression O 0 4.586025781350145e-08
of O 0 9.665122036039975e-08
type O 0 6.84123660903424e-05
XVII O 1 0.9998974800109863
collagen O 0 0.00012785752187483013
, O 0 2.905749738602026e-07
a O 0 3.852404404369736e-07
transmembrane O 0 4.1291086745331995e-06
hemidesmosomal O 0 5.523923391592689e-06
protein O 0 7.9718141421381e-08
encoded O 0 2.2735060056788825e-08
by O 0 2.989060021718615e-08
COL17A1 O 0 0.0007262915605679154
. O 0 9.592004062142223e-06

This O 0 6.387646322991714e-08
report O 0 4.069896419878205e-08
documents O 0 3.265821746367692e-08
a O 0 3.3533272159047556e-08
novel O 0 3.8621525533244494e-08
splice O 0 8.326501301780809e-07
- O 0 1.1532564769822784e-07
site O 0 2.3982524410826045e-08
mutation O 0 5.380310419411671e-09
in O 0 9.00986041330043e-09
COL17A1 O 0 0.0002673902199603617
in O 0 1.620326450790799e-08
a O 0 1.740605881650481e-08
patient O 0 2.213583272236974e-08
with O 0 9.086399188618088e-09
generalized O 0 0.0007162051042541862
atrophic B-Disease 1 1.0
benign I-Disease 1 0.9999998807907104
epidermolysis I-Disease 1 0.9999998807907104
bullosa I-Disease 1 0.9999421834945679
, O 0 1.691543758397529e-07
and O 0 5.504813049839186e-09
applies O 0 8.136952445170209e-09
a O 0 1.2770000612505328e-09
new O 0 1.906668989359872e-10
methodology O 0 2.558657952178578e-09
to O 0 1.4475627641008515e-10
define O 0 1.930821014184403e-08
and O 0 2.574764401686025e-09
characterize O 0 1.7484961745140026e-07
the O 0 2.929156117659204e-08
resulting O 0 7.215793829118411e-08
mRNA O 0 7.281263378899894e-07
splice O 0 2.5619151529099327e-06
variants O 0 2.4543819563405123e-06
. O 0 2.2768442704546032e-06

Mutational O 0 8.476285438518971e-05
analysis O 0 1.346999511042668e-06
of O 0 9.886341558740241e-07
COL17A1 O 0 0.0008537787362001836
identified O 0 8.331655863003107e-07
a O 0 1.0904389569077466e-07
maternally O 0 3.487857838990749e-06
inherited O 0 5.325628080754541e-05
G O 0 7.970613660290837e-05
- O 0 4.699251803685911e-06
to O 0 1.5023466914954042e-07
- O 0 0.0004558576620183885
T O 0 5.274132490740158e-05
transversion O 0 9.817821592150722e-06
at O 0 3.5861472724718624e-07
the O 0 1.193929133336269e-08
- O 0 8.313966048945076e-08
1 O 0 4.569793787823073e-08
position O 0 1.0934778060800454e-07
of O 0 2.5936145675586886e-07
exon O 0 1.9690101908054203e-05
32 O 0 8.547649485990405e-06
. O 0 5.705839612346608e-06

This O 0 8.156099084999369e-08
acceptor O 0 3.0838933184895723e-07
splice O 0 5.414256520452909e-06
- O 0 1.0058994348582928e-06
site O 0 8.432546394487872e-08
mutation O 0 1.4311281049117497e-08
led O 0 1.2443678087947774e-08
to O 0 7.544705415973851e-10
the O 0 2.0386263344107647e-08
formation O 0 9.060681804839987e-07
of O 0 4.014801220364461e-07
aberrant O 0 6.162885597404966e-07
transcripts O 0 7.785423008499492e-07
present O 0 2.018414235749333e-08
at O 0 1.5457037250143912e-07
extremely O 0 2.9373981647040637e-07
low O 0 3.6984741313972336e-07
levels O 0 9.289058198191924e-07
. O 0 3.2229331736743916e-07

Based O 0 7.485533615181339e-07
on O 0 7.58531513156413e-08
our O 0 1.2098082535771937e-08
recent O 0 5.1217803331837786e-09
finding O 0 1.5274022047151448e-08
that O 0 1.1415558498484302e-09
cycloheximide O 0 1.8742899783319444e-06
stabilized O 0 2.1058813217678107e-05
mutant O 0 1.3942686791779124e-06
COL17A1 O 0 4.091022128704935e-05
transcripts O 0 2.298986373716616e-06
in O 0 3.51397488884686e-08
keratinocytes O 0 3.675877735531685e-07
homozygous O 0 5.2668273298195345e-08
for O 0 3.698521044981362e-09
a O 0 1.7836274679439157e-08
frameshift O 0 4.420882646627433e-07
mutation O 0 7.803111934379103e-09
, O 0 1.7337793423166659e-09
the O 0 1.3632802664531596e-09
effects O 0 1.6357039100967086e-07
of O 0 3.0522841143465484e-08
the O 0 3.3297453683189815e-08
splice O 0 6.419916758204636e-07
- O 0 1.0942351025278185e-07
site O 0 1.3737976978234201e-08
mutation O 0 3.0406264173166164e-09
on O 0 1.8693075531928116e-08
splicing O 0 1.775903939460477e-07
of O 0 8.858800981670356e-08
COL17A1 O 0 4.032783908769488e-05
transcripts O 0 6.17556395354768e-07
were O 0 6.213001668697871e-09
determined O 0 4.66201122151233e-09
using O 0 1.6362452504026237e-09
reverse O 0 3.3957231693193535e-08
transcriptase O 0 1.5730036295735772e-07
polymerase O 0 2.819611779614206e-07
chain O 0 4.360668626191e-08
reaction O 0 2.45831976997124e-09
of O 0 7.837344107031186e-09
total O 0 1.898201773542496e-08
RNA O 0 7.957091838761698e-07
from O 0 5.035985850554425e-08
keratinocytes O 0 6.080852585910179e-07
incubated O 0 5.31774276169017e-07
for O 0 3.762947997643096e-08
2 O 0 1.7787424440030009e-06
. O 0 1.094197159545729e-06

5 O 0 1.0010560799855739e-05
h O 0 3.911909971066052e-06
in O 0 1.6401330071857956e-08
the O 0 7.836209015010809e-09
presence O 0 1.9424419406277593e-08
or O 0 6.079527548052965e-09
absence O 0 1.6832963467550144e-07
of O 0 1.3684292810012266e-07
10 O 0 3.901099034919753e-07
microg O 0 1.223551771545317e-05
cycloheximide O 0 8.253628948295955e-06
per O 0 4.606601464729465e-07
ml O 0 5.086743840365671e-06
. O 0 1.303648218708986e-06

Using O 0 1.37758590312842e-07
this O 0 4.75104267039228e-09
approach O 0 3.316915808682097e-08
, O 0 3.2871743105289397e-09
an O 0 3.4420195582640645e-09
abnormally O 0 2.4484714344907843e-07
spliced O 0 4.481247515286668e-07
transcript O 0 6.273281201174541e-07
was O 0 9.519870758367688e-08
identified O 0 7.541788527021254e-09
that O 0 1.7440136834689923e-10
contains O 0 3.9526285022795093e-10
an O 0 2.0572013537112355e-10
extra O 0 5.8675939662578e-09
264 O 0 5.642906586444951e-09
bases O 0 3.7982506029266005e-09
upstream O 0 2.1563215213404874e-08
from O 0 1.3155081468596563e-08
exon O 0 7.103109851414047e-07
32 O 0 7.256191025817316e-08
, O 0 4.476166992617436e-09
resulting O 0 6.820107589788904e-09
in O 0 2.5819739679633358e-09
a O 0 5.440223382890963e-09
premature O 0 1.6688460391378612e-08
termination O 0 4.470196657280212e-08
codon O 0 1.6479448561312893e-07
27 O 0 1.1900298204636783e-06
bp O 0 8.043037382776674e-07
downstream O 0 3.827736065886711e-07
from O 0 4.9280799885309534e-08
the O 0 4.477876913711043e-08
cryptic O 0 2.3880816115706693e-06
splice O 0 3.5758719150180696e-06
site O 0 1.6555105730731157e-06
. O 0 3.4842473723983858e-06

Three O 0 3.8209526564969565e-07
other O 0 2.2631654772453658e-08
splice O 0 8.745943205212825e-07
variants O 0 2.0939091882610228e-07
, O 0 9.44518951939699e-09
including O 0 3.7203551350728503e-09
one O 0 7.533431656270295e-10
derived O 0 2.0162123082201333e-09
from O 0 1.202595134586204e-09
the O 0 1.5110529494322122e-09
skipping O 0 3.811896576166873e-08
of O 0 2.6551147058739843e-08
exon O 0 2.540986770327436e-06
32 O 0 3.088190396738355e-07
, O 0 2.724369529971682e-08
were O 0 5.36209832091572e-08
also O 0 2.5362597355638172e-08
identified O 0 6.484377195192792e-07
. O 0 8.307021630571398e-07

These O 0 1.2728030185371608e-07
results O 0 5.478096554156764e-08
indicate O 0 7.428563719713566e-08
the O 0 1.1679501810135662e-08
usefulness O 0 3.770499290567386e-07
of O 0 3.360831613008486e-08
cycloheximide O 0 2.4008418222365435e-06
treatment O 0 6.02047194320221e-08
in O 0 4.246445417521727e-09
evaluating O 0 2.486217631769705e-08
the O 0 1.3784295926910772e-09
abnormal O 0 1.5812105402801535e-08
processing O 0 4.367152683926179e-08
of O 0 6.75321132348472e-09
mRNA O 0 2.8997609646808087e-08
due O 0 1.6010275771805027e-08
to O 0 2.2441180025367657e-09
splice O 0 2.8165933940726973e-07
- O 0 8.96250682558275e-08
site O 0 9.77069447571921e-09
mutations O 0 3.931629688480598e-09
, O 0 3.923591673782312e-09
because O 0 7.524431744343474e-09
( O 0 1.882305689093755e-08
i O 0 1.2471947741232725e-07
) O 0 5.8469820096718195e-09
aberrant O 0 5.431331118188609e-08
splicing O 0 1.235473661154174e-07
often O 0 3.370780543576757e-09
generates O 0 5.922305312822118e-09
a O 0 3.9501810711328744e-09
premature O 0 1.1742515404478127e-08
termination O 0 2.1870432576065468e-08
codon O 0 5.6928868730210525e-08
, O 0 1.647337732890719e-08
( O 0 1.6445310890844667e-08
ii O 0 5.145413524587639e-05
) O 0 1.4067118137006673e-08
transcripts O 0 3.11636455307962e-07
with O 0 7.611660635120643e-09
premature O 0 1.4530793635003647e-07
termination O 0 5.082836551650871e-08
codons O 0 2.200344617619976e-08
can O 0 1.2745230426602916e-09
occur O 0 2.282916744533736e-09
at O 0 2.293825396293414e-08
low O 0 5.9211110681189894e-08
or O 0 2.021310452349212e-09
undetectable O 0 8.637245230147528e-08
levels O 0 4.925136298794541e-09
due O 0 5.23059418000571e-09
to O 0 2.074389549022726e-09
nonsense O 0 3.294885004834214e-07
- O 0 6.692638976346643e-08
mediated O 0 4.583157675597249e-08
mRNA O 0 4.5573028017997785e-08
decay O 0 4.807241680282459e-07
, O 0 4.1750163326526035e-09
and O 0 1.897357604363492e-09
( O 0 3.4440750251718555e-09
iii O 0 9.905632396112196e-06
) O 0 1.372872371341316e-09
the O 0 6.622311032877803e-10
levels O 0 1.2181043729242447e-08
of O 0 1.5823561350103432e-09
these O 0 2.6876859071656156e-10
transcripts O 0 1.1820264766981836e-08
can O 0 2.3599158738285553e-10
be O 0 2.521699515867226e-10
increased O 0 2.189592285262165e-09
by O 0 3.4593292674856002e-09
cycloheximide O 0 5.737991614296334e-06
. O 0 1.0680959121600608e-06

A O 0 8.374078788619954e-06
deletion O 0 3.6697238101623952e-06
mutation O 0 1.0162245445144436e-07
in O 0 3.590191610669535e-08
COL17A1 O 0 9.382280404679477e-05
in O 0 1.9535622897137728e-08
five O 0 3.464593945068373e-08
Austrian O 0 2.399956201770692e-06
families O 0 3.713789942239032e-09
with O 0 2.0907199527187004e-08
generalized O 0 0.00013671540364157408
atrophic B-Disease 1 0.9999986886978149
benign I-Disease 1 0.999998927116394
epidermolysis I-Disease 1 0.9999988079071045
bullosa I-Disease 1 0.9941874742507935
represents O 0 1.3115093224769225e-06
propagation O 0 1.0702636927817366e-06
of O 0 1.0015652662787033e-07
an O 0 7.28621643020233e-08
ancestral O 0 7.046608970995294e-06
allele O 0 5.1231886573077645e-06
. O 0 5.220334514888236e-06

Patients O 0 1.3134258551872335e-05
with O 0 7.462617759301793e-07
generalized O 0 0.009914525784552097
atrophic B-Disease 1 0.9999998807907104
benign I-Disease 1 0.9999998807907104
epidermolysis I-Disease 1 0.9999998807907104
bullosa I-Disease 1 0.9999771118164062
, O 0 5.858281042492308e-07
a O 0 6.931701790335865e-08
usually O 0 1.752284539691118e-08
nonlethal O 0 7.193888222900569e-07
form O 0 6.395156049165962e-08
of O 0 2.9152861316106282e-06
junctional B-Disease 1 0.9999984502792358
epidermolysis I-Disease 1 0.9999982118606567
bullosa I-Disease 1 0.9986787438392639
, O 0 3.116174411843531e-07
have O 0 1.5358800453668664e-08
generalized O 0 4.994118398826686e-07
blistering B-Disease 0 4.543950581137324e-06
, O 0 2.011519427469466e-06
nail B-Disease 1 0.9999994039535522
dystrophy I-Disease 1 0.9999672174453735
, O 0 1.3785487681161612e-05
patchy B-Disease 1 0.9999696016311646
alopecia I-Disease 1 0.9999998807907104
, O 0 5.260976467980072e-05
and O 0 8.946425805334002e-05
dental B-Disease 1 0.9999998807907104
abnormalities I-Disease 1 1.0
. O 0 0.4711149036884308

Skin B-Disease 1 0.9987395405769348
fragility I-Disease 1 0.8815739154815674
in O 0 2.211893530557063e-07
most O 0 7.752377406688993e-09
cases O 0 1.1108363118239595e-09
is O 0 8.401613432740263e-11
due O 0 1.0608189882077568e-09
to O 0 1.8667119239257346e-10
mutations O 0 1.8374076704574804e-09
in O 0 6.29312157940376e-10
the O 0 2.1293009577760813e-09
gene O 0 1.0040362319330143e-08
encoding O 0 7.357010645137052e-07
type O 0 0.0003704525879584253
XVII O 1 0.9999864101409912
collagen O 1 0.808574378490448
( O 0 1.8881954019889235e-05
COL17A1 O 1 0.9973070621490479
) O 0 3.6007093058287865e-06
. O 0 4.2091669456567615e-06

Recently O 0 1.1040890967706218e-05
, O 0 7.792080225499376e-08
we O 0 1.6546811920647997e-08
reported O 0 1.4190839614514061e-08
five O 0 1.895248624705914e-09
Austrian O 0 2.0391848920553457e-07
families O 0 7.266557910945437e-10
with O 0 3.6428338123783988e-09
generalized O 0 2.4807788577163592e-05
atrophic B-Disease 1 0.9999995231628418
benign I-Disease 1 0.9999998807907104
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999982118606567
who O 0 1.3352560017665382e-06
share O 0 1.0940306083284668e-07
the O 0 7.897491371977594e-08
same O 0 3.1535324751530425e-07
COL17A1 O 0 0.002689519664272666
mutation O 0 1.6555105730731157e-06
. O 0 2.153400828319718e-06

Affected O 0 7.456969228769594e-07
individuals O 0 6.480962433386139e-09
in O 0 1.2363242873902891e-08
three O 0 3.775973755892892e-09
families O 0 3.974627571512457e-10
are O 0 1.2967828200149967e-10
homozygous O 0 2.2744415240083526e-09
for O 0 1.151958417544563e-09
4003delTC O 0 1.6557805793127045e-07
, O 0 5.3174864511618125e-09
whereas O 0 1.2502917812184933e-08
those O 0 1.0690370810806371e-09
in O 0 1.6695839155644876e-09
two O 0 1.342774447188333e-09
others O 0 2.5144295534573757e-09
are O 0 1.907262792144593e-09
compound O 0 3.5073369986093894e-07
heterozygotes O 0 9.206456525134854e-06
. O 0 1.958011125680059e-06

To O 0 4.34062883414299e-07
determine O 0 6.833535053374362e-07
if O 0 1.665224402813692e-08
the O 0 3.6897980226768823e-09
occurrence O 0 9.241960974293306e-09
of O 0 9.394772959581132e-09
4003delTC O 0 1.0900355817966556e-07
in O 0 1.3235512685838557e-09
these O 0 2.9613303476061503e-10
unrelated O 0 9.621563989981041e-09
families O 0 2.0559422220234325e-10
signifies O 0 2.2213899608658494e-09
propagation O 0 1.7115821648872043e-08
of O 0 5.388413715223805e-09
an O 0 2.4777708773626728e-09
ancestral O 0 6.888997461373947e-08
allele O 0 2.3509510782560028e-08
or O 0 6.917896477887098e-09
a O 0 2.856787162386354e-08
mutational O 0 4.815537977265194e-06
hot O 0 2.026961510637193e-06
spot O 0 3.822746066362015e-07
, O 0 9.707555648219568e-09
haplotypes O 0 7.27893834095994e-08
were O 0 4.846633760990926e-09
determined O 0 5.855418816480551e-09
for O 0 4.297427302901724e-09
polymorphisms O 0 1.1132383548329017e-07
both O 0 1.4201019915560664e-08
within O 0 3.24847405863693e-07
and O 0 2.3642891733288707e-07
flanking O 0 0.01294123288244009
COL17A1 O 1 0.9997071623802185
. O 0 2.692360976652708e-05

Five O 0 2.1570883745880565e-06
intragenic O 0 4.4282383896643296e-05
polymorphisms O 0 6.464027251240623e-07
were O 0 2.441475643877311e-08
chosen O 0 2.355286632393927e-08
based O 0 5.77491787723261e-09
on O 0 2.113441155415785e-08
their O 0 1.6986025030973906e-08
informativeness O 0 1.1624523722275626e-05
. O 0 6.773182121833088e-07

One O 0 3.0610823387178243e-07
of O 0 9.248806520645303e-08
these O 0 3.352442767834418e-09
, O 0 2.2392994125652876e-09
not O 0 5.148968473811522e-10
previously O 0 9.98886484637751e-09
reported O 0 3.729847541933395e-09
, O 0 1.2471829125004774e-09
was O 0 3.627180689136367e-08
2988 O 0 3.617346067130711e-07
A O 0 9.802619160836912e-08
or O 0 7.964728432341417e-09
C O 0 9.222996482094459e-07
that O 0 3.972596418488905e-10
introduces O 0 4.517843876783445e-09
a O 0 6.896760940122704e-10
new O 0 4.912609208318486e-10
restriction O 0 3.365371537000783e-09
site O 0 1.1838902302940824e-08
for O 0 1.201502097814e-08
Eco0109 O 0 1.5221813555399422e-05
I O 0 5.745965609094128e-05
. O 0 8.708226232556626e-06

All O 0 2.76895463002802e-07
the O 0 9.670672795891733e-08
4003delTC O 0 1.2558135722429142e-06
alleles O 0 3.553423866264893e-08
showed O 0 4.715474943850495e-08
the O 0 3.864559783295363e-09
same O 0 4.194524283462897e-09
haplotype O 0 5.4316622311034735e-08
for O 0 3.1486560025939525e-09
these O 0 1.1795012744286737e-09
five O 0 1.9633192849255465e-08
polymorphic O 0 6.648800194852811e-07
markers O 0 3.9033047869452275e-06
. O 0 4.940983671986032e-06

Fourteen O 0 6.908123759785667e-05
microsatellite O 0 0.00017389912682119757
polymorphisms O 0 2.958448476420017e-06
were O 0 7.457325779114399e-08
selected O 0 2.0136999623332485e-08
based O 0 3.50004003557558e-09
on O 0 2.4014326083232618e-09
their O 0 7.556976155953521e-10
high O 0 2.3441056384854164e-07
heterozygosity O 0 2.7561238766793394e-06
and O 0 2.3292359152549125e-09
their O 0 1.1727445681231075e-09
location O 0 4.7297881167196465e-08
within O 0 7.870978890878177e-08
10q23 O 0 4.638908649212681e-06
- O 0 2.579859256002237e-06
q25 O 0 2.0815101379412226e-05
near O 0 1.7628815839998424e-05
COL17A1 O 0 0.004552315454930067
. O 0 1.1323258149786852e-05

Three O 0 6.91127127083746e-07
families O 0 4.3678110017708605e-08
shared O 0 4.367690564777149e-07
microsatellite O 0 1.8323660697205923e-05
polymorphisms O 0 9.751259995027795e-07
covering O 0 1.4229794942366425e-06
at O 0 9.054376732819946e-07
most O 0 2.0597004990463574e-08
19 O 0 2.1604593314350495e-07
cM O 0 1.504269278029824e-07
, O 0 3.736761566841551e-09
whereas O 0 7.20101089868308e-09
the O 0 3.925245906089003e-09
others O 0 3.330925313349553e-09
shared O 0 4.828226707331851e-09
smaller O 0 8.394254180643657e-09
regions O 0 5.013623738392425e-09
consistent O 0 1.0924287252578324e-08
with O 0 9.239559117801832e-10
cross O 0 3.1406084843865756e-08
- O 0 3.9364937975960856e-08
over O 0 1.5379313378360848e-09
events O 0 5.103854006094366e-10
during O 0 2.1715336195882173e-09
passage O 0 2.7119100298733656e-09
of O 0 6.433382160331291e-10
this O 0 8.420994457303266e-11
mutation O 0 4.087224447779647e-10
through O 0 1.0605377687156192e-09
several O 0 9.057986360971881e-09
generations O 0 4.120338985558192e-07
. O 0 1.6113997389766155e-06

These O 0 4.232329331443907e-08
results O 0 3.287439298560457e-08
indicate O 0 1.600716004190872e-08
that O 0 8.79646133711276e-10
4003delTC O 0 3.670328752036767e-08
occurs O 0 1.7691691445165247e-09
on O 0 2.3519679537287175e-09
a O 0 1.5817465115475215e-09
single O 0 1.2333748466986094e-09
ancestral O 0 4.128740016540178e-08
allele O 0 4.089021743425292e-08
. O 0 3.5679235566021816e-08
. O 0 3.3078342198678e-07

The O 0 3.2473606097482843e-06
haptoglobin O 0 0.0006695038173347712
- O 0 1.095086736313533e-05
gene O 0 2.856390324268432e-07
deletion O 0 7.852996759538655e-07
responsible O 0 6.874990390315361e-07
for O 0 4.252883627486881e-07
anhaptoglobinemia B-Disease 0 0.0013749405043199658
. O 0 1.897462789202109e-05

We O 0 1.0390242550784023e-06
have O 0 3.7700960575648423e-08
found O 0 1.7844238087150188e-08
an O 0 1.639541058473526e-09
allelic O 0 3.602937681534968e-07
deletion O 0 7.378363875432115e-07
of O 0 1.9836004128137574e-07
the O 0 3.244786341838335e-07
haptoglobin O 0 0.0009157389868050814
( O 0 4.626316183475865e-07
Hp O 0 6.978555688874621e-07
) O 0 9.026665637179576e-09
gene O 0 1.3010578392425032e-08
from O 0 6.081522396783612e-09
an O 0 2.1746962008961646e-09
individual O 0 6.2085119267862865e-09
with O 0 1.6234484689903184e-07
anhaptoglobinemia B-Disease 0 0.04133421927690506
. O 0 1.55581183207687e-05

The O 0 1.3835181562171783e-05
Hp O 0 1.2679580322583206e-05
gene O 0 2.649317991654243e-07
cluster O 0 2.6783320095091767e-07
consists O 0 9.832167080503496e-08
of O 0 4.34696687534597e-08
coding O 0 2.373147253820207e-06
regions O 0 6.768391358491499e-08
of O 0 2.7803558566574793e-08
the O 0 1.7683538189317005e-08
alpha O 0 5.644017733175133e-07
chain O 0 5.6083589328181915e-08
and O 0 1.6501231492327406e-09
beta O 0 1.3293637834976835e-07
chain O 0 3.051422936550807e-08
of O 0 5.306796779791512e-09
the O 0 2.5848038376352633e-08
haptoglobin O 0 6.410149126168108e-06
gene O 0 1.144852674883623e-07
( O 0 3.3746289318514755e-08
Hp O 0 3.0509809789691644e-07
) O 0 3.304121198866028e-09
and O 0 2.9035229776042115e-09
of O 0 3.0803743555907204e-08
the O 0 3.040651463948052e-08
alpha O 0 8.711696750651754e-07
chain O 0 5.8409099779055396e-08
and O 0 2.422511746758005e-09
beta O 0 1.1481579775818318e-07
chain O 0 4.210067672261175e-08
of O 0 3.6342839848657604e-09
the O 0 1.1482078399183138e-08
haptoglobin O 0 4.256350621290039e-06
- O 0 2.3622381206678256e-07
related O 0 5.575040518124297e-08
gene O 0 8.093245185136766e-08
( O 0 4.274988540942104e-08
Hpr O 0 5.066091034677811e-06
) O 0 2.5574394157956704e-08
, O 0 1.5919715323775563e-08
in O 0 2.0690322344307788e-08
tandem O 0 4.424216058396269e-06
from O 0 5.3628856022669424e-08
the O 0 1.2538362170744222e-07
5 O 0 1.1259736538704601e-06
side O 0 1.0469377684785286e-06
. O 0 1.7604068034415832e-06

Southern O 0 9.28317695070291e-06
blot O 0 5.675729880749714e-06
and O 0 4.5800028658504743e-08
PCR O 0 7.577405085612554e-07
analyses O 0 8.516241223333054e-08
have O 0 2.1361594715330057e-09
indicated O 0 6.256716478247881e-09
that O 0 4.379015552946619e-11
the O 0 1.272739275082202e-10
individual O 0 9.50425432799662e-11
with O 0 4.5398254600037546e-10
anhaptoglobinemia B-Disease 0 9.166595305032388e-07
was O 0 8.208912305462945e-08
homozygous O 0 4.367658679171882e-09
for O 0 4.6092596406310804e-10
the O 0 2.001273813334592e-09
gene O 0 6.024237109159003e-09
deletion O 0 4.216134641410463e-08
and O 0 1.7404655494601684e-09
that O 0 4.6306899981196636e-10
the O 0 3.2307225783512195e-09
gene O 0 1.96715390643476e-08
deletion O 0 1.6278421810511645e-07
was O 0 1.5314591905735142e-07
included O 0 2.2512658404139074e-08
at O 0 2.2757279793950147e-07
least O 0 8.727976563704942e-09
from O 0 9.115561638850522e-09
the O 0 2.654431163762183e-08
promoter O 0 5.42624547961168e-05
region O 0 8.981730843515834e-07
of O 0 4.651945744171826e-07
Hp O 0 1.6284427601931384e-06
to O 0 4.3266677351994076e-08
Hpr O 0 1.2160601727373432e-05
alpha O 0 6.96109395903477e-07
but O 0 9.863041938729111e-09
not O 0 3.2052323017950357e-09
to O 0 4.934049613325442e-09
Hpr O 0 6.483007382485084e-06
beta O 0 4.809076017409097e-06
( O 0 3.388102811641147e-07
Hpdel O 0 2.7622114430414513e-05
) O 0 5.254230472928612e-07
. O 0 2.009578793149558e-06

In O 0 2.5838431838565157e-07
addition O 0 1.5313409562622837e-07
, O 0 1.524288251175676e-08
we O 0 6.041013467239509e-09
found O 0 4.511962359288191e-09
seven O 0 1.107574032488401e-09
individuals O 0 1.4112333523996767e-10
with O 0 8.398285400446071e-10
hypohaptoglobinemia B-Disease 0 6.447861778724473e-06
in O 0 6.357342652307807e-09
three O 0 2.317523284389722e-09
families O 0 2.6619473292299745e-10
, O 0 6.816359143790862e-10
and O 0 3.9684008856788466e-10
the O 0 1.5261609753736138e-09
genotypes O 0 4.121454111327694e-08
of O 0 1.1852526071720604e-08
six O 0 9.115544763460548e-09
of O 0 5.18897902423987e-09
the O 0 4.699239219974061e-09
seven O 0 3.6474785414242206e-09
individuals O 0 3.2105479386146385e-10
were O 0 2.8101894145038386e-09
found O 0 6.231500315756477e-10
to O 0 5.418236415088984e-10
be O 0 2.0171750492181673e-08
Hp2 O 0 0.00019795041589532048
/ O 0 0.00039617824950255454
Hpdel O 0 0.000521956360898912
. O 0 3.553099531927728e-06

The O 0 7.142167532947497e-07
phenotypes O 0 1.9163637716701487e-06
and O 0 4.43324452703564e-08
genotypes O 0 1.0945572057607933e-06
in O 0 1.1381692033296531e-08
one O 0 2.645291763414548e-09
of O 0 4.7254666846185955e-09
these O 0 4.5363371392603824e-10
three O 0 2.0660184674170523e-09
families O 0 8.587644484414625e-10
showed O 0 1.5616862469869375e-08
the O 0 2.1055617249743364e-09
father O 0 1.3615087723906072e-08
to O 0 1.461682663794761e-09
be O 0 1.5184816959390446e-08
hypohaptoglobinemic B-Disease 0 3.8130713164719054e-06
( O 0 1.3878643123632628e-08
Hp2 O 0 1.632373596294201e-06
) O 0 6.815400688253703e-09
and O 0 1.9087085689761807e-08
Hp2 O 0 9.561921615386382e-05
/ O 0 3.6212899431120604e-05
Hpdel O 0 6.654478056589141e-05
, O 0 1.2885934097539575e-08
the O 0 7.453909489640864e-09
mother O 0 8.298404630124878e-09
to O 0 9.982117354923048e-10
be O 0 7.508045740678426e-09
Hp2 O 0 2.794796955640777e-06
- O 0 2.1509961811716494e-07
1 O 0 7.874763241488836e-08
and O 0 8.553190156135315e-09
Hp1 O 0 4.463750883587636e-05
/ O 0 9.262809726351406e-06
Hp2 O 0 3.74488445231691e-05
, O 0 8.844462939805453e-09
one O 0 9.79767600384207e-10
of O 0 2.2706272417849505e-09
the O 0 2.24623764033538e-09
two O 0 8.357983749540665e-10
children O 0 3.0969904418753913e-10
to O 0 2.2453200410055274e-10
be O 0 7.643375710131295e-09
hypohaptoglobinemic B-Disease 0 2.7100245461042505e-06
( O 0 2.828495837547962e-08
Hp2 O 0 2.7236064852331765e-06
) O 0 7.2350294644252244e-09
and O 0 1.4383416235830282e-08
Hp2 O 0 7.958089554449543e-05
/ O 0 3.625229146564379e-05
Hpdel O 0 0.00021975464187562466
, O 0 8.558461495056235e-09
and O 0 7.405525637160792e-10
the O 0 8.887749425312563e-10
other O 0 8.005083818041214e-10
child O 0 2.5508906098536954e-09
to O 0 4.637009665131586e-10
be O 0 5.325158980440392e-09
Hp1 O 0 4.5524388951889705e-06
and O 0 5.217564336135183e-08
Hp1 O 0 0.0017447362188249826
/ O 0 0.00014421735249925405
Hpdel O 0 5.162192974239588e-05
, O 0 5.224273458281914e-09
showing O 0 2.0519248522532507e-08
an O 0 1.2045372477231808e-09
anomalous O 0 2.5832025585259544e-07
inheritance O 0 1.630643282624078e-06
of O 0 2.2467011149274185e-06
Hp O 0 8.04714818514185e-06
phenotypes O 0 6.10910831255751e-07
in O 0 1.366967872229452e-08
the O 0 2.4813900267872668e-08
child O 0 1.7595799306491244e-07
with O 0 9.870949924106753e-08
Hp1 O 0 0.0013274665689095855
. O 0 4.9206314542971086e-06

The O 0 5.309438620315632e-06
Hp2 O 0 0.006248600780963898
/ O 0 0.00024779498926363885
Hpdel O 0 3.701433524838649e-05
individuals O 0 8.247043936648879e-09
had O 0 1.2285294559433169e-08
an O 0 8.546581220514327e-10
extremely O 0 1.4434479389535682e-08
low O 0 4.414377485773002e-08
level O 0 8.092797543213237e-08
of O 0 4.5844689822160944e-08
Hp O 0 1.3597367853890319e-07
( O 0 4.773860862172796e-09
mean O 0 3.813751092707207e-08
+ O 0 1.1171457714453936e-07
/ O 0 7.767883403175802e-07
- O 0 2.5742164666553435e-07
SD O 0 3.855848262901418e-06
= O 0 2.3875685428720317e-07
0 O 0 4.473574222174648e-08
. O 0 4.595357427916724e-09
049 O 0 1.1525015679580974e-06
+ O 0 3.2843439612406655e-07
/ O 0 1.1922357998628286e-06
- O 0 4.7231623057086836e-07
0 O 0 5.4916128533477604e-08
. O 0 8.04442379376269e-09
043 O 0 2.0268223579478217e-06
mg O 0 7.63757782351604e-07
/ O 0 3.4463513998161943e-07
ml O 0 1.629639285738449e-07
; O 0 3.807672843691989e-09
n O 0 4.719262847174832e-08
= O 0 5.848947637332458e-08
6 O 0 4.7885453824392243e-08
) O 0 6.077043313013064e-10
, O 0 3.5450056778962846e-10
compared O 0 1.1437090163823882e-09
with O 0 1.0305344771976976e-10
the O 0 1.1587898418596865e-09
level O 0 9.585939153566869e-08
( O 0 1.6655286039224393e-09
1 O 0 1.4159475369979191e-08
. O 0 8.111690208423283e-10
64 O 0 4.4927112696768745e-08
+ O 0 7.66867174206709e-08
/ O 0 5.00988846852124e-07
- O 0 1.456130007682077e-07
1 O 0 8.364849435338328e-08
. O 0 4.44677494826351e-09
07 O 0 3.016664038568706e-07
mg O 0 4.237653001837316e-07
/ O 0 1.5173779388533148e-07
ml O 0 4.694860678000623e-08
) O 0 1.0404953565412711e-09
obtained O 0 1.1541978928164554e-08
from O 0 1.9891579938757786e-08
52 O 0 3.8321852002809464e-07
healthy O 0 3.0785250260123576e-07
volunteers O 0 3.5319700941727206e-08
having O 0 5.535771663289779e-08
phenotype O 0 6.39679029745821e-08
Hp2 O 0 3.2289058253809344e-06
, O 0 9.248944721207408e-09
whereas O 0 1.757885037534379e-08
the O 0 1.0180497334033589e-08
serum O 0 6.141908670542762e-08
Hp O 0 3.998149367134829e-08
level O 0 5.6571668238802886e-08
of O 0 5.252939860866945e-09
an O 0 2.4825286271124014e-10
individual O 0 4.4500139684267026e-10
with O 0 8.20030177095532e-09
Hp1 O 0 0.00020072053303010762
/ O 0 0.00011114002700196579
Hpdel O 0 0.00040615766192786396
was O 0 5.1014435484830756e-06
0 O 0 1.792623265828297e-06
. O 0 9.874129318632185e-07

50 O 0 3.5053424653597176e-05
mg O 0 0.0002127396292053163
/ O 0 6.456510891439393e-05
ml O 0 8.922192137106322e-06
, O 0 3.950114901840607e-08
which O 0 1.902898949524001e-09
was O 0 2.6939295239003513e-08
approximately O 0 1.733319709984471e-09
half O 0 1.0021721230657477e-09
the O 0 5.715881656875865e-10
level O 0 3.971691242554698e-08
of O 0 1.2165254581475438e-08
Hp O 0 8.167649667711885e-08
in O 0 4.415537269153447e-09
control O 0 4.24480816718642e-07
sera O 0 6.792458293602976e-07
from O 0 7.145885216885972e-09
the O 0 1.027583529378262e-08
Hp1 O 0 1.1776133987950743e-06
phenotype O 0 1.3425651701481911e-08
( O 0 4.460706470865716e-09
1 O 0 2.744438454271858e-08
. O 0 1.4694537808779273e-09
26 O 0 6.528046725406966e-08
+ O 0 5.5511982566258666e-08
/ O 0 4.655856002955261e-07
- O 0 1.8642218435616087e-07
0 O 0 2.688478062395916e-08
. O 0 3.927859371088971e-09
33 O 0 2.9887726782362734e-07
mg O 0 6.008656328049256e-07
/ O 0 4.155238002567785e-07
ml O 0 2.5596335717636975e-07
; O 0 6.786720074813957e-09
n O 0 1.281202486325128e-07
= O 0 6.48410534154209e-08
9 O 0 1.5714756784745987e-07
) O 0 2.7258184598366597e-09
, O 0 2.0374162357228442e-09
showing O 0 1.7631805349083152e-08
a O 0 1.4211505749983644e-08
gene O 0 4.289126209755523e-08
- O 0 1.4776607315525325e-07
dosage O 0 6.755545314263145e-07
effect O 0 1.421808860868623e-06
. O 0 1.074891315511195e-06

The O 0 2.5481767806923017e-07
other O 0 4.176452250703733e-08
allele O 0 8.810103224732302e-08
( O 0 2.089711159669605e-08
Hp2 O 0 2.1975970412313472e-06
) O 0 4.451153223783422e-09
of O 0 6.2253380228582955e-09
individuals O 0 2.1396580063282045e-09
with O 0 3.501918399706483e-08
Hp2 O 1 0.5470708608627319
/ O 0 0.012227894738316536
Hpdel O 0 0.013384138233959675
was O 0 1.0821528348969878e-06
found O 0 3.7204401781565366e-09
to O 0 3.9469780221956796e-10
have O 0 2.5752688870284146e-10
, O 0 2.755760619699288e-10
in O 0 1.4178407059528553e-10
all O 0 2.331118909015828e-10
exons O 0 1.2388547965258567e-08
, O 0 2.8428256970691734e-10
no O 0 3.62775837148277e-10
mutation O 0 3.9422978770353723e-10
, O 0 3.4468991549907457e-10
by O 0 5.213937614989561e-10
DNA O 0 1.5947925646742078e-07
sequencing O 0 6.292196417234663e-07
. O 0 1.177025069409865e-06

On O 0 5.996760137350066e-07
the O 0 1.8926776590433292e-08
basis O 0 1.8920099265073986e-08
of O 0 4.755031479675154e-09
the O 0 1.4375317602954851e-09
present O 0 1.1596300586447228e-09
study O 0 1.11530740198873e-09
, O 0 1.970542895524119e-10
the O 0 5.165139427276699e-10
mechanism O 0 2.4434788414851027e-08
of O 0 1.058816234689175e-08
anhaptoglobinemia B-Disease 0 1.3556197018260718e-06
and O 0 1.5352847881899834e-09
the O 0 2.100836171692322e-09
mechanism O 0 4.42078125217904e-08
of O 0 1.0397875449541516e-08
anomalous O 0 5.466546895149804e-07
inheritance O 0 7.368561227849568e-07
of O 0 9.68685981206363e-07
Hp O 0 1.0105992259923369e-05
phenotypes O 0 1.6223183365582372e-06
were O 0 1.873144839237284e-07
well O 0 3.6064372466171335e-07
explained O 0 4.256228749000002e-06
. O 0 1.6768278783274582e-06

However O 0 2.315873416591785e-06
, O 0 6.313276657010647e-08
the O 0 2.7369058130943813e-08
mechanism O 0 1.4612313634643215e-06
of O 0 9.895887842503726e-07
hypohaptoglobinemia B-Disease 0 0.00041552624315954745
remains O 0 8.215331035898998e-05
unknown O 0 0.00019824846822302788

ATM O 0 0.0007923118537291884
mutations O 0 1.7485555190432933e-06
and O 0 1.0752157209026336e-07
phenotypes O 0 1.24850512293051e-05
in O 0 1.2020555914205033e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
families O 0 1.0273526385162768e-07
in O 0 2.6829763299929255e-08
the O 0 1.0583316445433866e-08
British O 0 1.0933108995914154e-07
Isles O 0 5.911575584605089e-08
: O 0 1.2402111559950413e-09
expression O 0 3.3484170991471274e-09
of O 0 1.3276098442815965e-08
mutant O 0 1.0240229642022314e-07
ATM O 0 1.336791228823131e-06
and O 0 1.1947713929316706e-09
the O 0 2.21975926528728e-09
risk O 0 7.340338470385177e-08
of O 0 4.904150614493119e-07
leukemia B-Disease 1 1.0
, O 0 0.13491171598434448
lymphoma B-Disease 1 1.0
, O 0 9.017928823595867e-05
and O 0 0.0020342671778053045
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999903440475464
. O 0 0.0003177888866048306

We O 0 3.903633682966756e-07
report O 0 2.0516196741482418e-08
the O 0 2.3102060264790225e-09
spectrum O 0 5.32782387097086e-08
of O 0 6.130858043462695e-09
59 O 0 7.988740691189378e-08
ATM O 0 1.0913956884905929e-06
mutations O 0 4.495503524992728e-09
observed O 0 1.953167405588374e-08
in O 0 1.6175464168100007e-07
ataxia B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999951124191284
telangiectasia I-Disease 1 1.0
( O 0 0.007908481173217297
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 4.386587590943236e-07
patients O 0 4.481661974864437e-08
in O 0 3.892686617490426e-09
the O 0 3.8214185593687944e-08
British O 0 2.7539565508050146e-06
Isles O 0 9.271550879930146e-06
. O 0 3.987323907495011e-06

Of O 0 3.296328941360116e-06
51 O 0 1.4037659639143385e-05
ATM O 0 0.00036866095615550876
mutations O 0 2.383546302553441e-07
identified O 0 7.653109435068473e-08
in O 0 4.326088376416237e-09
families O 0 7.510891908424355e-10
native O 0 2.9193156780848994e-09
to O 0 7.275294255926212e-10
the O 0 6.33295682561652e-09
British O 0 1.424346578460245e-07
Isles O 0 2.5089411792578176e-07
, O 0 1.1063879590267334e-08
11 O 0 8.877457702283209e-08
were O 0 3.738709608569479e-08
founder O 0 3.457128627815109e-07
mutations O 0 1.1249262854562403e-08
, O 0 3.758477085114009e-09
and O 0 3.290197669869599e-09
2 O 0 1.6022700322082528e-07
of O 0 1.4540448844968523e-08
these O 0 9.944338685841103e-10
11 O 0 1.3758667094521115e-08
conferred O 0 5.078146259052119e-08
a O 0 6.909628424978109e-09
milder O 0 2.7665967294865368e-08
clinical O 0 1.5246401474655613e-08
phenotype O 0 1.5947028142448971e-09
with O 0 2.0538100387046399e-10
respect O 0 7.361113496529015e-09
to O 0 1.7259671025726675e-08
both O 0 1.1458631888672244e-05
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 0.9999998807907104
and O 0 1.3749239769822452e-05
cellular O 0 0.16860510408878326
features O 0 9.433230843569618e-06
. O 0 4.413659098645439e-06

We O 0 4.0988263094732247e-07
report O 0 5.4024944518005213e-08
, O 0 6.3466929489663926e-09
in O 0 3.208767918039257e-09
two O 0 1.4747387311331295e-08
A B-Disease 0 0.264003187417984
- I-Disease 0 0.06927606463432312
T I-Disease 0 0.377273827791214
families O 0 1.0845162545791709e-09
, O 0 1.2159403484091058e-09
an O 0 6.538146690715507e-10
ATM O 0 1.3203165281083784e-06
mutation O 0 9.80807612904755e-09
( O 0 8.387083916261417e-09
7271T O 0 1.6849647863637074e-06
- O 0 1.795749426491966e-06
- O 0 1.4308163827081444e-06
> O 0 6.705965347464371e-07
G O 0 3.3771323160181055e-06
) O 0 4.300338307672291e-09
that O 0 8.642296323024823e-10
may O 0 2.8693347697839044e-09
be O 0 2.230193668628644e-10
associated O 0 4.872370840125484e-10
with O 0 3.379390517421754e-11
an O 0 8.338855994605154e-11
increased O 0 5.381131540360684e-09
risk O 0 4.548445531327161e-08
of O 0 1.467586798753473e-07
breast B-Disease 1 0.9206493496894836
cancer I-Disease 0 9.874329407466576e-06
in O 0 5.338114839048558e-09
both O 0 1.9316313881745373e-08
homozygotes O 0 2.4675039185240166e-06
and O 0 5.976330097468008e-09
heterozygotes O 0 3.017325695964246e-07
( O 0 5.89623549984708e-09
relative O 0 3.5262490882814745e-07
risk O 0 2.3792698300439952e-07
12 O 0 6.229236504395885e-08
. O 0 3.1394569166565134e-09
7 O 0 5.186844376225963e-08
; O 0 4.1197072420118275e-09
P O 0 2.666330829015351e-06
= O 0 1.0679212181230469e-07
. O 0 6.738363200753383e-09
0025 O 0 1.2164139207015978e-06
) O 0 3.0566169595402926e-09
, O 0 1.0557645868658483e-09
although O 0 9.463902994610862e-10
there O 0 1.1773884089905096e-09
is O 0 4.1930819927316065e-10
a O 0 1.5520702500992911e-09
less O 0 4.294029309903635e-08
severe O 0 2.1062407540739514e-05
A B-Disease 1 0.9999728202819824
- I-Disease 1 0.9852080345153809
T I-Disease 1 0.9578342437744141
phenotype O 0 1.3289096045809856e-08
in O 0 5.328610885868557e-10
terms O 0 2.039768798312025e-09
of O 0 1.9371166892767633e-09
the O 0 5.568385308407642e-09
degree O 0 1.2511837894635391e-06
of O 0 5.866080300620524e-06
cerebellar B-Disease 1 0.9999971389770508
degeneration I-Disease 1 0.9999972581863403
. O 0 0.00019462115596979856

This O 0 1.5965835586939647e-07
mutation O 0 2.4287709265991e-07
( O 0 9.300779879595211e-08
7271T O 0 1.1401894880691543e-05
- O 0 9.520063940726686e-06
- O 0 4.529742000158876e-06
> O 0 1.0912541483776295e-06
G O 0 1.2292276778680389e-06
) O 0 2.18562412612755e-09
also O 0 6.599261692663561e-10
allows O 0 2.1284755902239993e-10
expression O 0 1.4155986383102004e-09
of O 0 2.5179374141259814e-09
full O 0 1.0398906624686788e-08
- O 0 4.492368788078238e-08
length O 0 1.1320938853032203e-08
ATM O 0 1.1932241932299803e-06
protein O 0 1.774746749561018e-08
at O 0 1.4091098066160157e-08
a O 0 2.485799122098342e-09
level O 0 4.3222961210176436e-08
comparable O 0 3.5717093282983114e-08
with O 0 3.9389308481574403e-10
that O 0 2.1085587442737364e-10
in O 0 2.182458214150529e-09
unaffected O 0 1.0122877824869647e-07
individuals O 0 1.2487856082543658e-08
. O 0 5.177938646738767e-07

In O 0 1.8567078541309456e-07
addition O 0 6.288135523391247e-08
, O 0 1.2318942310685088e-08
we O 0 3.0264393213741414e-09
have O 0 3.776937096411359e-10
studied O 0 5.921935297692471e-08
18 O 0 5.20107619195187e-07
A B-Disease 1 0.9998692274093628
- I-Disease 1 0.9999322891235352
T I-Disease 1 0.9999924898147583
patients O 0 4.093048389108844e-08
, O 0 5.787109680355229e-10
in O 0 3.541592852318587e-10
15 O 0 5.369484856743156e-09
families O 0 1.6213819176158495e-10
, O 0 1.111858050073522e-09
who O 0 5.710425465821345e-09
developed O 0 3.5176526580471545e-05
leukemia B-Disease 1 1.0
, O 0 0.0038298829458653927
lymphoma B-Disease 1 1.0
, O 0 3.296842987765558e-05
preleukemic O 1 0.9981132745742798
T O 1 0.9705434441566467
- O 0 0.00040371320210397243
cell O 0 3.4482785849832e-05
proliferation O 0 0.00021447976178023964
, O 0 5.384686829756902e-08
or O 0 3.312332046334632e-05
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 1.4296351764642168e-06
mostly O 0 9.841773618290972e-08
in O 0 1.167047756212014e-07
childhood O 0 2.0362213035696186e-05
. O 0 3.580229531507939e-06

A O 0 4.47379716206342e-06
wide O 0 2.071333113917717e-07
variety O 0 2.465176507371325e-08
of O 0 1.9535809414605865e-08
ATM O 0 3.134587359454599e-06
mutation O 0 5.48605116890144e-09
types O 0 4.1411833962001765e-09
, O 0 1.234561008978119e-09
including O 0 4.312610268897288e-09
missense O 0 1.0138002153325942e-06
mutations O 0 5.928445290237505e-08
and O 0 2.2363167317962507e-08
in O 0 1.0902456182293463e-07
- O 0 6.08851087235962e-06
frame O 0 2.4541512175346725e-05
deletions O 0 5.692777449439745e-07
, O 0 2.3451020680909096e-08
were O 0 1.8906499477111538e-08
seen O 0 3.259151171164376e-08
in O 0 1.9268211470802044e-09
these O 0 2.648386399073388e-09
patients O 0 2.1812532224885217e-07
. O 0 4.6228626615629764e-07

We O 0 6.175293378873903e-07
also O 0 3.0494792468971355e-08
show O 0 4.771930850466788e-09
that O 0 2.038072210996944e-10
25 O 0 3.761324141038358e-09
% O 0 1.2135052962491955e-09
of O 0 3.862739905713397e-09
all O 0 1.4541281956326202e-08
A B-Disease 1 0.9999895095825195
- I-Disease 1 0.9999710321426392
T I-Disease 1 0.9999841451644897
patients O 0 1.2668702709106583e-07
carried O 0 1.3404976684228131e-08
in O 0 1.3918567631776568e-08
- O 0 3.1901879538054345e-07
frame O 0 1.1930274013138842e-06
deletions O 0 1.0343010359292748e-07
or O 0 2.8387539430241304e-08
missense O 0 1.4326174095913302e-06
mutations O 0 3.614762889014855e-08
, O 0 7.61581375741116e-09
many O 0 1.155554207876719e-09
of O 0 1.4545859627901336e-08
which O 0 1.6653379786291111e-09
were O 0 5.803627356470997e-09
also O 0 7.378441746475062e-10
associated O 0 2.207594995695672e-09
with O 0 3.992589869827867e-10
expression O 0 1.1850853631756308e-08
of O 0 7.263695778192414e-08
mutant O 0 5.751205662818393e-06
ATM O 0 0.0007841506158001721
protein O 0 1.1853082469315268e-05
. O 0 2.248919599878718e-06

The O 0 2.5957328944059554e-06
DMPK O 0 0.0009242310770787299
gene O 0 2.3597688141308026e-06
of O 0 2.4373846372327534e-06
severely O 1 0.9997168183326721
affected O 1 0.9999338388442993
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.23670504987239838
is O 0 8.190033895516535e-07
hypermethylated O 0 0.00018475671822670847
proximal O 0 7.600689514219994e-06
to O 0 3.4710364360535095e-08
the O 0 7.750472974521472e-08
largely O 0 6.000192342980881e-07
expanded O 0 1.2408527254592627e-06
CTG O 0 0.00028408668003976345
repeat O 0 7.14578345650807e-06
. O 0 2.598274022602709e-06

Using O 0 1.1728781146302936e-06
methylation O 0 3.139736236335011e-06
- O 0 3.6141841519565787e-07
sensitive O 0 2.8169375809738995e-07
restriction O 0 1.5770780237289728e-08
enzymes O 0 8.274128049379215e-09
, O 0 6.60167864818817e-10
we O 0 6.189531664979597e-10
characterized O 0 4.858573543486955e-09
the O 0 7.315648087313775e-10
methylation O 0 2.1097839919548278e-08
pattern O 0 5.227007093822067e-08
on O 0 2.398760123867305e-08
the O 0 9.861424565826837e-09
5 O 0 3.387481584127272e-08
side O 0 2.1992075716070758e-08
of O 0 2.2148164191548858e-08
the O 0 7.84259626129824e-08
CTG O 0 0.00012230001448187977
repeat O 0 1.1382760334299746e-07
in O 0 2.5970974260047797e-09
the O 0 3.1956426393975335e-09
DMPK O 0 2.823044269462116e-06
gene O 0 3.6251108781470975e-09
of O 0 3.0499081038470877e-09
normal O 0 1.4487049782019312e-08
individuals O 0 2.3069464394342987e-10
and O 0 1.558168705173557e-09
of O 0 1.3657930253430095e-07
patients O 0 2.2377305413101567e-06
affected O 0 1.1056306448153919e-06
with O 0 0.08877314627170563
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 1.1903385939149302e-06
showing O 0 4.977314915777242e-07
expansions O 0 1.3454611291763285e-07
of O 0 3.0672712370005684e-08
the O 0 2.5056312580318263e-08
repetitive O 0 4.8735932978161145e-06
sequence O 0 7.103827783794259e-07
. O 0 2.8446402211557142e-06

The O 0 1.3276170420795097e-06
gene O 0 5.073316060588695e-07
segment O 0 2.5502967559987155e-07
analyzed O 0 6.116540163247919e-08
corresponds O 0 2.7526745327577373e-08
to O 0 2.2461263959883127e-09
the O 0 1.2265767956876061e-08
genomic O 0 4.4758576223102864e-07
SacI O 0 5.63557114219293e-05
- O 0 1.1222987268411089e-06
HindIII O 0 2.421812041575322e-06
fragment O 0 4.029108140457538e-07
carrying O 0 2.2164736890317727e-07
exons O 0 2.1474943423527293e-06
11 O 0 2.6514817363931797e-06
- O 0 5.172270903130993e-06
15 O 0 2.9286029530339874e-06
. O 0 1.4723772210345487e-06

There O 0 8.459383025183342e-07
is O 0 3.66988075484187e-08
constitutive O 0 1.1236652426305227e-06
methylation O 0 9.937803042703308e-07
in O 0 1.6225537535774492e-07
intron O 0 1.850307126005646e-05
12 O 0 1.1712288738863208e-07
at O 0 3.5492174532691934e-08
restriction O 0 5.2281605711357315e-09
sites O 0 2.043358815484453e-09
of O 0 5.6017066540903215e-09
SacII O 0 6.980939133427455e-07
and O 0 1.0400929895126865e-08
HhaI O 0 2.401118990746909e-06
, O 0 6.2870300077122465e-09
localized O 0 1.026130576065043e-07
1 O 0 1.1468163307881696e-07
, O 0 3.1277600509582726e-09
159 O 0 1.4868072106821728e-08
- O 0 4.169313072566183e-08
1 O 0 4.8370505822958876e-08
, O 0 3.5649561080930425e-09
232 O 0 1.5611293591177855e-08
bp O 0 1.0490550295116918e-07
upstream O 0 4.568704170537785e-08
of O 0 1.8392563916336258e-08
the O 0 3.4945916382866926e-08
CTG O 0 0.00013757839042227715
repeat O 0 3.122317195902724e-07
, O 0 5.549956494377284e-09
whereas O 0 6.8346932557972195e-09
most O 0 1.0803643535339802e-09
, O 0 3.629419265127609e-10
if O 0 3.874758014443813e-10
not O 0 1.816221895101222e-10
all O 0 2.251014652454586e-10
, O 0 2.791298858717539e-10
of O 0 3.7223973903266483e-10
the O 0 1.9386534044762982e-10
other O 0 5.668682884207854e-11
sites O 0 6.426502108247689e-10
of O 0 2.3008877025887386e-09
SacII O 0 1.560879923090397e-06
, O 0 1.216228451283996e-08
HhaI O 0 2.518365135983913e-06
, O 0 5.1509752019285315e-09
and O 0 3.91106880215375e-09
HpaII O 0 1.7118583173214574e-06
in O 0 1.8097978671249848e-09
this O 0 4.774996509304685e-10
region O 0 1.4970142458992086e-08
are O 0 5.60810731187189e-10
unmethylated O 0 4.320054642903415e-07
, O 0 8.032859377671286e-10
in O 0 7.81202824651217e-10
normal O 0 1.3159649370209081e-08
individuals O 0 3.8272793267957184e-10
and O 0 8.384520855386768e-10
most O 0 1.2166176954764296e-09
of O 0 1.3959669864505031e-08
the O 0 8.196177248009917e-08
patients O 0 4.844949899052153e-07
. O 0 9.051562415152148e-07

In O 0 2.429521543945157e-07
a O 0 2.9110603705362337e-08
number O 0 7.560324810640395e-09
of O 0 6.199674373874586e-08
young O 0 1.0352661661272577e-07
and O 0 7.336755203368739e-08
severely O 0 0.0012445481261238456
affected O 0 1.1658352150334395e-07
patients O 0 2.0098973152471444e-08
, O 0 1.1101966013171705e-09
however O 0 1.1192455851016803e-09
, O 0 2.3050727993023656e-10
complete O 0 8.446784938165308e-10
methylation O 0 3.6935861036369033e-09
of O 0 9.003516820982327e-10
these O 0 9.206763823543795e-11
restriction O 0 1.4574955686796898e-09
sites O 0 1.3787083696925606e-09
was O 0 1.650999159608091e-08
found O 0 1.881174327422741e-09
in O 0 1.399533378076967e-09
the O 0 9.496056385671636e-09
mutated O 0 1.3817054878018098e-07
allele O 0 2.731649715315143e-07
. O 0 8.775920719017449e-07

In O 0 2.797693241518573e-07
most O 0 2.0247455267963232e-08
of O 0 1.7325570311754745e-08
these O 0 1.4967879158334085e-09
patients O 0 1.0141019579634758e-08
, O 0 7.807217095034957e-10
the O 0 2.975123258863732e-09
onset O 0 2.9490681754396064e-06
of O 0 1.3282981115025905e-07
the O 0 2.6728230295702815e-06
disease O 1 0.9984452128410339
was O 0 0.4819313883781433
congenital O 1 1.0
. O 0 0.0010735405376181006

Preliminary O 0 3.601780690587475e-06
in O 0 4.1309701259706344e-07
vivo O 0 5.8808786889130715e-06
footprinting O 0 1.34819965751376e-05
data O 0 5.863524421556576e-08
gave O 0 2.2142927491586306e-08
evidence O 0 2.076235006143179e-08
for O 0 4.183274615598975e-09
protein O 0 1.4706242268403003e-07
- O 0 7.069347418564575e-08
DNA O 0 3.665256897988911e-08
contact O 0 1.7925220419101606e-08
in O 0 2.566654444535743e-09
normal O 0 4.5218204292041264e-08
genes O 0 5.370345501631846e-09
at O 0 1.5287808352582033e-08
an O 0 1.597555421284369e-09
Sp1 O 0 4.918741183246311e-07
consensus O 0 6.172183475428028e-08
binding O 0 3.414440641336114e-08
site O 0 2.8111934113894677e-08
upstream O 0 3.9559356679319535e-08
of O 0 1.1235667507492053e-08
the O 0 2.752485528390025e-08
CTG O 0 5.769103154307231e-05
repeat O 0 8.91626683596769e-08
and O 0 7.425072223732343e-10
for O 0 2.918512931326944e-10
a O 0 6.506721828003492e-10
significant O 0 1.0857000853903287e-09
reduction O 0 4.834741940129561e-09
of O 0 2.275726052047844e-09
this O 0 1.7077975145163293e-10
interaction O 0 1.0617243084709571e-08
in O 0 1.8052678241176068e-09
cells O 0 6.349160086571715e-10
with O 0 3.368079704024751e-10
a O 0 1.6659994273027223e-08
hypermethylated O 0 6.343231689243112e-06
DMPK O 0 0.00036218794411979616
gene O 0 7.441098546223657e-07
. O 0 1.5356464189153485e-07
. O 0 1.6984427020361181e-06

The O 0 8.827740384731442e-05
hemochromatosis B-Disease 1 1.0
gene O 0 5.893488832953153e-06
product O 0 7.263474230967404e-07
complexes O 0 1.2700495517492527e-06
with O 0 2.100444795871681e-08
the O 0 1.8774335330817848e-07
transferrin O 0 6.316718554444378e-06
receptor O 0 1.1682815426183879e-07
and O 0 8.757526259728365e-09
lowers O 0 3.669957493457332e-08
its O 0 6.806887831167785e-10
affinity O 0 1.4414587745648078e-08
for O 0 9.184375926452049e-09
ligand O 0 1.0822003559951554e-06
binding O 0 2.00929525817628e-06
. O 0 4.45119985670317e-06

We O 0 1.6364166413040948e-06
recently O 0 6.015777103129949e-07
reported O 0 3.039793128323254e-08
the O 0 3.1546913970004198e-09
positional O 0 7.123705358935695e-07
cloning O 0 6.651432471471708e-08
of O 0 8.608837198664787e-09
a O 0 1.5362257244078137e-08
candidate O 0 4.364504846421369e-08
gene O 0 3.8354244225047296e-07
for O 0 8.499958312313538e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.9999959468841553
HFE O 1 0.9999986886978149
. O 0 0.0004306543560232967

The O 0 9.81651737674838e-07
gene O 0 2.1386804860412667e-07
product O 0 6.449999290225605e-08
, O 0 7.16247816612281e-09
a O 0 8.057615907830495e-09
member O 0 9.934598921290672e-09
of O 0 1.4327231845356891e-08
the O 0 8.18564416249501e-09
major O 0 7.187661594798556e-07
histocompatibility O 1 0.5402539372444153
complex O 0 6.095919161452912e-05
class O 0 1.956833102667588e-06
I O 0 0.00012625804811250418
- O 0 4.83139774587471e-06
like O 0 3.048031516073024e-08
family O 0 1.7632746818208034e-08
, O 0 3.2103779634695684e-09
was O 0 4.1277399276395954e-08
found O 0 4.44078857020358e-10
to O 0 1.1192962529049666e-10
have O 0 1.533750348947649e-10
a O 0 1.0760190516378998e-09
mutation O 0 6.762385096337198e-10
, O 0 6.236890559563335e-09
Cys O 0 4.4323864131001756e-05
- O 0 2.386176220170455e-06
282 O 0 1.1754513025152846e-06
- O 0 1.6719654013286345e-05
- O 0 1.2192745998618193e-05
> O 0 2.54099154517462e-06
Tyr O 0 2.459626102790935e-06
( O 0 1.3651778374423884e-08
C282Y O 0 2.913572245688556e-07
) O 0 2.9406974633161553e-09
, O 0 5.568488448126629e-10
in O 0 6.420339260237995e-10
85 O 0 1.7288929399228437e-08
% O 0 2.717296254672874e-08
of O 0 2.0941247669270524e-07
patient O 0 1.0170415407628752e-05
chromosomes O 0 4.013968919025501e-06
. O 0 1.8991670458490262e-06

This O 0 2.503035716472368e-07
mutation O 0 2.693133751563437e-07
eliminates O 0 1.104577791011252e-06
the O 0 2.058066783661161e-08
ability O 0 5.661732771500283e-08
of O 0 1.767943160757568e-07
HFE O 0 0.0001268048508791253
to O 0 7.282020675347667e-08
associate O 0 3.909038241545204e-06
with O 0 8.674954443677052e-08
beta2 O 0 0.005485435947775841
- O 0 0.00016006003716029227
microglobulin O 0 0.0004686677420977503
( O 0 6.504420468900207e-08
beta2m O 0 4.383607574709458e-06
) O 0 8.437674559047537e-09
and O 0 1.1306265257360337e-08
prevents O 0 2.037433404211697e-07
cell O 0 5.602720193564892e-06
- O 0 3.408835596019344e-07
surface O 0 6.579579121535062e-07
expression O 0 9.40606923904852e-07
. O 0 1.4314277905214112e-06

A O 0 4.9951745495491195e-06
second O 0 3.5847179447046074e-07
mutation O 0 1.3979867041769012e-08
that O 0 3.3824809619886764e-10
has O 0 3.870001819006319e-10
no O 0 3.4177666252688255e-10
effect O 0 5.823753035372192e-09
on O 0 1.038358643512538e-08
beta2m O 0 1.208417302223097e-06
association O 0 2.294267353875057e-08
, O 0 1.1191628956908062e-08
H63D O 0 7.680559065192938e-05
, O 0 8.213670632528647e-09
was O 0 5.779460465760167e-08
found O 0 1.3662738718167589e-09
in O 0 3.665581727041456e-10
eight O 0 1.0170846387325128e-09
out O 0 2.8253008266254653e-10
of O 0 3.668884973606623e-09
nine O 0 4.8456197276891544e-08
patients O 0 1.5096995653607337e-08
heterozygous O 0 7.940338164758032e-09
for O 0 3.993932295998093e-09
the O 0 2.223014305968718e-08
C282Y O 0 9.29127236304339e-06
mutant O 0 2.089860345222405e-06
. O 0 9.125242854679527e-07

In O 0 1.1250940445961533e-07
this O 0 3.5609466486619112e-09
report O 0 3.926563518774628e-09
, O 0 9.769796083247684e-10
we O 0 1.1449705628052698e-09
demonstrate O 0 4.605008818714396e-09
in O 0 3.0356659408425912e-09
cultured O 0 1.0322041532617732e-07
293 O 0 1.114638479293717e-07
cells O 0 4.858780044969535e-08
overexpressing O 0 1.3538613075070316e-06
wild O 0 1.8096917742127516e-08
- O 0 5.078698350757804e-08
type O 0 7.81796813953406e-08
or O 0 2.3343917021634297e-08
mutant O 0 7.603935614497459e-07
HFE O 0 6.962427869439125e-05
proteins O 0 8.052530198199292e-09
that O 0 3.0302269027338014e-10
both O 0 1.276011629691709e-09
the O 0 2.865719439526515e-09
wild O 0 1.4140395521167193e-08
- O 0 5.171227002165324e-08
type O 0 4.319510793493464e-08
and O 0 1.7630057413953182e-08
H63D O 1 0.8165642023086548
HFE O 0 0.016684820875525475
proteins O 0 2.386516051444687e-08
form O 0 2.5426244221193883e-08
stable O 0 5.251527454674942e-06
complexes O 0 2.7218953846386285e-07
with O 0 8.245297777875749e-09
the O 0 2.163420163014962e-07
transferrin O 0 1.4812225344940089e-05
receptor O 0 1.9207861896575196e-06
( O 0 5.939689344813814e-07
TfR O 0 5.938480171607807e-05
) O 0 8.391230039705988e-07
. O 0 4.086927674507024e-06

The O 0 1.669312950980384e-06
C282Y O 0 2.3887307179393247e-05
mutation O 0 1.8623383368776558e-07
nearly O 0 3.6858047280929895e-08
completely O 0 9.868841743809753e-08
prevents O 0 1.822838591181153e-08
the O 0 4.429185018750559e-09
association O 0 1.0261654637133688e-08
of O 0 7.227347165184028e-09
the O 0 2.754008399108443e-08
mutant O 0 1.9317328678880585e-06
HFE O 0 0.0003778316604439169
protein O 0 2.6130294372705976e-07
with O 0 1.387123305107707e-08
the O 0 5.168880647943297e-07
TfR O 0 0.0007255513337440789
. O 0 7.086781806719955e-06

Studies O 0 6.716039706589072e-07
on O 0 4.6699392441951204e-07
cell O 0 3.550345809344435e-06
- O 0 2.917812480518478e-07
associated O 0 8.875696977383996e-08
transferrin O 0 8.031884703996184e-07
at O 0 2.895100408295548e-07
37 O 0 1.6252174361852667e-07
degrees O 0 7.450692578458984e-07
C O 0 1.8463514379618573e-06
suggest O 0 5.4401301241568945e-09
that O 0 1.4236398171441067e-10
the O 0 3.130021797304039e-09
overexpressed O 0 8.94122933914332e-07
wild O 0 5.1230923503453596e-08
- O 0 2.555494518219348e-07
type O 0 5.775129352514341e-07
HFE O 0 0.00014920849935151637
protein O 0 3.0029005415599386e-07
decreases O 0 5.6403589354658834e-08
the O 0 2.5404611747603667e-09
affinity O 0 1.770831126179928e-08
of O 0 2.132106224905783e-08
the O 0 1.0415704565502892e-07
TfR O 0 1.891996907943394e-05
for O 0 2.851520832791721e-07
transferrin O 0 4.8714951844885945e-05
. O 0 4.193893346382538e-06

The O 0 2.1864587324671447e-05
overexpressed O 0 0.0227720458060503
H63D O 1 0.6229177713394165
protein O 0 3.151054215777549e-06
does O 0 9.52359080486076e-09
not O 0 8.42703962167235e-10
have O 0 4.556826443957718e-11
this O 0 1.3278585696274714e-11
effect O 0 1.2756271594582813e-09
, O 0 1.075288053042911e-10
providing O 0 3.5572855772159073e-10
the O 0 7.272918378653515e-11
first O 0 1.0046442844302561e-10
direct O 0 3.496135048131066e-10
evidence O 0 1.0215853718520407e-09
for O 0 1.6641496514147036e-10
a O 0 1.1115315334819797e-09
functional O 0 8.258901118551876e-08
consequence O 0 6.899082904965326e-08
of O 0 1.8261932410723603e-08
the O 0 7.790178102595746e-08
H63D O 0 0.001265959464944899
mutation O 0 5.077100695416448e-07
. O 0 1.0689540204111836e-06

Addition O 0 7.622035695931118e-07
of O 0 7.69286430113425e-07
soluble O 0 2.5827053832472302e-05
wild O 0 5.570086614170577e-07
- O 0 3.0114063065411756e-06
type O 0 2.085056621581316e-05
HFE O 1 0.9999797344207764
/ O 1 0.9973636269569397
beta2m O 0 0.38011080026626587
heterodimers O 0 0.0011069265892729163
to O 0 9.035385062361456e-08
cultured O 0 1.5061889826029073e-05
cells O 0 3.6784864931860284e-08
also O 0 6.676109665093577e-10
decreased O 0 8.804052598065937e-09
the O 0 5.153665272317198e-10
apparent O 0 1.3994914560555571e-08
affinity O 0 1.1446153358463107e-08
of O 0 1.0902992286787594e-08
the O 0 1.355786949375215e-08
TfR O 0 4.893162781627325e-07
for O 0 5.942080716359044e-10
its O 0 3.2594213439374187e-10
ligand O 0 3.111155422175216e-08
under O 0 6.318456513554338e-08
steady O 0 1.7911912664203555e-06
- O 0 2.1784668291502385e-08
state O 0 5.93013527172559e-10
conditions O 0 8.69771454858892e-09
, O 0 3.716055518854233e-10
both O 0 4.908028983230395e-10
in O 0 2.0849884041496125e-09
293 O 0 1.8283017766407283e-08
cells O 0 5.497845734225848e-09
and O 0 5.028525595918154e-09
in O 0 7.198843832156854e-08
HeLa O 0 5.0604739953996614e-05
cells O 0 4.197823955109925e-07
. O 0 6.841490289843932e-07

Furthermore O 0 4.207919118925929e-06
, O 0 9.376534393368274e-08
at O 0 3.356501565576764e-07
4 O 0 2.0017374424696754e-07
degrees O 0 4.775848765348201e-07
C O 0 2.1220705548330443e-06
, O 0 3.881535981520301e-09
the O 0 4.913689011232236e-09
added O 0 1.3166609846848587e-07
soluble O 0 2.872085644867184e-07
complex O 0 6.928865445843257e-07
of O 0 1.7776831384708203e-07
HFE O 0 0.4365772604942322
/ O 0 7.533184543717653e-05
beta2m O 0 7.584137620142428e-06
inhibited O 0 8.834469156226987e-08
binding O 0 2.7153273407520828e-08
of O 0 3.733009279471844e-08
transferrin O 0 1.0325384209863842e-06
to O 0 8.015557995122435e-08
HeLa O 0 7.965553231770173e-05
cell O 0 4.585523583955364e-06
TfR O 0 3.7182544474489987e-06
in O 0 1.0819197093780986e-08
a O 0 2.8528285511697504e-08
concentration O 0 1.0402822226751596e-05
- O 0 9.327629300059925e-07
dependent O 0 1.8803973489411874e-07
manner O 0 8.710624683772039e-07
. O 0 1.440994992663036e-06

Scatchard O 0 0.0004637275997083634
plots O 0 5.9604003581625875e-06
of O 0 1.2859518960794958e-07
these O 0 3.797409942052354e-09
data O 0 2.852115699170099e-08
indicate O 0 8.674140516973239e-09
that O 0 5.821217952117763e-10
the O 0 4.457202606999999e-09
added O 0 7.323417605675786e-08
heterodimer O 0 4.194802443180379e-07
substantially O 0 7.194231699259035e-08
reduced O 0 1.495464552192516e-08
the O 0 1.1044414272021186e-09
affinity O 0 1.325312659616884e-08
of O 0 9.368722686531328e-08
TfR O 0 2.2234431526158005e-05
for O 0 2.804104042297695e-07
transferrin O 0 8.369436545763165e-05
. O 0 6.959335678402567e-06

These O 0 4.129826791654523e-08
results O 0 4.3843375152619046e-08
establish O 0 7.41064809517411e-08
a O 0 3.394810121903902e-08
molecular O 0 3.529021341819316e-07
link O 0 8.194862175514572e-07
between O 0 6.57122029679158e-07
HFE O 0 0.040406763553619385
and O 0 5.868839281220062e-08
a O 0 1.1050513393229267e-07
key O 0 5.319580850482453e-06
protein O 0 1.619306004840837e-07
involved O 0 3.3498622542538214e-08
in O 0 1.0195750910213519e-08
iron O 0 0.007864408195018768
transport O 0 1.4754639323655283e-06
, O 0 1.8989622319054433e-08
the O 0 4.134595243954209e-08
TfR O 0 6.368122558342293e-05
, O 0 6.87648338271174e-09
and O 0 1.5644342488130292e-09
raise O 0 5.1761683828033256e-09
the O 0 1.5874770387114268e-09
possibility O 0 1.3277744237427669e-08
that O 0 1.4628087630086384e-10
alterations O 0 9.782405996361376e-09
in O 0 2.5308741213869723e-10
this O 0 9.145576657099141e-11
regulatory O 0 3.7105063910303215e-08
mechanism O 0 4.6104119633127993e-07
may O 0 7.763356180134906e-09
play O 0 4.801102093665577e-08
a O 0 6.349260228688536e-09
role O 0 3.0135609563330945e-08
in O 0 3.7183047751909726e-09
the O 0 4.134239972586329e-08
pathogenesis O 0 0.3157828748226166
of O 0 0.00023994890216272324
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.22030183672904968
. O 0 0.00018420701962895691

Genomic O 0 6.492833108495688e-06
organization O 0 2.1246209769287816e-07
of O 0 4.898606675851624e-07
the O 0 3.3213457300007576e-06
UBE3A O 1 0.9996905326843262
/ O 1 0.9936780333518982
E6 O 0 0.10139301419258118
- O 0 0.0001781042810762301
AP O 0 9.303505794377998e-05
gene O 0 9.66844098115871e-08
and O 0 1.3779546392811426e-08
related O 0 8.971620104603062e-07
pseudogenes O 0 1.87939058378106e-05
. O 0 2.6137722670682706e-06

The O 0 4.877964329352835e-06
UBE3A O 0 0.0003496298741083592
gene O 0 7.895561111581628e-07
encodes O 0 1.1748444705972361e-07
the O 0 2.0174141468487505e-07
E6 O 0 6.507171201519668e-05
- O 0 3.0189139579306357e-05
AP O 0 0.00015648380212951452
ubiquitin O 0 7.879751137807034e-06
- O 0 1.3477422271535033e-06
protein O 0 2.1525002580347063e-07
ligase O 0 1.547518024835881e-07
and O 0 4.835950306869563e-09
has O 0 4.816361531823077e-09
recently O 0 2.5844240525429996e-08
been O 0 1.7243276806411245e-09
shown O 0 7.44788009043873e-10
to O 0 8.018710695445463e-11
be O 0 5.887141329985468e-10
mutated O 0 7.26365456671374e-08
in O 0 1.0948849649139447e-06
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.016315683722496033
who O 0 7.158594712564081e-07
lack O 0 5.980004061711952e-06
15q11 O 0 0.00028594699688255787
- O 0 1.0858841051231138e-05
q13 O 0 6.776077952963533e-06
deletions O 0 7.029145763226552e-07
or O 0 2.6255091256643937e-07
chromosome O 0 1.3351361303648446e-05
15 O 0 7.42288011679193e-06
paternal O 0 0.00011351827561156824
uniparental B-Disease 1 0.9909867644309998
disomy I-Disease 0 0.1330149918794632
. O 0 4.327522765379399e-05

Previous O 0 1.3998022950545419e-05
UBE3A O 0 0.0007015175651758909
cDNA O 0 1.0330907571187709e-05
analysis O 0 1.606765778205954e-07
has O 0 7.073903685039795e-09
shown O 0 6.055987711306443e-09
a O 0 7.503121679519609e-09
coding O 0 2.994869987560378e-07
region O 0 8.695744924125393e-08
of O 0 7.48539932260428e-08
approximately O 0 3.059120956550032e-07
2 O 0 3.59214163836441e-06
. O 0 5.748599392063625e-07

6 O 0 4.214837827021256e-05
kb O 0 6.571452104253694e-05
and O 0 2.443311757360789e-07
a O 0 3.5331498793311766e-07
3 O 0 1.0543885764491279e-06
- O 0 1.1688125596265309e-06
untranslated O 0 0.00021120058954693377
region O 0 9.036485835167696e-07
( O 0 2.5419891969136188e-08
UTR O 0 2.2693853679811582e-05
) O 0 9.08473563043799e-09
of O 0 4.72429739772906e-08
< O 0 2.497337618478923e-06
50 O 0 3.079987607179646e-07
bp O 0 4.205436994197953e-07
, O 0 2.39822384173749e-09
whereas O 0 4.463770242324472e-09
Northern O 0 8.165932818826604e-09
analysis O 0 1.681654926422027e-09
has O 0 2.8930680073813164e-10
indicated O 0 2.048091918283035e-09
mRNA O 0 3.155786743036515e-09
sizes O 0 2.840019774907887e-09
of O 0 6.102275129649115e-09
5 O 0 1.9242554571974324e-07
- O 0 1.2625478120753542e-06
8 O 0 1.716445467536687e-06
kb O 0 6.872392987133935e-05
. O 0 3.933585503546055e-06

We O 0 1.7507019833828963e-07
have O 0 5.101617794878166e-09
analyzed O 0 7.153877046306434e-09
additional O 0 4.859908031562554e-09
cDNA O 0 1.6496808541432983e-07
clones O 0 2.2559509815778256e-08
and O 0 5.587639240189901e-10
provide O 0 1.8960442105253605e-09
evidence O 0 5.0260897666021265e-09
for O 0 8.365384496222816e-10
an O 0 1.036306374047058e-09
additional O 0 4.993327351598964e-08
0 O 0 7.979296583471296e-07
. O 0 8.95259461231035e-07

5 O 0 1.4066927178646438e-05
kb O 0 3.605246456572786e-05
of O 0 1.8213947896583704e-06
5 O 0 3.3260687359870644e-06
- O 0 1.7994678955801646e-06
UTR O 0 4.966624692315236e-05
and O 0 2.90497013111235e-08
> O 0 4.323364066749491e-07
2 O 0 3.852140082472033e-07
kb O 0 4.150914719502907e-06
of O 0 3.6809083781008667e-07
3 O 0 1.4871317944198381e-05
- O 0 3.486858622636646e-05
UTR O 0 0.002024731133133173
. O 0 6.493390628747875e-06

We O 0 7.669050319236703e-07
have O 0 1.8808091084565604e-08
established O 0 1.6642209388351148e-08
the O 0 1.7709247401853645e-09
genomic O 0 1.6086676879467632e-08
organization O 0 2.757707395772968e-09
of O 0 4.4353079431402875e-08
UBE3A O 0 3.115850267931819e-05
and O 0 4.957292798479784e-09
the O 0 4.70401007035548e-09
sequence O 0 2.5256202462742294e-08
of O 0 3.728921171841648e-07
intron O 0 0.0018131289398297668
- O 0 7.432778511429206e-05
exon O 0 3.374501466169022e-05
borders O 0 1.406882915944152e-06
. O 0 4.144597824051743e-06

We O 0 4.048237769893603e-06
have O 0 6.904914329197709e-08
also O 0 8.451768174211338e-09
mapped O 0 7.120959377715508e-09
two O 0 1.3500266460297894e-09
highly O 0 2.4070695658906516e-08
homologous O 0 2.7678526137719928e-08
processed O 0 5.348635312429906e-08
pseudogenes O 0 3.0386979688046267e-07
, O 0 9.458529071082467e-09
UBE3AP1 O 0 1.6025685908971354e-05
and O 0 5.304664085770128e-08
UBE3AP2 O 0 0.0003260836820118129
, O 0 7.805494028900739e-09
to O 0 1.2814871386268578e-09
chromosomes O 0 1.9414306606790888e-08
2 O 0 4.41890932734168e-08
and O 0 3.695136641113095e-09
21 O 0 6.246499850703913e-08
, O 0 1.8118702094227501e-09
respectively O 0 1.6938498603735752e-08
, O 0 1.2110104030682578e-09
and O 0 9.441707415902556e-10
determined O 0 7.130690704570952e-09
their O 0 4.99945285170611e-09
genomic O 0 3.123717249309266e-07
organization O 0 1.1741690997268961e-07
. O 0 7.59887541335047e-07

These O 0 5.6795144587340474e-08
results O 0 4.947528609022811e-08
will O 0 1.2368047697108864e-09
form O 0 1.3867575976433955e-09
the O 0 5.669226754712042e-10
basis O 0 1.8715970995231146e-09
for O 0 4.339357484450801e-10
studies O 0 1.6776184885713974e-09
of O 0 2.700801582378176e-09
mutation O 0 3.286679151059957e-09
and O 0 5.957608184559149e-09
imprinting O 0 6.770786967535969e-06
of O 0 8.529800652468111e-06
UBE3A O 1 0.9990043044090271
. O 0 5.835516640217975e-05

Mutation O 0 7.4333361226308625e-06
spectrum O 0 9.0937764980481e-06
and O 0 1.3089110950659233e-07
genotype O 0 1.2070536286046263e-06
- O 0 3.8668150637022336e-07
phenotype O 0 2.3981517216498105e-08
analyses O 0 2.7643494604490115e-08
in O 0 2.1336358457801907e-08
Cowden B-Disease 1 0.8793703317642212
disease I-Disease 0 1.0819107046700083e-05
and O 0 1.0786830983988693e-07
Bannayan B-Disease 1 0.9999951124191284
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
, O 0 1.2242742286616703e-06
two O 0 6.480256615759572e-06
hamartoma B-Disease 1 0.9999886751174927
syndromes I-Disease 1 0.924139142036438
with O 0 0.00012826660531572998
germline O 1 0.9999927282333374
PTEN O 1 0.9999129772186279
mutation O 0 8.158761193044484e-05
. O 0 2.2197737052920274e-05

The O 0 3.2389845728175715e-05
tumour B-Disease 1 0.9999997615814209
suppressor O 0 0.003957483451813459
gene O 0 2.158187453460414e-05
PTEN O 0 0.0006152548594400287
, O 0 1.0680903272941578e-07
which O 0 6.9719416906366405e-09
maps O 0 8.143352658862568e-08
to O 0 6.369943861272986e-08
10q23 O 0 0.00010918867337750271
. O 0 6.813057552790269e-06

3 O 0 3.7396875995909795e-06
and O 0 6.402320451570631e-08
encodes O 0 7.014253355919209e-08
a O 0 1.6032766225748674e-08
403 O 0 9.19873421878492e-09
amino O 0 1.6314315232079935e-08
acid O 0 4.4810295918296106e-08
dual O 0 3.213299351045862e-07
specificity O 0 1.4364397884492064e-06
phosphatase O 0 0.0001981860987143591
( O 0 1.9628575387287128e-07
protein O 0 1.0422178320368403e-06
tyrosine O 0 8.204159485103446e-07
phosphatase O 0 1.1565045497263782e-05
; O 0 4.797577801696207e-08
PTPase O 0 1.2257673006388359e-05
) O 0 3.3653023479018884e-08
, O 0 2.6524269003402878e-08
was O 0 1.9412200913393463e-07
shown O 0 1.946929906182504e-08
recently O 0 1.2100921154001298e-08
to O 0 6.984795519748843e-10
play O 0 4.172550660541674e-08
a O 0 1.3115122321494255e-08
broad O 0 3.507533463675827e-08
role O 0 1.3193042036618863e-07
in O 0 2.1519046100593187e-08
human O 0 3.983823546604981e-07
malignancy B-Disease 0 0.01757192797958851
. O 0 6.141478934296174e-06

Somatic O 0 0.0047791809774935246
PTEN O 0 0.0030274030286818743
deletions O 0 4.093754341738531e-06
and O 0 3.493032352253067e-08
mutations O 0 4.263547737082263e-08
were O 0 6.0683138514150414e-09
observed O 0 5.687229354123247e-09
in O 0 1.6517605061494578e-09
sporadic B-Disease 0 1.9532403712219093e-06
breast I-Disease 0 0.0009983363561332226
, I-Disease 0 1.8853226890769292e-07
brain I-Disease 1 0.91069495677948
, I-Disease 0 1.7459846048950567e-06
prostate I-Disease 1 0.9999985694885254
and I-Disease 1 0.8955498933792114
kidney I-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.999988317489624
lines O 0 3.1924753329803934e-06
and O 0 9.554921298615682e-09
in O 0 1.8330321704951302e-09
several O 0 3.224726263795219e-09
primary O 0 5.494739525602199e-07
tumours B-Disease 1 0.98819899559021
such O 0 1.638138336090833e-08
as O 0 1.0949248462566175e-05
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 0.9999998807907104
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9999997615814209
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 1 0.9988948702812195

In O 0 1.1418436542953714e-06
addition O 0 7.339372132264543e-07
, O 0 4.682680412315676e-07
PTEN O 0 0.00029148563044145703
was O 0 5.497853408087394e-07
identified O 0 3.489662958600093e-08
as O 0 1.500896074091429e-09
the O 0 8.92619589354382e-10
susceptibility O 0 2.1427794649753196e-08
gene O 0 5.066108865747765e-09
for O 0 6.459735857333726e-09
two O 0 4.4686456135423214e-07
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 1 0.9999849796295166
( O 0 9.278452353100874e-07
CD B-Disease 0 0.0001016364258248359
; O 0 1.5804000952357455e-07
MIM O 0 0.0004007615789305419
158350 O 0 3.135203314741375e-06
) O 0 6.616683645432886e-09
and O 0 1.0668927075130341e-08
Bannayan B-Disease 0 6.506520003313199e-05
- I-Disease 0 6.221616786206141e-05
Zonana I-Disease 0 0.03697819262742996
( I-Disease 0 3.3105072816397296e-07
BZS I-Disease 0 0.0002468204475007951
) I-Disease 0 7.054611472767647e-08
or I-Disease 0 1.5983630419214023e-07
Ruvalcaba I-Disease 0 0.0001067678676918149
- I-Disease 0 0.00011401468509575352
Riley I-Disease 0 0.0006379683618433774
- I-Disease 1 0.9914310574531555
Smith I-Disease 1 0.9971964359283447
syndrome I-Disease 1 0.9999986886978149
( O 0 9.821941603149753e-06
MIM O 1 0.9973763227462769
153480 O 0 0.0008843252435326576
) O 0 2.123631475114962e-06
. O 0 3.444107960604015e-06

Constitutive O 0 4.3203031964367256e-05
DNA O 0 6.231438874237938e-06
from O 0 4.257968839738169e-07
37 O 0 1.3122649988872581e-06
CD B-Disease 0 4.345982688391814e-06
families O 0 9.889716601207965e-09
and O 0 1.3591788139422079e-08
seven O 0 1.7951177255781658e-07
BZS B-Disease 0 0.0006922387983649969
families O 0 6.7586363172722486e-09
was O 0 1.3810296195515548e-07
screened O 0 2.1420608220523718e-07
for O 0 1.9725855793240044e-07
germline O 0 0.00020345044322311878
PTEN O 0 0.009518424980342388
mutations O 0 2.6215480829705484e-05
. O 0 1.738740138534922e-05

PTEN O 0 0.0032140130642801523
mutations O 0 1.1250398301854148e-06
were O 0 9.019733226978133e-08
identified O 0 3.239721024783648e-08
in O 0 5.5983093716349686e-09
30 O 0 1.702813001713821e-08
of O 0 1.1627224516530532e-08
37 O 0 1.973104986063845e-07
( O 0 7.455331463290804e-09
81 O 0 1.392752153606125e-07
% O 0 1.6441296324387622e-08
) O 0 3.717560259630659e-09
CD B-Disease 0 4.58844084505472e-07
families O 0 1.7410798358596935e-09
, O 0 1.6183240303391244e-09
including O 0 4.96965668617122e-09
missense O 0 3.692620111905853e-07
and O 0 6.924563145105367e-09
nonsense O 0 2.3112706912797876e-06
point O 0 6.730273298671818e-07
mutations O 0 1.254972215036787e-08
, O 0 5.142180015127451e-09
deletions O 0 2.2656100995277484e-08
, O 0 7.134404622632928e-09
insertions O 0 2.260944285126243e-07
, O 0 2.835269086176595e-08
a O 0 6.663495355496707e-08
deletion O 0 4.909007202513749e-06
/ O 0 1.5145835277508013e-05
insertion O 0 2.494069804015453e-06
and O 0 2.1558696516876807e-07
splice O 0 1.5034251191536896e-05
site O 0 2.991666633533896e-06
mutations O 0 3.9297119656112045e-06
. O 0 6.4626674429746345e-06

These O 0 7.26323889921332e-08
mutations O 0 1.2813393368560355e-07
were O 0 2.707652591027454e-08
scattered O 0 1.3551717081838888e-08
over O 0 3.747432142375828e-09
the O 0 2.7842654848342363e-09
entire O 0 1.1100659946805536e-08
length O 0 6.02226135626438e-09
of O 0 1.9122685657180227e-08
PTEN O 0 3.1252982353180414e-06
, O 0 1.3757532890679158e-09
with O 0 6.370643457209724e-10
the O 0 2.1061119515053406e-09
exception O 0 9.107480103409671e-09
of O 0 9.705112269386973e-09
the O 0 7.518305977782802e-09
first O 0 2.0902772845943218e-08
, O 0 1.1800329602351667e-08
fourth O 0 1.3678513255399594e-07
and O 0 1.2762654044706778e-08
last O 0 5.558004545491713e-07
exons O 0 1.3860536455467809e-05
. O 0 3.240115574953961e-06

A O 0 2.5703902792884037e-05
hot O 0 7.223694410640746e-06
spot O 0 5.565934202422795e-07
for O 0 4.810662446175229e-08
PTEN O 0 1.0271297469444107e-05
mutation O 0 1.3970377743532936e-08
in O 0 5.3585580417347956e-09
CD B-Disease 0 8.839110137159878e-07
was O 0 9.040159909545764e-08
identified O 0 1.9354853719733e-08
in O 0 7.025872772459252e-09
exon O 0 2.709606121698016e-07
5 O 0 9.547089341310766e-09
that O 0 1.6256676560466587e-10
contains O 0 1.119484616118882e-09
the O 0 2.448558245049526e-09
PTPase O 0 7.246591167131555e-07
core O 0 7.798182082296989e-07
motif O 0 7.599840756711274e-08
, O 0 1.0445896370114838e-09
with O 0 5.60798962823128e-10
13 O 0 5.646537815096053e-08
of O 0 2.2536459809430198e-08
30 O 0 1.4373165413417155e-07
( O 0 1.0121618210234828e-08
43 O 0 1.219047334188872e-07
% O 0 2.1819476003770433e-08
) O 0 1.1602523386500252e-08
CD B-Disease 0 1.3836955758961267e-06
mutations O 0 5.552701765054735e-08
identified O 0 4.9100282950576e-08
in O 0 5.547353243429143e-09
this O 0 2.5961480076830412e-08
exon O 0 1.7633439711062238e-05
. O 0 1.3535799325836706e-06

Seven O 0 1.980486558750272e-06
of O 0 5.088147645437857e-07
30 O 0 4.765766163927765e-07
( O 0 1.5730012847825492e-08
23 O 0 1.1908808517091529e-07
% O 0 1.1518666909182684e-08
) O 0 1.5986831858327832e-09
were O 0 4.7235739764062146e-09
within O 0 4.195596314815475e-09
the O 0 1.7460316525941266e-09
core O 0 1.8290383252406173e-07
motif O 0 1.4747810084259072e-08
, O 0 2.7364646659755465e-10
the O 0 4.6287737531791606e-10
majority O 0 1.4591617913950472e-09
( O 0 9.174723203386748e-10
five O 0 9.919030041771748e-10
of O 0 3.502771628305368e-09
seven O 0 1.887190181903975e-09
) O 0 5.088302001965417e-10
of O 0 2.015028366386673e-09
which O 0 4.293991828774324e-10
were O 0 1.0566151509294741e-08
missense O 0 4.4665236487162474e-07
mutations O 0 3.642280077542637e-08
, O 0 1.3323103509321754e-08
possibly O 0 7.687592784577646e-08
pointing O 0 9.643246556834129e-08
to O 0 8.124356187799719e-10
the O 0 5.3964668289552264e-09
functional O 0 2.2696028167956683e-07
significance O 0 1.1657006382392865e-07
of O 0 3.152064564915236e-08
this O 0 1.259951343257626e-08
region O 0 1.0408431307951105e-06
. O 0 1.3073683930997504e-06

Germline O 1 0.5837252140045166
PTEN O 0 0.00556917255744338
mutations O 0 6.212825951479317e-07
were O 0 9.843537895903864e-08
identified O 0 3.2223791635033194e-08
in O 0 3.653563895866796e-09
four O 0 2.0815313916955347e-09
of O 0 7.096553122920568e-09
seven O 0 2.664632248183807e-08
( O 0 9.43535827246933e-09
57 O 0 3.3471869187451375e-07
% O 0 1.9154634856022312e-07
) O 0 2.6721426138465176e-07
BZS B-Disease 0 0.11365363746881485
families O 0 2.5842646778073686e-07
studied O 0 3.339036265970208e-05
. O 0 2.97469910037762e-06

Interestingly O 0 3.622298390837386e-05
, O 0 3.949226652366633e-07
none O 0 7.574053739745068e-08
of O 0 6.602765001417765e-09
these O 0 6.476991720738567e-10
mutations O 0 5.2040247666695905e-09
was O 0 1.798148296927593e-08
observed O 0 7.345237307276875e-09
in O 0 5.086936649689733e-09
the O 0 3.03357801101356e-08
PTPase O 0 3.496652061585337e-05
core O 0 5.3056603064760566e-05
motif O 0 3.3618842280702665e-05
. O 0 5.249919922789559e-06

It O 0 8.168709086930903e-08
is O 0 1.2213800637539407e-08
also O 0 2.9559541481205542e-09
worthy O 0 3.6046625240260255e-08
of O 0 7.746375985107079e-09
note O 0 1.0256176352640978e-08
that O 0 2.2739633787072222e-10
a O 0 9.829158598151366e-10
single O 0 9.449652171866774e-10
nonsense O 0 1.2008634087123937e-07
point O 0 3.2642709868468955e-08
mutation O 0 2.2531374543888205e-09
, O 0 3.1957765322943033e-09
R233X O 0 2.538721730616089e-07
, O 0 2.8857671807713814e-09
was O 0 1.3999639669748376e-08
observed O 0 3.4051974573401367e-09
in O 0 6.405844743540001e-10
the O 0 1.7215343595111676e-09
germline O 0 1.415389334624706e-07
DNA O 0 3.8223806342330136e-08
from O 0 5.8431464111663445e-09
two O 0 3.1354114859993842e-09
unrelated O 0 9.537846068496947e-08
CD B-Disease 0 1.855785171755997e-06
families O 0 4.404661080315009e-09
and O 0 2.3733973009143483e-08
one O 0 5.79662696509331e-07
BZS B-Disease 1 0.9979179501533508
family O 0 5.709464858227875e-06
. O 0 5.0295443543291185e-06

Genotype O 0 3.222931991331279e-05
- O 0 4.64875756733818e-06
phenotype O 0 4.78903885436921e-08
studies O 0 2.5193079622454206e-08
were O 0 4.0453147498453745e-09
not O 0 3.224546185620625e-10
performed O 0 1.029244955930153e-08
on O 0 6.529077722916554e-09
this O 0 9.256722055539512e-10
small O 0 2.903467688497585e-09
group O 0 7.635725829402418e-09
of O 0 2.256950040191441e-07
BZS B-Disease 1 0.9989572763442993
families O 0 5.053661880083382e-07
. O 0 1.989448037420516e-06

However O 0 4.890260697720805e-06
, O 0 5.968842629044957e-07
genotype O 0 1.7554142459630384e-06
- O 0 4.679876610680367e-07
phenotype O 0 5.7548426468656544e-08
analysis O 0 5.855555684775027e-08
inthe O 0 2.5892204575939104e-06
group O 0 3.549407168179641e-08
of O 0 1.1357559515090543e-07
CD B-Disease 0 4.997168434783816e-05
families O 0 2.134449950119688e-08
revealed O 0 7.804960944213235e-08
two O 0 7.428869186476561e-10
possible O 0 2.1105959202571967e-09
associations O 0 4.995599489632241e-10
worthy O 0 1.8612814400853495e-08
of O 0 6.907401761679921e-09
follow O 0 8.453605815361698e-09
- O 0 5.682418091623731e-08
up O 0 8.984445187820711e-09
in O 0 9.201155393157023e-09
independent O 0 2.956028843925651e-08
analyses O 0 1.952307542296694e-07
. O 0 8.174341701305821e-07

The O 0 3.6931166391696024e-07
first O 0 1.2222299972108885e-07
was O 0 2.4342736537619203e-07
an O 0 3.460286057688222e-09
association O 0 1.0520763815691225e-08
noted O 0 1.5004559372755466e-08
in O 0 8.521204852840469e-10
the O 0 1.1529343035832085e-09
group O 0 2.5787945112654143e-09
of O 0 1.83987740598468e-08
CD B-Disease 0 7.704200834268704e-05
families O 0 2.144709476681328e-08
with O 0 1.6505384792253608e-06
breast B-Disease 1 0.9999997615814209
disease I-Disease 1 0.9999442100524902
. O 0 5.407854405348189e-05

A O 0 4.621254902303917e-06
correlation O 0 1.7285060494032223e-06
was O 0 7.621861186635215e-07
observed O 0 5.145478709778217e-08
between O 0 2.334088833322312e-08
the O 0 2.0146373458374e-08
presence O 0 1.9643424309379043e-07
/ O 0 3.153684929202427e-06
absence O 0 6.290954388532555e-07
of O 0 9.244397602969912e-08
a O 0 2.6306773293072183e-07
PTEN O 0 9.186652278003749e-06
mutation O 0 3.6430356509242756e-09
and O 0 1.4157416350357721e-09
the O 0 2.6112585427284785e-09
type O 0 1.35848992499632e-07
of O 0 2.3855565700614534e-07
breast O 0 0.019200695678591728
involvement O 0 0.0001853925350587815
( O 0 7.073359142850677e-07
unaffected O 0 2.4784376364550553e-05
versus O 1 0.7556501626968384
benign O 1 0.9676069021224976
versus O 1 0.9988895058631897
malignant O 1 0.9998064637184143
) O 0 1.4999202448962023e-06
. O 0 2.670761659828713e-06

Specifically O 0 1.4422529375224258e-06
and O 0 2.5558156480087746e-08
more O 0 3.467560460990171e-09
directly O 0 1.4225066458095625e-08
, O 0 2.8274047547682812e-09
an O 0 2.972774915122045e-09
association O 0 6.098565563661396e-08
was O 0 2.497358480013645e-07
also O 0 3.590970854006059e-09
observed O 0 4.27774349276433e-09
between O 0 2.530363474306796e-09
the O 0 9.340451745387668e-10
presence O 0 3.076098709087205e-09
of O 0 6.6800356357532564e-09
a O 0 5.997595309281678e-08
PTEN O 0 0.0002815944899339229
mutation O 0 5.843205030942045e-07
and O 0 3.0427859201154206e-06
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 0.9999980926513672
. O 0 0.00019239327230025083

Secondly O 0 0.0004689577326644212
, O 0 3.6990172702644486e-07
there O 0 6.539723784726448e-08
appeared O 0 9.964719538402278e-08
to O 0 8.883123681080463e-10
be O 0 1.0824785512397739e-09
an O 0 1.5983111500972313e-09
interdependent O 0 9.057399665834964e-07
association O 0 1.1819052048167578e-07
between O 0 1.9423980290866893e-07
mutations O 0 1.117427075314481e-07
upstream O 0 2.9823320346622495e-07
and O 0 8.074862556384232e-09
within O 0 4.638084760699712e-08
the O 0 3.6337176823053596e-08
PTPase O 0 4.5807657443219796e-05
core O 0 2.0877905626548454e-05
motif O 0 1.2116922789573437e-06
, O 0 9.94301529999575e-09
the O 0 7.1196422091190925e-09
core O 0 4.5735257003798324e-07
motif O 0 5.686820259143133e-08
containing O 0 3.4721598929365882e-09
the O 0 1.0827263530188702e-09
majority O 0 9.558837055223535e-10
of O 0 1.4391044800277086e-08
missense O 0 1.122405706155405e-06
mutations O 0 2.8244633298868393e-08
, O 0 2.4685062882667808e-09
and O 0 7.962294157337624e-10
the O 0 3.903779965952481e-09
involvement O 0 9.179824900229505e-08
of O 0 1.694318463307809e-08
all O 0 3.455840724697623e-09
major O 0 4.895505867352767e-07
organ O 1 0.9880319833755493
systems O 1 0.9977133274078369
( O 0 1.100018607758102e-06
central O 0 4.8267742386087775e-05
nervous O 0 0.00010841221956070513
system O 0 5.418249202193692e-06
, O 0 1.4268129007177777e-06
thyroid O 1 1.0
, O 0 0.0056728096678853035
breast O 1 0.9999996423721313
, O 0 0.002043508691713214
skin O 1 0.9999805688858032
and O 1 0.989575207233429
gastrointestinal O 1 1.0
tract O 1 0.9999992847442627
) O 0 0.00016894633881747723
. O 0 0.000104909973742906

However O 0 8.93257151801663e-07
, O 0 3.7138057962238236e-08
these O 0 1.9734252010294995e-09
observations O 0 1.884551004138757e-08
would O 0 5.507039269048164e-09
need O 0 4.978764955865245e-09
to O 0 7.666074997025873e-10
be O 0 7.942939639349333e-10
confirmed O 0 5.158602434107706e-10
by O 0 5.823280746497517e-11
studying O 0 3.650318047832002e-09
a O 0 7.239663868396917e-10
larger O 0 6.156446463734255e-10
number O 0 7.395645207353141e-10
of O 0 7.891645559254812e-09
CD B-Disease 0 3.2751436265243683e-06
families O 0 5.165676952856302e-08
. O 0 6.351866659315419e-07

Molecular O 0 0.3448043763637543
defects O 1 0.9734576940536499
leading O 0 9.288401088269893e-06
to O 0 3.516388602520237e-08
human O 0 3.0559138508579053e-07
complement B-Disease 0 9.619574848329648e-05
component I-Disease 1 0.9999998807907104
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.6245806477854785e-07
an O 0 2.0937170219781365e-08
African O 0 8.455575652988045e-07
- O 0 7.843605089874472e-06
American O 0 1.4163967989588855e-06
family O 0 1.8084309658661368e-06
. O 0 2.7781404696725076e-06

Complement B-Disease 0 0.00037992457509972155
component I-Disease 1 0.9999988079071045
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 7.894116606621537e-06
C6D B-Disease 1 0.9958101511001587
) O 0 1.8032129389666807e-07
was O 0 3.262764039391186e-06
diagnosed O 0 6.211236268427456e-06
in O 0 6.665603180522339e-09
a O 0 9.335754391770479e-09
16 O 0 4.7218470911047916e-08
- O 0 3.34638841081869e-08
year O 0 5.117220869266248e-09
- O 0 1.6381173395529913e-07
old O 0 2.2466338123194873e-07
African O 0 1.884885989511531e-07
- O 0 7.932573566904466e-07
American O 0 2.544150845551485e-07
male O 0 1.5442303720192285e-06
with O 0 3.5061082598986104e-05
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 7.713889499427751e-05

The O 0 4.9791938181442674e-06
patients O 0 1.3650701475853566e-05
father O 0 1.8407712332191295e-06
and O 0 9.982316129253377e-08
two O 0 2.396799061443744e-07
brothers O 0 1.8622688003233634e-05
also O 0 9.107397147545271e-08
had O 0 5.00359533361916e-07
C6D B-Disease 0 0.06503157317638397
, O 0 9.60912949210524e-09
but O 0 1.3694437805966686e-09
gave O 0 5.79103254239044e-09
no O 0 3.853878993709259e-09
history O 0 2.9763791431491882e-08
of O 0 3.574940592443454e-07
meningitis B-Disease 1 0.9094555377960205
or O 0 5.5028738898954543e-08
other O 0 7.717092387338198e-08
neisserial B-Disease 0 0.07336422801017761
infection I-Disease 0 0.0005009299493394792
. O 0 3.2810173706820933e-06

By O 0 1.686373423126497e-07
using O 0 2.9419877023428853e-07
exon O 0 2.7900459826923907e-06
- O 0 6.086909820623987e-08
specific O 0 7.086367936892657e-09
polymerase O 0 4.459271281120891e-07
chain O 0 7.300378257468765e-08
reaction O 0 9.131606582002405e-09
( O 0 4.112241214215828e-09
PCR O 0 7.771033949666162e-08
) O 0 5.488583809665215e-09
/ O 0 1.266649292119837e-07
single O 0 1.049723152846127e-08
- O 0 1.0870810740470915e-07
strand O 0 1.7037745436709884e-08
conformation O 0 1.0277129369740123e-08
polymorphism O 0 9.995726024669693e-09
as O 0 1.3690181210890273e-09
a O 0 1.783691416790134e-09
screening O 0 9.804353773290586e-09
step O 0 8.261308082069263e-09
and O 0 8.298415843377427e-10
nucleotide O 0 1.757432599447384e-08
sequencing O 0 2.578190994029228e-08
of O 0 1.839786101243135e-08
target O 0 7.607730623249154e-08
exons O 0 3.2482540746059385e-07
, O 0 5.376269207602036e-09
we O 0 2.2152208956072172e-09
determined O 0 6.418641174121831e-09
that O 0 1.7441967314901774e-10
the O 0 1.9947763441052757e-09
proband O 0 5.436817787085602e-07
was O 0 9.564681135998399e-08
a O 0 6.433176658049433e-09
compound O 0 5.555625648412388e-08
heterozygote O 0 7.258945515786763e-07
for O 0 2.3411246274918085e-08
two O 0 1.6169865091342217e-07
C6 O 1 0.7301449179649353
gene O 0 2.4714790924917907e-06
mutations O 0 1.9936569515266456e-06
. O 0 3.950457539758645e-06

The O 0 3.217021742329962e-07
first O 0 1.448639324053147e-07
, O 0 2.2145714595467325e-08
1195delC O 0 5.967448259980301e-07
located O 0 4.059554115087849e-08
in O 0 8.385613092798394e-09
exon O 0 7.077840109559475e-07
7 O 0 1.5403239217448572e-07
, O 0 4.173026368903265e-09
is O 0 8.569841503103248e-10
a O 0 1.5122580965254429e-09
novel O 0 1.5323737834194162e-09
mutation O 0 1.355005441183721e-09
, O 0 1.70289005119173e-09
while O 0 1.982350950058276e-09
the O 0 1.3044887392510418e-09
second O 0 1.2261767601273732e-08
, O 0 1.145097350274682e-09
1936delG O 0 6.380364681035644e-08
in O 0 1.1282870637785436e-08
exon O 0 1.1505928796395892e-06
12 O 0 7.782588795635093e-08
, O 0 3.8111966915721496e-09
has O 0 7.139042690340602e-10
been O 0 7.689990311199324e-10
described O 0 1.7145020958508894e-09
before O 0 1.9664063710678192e-09
to O 0 4.674635123436133e-10
cause O 0 2.0623028618160788e-08
C6D B-Disease 0 1.952057755261194e-05
in O 0 3.5840665990605203e-09
an O 0 2.3077662003601063e-09
unrelated O 0 2.488851578164031e-07
African O 0 3.249586484344036e-07
- O 0 7.638743682036875e-07
American O 0 2.0944942491496477e-07
individual O 0 1.430550042869072e-07
. O 0 1.9228903056500712e-06

Both O 0 4.7141668346739607e-07
mutations O 0 2.439674915422074e-07
result O 0 6.026802168435097e-08
in O 0 5.166011973756213e-08
premature O 0 3.8209526564969565e-07
termination O 0 6.330549240374239e-07
codons O 0 9.122589403887105e-07
and O 0 2.6102745209755085e-07
C6 O 0 0.002274902770295739
null O 0 3.366748205735348e-05
alleles O 0 3.8648900044790935e-06
. O 0 7.22554796084296e-06

Allele O 0 2.757820084298146e-06
- O 0 5.610615971818333e-07
specific O 0 2.3962087425388745e-08
PCR O 0 4.244156457389181e-07
indicated O 0 7.711618366101902e-08
that O 0 9.190906924416709e-10
the O 0 2.5745383602782113e-09
probands O 0 3.3153899039461976e-06
two O 0 2.116329156365282e-08
brothers O 0 5.910803224651318e-07
also O 0 1.5051453416958793e-08
inherited O 0 1.0839232800208265e-06
the O 0 3.08241396851372e-08
1195delC O 0 2.562469489930663e-07
mutation O 0 4.0983585414267054e-09
from O 0 3.643292778576779e-09
their O 0 1.6289898319143958e-09
heterozygous O 0 3.677693882764288e-08
mother O 0 8.782299332210641e-09
and O 0 1.7000245655651725e-09
the O 0 7.174647098651121e-09
1936delG O 0 1.6510297484728653e-07
mutation O 0 3.688151561931363e-09
from O 0 3.708084950204693e-09
their O 0 2.0391384136786428e-09
homozygous O 0 2.6399433750157186e-07
father O 0 4.877457513430272e-07
. O 0 1.1822152146123699e-07
. O 0 1.7581971860636258e-06

PAX6 O 0 0.04413747042417526
mutations O 0 5.313898509484716e-05
reviewed O 0 8.048121526371688e-05
. O 0 2.317226790182758e-05

Mutations O 0 9.875007890514098e-06
in O 0 5.067702204542002e-07
PAX6 O 0 0.0001816309813875705
are O 0 5.509981360063421e-09
responsible O 0 1.945760530475127e-08
for O 0 5.053340856875366e-09
human O 0 8.09012732361225e-08
aniridia B-Disease 1 0.9999977350234985
and O 0 4.553549004526758e-08
have O 0 2.2539112798369842e-09
also O 0 6.610372804694009e-10
been O 0 3.028944040028847e-10
found O 0 1.6048445905525455e-10
in O 0 1.6934249835731663e-10
patients O 0 1.1272280886487351e-09
with O 0 4.747926052317553e-09
Peters B-Disease 1 0.9999994039535522
anomaly I-Disease 1 1.0
, O 0 4.21822051066556e-06
with O 1 0.6208038926124573
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 1 0.5863534212112427
with O 0 0.005177502054721117
autosomal B-Disease 1 0.9999994039535522
dominant I-Disease 1 1.0
keratitis I-Disease 1 0.9999998807907104
, O 0 1.6012527339626104e-06
and O 0 1.1987030745785887e-07
with O 0 6.934756129339803e-06
isolated B-Disease 1 0.9999914169311523
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.08646516501903534

No O 0 1.5205617955871276e-06
locus O 0 3.8721253758922103e-07
other O 0 1.0738545164201696e-08
than O 0 1.2198015930664496e-08
chromosome O 0 8.70618123371969e-07
11p13 O 0 2.2522895051224623e-06
has O 0 9.809983936293065e-09
been O 0 9.909467024726837e-09
implicated O 0 1.4572691497960477e-07
in O 0 2.982294589060075e-08
aniridia B-Disease 1 0.9999945163726807
, O 0 3.661930847442818e-08
and O 0 2.0783508247745885e-08
PAX6 O 0 0.012947319075465202
is O 0 2.1661445970266868e-08
clearly O 0 1.6684959192048154e-08
the O 0 3.976919682457947e-09
major O 0 5.1367319287010105e-08
, O 0 2.599788828661076e-09
if O 0 6.627340343179355e-10
not O 0 3.1619123985748843e-10
only O 0 1.3338582460775683e-09
, O 0 5.061453478560907e-09
gene O 0 7.586994144048731e-08
responsible O 0 1.1390050076443003e-06
. O 0 1.7784693682187935e-06

Twenty O 0 6.101623876020312e-05
- O 0 5.255866653897101e-06
eight O 0 8.85299016317731e-08
percent O 0 4.2237090269736655e-08
of O 0 2.086429518044497e-08
identified O 0 2.820523263835639e-07
PAX6 O 0 3.8160527765285224e-05
mutations O 0 5.7626849070402386e-08
are O 0 6.5961947015580336e-09
C O 0 9.628907719161361e-05
- O 0 3.265335180913098e-06
T O 0 3.4665049497561995e-07
changes O 0 1.1642535824307743e-08
at O 0 8.93242031452246e-08
CpG O 0 1.4467423170572147e-07
dinucleotides O 0 3.681206806049886e-07
, O 0 2.7860771467658196e-09
20 O 0 9.173747983481917e-09
% O 0 1.9009254170754275e-09
are O 0 1.850271325043451e-10
splicing O 0 1.8611073571150882e-08
errors O 0 3.646325552608687e-08
, O 0 1.416014527855225e-09
and O 0 5.482533871337125e-10
more O 0 2.992822101255399e-10
than O 0 5.314836903913545e-10
30 O 0 6.205587599339424e-09
% O 0 2.0563630798164922e-09
are O 0 3.1821140167309636e-10
deletion O 0 1.868637333757306e-08
or O 0 4.0575858228919515e-09
insertion O 0 1.8128758938473766e-07
events O 0 2.543291941492498e-07
. O 0 1.2256831496415543e-06

There O 0 3.72027625417104e-06
is O 0 1.7332089896626712e-07
a O 0 1.637567379475513e-07
noticeably O 0 3.5678738186106784e-06
elevated O 0 1.4647849866378237e-06
level O 0 1.5947102838254068e-07
of O 0 1.1627578899719992e-08
mutation O 0 4.222200367109963e-09
in O 0 1.5452704671403694e-09
the O 0 2.690118128256813e-09
paired O 0 2.0641762077389103e-08
domain O 0 2.7368901811541946e-08
compared O 0 9.17042353165698e-09
with O 0 9.485805474440667e-10
the O 0 1.0992049048752506e-08
rest O 0 4.380408924475887e-08
of O 0 2.4961387623534392e-08
the O 0 4.9647514543949e-08
gene O 0 1.0936514627246652e-06
. O 0 1.6491097767357132e-06

Increased O 0 9.863588275038637e-07
mutation O 0 9.982106519146328e-08
in O 0 1.607287636318233e-08
the O 0 3.122129044186295e-08
homeodomain O 0 2.049407839876949e-06
is O 0 3.839579321152087e-09
accounted O 0 1.342337263565696e-08
for O 0 7.647513733388678e-10
by O 0 1.1806942090686334e-09
the O 0 1.3121302266938528e-08
hypermutable O 0 4.277592779544648e-06
CpG O 0 1.8833941339835292e-06
dinucleotide O 0 6.0521383602463175e-06
in O 0 9.618887730766801e-08
codon O 0 1.3584423186330241e-06
240 O 0 1.840077970882703e-06
. O 0 3.3443577649450162e-06

Very O 0 1.244970690095215e-06
nearly O 0 1.4111665791460837e-07
all O 0 9.244993215418162e-09
mutations O 0 3.9573695431727174e-08
appear O 0 2.957619216203966e-08
to O 0 2.2194586168922115e-09
cause O 0 9.783398269291865e-08
loss O 0 7.616979758040543e-08
of O 0 4.04196924819189e-08
function O 0 7.99105634996522e-08
of O 0 2.371143992263569e-08
the O 0 5.9289622100777706e-09
mutant O 0 1.3136927989876312e-08
allele O 0 3.183074470669567e-09
, O 0 1.0983114417939532e-09
and O 0 3.063666542679755e-10
more O 0 5.308019024319321e-10
than O 0 7.497809040302172e-10
80 O 0 1.1335329119788184e-08
% O 0 6.99578572849191e-09
of O 0 2.0454031357530766e-08
exonic O 0 1.117163265007548e-06
substitutions O 0 9.405031420328669e-08
result O 0 1.8736052709300566e-08
in O 0 1.6454347218086696e-08
nonsense O 0 1.132783836510498e-06
codons O 0 9.56149506237125e-07
. O 0 1.0923391755568446e-06

In O 0 1.2409581131578307e-06
a O 0 2.3370341750705848e-07
gene O 0 1.8675043733651364e-08
with O 0 1.340397348670308e-09
such O 0 5.067790631585467e-09
extraordinarily O 0 2.8253208483874914e-07
high O 0 3.0342668821958796e-08
sequence O 0 2.101573581825278e-09
conservation O 0 1.7455786816000796e-09
throughout O 0 1.372589597536944e-09
evolution O 0 7.2561321395880896e-09
, O 0 1.2300154228483962e-09
there O 0 1.409810712615922e-09
are O 0 1.0320220233950295e-09
presumed O 0 2.678720250059996e-07
undiscovered O 0 5.820133810630068e-05
missense O 0 1.6138542378030252e-06
mutations O 0 5.841823380592359e-08
, O 0 2.251616892934294e-09
these O 0 6.924335549385319e-10
are O 0 4.5535100690052843e-10
hypothesized O 0 6.939146590667633e-09
to O 0 2.4025811895533877e-10
exist O 0 4.9710409122383226e-09
in O 0 3.222371480759989e-09
as O 0 1.7695953147267574e-08
- O 0 2.096818576546866e-07
yet O 0 1.9533947792638173e-08
unidentified O 0 6.641062668677478e-07
phenotypes O 0 4.462955871531449e-07
. O 0 1.1560248225350733e-07
. O 0 1.364767399536504e-06

Genetic O 0 2.7409778340370394e-05
heterogeneity O 0 1.741152664180845e-05
and O 0 2.2906998253802158e-07
penetrance O 0 1.0216277587460354e-05
analysis O 0 8.190644962269289e-08
of O 0 4.318538415759576e-08
the O 0 3.1629230790031215e-08
BRCA1 O 0 3.542529327660304e-07
and O 0 3.0607782974811926e-08
BRCA2 O 0 8.89241960067011e-07
genes O 0 8.913783489106208e-08
in O 0 3.119870655154955e-07
breast B-Disease 1 0.9998794794082642
cancer I-Disease 1 0.9360495209693909
families O 0 5.802921236863767e-07
. O 0 1.3295568351168185e-05

The O 0 0.00041849317494779825
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 1 0.6343650817871094
Consortium O 0 0.00020680307352449745
. O 0 1.2266079465916846e-05

The O 0 1.5145832321650232e-07
contribution O 0 2.452731848734402e-07
of O 0 5.112340772939206e-07
BRCA1 O 0 1.4350390529216384e-06
and O 0 1.0775027448062247e-07
BRCA2 O 0 9.846823559200857e-06
to O 0 2.2769920633436413e-06
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.00030130555387586355
assessed O 0 5.244053227215772e-07
by O 0 8.941774432003058e-09
linkage O 0 2.4725372327338846e-07
and O 0 2.999956283389338e-09
mutation O 0 6.156614329455579e-09
analysis O 0 9.527696853695033e-09
in O 0 2.2322033110810935e-09
237 O 0 1.3808566734496708e-08
families O 0 5.037316119782531e-10
, O 0 1.0460849964033514e-09
each O 0 1.1427882945502787e-10
with O 0 1.920480025008331e-10
at O 0 1.902253821128852e-08
least O 0 9.057773975307271e-10
four O 0 4.2458439541981363e-10
cases O 0 9.715460658199504e-10
of O 0 5.433102501228859e-08
breast B-Disease 0 0.1566665917634964
cancer I-Disease 0 1.444890585844405e-05
, O 0 2.4028528056163623e-09
collected O 0 1.1297680568844726e-09
by O 0 1.6911889666459956e-09
the O 0 1.0130717100764741e-06
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 1 0.6556870341300964
Consortium O 0 8.735609299037606e-05
. O 0 6.877528903714847e-06

Families O 0 1.877326241128685e-07
were O 0 6.082499481863124e-08
included O 0 2.1044748166332283e-08
without O 0 9.698912784017466e-09
regard O 0 1.0777921666260681e-08
to O 0 2.8903046622730244e-10
the O 0 4.804303066485716e-10
occurrence O 0 1.2661933723734364e-08
of O 0 4.923631422570907e-07
ovarian B-Disease 1 0.9999963045120239
or I-Disease 0 6.061339263396803e-06
other I-Disease 0 5.7068677961069625e-06
cancers I-Disease 1 0.9998733997344971
. O 0 2.6160962079302408e-05

Overall O 0 0.0001172893971670419
, O 0 2.3693304683547467e-05
disease O 0 0.024032628163695335
was O 0 3.5496755117492285e-06
linked O 0 3.707150426635053e-07
to O 0 6.285902909297647e-09
BRCA1 O 0 8.383985061755084e-08
in O 0 3.480089771912276e-09
an O 0 7.528030421255494e-10
estimated O 0 5.148794723908168e-09
52 O 0 3.3630630724701405e-08
% O 0 7.076035757336285e-09
of O 0 1.6201472163857034e-08
families O 0 1.555288453580772e-09
, O 0 1.6533081570457853e-09
to O 0 7.243725064220996e-10
BRCA2 O 0 1.1895421536678441e-08
in O 0 3.345320687131448e-09
32 O 0 3.4733673714981705e-08
% O 0 9.721063953804787e-09
of O 0 3.747484100813381e-08
families O 0 2.933672416105537e-09
, O 0 2.1055939214420505e-09
and O 0 8.22203582995229e-10
to O 0 5.741110364887447e-10
neither O 0 1.5513636597574987e-08
gene O 0 2.0109045539840054e-09
in O 0 1.734358101579403e-09
16 O 0 4.1219259117042384e-08
% O 0 9.49924494619836e-09
( O 0 4.7915027501233e-09
95 O 0 7.346949359998689e-08
% O 0 3.7286827847538007e-08
confidence O 0 1.2498790056270082e-06
interval O 0 2.0560796656354796e-06
[ O 0 5.632134616462281e-07
CI O 0 9.563033381709829e-05
] O 0 2.4057391101450776e-07
6 O 0 7.306395843897917e-08
% O 0 5.493862698102703e-09
- O 0 2.546662436486713e-08
28 O 0 2.2990070291939446e-08
% O 0 3.3061009485635395e-09
) O 0 1.0603172784229287e-09
, O 0 1.5027808997203351e-09
suggesting O 0 1.7192348877870245e-08
other O 0 6.6670269305291185e-09
predisposition O 0 4.480004918150371e-06
genes O 0 1.103536419577722e-06
. O 0 2.105640760419192e-06

The O 0 8.775577953201719e-07
majority O 0 2.2811273936440557e-07
( O 0 5.515420298252138e-08
81 O 0 4.50185979161688e-07
% O 0 2.0795365429648882e-08
) O 0 2.6053434964978806e-09
of O 0 1.4148110238920708e-08
the O 0 1.2707172345471918e-06
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.236655281099956e-08
were O 0 3.429714467984013e-08
due O 0 1.192661756022062e-07
to O 0 9.643611242893257e-09
BRCA1 O 0 1.4487996224943345e-07
, O 0 2.407160248907303e-09
with O 0 1.2880225774836163e-09
most O 0 3.6941778525090285e-09
others O 0 5.943704639577163e-09
( O 0 3.115156133048913e-09
14 O 0 3.9754883829346e-08
% O 0 9.984255200379266e-09
) O 0 1.611455413552676e-09
due O 0 4.6072955228737555e-08
to O 0 4.608534354133553e-08
BRCA2 O 0 4.7743733375682496e-06
. O 0 1.0895404329858138e-06

Conversely O 0 1.3791261153528467e-05
, O 0 5.1465981698584073e-08
the O 0 9.30826615785918e-09
majority O 0 3.2067914990108193e-09
of O 0 9.525225941331428e-09
families O 0 3.701659812005431e-10
with O 0 1.3491617822936064e-09
male B-Disease 0 3.0718354082637234e-07
and I-Disease 0 2.533847691665869e-07
female I-Disease 1 0.9936864972114563
breast I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.99857497215271
were O 0 1.779102149157552e-06
due O 0 3.951086910092272e-06
to O 0 1.0727207921945592e-07
BRCA2 O 0 1.2512243756646058e-06
( O 0 1.095768098480221e-07
76 O 0 3.4191571103292517e-06
% O 0 1.2405889719957486e-06
) O 0 9.433863965568889e-07
. O 0 3.338723900014884e-06

The O 0 7.163887403294211e-07
largest O 0 3.926045621938101e-07
proportion O 0 6.317528544741435e-08
( O 0 6.9933170365743536e-09
67 O 0 6.967291454884617e-08
% O 0 9.399540701338083e-09
) O 0 1.0279946893732017e-09
of O 0 4.129289354892762e-09
families O 0 3.0847868703887116e-10
due O 0 6.057408796777963e-09
to O 0 3.299163442438413e-10
other O 0 8.168670739827633e-10
genes O 0 2.5975037676317925e-09
was O 0 3.698495021353665e-08
found O 0 3.2471429989300304e-09
in O 0 1.2930587711679209e-09
families O 0 1.2047066122455874e-10
with O 0 5.53606160913489e-10
four O 0 3.371860790579717e-09
or O 0 2.022344069985138e-09
five O 0 1.4840354500833541e-09
cases O 0 2.5773390088801307e-09
of O 0 1.111184886326555e-07
female O 0 0.36975935101509094
breast B-Disease 1 0.9999982118606567
cancer I-Disease 1 0.9977378845214844
only O 0 2.193348791479366e-06
. O 0 2.0526180378510617e-05

These O 0 1.6300013783165923e-07
estimates O 0 1.4544409054906282e-07
were O 0 1.681742389791907e-08
not O 0 1.9182113675242363e-09
substantially O 0 3.0540078910235025e-08
affected O 0 8.488501568315598e-10
either O 0 3.2111602266127193e-10
by O 0 9.178061782799674e-11
changing O 0 3.6941922854083487e-09
the O 0 2.1530861538110457e-09
assumed O 0 3.257964209524289e-08
penetrance O 0 5.809322800587324e-08
model O 0 4.121404995061084e-09
for O 0 3.0727269617614184e-09
BRCA1 O 0 1.6924838419640764e-08
or O 0 7.518818345708667e-10
by O 0 4.05505379275084e-10
including O 0 6.162394594610987e-09
or O 0 2.582586056121272e-08
excluding O 0 1.333148816229368e-06
BRCA1 O 0 4.69386236545688e-07
mutation O 0 4.490030036663484e-08
data O 0 3.52910547007923e-07
. O 0 1.7842251054389635e-06

Among O 0 5.465300887408375e-07
those O 0 3.264295855842647e-08
families O 0 9.548362989164616e-09
with O 0 3.66411754271212e-08
disease O 0 5.5893356147862505e-06
due O 0 2.2652326947536494e-07
to O 0 2.4667709652703707e-08
BRCA1 O 0 2.8020133413519943e-07
that O 0 2.5562578720439433e-09
were O 0 6.310769684603201e-09
tested O 0 2.1017381168775273e-09
by O 0 5.507286293671143e-11
one O 0 5.602427202711091e-11
of O 0 3.1247890386332244e-10
the O 0 2.8467703194756666e-10
standard O 0 4.341313974975947e-09
screening O 0 1.6799942548217928e-09
methods O 0 1.0466059130465055e-09
, O 0 3.285467731206637e-10
mutations O 0 7.780786015487706e-10
were O 0 1.2044270025768355e-09
detected O 0 9.768905684381934e-09
in O 0 1.003714000802347e-09
the O 0 1.1104804853445671e-09
coding O 0 6.279458375502145e-08
sequence O 0 1.335169752536558e-08
or O 0 4.727630287248985e-09
splice O 0 2.9371788556886713e-08
sites O 0 3.8548573222385585e-09
in O 0 9.991603100445445e-10
an O 0 3.930315517486349e-10
estimated O 0 2.6383983886546503e-09
63 O 0 5.817039649969047e-08
% O 0 1.7457161050060677e-08
( O 0 5.261282076673979e-09
95 O 0 1.047567508294378e-07
% O 0 8.320343169998523e-08
CI O 0 0.0016411616234108806
51 O 0 3.5587663660407998e-06
% O 0 3.1351504503618344e-07
- O 0 1.2646590903386823e-06
77 O 0 5.733411967412394e-07
% O 0 2.344964258327309e-07
) O 0 2.4832041845002095e-07
. O 0 1.9704732494574273e-06

The O 0 9.689595117379213e-07
estimated O 0 1.689862045850532e-07
sensitivity O 0 2.3453621622593346e-07
was O 0 9.707059689390007e-08
identical O 0 5.418838266990633e-09
for O 0 9.496559094657187e-10
direct O 0 6.023018972456384e-09
sequencing O 0 1.3094625828102835e-08
and O 0 2.4125932363006086e-09
other O 0 5.624928967051801e-09
techniques O 0 4.2534938984317705e-06
. O 0 1.431006012353464e-06

The O 0 2.4965447664726526e-06
penetrance O 0 6.447497435146943e-05
of O 0 3.070244019909296e-06
BRCA2 O 0 2.0691545614681672e-06
was O 0 3.63660575430913e-07
estimated O 0 5.100139421898575e-09
by O 0 1.177931974183366e-09
maximizing O 0 1.217905065686864e-07
the O 0 2.121761433215852e-08
LOD O 0 7.153017941163853e-05
score O 0 2.382355432928307e-07
in O 0 5.915816458923473e-08
BRCA2 O 0 3.8390288636946934e-07
- O 0 3.3324272408208344e-07
mutation O 0 6.972951993589049e-09
families O 0 1.1101648489386662e-09
, O 0 2.0178976267715143e-09
over O 0 2.7685429504487047e-09
all O 0 1.762285317674639e-09
possible O 0 3.710152540747913e-08
penetrance O 0 1.9402998532314086e-06
functions O 0 1.2751322628901107e-06
. O 0 1.7495948441137443e-06

The O 0 1.4371053680406476e-07
estimated O 0 5.1639332809827465e-08
cumulative O 0 1.8784024291562673e-07
risk O 0 2.8892446835016017e-07
of O 0 3.093841201007308e-07
breast B-Disease 0 0.00021129987726453692
cancer I-Disease 0 1.8661852436707704e-06
reached O 0 7.842339755370631e-07
28 O 0 6.342345386656234e-07
% O 0 1.445255115584132e-08
( O 0 3.76060693696445e-09
95 O 0 5.2408434925155234e-08
% O 0 3.5201466630496725e-08
CI O 0 0.00018817398813553154
9 O 0 7.847037863939477e-07
% O 0 1.5449911572318342e-08
- O 0 3.669278925144681e-08
44 O 0 8.37854674529126e-09
% O 0 8.72873884283365e-10
) O 0 3.076507937294082e-10
by O 0 2.9294883185926324e-10
age O 0 3.2053868892489845e-08
50 O 0 2.3322510145362685e-08
years O 0 7.505081889291887e-09
and O 0 2.6286837151445752e-09
84 O 0 6.95820787655066e-08
% O 0 1.9055729438832714e-08
( O 0 8.904263992803862e-09
95 O 0 1.1817102318900652e-07
% O 0 1.1745072470148443e-07
CI O 0 0.00033822920522652566
43 O 0 7.039369052108668e-07
% O 0 4.965717792515534e-08
- O 0 5.294737803751559e-08
95 O 0 2.1731299426619444e-08
% O 0 2.8388391637435006e-09
) O 0 6.251393291911711e-10
by O 0 1.355039080941367e-09
age O 0 2.1351038981265447e-07
70 O 0 4.920092351312633e-07
years O 0 8.796869224170223e-07
. O 0 1.1863515965160332e-06

The O 0 7.173007361416239e-07
corresponding O 1 0.9300287365913391
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.0015830607153475285
were O 0 1.3295859844220104e-06
0 O 0 3.4157353638875065e-06
. O 0 9.590966101313825e-07

4 O 0 1.5123737284739036e-05
% O 0 6.310934850262129e-07
( O 0 1.0626100532817873e-07
95 O 0 7.114397817531426e-07
% O 0 1.7981179212256393e-07
CI O 0 0.0012711507733911276
0 O 0 2.2075481354022486e-07
% O 0 2.0590642080264843e-08
- O 0 4.837880851482623e-08
1 O 0 2.3950892824586845e-08
% O 0 1.2101467605774019e-09
) O 0 1.0762195301605715e-10
by O 0 7.45137215818481e-11
age O 0 3.985363594694036e-09
50 O 0 5.8046900619501685e-09
years O 0 1.527037385429253e-09
and O 0 1.0324000543349143e-09
27 O 0 3.4158283312990534e-08
% O 0 5.467686303717301e-09
( O 0 4.9661128542766164e-09
95 O 0 5.45912328675513e-08
% O 0 5.219863652428103e-08
CI O 0 8.88381473487243e-05
0 O 0 8.994256006644719e-08
% O 0 9.131536415907249e-09
- O 0 2.450456548785951e-08
47 O 0 1.826234985458086e-08
% O 0 2.520604613920341e-09
) O 0 3.761020939130333e-10
by O 0 6.736612379043549e-10
age O 0 1.374675093757105e-07
70 O 0 5.425107474366087e-07
years O 0 9.700032705950434e-07
. O 0 1.9456606423773337e-06

The O 0 4.680568395087903e-07
lifetime O 0 1.7283247188970563e-06
risk O 0 1.4344588635140099e-05
of O 0 9.568469067744445e-06
breast B-Disease 1 0.999976634979248
cancer I-Disease 0 0.10226792097091675
appears O 0 8.156316511076511e-08
similar O 0 1.7363539495107716e-09
to O 0 5.973956329619057e-10
the O 0 5.885291809448745e-09
risk O 0 9.751224183673912e-08
in O 0 8.73577121751623e-09
BRCA1 O 0 6.851376355143657e-08
carriers O 0 3.618129085225519e-08
, O 0 2.0644663756286263e-09
but O 0 8.539981499744442e-10
there O 0 1.4380115986867281e-09
was O 0 1.0002706218870117e-08
some O 0 1.597377785600429e-10
suggestion O 0 8.624220448893993e-09
of O 0 1.5966353794638621e-09
a O 0 3.6864216124143923e-09
lower O 0 1.257720043668087e-07
risk O 0 3.234423573417189e-08
in O 0 4.646883766667997e-09
BRCA2 O 0 1.5053492674610425e-08
carriers O 0 1.705982555222363e-08
< O 0 2.5842842887868755e-07
50 O 0 1.9816599916566702e-08
years O 0 1.1874430327907248e-08
of O 0 4.516958540534688e-08
age O 0 3.748950348381186e-06
. O 0 2.22785456571728e-06

Eye B-Disease 1 0.7782389521598816
movement I-Disease 0 4.3673022446455434e-05
abnormalities I-Disease 0 0.0007389021920971572
correlate O 0 9.272967531614995e-07
with O 0 4.716671142546147e-08
genotype O 0 5.539955964195542e-06
in O 0 5.504983278115105e-07
autosomal O 1 0.9801263213157654
dominant O 1 0.9999995231628418
cerebellar B-Disease 1 1.0
ataxia I-Disease 1 1.0
type I-Disease 1 0.9999990463256836
I I-Disease 1 0.9999938011169434
. O 0 0.00023331152624450624

We O 0 2.595653768366901e-06
compared O 0 2.7304226932756137e-06
horizontal O 0 1.0748475688160397e-05
eye O 0 2.4017348550842144e-05
movements O 0 3.7048710055387346e-07
( O 0 2.2093736617989634e-08
visually O 0 1.326401815049394e-07
guided O 0 1.610642357263714e-06
saccades O 0 1.4991383977758233e-05
, O 0 5.766665012174599e-08
antisaccades O 0 8.410182090301532e-06
, O 0 9.81118208898124e-09
and O 0 2.625817563384203e-09
smooth O 0 4.933638138027163e-07
pursuit O 0 2.010689570397517e-07
) O 0 1.9802874895447076e-09
in O 0 3.510208790302727e-09
control O 0 9.34110104822139e-08
subjects O 0 2.459679535604664e-07
( O 0 4.886435256423738e-09
n O 0 9.626688068919975e-08
= O 0 1.1216786077739016e-07
14 O 0 9.785806298623356e-08
) O 0 1.6755238307908371e-09
and O 0 1.2958042416855164e-09
patients O 0 1.263729232370281e-09
with O 0 2.2611525152260725e-10
three O 0 8.219903091521985e-10
forms O 0 1.9996837963276448e-08
of O 0 5.27233055436227e-07
autosomal O 0 0.01686188392341137
dominant O 1 0.9996335506439209
cerebellar B-Disease 1 0.9999881982803345
ataxias I-Disease 1 0.9973379969596863
type I-Disease 0 0.4306793510913849
I I-Disease 1 0.9669623374938965
spinocerebellar B-Disease 1 0.9998496770858765
ataxias I-Disease 0 0.000518381071742624
1 I-Disease 0 2.3167217477748636e-06
and I-Disease 0 4.044012769099936e-08
2 I-Disease 0 6.730350605721469e-07
( O 0 1.7262831164543968e-08
SCA1 B-Disease 0 5.47314311916125e-06
, O 0 9.075175277928338e-09
n O 0 4.5658296699002676e-08
= O 0 4.245832130322924e-08
11 O 0 1.5056162538940043e-08
; O 0 1.4320612473639471e-09
SCA2 B-Disease 0 8.890154958862695e-07
, O 0 3.4168170515158636e-09
n O 0 1.844571961839847e-08
= O 0 2.091968376305431e-08
10 O 0 9.767956221651275e-09
) O 0 1.4246944735063494e-09
and O 0 1.837212160182844e-08
SCA3 B-Disease 1 0.9999996423721313
/ O 0 0.036113739013671875
Machado B-Disease 0 5.775917452410795e-05
- I-Disease 0 0.0033061474096029997
Joseph I-Disease 1 0.5222610831260681
disease I-Disease 0 0.007661772891879082
( O 0 4.6329697056535224e-07
MJD B-Disease 1 0.9999997615814209
) O 0 1.8287522607352003e-07
( O 0 4.7534740588162094e-08
n O 0 5.919699788137223e-07
= O 0 9.677431762611377e-07
16 O 0 8.921095400182821e-07
) O 0 8.199930334740202e-08
. O 0 5.683089625563298e-07

In O 0 2.467790864102426e-06
SCA1 B-Disease 0 0.00022276864910963923
, O 0 8.672257933994842e-08
saccade O 0 1.5571821450066636e-06
amplitude O 0 4.231014258948562e-07
was O 0 9.548913482149146e-08
significantly O 0 2.3000946924867094e-08
increased O 0 1.2231168966536643e-08
, O 0 1.047890219041392e-09
resulting O 0 1.1041996650362762e-08
in O 0 1.746245459344209e-08
hypermetria B-Disease 0 8.024810995266307e-06
. O 0 7.588614039377717e-07

The O 0 3.926584213331807e-06
smooth O 0 1.9001900000148453e-05
pursuit O 0 3.79255152438418e-06
gain O 0 7.487021775887115e-06
was O 0 9.560259968566243e-06
decreased O 0 2.1193271095398813e-05
. O 0 1.7760540913513978e-06

In O 0 2.526575372030493e-06
SCA2 B-Disease 0 0.0006263836985453963
, O 0 3.5133291476086015e-07
saccade O 0 5.78657500227564e-06
velocity O 0 1.9095443803962553e-06
was O 0 2.0122272417211207e-06
markedly O 0 8.828799764160067e-06
decreased O 0 7.746652954665478e-06
. O 0 1.4872517795083695e-06

The O 0 5.33327352059132e-07
percentage O 0 1.65113829098118e-06
of O 0 1.8633632237197162e-07
errors O 0 2.0329550807218766e-06
in O 0 7.672446145079448e-08
antisaccades O 0 1.8871334759751335e-05
was O 0 2.0919091525684053e-07
greatly O 0 5.0299668430398015e-08
increased O 0 8.971670517610164e-09
and O 0 6.412103070729813e-10
was O 0 4.372943340769098e-09
significantly O 0 3.1585687398916207e-09
correlated O 0 5.349714449209841e-09
with O 0 6.985435008211027e-10
age O 0 8.8071942627721e-07
at O 0 0.00011030530004063621
disease O 0 0.005535435397177935
onset O 0 0.0004063067026436329
. O 0 8.451685062027536e-06

In O 0 2.7654897394313593e-07
addition O 0 1.0474315814690272e-07
, O 0 1.180908792974833e-08
a O 0 9.456905480931255e-09
correlation O 0 5.903473976331952e-08
between O 0 8.396307293878635e-08
smooth O 0 2.0573877463903045e-06
pursuit O 0 7.888787649790174e-07
gain O 0 2.4589854774603737e-07
and O 0 4.3551637851635405e-09
the O 0 2.0395898303604554e-09
number O 0 5.022697369128082e-09
of O 0 1.2787573666628305e-07
trinucleotide O 0 0.0008652707911096513
repeats O 0 1.5394956562886364e-06
was O 0 2.4743726498854812e-06
found O 0 3.8310193417601113e-07
. O 0 7.88225918313401e-07

In O 0 3.270791421527974e-05
SCA3 B-Disease 1 0.9999996423721313
, O 0 6.585074515896849e-06
gaze B-Disease 0 0.0006394056254066527
- I-Disease 0 8.724637882551178e-05
evoked I-Disease 0 4.555287887342274e-06
nystagmus I-Disease 0 1.4777997421333566e-05
was O 0 4.850271011491714e-07
often O 0 2.9312337002096456e-09
present O 0 3.0785110016751105e-09
as O 0 6.461731594242792e-09
was O 0 1.4629210909333779e-07
saccade O 0 8.787570209278783e-07
hypometria O 0 1.8967542700920603e-06
and O 0 9.116674526410407e-09
smooth O 0 1.790661826817086e-06
pursuit O 0 1.541680262562295e-06
gain O 0 3.781698751481599e-06
was O 0 4.1907064769475255e-06
markedly O 0 1.3356379895412829e-05
decreased O 0 7.775956873956602e-06
. O 0 9.85424321697792e-07

Three O 0 1.4970206052566937e-07
major O 0 1.3747420268828137e-07
criteria O 0 1.4662381886410003e-07
, O 0 1.541982541652942e-08
saccade O 0 2.7830120075122977e-07
amplitude O 0 1.7382411954258714e-07
, O 0 1.344387090540522e-08
saccade O 0 1.905331856733028e-07
velocity O 0 1.0646530057556447e-07
, O 0 4.421175425761703e-09
and O 0 1.4710128670714084e-09
presence O 0 2.5901732314537185e-08
of O 0 1.714351895998334e-07
gaze B-Disease 0 0.00014168384950608015
- I-Disease 0 8.28740212455159e-06
evoked I-Disease 0 2.1338500744150224e-07
nystagmus I-Disease 0 2.673322683222068e-07
, O 0 1.4994797625789147e-09
permitted O 0 2.017685796218416e-09
the O 0 1.1686158707391314e-09
correct O 0 1.488239931290991e-08
assignment O 0 1.4646471591106547e-08
of O 0 5.090071475422064e-09
90 O 0 1.3619944283504992e-08
% O 0 3.1052729276837e-09
of O 0 8.586273025912305e-09
the O 0 2.052688152787141e-08
SCA1 B-Disease 0 2.2721616915077902e-05
, O 0 4.7846442363663755e-09
90 O 0 1.542356109496268e-08
% O 0 1.6526113810755305e-09
of O 0 6.244365469143531e-09
the O 0 1.2757203293745079e-08
SCA2 B-Disease 0 2.2711737983627245e-05
, O 0 3.837368200976243e-09
and O 0 1.0501692848663424e-09
93 O 0 4.6515509666278376e-08
% O 0 9.441443182822695e-09
of O 0 1.7254107476105673e-08
the O 0 1.962589202264553e-08
patients O 0 2.002340160345284e-08
with O 0 4.500050110323173e-09
SCA3 B-Disease 1 0.9999998807907104
to O 0 3.6375158440904443e-09
their O 0 2.393891307406193e-09
genetically O 0 9.541881951236064e-09
confirmed O 0 5.614670950393474e-09
patient O 0 1.2999439746863573e-08
group O 0 1.949764572017898e-09
and O 0 1.5440566603075467e-09
, O 0 5.224891186372815e-09
therefore O 0 1.8865723205863105e-08
, O 0 4.374411943786072e-09
may O 0 5.48305933989468e-09
help O 0 1.1587992787553958e-08
orient O 0 2.015141762967687e-05
diagnoses O 0 1.7576741129232687e-06
of O 0 5.94527762132202e-07
SCA1 B-Disease 1 0.9887052178382874
, O 0 4.533055175670597e-07
SCA2 B-Disease 0 0.048907339572906494
, O 0 3.357871491971309e-08
and O 0 4.8903729066296364e-08
SCA3 B-Disease 1 0.9999988079071045
at O 0 6.369925813487498e-07
early O 0 9.741966522369694e-08
clinical O 0 2.4882345428522967e-07
stages O 0 1.8701176429658517e-07
of O 0 9.232238795675585e-08
the O 0 5.529555551220255e-07
diseases O 0 0.32422468066215515
. O 0 5.194418122300704e-07
. O 0 3.505060476527433e-06

Genetic O 0 1.8504339323044405e-06
basis O 0 2.823311433530762e-07
and O 0 1.0551269191694246e-08
molecular O 0 9.811462859943276e-07
mechanism O 0 4.69946689918288e-06
for O 0 2.8398915219440823e-06
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 1 0.9999620914459229

Ventricular B-Disease 1 0.9999904632568359
fibrillation I-Disease 1 0.9999964237213135
causes O 0 4.684562736656517e-05
more O 0 4.3711281705327565e-08
than O 0 1.020584861066709e-08
300 O 0 1.1273963984592683e-08
, O 0 1.75295233884043e-09
000 O 0 1.2332037613305147e-08
sudden O 0 1.2084729661410165e-08
deaths O 0 6.174132316516534e-10
each O 0 9.744871576344849e-11
year O 0 5.935148483793284e-10
in O 0 1.4681931226334655e-09
the O 0 1.503197388785793e-08
USA O 0 8.391102142013551e-07
alone O 0 4.586498505432246e-07
. O 0 5.350171363716072e-07

In O 0 5.91958666973369e-07
approximately O 0 1.2139543059674907e-07
5 O 0 2.4085537120299705e-07
- O 0 9.124001110194513e-08
12 O 0 1.4444668572366481e-08
% O 0 1.1487242268515274e-09
of O 0 7.711552507672081e-10
these O 0 1.8783480326689528e-10
cases O 0 6.910086391975767e-10
, O 0 1.5757534166382925e-10
there O 0 2.403378884796581e-10
are O 0 1.1067118749208404e-10
no O 0 3.656477787217227e-09
demonstrable O 0 3.245274001528742e-06
cardiac O 0 0.02811462990939617
or O 0 8.604981189819227e-07
non O 1 0.7051221132278442
- O 1 0.9984062314033508
cardiac O 1 0.999909520149231
causes O 0 1.1608359784531785e-07
to O 0 1.5853589552250469e-09
account O 0 4.105070949833589e-09
for O 0 3.780932011920868e-09
the O 0 7.991754813474472e-09
episode O 0 1.2090723089386302e-08
, O 0 4.208529913451997e-10
which O 0 6.491075038583816e-11
is O 0 5.141782138951001e-11
therefore O 0 6.363465865355522e-10
classified O 0 1.2199737220441875e-08
as O 0 8.644975224569862e-08
idiopathic B-Disease 1 0.9999998807907104
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 1 0.9999997615814209
IVF B-Disease 1 1.0
) O 0 1.3174261766835116e-05
. O 0 7.651206033187918e-06

A O 0 3.918638412869768e-06
distinct O 0 4.69569812366899e-07
group O 0 1.4299840245257656e-07
of O 0 2.0007837520097382e-05
IVF B-Disease 1 1.0
patients O 0 9.832626346906181e-06
has O 0 1.5582141799086457e-08
been O 0 3.287262018147885e-09
found O 0 5.026125626805822e-10
to O 0 1.4681475479783046e-10
present O 0 1.4616381438514736e-09
with O 0 2.621468819796746e-09
a O 0 5.289730609092658e-08
characteristic O 0 9.577693163009826e-07
electrocardiographic O 0 0.0001730802614474669
pattern O 0 1.7761538401828147e-05
. O 0 4.127880401938455e-06

Because O 0 1.011174049381225e-06
of O 0 1.6955816306563065e-07
the O 0 1.6323030038734032e-08
small O 0 5.202446473617783e-09
size O 0 3.582159457948819e-09
of O 0 4.602936698461235e-09
most O 0 2.70427058524092e-09
pedigrees O 0 2.9136431933807216e-08
and O 0 1.19363252615301e-09
the O 0 2.8498521320585724e-09
high O 0 2.407198849141423e-07
incidence O 0 4.239528266225534e-07
of O 0 2.570045687377842e-08
sudden B-Disease 0 3.406265136618458e-07
death I-Disease 0 4.214912863176323e-08
, O 0 1.470092936273204e-09
however O 0 1.0915138792810808e-09
, O 0 4.96542862382654e-10
molecular O 0 9.986901972069973e-09
genetic O 0 7.195587681252391e-09
studies O 0 1.2616587774516574e-08
of O 0 4.146034768837126e-07
IVF B-Disease 1 0.9999860525131226
have O 0 6.488445336572113e-09
not O 0 1.9392758510150543e-09
yet O 0 2.0431846436963497e-08
been O 0 2.2715122227623397e-08
done O 0 2.1805377059536113e-07
. O 0 6.391595661625615e-07

Because O 0 0.0003030780062545091
IVF B-Disease 1 0.9999998807907104
causes O 0 0.00729279825463891
cardiac O 1 0.9999982118606567
rhythm O 1 0.9999982118606567
disturbance O 1 0.9996023774147034
, O 0 1.4417726390547614e-07
we O 0 4.130244235511782e-08
investigated O 0 5.120498940414109e-07
whether O 0 1.0873797151589315e-07
malfunction O 0 8.057244122028351e-05
of O 0 4.9315683980921676e-08
ion O 0 1.3695963389181998e-05
channels O 0 9.022500648825371e-07
could O 0 2.6590525337155668e-08
cause O 0 1.8305069460211598e-08
the O 0 3.0763629421670657e-09
disorder O 0 3.5554316468733305e-07
by O 0 9.280145540913054e-10
studying O 0 9.52508401041996e-08
mutations O 0 9.290918256965597e-09
in O 0 4.0758219022052344e-09
the O 0 3.96894250798141e-08
cardiac O 0 0.0006282353424467146
sodium O 0 5.741023869632045e-06
channel O 0 8.938741302699782e-06
gene O 0 2.4301782559632557e-06
SCN5A O 0 0.0008432592148892581
. O 0 5.925397090322804e-06

We O 0 9.732585795063642e-07
have O 0 2.820146072224361e-08
now O 0 1.7404497398842977e-08
identified O 0 1.1692162793508487e-08
a O 0 7.353198938631067e-09
missense O 0 1.68274269185531e-07
mutation O 0 9.222555164001278e-09
, O 0 3.897619560433441e-09
a O 0 1.8233603071848847e-08
splice O 0 7.371850188064855e-07
- O 0 2.791962856463215e-07
donor O 0 1.8334665341512846e-08
mutation O 0 1.2618897926586214e-08
, O 0 3.1994358273834678e-09
and O 0 2.0743262663103224e-09
a O 0 2.976560686818175e-08
frameshift O 0 3.4016878203146916e-07
mutation O 0 6.588599443801968e-09
in O 0 2.1012849238388753e-09
the O 0 6.641643235383299e-09
coding O 0 3.646906918675086e-07
region O 0 7.243399835488162e-08
of O 0 1.2080330691333074e-07
SCN5A O 0 0.002151517430320382
in O 0 1.3725070857617538e-07
three O 0 1.0422675131849246e-06
IVF B-Disease 1 0.9993977546691895
families O 0 8.006084328826546e-08
. O 0 8.02041881797777e-07

We O 0 5.438726589090948e-07
show O 0 7.242488209158182e-08
that O 0 9.459607541728587e-10
sodium O 0 7.750691644048402e-09
channels O 0 3.178269647463594e-09
with O 0 1.4887750754422058e-10
the O 0 2.9760427455727267e-09
missense O 0 1.552684665284687e-07
mutation O 0 1.0001561356887123e-08
recover O 0 1.3338173232568806e-07
from O 0 1.6695112847742166e-08
inactivation O 0 2.3059822069626534e-06
more O 0 2.2102912833332766e-09
rapidly O 0 1.421616957486549e-08
than O 0 3.7167927069425843e-10
normal O 0 2.457063663641179e-09
and O 0 9.749723944851851e-11
that O 0 3.372288559511105e-11
the O 0 7.922044686914376e-10
frameshift O 0 6.255287132717058e-08
mutation O 0 1.9699275544127204e-09
causes O 0 2.6588988788489587e-09
the O 0 2.1046542286740078e-09
sodium O 0 3.6593053920341845e-08
channel O 0 2.5585665142102698e-08
to O 0 8.545815166627335e-10
be O 0 5.199460861859961e-09
non O 0 3.2109190328810655e-07
- O 0 1.6266360489680665e-06
functional O 0 1.253233858733438e-05
. O 0 3.2665716389601585e-06

Our O 0 2.6129546881747956e-07
results O 0 3.875988952017906e-08
indicate O 0 2.4721403590888258e-08
that O 0 3.911163892755809e-10
mutations O 0 7.314926442347769e-09
in O 0 1.0453275578470311e-08
cardiac O 0 3.8256683183135465e-05
ion O 0 4.633437856682576e-05
- O 0 2.7130448870593682e-05
channel O 0 4.674171805163496e-07
genes O 0 4.113740015299072e-09
contribute O 0 4.8242410066734465e-09
to O 0 7.347321639983306e-10
the O 0 3.1980327275249465e-09
risk O 0 6.356096804438494e-08
of O 0 8.847014498769568e-08
developing O 0 9.383811266161501e-05
IVF B-Disease 1 0.9974345564842224
. O 0 1.2396753845678177e-07
. O 0 9.892065691019525e-07

Molecular O 0 0.00011284653737675399
heterogeneity O 0 7.4788011261262e-05
in O 0 2.0550444332911866e-06
mucopolysaccharidosis B-Disease 0 0.01499295886605978
IVA I-Disease 1 0.9998910427093506
in O 0 3.067959255531605e-07
Australia O 0 3.53330413815911e-08
and O 0 3.1455347215825213e-09
Northern O 0 3.265030557031423e-08
Ireland O 0 7.574818994271482e-08
: O 0 1.953621042716236e-09
nine O 0 5.928510127262143e-09
novel O 0 1.969627128062257e-09
mutations O 0 3.739064169394624e-09
including O 0 3.1207880724082315e-09
T312S O 0 9.819879096539808e-07
, O 0 5.4316591224790045e-09
a O 0 4.995811320185339e-09
common O 0 4.6075832038638964e-09
allele O 0 6.127163221236742e-09
that O 0 1.5534977748643541e-09
confers O 0 2.217107777369165e-07
a O 0 1.5358484972693986e-07
mild O 0 2.8509084586403333e-06
phenotype O 0 1.1740239642676897e-06
. O 0 1.1890633686562069e-06

Mucopolysaccharidosis B-Disease 1 0.9992535710334778
IVA I-Disease 1 0.9999998807907104
( O 0 0.005413221661001444
MPS B-Disease 1 0.9999972581863403
IVA I-Disease 1 1.0
) O 0 4.0659091382622137e-07
is O 0 2.217052319508639e-08
an O 0 2.572753032836772e-08
autosomal B-Disease 0 0.26150214672088623
recessive I-Disease 1 0.9998065829277039
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 2.2947040633880533e-05
by O 0 3.628661460197691e-08
a O 0 1.9741523828997742e-06
genetic B-Disease 1 0.9999302625656128
defect I-Disease 1 0.9999721050262451
in O 0 1.1954670071645523e-06
N O 0 0.1205923780798912
- O 0 0.00019979503122158349
acetylgalactosamine O 0 0.0004401894111651927
- O 0 5.06458745803684e-05
6 O 0 1.784721462172456e-05
- O 0 2.0606985344784334e-05
sulfate O 0 9.635163587518036e-05
sulfatase O 0 0.06563223153352737
( O 0 2.9711040951951873e-06
GALNS O 1 0.6397218108177185
) O 0 1.1885780395459733e-06
. O 0 3.4329127629462164e-06

Previous O 0 4.6968222022769623e-07
studies O 0 1.8536613310971006e-07
of O 0 8.442862053925637e-08
patients O 0 4.8482640124802856e-08
from O 0 1.416531070219662e-08
a O 0 4.2822435375455825e-08
British O 0 9.25411484331562e-07
- O 0 1.090852492779959e-06
Irish O 0 9.242807550435828e-07
population O 0 7.74124764291173e-10
showed O 0 1.2183506648000275e-08
that O 0 2.4243640428522895e-10
the O 0 1.4162926387228936e-09
I113F O 0 3.9621170344616985e-07
mutation O 0 3.0890927593674178e-09
is O 0 4.089595051492978e-10
the O 0 2.4162022382867576e-10
most O 0 1.4525881886218173e-10
common O 0 3.3990826819874087e-10
single O 0 5.77718428651508e-10
mutation O 0 8.785499439056821e-09
among O 0 4.164170874787487e-08
MPS B-Disease 1 0.9999909400939941
IVA I-Disease 1 1.0
patients O 0 0.0069472910836339
and O 0 6.894794779555014e-08
produces O 0 2.8082620673330894e-08
a O 0 3.828385430892922e-08
severe O 0 5.8645368881116156e-06
clinical O 0 1.0109299182659015e-05
phenotype O 0 3.2482867027283646e-06
. O 0 3.0646683626400772e-06

We O 0 7.983978207448672e-07
studied O 0 3.3156873087136773e-06
mutations O 0 4.637828254772103e-08
in O 0 4.9604231833200174e-09
the O 0 1.4422260719015867e-08
GALNS O 0 5.876309842278715e-06
gene O 0 3.041625618038779e-08
from O 0 1.2439406837927436e-08
23 O 0 1.3889388128518476e-07
additional O 0 3.5967067901765404e-07
MPS B-Disease 1 0.9997816681861877
IVA I-Disease 1 1.0
patients O 0 1.2592729945026804e-05
( O 0 2.487574235487955e-08
15 O 0 5.195568064664258e-08
from O 0 4.630551053708132e-09
Australia O 0 2.8582192168613574e-09
, O 0 1.0354054280625746e-09
8 O 0 9.28942966993418e-09
from O 0 1.584832820533677e-09
Northern O 0 1.6891393173068536e-08
Ireland O 0 2.8911568250578057e-08
) O 0 8.908608850610733e-10
, O 0 4.241149653694265e-10
with O 0 1.714877406744364e-10
various O 0 7.1218013708573835e-09
clinical O 0 4.5108717472430726e-07
phenotypes O 0 4.5034698814561125e-07
( O 0 5.52994627867065e-08
severe O 0 8.173131391231436e-06
, O 0 2.3613276667333594e-08
16 O 0 4.980961421097163e-08
cases O 0 1.8341407281852184e-09
; O 0 3.2345065514860494e-10
intermediate O 0 1.143457026842043e-07
, O 0 9.253544597243035e-10
4 O 0 4.414804521957194e-09
cases O 0 6.29343355207368e-10
; O 0 7.816634006729828e-10
mild O 0 7.676558766434027e-08
, O 0 3.745202814542381e-09
3 O 0 4.47328396546709e-08
cases O 0 1.564166574041792e-08
) O 0 2.1931755966875244e-08
. O 0 3.4913847457573866e-07

We O 0 1.1402679547245498e-06
found O 0 9.401463074709682e-08
two O 0 2.250079900179003e-09
common O 0 3.96375865463483e-09
mutations O 0 1.1775703745442456e-09
that O 0 1.6022050353114992e-10
together O 0 1.2650750447207315e-09
accounted O 0 3.421788363766609e-08
for O 0 2.6363158323050584e-09
32 O 0 4.267550579584167e-08
% O 0 6.4405800692668436e-09
of O 0 6.648994244073947e-09
the O 0 6.885434444825478e-09
44 O 0 5.0630593051437245e-08
unrelated O 0 2.3344627564370057e-08
alleles O 0 3.4920715208386355e-09
in O 0 3.964098826969575e-09
these O 0 9.691664359934293e-09
patients O 0 2.3815400140847487e-07
. O 0 8.000815228115243e-07

One O 0 6.220046770977206e-07
is O 0 2.4971770429260687e-08
the O 0 2.9683400626367984e-08
T312S O 0 1.4046963769942522e-06
mutation O 0 2.1556141760470382e-08
, O 0 3.10586534268964e-09
a O 0 4.814313392387248e-09
novel O 0 3.850330276833347e-09
mutation O 0 2.64144972561553e-09
found O 0 2.843651314421436e-09
exclusively O 0 1.4086745103725207e-08
in O 0 1.7104463623240918e-08
milder O 0 9.460911769565428e-07
patients O 0 3.5604873005468107e-07
. O 0 1.2415263199727633e-06

The O 0 4.975905767423683e-07
other O 0 3.559087602411637e-08
is O 0 2.8432500798203364e-09
the O 0 2.4237085671785508e-09
previously O 0 2.2441875913159492e-08
described O 0 1.6395388158230162e-08
I113F O 0 9.46338758467391e-08
that O 0 7.358260112333426e-10
produces O 0 1.724314357964829e-09
a O 0 1.2361592638399088e-08
severe O 0 1.1244970892221318e-06
phenotype O 0 1.4952214542063302e-06
. O 0 1.4512667121380218e-06

The O 0 1.581239757797448e-06
I113F O 0 9.720687558001373e-06
and O 0 1.013153152484847e-07
T312S O 0 1.5103886426004465e-06
mutations O 0 1.790133730139587e-08
accounted O 0 5.888641041451592e-08
for O 0 8.84488482455481e-09
8 O 0 1.2020504414067545e-07
( O 0 3.7009344477922923e-09
18 O 0 1.9833803932556293e-08
% O 0 3.8011060965459365e-09
) O 0 1.0362787294937448e-09
and O 0 1.4452488095173521e-09
6 O 0 9.439303738645322e-08
( O 0 3.3238869434626395e-09
14 O 0 1.9029069875386995e-08
% O 0 1.9090133918098218e-09
) O 0 6.257047102664615e-10
of O 0 8.19582979261213e-09
44 O 0 8.335258172564863e-08
unrelated O 0 1.047159940981146e-07
alleles O 0 1.247319136865599e-08
, O 0 2.3307345387024725e-08
respectively O 0 7.675518531868875e-07
. O 0 1.537050025035569e-06

The O 0 6.04676870352705e-07
relatively O 0 6.649110559919791e-07
high O 0 5.592698357759218e-07
residual O 0 7.613552952534519e-06
GALNS O 0 6.111943366704509e-05
activity O 0 7.677628133251346e-08
seen O 0 1.8445401650524218e-08
when O 0 1.7914240091343459e-09
the O 0 3.480448151904625e-09
T312S O 0 2.940192587175261e-07
mutant O 0 7.429485293641847e-08
cDNA O 0 2.2580975667096936e-07
is O 0 1.1258964427440787e-08
overexpressed O 0 1.025407300403458e-06
in O 0 1.1008434164239134e-08
mutant O 0 1.2433268636868888e-07
cells O 0 6.1697802422600034e-09
provides O 0 1.3510286223095136e-09
an O 0 3.723803487787336e-10
explanation O 0 2.1420836215924055e-09
for O 0 1.035164509666231e-09
the O 0 9.473117401626041e-09
mild O 0 3.1446072057406127e-07
phenotype O 0 3.9167591836530846e-08
in O 0 7.152103354002293e-09
patients O 0 3.836936546264269e-09
with O 0 1.5556088639456789e-09
this O 0 1.4261280156802059e-08
mutation O 0 2.364487698969242e-07
. O 0 9.450731113247457e-07

The O 0 3.7114520523573447e-07
distribution O 0 6.399841367965564e-08
and O 0 2.4339004145446097e-09
relative O 0 1.9520799199312933e-08
frequencies O 0 3.034463702533685e-08
of O 0 4.032234546258451e-09
the O 0 6.042742306533455e-09
I113F O 0 2.4387094299527234e-07
and O 0 3.1966056468490933e-09
T312S O 0 3.0915290949451446e-07
mutations O 0 5.718272966248605e-09
in O 0 2.403691690133769e-09
Australia O 0 2.027832568529675e-09
corresponded O 0 3.987355778889423e-09
to O 0 2.56249521601859e-10
those O 0 5.653698620378123e-10
observed O 0 3.728638287014974e-09
in O 0 2.0720207771773858e-09
Northern O 0 1.912341573984122e-08
Ireland O 0 4.790070917692901e-08
and O 0 1.2927677817131666e-09
are O 0 2.330474424550033e-10
unique O 0 6.134644459088179e-10
to O 0 1.3056429548630177e-10
these O 0 1.9344058299619604e-10
two O 0 6.837088672995151e-10
populations O 0 1.1493204166157511e-09
, O 0 1.5340875236802276e-09
suggesting O 0 8.012084329322988e-09
that O 0 1.2625554768330716e-10
both O 0 1.2528119652799319e-09
mutations O 0 3.4917719826665916e-09
were O 0 4.752565452292856e-09
probably O 0 5.3192712456962e-09
introduced O 0 9.601813788506774e-10
to O 0 1.3461870507214257e-10
Australia O 0 2.7638566435506107e-10
by O 0 1.2998087328686125e-10
Irish O 0 6.361226212447946e-08
migrants O 0 6.326799528721949e-09
during O 0 2.0844764136995764e-08
the O 0 2.4432038614463636e-08
19th O 0 1.5429673112521414e-06
century O 0 1.7659828017713153e-06
. O 0 1.2163037581558456e-06

Haplotype O 0 1.661242094996851e-05
analysis O 0 8.790580068307463e-07
using O 0 3.3800665732997004e-07
6 O 0 9.366985977976583e-07
RFLPs O 0 2.176433554268442e-06
provides O 0 6.522679729670244e-09
additional O 0 2.619434669171028e-09
data O 0 2.2031656499166274e-09
that O 0 9.328981337430875e-11
the O 0 8.019082065047201e-10
I113F O 0 1.1455068005261637e-07
mutation O 0 4.775007944601839e-09
originated O 0 1.556915840694728e-08
from O 0 3.4452707353693768e-09
a O 0 1.4831165628947929e-08
common O 0 5.487142118454358e-08
ancestor O 0 3.539899125826196e-06
. O 0 2.113275286319549e-06

The O 0 5.285323823045474e-07
other O 0 2.9485789809768903e-08
9 O 0 1.5832029021112248e-07
novel O 0 4.951518750573314e-09
mutations O 0 2.5634303568722316e-09
identified O 0 1.7749759440022217e-09
in O 0 8.508959092878854e-10
these O 0 5.216693188536681e-10
23 O 0 1.5022722266166966e-07
patients O 0 1.5852327450716075e-08
were O 0 2.572187352001265e-09
each O 0 2.0292359459439524e-10
limited O 0 1.1524506904336818e-09
to O 0 5.132417824071922e-10
a O 0 8.639498894069675e-09
single O 0 4.0346520790990326e-08
family O 0 1.1320036463757788e-07
. O 0 6.056948791410832e-07

These O 0 3.841874374188592e-08
data O 0 3.0718261712081585e-08
provide O 0 3.5016092247985853e-09
further O 0 1.5404559849940824e-09
evidence O 0 3.975114903909116e-09
for O 0 6.362859128472564e-10
extensive O 0 3.9675875029843155e-08
allelic O 0 4.6160917577253713e-07
heterogeneity O 0 1.5402209783133003e-06
in O 0 3.593902135889948e-07
MPS B-Disease 1 0.9832025170326233
IVA I-Disease 1 1.0
in O 0 3.3877441296681354e-07
British O 0 4.685763087763917e-06
- O 0 5.641430561809102e-06
Irish O 0 2.3279392280528555e-06
patients O 0 1.6298608684905957e-08
and O 0 1.3868634018976422e-09
provide O 0 4.679919118899534e-09
evidence O 0 2.1417374540533274e-08
for O 0 1.18185228270562e-09
their O 0 7.409793334467452e-10
transmission O 0 1.9491890768108533e-08
to O 0 1.9169009435326956e-10
Australia O 0 4.0716008342656096e-10
by O 0 1.7020157505598377e-10
British O 0 5.758312227044371e-08
- O 0 1.446778128411097e-07
Irish O 0 6.444373639169498e-07
migrants O 0 6.391619677970084e-08
. O 0 4.5403670156929365e-08
. O 0 6.9448157091756e-07

Identification O 0 6.962349061723216e-07
of O 0 3.3496266382826434e-07
constitutional O 0 5.626077836495824e-05
WT1 O 0 0.26273998618125916
mutations O 0 5.884301117475843e-07
, O 0 2.0668865730044672e-08
in O 0 1.3511041174751881e-08
patients O 0 2.289332101668151e-08
with O 0 1.699623375372994e-08
isolated O 0 0.011507129296660423
diffuse B-Disease 1 0.999996542930603
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 4.4948285449208925e-07
and O 0 7.867043905207538e-09
analysis O 0 2.0188069882465243e-08
of O 0 8.442314936019102e-08
genotype O 0 1.3813275927532231e-06
/ O 0 4.136869847570779e-06
phenotype O 0 4.6200376857541414e-08
correlations O 0 4.390823349353923e-08
by O 0 6.701293409072662e-10
use O 0 3.370818957293409e-09
of O 0 1.4146815274784785e-08
a O 0 6.27271887765346e-08
computerized O 0 3.813667717622593e-06
mutation O 0 2.071070355214033e-07
database O 0 1.2020908570775646e-06
. O 0 2.7149681045557372e-06

Constitutional O 0 2.0648985810112208e-05
mutations O 0 3.877842118527042e-07
of O 0 1.9346758506344486e-07
the O 0 1.1224190643588372e-07
WT1 O 0 2.077532008115668e-05
gene O 0 7.69078951634583e-08
, O 0 6.649070627418041e-09
encoding O 0 1.2860121501034882e-07
a O 0 2.627036792546278e-07
zinc O 0 0.01175724808126688
- O 0 2.5008788725244813e-05
finger O 0 1.8236160030937754e-06
transcription O 0 4.556044132186798e-06
factor O 0 5.761162356066052e-07
involved O 0 2.5708698103699135e-07
in O 0 2.4086546090984484e-07
renal O 1 0.9999979734420776
and O 0 3.5603786727733677e-06
gonadal O 1 0.9999998807907104
development O 0 0.005536096170544624
, O 0 1.7312827083060256e-07
are O 0 1.672704308397499e-09
found O 0 2.9937485823694487e-09
in O 0 7.531994472564918e-10
most O 0 1.6281697101661052e-09
patients O 0 8.111260996201963e-09
with O 0 3.309698470843614e-08
Denys B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999998807907104
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00012059372966177762
DDS B-Disease 1 1.0
) O 0 5.410428229879471e-07
, O 0 9.86182371320865e-08
or O 0 1.779232889020932e-06
diffuse B-Disease 1 0.9999575614929199
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 0.016279445961117744
DMS B-Disease 1 0.999998927116394
) O 0 1.4686719396195258e-07
associated O 0 4.5618995159202314e-07
with O 0 1.004116967351365e-07
pseudohermaphroditism B-Disease 1 0.9999998807907104
and O 0 5.939904440310784e-06
/ O 1 0.9973326921463013
or O 0 0.014915651641786098
Wilms B-Disease 1 1.0
tumor I-Disease 1 0.9998500347137451
( O 0 2.1465080862981267e-05
WT B-Disease 1 0.9999858140945435
) O 0 3.508173904265277e-06
. O 0 7.997969987627584e-06

Most O 0 5.47664399164205e-07
mutations O 0 1.4420630805034307e-06
in O 0 1.1394830607969197e-06
DDS B-Disease 1 1.0
patients O 0 2.092514478135854e-05
lie O 0 6.329194548015948e-06
in O 0 1.558877613661025e-07
exon O 0 4.0067784539132845e-06
8 O 0 3.4766588896673056e-07
or O 0 6.341190328384982e-08
exon O 0 2.592103783172206e-06
9 O 0 2.5305828899035987e-07
, O 0 2.282861366609268e-08
encoding O 0 7.016152494543348e-07
zinc O 0 0.0004625817819032818
finger O 0 2.2936581444810145e-05
2 O 0 7.959468348417431e-06
or O 0 4.116662637443369e-07
zinc O 0 0.297970175743103
finger O 0 2.24797913688235e-05
3 O 0 5.080457299300178e-07
, O 0 7.478660357662648e-09
respectively O 0 6.893518644801588e-08
, O 0 2.393096831809771e-09
with O 0 1.1726505322329217e-09
a O 0 2.3444000518679786e-08
hot O 0 3.3224154094568803e-07
spot O 0 8.289438824249373e-08
( O 0 7.471730789632147e-09
R394W O 0 2.3097143753147975e-07
) O 0 5.015221127280256e-09
in O 0 3.295494011013034e-08
exon O 0 1.0715612006606534e-05
9 O 0 1.2669475836446509e-05
. O 0 2.8258211841603043e-06

We O 0 3.107769543930772e-07
analyzed O 0 3.4410373928039917e-07
a O 0 2.5098593425809668e-08
series O 0 4.4439003588081505e-09
of O 0 8.731157130625888e-09
24 O 0 1.5840697642488522e-07
patients O 0 1.9236567894154177e-08
, O 0 3.0836591058402973e-09
10 O 0 1.0954354756620432e-08
with O 0 7.213589281462873e-09
isolated B-Disease 0 3.014957883351599e-06
DMS I-Disease 1 0.9997069239616394
( O 0 1.1480522061901866e-06
IDMS B-Disease 0 0.10007495433092117
) O 0 4.87376965452313e-08
, O 0 1.547666350631971e-08
10 O 0 1.751582878739555e-08
with O 0 1.0566454378135859e-08
DDS B-Disease 1 0.9999998807907104
, O 0 4.856167379330145e-08
and O 0 1.7190219026019804e-08
4 O 0 3.527163983108039e-07
with O 0 1.299475940186312e-07
urogenital B-Disease 1 0.9999655485153198
abnormalities I-Disease 1 0.9999961853027344
and O 0 0.0007293308735825121
/ O 1 0.9999974966049194
or O 1 0.9902932643890381
WT B-Disease 1 1.0
. O 0 0.00018503668252378702

We O 0 9.016892477120564e-07
report O 0 3.883604335896962e-07
WT1 O 0 2.333387965336442e-05
heterozygous O 0 2.1300500918641774e-07
mutations O 0 3.415215843460828e-08
in O 0 1.0905321978782467e-08
16 O 0 4.2613041273398267e-07
patients O 0 4.249558926971986e-08
, O 0 1.8128874401668327e-08
4 O 0 1.9310924415094632e-07
of O 0 1.1470635996602141e-07
whom O 0 4.066932888235897e-07
presented O 0 6.895161845932307e-07
with O 0 4.870396423939383e-07
IDMS B-Disease 1 0.9945976734161377
. O 0 3.353200736455619e-05

One O 0 1.1206772114746855e-06
male O 0 9.509097935733735e-07
and O 0 4.0864492234504723e-08
two O 0 1.8592008643736335e-07
female O 0 0.0005947171011939645
IDMS B-Disease 1 0.9999990463256836
patients O 0 2.3411806978401728e-05
with O 0 2.67137556875241e-06
WT1 O 1 0.9999991655349731
mutations O 0 0.00014219179865904152
underwent O 0 0.005873741116374731
normal O 0 5.3558604122372344e-05
puberty O 0 0.0004698745906352997
. O 0 8.451056601188611e-06

Two O 0 1.0732380815170472e-06
mutations O 0 2.163394356102799e-06
associated O 0 1.5985916661520605e-06
with O 0 1.4102450052178028e-07
IDMS B-Disease 1 0.7892266511917114
are O 0 6.443910294251509e-09
different O 0 1.7183718892255229e-09
from O 0 2.639989116204333e-09
those O 0 1.4125157710154213e-09
described O 0 6.8782966877734e-08
in O 0 1.678242540492647e-07
DDS B-Disease 1 1.0
patients O 0 3.772678610403091e-05
. O 0 4.911385985906236e-06

No O 0 2.2441001419792883e-05
WT1 O 0 0.002120068995282054
mutations O 0 6.820012572461565e-07
were O 0 6.153787523999199e-08
detected O 0 2.840866955011734e-07
in O 0 1.5242235251733405e-09
the O 0 1.8904109388984125e-09
six O 0 3.709775819871197e-09
other O 0 1.1883810380197701e-08
IDMS B-Disease 1 0.996920108795166
patients O 0 1.1762396070480463e-06
, O 0 2.6281536946726192e-08
suggesting O 0 1.6104183941934025e-07
genetic O 0 1.8411013513741636e-07
heterogeneity O 0 1.0081158734465134e-06
of O 0 4.851593757848605e-07
this O 0 8.362837888853392e-07
disease O 0 0.03258255496621132
. O 0 7.545138942077756e-06

We O 0 2.4019709599087946e-06
analyzed O 0 9.637924449634738e-06
genotype O 0 1.1160078429384157e-05
/ O 0 1.55220041051507e-05
phenotype O 0 3.5224209682382934e-07
correlations O 0 1.179870650958037e-06
, O 0 1.4855259244939134e-08
on O 0 4.980398315979073e-09
the O 0 7.771234211695344e-10
basis O 0 3.0226896541307724e-09
of O 0 1.0876234357581893e-09
the O 0 7.785476707766747e-10
constitution O 0 3.1252376242463242e-09
of O 0 3.680913129855412e-09
a O 0 8.784359906144346e-09
WT1 O 0 9.73120222624857e-07
mutation O 0 3.967918882352706e-09
database O 0 1.393301651830825e-08
of O 0 1.444740291844937e-07
84 O 0 0.00014120747800916433
germ O 1 0.9999971389770508
- O 0 0.0005406960844993591
line O 0 1.4190806041369797e-06
mutations O 0 9.979913784263772e-09
, O 0 1.807700211742258e-09
to O 0 5.418102078103004e-10
compare O 0 1.1036395797248133e-08
the O 0 1.8746624252941047e-09
distribution O 0 6.315743039664312e-09
and O 0 8.273287610549573e-10
type O 0 2.8187587375327894e-08
of O 0 7.032227689052206e-09
mutations O 0 4.20710355442111e-09
, O 0 1.05850672671437e-09
according O 0 5.379856560239205e-10
to O 0 3.4518071734268574e-10
the O 0 4.2766337138289146e-09
different O 0 3.661993375203565e-08
symptoms O 0 1.2363178939267527e-05
. O 0 1.4656178564109723e-06

This O 0 2.35136212722864e-07
demonstrated O 0 2.1016203390900046e-06
( O 0 4.807415621144173e-08
1 O 0 2.297142600582447e-07
) O 0 4.223182692442151e-09
the O 0 3.0660411987071257e-09
association O 0 7.392320977572808e-09
between O 0 2.0062127958908604e-08
mutations O 0 1.1839195401819325e-08
in O 0 1.2473667432288948e-08
exons O 0 1.0275643091972597e-07
8 O 0 1.562840168389812e-07
and O 0 8.203211443458258e-09
9 O 0 3.91955495615548e-07
and O 0 7.754288589012504e-08
DMS B-Disease 1 0.9875034689903259
; O 0 4.4896960815776765e-08
( O 0 2.8741233393247967e-08
2 O 0 4.7628128641008516e-07
) O 0 4.960527544284332e-09
among O 0 5.554743331970258e-09
patients O 0 1.724861320440141e-08
with O 0 1.892237122547158e-08
DMS B-Disease 1 0.9989894032478333
, O 0 1.6571291894251772e-08
a O 0 5.00256236435348e-09
higher O 0 9.230299191642644e-09
frequency O 0 3.394096115272305e-09
of O 0 3.995052288985335e-09
exon O 0 1.339246011866635e-07
8 O 0 2.67005564325018e-08
mutations O 0 6.147204079098856e-09
among O 0 2.041068425384651e-09
46 O 0 1.8078793573295115e-07
, O 0 8.787547756128333e-08
XY O 0 0.03655469790101051
patients O 0 1.442366794890404e-07
with O 0 5.720018680932526e-09
female O 0 2.1370351532823406e-07
phenotype O 0 3.07438163815732e-08
than O 0 2.933320031317521e-09
among O 0 5.890525400786828e-09
46 O 0 5.809677077195374e-07
, O 0 1.4045247098692926e-07
XY O 0 0.004110923036932945
patients O 0 8.130098905212435e-08
with O 0 6.254425422014265e-09
sexual O 0 3.4670537729653006e-07
ambiguity O 0 5.545065278056427e-07
or O 0 5.491811805313773e-08
male O 0 8.900701686798129e-08
phenotype O 0 1.3915859575774903e-08
; O 0 1.6189137808098053e-09
and O 0 5.9831961607415e-09
( O 0 1.1539623478995509e-08
3 O 0 5.790648671677445e-08
) O 0 9.068180095717082e-10
statistically O 0 5.01559416221653e-09
significant O 0 1.3497949424845501e-09
evidence O 0 1.805178118097217e-09
that O 0 8.313811444837782e-11
mutations O 0 1.0069757250263933e-09
in O 0 2.054841630183546e-09
exons O 0 1.3214170735409425e-07
8 O 0 1.0447738674201901e-07
and O 0 3.280935523264361e-09
9 O 0 5.903429212139599e-08
preferentially O 0 1.2997555920435389e-08
affect O 0 6.394641260953904e-09
amino O 0 6.054971635194306e-09
acids O 0 4.096107897311185e-09
with O 0 2.6813878895026733e-10
different O 0 6.642754124541739e-10
functions O 0 2.7912697930787544e-08
. O 0 2.098158269348005e-08
. O 0 2.9786431809952774e-07

The O 0 4.203190201224061e-06
185delAG O 0 4.3960164475720376e-05
BRCA1 O 0 2.82572159449046e-06
mutation O 0 1.1181882797473008e-07
originated O 0 5.430678129414446e-08
before O 0 6.856707202018697e-09
the O 0 1.745968369881723e-09
dispersion O 0 4.694511446245997e-08
of O 0 7.3913337672593116e-09
Jews O 0 9.326909022888685e-09
in O 0 8.680027807628221e-10
the O 0 9.434056869039864e-10
diaspora O 0 3.2274583006142166e-09
and O 0 7.476588792521e-10
is O 0 1.209903982557492e-10
not O 0 1.024115306447193e-10
limited O 0 1.6671621860808727e-09
to O 0 6.871763158500244e-09
Ashkenazim O 0 4.015602826257236e-05
. O 0 3.929348622477846e-06

The O 0 5.297303573570389e-07
185delAG O 0 3.6357948829390807e-06
mutation O 0 1.288199484861252e-07
in O 0 2.5278806603523662e-08
BRCA1 O 0 9.443156301358613e-08
is O 0 2.217004801963185e-09
detected O 0 1.7445310973585038e-08
in O 0 1.4485384003393165e-09
Ashkenazi O 0 3.897443079381446e-08
Jews O 0 4.1093168867689656e-09
both O 0 1.2477802124877257e-09
in O 0 1.576247932177921e-08
familial B-Disease 0 0.4487665593624115
breast I-Disease 1 1.0
and I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.784806590876542e-05
in O 0 1.2882473754416424e-07
the O 0 5.821790338700339e-08
general O 0 1.5542460118922463e-07
population O 0 1.1745225236836632e-08
. O 0 4.6320022306645114e-07

All O 0 2.663641964772978e-07
tested O 0 1.6808434111226234e-06
Ashkenazi O 0 1.9237029391661054e-06
mutation O 0 4.285577048790401e-08
carriers O 0 2.1260756710717033e-08
share O 0 2.7983901862427274e-09
the O 0 2.744138916099814e-09
same O 0 2.2050321568656273e-09
allelic O 0 1.2346386313311086e-07
pattern O 0 1.398943538788444e-07
at O 0 3.4330332709942013e-07
the O 0 2.419581051071873e-07
BRCA1 O 0 2.6819589038495906e-06
locus O 0 2.8589265639311634e-06
. O 0 2.9969435217935825e-06

Our O 0 5.971137397864368e-07
previous O 0 1.915872616109482e-07
study O 0 5.408381298366294e-08
showed O 0 2.380319941153175e-08
that O 0 2.056063791444629e-10
this O 0 2.0264280531367973e-10
Ashkenazi O 0 2.920587149901621e-08
mutation O 0 3.2434166463701786e-09
also O 0 1.000678429008417e-09
occurs O 0 7.756248421308953e-10
in O 0 4.879810999725009e-10
Iraqi O 0 3.173340701323468e-08
Jews O 0 3.3359479623129573e-09
with O 0 5.403674174786488e-10
a O 0 2.151115729986941e-09
similar O 0 2.5322994812171373e-09
allelic O 0 6.360717179632047e-07
pattern O 0 2.698169510040316e-06
. O 0 1.8722283812167007e-06

We O 0 7.969212560965389e-07
extended O 0 9.729414074399756e-08
our O 0 8.918321192652456e-09
analysis O 0 1.4193946018536963e-09
to O 0 3.7573355538000897e-10
other O 0 6.870973789929735e-10
non O 0 9.336541495486017e-08
- O 0 6.203152480566132e-08
Ashkenazi O 0 7.111827216021993e-08
subsets O 0 5.004778813599842e-08
354 O 0 1.230377399963345e-08
of O 0 3.8467922180984715e-09
Moroccan O 0 8.36863165432078e-08
origin O 0 2.6733053548610997e-09
, O 0 1.4408174653368633e-09
200 O 0 4.002542297598666e-09
Yemenites O 0 1.9668749473567004e-07
and O 0 2.580752722636248e-09
150 O 0 1.410228289699944e-08
Iranian O 0 1.4696288985760475e-07
Jews O 0 1.0705173281166935e-07
. O 0 2.413589186289755e-07

Heteroduplex O 0 9.197888721246272e-05
analysis O 0 3.724397288351611e-07
complemented O 0 3.092758902312198e-07
by O 0 2.6464626046163175e-09
direct O 0 7.1513661659139416e-09
DNA O 0 4.6577117274182456e-08
sequencing O 0 2.03924468422656e-08
of O 0 1.3599255943574917e-08
abnormally O 0 1.4015688520885305e-07
migrating O 0 9.102218534451367e-09
bands O 0 1.2206410815451818e-07
were O 0 9.713949822298673e-08
employed O 0 1.4417717011383502e-06
. O 0 1.025633196150011e-06

Four O 0 6.021924718879745e-07
of O 0 1.6429109450655233e-07
Moroccan O 0 2.5087022095249267e-06
origin O 0 2.5580737528230202e-08
( O 0 4.0083865116002926e-09
1 O 0 1.8916633592880316e-08
. O 0 4.1737882594539144e-10
1 O 0 9.057778527221672e-09
% O 0 1.3242885676945093e-09
) O 0 2.8644225880114504e-10
and O 0 6.985221845390299e-10
none O 0 7.501947507648765e-09
of O 0 6.148094922053815e-09
the O 0 1.3205763593759912e-08
Yemenites O 0 1.6034837244660594e-06
or O 0 9.907124010055668e-09
Iranians O 0 5.091627386377695e-08
was O 0 3.294142914000986e-08
a O 0 3.2339655398061495e-09
carrier O 0 7.213107888759396e-09
of O 0 3.1953011347951588e-09
the O 0 8.419733354969594e-09
185delAG O 0 9.81785660769674e-07
mutation O 0 1.9514104110385233e-07
. O 0 6.535964303111541e-07

BRCA1 O 0 2.680195393622853e-05
allelic O 0 8.592331141699106e-06
patterns O 0 3.285340142156201e-07
were O 0 2.9419558345011865e-08
determined O 0 1.0312433573744784e-08
for O 0 8.848288768348311e-10
four O 0 6.48289977256411e-10
of O 0 6.337786406795942e-10
these O 0 4.5232630141445185e-11
individuals O 0 1.8788595679275488e-11
and O 0 8.742730150945732e-11
for O 0 3.2032812513627107e-10
12 O 0 3.2152436268972906e-09
additional O 0 1.9024923858523834e-09
non O 0 5.591291341033866e-08
- O 0 5.7309637924163326e-08
Ashkenazi O 0 2.341709581799023e-08
185delAG O 0 4.254635754818992e-08
mutation O 0 6.5421414952027135e-09
carriers O 0 3.51500730744192e-08
who O 0 6.954744691256565e-08
had O 0 3.065801865886897e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.03599599376320839

Six O 0 5.576504008786287e-06
non O 0 6.471798405982554e-05
- O 0 1.53109594975831e-05
Ashkenazi O 0 6.962349061723216e-07
individuals O 0 3.155401273602365e-09
shared O 0 9.613161822130678e-09
the O 0 4.012624454929892e-09
common O 0 1.4506791323753987e-08
Ashkenazi O 0 5.943599603597249e-07
haplotype O 0 1.5695180763941607e-06
, O 0 2.2897122420317828e-08
four O 0 1.5265053221469316e-08
had O 0 3.0021670482938134e-08
a O 0 1.0194545652097986e-08
closely O 0 4.992134705616991e-09
related O 0 6.834406374167656e-09
pattern O 0 4.155054611487685e-08
, O 0 2.229594953107039e-09
and O 0 9.030656777930801e-10
the O 0 7.668433887886295e-09
rest O 0 1.0913774417531386e-07
( O 0 7.92526844151098e-09
n O 0 8.850356181255847e-08
= O 0 1.163741316645428e-07
6 O 0 1.0344569290055006e-07
) O 0 2.216155037260137e-09
displayed O 0 4.388897067997277e-08
a O 0 1.1571736457938187e-08
distinct O 0 7.869688545270037e-08
BRCA1 O 0 1.0420548051115475e-06
allelic O 0 8.966156201495323e-06
pattern O 0 2.636136196088046e-05
. O 0 4.039028681290802e-06

We O 0 1.2986599813302746e-06
conclude O 0 1.7454501630709274e-06
that O 0 3.83909615209177e-09
the O 0 2.074611948899019e-08
185delAG O 0 7.25718678040721e-07
BRCA1 O 0 6.524001605612284e-08
mutation O 0 2.7319497775124546e-09
occurs O 0 1.3348253613543193e-09
in O 0 5.19794096653925e-10
some O 0 5.381354806210936e-10
non O 0 1.610553539421744e-07
- O 0 2.601209416752681e-07
Ashkenazi O 0 8.159101838600691e-08
populations O 0 2.0664598920916433e-09
at O 0 1.7315064937406532e-08
rates O 0 2.0235949804714437e-08
comparable O 0 4.0241765475457214e-08
with O 0 7.524471046238546e-10
that O 0 3.295925976587455e-09
of O 0 2.1011665296555293e-07
Ashkenazim O 0 0.00022366379562299699
. O 0 5.236874130787328e-06

The O 0 5.273381589177006e-07
majority O 0 7.346907437977279e-08
of O 0 4.441259093823646e-08
Jewish O 0 8.33875617445301e-08
185delAG O 0 1.0802123142639175e-06
mutation O 0 3.0116474647456926e-08
carriers O 0 3.0075778312266266e-08
have O 0 6.585166856254432e-10
a O 0 1.6300557570403384e-09
common O 0 1.9104886561649437e-09
allelic O 0 1.234975428587859e-07
pattern O 0 1.8593232198327314e-07
, O 0 8.201787693451479e-09
supporting O 0 2.3248562186495292e-08
the O 0 6.274666564110021e-09
founder O 0 1.1372917896323997e-07
effect O 0 1.1380502229485501e-07
notion O 0 1.8360672981998505e-07
, O 0 3.2925897563984563e-09
but O 0 5.335974440079383e-10
dating O 0 8.236621162893698e-09
the O 0 1.0465199817843995e-09
mutations O 0 1.0009265638544207e-09
origin O 0 6.37608910114551e-10
to O 0 2.47972697930976e-10
an O 0 4.945400755573814e-10
earlier O 0 7.254250533605955e-09
date O 0 2.4017177580049065e-08
than O 0 2.3558066608586614e-09
currently O 0 1.2429256734947103e-08
estimated O 0 6.366312277350517e-08
. O 0 3.0336855161294807e-07

However O 0 1.3996964298712555e-06
, O 0 3.234250911532399e-08
the O 0 6.118113127229208e-09
different O 0 3.375773216518496e-09
allelic O 0 2.87975666424245e-07
pattern O 0 2.714126878800016e-07
at O 0 1.9479631419017096e-07
the O 0 4.068445136340415e-08
BRCA1 O 0 6.997282753218315e-08
locus O 0 2.8426550002791373e-08
even O 0 4.121468055728883e-09
in O 0 8.822875208203129e-10
some O 0 3.918653179724174e-10
Jewish O 0 8.274680496356268e-09
mutation O 0 9.249861321336539e-09
carriers O 0 3.341413545854266e-08
, O 0 8.105121018786576e-09
might O 0 6.077835124074227e-09
suggest O 0 4.313909673925309e-09
that O 0 2.4741994564259073e-10
the O 0 9.636692555048398e-10
mutation O 0 3.6350602528045783e-09
arose O 0 2.600529214191738e-08
independently O 0 4.434800260355587e-08
. O 0 4.3088792978096535e-08
. O 0 6.521793238789542e-07

Crystal O 1 0.8716384172439575
structure O 0 5.802925443276763e-05
of O 0 6.671597930107964e-06
the O 0 0.00018031918443739414
hemochromatosis B-Disease 1 1.0
protein O 0 0.000109711560071446
HFE O 0 0.004938357509672642
and O 0 5.00355739063707e-08
characterization O 0 4.6237181550168316e-07
of O 0 2.2629411233765495e-08
its O 0 3.786799318561407e-09
interaction O 0 1.3111463204040774e-07
with O 0 1.2857189801707136e-07
transferrin O 0 5.919645991525613e-05
receptor O 0 7.05486627339269e-06
. O 0 2.6066852569783805e-06

HFE O 0 0.02946161851286888
is O 0 6.732302040290961e-07
an O 0 9.266322820167261e-08
MHC O 0 0.0010396434227004647
- O 0 0.00018639380868989974
related O 0 2.8156907774246065e-06
protein O 0 4.865029978873281e-08
that O 0 2.342149529876991e-10
is O 0 3.63569646610884e-10
mutated O 0 3.3001594790249555e-09
in O 0 1.1747818273732946e-09
the O 0 3.3477800087666765e-08
iron B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 1 0.9999759197235107

HFE O 0 0.0017089270986616611
binds O 0 4.124515726289246e-06
to O 0 5.787661621070583e-07
transferrin O 0 2.7422065613791347e-05
receptor O 0 1.9835617877106415e-06
( O 0 1.738251143024172e-07
TfR O 0 5.455575774249155e-06
) O 0 5.980070216793365e-09
and O 0 1.3189395131618653e-09
reduces O 0 1.0030638541991266e-08
its O 0 8.593542544232946e-10
affinity O 0 1.2005216376564931e-08
for O 0 3.1855844184747184e-08
iron O 1 0.7116889953613281
- O 0 7.632104825461283e-06
loaded O 0 5.890067313885083e-07
transferrin O 0 5.202844477025792e-06
, O 0 2.159837180215618e-07
implicating O 0 0.0012404166627675295
HFE O 1 0.9989243149757385
in O 0 2.859167943825014e-05
iron O 1 0.9999973773956299
metabolism O 0 0.26376107335090637
. O 0 2.7675481760525145e-05

The O 0 2.109766865032725e-05
2 O 0 0.00013950314314570278
. O 0 1.7072679838747717e-05

6 O 0 0.0001863753132056445
A O 0 6.931272218935192e-05
crystal O 0 0.44353175163269043
structure O 0 5.533341391128488e-05
of O 0 6.743907761119772e-06
HFE O 1 0.8819305896759033
reveals O 0 4.947830234414141e-07
the O 0 1.3887991201499972e-08
locations O 0 7.172597804583347e-08
of O 0 1.7811105408327421e-06
hemochromatosis B-Disease 1 1.0
mutations O 0 1.6285794117720798e-06
and O 0 1.761898857921551e-07
a O 0 6.367478135871352e-07
patch O 0 0.0008182282908819616
of O 0 1.4589904822059907e-05
histidines O 0 0.0745919719338417
that O 0 5.9557105913654595e-09
could O 0 8.830320474828568e-09
be O 0 8.341675683531946e-10
involved O 0 6.235510330299121e-09
in O 0 3.0873903433814576e-09
pH O 0 7.303626262000762e-06
- O 0 5.20272533321986e-06
dependent O 0 8.508657174388645e-07
interactions O 0 2.8028630367771257e-06
. O 0 2.1423968519229675e-06

We O 0 1.122414232668234e-06
also O 0 9.123183275505653e-08
demonstrate O 0 1.453485367619578e-07
that O 0 1.3957966338296046e-08
soluble O 0 7.912281034805346e-06
TfR O 0 5.1384700782364234e-05
and O 0 1.2277698147045157e-07
HFE O 0 0.0029595796950161457
bind O 0 5.387444161897292e-07
tightly O 0 1.1737049590010429e-06
at O 0 1.7855583678283438e-07
the O 0 8.432043507866638e-09
basic O 0 6.496509286080254e-08
pH O 0 3.3788839459703013e-07
of O 0 1.6923321410899916e-08
the O 0 1.224998680271483e-08
cell O 0 2.244466514866872e-07
surface O 0 8.139905816051396e-08
, O 0 3.3217639749949512e-09
but O 0 9.991489857696934e-10
not O 0 6.202507951691416e-10
at O 0 1.2821895545300777e-08
the O 0 3.810440851736985e-09
acidic O 0 9.169868064873299e-08
pH O 0 1.7259478681808105e-06
of O 0 7.96622657617263e-07
intracellular O 0 2.8733436920447275e-05
vesicles O 0 3.196772377123125e-05
. O 0 4.73954150947975e-06

TfR O 0 0.024010857567191124
HFE O 0 0.011110533960163593
stoichiometry O 0 0.00010627197480062023
( O 0 1.931640781549504e-06
2 O 0 2.8047024898114614e-06
1 O 0 6.376958481268957e-07
) O 0 6.709468980403699e-09
differs O 0 2.5749375964778665e-08
from O 0 3.080961974433194e-08
TfR O 0 5.548812168854056e-06
transferrin O 0 1.84048678875115e-06
stoichiometry O 0 7.660950700483227e-07
( O 0 4.594176061800681e-08
2 O 0 3.5814753118756926e-07
2 O 0 1.0646814274650751e-07
) O 0 1.8156202097330265e-09
, O 0 1.5460723812310562e-09
implying O 0 8.476242818744595e-09
a O 0 1.000340699164326e-09
different O 0 1.6615551989840327e-10
mode O 0 1.4753464228078883e-08
of O 0 1.4081392718523489e-09
binding O 0 3.704762274736595e-09
for O 0 1.0239189940364213e-08
HFE O 0 3.907680365955457e-05
and O 0 8.789090344407668e-08
transferrin O 0 3.85483372156159e-06
to O 0 6.245344508215567e-08
TfR O 0 8.701854676473886e-05
, O 0 9.12478181902543e-09
consistent O 0 1.6699061688996153e-08
with O 0 1.1469509786365961e-09
our O 0 7.076413677253868e-09
demonstration O 0 6.285137743589075e-08
that O 0 2.9585149885491546e-09
HFE O 0 2.9817836548318155e-05
, O 0 6.523515594381024e-08
transferrin O 0 2.7238038455834612e-06
, O 0 3.264607428832278e-08
and O 0 3.070970677754303e-08
TfR O 0 6.949135695322184e-06
form O 0 4.2342918504800764e-08
a O 0 1.390820898450329e-07
ternary O 0 1.0726030268415343e-05
complex O 0 8.237420843215659e-05
. O 0 4.5872252485423815e-06

Identification O 0 1.220383296640648e-06
of O 0 1.6816036918498867e-07
three O 0 2.03897236872308e-08
novel O 0 1.3530846665332774e-08
mutations O 0 4.10761646918445e-09
and O 0 7.294469472896026e-10
a O 0 2.319371805725723e-09
high O 0 1.8683095959204365e-08
frequency O 0 1.3250648578377877e-08
of O 0 1.4847064688794376e-09
the O 0 1.6708198158355003e-09
Arg778Leu O 0 3.4513834634708473e-07
mutation O 0 3.094476674903035e-09
in O 0 3.417025551399888e-09
Korean O 0 1.0067353287013248e-05
patients O 0 5.9181868294899687e-08
with O 0 7.908705867976096e-08
Wilson B-Disease 0 0.39985668659210205
disease I-Disease 1 0.6624774932861328
. O 0 9.08053607417969e-06

Four O 0 9.687894362286897e-07
mutations O 0 5.382827339417418e-07
- O 0 3.013020887010498e-06
- O 0 1.0148178262170404e-06
R778L O 0 7.816028642082529e-07
, O 0 9.373205323015554e-09
A874V O 0 2.254033404369693e-07
, O 0 4.222715954682599e-09
L1083F O 0 1.7167486987546e-07
, O 0 1.6430942162415363e-09
and O 0 1.8155302816680319e-09
2304delC O 0 2.4117852603922074e-07
- O 0 1.6065909846929571e-07
- O 0 2.221412209735263e-08
in O 0 1.3140530885635826e-09
the O 0 4.34968505658162e-09
copper O 0 6.714817118336214e-06
- O 0 1.3605746573830402e-07
transporting O 0 3.3970771085023443e-08
enzyme O 0 6.014019504618773e-09
, O 0 9.81204273386993e-09
P O 0 1.3492003745341208e-05
- O 0 1.144079305959167e-06
type O 0 9.830702083490905e-07
ATPase O 0 1.6701536651453353e-06
( O 0 3.2351888279436025e-08
ATP7B O 0 5.29524331795983e-05
) O 0 9.20859921649253e-09
, O 0 1.2625029910395824e-09
were O 0 1.8121260048076238e-09
identified O 0 1.1088640228251734e-08
in O 0 5.396158186954381e-09
Korean O 0 1.0651831871655304e-05
Patients O 0 1.0550427731459422e-07
with O 0 9.575175852205575e-08
Wilson B-Disease 0 0.0056123556569218636
disease I-Disease 0 0.07662861049175262
. O 0 6.085869699745672e-06

Arg778Leu O 0 0.008383735083043575
, O 0 3.412364719679317e-07
the O 0 2.564072332233991e-08
most O 0 2.206205884647261e-09
frequently O 0 2.0557431312795416e-09
reported O 0 9.778763354617581e-10
mutation O 0 3.744050902643181e-10
of O 0 2.3170139418215996e-10
this O 0 1.8234695697838532e-10
enzyme O 0 4.365401817807424e-09
, O 0 1.5050298785013183e-09
was O 0 2.7355541831752817e-08
found O 0 2.0260038091635124e-09
in O 0 1.3191960857028562e-09
six O 0 4.20692680691559e-09
of O 0 7.666780987847233e-09
eight O 0 4.08872544710448e-08
unrelated O 0 2.1511952752462093e-07
patients O 0 7.95346455362278e-09
studied O 0 3.66196566403687e-08
, O 0 6.581977185504684e-10
an O 0 2.547033972621904e-10
allele O 0 2.472148485921366e-09
frequency O 0 5.4378197944515705e-08
of O 0 7.423989245580742e-08
37 O 0 5.469171810545959e-06
. O 0 2.4103787836793344e-06

5 O 0 1.0138379366253503e-05
% O 0 3.500029208680644e-07
, O 0 7.175249727708888e-09
which O 0 5.076494780098528e-10
is O 0 3.23876619967578e-10
considerably O 0 8.878977553195e-09
higher O 0 3.8629166532189174e-09
than O 0 1.5340750891823518e-10
those O 0 1.200353288988154e-10
in O 0 4.3523881720908264e-10
other O 0 1.0538995232067805e-09
Asian O 0 1.2901480772598006e-07
populations O 0 5.2287617791080265e-08
. O 0 2.893965813655086e-07

The O 0 2.601784956368647e-07
novel O 0 3.907171475248106e-08
single O 0 8.251732630526476e-09
nucleotide O 0 5.108368483774939e-08
deletion O 0 9.578427295764413e-08
, O 0 6.656303508378869e-09
2304delC O 0 3.514605850796215e-07
, O 0 7.535806645364573e-09
was O 0 7.590497119736028e-08
found O 0 4.219503413338543e-09
in O 0 3.892018707318812e-09
one O 0 1.771817714768531e-08
patient O 0 1.2523989880719455e-06
. O 0 1.1740944501070771e-06

Since O 0 7.841023830224003e-07
a O 0 1.1802393373727682e-07
mutation O 0 1.987083741994411e-08
at O 0 1.9491655223191628e-07
cDNA O 0 1.132527813751949e-06
nucleotide O 0 3.055134811802418e-06
2302 O 0 0.00020995471277274191
( O 0 1.7447598565922817e-07
2302insC O 0 3.2094972084451e-06
) O 0 4.088382254963108e-08
had O 0 4.4228979589888695e-08
been O 0 7.435932758426134e-09
previously O 0 1.938370708387538e-08
described O 0 4.883286219836691e-09
, O 0 1.7527441997788884e-10
this O 0 7.300757914885381e-11
region O 0 2.0184325322247787e-09
of O 0 2.882900806966404e-09
the O 0 1.1697738777627364e-08
ATP7B O 0 0.00022807699861004949
gene O 0 6.409773334326019e-08
may O 0 1.09327711328433e-08
be O 0 2.7298765470362696e-09
susceptible O 0 3.058706710135084e-08
to O 0 2.277319666177391e-09
gene O 0 1.2980246992810862e-06
rearrangements O 0 0.03648395091295242
causing O 1 0.8698126673698425
Wilson B-Disease 1 0.997684121131897
disease I-Disease 1 0.995012104511261
. O 0 1.8362567061558366e-05

Disruption O 0 4.070862632943317e-05
of O 0 3.9404008589372097e-07
splicing O 0 5.9867488744203e-07
regulated O 0 9.407830248164828e-08
by O 0 3.234446710465022e-09
a O 0 2.7121803469754013e-08
CUG O 0 4.1711184167070314e-05
- O 0 9.754681968843215e-07
binding O 0 3.2597858989902306e-07
protein O 0 1.1079189789597876e-05
in O 0 9.207123184751254e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0005779481725767255

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9940124154090881
DM B-Disease 1 1.0
) O 0 9.489243893767707e-06
is O 0 1.7883870384594047e-07
caused O 0 1.319547067168969e-07
by O 0 9.463202665926929e-09
a O 0 1.5793739294167608e-07
CTG O 0 9.582642087480053e-05
expansion O 0 5.122057018525084e-07
in O 0 1.9826277508627754e-08
the O 0 1.913709901657512e-08
3 O 0 3.289425194452633e-07
untranslated O 0 1.6922480426728725e-05
region O 0 9.511686016594467e-08
of O 0 4.168684597516403e-08
the O 0 7.602601499456796e-07
DM B-Disease 1 1.0
gene O 0 1.698652522463817e-05
. O 0 6.777150701964274e-06

One O 0 4.423324355684599e-07
model O 0 1.6488676237713662e-06
of O 0 2.9744080165983178e-05
DM B-Disease 1 1.0
pathogenesis O 1 0.9999785423278809
suggests O 0 2.5208544229826657e-06
that O 0 9.239035314578814e-09
RNAs O 0 3.3320935699521215e-07
from O 0 3.4390732484013142e-09
the O 0 2.1374839676013835e-09
expanded O 0 5.444396045106714e-09
allele O 0 2.8318736244870024e-09
create O 0 3.475718157730512e-09
a O 0 6.053793466520574e-09
gain O 0 1.2940482463363878e-07
- O 0 1.6992416362882068e-07
of O 0 1.5919441764822295e-08
- O 0 5.2314753418158944e-08
function O 0 5.3593551818664764e-09
mutation O 0 3.9089786962875905e-10
by O 0 1.1666599630810737e-10
the O 0 7.305329674522909e-10
inappropriate O 0 1.3467611026385384e-08
binding O 0 1.2636866664195168e-08
of O 0 2.378409291736716e-08
proteins O 0 5.792081925193315e-09
to O 0 4.372910478167569e-09
the O 0 1.5171708867001144e-07
CUG O 0 0.011149237863719463
repeats O 0 1.4261409887694754e-05
. O 0 3.861522600345779e-06

Data O 0 1.2093800023649237e-06
presented O 0 7.214403012767434e-07
here O 0 4.8464698920724913e-08
indicate O 0 1.788673031910548e-08
that O 0 2.904800844305555e-10
the O 0 1.4131356085300695e-09
conserved O 0 1.158002049805873e-07
heterogeneous O 0 1.0560348755461746e-06
nuclear O 0 6.917199698364129e-06
ribonucleoprotein O 0 1.2419027370924596e-05
, O 0 2.633663598317071e-08
CUG O 0 9.678866263129748e-06
- O 0 2.3150995787091233e-07
binding O 0 4.5748606680717785e-08
protein O 0 1.5430248367920285e-07
( O 0 1.8995924833120625e-08
CUG O 0 0.0001644627918722108
- O 0 1.3037604730925523e-05
BP O 0 7.838938472559676e-06
) O 0 1.0261067551198266e-08
, O 0 9.888622365394895e-09
may O 0 2.5415285875851623e-08
mediate O 0 2.491226211986941e-07
the O 0 1.0165579311660622e-07
trans O 0 3.90781542591867e-06
- O 0 6.991705845393881e-07
dominant O 0 6.530848963848257e-07
effect O 0 1.7107733185639518e-07
of O 0 6.873470681512117e-08
the O 0 2.249408055376989e-07
RNA O 0 1.943973074958194e-05
. O 0 1.4958203564674477e-06

CUG O 1 0.9987859129905701
- O 0 0.28490954637527466
BP O 0 0.000311561074340716
was O 0 1.2935352060594596e-06
found O 0 3.773712453636335e-09
to O 0 6.939221974811005e-10
bind O 0 2.1814676731679583e-09
to O 0 1.7451460276873831e-09
the O 0 3.268807091671988e-08
human O 0 4.938534061693645e-07
cardiac O 1 0.9953396320343018
troponin O 1 0.9156464338302612
T O 0 0.00048485255683772266
( O 0 1.2840585839057894e-07
cTNT O 0 2.366498392802896e-06
) O 0 1.195599530490199e-08
pre O 0 1.2630017636183766e-06
- O 0 3.4885391642092145e-07
messenger O 0 3.683520688468889e-08
RNA O 0 3.3524063525192105e-08
and O 0 7.474435514964739e-10
regulate O 0 7.089166587093132e-09
its O 0 1.4144649895797556e-09
alternative O 0 1.9416755492329685e-07
splicing O 0 2.187975269407616e-06
. O 0 1.2796947430615546e-06

Splicing O 0 2.2467876988230273e-05
of O 0 2.3414831957779825e-06
cTNT O 0 0.00023762710043229163
was O 0 3.354806176503189e-05
disrupted O 0 8.31896613817662e-05
in O 0 4.6446812120848335e-06
DM B-Disease 1 1.0
striated O 0 0.3474474549293518
muscle O 0 1.904249620565679e-05
and O 0 4.7309342221524275e-08
in O 0 3.1742612094376454e-08
normal O 0 1.2958771833382343e-07
cells O 0 6.430919796684975e-09
expressing O 0 5.358547827682969e-09
transcripts O 0 4.130598796336926e-08
that O 0 1.0876359812783676e-09
contain O 0 5.051214202467236e-08
CUG O 0 0.00010979340004269034
repeats O 0 5.740782853536075e-06
. O 0 9.743190503286314e-07

Altered O 0 2.291607415827457e-06
expression O 0 3.746905576917925e-07
of O 0 1.3487589001215383e-07
genes O 0 5.7366833061678335e-08
regulated O 0 4.779785172104312e-07
posttranscriptionally O 0 9.828902420849772e-07
by O 0 3.168321072166691e-08
CUG O 1 0.6065263152122498
- O 0 7.58533860789612e-05
BP O 0 1.149561649071984e-05
therefore O 0 1.1104813779638789e-07
may O 0 3.5959072164359895e-08
contribute O 0 4.5665260017813125e-08
to O 0 4.6082095650490373e-07
DM B-Disease 1 1.0
pathogenesis O 1 0.9999722242355347
. O 0 1.8935750176751753e-06
. O 0 3.7929894460830837e-06

Identification O 0 2.5707304303068668e-06
of O 0 4.6968494871180155e-07
a O 0 1.3625587769183767e-07
novel O 0 4.698049949070082e-08
nonsense O 0 3.4033621432172367e-07
mutation O 0 1.4733330111482701e-08
and O 0 1.6005351488601605e-09
a O 0 1.5041553780292816e-08
missense O 0 1.4433328487939434e-07
substitution O 0 4.308082068860131e-08
in O 0 6.314586631361863e-09
the O 0 1.9476727786127412e-08
vasopressin O 0 2.9200416520325234e-06
- O 0 6.846556516393321e-06
neurophysin O 0 3.0225926821003668e-05
II O 1 0.998680055141449
gene O 0 6.383420014799412e-08
in O 0 3.3706777369246765e-09
two O 0 1.9902308689978554e-09
Spanish O 0 2.098218772061955e-07
kindreds O 0 1.9371309463167563e-06
with O 0 9.383637689097668e-08
familial B-Disease 1 0.9997811913490295
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999898672103882
. O 0 0.00014250520325731486

Familial B-Disease 1 0.9999854564666748
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999998807907104
( O 0 0.0010787417413666844
FNDI B-Disease 1 1.0
) O 0 2.7554568760024267e-07
is O 0 5.290878402064436e-09
an O 0 1.360013790474568e-08
autosomal B-Disease 1 0.9997037053108215
dominant I-Disease 1 1.0
disease I-Disease 1 0.9999996423721313
caused O 0 0.0003370397025719285
by O 0 4.833628395317646e-07
deficiency O 1 0.9999960660934448
in O 0 7.783922910675756e-07
the O 0 2.16175067180302e-06
antidiuretic O 0 5.112842336529866e-05
hormone O 0 2.891214990086155e-06
arginine O 0 2.3724569473415613e-06
vasopressin O 0 1.1233652003284078e-05
( O 0 3.023147030489781e-07
AVP O 0 8.814481589070056e-06
) O 0 1.2211144984064504e-08
encoded O 0 1.2491119250057636e-08
by O 0 3.6544003378935486e-09
the O 0 4.8847329736645406e-08
AVP O 0 0.00019801384769380093
- O 0 0.0002853636397048831
neurophysin O 0 0.017554081976413727
II O 1 0.9999996423721313
( O 0 1.3119849427312147e-05
AVP O 0 0.0183101873844862
- O 0 0.00028690905310213566
NPII O 0 0.0005530605558305979
) O 0 5.343169817706439e-08
gene O 0 1.0543568151888394e-07
on O 0 3.4255111813763506e-07
chromosome O 0 1.0113850294146687e-05
20p13 O 0 6.732874317094684e-05
. O 0 7.3480391620250884e-06

In O 0 7.393114032083759e-08
this O 0 1.9534385220509876e-09
study O 0 5.09171238505246e-09
, O 0 8.8216295379695e-10
we O 0 1.2246241798408164e-09
analyzed O 0 6.654119921734036e-09
two O 0 3.30163757444879e-10
families O 0 1.2630420320736135e-10
with O 0 7.0049149814011e-10
FNDI B-Disease 0 0.26076874136924744
using O 0 2.88489743205389e-09
direct O 0 2.5159549998932107e-09
automated O 0 5.838559502535645e-08
fluorescent O 0 7.438173632579037e-09
, O 0 5.773659328411895e-10
solid O 0 1.562019846801377e-08
phase O 0 6.484365400183378e-08
, O 0 9.488175800598242e-10
single O 0 7.270911095424992e-10
- O 0 5.752073928277923e-09
stranded O 0 1.982033204228628e-09
DNA O 0 1.3827007316891127e-09
sequencing O 0 1.997730869618408e-09
of O 0 4.293273736521996e-09
PCR O 0 3.417640641600883e-07
- O 0 1.2759510354953818e-06
amplified O 0 4.7009680201881565e-06
AVP O 0 0.0005250053363852203
- O 0 8.825620170682669e-05
NPII O 0 0.004028882831335068
DNA O 0 1.3972882697999012e-05
. O 0 1.4649680224465556e-06

In O 0 8.160686775227077e-07
one O 0 5.370900879597684e-08
of O 0 6.175940114871992e-08
the O 0 7.7490955874282e-09
families O 0 1.1349039485963885e-09
, O 0 9.77505187904626e-10
affected O 0 5.924979951110743e-10
individuals O 0 1.0142209294627946e-10
presented O 0 6.274941899420128e-09
a O 0 2.1110910797261795e-09
novel O 0 2.2979536051792593e-09
nonsense O 0 2.3441808494339966e-08
mutation O 0 3.220558708605381e-09
in O 0 4.7540158476522265e-09
exon O 0 5.475641273733345e-07
3 O 0 1.9456045663446275e-08
of O 0 3.834646378209072e-09
the O 0 3.1265969813176753e-09
gene O 0 4.856470336989105e-09
, O 0 1.1583853876118155e-09
consisting O 0 5.825763871314393e-09
in O 0 3.164073891781527e-09
a O 0 1.6518084677841216e-08
G O 0 1.2280162309252773e-06
to O 0 2.4010535781826547e-08
T O 0 6.309668606263585e-06
transition O 0 5.048583716416033e-06
at O 0 1.6901179833439528e-06
nucleotide O 0 4.770800501319172e-07
2101 O 0 5.673181021847995e-06
, O 0 5.9459042134335505e-09
which O 0 2.7059512963667487e-10
produces O 0 1.8673956825310256e-10
a O 0 4.031447953245504e-10
stop O 0 1.7110229899586216e-09
signal O 0 1.2227880041848493e-08
in O 0 1.772567204127995e-09
codon O 0 2.0292612035177626e-08
82 O 0 3.6527023894450394e-07
( O 0 7.577593663654625e-08
Glu O 0 3.903348988387734e-05
) O 0 7.817715186320129e-08
of O 0 1.1628675338215544e-06
NPII O 1 0.836698591709137
. O 0 1.5075154806254432e-05

The O 0 1.499255176895531e-06
premature O 0 2.3708919343334856e-06
termination O 0 5.149951789462648e-07
eliminates O 0 6.647842383245006e-07
part O 0 3.385227387298073e-08
of O 0 2.3964874529269764e-08
the O 0 4.294127720072538e-08
C O 0 0.0008261206094175577
- O 0 1.36773303438531e-06
terminal O 0 4.886209694632271e-07
domain O 0 5.8375132283572384e-08
of O 0 2.7903862331868368e-08
NPII O 0 9.231437434209511e-05
, O 0 1.271706828731567e-08
including O 0 4.7174877337852195e-09
a O 0 6.2945768597444385e-09
cysteine O 0 1.0582751563958936e-08
residue O 0 3.7839061661770756e-08
in O 0 2.700698331636886e-09
position O 0 9.31857258024138e-08
85 O 0 1.2854970066200622e-07
, O 0 7.354952646920765e-09
which O 0 9.858561744735539e-10
could O 0 2.236132390365242e-09
be O 0 1.2477372468566728e-09
involved O 0 8.060244027774388e-09
in O 0 1.727665788209265e-09
the O 0 2.9689668501475808e-09
correct O 0 3.192869542090193e-07
folding O 0 3.755380248549045e-06
of O 0 5.855382596564596e-07
the O 0 1.7024319731717696e-06
prohormone O 0 0.004937441553920507
. O 0 8.147590051521547e-06

In O 0 1.1114123026345624e-06
the O 0 3.6894064692205575e-07
second O 0 1.0500234566279687e-06
family O 0 5.391438406832094e-08
, O 0 3.745988852443816e-09
a O 0 4.846726575635785e-09
G279A O 0 8.584704858094483e-08
substitution O 0 2.9505986987032884e-08
at O 0 4.6233520123450944e-08
position O 0 1.3733202308685577e-07
- O 0 1.7684926945094048e-07
1 O 0 4.3853830788975756e-08
of O 0 4.895690075557013e-09
the O 0 2.660126785514194e-09
signal O 0 7.896512244087717e-08
peptide O 0 1.9145934615494298e-08
was O 0 2.0473899908779458e-08
observed O 0 4.636808270674919e-09
in O 0 8.928306982625145e-10
all O 0 1.0899847691092646e-09
affected O 0 5.146879811235294e-09
individuals O 0 7.680729829928623e-09
. O 0 5.477667741615733e-07

This O 0 4.4165884105495934e-07
missense O 0 1.166958645626437e-05
mutation O 0 3.9912620763971063e-07
, O 0 4.1781174076049865e-08
which O 0 1.6474068331717717e-08
replaces O 0 2.2864031052449718e-05
Ala O 0 7.01693061273545e-05
with O 0 2.6415324327899725e-07
Thr O 0 0.13081693649291992
, O 0 7.102988064389137e-08
is O 0 5.718392870335265e-09
frequent O 0 2.8432404874934036e-08
among O 0 7.797640222406699e-08
FNDI B-Disease 1 1.0
patients O 0 4.164165602560388e-06
and O 0 3.913256918508523e-08
is O 0 7.113954314519333e-09
thought O 0 2.048041292113112e-09
to O 0 8.976728388399025e-11
reduce O 0 1.870176902230014e-09
the O 0 6.016930842456247e-10
efficiency O 0 1.266318960801982e-08
of O 0 5.8173252881488224e-09
cleavage O 0 5.765961574866196e-08
by O 0 8.172243326498574e-09
signal O 0 6.214192580955569e-06
peptidases O 0 2.551847865106538e-05
. O 0 1.8752754726847343e-07
. O 0 1.817314000618353e-06

Genetic O 0 9.030851288116537e-06
heterogeneity O 0 1.0885094525292516e-05
of O 0 5.453874564409489e-06
Saethre B-Disease 1 0.9999954700469971
- I-Disease 1 0.9999985694885254
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 0.9999983310699463
, O 0 5.404050540391836e-08
due O 0 3.6724895835504867e-07
to O 0 3.578309915042155e-08
TWIST O 0 3.240956357331015e-05
and O 0 8.787042133917566e-07
FGFR O 1 0.815348744392395
mutations O 0 9.205824426317122e-06
. O 0 7.220155112008797e-06

Thirty O 0 0.00018198549514636397
- O 0 4.2628107621567324e-05
two O 0 8.817769270308418e-08
unrelated O 0 7.229003813336021e-07
patients O 0 1.0044632681172061e-08
with O 0 1.873003141472651e-10
features O 0 1.013746064870702e-08
of O 0 2.568857837559335e-07
Saethre B-Disease 1 0.9999982118606567
- I-Disease 1 0.9999991655349731
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 0.9999995231628418
, O 0 4.00210922180122e-08
a O 0 8.013937247142167e-08
common O 0 5.08063635606959e-07
autosomal B-Disease 0 0.00013313128147274256
dominant I-Disease 0 0.19342252612113953
condition I-Disease 0 0.032832395285367966
of O 0 0.023340988904237747
craniosynostosis B-Disease 1 1.0
and O 0 0.0018919800641015172
limb B-Disease 1 0.9999964237213135
anomalies I-Disease 1 0.999885082244873
, O 0 3.6482043697105837e-07
were O 0 5.04776629384196e-08
screened O 0 2.060753701016438e-08
for O 0 1.6417346371255803e-09
mutations O 0 1.0139685535648368e-08
in O 0 1.128407500772255e-08
TWIST O 0 1.8377752439846518e-06
, O 0 4.4654417052925055e-08
FGFR2 O 0 0.0012084885966032743
, O 0 7.543331292936273e-08
and O 0 1.5467993819129333e-07
FGFR3 O 1 0.5908337831497192
. O 0 9.499820407654624e-06

Nine O 0 3.8766575016779825e-06
novel O 0 3.5655909869092284e-07
and O 0 1.222871937045511e-08
three O 0 1.3924940311937917e-08
recurrent O 0 4.82324094264186e-06
TWIST O 0 6.635550107603194e-06
mutations O 0 2.750276095753179e-08
were O 0 1.6449106965410465e-08
found O 0 9.7969694579092e-09
in O 0 6.575129329888796e-09
12 O 0 2.68873009190429e-07
families O 0 3.985259411365405e-08
. O 0 7.161100370467466e-07

Seven O 0 2.7040866825700505e-06
families O 0 4.3933948035146386e-08
were O 0 6.586114409401489e-08
found O 0 7.341091290413715e-09
to O 0 7.763604203958607e-10
have O 0 4.2153586177207103e-10
the O 0 2.356678630022202e-09
FGFR3 O 0 1.1520518455654383e-05
P250R O 0 1.0651815500750672e-06
mutation O 0 8.514385640978617e-09
, O 0 1.1565067792318473e-09
and O 0 5.297469685139333e-10
one O 0 3.8072275887479634e-10
individual O 0 3.3338090621448657e-10
was O 0 6.003432417855947e-08
found O 0 5.927195401156382e-10
to O 0 1.6079974851646028e-10
have O 0 1.5096232597322512e-10
an O 0 6.735725865958386e-10
FGFR2 O 0 1.7448262951802462e-05
VV269 O 0 8.525051271135453e-06
- O 0 1.6115503740365966e-06
270 O 0 3.216469508515729e-07
deletion O 0 4.162887307757046e-06
. O 0 1.5651118019377463e-06

To O 0 1.1990415771379048e-07
date O 0 3.652918110219616e-07
, O 0 4.390335206494456e-09
our O 0 1.7417407516262529e-09
detection O 0 4.011539544990228e-08
rate O 0 9.977592085874676e-09
for O 0 1.119228487667101e-09
TWIST O 0 1.9836649300941644e-07
or O 0 1.0021802943072089e-08
FGFR O 0 1.5226590221573133e-05
mutations O 0 2.125791809248767e-08
is O 0 5.466310071255975e-09
68 O 0 4.6088864280591224e-08
% O 0 6.130437046891757e-09
in O 0 1.5002434849975543e-09
our O 0 2.5179964779908914e-08
Saethre B-Disease 0 0.03224019706249237
- I-Disease 1 0.6151453256607056
Chotzen I-Disease 1 0.9999955892562866
syndrome I-Disease 1 0.9999978542327881
patients O 0 9.767453548192861e-07
, O 0 1.9486909863530855e-08
including O 0 1.6704893468499904e-08
our O 0 6.215837089484921e-08
five O 0 1.0900584612727471e-07
patients O 0 4.389910301938471e-08
elsewhere O 0 6.741733926673987e-08
reported O 0 1.11491020859944e-08
with O 0 7.06983049880705e-09
TWIST O 0 9.71085682976991e-06
mutations O 0 1.2855134627898224e-06
. O 0 1.5932084806991043e-06

More O 0 6.893650095207704e-08
than O 0 1.263857818400993e-08
35 O 0 1.4525009639498876e-08
different O 0 1.0130343230940753e-09
TWIST O 0 2.673291987775883e-07
mutations O 0 5.5396771614368845e-09
are O 0 6.643236516445938e-10
now O 0 9.421325941616487e-10
known O 0 6.553553255628231e-10
in O 0 7.469347362842882e-10
the O 0 1.9496836145549423e-08
literature O 0 2.657521918081329e-07
. O 0 4.4171738977638597e-07

The O 0 4.634662502667197e-07
most O 0 1.4310081120072482e-08
common O 0 6.83765266629166e-09
phenotypic O 0 2.373635652475059e-07
features O 0 6.603774949098806e-08
, O 0 3.859697894625924e-09
present O 0 7.007885383103485e-09
in O 0 3.0476288159775322e-09
more O 0 4.254193664010586e-10
than O 0 4.927708241453388e-10
a O 0 1.150443296182857e-09
third O 0 5.915508971554573e-09
of O 0 8.099820369977806e-09
our O 0 1.2632383139532521e-08
patients O 0 8.357924130564243e-09
with O 0 1.5885794901748795e-09
TWIST O 0 2.2098977296991507e-06
mutations O 0 2.588281589055441e-08
, O 0 5.4896518442149045e-09
are O 0 2.946991761731965e-09
coronal B-Disease 0 2.1944074433122296e-06
synostosis I-Disease 0 1.49637171489303e-05
, O 0 8.316344946024401e-08
brachycephaly B-Disease 0 1.2241189324413426e-05
, O 0 1.6627431875804177e-07
low B-Disease 0 2.9964012355776504e-05
frontal I-Disease 1 0.9829351902008057
hairline I-Disease 1 0.999997615814209
, O 0 2.9152472507121274e-06
facial B-Disease 1 0.6920797228813171
asymmetry I-Disease 1 0.9986326098442078
, O 0 6.659329301328398e-06
ptosis B-Disease 0 0.05427590012550354
, O 0 9.137687584370724e-07
hypertelorism B-Disease 1 0.7313088178634644
, O 0 2.926409763404081e-07
broad B-Disease 0 9.406317985849455e-06
great I-Disease 0 0.00035097674117423594
toes I-Disease 0 0.0001486848632339388
, O 0 1.9209788604257483e-07
and O 0 3.0964449138082273e-07
clinodactyly B-Disease 0 0.0017360696801915765
. O 0 8.31400029710494e-06

Significant O 0 5.910182153456844e-06
intra O 0 0.00017056088836397976
- O 0 1.2000923561572563e-05
and O 0 3.82186335912138e-08
interfamilial O 0 3.904954610334244e-06
phenotypic O 0 3.386107437108876e-06
variability O 0 9.340536053059623e-06
is O 0 9.742632478548785e-09
present O 0 3.393746617064153e-09
for O 0 4.692807920037012e-09
either O 0 1.3966825918032555e-07
TWIST O 0 2.6537304620433133e-06
mutations O 0 8.756361324913087e-08
or O 0 1.1166898161718564e-07
FGFR O 0 0.09336511045694351
mutations O 0 9.372541171615012e-06
. O 0 4.682949111156631e-06

The O 0 6.657924132014159e-07
overlap O 0 1.1236716090934351e-06
in O 0 3.054660524526298e-08
clinical O 0 2.688601909994759e-07
features O 0 2.039816493493163e-08
and O 0 2.228638384949022e-09
the O 0 5.41792877228886e-09
presence O 0 2.4046880042760677e-08
, O 0 1.4977903362023426e-09
in O 0 4.762680805292518e-10
the O 0 2.545708088774745e-10
same O 0 5.665367619478445e-10
genes O 0 3.605738763123867e-10
, O 0 1.7807329222296886e-10
of O 0 7.500985388375625e-10
mutations O 0 1.0660683447127894e-09
for O 0 8.920102434473165e-10
more O 0 7.708008120665966e-10
than O 0 1.4087435662446524e-09
one O 0 2.4827948585937065e-09
craniosynostotic B-Disease 0 1.0568539892119588e-06
condition I-Disease 0 4.6877696036062844e-07
- O 0 9.396945443995719e-08
such O 0 4.5563965933581585e-09
as O 0 3.422179872814013e-08
Saethre B-Disease 0 1.5395384252769873e-05
- I-Disease 0 2.6899917884293245e-06
Chotzen I-Disease 0 1.4662520698038861e-05
, I-Disease 0 4.18661336709647e-08
Crouzon I-Disease 0 1.9852024706779048e-05
, I-Disease 0 5.064643104901734e-08
and I-Disease 0 1.8997270956333523e-07
Pfeiffer I-Disease 1 0.9998666048049927
syndromes I-Disease 0 0.20787280797958374
- O 0 3.808383326031617e-06
support O 0 2.5358245281381642e-08
the O 0 2.2258060283775194e-08
hypothesis O 0 1.99851317717048e-08
that O 0 1.1571200664306502e-09
TWIST O 0 2.8403579221958353e-07
and O 0 7.530347012618677e-09
FGFRs O 0 3.91489948015078e-06
are O 0 1.6609792430344328e-09
components O 0 5.928004043198598e-08
of O 0 2.9034785686832265e-09
the O 0 1.2200266352735412e-09
same O 0 2.37644015577132e-09
molecular O 0 5.281735937501253e-08
pathway O 0 1.0563149466236155e-08
involved O 0 2.9645985666348906e-09
in O 0 4.2575704073399834e-10
the O 0 1.6039181094384958e-09
modulation O 0 1.0617039833960007e-06
of O 0 3.79821995011298e-06
craniofacial O 1 0.9999995231628418
and O 0 0.000389773806091398
limb O 1 0.9997413754463196
development O 0 0.0005544188898056746
in O 0 2.7436803975433577e-06
humans O 0 1.2524360499810427e-06
. O 0 1.239202589431443e-07
. O 0 5.718563897971762e-07

Mutation O 0 4.7589537643943913e-07
analysis O 0 2.9021492764513823e-07
of O 0 5.402952183430898e-07
UBE3A O 1 0.9999837875366211
in O 1 0.9812045097351074
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.8887476325035095
. O 0 4.1158396925311536e-05

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.026186076924204826
AS B-Disease 1 0.9999997615814209
) O 0 2.7015374826078187e-07
is O 0 1.584579933933128e-08
caused O 0 2.195590553810689e-08
by O 0 6.080896230997723e-09
chromosome O 0 1.71255726399977e-06
15q11 O 0 1.555162452859804e-05
- O 0 2.5322776764369337e-06
q13 O 0 1.575724127178546e-06
deletions O 0 4.6819838672718106e-08
of O 0 2.577596092123713e-08
maternal O 0 1.0546786199938651e-07
origin O 0 1.0523252491623225e-08
, O 0 3.8584024864007915e-09
by O 0 7.3719044202391615e-09
paternal O 0 1.1940429430978838e-05
uniparental B-Disease 1 0.9998792409896851
disomy I-Disease 1 0.9998852014541626
( O 0 5.030258762417361e-05
UPD B-Disease 1 0.9999990463256836
) O 0 4.3377033875913185e-07
15 O 0 2.3531993065262213e-07
, O 0 2.9443008031648787e-09
by O 0 5.645942824372696e-09
imprinting O 0 0.00015819996770005673
defects O 0 0.004408495035022497
, O 0 2.0431883740457124e-08
and O 0 6.2601426265018745e-09
by O 0 6.646775574381536e-09
mutations O 0 5.986897377852074e-08
in O 0 2.6418391030347266e-08
the O 0 4.1707414766278816e-07
UBE3A O 0 0.29239028692245483
gene O 0 2.0049037630087696e-05
. O 0 7.607731276948471e-06

UBE3A O 0 0.002118816366419196
encodes O 0 4.079179234395269e-06
a O 0 1.5946935718602617e-06
ubiquitin O 0 1.8172158888773993e-05
- O 0 1.0139114237972535e-05
protein O 0 3.300577304798935e-07
ligase O 0 7.404854613923817e-07
and O 0 1.6092508658971383e-08
shows O 0 3.353503643666045e-07
brain O 0 1.3356111594475806e-05
- O 0 4.106961171146395e-07
specific O 0 5.4339423627425276e-08
imprinting O 0 1.7940148609341122e-05
. O 0 4.0752170207269955e-06

Here O 0 3.522938641253859e-06
we O 0 1.537712819299486e-07
describe O 0 1.1434564157752902e-06
UBE3A O 0 0.00043095267028547823
coding O 0 0.00012057993444614112
- O 0 5.995232640998438e-06
region O 0 2.668060687938123e-07
mutations O 0 5.504437794456862e-08
detected O 0 4.320713742345106e-08
by O 0 1.3893891592786645e-09
SSCP O 0 2.8296399250393733e-06
analysis O 0 1.2198202448132633e-08
in O 0 7.213506236780631e-09
13 O 0 2.3007206095826405e-07
AS B-Disease 0 0.0029088016599416733
individuals O 0 1.0439766384706672e-08
or O 0 1.196558088167876e-07
families O 0 8.802997797374701e-08
. O 0 1.1638117030088324e-06

Two O 0 1.0590201782179065e-06
identical O 0 1.5357650227088016e-06
de O 0 1.2516368769865949e-05
novo O 0 6.633468728978187e-06
5 O 0 2.9134655505913543e-06
- O 0 2.491473651389242e-06
bp O 0 5.945867087575607e-07
duplications O 0 1.5946752682793885e-06
in O 0 1.1540772248963549e-07
exon O 0 1.14009490062017e-05
16 O 0 9.391575304107391e-07
were O 0 2.0349051510493155e-07
found O 0 1.9600197731506341e-07
. O 0 4.399508384267392e-07

Among O 0 2.419530460429087e-07
the O 0 1.91771469815194e-08
other O 0 2.9509685806061725e-09
11 O 0 1.4289024186098231e-08
unique O 0 2.5401507564026815e-09
mutations O 0 4.486320648311448e-09
, O 0 2.057610526406961e-09
8 O 0 2.7102721844585176e-08
were O 0 5.4578506158975415e-09
small O 0 3.9642049642907295e-09
deletions O 0 3.313918384151293e-08
or O 0 4.1313530374509355e-09
insertions O 0 2.4014826749407803e-07
predicted O 0 4.1219738022846286e-07
to O 0 1.4805841885845439e-08
cause O 0 1.8541469444244285e-06
frameshifts O 0 5.364018215914257e-05
, O 0 7.985114791608794e-08
1 O 0 4.442407259830361e-07
was O 0 7.467887286338737e-08
a O 0 4.59667193197788e-09
mutation O 0 5.074752285061379e-10
to O 0 3.7454866985697777e-10
a O 0 1.4615433308051706e-09
stop O 0 5.187573925979905e-09
codon O 0 1.0123432758746276e-08
, O 0 2.2437498525818e-09
1 O 0 5.836065852804495e-08
was O 0 3.2526987325809387e-08
a O 0 7.897321907535115e-09
missense O 0 7.616645092412e-08
mutation O 0 7.408214042214922e-09
, O 0 5.128271585164157e-09
and O 0 8.297059039819032e-09
1 O 0 8.991072490971419e-07
was O 0 4.952674430569459e-07
predicted O 0 7.03636260368512e-08
to O 0 2.798080656063462e-09
cause O 0 3.0997593825077274e-08
insertion O 0 7.655503964087984e-08
of O 0 7.988085570787007e-08
an O 0 4.099102923760256e-08
isoleucine O 0 1.0126174856850412e-05
in O 0 3.7967673449657013e-08
the O 0 3.0164017061906634e-08
hect O 0 1.8880409697885625e-06
domain O 0 9.368704922962934e-08
of O 0 3.69343311490411e-08
the O 0 1.1796385024354095e-07
UBE3A O 0 0.002275605220347643
protein O 0 2.926225590726972e-07
, O 0 3.2772142777304225e-09
which O 0 2.7117225132045064e-10
functions O 0 9.724475447114855e-09
in O 0 1.6194055874052538e-08
E2 O 0 3.9051074054441415e-06
binding O 0 6.533826280019639e-08
and O 0 3.380207758141296e-08
ubiquitin O 0 6.608691819565138e-06
transfer O 0 1.2264372344361618e-05
. O 0 7.39409642847022e-06

Eight O 0 1.2113064258301165e-06
of O 0 1.420114728034605e-07
the O 0 1.9376498627821093e-08
cases O 0 1.126884718871679e-08
were O 0 6.69797417529594e-09
familial O 0 3.548209690507065e-07
, O 0 2.2487808948312704e-08
and O 0 1.1100977026501369e-08
five O 0 9.291063918226428e-08
were O 0 1.702537844039398e-07
sporadic O 0 6.042368568159873e-06
. O 0 1.7156812646135222e-06

In O 0 1.2699708804575494e-06
two O 0 1.1148107148528652e-07
familial O 0 9.774846148502547e-06
cases O 0 1.8339621021823405e-07
and O 0 1.775809899129399e-08
one O 0 5.819367210335713e-09
sporadic O 0 3.2655731274644495e-07
case O 0 5.3865562676946865e-08
, O 0 3.7186664858523955e-09
mosaicism O 0 7.168642696342431e-06
for O 0 4.044360224497723e-08
UBE3A O 0 0.026323264464735985
mutations O 0 1.6414716696999676e-07
was O 0 2.6143504783249227e-07
detected O 0 1.349137193074057e-07
in O 0 2.3532917836632805e-09
the O 0 3.79490483481959e-09
mother O 0 1.830873763708496e-08
of O 0 3.750773203137214e-08
three O 0 6.764145865645332e-08
AS B-Disease 1 0.9999966621398926
sons O 0 3.405666211619973e-05
, O 0 1.3583261626592957e-08
in O 0 2.886923144984621e-09
the O 0 1.4981482721054817e-08
maternal O 0 9.290316711485502e-07
grandfather O 0 2.1080095393699594e-06
of O 0 1.744848106000063e-07
two O 0 4.719326085478315e-08
AS B-Disease 1 0.9999902248382568
first O 0 6.086730195420387e-07
cousins O 0 1.2216967206768459e-06
, O 0 9.07626596102773e-09
and O 0 2.514908947759409e-09
in O 0 4.259229413605681e-09
the O 0 7.972936089117866e-09
mother O 0 2.4377065699354716e-08
of O 0 4.4110443297995516e-08
an O 0 9.401641420936357e-08
AS B-Disease 1 0.999981164932251
daughter O 0 0.018563345074653625
. O 0 2.4180033506127074e-05

The O 0 1.4093456002228777e-07
frequencies O 0 1.2571553043017047e-07
with O 0 2.8491999870539075e-09
which O 0 4.868478398201148e-10
we O 0 6.433100163683036e-10
detected O 0 3.0978133391812435e-09
mutations O 0 3.133042714154044e-10
were O 0 1.3397762899103327e-09
5 O 0 7.85957432469786e-09
( O 0 8.411944474318034e-10
14 O 0 6.6926615360785036e-09
% O 0 1.5385767104802994e-09
) O 0 3.190847308598421e-10
of O 0 2.8142499441941027e-09
35 O 0 1.6798509250293137e-08
in O 0 1.05058395316604e-09
sporadic O 0 1.7458326340147323e-08
cases O 0 1.0533207639440434e-09
and O 0 3.3714347980051684e-10
8 O 0 2.1876148892374658e-08
( O 0 1.1387526477335541e-09
80 O 0 6.226216875404589e-09
% O 0 1.6619997600386682e-09
) O 0 3.934275683015187e-10
of O 0 5.765936617052603e-09
10 O 0 2.4109107599201707e-08
in O 0 4.207600934336142e-09
familial O 0 1.3077008986783767e-07
cases O 0 2.7834865079512383e-08
. O 0 6.353381820645154e-08
. O 0 6.317853831205866e-07

The O 0 4.9034268158720806e-05
hemochromatosis B-Disease 1 0.9999998807907104
845 O 0 0.00012428163609001786
G O 0 0.00017262404435314238
- O 0 1.1751804777304642e-05
- O 0 9.791253887669882e-07
> O 0 2.1034661301655433e-07
A O 0 4.826516786238244e-08
and O 0 1.3828694855888557e-09
187 O 0 1.1379541753342437e-08
C O 0 2.302600250914111e-06
- O 0 4.599937426519318e-07
- O 0 2.2694555923408188e-07
> O 0 1.234698743246554e-07
G O 0 3.9729496847940027e-07
mutations O 0 3.4581089103369322e-09
: O 0 9.512620691154439e-10
prevalence O 0 4.52654909111061e-08
in O 0 6.808917429879102e-09
non O 0 3.2500436191185145e-06
- O 0 1.2991346011403948e-05
Caucasian O 0 6.155769369797781e-06
populations O 0 3.389912706097675e-07
. O 0 1.8799933059199248e-06

Hemochromatosis B-Disease 1 0.9999995231628418
, O 0 1.2402658285282087e-05
the O 0 0.00018070008081849664
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 0.9999901056289673
iron I-Disease 1 1.0
metabolism I-Disease 1 0.9999983310699463
, O 0 3.1478944038099144e-06
leads O 0 4.458243893168401e-06
, O 0 1.338185029453598e-07
if O 0 3.9238483395820367e-07
untreated O 0 0.07150927931070328
, O 0 3.432803197256362e-08
to O 0 5.42290479188523e-08
progressive O 1 0.9999831914901733
iron B-Disease 1 1.0
overload I-Disease 1 0.999998927116394
and O 0 1.896985122584738e-05
premature B-Disease 0 0.0005092349019832909
death I-Disease 0 2.915146978921257e-05
. O 0 6.669530648650834e-06

The O 0 0.0001968870492419228
hemochromatosis B-Disease 1 1.0
gene O 0 2.0411673176568e-05
, O 0 1.2666832844843157e-06
HFE O 1 0.9974351525306702
, O 0 8.164742553162796e-07
recently O 0 8.81073901837226e-07
has O 0 8.245486959879145e-09
been O 0 2.6864979130181155e-09
identified O 0 3.236298118380887e-09
, O 0 7.01600000319047e-10
and O 0 6.710067501636274e-10
characterization O 0 1.8750066388406594e-08
of O 0 3.7139031849875437e-09
this O 0 9.086983943085158e-10
gene O 0 1.0741678657666398e-08
has O 0 9.906967468609196e-10
shown O 0 1.5119351326475794e-09
that O 0 5.584099155298006e-11
it O 0 2.2402198152082775e-11
contains O 0 1.058694035216412e-10
two O 0 2.8436430293821147e-11
mutations O 0 1.2119387438058737e-10
that O 0 4.9953680081316065e-11
result O 0 9.099332953788064e-10
in O 0 6.619482184611059e-10
amino O 0 1.5154631993752332e-09
acid O 0 1.6603657115865644e-08
substitutions O 0 9.181454174722603e-08
- O 0 1.802588798227589e-07
cDNA O 0 1.8753254948933318e-07
nucleotides O 0 2.3344005839476267e-08
845 O 0 2.3897942469375266e-07
G O 0 1.3206893072492676e-06
- O 0 1.2572527339216322e-06
- O 0 3.41681300142227e-07
> O 0 2.2893196671702754e-07
A O 0 1.77526558786667e-07
( O 0 6.718496869950741e-09
C282Y O 0 1.3273178467443358e-07
) O 0 1.4389170965856124e-09
and O 0 1.7176181588141048e-09
187 O 0 3.116423386018141e-08
C O 0 2.733009750954807e-06
- O 0 9.636220283937291e-07
- O 0 8.952133612183388e-07
> O 0 1.1851507224491797e-06
G O 0 1.0850291801034473e-05
( O 0 1.6638122701806424e-07
H63D O 0 0.00025202208780683577
) O 0 3.153959369228687e-07
. O 0 1.4162225170366582e-06

Although O 0 0.0025452938862144947
hemochromatosis B-Disease 1 1.0
is O 0 4.383957161735452e-07
common O 0 1.3253560382509022e-07
in O 0 6.326560253455682e-08
Caucasians O 0 1.050129526447563e-06
, O 0 2.5202020026426908e-08
affecting O 0 1.2238361080108007e-07
> O 0 4.055519013945741e-07
= O 0 4.675210334426083e-07
1 O 0 9.160766580862401e-07
/ O 0 1.6364153054837516e-07
300 O 0 3.3614582228835843e-09
individuals O 0 1.4181003593627395e-10
of O 0 1.3174812352190202e-09
northern O 0 3.4068083909488678e-09
European O 0 3.6720495533160147e-09
origin O 0 4.658207153340754e-09
, O 0 7.381806277351188e-10
it O 0 5.5862935804951164e-11
has O 0 5.914352341207518e-11
not O 0 6.631281634916775e-11
been O 0 1.5789605734006784e-10
recognized O 0 6.312319555945578e-10
in O 0 7.666821622009934e-10
other O 0 2.133472065679598e-09
populations O 0 4.48288481891268e-08
. O 0 3.999991804448655e-07

The O 0 2.480448983988026e-07
present O 0 5.4865978427187656e-08
study O 0 5.9763189952377616e-09
used O 0 3.2247386982930948e-09
PCR O 0 1.7174290434240902e-08
and O 0 7.782047783955193e-10
restriction O 0 1.7904138616131604e-08
- O 0 3.666368542099008e-08
enzyme O 0 2.8285913611370006e-09
digestion O 0 4.409410614414355e-09
to O 0 2.307060792405835e-10
analyze O 0 3.904979006819076e-09
the O 0 2.0600019468020037e-09
frequency O 0 2.1483533174659897e-08
of O 0 1.1825068035875574e-08
the O 0 2.4612862858930384e-08
845 O 0 2.335204953851644e-07
G O 0 1.2223842986713862e-06
- O 0 3.161050869948667e-07
- O 0 7.155666992275656e-08
> O 0 2.7180114159364166e-08
A O 0 1.4402522729994871e-08
and O 0 1.2548400096790147e-09
187 O 0 9.15742059959257e-09
C O 0 1.6796527688711649e-06
- O 0 4.86965404888906e-07
- O 0 3.2770853408692346e-07
> O 0 2.2546956301994214e-07
G O 0 7.171488505264279e-07
mutations O 0 1.0017425999819807e-08
in O 0 9.95966153993777e-09
HLA O 0 2.168800619983813e-06
- O 0 2.489345263256837e-07
typed O 0 1.6674205127742425e-08
samples O 0 3.0919633520198886e-09
from O 0 4.948535359261541e-09
non O 0 6.644039558523218e-07
- O 0 1.1659512892947532e-06
Caucasian O 0 3.9261092865672254e-07
populations O 0 7.808710122958473e-09
, O 0 3.487292454806834e-09
comprising O 0 9.471148310069566e-09
Australian O 0 7.049123951219372e-08
Aboriginal O 0 1.8156737269237055e-07
, O 0 5.16338882761147e-09
Chinese O 0 7.206551089211644e-08
, O 0 1.1964366386507663e-08
and O 0 2.5995671393275188e-08
Pacific O 0 2.5032916255440796e-06
Islanders O 0 1.3980067706143018e-05
. O 0 1.5333986311816261e-06

Results O 0 3.964164534409065e-06
showed O 0 6.852721980976639e-07
that O 0 3.9468219803495685e-09
the O 0 4.0406590073871484e-08
845 O 0 8.534972266716068e-07
G O 0 1.2052007150487043e-05
- O 0 2.823779368554824e-06
- O 0 6.250677415664541e-07
> O 0 9.825492952586501e-08
A O 0 2.548771504962133e-08
mutation O 0 1.3659352537942482e-09
was O 0 5.746328302080883e-09
present O 0 1.1007442735078143e-09
in O 0 3.442457707780733e-10
these O 0 3.771996257007082e-11
populations O 0 8.496207903885278e-11
( O 0 5.387668089440467e-11
allele O 0 2.097639978382304e-10
frequency O 0 2.643375074384835e-09
0 O 0 2.812516664008058e-09
. O 0 1.4824702576632376e-10
32 O 0 7.635653886950422e-09
% O 0 2.1915187442544948e-09
) O 0 1.0188611065942155e-09
, O 0 7.920942235450923e-10
and O 0 5.640450329025271e-10
, O 0 1.3975407497923698e-09
furthermore O 0 8.076479929286506e-09
, O 0 6.964295806710652e-10
it O 0 3.1798810806726863e-10
was O 0 3.065621712039501e-08
always O 0 5.323229856912803e-09
seen O 0 7.473897944976216e-09
in O 0 4.746800730259793e-10
conjunction O 0 3.728581443596113e-09
with O 0 5.783206358245252e-09
HLA O 0 0.0004857388266827911
haplotypes O 0 4.2241708797519095e-06
common O 0 2.6998455382454267e-07
in O 0 7.593972384256631e-08
Caucasians O 0 6.080644538997149e-07
, O 0 6.526537976725422e-09
suggesting O 0 6.873365521187225e-08
that O 0 4.3012735595482354e-09
845 O 0 2.9458365702339506e-07
G O 0 1.817306110751815e-05
- O 0 2.90018469968345e-05
- O 0 1.1947730854444671e-05
> O 0 3.2728050882724347e-06
A O 0 8.415464662903105e-07
may O 0 9.131014166996465e-09
have O 0 1.6596736485130492e-10
been O 0 1.56119020489065e-10
introduced O 0 1.4153035687858306e-10
into O 0 7.011635022591278e-11
these O 0 2.6817955842139973e-11
populations O 0 1.8885143449054453e-10
by O 0 1.7002385055420177e-09
Caucasian O 0 1.3328424302017083e-06
admixture O 0 9.336617040389683e-06
. O 0 8.721657650312409e-06

187 O 0 9.000603313324973e-06
C O 0 0.0002223143819719553
- O 0 2.5041794287972152e-05
- O 0 5.362739557313034e-06
> O 0 1.2677721770160133e-06
G O 0 1.8256101839142502e-06
was O 0 6.103743999119615e-08
present O 0 3.7555323295634935e-09
at O 0 7.809618729481826e-09
an O 0 2.015734523741486e-10
allele O 0 9.582329374424603e-10
frequency O 0 2.5520987989580135e-08
of O 0 4.383451113199044e-08
2 O 0 1.61426066824788e-06
. O 0 8.474232231492351e-07

68 O 0 2.2655709472019225e-05
% O 0 5.600159624918888e-07
in O 0 3.7508019801180126e-08
the O 0 9.10617803384639e-09
two O 0 2.226488549084138e-09
populations O 0 9.96142390796706e-10
analyzed O 0 2.139593924255223e-08
( O 0 2.25180563084848e-09
Australian O 0 4.2826435731058154e-08
Aboriginal O 0 1.0309508269301659e-07
and O 0 2.9408449009338256e-08
Chinese O 0 1.7829460148277576e-06
) O 0 2.426761227525276e-07
. O 0 1.4307399851531954e-06

In O 0 2.6911209261015756e-07
the O 0 3.2232765789785844e-08
Australian O 0 4.682572907199756e-08
Aboriginal O 0 3.6002994363570906e-08
samples O 0 3.5594798220017765e-09
, O 0 1.6735851593452367e-09
187 O 0 1.109460523451844e-08
C O 0 1.355782615064527e-06
- O 0 7.733402753729024e-07
- O 0 5.625483368021378e-07
> O 0 4.82739096696605e-07
G O 0 4.423916834639385e-06
was O 0 2.2454000259131135e-07
found O 0 2.223144557333967e-09
to O 0 3.238136148109305e-10
be O 0 1.3763936657085196e-09
associated O 0 2.3542986227198526e-08
with O 0 1.9372027537656322e-08
HLA O 1 0.9367615580558777
haplotypes O 0 3.324892895761877e-05
common O 0 7.27632766484021e-07
in O 0 1.2153176953688671e-07
Caucasians O 0 1.4088162743064458e-06
, O 0 1.4184912799919402e-08
suggesting O 0 1.0621618251605014e-08
that O 0 1.5724357926849564e-10
it O 0 1.1804773825119241e-10
was O 0 2.4958233257876827e-09
introduced O 0 8.551326313721574e-10
by O 0 5.561440752366309e-10
recent O 0 1.6445500961026482e-08
admixture O 0 1.441172230443044e-06
. O 0 1.7164569499072968e-06

In O 0 2.2768523422200815e-07
the O 0 2.1766808799839055e-08
Chinese O 0 1.3772530671474215e-08
samples O 0 9.117226418275948e-10
analyzed O 0 4.224826266607806e-09
, O 0 8.511848448300441e-10
187 O 0 1.0662905225444774e-08
C O 0 1.2976905736650224e-06
- O 0 9.005583478938206e-07
- O 0 7.539633770647924e-07
> O 0 6.058711505829706e-07
G O 0 2.152208026018343e-06
was O 0 1.9673872486691835e-07
present O 0 1.3290160083556657e-08
in O 0 1.0065402733516748e-08
association O 0 6.1137157558732724e-09
with O 0 1.3998697756534284e-09
a O 0 8.75271677358569e-09
wide O 0 2.256639675124461e-08
variety O 0 2.2771601493332128e-08
of O 0 1.4669431891434215e-07
HLA O 0 0.010492357425391674
haplotypes O 0 3.214704520360101e-06
, O 0 1.44442005023393e-08
showing O 0 1.3359415795832774e-08
this O 0 2.4354548933125386e-10
mutation O 0 1.5273016185091137e-10
to O 0 1.5569676103943664e-10
be O 0 8.611921176182591e-10
widespread O 0 5.9350608871966415e-09
and O 0 1.656344617018135e-09
likely O 0 1.00707611139228e-08
to O 0 3.6602179065425844e-09
predate O 0 2.1313037734671525e-07
the O 0 6.8322170143630956e-09
more O 0 1.6019736648331673e-09
genetically O 0 8.0378148581417e-09
restricted O 0 5.0244697291645934e-09
845 O 0 1.5173620226960338e-07
G O 0 4.058938429807313e-06
- O 0 2.9336626994336257e-06
- O 0 3.146447625113069e-06
> O 0 1.158830059466709e-06
A O 0 7.250504268085933e-07
mutation O 0 3.2719043474571663e-07
. O 0 6.24320023234759e-07

Genotype O 0 0.00015875908138696104
- O 0 4.430455373949371e-05
phenotype O 0 2.2659141905023716e-06
correlations O 0 1.2686837180808652e-05
in O 0 7.3722549132071435e-06
attenuated B-Disease 1 0.9148304462432861
adenomatous I-Disease 1 0.9999997615814209
polyposis I-Disease 1 0.9999996423721313
coli I-Disease 1 0.9999539852142334
. O 0 0.0001256420509889722

Germ O 1 0.9999942779541016
- O 0 0.0002445989230182022
line O 0 9.375905847264221e-07
mutations O 0 2.0652983323543594e-08
of O 0 7.888530717536923e-09
the O 0 4.905488282247461e-08
tumor B-Disease 0 5.41402114322409e-05
suppressor O 0 1.3754879546468146e-05
APC O 0 8.503059802933421e-07
are O 0 9.968727177067649e-09
implicated O 0 1.9116159819532186e-06
in O 0 8.95145092272287e-07
attenuated B-Disease 1 0.9934828877449036
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 0.005932031199336052
AAPC B-Disease 1 1.0
) O 0 2.084524908241292e-07
, O 0 1.1617381723283415e-08
a O 0 1.973817553846402e-08
variant O 0 8.931412480706058e-07
of O 0 7.499391358578578e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.7091715931892395
FAP B-Disease 0 0.06787758320569992
) O 0 1.7468757505412214e-05
. O 0 2.4560615202062763e-05

AAPC B-Disease 1 0.9999908208847046
is O 0 4.4848945890407776e-07
recognized O 0 9.245543708402693e-08
by O 0 2.1250325943356074e-09
the O 0 3.2465115040736237e-09
occurrence O 0 1.3365047735192093e-08
of O 0 3.5242784690581175e-08
< O 0 4.603554316418013e-06
100 O 0 1.086838096853171e-06
colonic B-Disease 0 0.0014412309974431992
adenomas I-Disease 0 6.395177479134873e-05
and O 0 1.2496814250084753e-08
a O 0 1.1493471951951051e-08
later O 0 8.747263535724414e-08
onset O 0 0.00036597810685634613
of O 1 0.6347249150276184
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.304285089849145e-06
age O 0 2.387644417467527e-05
> O 0 8.431278729403857e-06
40 O 0 8.531529829269857e-07
years O 0 1.8210042185273778e-07
) O 0 6.337405977774324e-08
. O 0 5.133833269610477e-07

The O 0 3.406408097816893e-07
aim O 0 2.70337267238574e-07
of O 0 1.6201472163857034e-08
this O 0 9.009117341030048e-10
study O 0 2.821833877675317e-09
was O 0 1.224545354006068e-08
to O 0 1.119587089704055e-09
assess O 0 1.3118942376877385e-07
genotype O 0 7.189581197053485e-07
- O 0 1.448213993171521e-06
phenotype O 0 3.1464608696296636e-07
correlations O 0 8.272131708508823e-06
in O 0 6.009646767779486e-06
AAPC B-Disease 1 0.9999992847442627
families O 0 4.019876087113516e-06
. O 0 1.1336753232171759e-05

By O 0 5.61167496471171e-07
protein O 0 1.6847527604113566e-06
- O 0 8.30104227134143e-07
truncation O 0 1.2669441957768868e-06
test O 0 5.436150019022534e-08
( O 0 1.1865373572561566e-08
PTT O 0 5.830329996570072e-07
) O 0 3.876231335908642e-09
assay O 0 4.513531237648749e-08
, O 0 1.9752854907295614e-09
the O 0 1.7335809454621653e-09
entire O 0 3.4327310771686825e-08
coding O 0 5.260282023300533e-07
region O 0 4.3158870255410875e-08
of O 0 1.5263159625078515e-08
the O 0 1.4018557870087989e-08
APC B-Disease 0 2.031310373240558e-07
gene O 0 4.438582834609406e-08
was O 0 1.1114646980558973e-07
screened O 0 2.6181124823665414e-08
in O 0 1.2389486103714376e-09
affected O 0 8.912347526646158e-10
individuals O 0 6.288249920771705e-10
from O 0 7.892807474263464e-08
11 O 0 0.0001174389326479286
AAPC B-Disease 1 1.0
kindreds O 0 0.001779029844328761
, O 0 8.59912603345947e-08
and O 0 4.007087106572271e-09
their O 0 1.4156741334758749e-09
phenotypic O 0 1.6585715911787702e-06
differences O 0 1.3388926163315773e-06
were O 0 2.9995462114129623e-07
examined O 0 3.6737437767442316e-06
. O 0 1.4050165191292763e-06

Five O 0 4.360313141660299e-06
novel O 0 8.891139259503689e-06
germ O 1 0.9989603757858276
- O 0 4.0483697375748307e-05
line O 0 2.0292727640480734e-06
APC B-Disease 0 8.827476563055825e-07
mutations O 0 4.92799507867403e-08
were O 0 1.879503841450969e-08
identified O 0 7.315711059163732e-08
in O 0 2.3134305138228228e-08
seven O 0 3.569690818494564e-07
kindreds O 0 4.857504609390162e-05
. O 0 4.773635737365112e-06

Mutations O 0 4.569171778712189e-06
were O 0 5.550747346205753e-07
located O 0 1.6297013871735544e-07
in O 0 4.253529972686465e-09
three O 0 4.081436300040764e-10
different O 0 3.180463392649102e-10
regions O 0 5.545977899146237e-09
of O 0 1.2262072246471689e-08
the O 0 1.5074640202783485e-08
APC B-Disease 0 2.1823392160058575e-07
gene O 0 1.0367758562779272e-07
( O 0 3.174055152044275e-08
1 O 0 3.9203959545375255e-07
) O 0 6.7821002147638865e-09
at O 0 6.712851075008075e-08
the O 0 1.3689926525728424e-08
5 O 0 5.197817998237042e-08
end O 0 7.504154808657404e-08
spanning O 0 3.279592704075185e-07
exons O 0 7.771286192337357e-08
4 O 0 4.736098446755932e-08
and O 0 2.7217348375074835e-09
5 O 0 4.7986119966481056e-08
, O 0 4.950262866287858e-09
( O 0 2.8267252982772106e-09
2 O 0 4.533980302312557e-08
) O 0 2.1499999558471927e-09
within O 0 2.484321548479329e-08
exon O 0 5.170211920813017e-07
9 O 0 9.160603298141723e-08
, O 0 6.21762463737241e-09
and O 0 4.028452238458158e-09
( O 0 4.691161237246888e-09
3 O 0 7.338798724276785e-08
) O 0 3.768792833369616e-09
at O 0 5.261094315756054e-08
the O 0 2.6573742317737015e-08
3 O 0 3.8327331708387646e-07
distal O 0 7.202538085948618e-07
end O 0 2.2561539481102955e-07
of O 0 1.8524488609727996e-07
the O 0 2.0271980361030728e-07
gene O 0 2.1941857539786724e-06
. O 0 2.528686991354334e-06

Variability O 0 2.481103001628071e-05
in O 0 2.493873552111836e-08
the O 0 6.895896298431126e-09
number O 0 2.787811403948126e-08
of O 0 0.0002635185664985329
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.014662828296422958
most O 0 2.1075035050444058e-08
apparent O 0 1.2098213630906685e-07
in O 0 1.5143998277622472e-09
individuals O 0 1.6500027733012956e-10
with O 0 1.0815085493831589e-09
mutations O 0 1.190668008632656e-08
in O 0 7.357324083301364e-09
region O 0 3.0480319423986657e-07
1 O 0 2.116560835929704e-06
, O 0 1.3260155640182347e-08
and O 0 2.35553834215807e-08
upper O 1 0.9988960027694702
- O 1 0.99913090467453
gastrointestinal O 1 0.9955770969390869
manifestations O 0 5.721939669456333e-05
were O 0 3.322903125990706e-07
more O 0 6.562200116633221e-09
severe O 0 1.3562649883169797e-06
in O 0 2.2564847768080654e-08
them O 0 4.3309363206844864e-08
. O 0 7.605626137774379e-07

In O 0 1.8319046546366735e-07
individuals O 0 3.7009484366024026e-09
with O 0 3.532075965040349e-09
mutations O 0 1.8489748399019845e-08
in O 0 7.278990299397492e-09
either O 0 5.22969969551923e-08
region O 0 2.8688828024314716e-07
2 O 0 3.5196035241824575e-07
or O 0 6.408511943334361e-09
region O 0 9.693054892068176e-08
3 O 0 2.7614090569727523e-08
, O 0 5.806680136721809e-10
the O 0 2.8869162616018684e-10
average O 0 1.0051661725185568e-09
number O 0 7.998979256740313e-10
of O 0 2.4706979573352328e-08
adenomas B-Disease 0 1.3911998394178227e-05
tended O 0 2.4026752143413432e-08
to O 0 7.905576748790111e-10
be O 0 3.14583448179917e-09
lower O 0 6.552122044922726e-08
than O 0 3.783628133025019e-10
those O 0 1.444173530762427e-10
in O 0 8.684909041933864e-11
individuals O 0 2.0090625343915924e-11
with O 0 1.9469539869199082e-10
mutations O 0 4.091625704916169e-09
in O 0 3.1501456998483945e-09
region O 0 4.620346061301461e-08
1 O 0 1.2312710850892472e-07
, O 0 1.1210936623484713e-09
although O 0 1.5275588571839194e-09
age O 0 5.310252149115513e-08
at O 0 5.611562983176555e-07
diagnosis O 0 3.3024018648575293e-06
was O 0 2.6249031748193374e-07
similar O 0 7.490426412459783e-08
. O 0 7.716192840234726e-07

In O 0 3.844942511932459e-06
all O 0 4.124402039451525e-06
AAPC B-Disease 1 0.9999990463256836
kindreds O 0 0.00015924104081932455
, O 0 5.287531834596848e-08
a O 0 2.57209560317051e-08
predominance O 0 1.0341723282181192e-06
of O 0 4.16643587186627e-07
right O 0 0.0008020904497243464
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 1 0.9990001320838928
rectal B-Disease 1 1.0
polyp I-Disease 1 0.9999860525131226
sparing O 0 6.086514258640818e-05
was O 0 9.911482266034e-06
observed O 0 2.0803834104299312e-06
. O 0 1.3202285344959819e-06

No O 0 0.00012245871766936034
desmoid B-Disease 1 0.9999949932098389
tumors I-Disease 1 1.0
were O 0 6.279398121478152e-07
found O 0 3.0661130523412794e-08
in O 0 1.2306895058600276e-08
these O 0 1.838663621356318e-08
kindreds O 0 1.7281947293668054e-05
. O 0 1.7379009022988612e-06

Our O 0 3.3657718745416787e-07
data O 0 2.422474381091888e-07
suggest O 0 6.447773159834469e-08
that O 0 1.3557656108886817e-09
, O 0 8.279543273204126e-09
in O 0 1.2209915212224587e-07
AAPC B-Disease 1 0.9999991655349731
families O 0 6.065883351169532e-09
, O 0 2.6428610411244335e-09
the O 0 8.462927025831846e-10
location O 0 1.077576339270081e-08
of O 0 3.504355250427693e-09
the O 0 1.0608215639251739e-08
APC B-Disease 0 6.666087983830948e-07
mutation O 0 5.467647667956044e-08
may O 0 2.8243448468856514e-08
partially O 0 5.0356685932229084e-08
predict O 0 4.095226913136685e-08
specific O 0 8.892281577743688e-09
phenotypic O 0 2.242328037027619e-06
expression O 0 1.7352545000903774e-06
. O 0 2.2405386062018806e-06

This O 0 1.0765618441155311e-07
should O 0 3.6956176785452044e-08
help O 0 1.260309456796449e-08
in O 0 3.773655166128265e-09
the O 0 1.5234677963604781e-09
design O 0 2.700395818067136e-08
of O 0 1.836883001260503e-08
tailored O 0 5.1601425354874664e-08
clinical O 0 1.3398391729424475e-06
- O 0 5.980010087114351e-07
management O 0 2.8173565169709036e-07
protocols O 0 1.1501375638545142e-06
in O 0 4.402384679025317e-09
this O 0 3.2065147759219315e-10
subset O 0 3.6900253519434045e-08
of O 0 6.681121789142708e-08
FAP B-Disease 0 7.956114131957293e-06
patients O 0 8.492638130519481e-07
. O 0 1.7178081179736182e-07
. O 0 2.565851445979206e-06

Wilms B-Disease 1 0.9999954700469971
' I-Disease 0 0.0007506240508519113
tumor I-Disease 0 0.0006127604865469038
1 O 0 4.761709533340763e-06
and O 0 1.690002306986571e-07
Dax O 1 0.9908079504966736
- O 0 7.39938013794017e-06
1 O 0 2.368692406662376e-07
modulate O 0 8.729479361591075e-08
the O 0 1.5275595899311156e-08
orphan O 0 3.18962833034675e-07
nuclear O 0 2.2760389128961833e-06
receptor O 0 1.4548584204021608e-07
SF O 0 4.4364718633005396e-05
- O 0 4.041815770960966e-07
1 O 0 6.958937603940285e-08
in O 0 2.3938684368118857e-09
sex O 0 1.1007174727239999e-08
- O 0 4.103270612176857e-09
specific O 0 1.0343158551862075e-09
gene O 0 1.8027533243980542e-08
expression O 0 1.7242321348476253e-07
. O 0 1.0910626997429063e-06

Products O 0 1.8341194163440377e-06
of O 0 9.810378287511412e-07
steroidogenic O 0 0.00018142744374927133
factor O 0 2.3324325866269646e-06
1 O 0 4.070777322340291e-06
( O 0 2.0247577481313783e-07
SF O 0 0.0005101111019030213
- O 0 4.412615453475155e-06
1 O 0 4.771373482981289e-07
) O 0 5.803151736927248e-09
and O 0 3.207252063930355e-08
Wilms B-Disease 1 0.9998828172683716
tumor I-Disease 0 0.0051134186796844006
1 O 0 1.1366328180884011e-05
( O 0 1.2688327899468277e-07
WT1 O 0 2.0628536731237546e-05
) O 0 6.949663511335302e-09
genes O 0 3.221714006684806e-09
are O 0 3.2222408075099906e-10
essential O 0 9.599072647858975e-09
for O 0 5.493328014694043e-09
mammalian O 0 3.5848412949235353e-07
gonadogenesis O 0 8.473949151266424e-07
prior O 0 5.624427501516038e-08
to O 0 1.533763516192721e-08
sexual O 0 1.6924196870604646e-06
differentiation O 0 1.8383223505225033e-05
. O 0 4.7632947826059535e-06

In O 0 1.5595840068272082e-06
males O 0 7.352009561145678e-07
, O 0 7.361719553955481e-07
SF O 1 0.9824851155281067
- O 0 1.4987624126661103e-05
1 O 0 5.723873073293362e-07
participates O 0 1.9038365550727576e-08
in O 0 6.052023882041624e-10
sexual O 0 2.940792942496273e-09
development O 0 1.6355027332437544e-09
by O 0 6.443611755280187e-10
regulating O 0 6.936952701153132e-08
expression O 0 6.321045908919132e-09
of O 0 5.995465013342027e-09
the O 0 3.2305269570542805e-08
polypeptide O 0 1.4033038269190001e-06
hormone O 0 3.4399809578644636e-07
Mullerian O 0 1.2765663996106014e-05
inhibiting O 0 3.510556780383922e-06
substance O 0 7.465575617970899e-05
( O 0 2.5196477508870885e-06
MIS O 0 0.17523875832557678
) O 0 1.172250676972908e-06
. O 0 4.236010227032239e-06

Here O 0 2.4946502890088595e-06
, O 0 8.235416260049533e-08
we O 0 1.5941530762120237e-08
show O 0 3.723870989347233e-08
that O 0 6.496085447338373e-09
WT1 O 0 5.749594856752083e-05
- O 0 1.658421206229832e-05
KTS O 0 0.00219287583604455
isoforms O 0 8.350867233275494e-07
associate O 0 1.5430555322382133e-06
and O 0 5.784588807955515e-08
synergize O 0 1.1496077604533639e-05
with O 0 7.16608099082805e-07
SF O 1 0.9999383687973022
- O 0 5.703933857148513e-05
1 O 0 1.0305452633474488e-06
to O 0 1.599074472835582e-08
promote O 0 4.81739789393032e-07
MIS O 0 0.00040602602530270815
expression O 0 2.307319846295286e-06
. O 0 3.012437673532986e-06

In O 0 1.2783407328242902e-06
contrast O 0 2.1954226667730836e-06
, O 0 6.756601464985579e-07
WT1 O 0 0.001831026398576796
missense O 0 2.1116711650392972e-05
mutations O 0 2.335082598392546e-07
, O 0 2.6570246447477075e-08
associated O 0 7.498545784301314e-08
with O 0 2.8443093214036708e-08
male B-Disease 0 0.00028591780574060977
pseudohermaphroditism I-Disease 1 1.0
in O 0 7.99347908468917e-05
Denys B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999997615814209
Drash I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
, O 0 4.967650397702528e-07
fail O 0 1.6791882444522344e-06
to O 0 6.9244997291662e-08
synergize O 0 9.28555746213533e-05
with O 0 5.892949502595002e-06
SF O 1 0.9999992847442627
- O 0 0.3100447654724121
1 O 0 9.661458170739934e-05
. O 0 3.227452907594852e-06

Additionally O 0 4.045231435156893e-06
, O 0 1.2560659001792374e-07
the O 0 8.869858447724255e-08
X O 0 1.664294359216001e-05
- O 0 2.8315294002823066e-06
linked O 0 8.10478439916551e-08
, O 0 1.1389937881745027e-09
candidate O 0 3.2055318399670796e-09
dosage O 0 4.720433111060629e-08
- O 0 2.527707110289157e-08
sensitive O 0 7.38420666834827e-08
sex O 0 2.4717820679143188e-08
- O 0 1.9904977222040543e-08
reversal O 0 3.186131181109886e-08
gene O 0 1.4264734282676272e-08
, O 0 2.6975182976229917e-08
Dax O 1 0.7904379963874817
- O 0 1.0180206118093338e-05
1 O 0 1.157506858362467e-06
, O 0 3.149738958541093e-08
antagonizes O 0 1.0282598168487311e-06
synergy O 0 1.3728438261750853e-06
between O 0 2.4809273782011587e-06
SF O 1 0.9997792840003967
- O 0 4.962345337844454e-05
1 O 0 6.127049232418358e-07
and O 0 1.0528431459988496e-08
WT1 O 0 4.5559118007076904e-05
, O 0 4.295944044940825e-09
most O 0 7.246102051716719e-10
likely O 0 1.0854784848746135e-09
through O 0 9.799239891750133e-11
a O 0 4.791911867307874e-10
direct O 0 1.0201134381659926e-09
interaction O 0 1.553880757398929e-08
with O 0 3.9088035919121467e-08
SF O 1 0.9986781477928162
- O 0 0.000368197332136333
1 O 0 2.1657209799741395e-05
. O 0 1.6353434375560028e-06

We O 0 8.068936381278036e-07
propose O 0 1.0588626082608243e-06
that O 0 7.982130512118601e-08
WT1 O 0 9.37610020628199e-05
and O 0 2.2153959378101717e-07
Dax O 1 0.9996496438980103
- O 0 2.5140978323179297e-05
1 O 0 5.811012329104415e-07
functionally O 0 1.8431146031616663e-07
oppose O 0 1.4536928105712832e-08
each O 0 4.0235817455602785e-10
other O 0 4.556829080737401e-10
in O 0 1.607403321557399e-09
testis O 0 2.171601636291598e-07
development O 0 1.2953799810588862e-08
by O 0 8.994184064192723e-09
modulating O 0 1.1601344340306241e-05
SF O 1 0.9972321391105652
- O 0 0.0009128415840677917
1 O 0 2.9216960683697835e-05
- O 0 3.4447782581992215e-06
mediated O 0 3.003089432240813e-06
transactivation O 0 6.328619929263368e-05
. O 0 3.221132374164881e-07
. O 0 1.8296574353371398e-06

A O 0 1.1345752682245802e-05
mouse O 0 5.160517275726306e-07
model O 0 1.5642119421954703e-07
for O 0 4.456648241557559e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.9999973773956299
- O 1 0.9999954700469971
centre O 1 0.9998505115509033
mutations O 0 5.416256681201048e-05
. O 0 1.5987114238669164e-05

Imprinting O 0 4.03003505198285e-05
in O 0 1.6751356213262625e-07
the O 0 1.3129844944614888e-07
15q11 O 0 1.4671317330794409e-05
- O 0 1.3170983947929926e-06
q13 O 0 1.09930965663807e-06
region O 0 4.7396952140843496e-08
involves O 0 1.496897183983492e-08
an O 0 3.0768791958735164e-09
imprinting O 0 2.4208839022321627e-06
centre O 0 9.99825497274287e-05
( O 0 6.658032702944183e-08
IC O 0 7.056386675685644e-05
) O 0 1.8411832058973232e-08
, O 0 5.001188352338204e-09
mapping O 0 3.961621430903506e-08
in O 0 7.259648437951682e-09
part O 0 6.252827144948014e-09
to O 0 1.2784281411271081e-09
the O 0 2.456563485964125e-08
promoter O 0 7.770324009470642e-05
and O 0 3.0041835685779006e-08
first O 0 3.7842457345504954e-07
exon O 0 2.411242894595489e-05
of O 0 3.3160793009301415e-06
SNRPN O 1 0.9073742628097534
. O 0 3.59049990947824e-05

Deletion O 0 4.2319672502344474e-05
of O 0 1.3500874729288626e-06
this O 0 9.96194557956187e-08
IC O 0 3.673887476907112e-05
abolishes O 0 1.5812623814781546e-06
local O 0 5.58522579297005e-08
paternally O 0 2.1001947914101038e-07
derived O 0 1.0129169503159119e-08
gene O 0 4.561509836520372e-09
expression O 0 1.3690860667381344e-09
and O 0 7.763471532307165e-10
results O 0 5.845844253116184e-09
in O 0 4.758150282668794e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999984502792358
PWS B-Disease 1 1.0
) O 0 0.00031397154089063406
. O 0 3.893693792633712e-05

We O 0 6.106632213231933e-07
have O 0 1.2154748318948805e-08
created O 0 1.1008959965863596e-08
two O 0 3.827222538888009e-09
deletion O 0 1.7214193803738453e-07
mutations O 0 5.4977228103325615e-08
in O 0 4.187986846204694e-08
mice O 0 9.67332951518074e-08
to O 0 1.6507598843418236e-08
understand O 0 0.0001638660760363564
PWS B-Disease 1 1.0
and O 0 9.35740018803699e-08
the O 0 4.2739532801761015e-08
mechanism O 0 8.788970262685325e-07
of O 0 1.2686318484611547e-07
this O 0 9.611240159301815e-08
IC O 0 0.0005483867134898901
. O 0 8.699560567038134e-06

Mice O 0 0.00023726533981971443
harbouring O 0 0.00012715175398625433
an O 0 8.42804368517136e-08
intragenic O 0 5.1486284064594656e-05
deletion O 0 2.2632013951806584e-06
in O 0 7.685261493861617e-08
Snrpn O 0 9.218123523169197e-06
are O 0 4.423208022075187e-09
phenotypically O 0 1.0018115972343367e-06
normal O 0 8.856468980411591e-08
, O 0 2.172275248568667e-09
suggesting O 0 6.588373402394154e-09
that O 0 1.5023331190189282e-10
mutations O 0 2.2546680078505688e-09
of O 0 1.1712228520366352e-08
SNRPN O 0 4.726113911601715e-05
are O 0 3.6008747095195304e-09
not O 0 2.935396370418175e-09
sufficient O 0 1.0267610406344829e-07
to O 0 6.31149461582936e-08
induce O 0 7.464764348696917e-05
PWS B-Disease 1 0.9999994039535522
. O 0 0.00010512317385291681

Mice O 0 1.4515155271510594e-05
with O 0 7.499318144255085e-08
a O 0 7.873201468555635e-08
larger O 0 3.63615093590397e-08
deletion O 0 1.7058646051282267e-07
involving O 0 6.705288058128644e-08
both O 0 1.3859781766711876e-08
Snrpn O 0 8.37626703287242e-06
and O 0 3.4875402121770094e-08
the O 0 2.6103793970833067e-07
putative O 0 0.0008168162894435227
PWS O 1 1.0
- O 0 0.016860177740454674
IC O 0 0.0008403594838455319
lack O 0 5.302145495988952e-07
expression O 0 3.1531047994803885e-08
of O 0 1.8329840756337035e-08
the O 0 1.9118493455039243e-08
imprinted O 0 2.486462449269311e-07
genes O 0 1.1663055943245126e-07
Zfp127 O 0 1.5076275303727016e-05
( O 0 6.562515153518689e-08
mouse O 0 3.020576286871801e-07
homologue O 0 1.2772975424013566e-06
of O 0 3.149222607135016e-07
ZNF127 O 1 0.8780933022499084
) O 0 4.0797365841171995e-07
, O 0 6.206673219821823e-07
Ndn O 0 0.00010548024874879047
and O 0 9.569151160349065e-08
Ipw O 0 9.24614942050539e-05
, O 0 2.872238269446825e-08
and O 0 3.2318012710419453e-09
manifest O 0 5.867529395686688e-08
several O 0 4.4479877558956105e-09
phenotypes O 0 1.4345516774483258e-07
common O 0 1.1579788861126872e-07
to O 0 1.0968320793836028e-06
PWS B-Disease 1 1.0
infants O 1 0.9982085227966309
. O 0 4.539613291854039e-05

These O 0 9.272404355442632e-08
data O 0 2.568497734500852e-07
demonstrate O 0 7.479134467303084e-08
that O 0 8.217144742417304e-10
both O 0 1.8154747705168006e-09
the O 0 1.3685012012487618e-09
position O 0 2.6472514846886952e-08
of O 0 1.3865387948897023e-08
the O 0 1.1009651856852543e-08
IC O 0 5.683973995473934e-06
and O 0 1.3593880465734287e-09
its O 0 4.553527277462166e-10
role O 0 1.2472525234841214e-08
in O 0 7.267250690112803e-10
the O 0 4.2912493003477437e-10
coordinate O 0 2.767898799049817e-09
expression O 0 4.929026964362038e-09
of O 0 8.031607379166417e-09
genes O 0 9.862891836576182e-09
is O 0 1.8990264916141086e-09
conserved O 0 1.9839410470012808e-07
between O 0 9.173979265142407e-08
mouse O 0 1.1326601878636211e-07
and O 0 7.225789744325084e-09
human O 0 2.104005147884891e-08
, O 0 1.1759301976610459e-08
and O 0 5.136190583954203e-09
indicate O 0 3.814631455156814e-08
that O 0 1.0805044636796879e-09
the O 0 7.570078786045542e-09
mouse O 0 1.2885467803869233e-08
is O 0 3.5134353759680437e-10
a O 0 6.396565499500184e-10
suitable O 0 1.1062909699433021e-08
model O 0 5.377704503928271e-09
system O 0 1.964401796783477e-08
in O 0 1.562555418388456e-09
which O 0 1.4677108139959927e-10
to O 0 2.588491365695944e-10
investigate O 0 1.338670863049174e-08
the O 0 2.778361096744675e-09
molecular O 0 6.749531422656219e-08
mechanisms O 0 3.723732788785128e-07
of O 0 3.764570166708836e-08
imprinting O 0 5.446340765047353e-07
in O 0 3.2824691853505783e-09
this O 0 6.62607635426582e-10
region O 0 2.8514957506331484e-08
of O 0 1.4674042425610878e-08
the O 0 3.4423692341079004e-08
genome O 0 2.642569896238456e-08
. O 0 3.452831265349232e-08
. O 0 6.627332709285838e-07

Mutations O 0 7.216701192191977e-07
of O 0 1.2326457010658487e-07
the O 0 4.352392579676234e-08
ATM O 0 1.625381992198527e-05
gene O 0 7.11189471758189e-08
detected O 0 1.0481510770432578e-07
in O 0 1.5879987103062376e-08
Japanese O 0 0.007993618957698345
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 9.768426025402732e-06
: O 0 1.87698905307343e-08
possible O 0 1.309810215843754e-07
preponderance O 0 3.259093500673771e-05
of O 0 1.0765618441155311e-07
the O 0 4.749776394419314e-08
two O 0 3.2912414127395095e-08
founder O 0 2.3233437786984723e-06
mutations O 0 2.40464970602261e-07
4612del165 O 0 8.823033567750826e-06
and O 0 4.535251889592473e-07
7883del5 O 0 0.0002482921117916703
. O 0 5.9253184190311e-06

The O 0 2.6032196274172748e-06
ATM O 0 0.014973942190408707
( O 0 4.627521775546484e-06
A O 1 0.9999452829360962
- O 1 0.9990416169166565
T O 1 0.9994887113571167
, O 0 1.228206158998546e-08
mutated O 0 5.131011171499722e-09
) O 0 1.3421497246923764e-09
gene O 0 7.76757769216374e-09
on O 0 4.048002821832597e-08
human O 0 1.903363084920784e-07
chromosome O 0 8.450967470707837e-06
11q22 O 0 6.218899216037244e-05
. O 0 4.733809419121826e-06

3 O 0 5.029726162320003e-05
has O 0 1.1329734661558177e-07
recently O 0 1.1838026381383315e-07
been O 0 2.768352880266889e-09
identified O 0 1.0743373968225e-09
as O 0 1.5413841036870934e-10
the O 0 2.4551605193323667e-10
gene O 0 3.7819830600582804e-10
responsible O 0 7.499396659227386e-10
for O 0 3.0556887575805547e-10
the O 0 7.580120531258672e-09
human O 0 1.8619045931700384e-06
recessive B-Disease 1 0.9999825954437256
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.998735249042511
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 5.218318619881757e-06
. O 0 6.72457736072829e-06

In O 0 1.8162278081490513e-07
order O 0 1.493660128915053e-08
to O 0 2.2087363049649866e-09
define O 0 2.6998963065238968e-08
the O 0 5.443243633607153e-09
types O 0 5.860986007633073e-08
of O 0 3.8685266190441325e-07
disease O 0 0.0031971524003893137
- O 0 9.829276450545876e-07
causing O 0 1.5926524099540984e-07
ATM O 0 3.274411574238911e-05
mutations O 0 1.7024266441012514e-08
in O 0 4.915301055063992e-09
Japanese O 0 8.944794899434783e-06
A B-Disease 1 0.9999986886978149
- I-Disease 1 0.9999973773956299
T I-Disease 1 0.9999997615814209
patients O 0 3.607950986861397e-07
as O 0 1.9950322283079913e-08
well O 0 8.251134886450018e-09
as O 0 3.2222668977510693e-09
to O 0 8.768987758145386e-10
look O 0 7.422754411123833e-09
for O 0 3.292759176432014e-09
possible O 0 4.320787994060993e-08
mutational O 0 1.7817577599998913e-06
hotspots O 0 1.2413901231411728e-06
, O 0 1.3175220914263264e-08
reverse O 0 1.449598414637876e-07
- O 0 1.0302137098960884e-07
transcribed O 0 4.3744808664314405e-08
RNA O 0 8.987293398377005e-08
derived O 0 6.137386154847491e-09
from O 0 5.095472044303051e-09
ten O 0 7.035423266188445e-08
patients O 0 1.1882858252931783e-08
belonging O 0 3.078958954461086e-08
to O 0 2.0264561140237447e-09
eight O 0 3.912085233537255e-08
unrelated O 0 5.90069873851462e-07
Japanese O 0 2.812829552567564e-05
A B-Disease 1 0.9999911785125732
- I-Disease 1 0.9984440207481384
T I-Disease 1 0.9995483756065369
families O 0 2.330840187525496e-09
was O 0 1.1947469680251288e-08
analyzed O 0 1.3162002598932077e-09
for O 0 1.2419622275050557e-10
mutations O 0 1.982954911383672e-10
by O 0 1.1046197984088124e-10
the O 0 1.354483636362147e-09
restriction O 0 6.2317768723119116e-09
endonuclease O 0 1.4244810131458507e-07
fingerprinting O 0 3.9207961322063056e-07
method O 0 4.079643360910268e-07
. O 0 9.136572316492675e-07

As O 0 3.52830511474167e-06
has O 0 5.3342294137337376e-08
been O 0 7.726337791780225e-09
reported O 0 2.275539534579707e-09
by O 0 1.9619360303035904e-10
others O 0 6.153464959801624e-10
, O 0 9.737871620174587e-10
mutations O 0 1.9805104223280523e-09
that O 0 3.901470535527807e-10
lead O 0 1.6608661113082235e-08
to O 0 1.9511343651856805e-08
exon O 0 1.4287014892033767e-05
skipping O 0 6.913426773280662e-07
or O 0 2.6384299189885496e-08
premature O 0 2.704202870518202e-07
protein O 0 9.698749892095293e-08
truncation O 0 9.295811196352588e-07
were O 0 4.20469916662114e-08
also O 0 1.197240262484911e-08
predominant O 0 2.5600243702683656e-07
in O 0 1.1493823670605252e-08
our O 0 1.274512015925211e-07
mutants O 0 1.6088202983155497e-06
. O 0 8.99866392956028e-07

Six O 0 4.07643881317199e-07
different O 0 1.881580580231912e-08
mutations O 0 2.9051198779939114e-08
were O 0 8.14393885661957e-09
identified O 0 1.0819052320698574e-08
on O 0 9.89598092360211e-09
12 O 0 2.5671795356174698e-08
of O 0 6.7526060298916946e-09
the O 0 6.861573975669444e-09
16 O 0 8.872057577491432e-08
alleles O 0 2.83190733085803e-08
examined O 0 2.030612449743785e-06
. O 0 1.9056531073147198e-06

Four O 0 2.588015831861412e-06
were O 0 5.623289780487539e-07
deletions O 0 1.9597539449023316e-06
involving O 0 5.15391207045468e-07
a O 0 8.782219396152868e-08
loss O 0 3.561777646154951e-07
of O 0 1.330559911139062e-07
a O 0 7.742421104239838e-08
single O 0 6.312313161060956e-08
exon O 0 4.163307949056616e-06
exon O 0 2.7705311822501244e-06
7 O 0 3.462209861027077e-07
, O 0 3.1640635000940165e-08
exon O 0 1.973107828234788e-06
16 O 0 4.301444107568386e-07
, O 0 6.455550050077363e-08
exon O 0 6.86759904056089e-06
33 O 0 2.441339574943413e-06
or O 0 7.395947250188328e-07
exon O 0 7.616484072059393e-05
35 O 0 1.4835609363217372e-05
. O 0 7.153222213673871e-06

The O 0 1.0836027968252893e-06
others O 0 1.709093737645162e-07
were O 0 4.6350070448397673e-08
minute O 0 1.0884088652574064e-07
deletions O 0 5.3028131219434727e-08
, O 0 7.658815803779362e-09
4649delA O 0 2.7649804223983665e-07
in O 0 2.903225215789007e-08
exon O 0 2.2006863673595944e-06
33 O 0 3.7354098481046094e-07
and O 0 4.8465256696772485e-08
7883del5 O 0 3.843226750177564e-06
in O 0 3.524581586589193e-07
exon O 0 2.34361086768331e-05
55 O 0 1.2362412235233933e-05
. O 0 3.997633484686958e-06

The O 0 4.01250446202539e-07
mutations O 0 1.7702612353787117e-07
4612del165 O 0 8.5376501601786e-07
and O 0 1.043598363281717e-08
7883del5 O 0 1.257526037079515e-06
were O 0 7.444617811103171e-09
found O 0 8.296738851498731e-10
in O 0 1.5998902203051557e-10
more O 0 4.166166717167741e-11
than O 0 9.334748252154412e-11
two O 0 1.7917989314497618e-10
unrelated O 0 2.7055140350285e-09
families O 0 9.499379755029125e-11
; O 0 2.5606389231214166e-10
44 O 0 9.278946500046459e-09
% O 0 1.663944892982272e-08
( O 0 1.0499614511161326e-08
7 O 0 7.586907457834968e-08
of O 0 1.7120228790190595e-08
16 O 0 5.702102257032493e-08
) O 0 7.726349005032773e-10
of O 0 2.724233061357495e-09
the O 0 2.846364477449015e-09
mutant O 0 3.655991775985967e-08
alleles O 0 1.081888800769093e-08
had O 0 3.204500487186124e-08
one O 0 3.2038387498545262e-09
of O 0 8.813410445895897e-09
the O 0 1.2014584882535928e-08
two O 0 4.0217443597612146e-08
mutations O 0 2.1235169356259576e-07
. O 0 9.226321822097816e-07

The O 0 1.8316685554964351e-06
4612del165 O 0 1.6445379515062086e-05
mutations O 0 6.96697242119626e-08
in O 0 6.215870040904292e-09
three O 0 6.940546470879383e-10
different O 0 4.676820042348595e-10
families O 0 1.8138886226370943e-10
were O 0 5.137471559280016e-10
all O 0 2.0534850209141808e-10
ascribed O 0 1.3323307790358285e-08
to O 0 1.0185949861352128e-09
the O 0 9.778525544845706e-09
same O 0 4.324333247041068e-08
T O 0 6.149344244477106e-06
- O 0 1.3133267202647403e-06
- O 0 2.1154681917323614e-07
> O 0 6.379416106483404e-08
A O 0 2.2722877801584218e-08
substitution O 0 2.1061532962107776e-08
at O 0 3.537977733003572e-08
the O 0 4.587003221701025e-09
splice O 0 9.202317130529991e-08
donor O 0 1.8103028409655053e-08
site O 0 9.50961762669067e-08
in O 0 1.1689569134887279e-07
intron O 0 0.00022022827761247754
33 O 0 4.060100036440417e-05
. O 0 1.4112842109170742e-05

Microsatellite O 0 0.0047623999416828156
genotyping O 0 0.00018114221165888011
around O 0 8.978759069577791e-07
the O 0 2.703050370200799e-07
ATM O 0 3.499407466733828e-05
locus O 0 3.01743824593359e-07
also O 0 1.6679516434692232e-08
indicated O 0 2.6880577763677138e-08
that O 0 2.8262603368744976e-10
a O 0 2.8529087980899703e-09
common O 0 8.5428695228984e-09
haplotype O 0 3.8635346299997764e-07
was O 0 2.1149678275378392e-07
shared O 0 8.864070366598753e-09
by O 0 7.111237154688865e-10
the O 0 2.3113255753770545e-09
mutant O 0 3.064505094130254e-08
alleles O 0 5.797210711477874e-09
in O 0 9.377944643063074e-09
both O 0 7.776015564786576e-08
mutations O 0 1.2993685913897934e-06
. O 0 3.4402148685330758e-06

This O 0 1.396746540649474e-07
suggests O 0 1.9373585757875844e-07
that O 0 8.560039899130345e-10
these O 0 4.2169590042107075e-10
two O 0 4.1112691029354664e-09
founder O 0 6.596643515877076e-07
mutations O 0 2.7039934735739735e-08
may O 0 1.9146957797033792e-08
be O 0 4.699759248438795e-09
predominant O 0 1.52341982584403e-07
among O 0 1.0091181223970125e-08
Japanese O 0 4.1609840195633296e-07
ATM O 0 2.1614006982417777e-05
mutant O 0 1.3824372899762238e-06
alleles O 0 5.036884545006615e-07
. O 0 1.6991214124573162e-06

W474C O 0 4.885349699179642e-05
amino O 0 5.863938099537336e-07
acid O 0 1.0385947746271995e-07
substitution O 0 6.013677733562872e-08
affects O 0 3.7241036920931947e-09
early O 0 3.681517091180808e-09
processing O 0 8.366633608147822e-09
of O 0 1.437616692356869e-09
the O 0 2.545252897334649e-09
alpha O 0 3.018254801645526e-08
- O 0 1.2647065616988584e-08
subunit O 0 2.3677364069385476e-08
of O 0 9.033314540829451e-09
beta O 0 6.578719649041886e-07
- O 0 9.807179139897926e-07
hexosaminidase O 0 2.6815191631612834e-06
A O 0 8.888758884495473e-08
and O 0 3.0400697514920694e-09
is O 0 3.518909830191319e-09
associated O 0 3.606313114801196e-08
with O 0 1.062794439121717e-07
subacute O 1 0.9997068047523499
G B-Disease 1 0.9965116381645203
( I-Disease 0 1.4359768101712689e-05
M2 I-Disease 1 0.8090162873268127
) I-Disease 0 1.838104708440369e-06
gangliosidosis I-Disease 0 0.00011188670032424852
. O 0 4.965366315445863e-06

Mutations O 0 3.681389671328361e-06
in O 0 1.8761234343855904e-07
the O 0 9.903990871862334e-08
HEXA O 0 8.293903374578804e-05
gene O 0 3.2957139239897515e-08
, O 0 4.800541297811378e-09
encoding O 0 1.5429797883825813e-08
the O 0 1.953905126583777e-08
alpha O 0 2.541027583902178e-07
- O 0 6.95481077173099e-08
subunit O 0 5.0150802621828916e-08
of O 0 2.6398495833745983e-08
beta O 0 1.2394594932629843e-06
- O 0 1.4184947758622002e-06
hexosaminidase O 0 4.9862269406730775e-06
A O 0 1.3018393474339973e-06
( O 0 2.1283966589180636e-08
Hex O 0 4.2854506432377093e-07
A O 0 2.458101562297088e-07
) O 0 2.5149280435954324e-09
, O 0 6.471546076802781e-10
that O 0 1.0517823417766081e-10
abolish O 0 1.1723582105105379e-08
Hex O 0 1.8723262940056884e-08
A O 0 5.1677138124262e-09
enzyme O 0 5.298594007996371e-09
activity O 0 7.252801026425004e-08
cause O 0 0.001304036471992731
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9999988079071045
( O 0 3.413820195419248e-06
TSD B-Disease 1 0.9975090026855469
) O 0 7.611199492885135e-08
, O 0 1.5820551979572883e-08
the O 0 4.3612509159629553e-08
fatal O 0 6.272309292398859e-06
infantile B-Disease 0 2.9868429010093678e-06
form I-Disease 0 2.504270355530025e-07
of I-Disease 0 2.9612901926157065e-05
G I-Disease 1 0.8541976809501648
( I-Disease 0 1.6368693422919023e-06
M2 I-Disease 0 0.003110067918896675
) I-Disease 0 1.1272098277004261e-07
gangliosidosis I-Disease 0 7.111499144230038e-06
, I-Disease 0 4.701303524257128e-08
Type I-Disease 0 1.8078982293445733e-06
1 I-Disease 0 5.032149147154996e-06
. O 0 1.2487603271438275e-06

Less O 0 1.4435587218031287e-05
severe O 0 0.0006028414936736226
, O 0 2.683962293303921e-06
subacute O 1 0.9922846555709839
( O 0 1.8491055016056634e-06
juvenile O 1 0.9641976356506348
- O 0 0.00020386309188324958
onset O 0 0.06847730278968811
) O 0 1.6862222196323273e-07
and O 0 1.1243190556342597e-06
chronic O 1 0.9999996423721313
( O 0 2.133346470145625e-06
adult O 0 3.976830339524895e-05
- O 0 4.834001447306946e-05
onset O 0 0.00019885598157998174
) O 0 1.9868185319182885e-08
variants O 0 6.874493152508876e-08
are O 0 9.544225409996443e-10
characterized O 0 8.273450369244983e-09
by O 0 7.417004233012392e-10
a O 0 7.53495843497376e-09
broad O 0 4.131386788230884e-08
spectrum O 0 2.2752460893116222e-07
of O 0 2.4558840294730544e-08
clinical O 0 5.065092523182102e-07
manifestations O 0 3.6195237385072687e-07
and O 0 8.676523499673294e-09
are O 0 6.430548316060936e-10
associated O 0 3.77470632528798e-09
with O 0 8.355529046433219e-10
residual O 0 2.084076868413831e-06
levels O 0 4.817613898921991e-07
of O 0 3.57863747524334e-08
Hex O 0 7.085512265803118e-07
A O 0 1.2885594458111882e-07
enzyme O 0 1.5385987239824317e-07
activity O 0 4.56074644716864e-07
. O 0 7.242176707222825e-07

We O 0 9.836882099989452e-07
identified O 0 7.093713634276355e-07
a O 0 2.9336300144677807e-07
1422 O 0 6.774396024411544e-05
G O 0 2.762517033261247e-05
- O 0 8.412475835939404e-06
- O 0 2.1591690710920375e-06
> O 0 4.911161681775411e-07
C O 0 4.972877832187805e-06
( O 0 6.665336282907219e-09
amino O 0 9.28762311502851e-09
acid O 0 1.5630332583782547e-08
W474C O 0 6.053333834188379e-08
) O 0 5.85896831051258e-10
substitution O 0 7.676775659604118e-09
in O 0 6.575853195300851e-10
the O 0 5.17277998213217e-10
first O 0 1.1498377805452265e-09
position O 0 2.4651575003531434e-08
of O 0 3.3015339795383625e-08
exon O 0 1.7243438605873962e-06
13 O 0 1.1020792101135157e-07
of O 0 1.1418824641395986e-07
HEXA O 0 0.0004499426868278533
of O 0 1.7100262539315736e-07
a O 0 3.38455592441278e-08
non O 0 6.616748464693956e-07
- O 0 6.044670044502709e-07
Jewish O 0 7.141024127577111e-08
proband O 0 1.4826499864284415e-05
who O 0 4.8190933910063904e-08
manifested O 0 2.8856069889116043e-07
a O 0 7.697481407831219e-08
subacute O 0 8.488685125485063e-05
variant O 0 7.334718929996598e-07
of O 0 1.7717993614496663e-06
G B-Disease 0 0.27593377232551575
( I-Disease 0 2.535849716878147e-06
M2 I-Disease 0 0.21911530196666718
) I-Disease 0 1.7355292811771506e-06
gangliosidosis I-Disease 0 9.735276398714632e-05
. O 0 3.6452452150115278e-06

On O 0 3.0094167868810473e-06
the O 0 2.4138839194165485e-07
second O 0 5.15769784215081e-07
maternally O 0 2.3245052034326363e-06
inherited O 0 3.828692570095882e-06
allele O 0 5.374938893965009e-08
, O 0 2.000850152228395e-09
we O 0 9.493190678000474e-10
identified O 0 4.4242458585586064e-09
the O 0 3.0512115056779976e-09
common O 0 3.5315969171278994e-07
infantile O 1 0.8268148303031921
disease O 1 0.8306859135627747
- O 0 5.647536090691574e-05
causing O 0 2.2633357730228454e-05
4 O 0 2.708724969124887e-05
- O 0 2.9384168556134682e-06
bp O 0 9.977880921496762e-08
insertion O 0 5.4412847561025046e-08
, O 0 1.2649381986307162e-08
+ O 0 6.905980285409896e-07
TATC O 0 0.00036480213748291135
1278 O 0 0.00013733185187447816
, O 0 1.2343643618351052e-07
in O 0 1.747707472077309e-07
exon O 0 2.5802684831432998e-05
11 O 0 8.521345080225728e-06
. O 0 5.461911314341705e-06

Pulse O 0 0.0030624994542449713
- O 0 1.956640880962368e-05
chase O 0 6.309508648882911e-07
analysis O 0 6.46148805572011e-08
using O 0 1.2178749386748677e-07
proband O 0 9.701517228677403e-06
fibroblasts O 0 3.500867080674652e-07
revealed O 0 1.299277698763035e-07
that O 0 9.059432648506061e-10
the O 0 3.791641667305612e-09
W474C O 0 2.479417844369891e-07
- O 0 2.6746684866907344e-08
containing O 0 4.605465786511331e-09
alpha O 0 4.562712874189856e-08
- O 0 9.238224407681628e-09
subunit O 0 2.304538782027521e-08
precursor O 0 1.1066943983450983e-07
was O 0 1.1150867784692764e-08
normally O 0 9.806500056441791e-10
synthesized O 0 5.706636496682904e-09
, O 0 4.837654721256968e-10
but O 0 2.3034026075396952e-10
not O 0 1.124294476961829e-10
phosphorylated O 0 5.009800130295616e-09
or O 0 1.9746602131220925e-09
secreted O 0 4.467918479633681e-09
, O 0 1.6695423932233666e-09
and O 0 7.891686193417513e-10
the O 0 6.491998494340123e-09
mature O 0 1.315875124419108e-07
lysosomal O 0 1.0574141015240457e-05
alpha O 0 9.922697472575237e-07
- O 0 1.7191963763707463e-07
subunit O 0 2.0572767311932694e-07
was O 0 1.6462075791423558e-07
not O 0 7.750854180699207e-09
detected O 0 1.3273993317852728e-06
. O 0 5.075435751678015e-07

When O 0 4.822338723897701e-07
the O 0 1.3275584365146642e-07
W474C O 0 1.1318218184896978e-06
- O 0 7.818535152637196e-08
containing O 0 3.346386501235088e-09
alpha O 0 8.819350227895484e-08
- O 0 3.963397432471538e-08
subunit O 0 1.0645270265285944e-07
was O 0 5.453107405628543e-07
transiently O 0 3.033743041669368e-06
co O 0 1.645414840822923e-06
- O 0 4.965802702372457e-08
expressed O 0 2.1108776948608465e-09
with O 0 5.190926577469668e-10
the O 0 2.7354902787379842e-09
beta O 0 6.559236709335892e-08
- O 0 2.5238579226538604e-08
subunit O 0 2.3445654306897268e-08
to O 0 1.289886197852752e-09
produce O 0 6.404650587654714e-09
Hex O 0 3.12225751031292e-07
A O 0 2.2947844513510063e-07
( O 0 6.5209140309718805e-09
alphabeta O 0 3.029091999451339e-07
) O 0 6.818989373158502e-09
in O 0 4.854444668467295e-08
COS O 0 0.2075098603963852
- O 0 9.770123870112002e-05
7 O 0 1.1096340131189208e-06
cells O 0 1.2771469215522302e-08
, O 0 1.0279946893732017e-09
the O 0 1.887341394279929e-09
mature O 0 1.3206493676420905e-08
alpha O 0 6.982883604678136e-08
- O 0 1.657331338833501e-08
subunit O 0 3.008868887377503e-08
was O 0 2.0303685843714447e-08
present O 0 2.531666876137706e-09
, O 0 1.0921885618131455e-09
but O 0 9.196776673547902e-11
its O 0 8.950502144999817e-11
level O 0 2.1739674949117216e-08
was O 0 1.7128394702581318e-08
much O 0 1.6809430514186374e-09
lower O 0 5.324042096077619e-09
than O 0 8.986664190580029e-11
that O 0 2.0047637161457743e-11
from O 0 1.6753728959706393e-10
normal O 0 1.9863477529469264e-09
alpha O 0 3.690447414328446e-08
- O 0 1.4833881678555372e-08
subunit O 0 3.0581929877371294e-08
transfections O 0 1.6713441652882466e-07
, O 0 9.361230679516552e-10
although O 0 7.953551706130213e-10
higher O 0 5.018924387201196e-09
than O 0 2.2754557960080746e-10
in O 0 2.765185302955331e-10
those O 0 7.344477248594217e-10
cells O 0 1.6339624098193894e-09
transfected O 0 2.15339923670399e-08
with O 0 1.617773970341574e-10
an O 0 6.343930381014218e-10
alpha O 0 1.4621971899941855e-07
- O 0 9.331378691967984e-08
subunit O 0 1.1782925923853327e-07
associated O 0 1.2803950255602103e-07
with O 0 2.1348819245758932e-07
infantile O 1 0.9174143075942993
TSD B-Disease 1 0.9998716115951538
. O 0 0.00011628335050772876

Furthermore O 0 3.7868123854423175e-06
, O 0 6.314191836054306e-08
the O 0 1.0062428223989173e-08
precursor O 0 1.3428896750156127e-07
level O 0 7.45542010349709e-08
of O 0 1.7108117589259564e-08
the O 0 7.403072377343278e-09
W474C O 0 2.0918373877520935e-07
alpha O 0 8.915484528415618e-08
- O 0 2.1973333375058246e-08
subunit O 0 2.6302149791490592e-08
was O 0 2.8719533418097853e-08
found O 0 1.4796460723331961e-09
to O 0 9.19630815943151e-10
accumulate O 0 2.9185212468973987e-08
in O 0 1.9637040882258816e-09
comparison O 0 3.203093346115793e-09
to O 0 2.429854373264817e-10
the O 0 1.4109001744699867e-09
normal O 0 4.576771672759605e-08
alpha O 0 2.073869040941645e-07
- O 0 9.696161384908919e-08
subunit O 0 2.7720747652892896e-07
precursor O 0 1.114131009671837e-06
levels O 0 1.0626358744048048e-06
. O 0 1.3256787951831939e-06

We O 0 6.787109896322363e-07
conclude O 0 1.0506585113034816e-06
that O 0 7.297256132687835e-09
the O 0 3.372750256858126e-08
1422 O 0 3.5114520869683474e-05
G O 0 3.618966366047971e-05
- O 0 9.475969818595331e-06
- O 0 1.6325540173056652e-06
> O 0 4.94244432047708e-07
C O 0 4.20870946982177e-06
mutation O 0 1.371852231812909e-08
is O 0 9.918880161663424e-10
the O 0 1.5027981081772168e-09
cause O 0 2.722535974442053e-08
of O 0 6.47743050308236e-08
Hex B-Disease 0 1.1592453120101709e-05
A I-Disease 0 0.000138868999783881
enzyme I-Disease 1 0.9999710321426392
deficiency I-Disease 1 0.9999998807907104
in O 0 7.154712022838794e-08
the O 0 2.0131628275521507e-07
proband O 0 0.0001982239045901224
. O 0 1.881324124042294e-06

The O 0 4.1896009861375205e-07
resulting O 0 3.647849382559798e-07
W474C O 0 1.170830728369765e-06
substitution O 0 1.0096999147890529e-07
clearly O 0 4.9842213911688305e-08
interferes O 0 3.0369299963695084e-08
with O 0 1.5255031682315234e-09
alpha O 0 1.0206981926330627e-07
- O 0 1.979797481510559e-08
subunit O 0 1.8022307202159027e-08
processing O 0 5.070693731568099e-08
, O 0 6.603189661724684e-10
but O 0 2.579826352544501e-10
because O 0 3.2092620227963664e-10
the O 0 5.613383091684909e-10
base O 0 1.092362023058513e-08
substitution O 0 3.0511198900740055e-08
falls O 0 3.016879759343283e-07
at O 0 3.2536171090669086e-08
the O 0 2.7922908429900417e-09
first O 0 4.807009457152844e-09
position O 0 4.8778712624653053e-08
of O 0 1.095573693987717e-07
exon O 0 1.6067948536147014e-06
13 O 0 7.632744569718852e-08
, O 0 6.525965101644715e-09
aberrant O 0 6.532381036095103e-08
splicing O 0 2.974589676796313e-07
may O 0 3.406842452591263e-08
also O 0 4.0019774161237365e-09
contribute O 0 1.0670230032872041e-08
to O 0 1.5879956904996106e-08
Hex B-Disease 0 5.6139924708986655e-05
A I-Disease 0 0.00017538534302730113
deficiency I-Disease 1 0.7225165963172913
in O 0 2.3156644601840526e-08
this O 0 1.4181125607137801e-08
proband O 0 8.598832209827378e-06
. O 0 7.906790244760487e-08
. O 0 4.593686071530101e-07

Two O 0 5.079745619696041e-07
frequent O 0 1.4051022390049184e-06
missense O 0 3.66669446520973e-05
mutations O 0 5.03594219480874e-06
in O 0 1.232148952112766e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0004610403557308018

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 1.3088778132441803e-06
an O 0 1.23492627608357e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9348708391189575
by O 0 5.920134071857319e-07
early O 1 0.9968454241752625
childhood O 1 1.0
deafness B-Disease 1 1.0
and O 1 0.9999983310699463
goiter B-Disease 1 1.0
. O 1 0.9997559189796448

A O 0 9.411864084540866e-06
century O 0 1.6179318436115864e-06
after O 0 2.4994260883204333e-08
its O 0 6.589425671776894e-10
recognition O 0 1.575454433577761e-08
as O 0 7.523831868638808e-08
a O 0 4.2285131485186866e-07
syndrome O 0 4.505473043536767e-06
by O 0 4.752456650436443e-09
Vaughan O 0 7.862942766223568e-06
Pendred O 0 0.00024219219631049782
, O 0 8.593912070864462e-08
the O 0 2.3974894247658085e-07
disease O 0 0.00030344113474711776
gene O 0 8.987462933873758e-07
( O 0 8.855656119521882e-07
PDS O 0 0.0006153972935862839
) O 0 3.184813408552145e-07
was O 0 2.336462330276845e-06
mapped O 0 1.9569418441278685e-07
to O 0 5.7508376727355426e-08
chromosome O 0 1.5520479792030528e-05
7q22 O 0 0.00015450917999260128
- O 0 6.96451315889135e-05
q31 O 0 0.00012044273898936808
. O 0 4.010800694231875e-06

1 O 0 9.318354386778083e-06
and O 0 7.165432691635942e-08
, O 0 3.2723626475217316e-08
recently O 0 6.638124716573657e-08
, O 0 2.5130533209960504e-09
found O 0 7.334705620642978e-10
to O 0 5.993587293140479e-10
encode O 0 2.588118697133268e-08
a O 0 1.8554476355348015e-07
putative O 0 1.1465792340459302e-05
sulfate O 0 0.001678747357800603
transporter O 0 0.1934034675359726
. O 0 2.7001724447472952e-05

We O 0 1.5240679829275905e-07
performed O 0 9.088689978398179e-08
mutation O 0 6.534410346148434e-09
analysis O 0 5.9905271854177045e-09
of O 0 7.310407390548335e-09
the O 0 1.836672858246402e-08
PDS B-Disease 0 6.056950587662868e-05
gene O 0 9.46040970006834e-08
in O 0 1.4157774508305465e-08
patients O 0 1.6232711175234726e-08
from O 0 2.2266085863975604e-08
14 O 0 4.769781298818998e-07
Pendred B-Disease 0 9.28439840208739e-06
families O 0 1.4485771471228759e-09
originating O 0 1.127323212557485e-08
from O 0 1.8661361345095884e-09
seven O 0 1.3286047817473445e-09
countries O 0 1.6627091370402525e-10
and O 0 7.472967245014672e-10
identified O 0 1.0313456755284278e-08
all O 0 7.563468962246134e-09
mutations O 0 2.491962902695377e-07
. O 0 8.614012472207833e-07

The O 0 7.435863835780765e-07
mutations O 0 2.1948414996586507e-07
include O 0 6.326958867930443e-08
three O 0 1.422682949225873e-08
single O 0 2.2995857662522212e-08
base O 0 1.9832734210467606e-07
deletions O 0 1.7651093742188095e-07
, O 0 9.557838964724397e-09
one O 0 2.061814052822797e-09
splice O 0 8.209037360984439e-08
site O 0 2.4301163747963983e-08
mutation O 0 7.295294590647927e-09
and O 0 1.6379948064582095e-08
10 O 0 1.0832907264557434e-06
missense O 0 4.0793347579892725e-05
mutations O 0 4.285318027541507e-06
. O 0 3.6889175589749357e-06

One O 0 2.545896222727606e-06
missense O 0 2.3379789126920514e-05
mutation O 0 8.622272957836685e-07
( O 0 1.8730983697423653e-07
L236P O 0 6.803701580793131e-06
) O 0 3.419471994448031e-08
was O 0 1.3999952841459162e-07
found O 0 2.7330546714665616e-09
in O 0 4.0738457052214017e-10
a O 0 1.1655018061773603e-09
homozygous O 0 1.6431006555350791e-09
state O 0 6.584437994838765e-10
in O 0 1.1830656454492328e-09
two O 0 2.168996315887739e-09
consanguineous O 0 1.8382204416411696e-06
families O 0 7.857172135139479e-10
and O 0 1.4751262433776446e-09
in O 0 2.6772395411711614e-09
a O 0 2.6780158091099793e-09
heterozygous O 0 1.5626686611369678e-09
state O 0 6.213780601171948e-10
in O 0 2.6697219435156683e-10
five O 0 5.862075824758506e-10
additional O 0 8.655695715731326e-09
non O 0 9.414011401531752e-07
- O 0 6.877869509480661e-06
consanguineous O 0 5.318634430295788e-05
families O 0 2.669923730991286e-07
. O 0 1.8654967561815283e-06

Another O 0 4.617334070644574e-06
missense O 0 2.6261444872943684e-05
mutation O 0 3.707751545789506e-07
( O 0 1.2390513859372732e-07
T416P O 0 6.953570391488029e-06
) O 0 3.209155252648088e-08
was O 0 2.713611877425137e-07
found O 0 6.346112080279909e-09
in O 0 1.9028916220520387e-09
a O 0 3.5100347073324656e-09
homozygous O 0 6.988930323359455e-09
state O 0 4.304687717393563e-09
in O 0 6.3016525331249795e-09
one O 0 4.646493856341749e-09
family O 0 1.9826875696793422e-09
and O 0 6.392784079878311e-10
in O 0 1.2916119285222294e-09
a O 0 2.614767291575504e-09
heterozygous O 0 2.392010811647083e-09
state O 0 7.002523561006058e-10
in O 0 1.3350417438218187e-09
four O 0 1.5099068662038917e-08
families O 0 8.650662408626886e-09
. O 0 3.8863757367835206e-07

Pendred B-Disease 0 0.008205539546906948
patients O 0 2.6925890779239126e-06
in O 0 4.55552111588986e-08
three O 0 3.4841693974385635e-08
non O 0 6.465509159170324e-06
- O 0 2.159422729164362e-05
consanguineous O 0 3.9161710446933284e-05
families O 0 1.0786004089879953e-08
were O 0 1.7150558306866515e-08
shown O 0 3.7132230623626583e-09
to O 0 5.276464265513425e-10
be O 0 2.2452353309887485e-09
compound O 0 3.7352315018779336e-08
heterozygotes O 0 2.742720539572474e-07
for O 0 1.9235393722283334e-08
L236P O 0 2.519453119020909e-06
and O 0 1.4399479653093294e-07
T416P O 0 4.452271241461858e-05
. O 0 3.880437816405902e-06

In O 0 2.4821954980325245e-07
total O 0 4.0381472388162365e-08
, O 0 1.027571805423122e-08
one O 0 1.1862426596565001e-09
or O 0 6.109795447351019e-10
both O 0 4.982904644457165e-10
of O 0 2.2116830589169467e-09
these O 0 2.7298335814052166e-10
mutations O 0 2.6559947574611442e-09
were O 0 3.4232683354673554e-09
found O 0 1.8357121378542729e-09
in O 0 8.101175841268571e-10
nine O 0 5.42811751103045e-09
of O 0 3.9759338044120796e-09
the O 0 7.685243552657539e-09
14 O 0 1.2591782194704138e-07
families O 0 3.036442208781409e-09
analyzed O 0 2.7855506345986214e-07
. O 0 4.0480188090441516e-07

The O 0 2.398708147666184e-07
identification O 0 3.1150690915637824e-07
of O 0 1.63388904184103e-07
two O 0 3.025552075541782e-08
frequent O 0 3.0812771001365036e-07
PDS B-Disease 0 3.818823097390123e-05
mutations O 0 3.2166926899890314e-08
will O 0 2.1342818623537596e-09
facilitate O 0 1.6325769180980387e-08
the O 0 6.312563360921786e-09
molecular O 0 1.6836253280416713e-06
diagnosis O 0 4.170561442151666e-05
of O 0 0.0001444512017769739
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0008519786642864347

Insertional O 0 0.00011453819752205163
mutation O 0 3.000805293140729e-07
by O 0 3.396390368948232e-08
transposable O 0 0.00018503685714676976
element O 0 2.1366071450756863e-05
, O 0 4.424176722750417e-07
L1 O 0 0.0022393816616386175
, O 0 7.89548764146275e-08
in O 0 2.753540684352629e-08
the O 0 1.0139476103177003e-07
DMD B-Disease 1 0.9998800754547119
gene O 0 3.372325352302141e-08
results O 0 1.7617955094806348e-08
in O 0 4.4875726246118575e-08
X B-Disease 1 0.8202467560768127
- I-Disease 1 0.9997389912605286
linked I-Disease 1 0.9639597535133362
dilated I-Disease 1 0.9992125034332275
cardiomyopathy I-Disease 1 1.0
. O 0 0.05521747097373009

X B-Disease 1 0.9996860027313232
- I-Disease 1 0.9999889135360718
linked I-Disease 1 0.9995958209037781
dilated I-Disease 1 0.9999674558639526
cardiomyopathy I-Disease 1 1.0
( O 0 0.0019539534114301205
XLDCM B-Disease 1 0.999993085861206
) O 0 1.660206407905207e-07
is O 0 1.8903760334865183e-08
a O 0 6.075215441825321e-09
clinical O 0 7.968348114673063e-08
phenotype O 0 3.3443082969597526e-08
of O 0 9.650532462046613e-08
dystrophinopathy B-Disease 0 0.0001453293371014297
which O 0 3.5381848562110463e-09
is O 0 8.773571869014063e-10
characterized O 0 2.4991673175378537e-09
by O 0 1.4994482322450153e-09
preferential O 0 1.9887045255018165e-06
myocardial B-Disease 1 0.9863348007202148
involvement I-Disease 0 1.8518779825171805e-06
without O 0 3.0886582180755795e-08
any O 0 8.357159408944881e-09
overt O 0 2.546099722167128e-07
clinical O 0 1.8140308384317905e-06
signs O 0 5.798882739327382e-06
of O 0 0.03833821415901184
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 1 0.9969447255134583

To O 0 1.1886024964269382e-07
date O 0 2.8802730867028004e-07
, O 0 4.984817447706291e-09
several O 0 1.446682995620563e-09
mutations O 0 1.4813128501600659e-08
in O 0 1.3058286008060804e-08
the O 0 1.3864397260476835e-05
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
gene O 1 0.8290132880210876
, O 0 0.2818385064601898
DMD O 1 1.0
, O 0 1.2814814454031875e-06
have O 0 6.314936129570015e-09
been O 0 4.674691300721179e-09
identified O 0 1.547719463701469e-08
in O 0 1.929704396275156e-09
patients O 0 3.6933749392176196e-09
with O 0 4.008616105721785e-09
XLDCM B-Disease 1 0.9992341995239258
, O 0 2.9514653832052318e-08
but O 0 1.1715707293191713e-09
a O 0 1.3057581682573982e-09
pathogenic O 0 5.766706667742483e-09
correlation O 0 1.586686892984801e-09
of O 0 2.4939958986891497e-09
these O 0 9.900432695886252e-10
cardiospecific O 0 2.1372704850364244e-06
mutations O 0 6.842313382549037e-08
in O 0 8.21021188812665e-08
DMD O 1 0.9999690055847168
with O 0 3.2237625902098443e-08
the O 0 3.743983540971385e-07
XLDCM B-Disease 1 0.9865488409996033
phenotype O 0 2.3118981573588826e-07
has O 0 1.1210535610928218e-08
remained O 0 2.826506602104928e-07
to O 0 1.6469473562708004e-09
be O 0 1.445293662527547e-08
elucidated O 0 2.8399286748026498e-05
. O 0 1.232580416399287e-06

We O 0 1.333161549155193e-06
report O 0 3.0256153138452646e-08
here O 0 6.008997299744578e-09
the O 0 5.94467697290213e-10
identification O 0 3.0350524315991834e-09
of O 0 2.9414606306232827e-09
a O 0 4.102174600006947e-09
unique O 0 1.621581624533519e-08
de O 0 1.5344269286288181e-06
novo O 0 2.1600442323688185e-06
L1 O 0 2.9301143513293937e-05
insertion O 0 8.325611702275637e-07
in O 0 5.614095499595351e-08
the O 0 9.150160451554257e-08
muscle O 0 1.7311948568021762e-06
exon O 0 6.855258106952533e-06
1 O 0 1.258183488062059e-06
in O 0 1.2323435782946035e-07
DMD O 1 0.9999624490737915
in O 0 3.7500793581557446e-08
three O 0 4.84319890858842e-08
XLDCM B-Disease 1 0.5822264552116394
patients O 0 9.952638890808885e-08
from O 0 1.4481911669861347e-08
two O 0 1.3127109177446528e-08
unrelated O 0 3.154494834234356e-07
Japanese O 0 1.6858842855071998e-06
families O 0 6.177695865972055e-08
. O 0 5.611076403511106e-07

The O 0 1.8307047184862313e-06
insertion O 0 5.112811777507886e-06
was O 0 3.169658839397016e-06
a O 0 1.4690725436139473e-07
5 O 0 1.3096529016820568e-07
- O 0 5.0880160529231944e-08
truncated O 0 1.186272680087086e-08
form O 0 6.040840716536877e-09
of O 0 1.6991112516961948e-08
human O 0 3.157727235247876e-08
L1 O 0 1.0135566299140919e-05
inversely O 0 5.491842784977052e-07
integrated O 0 1.044438704411732e-06
in O 0 1.0439407560625114e-08
the O 0 2.26013732174124e-08
5 O 0 3.7277231967891566e-07
- O 0 5.344755322767014e-07
untranslated O 0 4.1684976167744026e-05
region O 0 1.0528897576023155e-07
in O 0 1.0773687719733971e-08
the O 0 1.5005133136014592e-08
muscle O 0 5.881187234990648e-07
exon O 0 8.509796316502616e-06
1 O 0 5.110766210236761e-07
, O 0 6.281875464253517e-09
which O 0 2.708331336975789e-10
affected O 0 5.731788377261182e-10
the O 0 1.1250221865211074e-09
transcription O 0 4.1186879684573796e-08
or O 0 3.31257066221724e-09
the O 0 4.871063108424778e-09
stability O 0 1.4123704659141367e-06
of O 0 5.8800214475240864e-08
the O 0 2.1297895003158374e-08
muscle O 0 5.782217016303548e-08
form O 0 2.0989709526020306e-08
of O 0 4.064548306814686e-07
dystrophin O 0 9.094444067159202e-06
transcripts O 0 1.168652033811668e-06
but O 0 1.926306447685988e-09
not O 0 2.6796903584980214e-10
that O 0 1.0417359336267751e-10
of O 0 2.4860644654012276e-09
the O 0 2.290813050365159e-08
brain O 0 4.443957732291892e-05
or O 0 2.3318158071106154e-07
Purkinje O 0 0.0005052185733802617
cell O 0 7.476091013813857e-06
form O 0 4.5882305954592084e-08
, O 0 1.1791981613384905e-08
probably O 0 1.4264625924909069e-08
due O 0 4.3775583158378595e-09
to O 0 2.452857639223538e-10
its O 0 1.691220358202017e-10
unique O 0 1.544145034060307e-09
site O 0 1.1646934083842098e-08
of O 0 2.838586077302807e-08
integration O 0 8.993602932605427e-06
. O 0 6.2431927290163e-06

We O 0 6.497742219835345e-07
speculate O 0 8.171215881702665e-07
that O 0 6.301168475886243e-10
this O 0 1.1999824744979293e-10
insertion O 0 7.1496750742028325e-09
of O 0 5.235415656557052e-09
an O 0 3.170302242949674e-09
L1 O 0 7.38366725272499e-06
sequence O 0 1.5027507060949574e-07
in O 0 2.341049309961818e-07
DMD O 1 0.9999914169311523
is O 0 7.846872485117729e-09
responsible O 0 8.942491191987756e-09
for O 0 8.126091466387209e-10
some O 0 2.3047869168735247e-10
of O 0 1.288464890336627e-09
the O 0 7.361531384475484e-10
population O 0 6.710473149373897e-11
of O 0 2.446807645384297e-09
Japanese O 0 4.4138513999314455e-07
patients O 0 1.6042921657799525e-08
with O 0 4.790863705750326e-09
XLDCM B-Disease 0 0.01897905208170414
. O 0 1.8202385376753227e-07
. O 0 1.4712852589582326e-06

Severe O 0 0.0002138630807166919
early O 0 0.00010616724466672167
- O 1 0.9940992593765259
onset O 1 0.9999997615814209
obesity B-Disease 1 1.0
, O 0 0.022169750183820724
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.9895137548446655
red O 1 0.985997200012207
hair O 1 0.7468801736831665
pigmentation O 0 0.2704697549343109
caused O 0 1.4814034329901915e-05
by O 0 4.770872692461126e-07
POMC O 1 0.9994200468063354
mutations O 0 2.7700002647179645e-06
in O 0 6.247900046219002e-07
humans O 0 2.3455595510313287e-06
. O 0 2.191623707403778e-06

Sequential O 0 1.5849198462092318e-05
cleavage O 0 7.502667813241715e-06
of O 0 2.1575128528183996e-07
the O 0 8.96705500963435e-08
precursor O 0 8.524242502971902e-07
protein O 0 1.2379057068301336e-07
pre O 0 2.9045934297755593e-06
- O 0 3.215339120288263e-06
pro O 0 5.259039971861057e-05
- O 0 0.00012279770453460515
opiomelanocortin O 0 0.000145939236972481
( O 0 2.0568765535244893e-07
POMC O 0 2.845105882443022e-05
) O 0 1.1307386138525999e-08
generates O 0 1.0296395736020258e-08
the O 0 1.8719621408536113e-08
melanocortin O 0 1.0306494004908018e-05
peptides O 0 1.6222752208250313e-07
adrenocorticotrophin O 0 7.5327802733227145e-06
( O 0 5.582989359709245e-08
ACTH O 0 1.2679934116022196e-06
) O 0 1.6003680158860334e-08
, O 0 5.093842148085059e-08
melanocyte O 0 1.3608835615741555e-05
- O 0 6.062894499336835e-06
stimulating O 0 5.223207608651137e-06
hormones O 0 4.815349257114576e-07
( O 0 4.494442507052554e-08
MSH O 0 1.860049997048918e-05
) O 0 1.8622756670083618e-08
alpha O 0 2.071015074989191e-07
, O 0 5.409038994486082e-09
beta O 0 3.2677721861773534e-08
and O 0 1.4618833921176133e-09
gamma O 0 1.826538031934888e-08
as O 0 8.23930423887731e-10
well O 0 8.20054746331067e-10
as O 0 5.090146637520832e-10
the O 0 9.623321028939813e-10
opioid O 0 2.5508705903121154e-07
- O 0 2.7910203925785027e-07
receptor O 0 5.733062735657768e-08
ligand O 0 6.63031698877603e-07
beta O 0 2.2039535906515084e-05
- O 0 3.590400956454687e-05
endorphin O 0 0.00011169109347974882
. O 0 2.964283339679241e-06

While O 0 1.6007396652639727e-06
a O 0 4.622840776846715e-08
few O 0 1.005914640472838e-08
cases O 0 3.1941800315848923e-09
of O 0 3.836257889133776e-08
isolated O 0 1.988326766877435e-05
ACTH B-Disease 1 0.9821334481239319
deficiency I-Disease 1 0.9997209906578064
have O 0 2.8167594479100444e-08
been O 0 3.082854860281259e-08
reported O 0 3.155343009098033e-08
( O 0 1.1487577111779501e-08
OMIM O 0 2.505749034753535e-05
201400 O 0 2.976199994009221e-06
) O 0 1.0450185605748175e-08
, O 0 5.121233659366453e-09
an O 0 2.4831512845935322e-08
inherited O 1 0.9999690055847168
POMC O 1 0.9999998807907104
defect O 1 0.9595850706100464
has O 0 5.8354423515538656e-08
not O 0 1.2271477167757894e-08
been O 0 1.1749661688043034e-08
described O 0 2.6049175261277924e-08
so O 0 6.3991678622699055e-09
far O 0 7.432036142063225e-08
. O 0 3.007993711889867e-07

Recent O 0 4.1395591665605025e-07
studies O 0 1.3409265875452547e-07
in O 0 1.670677107767915e-08
animal O 0 1.667614668576789e-08
models O 0 1.9010061080848573e-08
elucidated O 0 1.142660607911239e-06
a O 0 2.5091225097639835e-08
central O 0 6.931503548912588e-08
role O 0 1.1662889676244959e-07
of O 0 2.6533510322224174e-07
alpha O 0 9.71458121057367e-06
- O 0 1.440358846593881e-05
MSH O 0 0.0001451540010748431
in O 0 4.597970004738272e-09
the O 0 2.141797850185867e-09
regulation O 0 2.6516378426322262e-08
of O 0 2.1844739350740383e-09
food O 0 1.0848761888837544e-09
intake O 0 3.560129691049241e-10
by O 0 2.2552765210903658e-11
activation O 0 2.757775785511285e-09
of O 0 6.158141108159043e-09
the O 0 2.5457687513608107e-08
brain O 0 3.449005589573062e-06
melanocortin O 0 3.653584644780494e-05
- O 0 1.0860599104489665e-06
4 O 0 3.9762286974109884e-07
- O 0 1.8541315682796267e-07
receptor O 0 3.42272841180602e-08
( O 0 2.869089854584672e-08
MC4 O 0 6.198047049110755e-05
- O 0 4.482535132410703e-06
R O 0 1.8921737137134187e-05
; O 0 1.4047545349171742e-08
refs O 0 2.5503677534288727e-06
3 O 0 4.229904675412399e-07
- O 0 9.592742600261772e-08
5 O 0 1.2861060660895873e-08
) O 0 2.399037080103028e-10
and O 0 2.783791530625024e-10
the O 0 2.060021708771842e-09
linkage O 0 2.2021274048711348e-07
of O 0 6.980646816145963e-08
human O 0 9.949438890544116e-07
obesity B-Disease 1 0.9998353719711304
to O 0 3.749221377802314e-08
chromosome O 0 3.515867092573899e-06
2 O 0 2.0076729470019927e-06
in O 0 3.270528381449367e-08
close O 0 2.4872807102838124e-07
proximity O 0 2.172819790757785e-07
to O 0 1.2914721736478896e-08
the O 0 1.0462235877639614e-07
POMC O 0 0.000454537890618667
locus O 0 5.717816975447931e-07
, O 0 4.531447217459572e-08
led O 0 2.348705585575317e-08
to O 0 1.799962512372133e-09
the O 0 2.632617457365427e-09
proposal O 0 7.761461695565686e-09
of O 0 3.984968355297269e-09
an O 0 2.1682600159778076e-09
association O 0 6.37323793739597e-08
of O 0 5.625354901894752e-07
POMC O 1 0.889382541179657
with O 0 1.1918357358808862e-06
human O 0 0.000623083848040551
obesity B-Disease 1 0.9999998807907104
. O 0 4.3207724957028404e-05

The O 0 6.367927767314541e-07
dual O 0 1.7627723991608946e-06
role O 0 1.6275546386168571e-06
of O 0 6.734183557455253e-07
alpha O 0 3.7738620449090376e-05
- O 0 3.845438186544925e-05
MSH O 0 0.00039222848135977983
in O 0 2.8641197857837142e-08
regulating O 0 8.13183362424752e-07
food O 0 3.875922516272112e-08
intake O 0 8.411487328885414e-08
and O 0 1.0113398118960504e-08
influencing O 0 9.735455932968762e-06
hair O 0 3.5765542634180747e-06
pigmentation O 0 1.2072898243786767e-05
predicts O 0 2.0731710037580342e-07
that O 0 5.666826452532803e-10
the O 0 2.617906114110724e-09
phenotype O 0 7.447173988595068e-09
associated O 0 8.663143979958932e-09
with O 0 1.8918682176405355e-09
a O 0 8.341842061554416e-08
defect O 0 3.934966116503347e-06
in O 0 9.82511778602202e-08
POMC O 0 0.0005923458957113326
function O 0 2.2880035999151005e-07
would O 0 2.22735607735558e-08
include O 0 5.818065460516664e-07
obesity B-Disease 1 0.9999997615814209
, O 0 3.448809948736198e-08
alteration O 0 1.732358032313641e-05
in O 0 1.3026416354477988e-06
pigmentation O 0 0.32660162448883057
and O 0 0.00025827003992162645
ACTH B-Disease 1 0.9999932050704956
deficiency I-Disease 1 0.9999986886978149
. O 0 0.00010606241266941652

The O 0 6.119720410424634e-07
observation O 0 1.0986077541019768e-05
of O 0 7.018723380269876e-08
these O 0 1.5952268839214412e-08
symptoms O 0 7.439693945343606e-07
in O 0 4.978565559810022e-09
two O 0 5.1126254341227195e-09
probands O 0 8.473238040096476e-07
prompted O 0 1.1282482503816027e-08
us O 0 1.5848026224674072e-09
to O 0 2.1000340355570302e-10
search O 0 2.985172775638034e-09
for O 0 2.106196328455212e-09
mutations O 0 9.539735223995649e-09
within O 0 2.449760039269222e-08
their O 0 3.305875395653857e-08
POMC O 0 0.0032551405020058155
genes O 0 1.4388815543497913e-06
. O 0 2.1939595171716064e-06

Patient O 0 0.00013008688983973116
1 O 0 1.773339135979768e-05
was O 0 1.5234605825753533e-06
found O 0 4.405996900658238e-09
to O 0 6.629236604105415e-10
be O 0 1.0884826373569467e-09
a O 0 3.3141949185022668e-09
compound O 0 2.8637920479468448e-08
heterozygote O 0 1.8292702463895694e-07
for O 0 2.6232043204288402e-09
two O 0 1.6758786580695073e-09
mutations O 0 3.5071170412237507e-09
in O 0 8.6805949095492e-09
exon O 0 1.5872468566158204e-06
3 O 0 2.8465922241593944e-07
( O 0 9.508199561025776e-09
G7013T O 0 5.962982640994596e-07
, O 0 1.1605068905851113e-08
C7133delta O 0 8.141020657603804e-07
) O 0 1.902985991009132e-09
which O 0 2.0134520439807346e-10
interfere O 0 8.405336426875465e-10
with O 0 1.4096056266676982e-10
appropriate O 0 4.793678787251565e-09
synthesis O 0 3.20560715749707e-08
of O 0 3.607977916431082e-08
ACTH O 0 2.400789298917516e-06
and O 0 1.1386342180230713e-07
alpha O 0 7.855781586840749e-05
- O 0 0.0003409883356653154
MSH O 0 0.027339667081832886
. O 0 4.032958258903818e-06

Patient O 0 6.6871551098302e-05
2 O 0 9.44309704209445e-06
was O 0 6.565544481418328e-07
homozygous O 0 2.0843691217464766e-08
for O 0 9.761507158145832e-10
a O 0 2.74557332424763e-09
mutation O 0 3.2893694434932286e-09
in O 0 1.3781097152332222e-08
exon O 0 1.5996225783965201e-06
2 O 0 5.885597715860058e-07
( O 0 6.475453773191475e-08
C3804A O 0 1.2684361081483075e-06
) O 0 1.6417887493958006e-08
which O 0 1.6925580936799633e-08
abolishes O 0 4.655137217923766e-06
POMC O 0 0.001186007633805275
translation O 0 2.430292806820944e-05
. O 0 7.955643013701774e-06

These O 0 1.7201426771862316e-07
findings O 0 5.824378135343977e-08
represent O 0 8.35988611669336e-09
the O 0 1.7927057616162756e-09
first O 0 1.714093422755525e-09
examples O 0 5.427868821072934e-09
of O 0 1.7132935070662825e-08
a O 0 3.130122649963596e-07
genetic B-Disease 1 0.9998683929443359
defect I-Disease 1 0.9999663829803467
within O 0 2.3567440621263813e-06
the O 0 8.782585609878879e-07
POMC O 0 0.000978420372121036
gene O 0 6.921304418483487e-08
and O 0 5.266453051433473e-09
define O 0 8.901245251990986e-08
a O 0 7.583753358630929e-08
new O 0 6.278530122472148e-07
monogenic B-Disease 1 0.9999997615814209
endocrine I-Disease 1 0.999998927116394
disorder I-Disease 1 0.9374975562095642
resulting O 0 2.9031738790763484e-07
in O 0 1.472507005217949e-08
early O 0 3.5678770018421346e-06
- O 0 0.19198471307754517
onset O 1 0.999998927116394
obesity B-Disease 1 1.0
, O 0 0.27873340249061584
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.9996843338012695
red O 1 0.9972146153450012
hair O 1 0.9514512419700623
pigmentation O 0 0.042222049087285995
. O 0 1.0551590321483673e-06
. O 0 3.934320830012439e-06

A O 0 7.98202927398961e-06
European O 0 1.757268478286278e-06
multicenter O 0 6.588317774003372e-05
study O 0 1.5885748894106655e-07
of O 0 1.8396515315544093e-06
phenylalanine B-Disease 1 0.999998927116394
hydroxylase I-Disease 1 0.9999991655349731
deficiency I-Disease 1 1.0
: O 0 1.8345218677495723e-07
classification O 0 1.8120632603313425e-06
of O 0 4.0579874394097715e-07
105 O 0 1.187372618005611e-06
mutations O 0 1.3163139023220083e-08
and O 0 2.3506359081437722e-09
a O 0 4.0256868949484215e-09
general O 0 4.897183991658949e-09
system O 0 8.03832023166251e-09
for O 0 1.3123273578941053e-09
genotype O 0 5.4497292012456455e-08
- O 0 4.9268297885873835e-08
based O 0 3.6192382424360403e-09
prediction O 0 2.551033730924246e-07
of O 0 5.112574967824912e-07
metabolic O 0 0.03485095500946045
phenotype O 0 1.5505729606957175e-05
. O 0 9.780534128367435e-06

Phenylketonuria B-Disease 1 0.9994819760322571
( O 0 5.669892925652675e-05
PKU B-Disease 1 0.8513263463973999
) O 0 6.058739927539136e-07
and O 0 9.304042123403633e-07
mild B-Disease 1 0.9873939752578735
hyperphenylalaninemia I-Disease 1 1.0
( O 0 0.02928943932056427
MHP B-Disease 1 1.0
) O 0 4.122512393678335e-07
are O 0 2.376368790635297e-08
allelic B-Disease 0 0.006169011816382408
disorders I-Disease 1 0.9998548030853271
caused O 0 3.626883824381366e-07
by O 0 3.1471070194299955e-09
mutations O 0 1.1861549076286337e-08
in O 0 6.740317193276724e-09
the O 0 1.187021769766261e-08
gene O 0 8.924330785475831e-08
encoding O 0 1.8164093944506021e-06
phenylalanine O 0 5.6391680118395016e-05
hydroxylase O 0 0.004157357383519411
( O 0 6.42070226604119e-05
PAH O 1 0.9999935626983643
) O 0 2.6943182092509232e-05
. O 0 3.498203295748681e-05

Previous O 0 1.1091008218500065e-06
studies O 0 3.7527811969084723e-07
have O 0 5.4370703495010275e-09
suggested O 0 1.9719474053658814e-08
that O 0 1.9702348086347854e-10
the O 0 4.3233966406930335e-10
highly O 0 1.5074437698103793e-08
variable O 0 6.053645762449378e-08
metabolic O 0 2.189699443988502e-05
phenotypes O 0 2.8376985028444324e-06
of O 0 0.0006841579452157021
PAH B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
correlate O 0 0.00281985173933208
with O 0 0.006920367479324341
PAH O 1 1.0
genotypes O 1 0.9895871877670288
. O 0 0.00023731443798169494

We O 0 3.8207340935514367e-07
identified O 0 1.5321531066092575e-07
both O 0 8.522672345634419e-09
causative O 0 9.066828283721406e-07
mutations O 0 5.9496510829148974e-08
in O 0 2.332219750655895e-08
686 O 0 1.448234797862824e-06
patients O 0 1.4100028522534558e-07
from O 0 3.744932897120634e-08
seven O 0 9.370062770130971e-08
European O 0 7.475867391804059e-07
centers O 0 4.437831194081809e-06
. O 0 1.5326018001360353e-06

On O 0 4.35543256571691e-07
the O 0 1.581774533576663e-08
basis O 0 2.3066142773586762e-08
of O 0 2.7056583640217013e-09
the O 0 1.2004958138689403e-09
phenotypic O 0 8.32620088431213e-08
characteristics O 0 4.10794740446363e-08
of O 0 4.166895806179127e-08
297 O 0 6.795490321565012e-07
functionally O 0 2.8117459805798717e-05
hemizygous O 0 6.111937545938417e-05
patients O 0 1.4902516909387487e-07
, O 0 6.3660428040179795e-09
105 O 0 6.146010633756305e-08
of O 0 1.2978158991927558e-08
the O 0 9.613015272691428e-09
mutations O 0 1.001599336802883e-08
were O 0 5.324387153393673e-09
assigned O 0 2.9029154191562156e-08
to O 0 7.213640240699704e-10
one O 0 1.013588990517178e-09
of O 0 4.12316625286735e-09
four O 0 2.319907155268197e-09
arbitrary O 0 1.8965296888495686e-08
phenotype O 0 6.956415887771072e-08
categories O 0 3.474186485163955e-07
. O 0 1.0565173624854651e-06

We O 0 5.080539722257527e-07
proposed O 0 1.7907662197558238e-07
and O 0 7.682649183493595e-09
tested O 0 2.304710200462523e-08
a O 0 1.4162413464191559e-09
simple O 0 1.2269669724673804e-09
model O 0 9.962468627833232e-10
for O 0 4.21523010940561e-10
correlation O 0 5.971271033189396e-09
between O 0 1.8927424960679673e-08
genotype O 0 4.7358273747022395e-08
and O 0 7.397031431821688e-09
phenotypic O 0 2.321352667422616e-06
outcome O 0 6.047257556929253e-06
. O 0 3.0286637411336415e-06

The O 0 5.05012621943024e-07
observed O 0 4.469549139685114e-07
phenotype O 0 7.093471054986367e-08
matched O 0 4.927337471372084e-08
the O 0 9.350225482762653e-09
predicted O 0 4.141872622653864e-08
phenotype O 0 4.4541512700391195e-09
in O 0 1.144682348908077e-09
79 O 0 2.4842078616416075e-08
% O 0 4.436981004829477e-09
of O 0 5.010813097783284e-09
the O 0 2.5879198783940183e-09
cases O 0 1.873790234085959e-09
, O 0 2.0898925645607136e-10
and O 0 1.1311473979702669e-10
in O 0 3.873605325388496e-10
only O 0 1.924506248807134e-10
5 O 0 4.043016144095191e-09
of O 0 4.4260435316800795e-09
184 O 0 3.734718490022715e-08
patients O 0 2.1030503560837133e-08
was O 0 2.4740508308696008e-08
the O 0 2.62961674657447e-09
observed O 0 5.498695276884291e-09
phenotype O 0 8.410612761799996e-10
more O 0 1.1834487556594553e-10
than O 0 9.525397137721825e-11
one O 0 1.7298476540084096e-10
category O 0 4.0861820593818265e-09
away O 0 5.16798026595211e-09
from O 0 2.052644054728603e-09
that O 0 1.031207452761862e-09
expected O 0 9.224212504932439e-08
. O 0 2.785282049444504e-07

Among O 0 6.285869176281267e-07
the O 0 5.702004202134958e-08
seven O 0 3.336528564545915e-08
contributing O 0 8.68772147555319e-08
centers O 0 1.3765859563363847e-08
, O 0 3.446715135524414e-10
the O 0 3.5304037471206584e-10
proportion O 0 5.695805604943871e-09
of O 0 1.869022447920088e-08
patients O 0 1.6695176796588385e-08
for O 0 2.604165993957963e-09
whom O 0 1.6248293377429945e-08
the O 0 3.790593172681156e-09
observed O 0 1.0561537422404399e-08
phenotype O 0 3.6161815764046423e-09
did O 0 1.4851654350778176e-09
not O 0 3.520787827948624e-10
match O 0 1.6919091905265304e-08
the O 0 3.4431426598757753e-09
predicted O 0 2.6580485368299378e-08
phenotype O 0 3.955768157481998e-09
was O 0 4.189352864614193e-08
4 O 0 3.1935542210703716e-08
% O 0 6.91697277233061e-09
- O 0 9.659962074692885e-08
23 O 0 1.0153623719588722e-07
% O 0 3.334690035217136e-08
( O 0 2.7963642068584704e-08
P O 0 1.0109617505804636e-05
< O 0 1.07687151285063e-06
. O 0 1.6869178054434997e-08
0001 O 0 1.4636323612648994e-05
) O 0 1.2270962024274468e-08
, O 0 6.633717575255105e-09
suggesting O 0 1.638138336090833e-08
that O 0 3.377626511813503e-10
differences O 0 1.1870874949693189e-08
in O 0 1.0370775349599626e-09
methods O 0 4.444688617155634e-09
used O 0 7.584122219128631e-10
for O 0 4.422665567105355e-10
mutation O 0 4.7065231711940214e-09
detection O 0 1.7454722467391548e-07
or O 0 8.329501532955419e-09
phenotype O 0 2.4809073906340018e-08
classification O 0 1.3011327837375575e-07
may O 0 1.4483789279040593e-08
account O 0 1.325521803430263e-09
for O 0 4.5878581489411374e-10
a O 0 1.3200593951268047e-09
considerable O 0 1.0749979573176915e-08
proportion O 0 2.810191013224994e-08
of O 0 7.929489953539814e-08
genotype O 0 4.5020196921541356e-06
- O 0 3.1936218874761835e-05
phenotype O 0 2.8331069188425317e-06
inconsistencies O 0 1.652455102885142e-05
. O 0 8.815783075988293e-06

Our O 0 5.526476911654754e-07
data O 0 3.993500854448939e-07
indicate O 0 1.012002002198642e-07
that O 0 4.543440290660783e-09
the O 0 1.345531757124263e-07
PAH O 1 0.9999775886535645
- O 0 4.772996180690825e-05
mutation O 0 8.330966494440872e-08
genotype O 0 1.9947094642702723e-07
is O 0 4.343848392096561e-09
the O 0 1.9070627299555554e-09
main O 0 4.149613630488602e-08
determinant O 0 3.1442348813470744e-07
of O 0 3.646200497087193e-08
metabolic O 0 4.08935229643248e-05
phenotype O 0 4.0953523239295464e-08
in O 0 5.401595171150575e-09
most O 0 1.881085509580771e-08
patients O 0 1.1514842981341644e-06
with O 0 0.0001550023298477754
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 1 0.9113710522651672

In O 0 2.6565211896922847e-07
the O 0 1.8743202545579152e-08
present O 0 2.271070087545013e-08
study O 0 8.79592754188252e-09
, O 0 1.0188359045315565e-09
the O 0 1.2860195131025876e-09
classification O 0 5.7140020714996353e-08
of O 0 1.58024917595867e-07
105 O 0 4.579547021421604e-05
PAH O 1 0.9999978542327881
mutations O 0 5.246544674264442e-07
may O 0 2.6072239478480697e-08
allow O 0 3.4833436135528473e-09
the O 0 6.376980277167377e-09
prediction O 0 4.928653396518712e-08
of O 0 3.866985398559564e-09
the O 0 5.87337156687795e-09
biochemical O 0 1.2220726830491913e-07
phenotype O 0 1.6635354427307902e-08
in O 0 7.30073690391464e-09
> O 0 1.778039120381436e-07
10 O 0 3.001474269126447e-08
, O 0 5.038077510732819e-09
000 O 0 3.427863504157358e-08
genotypes O 0 1.2208332123009313e-07
, O 0 2.1952166751049162e-09
which O 0 2.3027831030919543e-10
may O 0 6.82400858043053e-10
be O 0 1.875942040596712e-10
useful O 0 1.8714971794508983e-09
for O 0 1.1534198596230283e-10
the O 0 1.1570936431226642e-09
management O 0 1.3573864521276846e-07
of O 0 5.977655064270948e-07
hyperphenylalaninemia B-Disease 1 0.9999973773956299
in O 0 1.3874906699129497e-06
newborns O 0 5.763042736361967e-06
. O 0 2.219109774159733e-06

Somatic O 0 0.0006525763892568648
instability O 0 0.00024535894044674933
of O 0 1.5832284816497122e-06
the O 0 6.472552627201367e-07
CTG O 0 0.040025919675827026
repeat O 0 1.9189130853192182e-06
in O 0 7.083965414267368e-08
mice O 0 2.0501397557382006e-07
transgenic O 0 8.584378008436033e-08
for O 0 3.5481480864518744e-08
the O 0 0.0005374215543270111
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 0.0004957366618327796
is O 0 5.8958111281981473e-08
age O 0 1.2926136605528882e-07
dependent O 0 1.2812606087209133e-08
but O 0 6.172166111539923e-10
not O 0 2.2833161750224207e-10
correlated O 0 3.9271701446352836e-09
to O 0 4.1487074886603637e-10
the O 0 2.129666443195788e-09
relative O 0 2.583624052476807e-07
intertissue O 0 3.2859868497325806e-06
transcription O 0 9.563327694195323e-07
levels O 0 5.297733309816977e-07
and O 0 8.582953370250834e-08
proliferative O 0 0.0557376854121685
capacities O 0 0.00019811431411653757
. O 0 7.275825737451669e-06

A O 0 0.0001895716559374705
( O 0 2.1864191239728825e-06
CTG O 0 0.0005691574770025909
) O 0 1.6492437282522587e-07
nexpansion O 0 5.6321528063563164e-06
in O 0 1.683279649000724e-08
the O 0 3.3949913103015206e-08
3 O 0 6.363047191371152e-07
- O 0 6.768519824618124e-07
untranslated O 0 9.943963232217357e-05
region O 0 6.93433264586929e-07
( O 0 4.6080863569386565e-08
UTR O 0 6.390515045495704e-05
) O 0 1.0189238786040278e-08
of O 0 3.2131854510453195e-08
the O 0 3.8671467450512864e-07
DM O 1 0.9999994039535522
protein O 0 2.063890633507981e-06
kinase O 0 3.581058649615443e-07
gene O 0 5.329084018512731e-08
( O 0 3.038216433992602e-08
DMPK O 0 2.4564318664488383e-05
) O 0 1.2832268581064454e-08
is O 0 4.634933770120142e-09
responsible O 0 6.213927861153934e-08
for O 0 3.4607276688802813e-07
causing O 1 0.9999980926513672
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9927043914794922
DM B-Disease 1 1.0
) O 0 3.079242378589697e-05
. O 0 1.221283309860155e-05

Major O 0 0.00011823941895272583
instability O 0 0.11374165862798691
, O 0 9.825811986274857e-08
with O 0 6.650059614088377e-09
very O 0 1.357815815339336e-08
large O 0 9.977724424459211e-09
expansions O 0 4.3554567952241996e-08
between O 0 3.207050269793399e-08
generations O 0 2.2509393460268257e-08
and O 0 1.7836641053037283e-09
high O 0 3.861769215518507e-08
levels O 0 4.165362099683989e-08
of O 0 3.568093731587396e-08
somatic O 0 9.412189001523075e-07
mosaicism O 0 6.791581836296245e-05
, O 0 8.800794759622477e-09
is O 0 1.3673426835225655e-09
observed O 0 1.501778790213848e-08
in O 0 1.5870448066834797e-08
patients O 0 2.6965466304318397e-07
. O 0 5.760887802352954e-07

There O 0 9.21424032185314e-07
is O 0 3.7813954634202673e-08
a O 0 1.083929479506196e-08
good O 0 1.161591889342617e-08
correlation O 0 1.2648657232716687e-08
between O 0 2.2457333770375953e-08
repeat O 0 7.006497781958387e-08
size O 0 4.5305398543860065e-08
( O 0 4.738173853269245e-09
at O 0 1.2173797081516113e-08
least O 0 1.0697774888157596e-09
in O 0 1.981186770194654e-09
leucocytes O 0 2.618002952203824e-07
) O 0 2.9460871520115006e-09
, O 0 2.337678717267977e-09
clinical O 0 6.96385029641533e-08
severity O 0 1.1705343183621153e-07
and O 0 1.0574095377080539e-08
age O 0 1.1990315442744759e-06
of O 0 2.44868670051801e-06
onset O 0 0.010611755773425102
. O 0 1.099277324101422e-05

The O 0 3.735895734280348e-05
trinucleotide O 1 0.9787565469741821
repeat O 0 8.383543172385544e-05
instability O 0 0.0006657942431047559
mechanisms O 0 8.835623157210648e-05
involved O 0 2.0808001863770187e-06
in O 0 5.01983663525607e-07
DM B-Disease 1 1.0
and O 0 7.411806990376135e-08
other O 0 8.862112821361734e-08
human O 0 1.751120544213336e-05
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 6.263477558832165e-08
unknown O 0 8.36889012134634e-06
. O 0 2.9732809707638808e-06

We O 0 1.183132781079621e-06
studied O 0 3.6376055504661053e-05
somatic O 0 1.077385513781337e-05
instability O 0 2.8084925816074247e-06
by O 0 2.1568190788912034e-08
measuring O 0 5.978150511509739e-06
the O 0 2.0689007840246632e-07
CTG O 0 0.00020393868908286095
repeat O 0 2.396888021394261e-07
length O 0 1.4779488743954516e-08
at O 0 2.969274426334323e-08
several O 0 1.117082981672013e-09
ages O 0 1.1838834801380926e-08
in O 0 8.091786685149316e-10
various O 0 1.7013609410199138e-09
tissues O 0 1.5806918440830486e-08
of O 0 8.908889270742293e-08
transgenic O 0 7.645506912012934e-07
mice O 0 3.0582516075128297e-08
carrying O 0 2.5526002644937762e-08
a O 0 7.420251790790644e-08
( O 0 8.170875531732236e-08
CTG O 0 0.00013259511615615338
) O 0 3.973070406004808e-08
55expansion O 0 1.762699980645266e-06
surrounded O 0 1.546671057894855e-07
by O 0 2.563405709921085e-09
45 O 0 4.137395848147207e-08
kb O 0 2.760719553407398e-06
of O 0 9.937862444076018e-08
the O 0 7.990843187144492e-08
human O 0 4.858242732552753e-07
DM B-Disease 1 0.9999991655349731
region O 0 1.545129066471418e-06
, O 0 9.992466409869394e-09
using O 0 9.512172383097095e-09
small O 0 4.048280644042279e-08
- O 0 4.652806637750473e-07
pool O 0 4.397395514388336e-06
PCR O 0 2.9871505375922425e-06
. O 0 8.582844088778074e-07

These O 0 1.1874598158101435e-06
mice O 0 1.705529371065495e-06
have O 0 5.1313828741683665e-09
been O 0 1.809418170850563e-09
shown O 0 4.989428870061374e-10
to O 0 9.273735945836137e-11
reproduce O 0 3.3654357078916064e-09
the O 0 1.88917459453819e-09
intergenerational O 0 1.1202482852468165e-07
and O 0 1.0718859577707462e-08
somatic O 0 8.545869150111685e-07
instability O 0 1.6001214362404426e-06
of O 0 1.1373481356713455e-07
the O 0 1.2549702432806953e-07
55 O 0 4.686728516389849e-06
CTG O 0 0.0005902239354327321
repeat O 0 1.470381789658859e-06
suggesting O 0 1.1056669535491892e-07
that O 0 6.310574285350867e-10
surrounding O 0 1.3421042943662087e-08
sequences O 0 9.735053652093484e-09
and O 0 8.855345901004341e-10
the O 0 3.0859537147875926e-09
chromatin O 0 2.7038137773160997e-07
environment O 0 3.5251051855311744e-08
are O 0 4.985832302573101e-10
involved O 0 5.980731909716042e-09
in O 0 7.172061167182164e-09
instability O 0 4.583420832204865e-06
mechanisms O 0 4.3735453800763935e-05
. O 0 5.132235855853651e-06

As O 0 3.287540550900303e-07
observed O 0 9.554433688663266e-08
in O 0 4.433106326473535e-09
some O 0 5.218096510439807e-10
of O 0 2.7324396079109192e-09
the O 0 4.9960684478378425e-09
tissues O 0 8.625836045439428e-08
of O 0 1.2925351029480225e-06
DM B-Disease 1 1.0
patients O 0 6.975354608584894e-06
, O 0 8.086606939627927e-09
there O 0 3.1812477097048486e-09
is O 0 6.82481515745792e-10
a O 0 8.005694440704758e-10
tendency O 0 1.3036478563321907e-09
for O 0 1.2442722407968176e-09
repeat O 0 3.360543132657767e-08
length O 0 9.923122767929726e-09
and O 0 7.301070859000447e-09
somatic O 0 3.034142821434216e-07
mosaicism O 0 3.6959813769499306e-06
to O 0 1.2043396280247975e-09
increase O 0 5.055085683380867e-09
with O 0 1.731690568718136e-09
the O 0 8.312471599936089e-09
age O 0 2.7396069413043733e-07
of O 0 6.910356376010895e-08
the O 0 1.5698039135259023e-07
mouse O 0 1.2557333093354828e-06
. O 0 5.816672796754574e-07

Furthermore O 0 5.20225876243785e-06
, O 0 3.090832834118373e-08
we O 0 7.41367012224714e-09
observed O 0 5.271256764416421e-09
no O 0 1.0439402675643805e-09
correlation O 0 1.9164925202375116e-09
between O 0 2.4533453046871045e-09
the O 0 1.5667633856963903e-09
somatic O 0 1.698450269316254e-08
mutation O 0 2.519816133528252e-09
rate O 0 1.1748047867854439e-08
and O 0 7.420885683728784e-09
tissue O 0 2.561673227319261e-06
proliferation O 0 0.00018543248006608337
capacity O 0 9.127739758696407e-06
. O 0 1.7327573686998221e-06

The O 0 3.863482902488613e-07
somatic O 0 8.234330266532197e-07
mutation O 0 4.1890736213190394e-08
rates O 0 3.90108745307316e-08
in O 0 8.431766396199691e-10
different O 0 1.5176846446252057e-09
tissues O 0 2.8095479720491312e-08
were O 0 5.887807130733336e-09
also O 0 3.907413281822869e-10
not O 0 9.689547081359606e-11
correlated O 0 1.468602017773435e-09
to O 0 2.410200372615634e-10
the O 0 6.9562675619749825e-09
relative O 0 1.6331336155417375e-05
inter O 1 0.990402340888977
- O 0 5.347760452423245e-05
tissue O 0 3.204244194421335e-07
difference O 0 1.3736961079757748e-07
in O 0 2.067248372483732e-09
transcriptional O 0 8.048725419484981e-08
levels O 0 3.701536144262718e-08
of O 0 4.491457872290994e-09
the O 0 2.388923947549415e-09
three O 0 3.192182074229777e-09
genes O 0 2.3824808792483054e-09
( O 0 3.942781212629143e-09
DMAHP O 0 2.0968192984582856e-05
, O 0 3.527876302200639e-08
DMPK O 0 5.522950959857553e-05
and O 0 2.7358725063209022e-08
59 O 0 4.6227083316807693e-07
) O 0 1.0271054229349375e-08
surrounding O 0 6.602540736366791e-08
the O 0 2.872084792215901e-08
repeat O 0 2.8975725285818044e-07
. O 0 6.398157381681813e-08
. O 0 5.839205527990998e-07

A O 0 4.4239800445211586e-06
novel O 0 5.648955720971571e-07
missense O 0 3.559017386578489e-06
mutation O 0 7.056280537653947e-08
in O 0 2.226455642073688e-08
patients O 0 8.126750117298798e-08
from O 0 8.155507913443216e-08
a O 0 1.4299241684057051e-06
retinoblastoma B-Disease 0 0.09874191135168076
pedigree O 0 1.5680848264310043e-06
showing O 0 9.617090057645328e-08
only O 0 6.421799980671494e-09
mild O 0 2.0585936510997271e-07
expression O 0 1.5229515426540274e-08
of O 0 3.824765570925592e-08
the O 0 1.6576149164393428e-07
tumor B-Disease 0 3.837587428279221e-05
phenotype O 0 1.3586638942797435e-06
. O 0 2.0766685793205397e-06

We O 0 5.773526936536655e-07
have O 0 6.228153104359535e-09
used O 0 3.6394101066150597e-09
single O 0 2.015728028936792e-09
strand O 0 8.543309171216151e-09
conformation O 0 4.381158547062114e-09
polymorphism O 0 1.2904872725982841e-08
analysis O 0 7.167749727088335e-10
to O 0 2.0965200409062135e-10
study O 0 9.012417478970747e-10
the O 0 3.3701246238138083e-09
27 O 0 2.4371425411118253e-07
exons O 0 1.3370330975703837e-07
of O 0 1.5098608585617512e-08
the O 0 3.7384815243513e-08
RB1 O 0 1.584579877089709e-05
gene O 0 2.4782730534411712e-08
in O 0 3.4906464385642266e-09
individuals O 0 1.2867997778442941e-09
from O 0 9.119356292330849e-08
a O 0 3.4407156590532395e-07
family O 0 4.546606646727014e-08
showing O 0 8.854205901798196e-08
mild O 0 1.5381189655272465e-07
expression O 0 1.4416429827690536e-08
of O 0 8.451208088899875e-08
the O 0 6.07840604516241e-07
retinoblastoma B-Disease 0 0.0007810500683262944
phenotype O 0 3.5650032259582076e-06
. O 0 3.376791028131265e-06

In O 0 5.038426706960308e-07
this O 0 1.7586430089977512e-08
family O 0 7.142860525277683e-09
affected O 0 2.863888903803513e-09
individuals O 0 4.0915457133472444e-10
developed O 0 1.660537236602977e-07
unilateral B-Disease 0 3.6282472137827426e-06
tumors I-Disease 1 1.0
and O 0 8.881420399120543e-08
, O 0 7.861133966002853e-09
as O 0 5.164491945208738e-09
a O 0 1.1053454818110708e-09
result O 0 1.6684028603108914e-09
of O 0 9.372257636641734e-09
linkage O 0 1.2240461444434914e-07
analysis O 0 9.577766135748789e-09
, O 0 4.0970609127555235e-09
unaffected O 0 5.948675152467331e-08
mutation O 0 3.0748199542074417e-09
carriers O 0 1.0564559893566638e-08
were O 0 3.990718866475618e-09
also O 0 1.0083460733056882e-09
identified O 0 9.615655827133196e-09
within O 0 1.589398657131369e-08
the O 0 5.7959528731998944e-08
pedigree O 0 3.1569195471092826e-06
. O 0 8.885857596396818e-07

A O 0 3.057449021071079e-06
single O 0 1.036661103626102e-07
band O 0 2.879841929370741e-07
shift O 0 1.883793174783932e-07
using O 0 5.733697250320802e-08
SSCP O 0 2.821883936121594e-05
was O 0 1.8127012424429267e-07
identified O 0 1.4060089981171586e-08
in O 0 4.654512331114802e-09
exon O 0 4.875113290836453e-07
21 O 0 2.2720493930705743e-08
which O 0 1.86373069754886e-10
resulted O 0 3.5500959949530397e-09
in O 0 1.4689549576729632e-09
a O 0 1.0505183389852846e-08
missense O 0 1.387581818335093e-07
mutation O 0 8.085404346047653e-09
converting O 0 3.7024901189397497e-07
a O 0 4.138162239541998e-07
cys O 0 0.0182202085852623
- O 0 0.00015109495143406093
- O 0 6.552790728164837e-05
> O 0 6.435139312088722e-06
arg O 0 3.1756238172420126e-07
at O 0 2.746046732227114e-07
nucleotide O 0 2.5703062078719086e-07
position O 0 3.6957555948902154e-07
28 O 0 8.130135142891959e-07
in O 0 2.5174633933033874e-08
the O 0 1.6754967191445758e-07
exon O 0 3.915006163879298e-05
. O 0 1.929129666677909e-06

The O 0 5.878097795175563e-07
mutation O 0 1.316819151497839e-07
destroyed O 0 1.1793498515544343e-06
an O 0 2.6827921217886797e-08
NdeI O 0 3.710616738317185e-06
restriction O 0 4.4877953087052447e-07
enzyme O 0 2.8068546953363693e-07
site O 0 1.2828324997826712e-06
. O 0 1.8672641317607486e-06

Analysis O 0 6.7299024522071704e-06
of O 0 6.994339969423891e-07
all O 0 7.762738363226163e-08
family O 0 4.3343661104700004e-08
members O 0 1.5094857586106514e-09
demonstrated O 0 6.020079101887177e-09
that O 0 7.9602248403976e-11
the O 0 1.1322272008840173e-09
missense O 0 2.002079213525576e-07
mutation O 0 8.022761477377571e-08
co O 0 1.0745729014161043e-05
- O 0 7.450844350387342e-06
segregated O 0 1.908324748001178e-06
with O 0 3.4825614392275384e-08
patients O 0 9.865989341051318e-06
with O 0 3.1749219488119707e-05
tumors B-Disease 1 1.0
or O 1 0.5200253129005432
who O 0 1.1937777344428468e-05
, O 0 3.9307543886479834e-08
as O 0 6.021594778360395e-09
a O 0 1.545282346526733e-09
result O 0 1.7775271254905078e-09
of O 0 8.801751327780494e-09
linkage O 0 3.31273071196847e-07
analysis O 0 1.8635121890042683e-08
had O 0 2.438632051848799e-08
been O 0 5.74672309738844e-09
predicted O 0 2.008441057910204e-08
to O 0 7.898522946803155e-10
carry O 0 6.827448384427726e-09
the O 0 2.1313702802672196e-08
predisposing O 0 6.3881125242915004e-06
mutation O 0 1.0668641152733471e-06
. O 0 3.081017666772823e-06

These O 0 8.981741217439776e-08
observations O 0 6.719191105730715e-07
point O 0 7.321741009036487e-07
to O 0 1.9083882918380368e-08
another O 0 3.193596853634517e-08
region O 0 4.925101393382647e-08
of O 0 2.378155272708682e-08
the O 0 6.693251464184868e-08
RB1 O 0 4.1312971006846055e-05
gene O 0 3.372827350744956e-08
where O 0 7.388838874078374e-09
mutations O 0 3.0186104726936946e-09
only O 0 2.9490540565113577e-10
modify O 0 2.9822135871881983e-09
the O 0 1.7564095733391127e-09
function O 0 2.04797583336358e-08
of O 0 9.815037671501159e-09
the O 0 4.187745261674536e-09
gene O 0 3.1598703653656912e-09
and O 0 1.6629827515046713e-09
raise O 0 4.348374105234143e-09
important O 0 4.7324477669974385e-09
questions O 0 2.5943647230519673e-09
for O 0 1.3257442921243978e-09
genetic O 0 3.292490902140344e-08
counseling O 0 9.639457942967056e-08
in O 0 4.204472325852748e-09
families O 0 3.4864727771477533e-10
with O 0 1.0292700025615886e-09
these O 0 2.1401642680274335e-09
distinctive O 0 7.479604846594157e-08
phenotypes O 0 3.695498094202776e-07
. O 0 1.3550739197398798e-07
. O 0 1.2284438071219483e-06

Maternal B-Disease 0 0.0003230574366170913
disomy I-Disease 0 0.053828269243240356
and O 0 0.00025035141152329743
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 0.000544405251275748
with O 0 7.353664273068716e-07
gamete O 0 0.001842728815972805
complementation O 0 0.00012574237189255655
in O 0 2.6408265796362684e-08
a O 0 2.695358247706281e-08
case O 0 4.000605358100984e-08
of O 0 6.390790474597452e-08
familial O 0 5.092102128401166e-06
translocation O 0 8.030359822441824e-06
( O 0 1.9336042100803752e-07
3 O 0 8.886086675374827e-07
; O 0 1.3276580723697862e-08
15 O 0 7.950343672291638e-08
) O 0 8.268354889651164e-09
( O 0 1.836599139437567e-08
p25 O 0 2.191763769587851e-06
; O 0 3.3036311464229584e-08
q11 O 0 1.382418872708513e-06
. O 0 2.7419845949339106e-08
2 O 0 8.819365007184388e-07
) O 0 7.383446387621007e-08
. O 0 5.242467864263745e-07

Maternal B-Disease 0 0.2751676142215729
uniparental I-Disease 1 0.9999111890792847
disomy I-Disease 1 0.999482274055481
( I-Disease 0 0.00011187497148057446
UPD I-Disease 1 0.9999946355819702
) I-Disease 0 1.7735428059495462e-07
for I-Disease 0 9.44335454278189e-08
chromosome I-Disease 0 6.91525315232866e-07
15 I-Disease 0 8.395602435484761e-08
is O 0 1.5044845369516224e-09
responsible O 0 1.7060077794894823e-09
for O 0 2.891550887618166e-10
an O 0 2.7288546422532534e-10
estimated O 0 1.0675395012427202e-09
30 O 0 4.891023142050699e-09
% O 0 1.2309401276056064e-09
of O 0 1.7549529607308045e-09
cases O 0 7.72418662364771e-09
of O 0 3.7483105188584886e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999828338623047
PWS B-Disease 1 1.0
) O 0 8.873654587659985e-05
. O 0 1.813900234992616e-05

We O 0 5.524990456251544e-07
report O 0 3.894909283985726e-08
on O 0 8.338657764284108e-09
an O 0 5.320506812900305e-10
unusual O 0 6.026283028148782e-09
case O 0 4.420491972467744e-09
of O 0 3.7126568486200995e-09
maternal B-Disease 0 2.535989835905639e-07
disomy I-Disease 0 1.5565537978545763e-05
15 I-Disease 0 5.104575393488631e-07
in O 0 1.2731501897178532e-07
PWS B-Disease 1 0.9999994039535522
that O 0 4.156804678245862e-09
is O 0 7.250774980427366e-10
most O 0 2.2433509216934766e-10
consistent O 0 2.86996937326478e-09
with O 0 5.683691295388371e-10
adjacent O 0 1.5915622952888953e-07
- O 0 4.820849426323548e-07
1 O 0 5.529175837182265e-07
segregation O 0 5.288561055749597e-07
of O 0 5.351625276261984e-08
a O 0 9.64747783882558e-08
paternal O 0 3.4406173199386103e-07
t O 0 5.066474386694608e-07
( O 0 1.3116547847857873e-08
3 O 0 6.677185382386597e-08
; O 0 3.847511198529219e-09
15 O 0 3.865239861511327e-08
) O 0 4.346881521399837e-09
( O 0 1.5427326971462207e-08
p25 O 0 1.5166515368036926e-06
; O 0 1.5345857917736794e-08
q11 O 0 8.184310900105629e-07
. O 0 6.989983702965219e-09
2 O 0 5.319061102682099e-08
) O 0 5.970038352565155e-10
with O 0 1.0017441320897547e-09
simultaneous O 0 6.028515286971015e-08
maternal O 0 1.0309640856576152e-06
meiotic O 0 2.32882648560917e-05
nondisjunction O 0 1.5035398973850533e-05
for O 0 2.855175296190282e-07
chromosome O 0 1.3670946827915031e-05
15 O 0 6.596463663299801e-06
. O 0 2.8723479772452265e-06

The O 0 4.2872065932897385e-06
patient O 0 2.2033149434719235e-05
( O 0 1.6914582090521435e-07
J O 0 4.139916654821718e-06
. O 0 5.5639470808444e-09
B O 0 6.576762530130509e-07
. O 0 1.0446653542217632e-09
) O 0 5.300956895659681e-10
, O 0 5.422072235639064e-10
a O 0 4.444934642577891e-09
17 O 0 6.40138040353122e-08
- O 0 9.232961417637853e-08
year O 0 1.6752274234477227e-08
- O 0 1.1422662282711826e-06
old O 0 1.1405942359488108e-06
white O 0 5.1412900603509115e-08
male O 0 2.338940419122082e-07
with O 0 1.7598466683921288e-07
PWS B-Disease 1 1.0
, O 0 1.4202151987774414e-06
was O 0 3.947783625335433e-06
found O 0 7.1250623179253125e-09
to O 0 1.4755848765091173e-09
have O 0 7.21617654519946e-09
47 O 0 1.7355048953504593e-07
chromosomes O 0 2.55801513304732e-08
with O 0 5.981074302496836e-09
a O 0 9.763806474438752e-08
supernumerary O 0 2.986809704452753e-05
, O 0 8.513870142223823e-08
paternal O 0 2.2668846213491634e-06
der O 0 0.0018966635689139366
( O 0 7.792110068294278e-08
15 O 0 5.884542630951728e-08
) O 0 1.7514951711206095e-09
consisting O 0 5.740697250899984e-09
of O 0 7.580857719347023e-09
the O 0 1.3426598499677311e-08
short O 0 3.065399667434576e-08
arm O 0 2.8480721425694355e-07
and O 0 5.045963202832127e-09
the O 0 6.642228100872671e-08
proximal O 0 5.030507963965647e-05
long O 0 1.6415247046097647e-06
arm O 0 5.078542017145082e-06
of O 0 8.000090474524768e-07
chromosome O 0 4.677066954172915e-06
15 O 0 1.3312912869878346e-06
, O 0 1.359385493060472e-07
and O 0 4.5266961024026386e-07
distal O 1 0.5420695543289185
chromosome O 0 0.4913538694381714
arm O 1 0.9249798655509949
3p O 1 0.999796450138092
. O 0 0.0002637211582623422

The O 0 9.944526027538814e-06
t O 0 5.433067599369679e-06
( O 0 5.206728204143474e-08
3 O 0 1.1916193187744284e-07
; O 0 2.5407904669094705e-09
15 O 0 1.6389041235242985e-08
) O 0 7.364733267678503e-10
was O 0 1.0760810909005158e-08
present O 0 4.321566160481183e-10
in O 0 4.14044687424564e-10
the O 0 4.961254185253949e-10
balanced O 0 2.1372801306540623e-09
state O 0 2.7507979227792134e-10
in O 0 2.85554219159323e-10
the O 0 2.6842086331413384e-09
patients O 0 1.530668569671434e-08
father O 0 6.705569433052005e-08
and O 0 2.8428015497183878e-08
a O 0 1.0559592737990897e-06
sister O 0 2.4667324396432377e-05
. O 0 5.869550022907788e-06

Fluorescent O 0 5.814770702272654e-06
in O 0 1.190502771919455e-07
situ O 0 2.735001771725365e-06
hybridization O 0 7.747532748680896e-08
analysis O 0 1.4641332590770162e-08
demonstrated O 0 2.56743923898739e-08
that O 0 7.122435974338259e-10
the O 0 3.7755576443032624e-08
PWS B-Disease 1 0.9999991655349731
critical O 0 2.2531510239787167e-06
region O 0 3.961788479500683e-07
resided O 0 3.8652996181554045e-07
on O 0 7.511712141194948e-09
the O 0 3.817045790555085e-09
derivative O 0 1.3236912366210163e-07
chromosome O 0 1.0728516741664862e-07
3 O 0 2.528097553522457e-08
and O 0 1.0952927453899974e-09
that O 0 2.2131420307491823e-10
there O 0 1.0164988850647205e-09
was O 0 1.63898850047417e-08
no O 0 1.8655881284246334e-09
deletion O 0 2.3238010626869254e-08
of O 0 2.613487382063795e-08
the O 0 2.4439106027784874e-07
PWS B-Disease 1 1.0
region O 0 2.994375336129451e-06
on O 0 6.530525098469298e-08
the O 0 6.7259851022072326e-09
normal O 0 8.774249948828583e-08
pair O 0 5.259238022858881e-08
of O 0 4.030306399727124e-08
15s O 0 2.7177163701708196e-06
present O 0 8.990173938627777e-08
in O 0 3.4887654010162805e-07
J O 0 0.0009907009080052376
. O 0 4.304728463466745e-06

B O 0 0.06279348582029343
. O 0 0.0001616535009816289

Methylation O 0 3.748689323401777e-06
analysis O 0 8.183881163859041e-07
at O 0 2.7492355911817867e-06
exon O 0 5.9477833929122426e-06
alpha O 0 6.471589131251676e-07
of O 0 4.366719963400101e-08
the O 0 2.6886421977678765e-08
small O 0 8.429137210441695e-08
nuclear O 0 1.7020072846207768e-05
ribonucleoprotein O 0 6.689598376397043e-05
- O 0 4.058088052261155e-07
associated O 0 1.7746509684002376e-07
polypeptide O 0 1.7628715340833878e-06
N O 0 1.342760424449807e-05
( O 0 4.883288795554108e-08
SNRPN O 0 3.369369005667977e-05
) O 0 1.2091415868553668e-08
gene O 0 1.8793246070458736e-08
showed O 0 3.5707966361542276e-08
a O 0 4.211342385929129e-09
pattern O 0 5.678366221673059e-08
characteristic O 0 2.6769141570071042e-08
of O 0 1.8690865744019902e-08
only O 0 6.152411469173558e-09
the O 0 2.6011194975694707e-08
maternal O 0 8.152084092216683e-07
chromosome O 0 1.5592640920658596e-06
15 O 0 1.1625737670328817e-06
in O 0 6.117438715591561e-07
J O 0 0.001164057059213519
. O 0 8.306217750941869e-06

B O 0 0.09689043462276459
. O 0 0.00014191911031957716

Maternal B-Disease 0 0.001012281747534871
disomy I-Disease 0 0.0010624718852341175
was O 0 5.311798759066733e-06
confirmed O 0 1.3720766389724304e-07
by O 0 7.977469351772015e-09
polymerase O 0 7.506214956265467e-07
chain O 0 4.586760482538921e-08
reaction O 0 4.904896488966415e-09
analysis O 0 7.4788024662098e-09
of O 0 1.8806227686241073e-08
microsatellite O 0 6.847077429483761e-07
repeats O 0 4.6211656723471606e-08
at O 0 3.858463415440383e-08
the O 0 7.053209571949992e-09
gamma O 0 5.977655064270948e-07
- O 0 3.8511410593855544e-07
aminobutyric O 0 9.205562605529849e-07
acid O 0 8.278031060626745e-08
receptor O 0 1.91856770470622e-07
beta3 O 0 3.125691591776558e-06
subunit O 0 3.6278840980230598e-06
( O 0 3.4146822258662723e-07
GABRB3 O 0 9.411034261574969e-05
) O 0 4.805985440725635e-07
locus O 0 7.644444849574938e-06
. O 0 4.382524821266998e-06

A O 0 0.0002566467737779021
niece O 0 0.000319599115755409
( O 0 5.4334697097147e-07
B O 0 8.842357601679396e-06
. O 0 1.0555173624027248e-08
B O 0 9.165074743577861e-07
. O 0 1.1227585527961992e-09
) O 0 3.6683514559321395e-10
with O 0 6.585643697043508e-10
45 O 0 1.8864174222699148e-08
chromosomes O 0 4.2925449861286324e-09
and O 0 4.16264217539819e-10
the O 0 1.11564779636808e-09
derivative O 0 2.3680570393480593e-08
3 O 0 6.605511249091478e-09
but O 0 1.3392466302608597e-10
without O 0 9.517139298864663e-10
the O 0 2.433742540830508e-09
der O 0 1.4490425201074686e-05
( O 0 5.8670455160836354e-09
15 O 0 1.8770391463363012e-08
) O 0 1.6920408407727905e-09
demonstrated O 0 1.2622291656327889e-08
a O 0 4.796751884583728e-09
phenotype O 0 3.5743656923159506e-09
consistent O 0 1.3796086939521501e-08
with O 0 7.18492820794836e-10
that O 0 6.741779357000155e-10
reported O 0 3.2520086623577527e-09
for O 0 2.0707919823337306e-09
haploinsufficiency O 0 1.5466622471649316e-06
of O 0 1.4534924730469356e-07
distal O 0 3.345104050822556e-05
3 O 0 4.075951437698677e-05
p O 0 0.00012122740008635446
. O 0 2.6837035420612665e-06

Uniparental B-Disease 1 0.9999986886978149
disomy I-Disease 1 0.9997105002403259
associated O 0 4.457886916497955e-06
with O 0 4.79053703372756e-08
unbalanced O 0 1.4387812370841857e-05
segregation O 0 8.778350093052723e-06
of O 0 1.366217787790447e-07
non O 0 9.617824616725557e-06
- O 0 9.71485860645771e-06
Robertsonian O 0 3.8921862142160535e-05
translocations O 0 9.263465585718222e-07
has O 0 5.458412832837212e-09
been O 0 3.085724342710705e-09
reported O 0 4.19916679206267e-09
previously O 0 4.208708936914718e-09
but O 0 4.6456233304681405e-10
has O 0 1.5142459508510342e-10
not O 0 1.5885182058639202e-10
, O 0 1.6798397395323406e-10
to O 0 1.3824258404682155e-10
our O 0 1.6727170759622823e-09
knowledge O 0 4.172391498968864e-08
, O 0 9.429703684560309e-10
been O 0 8.550706254162321e-10
observed O 0 1.3955882005589615e-09
in O 0 8.063607559449792e-10
a O 0 6.1240790216743335e-09
case O 0 6.780653905025247e-08
of O 0 7.093449880812841e-07
PWS B-Disease 1 0.9999995231628418
. O 0 3.15663855872117e-05

Furthermore O 0 1.2080534361302853e-05
, O 0 6.41538733248126e-08
our O 0 9.717282090093704e-09
findings O 0 3.659520020349305e-09
are O 0 8.309340715495495e-11
best O 0 3.6199132580350124e-10
interpreted O 0 1.3577011737098132e-09
as O 0 1.7988334155560892e-09
true O 0 1.8260470469044776e-08
gamete O 0 5.839689833919692e-07
complementation O 0 2.5590165932953823e-06
resulting O 0 2.7024600512959296e-07
in O 0 3.582824774639448e-07
maternal B-Disease 0 0.00030691828578710556
UPD I-Disease 1 0.9999988079071045
15 I-Disease 0 0.0005167237250134349
and O 0 0.00014630373334512115
PWS B-Disease 1 0.9999997615814209

Schwartz B-Disease 1 0.9887526631355286
- I-Disease 1 0.9999098777770996
Jampel I-Disease 1 0.9999884366989136
syndrome I-Disease 1 0.9999822378158569
type I-Disease 0 3.6972032830817625e-05
2 I-Disease 0 5.6484182096028235e-06
and O 0 9.300177339355287e-08
Stuve B-Disease 1 0.99970942735672
- I-Disease 1 0.9999690055847168
Wiedemann I-Disease 1 0.9999978542327881
syndrome I-Disease 1 0.9997389912605286
: O 0 3.4865891507251945e-08
a O 0 3.210098142858442e-08
case O 0 2.6704885414119417e-08
for O 0 2.8928102135949985e-09
" O 0 3.300268147654606e-08
lumping O 0 6.213270467014809e-07
" O 0 7.02525881024485e-07
. O 0 7.278243288055819e-07

Recent O 0 3.562334711659787e-07
studies O 0 7.75681812115181e-08
demonstrated O 0 3.996632003122613e-08
the O 0 7.219080888631879e-09
existence O 0 1.7839303367850334e-08
of O 0 1.0572179576229246e-08
a O 0 9.470606521233549e-09
genetically O 0 4.856664848063019e-09
distinct O 0 1.977720653911774e-09
, O 0 8.723878286431841e-10
usually O 0 5.826405469200324e-10
lethal O 0 2.2136328325927934e-09
form O 0 3.76532777179861e-10
of O 0 1.6708485706118381e-09
the O 0 1.5006163422981444e-08
Schwartz B-Disease 0 0.0016215350478887558
- I-Disease 1 0.8470105528831482
Jampel I-Disease 1 0.9999805688858032
syndrome I-Disease 1 0.999997615814209
( O 0 3.723307145264698e-06
SJS B-Disease 1 0.9999983310699463
) O 0 5.130368094796722e-07
of O 0 6.4884836319834e-05
myotonia B-Disease 1 1.0
and O 1 0.6943739056587219
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 9.525248970021494e-06
which O 0 5.034420524907546e-08
we O 0 6.069635816174923e-08
called O 0 1.5845124607949401e-06
SJS B-Disease 1 0.9999889135360718
type I-Disease 0 0.00021286441187839955
2 I-Disease 0 7.120046211639419e-05
. O 0 4.216571596771246e-06

This O 0 1.018727402879449e-06
disorder O 1 0.9996514320373535
is O 0 1.620640830424236e-07
reminiscent O 0 8.804441677057184e-06
of O 0 2.1877845313156286e-07
another O 0 6.162443355606229e-08
rare O 0 4.885077586891384e-08
condition O 0 4.5518646629716386e-07
, O 0 8.240754745258982e-09
the O 0 5.344250197936162e-08
Stuve B-Disease 1 0.997159481048584
- I-Disease 1 0.9999957084655762
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.7068252418539487e-05
SWS B-Disease 0 0.2921505570411682
) O 0 9.474422313360265e-08
, O 0 1.2889129763493656e-08
which O 0 1.9930421757408112e-09
comprises O 0 3.308625551312616e-08
campomelia B-Disease 0 3.3785918276407756e-06
at O 0 9.156661349152273e-07
birth O 0 9.45844021771336e-07
with O 0 1.0861097052838886e-06
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 0.01879691332578659
contractures B-Disease 1 0.9999959468841553
, O 0 1.493747731728945e-06
and O 0 1.5324044966291694e-07
early B-Disease 0 1.0326652045478113e-05
death I-Disease 0 7.871646630519535e-06
. O 0 3.244747858843766e-06

To O 0 1.4635001832630223e-07
test O 0 3.252922198271335e-08
for O 0 3.7189928914216352e-09
possible O 0 5.6413920646036786e-08
nosologic O 0 4.715160685009323e-06
identity O 0 6.139659802784081e-08
between O 0 1.1084753026580074e-07
these O 0 1.5676818065912812e-08
disorders O 0 0.03022145666182041
, O 0 3.033732820512114e-09
we O 0 8.949294638682659e-10
reviewed O 0 3.2552851525480264e-09
the O 0 2.709706070636031e-10
literature O 0 9.68382485311281e-10
and O 0 1.0015218515624369e-10
obtained O 0 1.2621321765493576e-09
a O 0 6.806070151910149e-10
follow O 0 5.398996805183742e-10
- O 0 4.3700087992704084e-09
up O 0 1.3187231306943659e-09
of O 0 2.96172752989321e-09
the O 0 2.408519605978654e-09
only O 0 1.300597962661243e-09
two O 0 3.878849241800708e-09
surviving O 0 1.6121467751872842e-06
patients O 0 6.935510299399539e-08
, O 0 1.2405240390478411e-08
one O 0 3.407302440194826e-09
with O 0 4.0115857302680524e-08
SJS B-Disease 1 0.9999557733535767
type I-Disease 0 1.247881300514564e-05
2 I-Disease 0 1.0272385679854779e-06
at O 0 1.9564751596590213e-07
age O 0 1.5454796198355325e-07
10 O 0 3.98682544755502e-08
years O 0 4.514200124816625e-09
and O 0 1.360469736866321e-09
another O 0 7.425133397021e-09
with O 0 9.26170695692008e-09
SWS B-Disease 0 2.9671751690329984e-05
at O 0 1.520973683000193e-06
age O 0 3.89232809538953e-06
7 O 0 5.396538654167671e-06
years O 0 9.379322136737755e-07
. O 0 2.117667463608086e-06

Patients O 0 1.2786791558028199e-05
reported O 0 2.1153411466912075e-07
as O 0 4.820839905050889e-08
having O 0 2.4442462631668604e-07
either O 0 1.3598145415016916e-05
neonatal O 1 0.9999996423721313
SJS B-Disease 1 1.0
or O 0 6.464053967647487e-06
SWS B-Disease 0 0.00017410666623618454
presented O 0 8.291146258443405e-08
a O 0 5.7711737611043645e-09
combination O 0 1.8088393005655234e-08
of O 0 2.694354517274178e-09
a O 0 7.207950236676197e-09
severe O 0 2.737118336426647e-07
, O 0 2.0113047227710013e-08
prenatal O 0 0.00020966028387192637
- O 1 0.5684865713119507
onset O 1 0.9999997615814209
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 0.0009872597875073552
with O 0 0.3423210382461548
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 0.9999653100967407
respiratory O 1 1.0
and O 0 0.0001688641932560131
feeding O 0 0.00019767897902056575
difficulties O 0 0.0038513222243636847
, O 0 5.982559514450259e-08
tendency O 0 8.27364274869069e-08
to O 0 3.242416468651754e-08
hyperthermia B-Disease 1 0.999994158744812
, O 0 4.333125858124731e-08
and O 0 6.803633656460306e-09
frequent O 0 6.827229981354321e-08
death O 0 8.016979080593956e-08
in O 0 1.7173832134176337e-08
infancy O 0 5.223618586569501e-07
) O 0 1.1304254199373531e-09
with O 0 9.963589953088103e-10
a O 0 8.127505779498279e-09
distinct O 0 8.006343676925098e-08
campomelic B-Disease 1 0.5693032145500183
- I-Disease 1 0.9931368827819824
metaphyseal I-Disease 1 0.9999089241027832
skeletal I-Disease 1 0.9999996423721313
dysplasia I-Disease 1 0.9999998807907104
. O 0 0.025935843586921692

The O 0 3.6740973996529647e-07
similarity O 0 7.754368311907456e-07
of O 0 2.598890773697349e-07
the O 0 6.411032416053786e-08
clinical O 0 1.4461037380897324e-06
and O 0 1.5439455935961632e-08
radiographic O 0 6.56820247968426e-06
findings O 0 6.14626785022665e-08
is O 0 3.1801676847464933e-09
so O 0 1.0151387508372522e-09
extensive O 0 3.840592199821913e-08
that O 0 8.235125359412621e-10
these O 0 5.5062203685452005e-09
disorders O 0 0.0034273213241249323
appear O 0 1.0912400227880426e-07
to O 0 4.276535570113538e-09
be O 0 1.029209606429049e-08
a O 0 2.0262907796109175e-08
single O 0 3.169052220641788e-08
entity O 0 2.3477705326513387e-06
. O 0 6.093465799494879e-06

The O 0 9.960670013242634e-07
follow O 0 5.676108116858813e-07
- O 0 1.0382872233094531e-06
up O 0 5.009668768707343e-08
observation O 0 5.062021273261053e-07
of O 0 7.355107189965793e-09
an O 0 5.310500372779359e-10
identical O 0 1.3310194058036018e-09
and O 0 2.2173418656734611e-10
unique O 0 3.5137321940936772e-09
pattern O 0 2.337905726790268e-07
of O 0 2.273320887979935e-06
progressive O 1 0.9999994039535522
bone B-Disease 1 1.0
dysplasia I-Disease 1 1.0
in O 0 1.009061361401109e-05
the O 0 6.344544999592472e-06
two O 0 1.858705900303903e-06
patients O 0 2.3844290808483493e-06
( O 0 1.4430625583372603e-08
one O 0 6.508562577778321e-09
with O 0 4.965907152154614e-08
SJS B-Disease 1 0.9999996423721313
type I-Disease 0 0.0013760036090388894
2 I-Disease 0 1.2313196748436894e-05
, O 0 5.628137511592968e-09
one O 0 2.4712150104022612e-09
with O 0 2.65063171411839e-08
SWS B-Disease 0 0.00063149823108688
) O 0 7.502794829861159e-08
surviving O 0 7.624226327607175e-06
beyond O 0 9.42293627304025e-06
infancy O 0 5.3951698646415025e-06
adds O 0 4.40626841680114e-08
to O 0 1.020648565663862e-09
the O 0 1.6974455174789682e-09
evidence O 0 1.5647184881117937e-08
in O 0 1.3891930938925157e-09
favor O 0 1.681052808066852e-08
of O 0 2.387490560806782e-08
identity O 0 3.973093782860815e-07
. O 0 1.178076217911439e-06

The O 0 9.382470693708456e-07
hypothesis O 0 2.7160167519468814e-06
that O 0 5.828145788200345e-08
SWS B-Disease 0 0.0005066972807981074
and O 0 9.027837108988024e-07
SJS B-Disease 1 0.9999980926513672
type I-Disease 0 0.0006492683314718306
2 I-Disease 0 2.563187990745064e-06
are O 0 1.000617477764365e-09
the O 0 1.0502172465010062e-09
same O 0 8.85528272931424e-09
disorder O 0 1.79889480023121e-06
should O 0 1.0619242152287711e-09
be O 0 4.800502217960911e-10
testable O 0 2.588897540789503e-09
by O 0 8.12335962385724e-11
molecular O 0 1.626509948948751e-08
methods O 0 2.6762196014828987e-08
. O 0 1.7877622937589877e-08
. O 0 6.528358085233776e-07

A O 0 1.0816744179464877e-05
mouse O 0 5.323222467268351e-07
model O 0 1.247681353788721e-07
of O 0 1.995931029341591e-07
severe O 1 0.9866522550582886
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 3.0475479434244335e-05
defects O 1 0.9828062653541565
in O 0 5.204670287639601e-06
hemostasis O 1 0.9999746084213257
and O 0 0.000411325047025457
thrombosis B-Disease 1 0.9999974966049194
. O 0 0.000926559092476964

von B-Disease 1 0.9315618276596069
Willebrand I-Disease 1 0.9997126460075378
factor I-Disease 0 0.00027668336406350136
( I-Disease 0 1.555880044179503e-05
vWf I-Disease 0 0.1901749223470688
) I-Disease 0 7.518594793509692e-05
deficiency I-Disease 1 0.9999996423721313
causes O 0 0.15754449367523193
severe O 1 0.9999997615814209
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 3.0193026759661734e-05
humans O 0 1.8008233382715844e-05
. O 0 3.5836010283674113e-06

We O 0 3.2775039926491445e-07
generated O 0 8.919158034359498e-08
a O 0 2.0334846695391207e-08
mouse O 0 7.331548257383247e-09
model O 0 1.3659560149648087e-09
for O 0 4.278230547605233e-10
this O 0 1.075930788907442e-09
disease O 0 1.4388822577870997e-08
by O 0 2.6202628955473983e-10
using O 0 1.1541053446251226e-08
gene O 0 9.972229975119262e-08
targeting O 0 8.705185337021248e-07
. O 0 1.2242088587299804e-06

vWf B-Disease 1 0.997141420841217
- I-Disease 1 0.9998636245727539
deficient I-Disease 1 0.9988390803337097
mice O 0 8.040598913794383e-06
appeared O 0 2.3105604896045406e-07
normal O 0 3.800100145667784e-08
at O 0 3.7419699339125145e-08
birth O 0 6.394983209645488e-09
; O 0 4.5052178654358954e-10
they O 0 6.098176408286804e-10
were O 0 6.240174599270176e-09
viable O 0 1.4595501340863848e-07
and O 0 2.7173635785970873e-08
fertile O 0 2.6164757400692906e-06
. O 0 1.2426268085619085e-06

Neither O 0 0.0004625830624718219
vWf O 0 0.0019336461555212736
nor O 0 0.00018556266149971634
vWf O 0 0.0010893874568864703
propolypeptide O 0 0.0007100681541487575
( O 0 2.137028104698402e-06
von B-Disease 0 0.016856620088219643
Willebrand I-Disease 1 0.5366535782814026
antigen O 0 6.219659553607926e-06
II O 1 0.9981654286384583
) O 0 3.648990087867787e-08
were O 0 1.9452633281957787e-08
detectable O 0 1.3946953458798816e-07
in O 0 3.819988325659551e-09
plasma O 0 3.0884348234394565e-07
, O 0 3.953263494338444e-09
platelets O 0 7.741962804175273e-08
, O 0 6.618702919070074e-09
or O 0 1.3606546112043816e-08
endothelial O 0 1.8228321607693942e-07
cells O 0 9.302621784001985e-09
of O 0 8.874558865556992e-09
the O 0 2.5638374978598222e-08
homozygous O 0 1.0514905852687662e-06
mutant O 0 7.438087322952924e-06
mice O 0 7.942604497657157e-06
. O 0 1.958515213118517e-06

The O 0 5.812397830595728e-06
mutant O 0 0.00022988120326772332
mice O 0 2.0295989088481292e-05
exhibited O 0 4.0361272112932056e-05
defects O 0 0.03407778590917587
in O 0 7.290163921425119e-07
hemostasis O 0 0.01176800113171339
with O 0 1.1160915391883464e-07
a O 0 1.0229820190943428e-06
highly O 0 0.0011851488379761577
prolonged O 1 0.9833582043647766
bleeding O 1 0.62406325340271
time O 0 2.2580093173019122e-07
and O 0 3.563353345725773e-08
spontaneous O 0 4.2337384797974664e-07
bleeding O 0 1.5357418305939063e-05
events O 0 1.180852482463024e-08
in O 0 4.992839031103813e-09
approximately O 0 5.544877446084229e-09
10 O 0 1.2753359257544616e-08
% O 0 1.7194514256857474e-08
of O 0 9.996492167374527e-08
neonates O 0 5.075249646324664e-06
. O 0 1.598262315383181e-06

As O 0 1.0460136081746896e-06
in O 0 4.496174810242337e-08
the O 0 3.116590008289677e-08
human O 0 2.409399257885525e-07
disease O 0 1.1328367008900386e-06
, O 0 1.6814690750877048e-09
the O 0 2.9724120942375976e-09
factor O 0 9.908298892469247e-08
VIII O 0 0.0006191047723405063
level O 0 2.0579293504852103e-06
in O 0 9.95347093635246e-09
these O 0 2.4753994409820734e-09
mice O 0 2.8472728175188422e-08
was O 0 2.1785998782775096e-08
reduced O 0 1.2615601008292288e-08
strongly O 0 2.4259101394363825e-09
as O 0 9.020844071727652e-10
a O 0 8.359419267911505e-10
result O 0 1.297151941415109e-09
of O 0 3.6626761623637094e-09
the O 0 3.0588567234701713e-09
lack O 0 1.713535269232125e-08
of O 0 1.3145751154297614e-08
protection O 0 1.1679106393103211e-07
provided O 0 5.091656518629861e-08
by O 0 3.9572714882751825e-08
vWf O 0 5.6562890677014366e-05
. O 0 5.8891737353405915e-06

Defective O 1 0.9993312358856201
thrombosis B-Disease 1 0.999717652797699
in O 0 8.808371603663545e-06
mutant O 0 0.00015283901302609593
mice O 0 3.629787443060195e-06
was O 0 1.9716169674666162e-07
also O 0 1.9557759856070334e-09
evident O 0 1.3733942871851923e-08
in O 0 4.8479625869291e-10
an O 0 1.6793400003933812e-10
in O 0 1.3312123625652816e-09
vivo O 0 1.3884115901419136e-07
model O 0 7.117472478057607e-08
of O 0 2.7944877274421742e-06
vascular B-Disease 1 0.9999996423721313
injury I-Disease 1 0.9999686479568481
. O 0 0.0008221892639994621

In O 0 4.8170994659813e-07
this O 0 2.274490462639278e-08
model O 0 1.0513265635836433e-07
, O 0 7.416442127095024e-09
the O 0 1.7572615362837496e-08
exteriorized O 0 1.5317065845010802e-05
mesentery O 0 4.854286089539528e-05
was O 0 1.6289258155666175e-06
superfused O 0 4.6457307689706795e-06
with O 0 2.6066969027738196e-08
ferric O 0 0.11938168853521347
chloride O 0 2.261950430693105e-05
and O 0 4.218354732188345e-08
the O 0 4.852852697467824e-08
accumulation O 0 3.5379582641326124e-06
of O 0 1.2632740435947198e-06
fluorescently O 0 0.00022111237922217697
labeled O 0 2.013598077610368e-06
platelets O 0 4.4802860088566376e-07
was O 0 9.406323187022281e-08
observed O 0 2.2796806220526378e-08
by O 0 7.156892856130526e-09
intravital O 0 5.73919533053413e-06
microscopy O 0 7.924899364297744e-06
. O 0 4.5216233957035e-06

We O 0 1.111646497520269e-06
conclude O 0 1.3498131465894403e-06
that O 0 3.6736886865895713e-09
these O 0 4.796825159303353e-09
mice O 0 6.923087170207509e-08
very O 0 6.1561795661191354e-09
closely O 0 5.882164089143771e-08
mimic O 0 1.9990372948086588e-06
severe O 0 0.00012464575411286205
human O 0 3.774042124859989e-05
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 1.9130391137878178e-07
will O 0 1.1364208241104734e-08
be O 0 2.055613901319475e-09
very O 0 9.573414283536863e-10
useful O 0 1.531450521952138e-09
for O 0 1.8966074544213285e-10
investigating O 0 7.917562605541661e-09
the O 0 1.0224957547322333e-09
role O 0 2.99086231336787e-08
of O 0 5.4900521462286633e-08
vWf O 0 6.402200597221963e-06
in O 0 1.841415198100549e-08
normal O 0 3.8854454942338634e-07
physiology O 0 3.982213172548654e-07
and O 0 2.698376411203185e-09
in O 0 2.884838501415743e-08
disease O 0 8.186551099242934e-07
models O 0 3.07449887770872e-08
. O 0 4.3674113214819954e-08
. O 0 6.857154062345217e-07

Oral O 0 0.08402963727712631
contraceptives O 0 0.0038703782483935356
and O 0 2.135492493948732e-08
the O 0 3.48300019936687e-08
risk O 0 2.1424336864583893e-06
of O 0 0.0001166087095043622
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9979526996612549

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 0.9999998807907104
Clinical O 0 0.47687068581581116
Study O 0 6.874912287457846e-06
Group O 0 4.655962584365625e-06
. O 0 9.45702959143091e-06

BACKGROUND O 0 0.00021690898574888706
Women O 0 1.7512145689124736e-07
with O 0 1.3982879742968635e-08
mutations O 0 2.3901877810317274e-08
in O 0 8.46541770016529e-09
either O 0 4.614858895024554e-08
the O 0 3.055755826153472e-08
BRCA1 O 0 1.1924912257654796e-07
or O 0 6.7186252117323875e-09
the O 0 1.4120773883519178e-08
BRCA2 O 0 4.56854749586455e-08
gene O 0 7.938369961379976e-09
have O 0 3.528929370943956e-10
a O 0 1.532327154052382e-09
high O 0 6.146432696141346e-08
lifetime O 0 6.500786042806794e-08
risk O 0 2.484559445292689e-06
of O 0 0.0676008015871048
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0008809226565063

Oral O 1 0.9590669870376587
contraceptives O 1 0.998900294303894
protect O 0 0.00038201065035536885
against O 1 1.0
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.4613790426665219e-06
general O 0 1.0709253501772764e-06
, O 0 1.05796029714611e-08
but O 0 1.0437650743710947e-09
it O 0 2.7518526346526073e-10
is O 0 2.93279789342904e-10
not O 0 1.9217330504694985e-10
known O 0 1.0493023117064126e-09
whether O 0 1.2144244498912826e-09
they O 0 3.078779731158221e-10
also O 0 4.710382084383014e-10
protect O 0 3.5334506431894397e-09
against O 0 5.0795122774616175e-08
hereditary B-Disease 1 0.9931226372718811
forms I-Disease 0 0.02369166538119316
of I-Disease 1 0.9999990463256836
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.017278268933296204

METHODS O 0 2.725390913838055e-05
We O 0 5.132393994244921e-07
enrolled O 0 3.8204348129511345e-06
207 O 0 1.1736613032553578e-06
women O 0 4.2286014689807416e-08
with O 0 8.950016763265012e-07
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.3646913379925536e-06
161 O 0 2.113309619744541e-06
of O 0 5.171197585696063e-07
their O 0 6.705249688820913e-08
sisters O 0 7.837704174562532e-07
as O 0 2.0847986448302436e-08
controls O 0 2.6487978743716667e-07
in O 0 6.308326749859816e-09
a O 0 8.560778752553233e-09
case O 0 6.000089314284196e-08
- O 0 1.230692276976697e-07
control O 0 2.991145038322429e-07
study O 0 9.94076287952339e-08
. O 0 5.750217155764403e-07

All O 0 1.2420788664257998e-07
the O 0 8.580694554893853e-08
patients O 0 2.145008082266031e-08
carried O 0 1.4869794284777527e-09
a O 0 1.1096759067186213e-09
pathogenic O 0 4.3546988237608275e-09
mutation O 0 7.039551164211844e-10
in O 0 7.571807625339488e-10
either O 0 3.217416733036771e-08
BRCA1 O 0 1.0717186427200431e-07
( O 0 1.1197371918569843e-08
179 O 0 6.933433382982912e-08
women O 0 1.3577433399802885e-08
) O 0 4.881023585312505e-09
or O 0 3.6050064267101334e-08
BRCA2 O 0 5.873692998648039e-07
( O 0 5.330415575599545e-08
28 O 0 1.7336053588223876e-06
women O 0 1.8029119530638127e-07
) O 0 2.595992896203825e-07
. O 0 1.7944158798854914e-06

The O 0 8.219328719860641e-07
control O 0 8.973589501692913e-06
women O 0 3.2819887252344415e-08
were O 0 8.790460803709266e-09
enrolled O 0 2.77223790590142e-08
regardless O 0 6.47918252383306e-09
of O 0 2.0777433107355137e-09
whether O 0 2.0964689984026563e-09
or O 0 1.3918453056760427e-09
not O 0 5.388698931518832e-10
they O 0 6.460101342753433e-10
had O 0 9.108471310526056e-09
either O 0 2.945155941347366e-08
mutation O 0 9.061878358807007e-08
. O 0 3.4471730714358273e-07

Lifetime O 0 9.492937351751607e-06
histories O 0 3.2404122976004146e-06
of O 0 1.0699504855438136e-06
oral O 0 0.00017014845798257738
- O 0 5.292933110467857e-06
contraceptive O 0 5.224879373599833e-07
use O 0 2.592840830928367e-09
were O 0 1.7933111662316037e-09
obtained O 0 2.4232740258867125e-09
by O 0 2.853337011110568e-10
interview O 0 1.0586183485372658e-08
or O 0 1.077616398892367e-10
by O 0 1.593457484017069e-11
written O 0 4.2979231285045216e-11
questionnaire O 0 2.373838625668867e-10
and O 0 1.0842178543857273e-10
were O 0 1.1549196043958432e-09
compared O 0 8.03666377890977e-09
between O 0 2.0220440433149633e-08
patients O 0 8.648567195734813e-09
and O 0 1.6483363562969089e-09
control O 0 7.049573468975723e-06
women O 0 6.917157513441907e-09
, O 0 6.786806672209877e-10
after O 0 3.6324199204074148e-09
adjustment O 0 1.7919100869789872e-08
for O 0 6.037508271106162e-10
year O 0 4.266479669556844e-10
of O 0 5.641808797918202e-09
birth O 0 2.7813475966809165e-08
and O 0 5.636154654098391e-08
parity O 0 0.00011005609121639282
. O 0 5.805539331049658e-06

RESULTS O 0 2.9214338610472623e-06
The O 0 8.848837040886792e-08
adjusted O 0 3.930998673240538e-07
odds O 0 1.7208807321367203e-06
ratio O 0 1.689157784312556e-06
for O 0 7.031920631561661e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
associated O 0 5.727766279051139e-07
with O 0 3.763075184792797e-09
any O 0 4.8377675199162695e-09
past O 0 3.151527927514053e-09
use O 0 1.9194483780182736e-09
of O 0 4.280716581206434e-08
oral O 0 6.104964995756745e-05
contraceptives O 0 0.000752264866605401
was O 0 1.041715768224094e-05
0 O 0 3.4495546969992574e-06
. O 0 1.5719838302175049e-06

5 O 0 7.69000416767085e-06
( O 0 2.0710368175969052e-07
95 O 0 4.97703013024875e-07
percent O 0 1.6528461799225624e-07
confidence O 0 1.9383935523364926e-07
interval O 0 8.937413298326646e-08
, O 0 3.6918816892494988e-09
0 O 0 6.553131370878873e-09
. O 0 4.712574774856648e-10
3 O 0 4.7155088722661276e-09
to O 0 8.17899192817606e-10
0 O 0 2.974880786155154e-08
. O 0 5.328044672125998e-09
8 O 0 2.501697053958196e-07
) O 0 5.902629851561869e-08
. O 0 4.3238094349362655e-07

The O 0 7.260440497702803e-07
risk O 0 4.0691753611099557e-07
decreased O 0 5.457426155430767e-08
with O 0 5.674549163892095e-10
increasing O 0 3.4132212611837076e-09
duration O 0 6.045969946910645e-09
of O 0 8.0971285232323e-10
use O 0 9.728144956255846e-10
( O 0 1.040771135940588e-09
P O 0 1.3875738602564525e-07
for O 0 1.6538223013284892e-09
trend O 0 1.878392907883608e-08
, O 0 1.982418895707383e-09
< O 0 3.8125655521525914e-08
0 O 0 1.0038638365017505e-08
. O 0 1.1373200159425778e-09
001 O 0 1.4459091346452624e-07
) O 0 7.877670182843133e-10
; O 0 1.069148658494612e-10
use O 0 2.6394339491808694e-10
for O 0 3.7387487550333276e-10
six O 0 1.9568617837251168e-09
or O 0 4.820973065200462e-10
more O 0 1.5136250586245126e-10
years O 0 1.7177295141834747e-09
was O 0 7.541169466662723e-09
associated O 0 6.979841704612966e-10
with O 0 1.5022241783846368e-10
a O 0 1.2354137712833335e-09
60 O 0 3.9973770959989e-09
percent O 0 6.816232911432962e-09
reduction O 0 3.4710097907009185e-08
in O 0 1.401804983203192e-08
risk O 0 4.780168296747433e-07
. O 0 3.148312828216149e-07

Oral O 0 0.0011008704314008355
- O 0 2.9063920010230504e-05
contraceptive O 0 4.134243226872059e-06
use O 0 6.48789111323822e-08
protected O 0 0.00010339827713323757
against O 1 0.9999867677688599
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 1.0545197426381492e-07
for O 0 1.2747084277009435e-08
carriers O 0 2.3161414119954316e-08
of O 0 8.628103564944922e-09
the O 0 6.470488145282616e-09
BRCA1 O 0 2.4410008236941394e-08
mutation O 0 1.774102753593354e-09
( O 0 1.4023391337047997e-09
odds O 0 1.2721828568373894e-07
ratio O 0 4.095789307712039e-08
, O 0 4.84783591048199e-09
0 O 0 9.711166981674069e-09
. O 0 8.354286151757151e-10
5 O 0 9.117091970267666e-09
; O 0 8.99924246233752e-10
95 O 0 2.3474919785826387e-08
percent O 0 2.1331556965265008e-08
confidence O 0 1.414726682469336e-07
interval O 0 7.742583818526327e-08
, O 0 2.516694186383006e-09
0 O 0 3.4389155967318175e-09
. O 0 2.6861279867063104e-10
3 O 0 3.330798303835536e-09
to O 0 4.4780945618327905e-10
0 O 0 7.105926513872873e-09
. O 0 1.0312153353453368e-09
9 O 0 2.6378412343319724e-08
) O 0 4.93700302861555e-10
and O 0 2.998215842264784e-10
for O 0 7.743683472227758e-10
carriers O 0 4.361722982793026e-09
of O 0 3.355321798181876e-09
the O 0 8.951295704662243e-09
BRCA2 O 0 2.8935067675206483e-08
mutation O 0 3.0499316405752097e-09
( O 0 2.1612902578738158e-09
odds O 0 1.6719275208743056e-07
ratio O 0 5.23137551056152e-08
, O 0 5.042701811674988e-09
0 O 0 1.2639156388161155e-08
. O 0 7.771857046812158e-10
4 O 0 1.2700246188046549e-08
; O 0 8.480410818023643e-10
95 O 0 3.060136322119433e-08
percent O 0 1.9278660445820606e-08
confidence O 0 1.1130727983754696e-07
interval O 0 9.964510638837965e-08
, O 0 4.323448266063679e-09
0 O 0 8.835240095095287e-09
. O 0 1.0299101571575875e-09
2 O 0 1.1516952724832663e-08
to O 0 7.312690453176174e-10
1 O 0 5.311548889608275e-08
. O 0 3.3461566850689906e-09
1 O 0 1.9099127257504733e-07
) O 0 4.8818545650419765e-08
. O 0 3.4785526281666534e-07

CONCLUSIONS O 0 2.4568535081925802e-05
Oral O 0 0.0005018830415792763
- O 0 1.716419865260832e-05
contraceptive O 0 6.98191740866605e-07
use O 0 5.650035994619884e-09
may O 0 1.824187134680244e-09
reduce O 0 1.7377257410799984e-09
the O 0 1.1886479578393505e-09
risk O 0 8.883468467502098e-07
of O 0 0.07136255502700806
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 3.9100459048313496e-07
women O 0 3.4072176191557446e-09
with O 0 1.5612804382669765e-09
pathogenic O 0 1.1358437035369207e-07
mutations O 0 1.334716515088985e-08
in O 0 6.8762213700779284e-09
the O 0 1.2409576299887703e-07
BRCA1 O 0 4.216306024318328e-06
or O 0 3.150080601699301e-06
BRCA2 O 0 0.00016096366744022816
gene O 0 0.0004852941201534122

A O 0 6.691065937047824e-05
Japanese O 0 0.00010754085087683052
family O 0 8.370329851459246e-07
with O 0 2.123498745731922e-07
adrenoleukodystrophy B-Disease 1 0.9999997615814209
with O 0 3.026099903991053e-08
a O 0 4.560763500194298e-08
codon O 0 5.7703623213001265e-08
291 O 0 5.523853374711507e-08
deletion O 0 1.3291457889863523e-07
: O 0 3.5943694687290417e-09
a O 0 5.188503848785331e-09
clinical O 0 2.1402637173650874e-07
, O 0 1.1017425194381758e-08
biochemical O 0 7.220526640594471e-06
, O 0 8.073617863146865e-08
pathological O 0 0.00028156445478089154
, O 0 5.908802691578785e-08
and O 0 2.560553546970823e-08
genetic O 0 7.027215360722039e-07
report O 0 1.8237849985780485e-07
. O 0 6.177207296786946e-07

We O 0 4.1506638126520556e-07
report O 0 4.2277548573110835e-08
a O 0 1.515411973684877e-08
Japanese O 0 4.794860615220387e-07
family O 0 2.8079837122163553e-08
with O 0 3.9763006043358473e-07
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.16422641277313232
ALD B-Disease 1 1.0
) O 0 2.452172793709906e-07
with O 0 2.1197308797127334e-08
a O 0 8.243178939437712e-08
three O 0 1.1186613413372015e-08
base O 0 1.1660142007485774e-07
pair O 0 2.0863623717559676e-07
deletion O 0 6.930920903869264e-07
( O 0 5.130484836968208e-08
delGAG O 0 1.5289973589460715e-06
291 O 0 8.162790976484757e-08
) O 0 9.280398671762669e-09
in O 0 1.8790988320915858e-08
the O 0 7.265219323926431e-07
ALD B-Disease 1 1.0
gene O 0 9.910159860737622e-05
. O 0 2.1210862541920505e-05

A O 0 4.857941348745953e-06
variety O 0 3.3729051551745215e-07
of O 0 1.8613705776715506e-07
phenotypes O 0 4.7250588863789744e-07
were O 0 2.266517817872682e-08
observed O 0 3.4930192072124555e-08
within O 0 2.1660124360778354e-08
this O 0 4.9942587843077035e-09
family O 0 8.216619562517735e-08
. O 0 5.058507781541266e-07

While O 0 9.123929771703843e-07
the O 0 3.303291862266633e-07
proband O 0 0.00012268991849850863
( O 0 6.371244154479427e-08
patient O 0 2.1690392770779e-07
1 O 0 4.915285103379574e-07
) O 0 2.6600301961110517e-09
was O 0 3.1963146795987996e-08
classified O 0 9.668695177822428e-09
as O 0 1.1200058658289436e-09
having O 0 1.0770045966168595e-09
a O 0 6.906871186096453e-10
rare O 0 1.0218172974418849e-09
intermediate O 0 2.219658590263407e-08
type O 0 1.8580179173000033e-08
of O 0 1.459418541571722e-08
adult O 0 9.090039725379029e-07
cerebral O 0 0.00011667754733934999
and O 0 2.3304485807784658e-07
cerebello O 1 0.9995819926261902
- O 1 0.5621266961097717
brain O 0 0.00011667521903291345
stem O 0 7.65870211694164e-08
forms O 0 4.917722762343146e-08
, O 0 1.4638652068299507e-08
his O 0 6.464175328346755e-08
younger O 0 1.330336817773059e-05
brother O 0 1.948238059412688e-05
( O 0 1.1162150315158215e-07
patient O 0 6.978343094488082e-07
2 O 0 1.2418483947840286e-06
) O 0 7.273591950962555e-09
and O 0 4.6056786828785334e-08
nephew O 0 0.001918506808578968
( O 0 1.325208245361864e-07
patient O 0 1.4809280628469423e-06
3 O 0 1.456798145227367e-06
) O 0 2.313898228578637e-08
had O 0 2.7224666609981796e-07
a O 0 8.179387123163906e-07
childhood O 0 0.06647419929504395
ALD B-Disease 1 1.0
type O 0 0.3543000817298889
. O 0 4.6017157728783786e-05

Another O 0 4.812549377675168e-05
nephew O 0 0.006124595645815134
( O 0 8.196105341085058e-07
patient O 0 4.3650061343214475e-06
4 O 0 1.5327099163187086e-06
) O 0 2.0922398036304912e-08
of O 0 6.222633430752467e-08
patient O 0 1.5170855931501137e-06
1 O 0 1.1139726439068909e-06
was O 0 1.2324493070536846e-07
classified O 0 2.690242695280176e-08
as O 0 6.383405803944697e-09
having O 0 1.0753322676748667e-08
an O 0 7.1924319833271966e-09
adolescent O 0 3.5633036077342695e-06
form O 0 1.3368461395657505e-06
. O 0 1.129911561292829e-05

The O 0 7.698375839026994e-07
tau O 0 1.6861994254213641e-06
level O 0 1.1693298347381642e-06
in O 0 1.2258330350789493e-08
the O 0 4.2810267331105933e-08
cerebrospinal O 0 0.00012529043306130916
fluid O 0 0.0009642838849686086
( O 0 1.503358589616255e-06
CSF O 1 0.9993715882301331
) O 0 3.940106907407426e-08
in O 0 2.4597751391297606e-08
patient O 0 1.963619524758542e-07
1 O 0 4.2694151147770754e-07
was O 0 1.059127683333827e-07
as O 0 2.7936810642614773e-09
high O 0 2.5782991741607475e-08
as O 0 6.920374273633456e-10
that O 0 7.570807869505813e-11
of O 0 5.830165683562427e-09
patients O 0 1.2293902784676902e-07
with O 0 1.4285993756857351e-06
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.9997640252113342
( O 0 8.426209774370363e-07
AD B-Disease 0 1.7915443095262162e-05
) O 0 4.6021838784326974e-07
. O 0 2.0972156562493183e-06

His O 0 7.2095390351023525e-06
brain O 0 1.5139987226575613e-05
magnetic O 0 3.060404196730815e-06
resonance O 0 6.351979209284764e-06
image O 0 1.5315468999688164e-06
( O 0 9.959608604503956e-08
MRI O 0 0.00018887849000748247
) O 0 7.457311568259684e-08
showed O 0 1.6542827552257222e-06
abnormalities B-Disease 0 0.00012168069224571809
in I-Disease 0 1.8770998977402087e-08
the I-Disease 0 5.794073842935177e-08
bilateral I-Disease 1 0.8861990571022034
cerebellar I-Disease 1 0.9999881982803345
hemispheres I-Disease 0 8.097620593616739e-05
and O 0 1.2180758801605407e-07
brain O 0 0.000578535720705986
stem O 0 2.287248719312629e-07
, O 0 2.083958783316575e-09
but O 0 2.1632233504487175e-10
not O 0 2.793365538877879e-10
in O 0 1.1776084551939903e-09
the O 0 1.4322641739283881e-08
cerebral O 0 6.479597504949197e-05
white O 0 4.951370513595066e-08
matter O 0 1.6824698434447782e-07
, O 0 8.076583291050099e-10
where O 0 3.4001074178391377e-10
marked O 0 1.0401559613626432e-09
reductions O 0 1.4349328836260611e-08
of O 0 3.286729111096065e-09
the O 0 1.8217297892419992e-08
cerebral O 0 3.683440581880859e-06
blood O 0 3.2798798343947055e-08
flow O 0 6.369081262391774e-08
and O 0 1.3924540631649052e-08
oxygen O 0 6.610592890865519e-07
metabolism O 0 6.715924314448785e-07
were O 0 5.724853480160164e-09
clearly O 0 2.7991802209470507e-09
demonstrated O 0 1.4991993202428944e-09
by O 0 1.6633562582857309e-10
positron O 0 1.8811141089258854e-08
emission O 0 3.034451978578545e-08
tomography O 0 7.80080767981417e-07
( O 0 7.915028987781625e-08
PET O 0 1.461797182855662e-06
) O 0 1.4740390952283633e-07
. O 0 1.453636855330842e-06

In O 0 1.8369936469753156e-06
patients O 0 1.1775797474911087e-06
2 O 0 1.6008617649276857e-06
and O 0 1.5048039259113466e-08
3 O 0 1.0941474215542257e-07
, O 0 1.6277101888562129e-09
the O 0 9.093086839051523e-10
autopsy O 0 2.3649516123214198e-08
findings O 0 6.11659611848836e-09
showed O 0 1.9662259376218572e-07
massive O 0 6.0250140450079925e-06
demyelination B-Disease 1 0.9999992847442627
of I-Disease 0 5.7521597227605525e-06
the I-Disease 0 1.986221377592301e-06
cerebral I-Disease 0 0.06518470495939255
white I-Disease 0 7.903322796209977e-08
matter I-Disease 0 4.0189455319250555e-08
with O 0 1.3846378488224786e-09
sparing O 0 2.47179610113335e-08
of O 0 2.524262221470508e-08
the O 0 2.5202362508025544e-07
U O 1 0.9997933506965637
- O 0 0.017630238085985184
fibers O 0 8.024978797038784e-07
, O 0 9.655352961601693e-09
compatible O 0 6.036765398675925e-08
with O 0 7.912410726618191e-10
the O 0 5.521227475213664e-09
findings O 0 2.7957028692071617e-08
of O 0 3.3062605098166387e-07
childhood O 0 0.11044807732105255
ALD B-Disease 1 1.0
. O 0 0.00018223744700662792

Oleic O 0 0.0016144841210916638
and O 0 1.988537633224041e-06
erucic O 0 0.008306793868541718
acids O 0 1.5760473388581886e-06
( O 0 1.937539622076656e-07
Lorenzos O 0 1.2973159755347297e-05
Oil O 0 5.350599963094282e-07
) O 0 1.3793712838605643e-09
were O 0 8.200860546203614e-10
administered O 0 1.3802398113327286e-09
to O 0 3.622696864713504e-10
patients O 0 4.922750651559227e-09
1 O 0 5.919790169173211e-08
and O 0 2.949528177254024e-09
4 O 0 2.6567610333927405e-08
, O 0 4.4803161181050655e-10
but O 0 1.1650522213635384e-10
sufficient O 0 5.4023576723238875e-09
effectiveness O 0 1.685631367820406e-08
was O 0 1.989719677908397e-08
not O 0 3.070992793396954e-09
obtained O 0 1.3808163146222796e-07
. O 0 3.6299979910836555e-07

The O 0 6.333224291665829e-07
findings O 0 1.0440865594318893e-07
in O 0 1.1379347242268523e-08
this O 0 2.3561033124508413e-09
family O 0 3.1386606647032522e-09
suggest O 0 5.544708692184486e-09
that O 0 1.7450452194367472e-10
delGAG291 O 0 6.641101180093756e-08
is O 0 1.3960808065149877e-09
part O 0 1.7957311193583791e-09
of O 0 6.110684402926836e-09
the O 0 7.216313768765303e-09
cause O 0 5.653046386555616e-08
of O 0 2.1955324314149038e-07
Japanese O 0 0.002835070714354515
ALD B-Disease 1 0.9999988079071045
with O 0 5.777740952339627e-08
phenotypic O 0 4.417128366185352e-05
variations O 0 1.3218284948379733e-05
. O 0 4.0591626202513e-06

Moreover O 0 1.0259921509714331e-05
, O 0 6.309496569656403e-08
although O 0 9.980941406695365e-09
the O 0 2.848265401311778e-09
scale O 0 5.389824409007815e-08
of O 0 2.393882203577391e-09
the O 0 9.667104894361955e-10
study O 0 3.946857562997508e-10
is O 0 1.6632990817999627e-10
limited O 0 6.294826326858072e-10
, O 0 3.983203489266174e-10
there O 0 6.689467868525867e-10
is O 0 4.5627254752211854e-10
a O 0 7.349858499594575e-10
possibility O 0 1.6945477909757756e-08
that O 0 6.656807882698956e-10
PET O 0 2.888665306954863e-08
can O 0 6.992367240776787e-10
detect O 0 6.544840402966656e-08
an O 0 2.3793349512857276e-08
insidious B-Disease 0 2.541181856940966e-05
lesion I-Disease 0 1.6975578546407633e-05
which O 0 6.216474446318898e-09
is O 0 1.8811132651563867e-09
undetectable O 0 8.714722810054809e-08
by O 0 1.8068110341218357e-09
computed O 0 4.2032797864521854e-07
tomogram O 0 2.70961900241673e-05
( O 0 1.4140401560780447e-07
CT O 0 0.00038544542621821165
) O 0 1.1574827318838743e-08
or O 0 1.941204885724801e-08
MRI O 0 5.962151590210851e-06
analysis O 0 2.5791992541712716e-08
, O 0 2.436008950112978e-09
and O 0 9.727550986937672e-10
that O 0 1.4811277204707096e-10
the O 0 5.077560039090656e-10
higher O 0 1.0787032600489965e-08
level O 0 4.3644963199085396e-08
of O 0 5.707561978596232e-09
tau O 0 4.3532889293373955e-08
reflects O 0 4.203181358519714e-09
the O 0 6.628200210911928e-10
process O 0 6.780884298507317e-09
of O 0 6.667411156513481e-08
neuronal B-Disease 0 0.0004374816198833287
degeneration I-Disease 1 0.9993957281112671
in O 0 2.820785994117614e-05
ALD B-Disease 1 1.0
. O 0 0.0003527201188262552

Lorenzos O 0 0.001929992693476379
Oil O 0 1.1324823390168604e-05
should O 0 7.908115051691311e-09
be O 0 4.2386993914789173e-10
given O 0 1.653581715999053e-10
in O 0 1.6982022732481283e-10
the O 0 2.2556648215932285e-10
early O 0 1.0892641455484409e-08
stage O 0 1.3789016861665004e-07
. O 0 2.4438470802579104e-08
. O 0 2.657613151768601e-07

Nonsense O 0 0.00010100079816766083
mutation O 0 6.988652785366867e-07
in O 0 2.0419598456555832e-07
exon O 0 1.695815080893226e-05
4 O 0 1.1297813671262702e-06
of O 0 1.021428488456877e-07
human O 0 7.456628736690618e-08
complement O 0 1.1826172112705535e-06
C9 O 0 0.0023003926035016775
gene O 0 1.6555785009586543e-07
is O 0 4.4867314308305595e-09
the O 0 3.804914161520401e-09
major O 0 1.2307440044878604e-07
cause O 0 5.625414800647377e-08
of O 0 1.6439140892998694e-07
Japanese O 0 0.00011786164395743981
complement B-Disease 0 0.0007428103708662093
C9 I-Disease 1 0.9999971389770508
deficiency I-Disease 1 0.9999886751174927
. O 0 5.168896677787416e-05

Deficiency B-Disease 1 0.9999918937683105
of I-Disease 0 9.245114597433712e-06
the I-Disease 0 1.3120222774887225e-06
ninth I-Disease 0 1.0338003448850941e-05
component I-Disease 0 1.950310434040148e-06
of I-Disease 0 1.2051586395500635e-07
human I-Disease 0 4.810534193211424e-08
complement I-Disease 0 1.9249710021540523e-06
( O 0 6.189407599777041e-07
C9 O 0 0.0597865954041481
) O 0 4.015091548126293e-08
is O 0 2.1068473632368523e-09
the O 0 1.3623705497067817e-09
most O 0 2.0398853717296106e-09
common O 0 1.4978745355165302e-07
complement B-Disease 1 0.9999940395355225
deficiency I-Disease 1 1.0
in O 0 2.8137799290561816e-07
Japan O 0 7.858616299927235e-07
but O 0 3.0165383524405343e-09
is O 0 6.045252076702923e-10
rare O 0 8.147539864999942e-10
in O 0 6.663845586452055e-10
other O 0 1.0030843933250821e-09
countries O 0 7.529097345582159e-09
. O 0 2.30208584639513e-07

We O 0 3.907291272753355e-07
studied O 0 5.62414300020464e-07
the O 0 1.2467578081043484e-08
molecular O 0 8.768176940066041e-08
basis O 0 1.0058536759061099e-07
of O 0 4.1272721773566445e-07
C9 B-Disease 1 0.9998505115509033
deficiency I-Disease 1 0.9673303961753845
in O 0 8.256775174686481e-08
four O 0 6.255417872580438e-08
Japanese O 0 4.406257357914001e-05
C9 B-Disease 1 0.9999899864196777
- I-Disease 1 0.999398946762085
deficient I-Disease 1 0.9997555613517761
patients O 0 4.886887109023519e-05
who O 0 1.2419253607731662e-06
had O 0 0.00010298086272086948
suffered O 1 0.999984622001648
from O 1 0.8442438840866089
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 0.9999995231628418
. O 0 1.3206855328462552e-05

Direct O 0 9.667174936112133e-07
sequencing O 0 6.122913305262045e-07
of O 0 4.2171643599431263e-07
amplified O 0 6.155540177132934e-06
C9 O 0 0.0001494187890784815
cDNA O 0 3.192932126694359e-06
and O 0 3.6808234682439434e-08
DNA O 0 1.4412324844670366e-07
revealed O 0 6.513879924341381e-08
a O 0 1.8370300836068054e-08
nonsense O 0 1.2397464388413937e-07
substitution O 0 6.457249668301301e-08
( O 0 2.3575340790671362e-08
CGA O 0 7.77159038989339e-06
- O 0 1.7909213738676044e-06
- O 0 6.182971219459432e-07
> O 0 1.831113394246131e-07
TGA O 0 4.470380190468859e-07
) O 0 2.4356696659566524e-09
at O 0 2.2856584180885875e-08
codon O 0 1.0043828879702232e-08
95 O 0 6.331292468075844e-08
in O 0 2.3297033635572006e-08
exon O 0 1.5819124428162468e-06
4 O 0 9.047111859672441e-08
in O 0 4.254325780550516e-09
the O 0 1.817571870788015e-08
four O 0 1.7823360565216717e-07
C9 B-Disease 0 0.3439462184906006
- I-Disease 0 0.0003445066977292299
deficient I-Disease 0 4.4476462790044025e-05
individuals O 0 2.3504294688336813e-07
. O 0 6.552636477863416e-06

An O 0 2.0037275305639923e-07
allele O 0 2.2621046014137391e-07
- O 0 9.968712078034514e-08
specific O 0 6.354857085000276e-09
polymerase O 0 3.357174023221887e-07
chain O 0 5.078049625240055e-08
reaction O 0 2.9537503554166733e-09
system O 0 7.652624312015632e-09
designed O 0 1.4208741738741537e-08
to O 0 1.2142739036491434e-09
detect O 0 7.157782988542749e-08
exclusively O 0 5.0283169628073665e-08
only O 0 9.481897489393987e-10
one O 0 3.600391929037272e-10
of O 0 1.4271367421159198e-09
the O 0 1.5421847132657263e-09
normal O 0 5.210550213519127e-09
and O 0 3.5664232678200847e-10
mutant O 0 5.594360530380982e-09
alleles O 0 2.439016988375897e-09
indicated O 0 7.624941567030419e-09
that O 0 1.350360795404626e-10
all O 0 2.2670516852674183e-10
the O 0 1.5581478329806941e-09
four O 0 3.4509466395604704e-09
patients O 0 2.1704198438499134e-09
were O 0 1.6543776348854067e-09
homozygous O 0 2.781754826486349e-09
for O 0 5.331884933568176e-10
the O 0 1.6510108835632309e-09
mutation O 0 3.584716079529926e-09
in O 0 5.996219964998772e-09
exon O 0 1.7961622233997332e-06
4 O 0 1.051956388664621e-07
and O 0 1.2560420481477763e-09
that O 0 2.1744131495360364e-10
the O 0 2.2926212039919847e-09
parents O 0 1.2541844229829735e-09
of O 0 7.80457121152267e-09
patient O 0 3.7948746012261836e-07
2 O 0 1.8225937310489826e-06
were O 0 4.2416556311764e-07
heterozygous O 0 1.7549690483065206e-06
. O 0 1.3205369668867206e-06

The O 0 3.94802924574833e-07
common O 0 8.074095347865295e-08
mutation O 0 1.618303357986406e-08
at O 0 6.393936047288662e-08
codon O 0 3.811969406797289e-08
95 O 0 1.3990008085329464e-07
in O 0 3.400285919497037e-08
exon O 0 3.9592114262632094e-06
4 O 0 1.2725796239010378e-07
might O 0 5.95357585453371e-09
be O 0 5.609668840556026e-10
responsible O 0 3.1817635193220895e-09
for O 0 1.1125708132553314e-09
most O 0 1.0665631045014834e-08
Japanese O 0 7.751910015940666e-05
C9 B-Disease 1 0.9999947547912598
deficiency I-Disease 1 0.9997548460960388
. O 0 5.399830342867062e-07
. O 0 2.768925241980469e-06

BRCA1 O 0 3.0017092740308726e-06
required O 0 2.919101405041147e-07
for O 0 9.816071155910322e-08
transcription O 0 4.1486884583719075e-05
- O 0 4.715079558081925e-05
coupled O 0 8.264058124041185e-06
repair O 0 7.275054667843506e-05
of O 0 2.7341463919583475e-06
oxidative O 0 0.0001388683303957805
DNA O 0 2.085235610138625e-05
damage O 0 9.057547140400857e-05
. O 0 4.852759957429953e-06

The O 0 1.592569606145844e-05
breast B-Disease 1 0.9999920129776001
and I-Disease 1 0.9949404001235962
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 1 0.9991469383239746
gene O 0 2.7559544832911342e-05
BRCA1 O 0 8.22055881144479e-06
encodes O 0 4.920678975395276e-07
a O 0 9.009465884446399e-07
zinc O 0 0.21341638267040253
finger O 0 5.0541806558612734e-05
protein O 0 7.393859959847759e-07
of O 0 1.564091007821844e-07
unknown O 0 2.6793566121341428e-06
function O 0 3.3224737308046315e-06
. O 0 2.5434305825910997e-06

Association O 0 7.386287506960798e-06
of O 0 9.638132496547769e-07
the O 0 5.241563485469669e-07
BRCA1 O 0 1.0077179695144878e-06
protein O 0 6.407059771618151e-08
with O 0 1.7594606882553876e-09
the O 0 3.981156737609126e-08
DNA O 0 2.5744325284904335e-06
repair O 0 7.39281895221211e-05
protein O 0 3.249721203246736e-06
Rad51 O 0 4.045983587275259e-06
and O 0 3.3743441374411987e-09
changes O 0 6.4000831301314065e-09
in O 0 1.60848900865318e-09
the O 0 1.0176337550404924e-09
phosphorylation O 0 4.996917102317866e-09
and O 0 1.7938859286914521e-09
cellular O 0 3.4955726846419566e-07
localization O 0 1.2563011750899022e-06
of O 0 3.190807973396659e-08
the O 0 7.769786591893535e-09
protein O 0 1.3809198229353115e-08
after O 0 8.163317133380588e-09
exposure O 0 7.525281375819759e-08
to O 0 2.2855222159279265e-09
DNA O 0 1.0487884765097988e-06
- O 0 7.651458986401849e-07
damaging O 0 1.8339113694310072e-07
agents O 0 9.677662227147721e-09
are O 0 1.8928707212761964e-10
consistent O 0 5.190582630376639e-09
with O 0 4.516902407658563e-10
a O 0 2.567868806480078e-09
role O 0 1.835215890366726e-08
for O 0 9.285054503038737e-09
BRCA1 O 0 3.2690383022782044e-07
in O 0 1.8309754068468465e-07
DNA O 0 1.0307968295819592e-05
repair O 0 0.0007265303866006434
. O 0 1.614081338630058e-05

Here O 0 5.569822860707063e-06
, O 0 5.229021127206579e-08
it O 0 1.159174534137719e-09
is O 0 1.1212283324013583e-09
shown O 0 1.92935112330872e-09
that O 0 9.205679551982371e-10
mouse O 0 6.904585347911052e-08
embryonic O 0 4.094173391422373e-07
stem O 0 8.176158416972612e-07
cells O 0 2.480541354543675e-07
deficient B-Disease 0 4.047766651638085e-06
in I-Disease 0 4.8225324178474693e-08
BRCA1 I-Disease 0 2.6220661197839945e-07
are O 0 3.911695412028848e-09
defective O 0 2.9172699100854516e-07
in O 0 2.209440186362599e-09
the O 0 6.109084349503746e-10
ability O 0 1.1336339644785198e-09
to O 0 1.3836340406747638e-10
carry O 0 4.869100678206451e-10
out O 0 4.150203514186046e-10
transcription O 0 4.089701235443499e-07
- O 0 4.0202493778451753e-07
coupled O 0 2.3269751636689762e-07
repair O 0 2.5782505872484762e-06
of O 0 9.986010240936594e-08
oxidative O 0 2.2115084448159905e-06
DNA O 0 1.9248552689532517e-06
damage O 0 9.932943612511735e-06
, O 0 9.363252395644395e-09
and O 0 4.695601685256179e-09
are O 0 2.839424029232873e-09
hypersensitive O 0 4.1488866031613725e-07
to O 0 1.2939378457588191e-08
ionizing O 0 0.00010688398469937965
radiation O 0 6.024840331519954e-05
and O 0 4.252956387063023e-08
hydrogen O 0 1.1121109082523617e-06
peroxide O 0 3.7300951589713804e-06
. O 0 7.671362141081772e-07

These O 0 4.281083931800822e-08
results O 0 6.113309325428418e-08
suggest O 0 5.640875500034781e-08
that O 0 4.0694598801849224e-09
BRCA1 O 0 7.995142681238576e-08
participates O 0 2.140761345970077e-08
, O 0 1.992833009722972e-09
directly O 0 3.154318140019541e-09
or O 0 1.767047952405676e-09
indirectly O 0 2.094627582494013e-08
, O 0 1.3535900178496263e-09
in O 0 3.6053140473057965e-09
transcription O 0 2.0736765691253822e-06
- O 0 3.4954566672240617e-06
coupled O 0 1.4039142115507275e-06
repair O 0 1.2010838872811291e-05
of O 0 5.382195809033874e-07
oxidative O 0 2.8805810870835558e-05
DNA O 0 9.026597581396345e-06
damage O 0 2.394976036157459e-05
. O 0 3.158537822400831e-07
. O 0 2.8422755349311046e-06

Truncation O 0 0.00019469148537609726
mutations O 0 1.1161846487084404e-06
in O 0 5.84075401377504e-08
the O 0 5.6653949087603905e-08
transactivation O 0 6.038575520506129e-05
region O 0 9.808750291995239e-07
of O 0 2.674327390650433e-07
PAX6 O 0 0.000283765111817047
result O 0 2.0587900451118912e-07
in O 0 1.3088212824641232e-07
dominant O 0 3.5335691791260615e-05
- O 0 4.0028371586231515e-06
negative O 0 2.291731249215445e-07
mutants O 0 1.583741891408863e-06
. O 0 1.590893020875228e-06

PAX6 O 0 0.0030024596489965916
is O 0 2.9634108500431466e-07
a O 0 7.858348283207306e-08
transcription O 0 5.56658164896362e-07
factor O 0 8.56093009815595e-08
with O 0 1.7654141482026375e-09
two O 0 3.193558528735707e-09
DNA O 0 3.8544548885965924e-08
- O 0 3.386460889487353e-08
binding O 0 1.3360894612901575e-08
domains O 0 4.456941553598881e-07
( O 0 3.672149162525784e-08
paired O 0 3.0170122045092285e-07
box O 0 2.6936934318655403e-06
and O 0 6.123730855733811e-08
homeobox O 0 6.507703801617026e-06
) O 0 7.806521651332332e-09
and O 0 1.2015089367878318e-08
a O 0 1.4243180146422674e-07
proline O 0 3.5632626804726897e-06
- O 0 7.081221610860666e-06
serine O 0 2.523098373785615e-06
- O 0 6.0782131185987964e-06
threonine O 0 3.020149506482994e-06
( O 0 3.782838575716596e-07
PST O 0 0.03472856804728508
) O 0 7.775969379508751e-07
- O 0 3.9478359212807845e-06
rich O 0 8.467728775940486e-07
transactivation O 0 9.232634329237044e-05
domain O 0 1.663215152802877e-05
. O 0 5.6247345128213055e-06

PAX6 O 1 0.896436333656311
regulates O 0 6.769442552467808e-05
eye O 0 7.006266241660342e-05
development O 0 4.973642830918834e-07
in O 0 2.5178957585580974e-08
animals O 0 2.415272648548239e-09
ranging O 0 1.5568495825846185e-07
from O 0 1.3948385557682741e-08
jellyfish O 0 1.1271641398025167e-08
to O 0 2.6501449923443943e-09
Drosophila O 0 5.554121074169416e-08
to O 0 2.8688930342468666e-08
humans O 0 9.95428877104132e-07
. O 0 9.891000445350073e-07

Heterozygous O 0 1.7793681763578206e-05
mutations O 0 1.1723133184204926e-06
in O 0 2.988125302749722e-08
the O 0 4.2175983594461286e-08
human O 0 1.5850397971917118e-07
PAX6 O 0 9.188332478515804e-05
gene O 0 7.403668433880739e-08
result O 0 1.1560397084053875e-08
in O 0 1.828618256816128e-09
various O 0 3.0550317831057328e-09
phenotypes O 0 3.6100910705272327e-08
, O 0 5.119690449362224e-09
including O 0 5.939525848930316e-08
aniridia B-Disease 1 0.9999998807907104
, O 0 3.922164069081191e-06
Peters B-Disease 1 0.9999990463256836
anomaly I-Disease 1 0.9999997615814209
, O 0 2.898992534028366e-06
autosomal B-Disease 0 0.08513159304857254
dominant I-Disease 1 0.999887228012085
keratitis I-Disease 1 0.9999953508377075
, O 0 1.9388828604860464e-06
and O 0 4.000989974883851e-06
familial B-Disease 1 0.9999861717224121
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.2812145948410034

It O 0 2.139457677685641e-07
is O 0 4.0575802273679074e-08
believed O 0 2.8156366127518595e-08
that O 0 2.2131757537735552e-10
the O 0 1.5700359901060779e-09
mutated O 0 4.61630955683745e-09
allele O 0 1.0735800692884823e-08
of O 0 5.177750850293705e-08
PAX6 O 0 1.8986665963893756e-05
produces O 0 2.3497138457173605e-08
an O 0 7.842652749445733e-09
inactive O 0 2.529207677071099e-06
protein O 0 5.514735903489054e-07
and O 0 4.4014132782876914e-08
aniridia B-Disease 1 0.9999971389770508
is O 0 5.577625117325624e-08
caused O 0 4.572051537365951e-08
due O 0 4.9273751301370794e-08
to O 0 1.1286098278162626e-08
genetic O 0 1.7395392433172674e-06
haploinsufficiency O 0 0.0002113393711624667
. O 0 5.4674460443493444e-06

However O 0 8.126313559841947e-07
, O 0 2.0893605068295074e-08
several O 0 4.1056975597086875e-09
truncation O 0 6.367879450408509e-07
mutations O 0 3.396364434138377e-08
have O 0 1.7051685619051682e-09
been O 0 2.330644566228557e-09
found O 0 4.3042255870595625e-10
to O 0 1.199932098128187e-10
occur O 0 4.880117976391318e-10
in O 0 8.089532932409327e-10
the O 0 8.52296544451292e-09
C O 0 0.0007848323439247906
- O 0 4.3733648453780916e-06
terminal O 0 1.248025796485308e-06
half O 0 1.4594519370803027e-08
of O 0 2.4373671081434622e-08
PAX6 O 0 0.00011394796456443146
in O 0 3.2031746144411954e-08
patients O 0 1.3146202348934821e-08
with O 0 5.177589912364056e-09
Aniridia B-Disease 1 0.9999725818634033
resulting O 0 2.183224125928973e-07
in O 0 9.348156027044752e-09
mutant O 0 1.832354890041188e-08
proteins O 0 1.5059773428305334e-09
that O 0 1.336350613501125e-10
retain O 0 5.740609765325644e-09
the O 0 2.1128152560834224e-09
DNA O 0 4.2995612403728956e-08
- O 0 2.1235186054013866e-08
binding O 0 1.1671618338482403e-08
domains O 0 1.392720321291563e-07
but O 0 9.777928688947668e-09
have O 0 2.649280572697421e-09
lost O 0 1.1723396653451346e-07
most O 0 1.8754922059827095e-09
of O 0 6.664560903146821e-09
the O 0 2.2305870928107652e-08
transactivation O 0 1.833047645050101e-05
domain O 0 6.713402399327606e-06
. O 0 3.881296834151726e-06

It O 0 5.194675978259511e-08
is O 0 3.818545923905958e-09
not O 0 4.933473074508754e-10
clear O 0 2.61014321267794e-09
whether O 0 1.8084382880090288e-09
such O 0 1.1912807407199466e-09
mutants O 0 2.7742744990177926e-08
really O 0 2.1142634309967434e-08
behave O 0 1.8744202634479734e-08
as O 0 8.37448865809165e-09
loss O 0 2.751118870492064e-07
- O 0 7.717782182226074e-07
of O 0 2.39970830762104e-07
- O 0 8.543783565073682e-07
function O 0 8.370179926942001e-08
mutants O 0 6.094926163768832e-08
as O 0 2.2366112517602232e-08
predicted O 0 1.0540491501842553e-07
by O 0 3.322741193301226e-08
haploinsufficiency O 0 6.623064837185666e-05
. O 0 4.817255558009492e-06

Contrary O 0 2.50829089054605e-06
to O 0 4.168827416606291e-08
this O 0 6.6859118241779925e-09
theory O 0 3.0049403676457587e-07
, O 0 2.865572001908845e-09
our O 0 2.333339965687742e-09
data O 0 7.91934429145158e-09
showed O 0 5.304904071579131e-09
that O 0 5.567540525830417e-11
these O 0 8.318665201123565e-11
mutants O 0 5.071203901252375e-09
are O 0 1.8437257276460173e-10
dominant O 0 8.267191020649989e-08
- O 0 1.968276031050209e-08
negative O 0 1.5147696430517499e-09
in O 0 1.9025867548094766e-09
transient O 0 1.0146789009013446e-07
transfection O 0 3.9209606939039077e-07
assays O 0 7.913006783155652e-08
when O 0 4.722150670488645e-09
they O 0 8.592658251593832e-10
are O 0 5.671584313304834e-10
coexpressed O 0 7.284938874363434e-08
with O 0 2.7489688303461435e-09
wild O 0 9.020920543889588e-08
- O 0 1.0145903388547595e-06
type O 0 6.446379757107934e-06
PAX6 O 0 0.024851400405168533
. O 0 7.810417628206778e-06

We O 0 8.702578497832292e-07
found O 0 3.967156558815077e-08
that O 0 1.1011285216966371e-09
the O 0 6.264501806185763e-09
dominant O 0 5.321055596141377e-07
- O 0 3.67517642985149e-08
negative O 0 4.281261567484762e-09
effects O 0 5.7615860526993856e-08
result O 0 5.454707796559433e-09
from O 0 1.1606899885663324e-09
the O 0 9.502284514795178e-10
enhanced O 0 1.657568482471561e-08
DNA O 0 9.716837112705434e-09
binding O 0 4.180435109191194e-09
ability O 0 1.0600124333848271e-08
of O 0 2.6172585876338417e-08
these O 0 2.3076792032838966e-08
mutants O 0 1.5229912833092385e-06
. O 0 1.179069840873126e-06

Kinetic O 0 1.8451211872161366e-05
studies O 0 7.597129751957254e-07
of O 0 3.652241886697993e-08
binding O 0 3.8457969253613555e-08
and O 0 7.00256741481553e-09
dissociation O 0 7.061706241984211e-08
revealed O 0 3.370987755602073e-08
that O 0 1.7324859602485532e-10
various O 0 1.5453530677334015e-09
truncation O 0 1.5982395495939272e-07
mutants O 0 5.830814231444492e-08
have O 0 3.874826681737886e-09
3 O 0 5.197223273967211e-08
- O 0 4.489961469289483e-08
5 O 0 3.474612952913958e-08
- O 0 1.6557862636545906e-08
fold O 0 4.037883361007744e-09
higher O 0 5.692286642045019e-09
affinity O 0 1.5022708632628223e-09
to O 0 2.972274371071393e-10
various O 0 1.2790916104066241e-09
DNA O 0 1.3194332737498371e-08
- O 0 4.7379389300772345e-09
binding O 0 1.5041344836319581e-09
sites O 0 1.0749522383335375e-09
when O 0 8.175248256137024e-10
compared O 0 4.030757949635699e-09
with O 0 4.4298922863283963e-10
the O 0 7.659136436188874e-09
wild O 0 5.9240932159809745e-08
- O 0 6.279314561652427e-07
type O 0 3.5269258660264313e-06
PAX6 O 0 0.002571858698502183
. O 0 7.74711043050047e-06

These O 0 1.0082008117251462e-07
results O 0 3.8696956750072786e-08
provide O 0 1.765728185887383e-08
a O 0 1.5235267269986252e-08
new O 0 5.033774730378582e-09
insight O 0 1.5270178010950985e-08
into O 0 2.2088162410227596e-09
the O 0 9.268046330390689e-10
role O 0 8.755821845340961e-09
of O 0 3.895466349490562e-08
mutant O 0 4.911311748401204e-07
PAX6 O 0 0.0001420266053173691
in O 0 2.3971463747329835e-07
causing O 0 8.429735316894948e-06
aniridia B-Disease 1 0.999977707862854
. O 0 7.417944516419084e-07
. O 0 4.6332183956110384e-06

Reversal O 0 8.105299639282748e-05
of O 0 2.4796529032755643e-05
severe O 1 0.9999719858169556
hypertrophic B-Disease 1 0.9999998807907104
cardiomyopathy I-Disease 1 1.0
and O 0 1.5846659152884968e-05
excellent O 0 5.345135286916047e-05
neuropsychologic O 0 0.00013102905359119177
outcome O 0 5.913904033150175e-07
in O 0 1.491963175226374e-08
very B-Disease 0 1.73537824110781e-08
- I-Disease 0 4.1948104012590193e-07
long I-Disease 0 7.082439168470955e-08
- I-Disease 0 5.566364507103572e-07
chain I-Disease 0 1.1444574710139932e-07
acyl I-Disease 0 1.1505618147111818e-07
- I-Disease 0 6.588483074665419e-07
coenzyme I-Disease 0 4.815151442016941e-07
A I-Disease 0 2.2463742425316013e-05
dehydrogenase I-Disease 0 0.0013937862822785974
deficiency I-Disease 1 0.9986072182655334
. O 0 3.466270209173672e-05

Very B-Disease 0 8.65744186739903e-06
- I-Disease 0 5.127862095832825e-05
long I-Disease 0 9.260603519578581e-07
- I-Disease 0 9.943055374606047e-07
chain I-Disease 0 4.543901610531975e-08
acyl I-Disease 0 2.1192740007336397e-08
- I-Disease 0 3.4508101265373625e-08
coenzyme I-Disease 0 1.664433568748791e-08
A I-Disease 0 1.204715118774402e-07
dehydrogenase I-Disease 0 5.583291908806132e-07
( I-Disease 0 9.467539996421692e-08
VLCAD I-Disease 1 0.9929059743881226
) I-Disease 0 1.97603026208526e-06
deficiency I-Disease 1 0.9970545768737793
is O 0 4.609035642033632e-08
a O 0 2.874025426535809e-07
disorder O 0 0.030358510091900826
of O 0 1.5337421928052208e-06
fatty O 0 5.373972726374632e-06
acid O 0 3.251145699323388e-07
beta O 0 8.090171377261868e-07
oxidation O 0 7.793490226504218e-07
that O 0 4.930126973334836e-09
reportedly O 0 6.398035168331262e-08
has O 0 5.699432592543019e-10
high O 0 1.635949509193324e-08
rates O 0 1.2398476023633975e-08
of O 0 8.908171089672123e-09
morbidity O 0 6.27672818609426e-07
and O 0 3.213430588289157e-08
mortality O 0 4.9161380957229994e-06
. O 0 8.965573101704649e-07

We O 0 2.621428336624376e-07
describe O 0 7.761079956480899e-08
the O 0 8.44880343464638e-09
outcome O 0 2.9359016551211425e-08
of O 0 9.244041976330664e-09
a O 0 1.0261107519227153e-08
5 O 0 4.150864540974908e-08
- O 0 5.6453639984965776e-08
year O 0 8.99804497578316e-09
- O 0 5.45727004919172e-07
old O 0 3.502413221667666e-07
girl O 0 4.226828025366558e-07
with O 0 9.288899605053302e-07
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 0.0002432126784697175
was O 0 4.0226324927061796e-05
first O 0 3.4772714485598044e-08
seen O 0 4.359296923439615e-08
at O 0 3.978363594114853e-08
5 O 0 1.0083273771499535e-08
months O 0 2.2368447094578414e-09
of O 0 1.8141835811391616e-09
age O 0 4.73315431293031e-08
with O 0 1.5204003389612808e-08
severe O 1 0.9979532957077026
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 0.9999979734420776
hepatomegaly B-Disease 1 1.0
, O 1 0.9999926090240479
encephalopathy B-Disease 1 0.9999982118606567
, O 0 3.0604860512539744e-06
and O 0 2.2418200387619436e-05
hypotonia B-Disease 1 0.9972007274627686
. O 0 3.352714702486992e-05

Biochemical O 0 0.00035437094629742205
studies O 0 1.1213293873879593e-05
indicated O 0 0.24661099910736084
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 1.2716222045128234e-05
by O 0 2.6885087933692375e-08
a O 0 1.853604771895334e-07
stable O 0 3.5013688375329366e-06
yet O 0 1.0256101035110987e-07
inactive O 0 1.6669680462655379e-06
enzyme O 0 6.195638775352563e-07
. O 0 5.90545653267327e-07

Molecular O 0 1.7425380065105855e-05
genetic O 0 7.80869754635205e-07
analysis O 0 3.488971458409651e-07
of O 0 3.7972171185174375e-07
her O 0 2.5430276195947954e-07
VLCAD O 0 0.45926278829574585
gene O 0 4.2471120309528487e-07
revealed O 0 4.7252345325432543e-07
a O 0 2.3090095169209235e-07
T1372C O 0 5.52511937712552e-06
( O 0 6.609735692109098e-08
F458L O 0 3.2631498925184133e-06
) O 0 5.2754437263047294e-08
missense O 0 2.169090066672652e-06
mutation O 0 5.001610858812455e-08
and O 0 1.787029368927051e-08
a O 0 5.983415576338302e-07
1668 O 0 0.0027253013104200363
ACAG O 1 0.8828383088111877
1669 O 0 0.0008931792690418661
splice O 0 3.952319821109995e-05
site O 0 2.91051628664718e-06
mutation O 0 4.267198619345436e-06
. O 0 6.403739462257363e-06

After O 0 1.0986577763105743e-06
initial O 0 2.927975515376602e-07
treatment O 0 8.737439429751248e-07
with O 0 4.748454074388064e-08
intravenous O 0 0.0002469847968313843
glucose O 0 2.075997144856956e-05
and O 0 7.22216881854365e-08
carnitine O 0 9.621374192647636e-05
, O 0 2.766791951103187e-08
the O 0 2.78450595914137e-08
patient O 0 1.0309527453955525e-07
has O 0 7.050250605544761e-09
thrived O 0 8.57312016933065e-08
on O 0 7.187152206711289e-09
a O 0 6.69018529464438e-09
low O 0 3.9354435443783586e-07
- O 0 2.0415220092218078e-07
fat O 0 5.736956865121101e-08
diet O 0 6.1003428974970575e-09
supplemented O 0 3.287324856771079e-09
with O 0 2.4352657668202937e-09
medium O 0 2.2711928977514617e-06
- O 0 6.170654387460672e-07
chain O 0 2.510808201350301e-07
triglyceride O 0 1.6910724980334635e-06
oil O 0 7.110822366485081e-07
and O 0 2.4563432177160394e-08
carnitine O 0 5.081361905467929e-06
and O 0 4.687210619636062e-08
avoidance O 0 2.5548015401000157e-05
of O 0 3.8678658711432945e-06
fasting O 0 8.867945325619075e-06
. O 0 2.979511464218376e-06

Her O 0 3.458263381617144e-05
ventricular O 1 0.986406147480011
hypertrophy O 1 0.8799809217453003
resolved O 0 7.245982124004513e-05
significantly O 0 1.1337293699398288e-06
over O 0 3.108522150796489e-08
1 O 0 5.53846462025831e-08
year O 0 1.7762223913919684e-09
, O 0 8.616356517165968e-10
and O 0 1.4252380386992058e-09
cognitively O 0 3.999246473540552e-06
, O 0 6.0293179338088976e-09
she O 0 3.091615408123971e-09
is O 0 5.015228232707614e-10
in O 0 4.825683186382435e-10
the O 0 2.7288511450507258e-09
superior O 0 4.174708294613083e-07
range O 0 4.115743124089022e-08
for O 0 2.857604641803846e-08
age O 0 2.200375774918939e-06
. O 0 2.530730171201867e-06

Clinical O 0 3.749043389689177e-05
recognition O 0 1.8798351447912864e-05
of O 1 0.987618088722229
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 8.83643849647342e-07
important O 0 1.6099930633117765e-07
because O 0 2.9760427455727267e-09
it O 0 3.043566787486185e-10
is O 0 4.4965819956388486e-10
one O 0 1.462122506401542e-10
of O 0 1.7357447701371598e-09
the O 0 2.247926289555835e-09
few O 0 5.653723267329269e-09
directly O 0 8.34477091871122e-08
treatable O 0 0.0013356920098885894
causes O 0 1.7288343201471434e-07
of O 0 1.538113247079309e-05
cardiomyopathy B-Disease 1 1.0
in O 0 2.975982533826027e-05
children O 0 8.672586773172952e-07
. O 0 3.306601286112709e-07
. O 0 3.5783521070698043e-06

Cloning O 0 1.2121709914936218e-05
of O 0 1.205605855147951e-07
a O 0 4.3800078231015505e-08
novel O 0 1.2446835562229808e-08
member O 0 1.0840308206638838e-08
of O 0 8.152890806911728e-09
the O 0 7.0691017484136864e-09
low O 0 7.049741839182389e-07
- O 0 2.3978736862773076e-07
density O 0 4.1362753222529136e-08
lipoprotein O 0 1.9286795577500015e-05
receptor O 0 3.5010784813493956e-06
family O 0 1.1514623565744841e-06
. O 0 2.9994798751431517e-06

A O 0 2.9001816983509343e-06
gene O 0 1.0047070020391402e-07
encoding O 0 2.9659355504918494e-07
a O 0 6.036545840970575e-08
novel O 0 6.443433164804446e-08
transmembrane O 0 1.4450546359512373e-06
protein O 0 7.138599755762698e-08
was O 0 2.1932676119718053e-08
identified O 0 1.2673089244685798e-09
by O 0 8.451872535175653e-11
DNA O 0 1.7675401142724922e-09
sequence O 0 5.877167086332236e-10
analysis O 0 5.416613824138494e-10
within O 0 1.9537849116346706e-09
the O 0 6.2729674787931344e-09
insulin B-Disease 0 8.011329555301927e-06
- I-Disease 0 0.0022085695527493954
dependent I-Disease 1 0.9980738162994385
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 8.54587233334314e-06
IDDM B-Disease 1 0.9726747870445251
) O 0 1.0283584117587452e-07
locus O 0 6.516962116620562e-07
IDDM4 O 0 4.993294714950025e-05
on O 0 7.632743290741928e-07
chromosome O 0 9.004209459817503e-06
11q13 O 0 3.334307257318869e-05
. O 0 3.3527310279168887e-06

Based O 0 7.143788707253407e-07
on O 0 1.3065876203199878e-07
its O 0 9.649240517717317e-09
chromosomal O 0 3.128656089756987e-06
position O 0 9.738657809066353e-07
, O 0 5.314788609211973e-09
this O 0 6.00957894558718e-10
gene O 0 6.847819644661968e-09
is O 0 7.589447958977757e-10
a O 0 2.339739735290891e-09
candidate O 0 7.1667147771847795e-09
for O 0 4.036743828095268e-09
conferring O 0 1.7768351199265453e-06
susceptibility O 0 3.52732022292912e-05
to O 0 1.5058294593472965e-06
diabetes B-Disease 1 0.9999676942825317
. O 0 4.617699232767336e-05

The O 0 7.998984301593737e-07
gene O 0 3.054410342429037e-07
, O 0 3.021837713390596e-08
termed O 0 1.977793857577126e-07
low O 0 6.84823362462339e-07
- O 0 1.585197111353409e-07
density O 0 1.379961478420455e-08
lipoprotein O 0 2.1935085214863648e-07
receptor O 0 8.236263937533295e-08
related O 0 8.56752961908569e-08
protein O 0 1.2039468799684983e-07
5 O 0 1.0084200852134018e-07
( O 0 9.300918257793e-09
LRP5 O 0 6.566235697391676e-06
) O 0 8.258630224133867e-09
, O 0 2.1191555177324517e-09
encodes O 0 1.0887946544357874e-08
a O 0 2.780398133950257e-08
protein O 0 4.828892485875258e-08
of O 0 4.176483869855474e-08
1615 O 0 3.3281155538134044e-06
amino O 0 4.392883923287627e-08
acids O 0 8.527225148213802e-09
that O 0 5.78088799052523e-10
contains O 0 2.5717508123079824e-09
conserved O 0 5.6049263008617345e-08
modules O 0 7.167155047227425e-08
which O 0 1.8768153697834578e-10
are O 0 4.5852491942222073e-11
characteristic O 0 1.5407616293927617e-09
of O 0 2.0239414588729687e-09
the O 0 1.9164776432489816e-09
low O 0 1.6439517480648647e-07
- O 0 5.5104049323517756e-08
density O 0 1.3322163816553712e-08
lipoprotein O 0 1.6271278582280502e-06
( O 0 1.428127802682866e-07
LDL O 0 1.3576026503869798e-05
) O 0 5.494430297403596e-07
receptor O 0 4.882012945017777e-06
family O 0 1.1081472166551976e-06
. O 0 1.788721192497178e-06

These O 0 1.0211869749809921e-07
modules O 0 1.2565719771373551e-06
include O 0 3.769312328927299e-08
a O 0 4.8797133445077634e-08
putative O 0 2.3478709465507563e-07
signal O 0 3.238881447487074e-07
peptide O 0 4.362208017028024e-08
for O 0 5.327922547593289e-09
protein O 0 3.280305449493426e-08
export O 0 3.9180743982569766e-08
, O 0 4.551185206480568e-09
four O 0 1.0217672041790138e-08
epidermal O 0 4.842967769036477e-07
growth O 0 8.041758547960853e-08
factor O 0 2.0698342950709048e-07
( O 0 4.254960828120602e-08
EGF O 0 5.643916665576398e-06
) O 0 2.1598820509893812e-08
repeats O 0 3.4895297318371377e-08
with O 0 3.370278944814231e-09
associated O 0 1.4495734035335772e-07
spacer O 0 2.300330834259512e-06
domains O 0 6.691323619634204e-07
, O 0 3.049281716016594e-08
three O 0 2.8882521263540184e-08
LDL O 0 1.396301195200067e-05
- O 0 3.653730163932778e-05
receptor O 0 3.8536097690666793e-07
( O 0 1.9514285298782852e-08
LDLR O 0 3.257602293160744e-05
) O 0 5.097085864491646e-09
repeats O 0 1.3906996443324715e-08
, O 0 1.0620924140170018e-09
a O 0 1.300141660998122e-09
single O 0 2.4709652102217206e-09
transmembrane O 0 1.988293689692e-07
spanning O 0 1.9589285216170538e-07
domain O 0 2.3271194038443355e-07
, O 0 1.0483985235509863e-08
and O 0 8.716114940909847e-09
a O 0 8.380627747328617e-08
cytoplasmic O 0 2.2502499632537365e-06
domain O 0 6.002280770189827e-06
. O 0 5.129192231834168e-06

The O 0 1.0305894875273225e-06
encoded O 0 1.2268362752365647e-06
protein O 0 1.8920123068255634e-07
has O 0 2.3568313967103904e-09
a O 0 1.917154213160188e-09
unique O 0 1.3654609665181283e-09
organization O 0 4.701014244545831e-09
of O 0 7.64317533707981e-08
EGF O 0 0.0001250941859325394
and O 0 1.9321313970976917e-07
LDLR O 0 0.345628559589386
repeats O 0 5.655682571159559e-07
; O 0 7.420914105438214e-09
therefore O 0 3.082249477870391e-08
, O 0 1.2486021105928558e-08
LRP5 O 0 3.134931102977134e-05
likely O 0 2.6054145507714566e-08
represents O 0 4.20938306433527e-09
a O 0 1.320359044321151e-09
new O 0 1.1800638244352513e-09
category O 0 8.420938613085127e-09
of O 0 9.380985765972127e-09
the O 0 9.034609149694006e-08
LDLR O 0 0.12421553581953049
family O 0 9.686526709629106e-07
. O 0 1.6464257441839436e-06

Both O 0 1.193876528304827e-06
human O 0 2.95943181072289e-07
and O 0 7.79642164161487e-08
mouse O 0 1.1281114211669774e-06
LRP5 O 0 0.013703455217182636
cDNAs O 0 3.977634696639143e-05
have O 0 5.078124143409468e-09
been O 0 6.092366167109731e-09
isolated O 0 4.299501643600934e-09
and O 0 2.3249070724151721e-10
the O 0 5.031295380319989e-10
encoded O 0 4.726295799173386e-09
mature O 0 6.1526814754131465e-09
proteins O 0 7.877790642041305e-10
are O 0 1.9848468701955113e-10
95 O 0 7.662745993286535e-09
% O 0 2.5827027183566997e-09
identical O 0 5.627837307287109e-09
, O 0 8.131239015440883e-10
indicating O 0 5.717640139124569e-09
a O 0 1.72123870711971e-09
high O 0 1.2892818368470671e-08
degree O 0 5.5460866121848085e-08
of O 0 7.1066308393596955e-09
evolutionary O 0 1.0394370519861695e-07
conservation O 0 6.874336122564273e-08
. O 0 2.2445814096272443e-08
. O 0 4.0123438793671085e-07

The O 0 2.5751839984877734e-06
APC B-Disease 0 4.353697931946954e-06
variants O 0 8.456414661850431e-07
I1307K O 0 3.1935594506649068e-06
and O 0 1.1300357982690912e-08
E1317Q O 0 5.062851755610609e-07
are O 0 8.442194165958483e-10
associated O 0 1.5694986643666198e-07
with O 0 0.026520688086748123
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 4.0933362470241264e-05
but O 0 4.597270830686284e-08
not O 0 6.439855315676368e-09
always O 0 1.205100819134941e-08
with O 0 2.710265567529291e-09
a O 0 7.672797153190913e-08
family O 0 3.437251905324956e-08
history O 0 3.8367414845197345e-07
. O 0 8.907467758945131e-07

Classical O 1 0.9989225268363953
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.0077769821509718895
FAP B-Disease 0 0.0005392449675127864
) O 0 3.3195394166796177e-07
is O 0 1.4542418824703418e-08
a O 0 4.256275687453126e-08
high O 0 3.2410862331744283e-05
- O 0 0.04393453896045685
penetrance O 1 0.9993044137954712
autosomal B-Disease 1 0.9999737739562988
dominant I-Disease 1 0.9999997615814209
disease I-Disease 1 0.9874266386032104
that O 0 1.3984241320486035e-08
predisposes O 0 8.15645478269289e-07
to O 0 9.666814904107923e-09
hundreds O 0 2.643436936011767e-08
or O 0 1.4627934419308986e-08
thousands O 0 3.717547869541704e-08
of O 1 0.9631629586219788
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999995231628418
carcinoma I-Disease 1 1.0
and O 0 3.5997197755932575e-07
that O 0 2.0127581823459195e-09
results O 0 5.096949973193432e-09
from O 0 7.215955832862164e-09
truncating O 0 2.396876652710489e-07
mutations O 0 2.7932829382848468e-08
in O 0 1.0100095870768655e-08
the O 0 1.2758691525505128e-07
APC B-Disease 0 1.2194351256766822e-05
gene O 0 9.705996490083635e-06
. O 0 8.397575584240258e-06

A O 0 4.402414106152719e-06
variant O 0 2.7259866328677163e-06
of O 0 7.932180210445949e-07
FAP B-Disease 0 6.223325908649713e-05
is O 0 4.026030183013063e-06
attenuated B-Disease 1 0.9841372966766357
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999995231628418
coli I-Disease 1 0.9954223036766052
, O 0 1.4620897559325385e-07
which O 0 2.7209148267814953e-09
results O 0 1.770733248918077e-08
from O 0 2.587004246379365e-07
germ O 1 0.9997453093528748
- O 0 4.586192972055869e-06
line O 0 1.4391544311820326e-07
mutations O 0 4.9600732410226556e-09
in O 0 2.096689044606137e-09
the O 0 8.948735974456667e-09
5 O 0 3.314082519523254e-08
and O 0 1.8550992963994872e-09
3 O 0 2.4560199207712685e-08
regions O 0 9.51378620328569e-09
of O 0 2.0738484707294447e-08
the O 0 5.144203640838896e-08
APC B-Disease 0 3.4217307529615937e-06
gene O 0 2.3364066237263614e-06
. O 0 2.594960506030475e-06

Attenuated B-Disease 1 0.9999408721923828
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 0.9999969005584717
patients O 0 9.764846709003905e-07
have O 0 3.819208949096264e-09
" O 0 1.2833639928544471e-08
multiple O 0 2.3698424911344773e-07
" O 0 0.002580506494268775
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 3.004905977377348e-07
typically O 0 1.3447641222796847e-08
fewer O 0 7.983877559070152e-09
than O 0 1.0723106846910468e-09
100 O 0 7.027749049370868e-09
) O 0 4.220829519230307e-10
without O 0 1.5423023969063365e-09
the O 0 3.848231067138386e-09
florid O 0 4.663721426823031e-07
phenotype O 0 2.1143200967799203e-08
of O 0 4.753664839540761e-08
classical O 0 2.248810778837651e-05
FAP B-Disease 0 7.215168443508446e-05
. O 0 1.5941970559651963e-05

Another O 0 4.3763852772826795e-06
group O 0 2.5791803182073636e-07
of O 0 3.4363941381343466e-07
patients O 0 2.572910773324111e-07
with O 0 3.8726785334119995e-08
multiple O 0 3.262451718910597e-05
adenomas B-Disease 1 0.9852839708328247
has O 0 2.0119417243336102e-08
no O 0 1.768002988455919e-08
mutations O 0 8.656224181891048e-09
in O 0 2.70230082755063e-09
the O 0 1.1636919872159979e-08
APC B-Disease 0 2.1697819363453164e-07
gene O 0 3.9911544291726386e-08
, O 0 6.146054332134554e-09
and O 0 1.6703449734478681e-09
their O 0 1.3500627282780897e-09
phenotype O 0 1.505955182778962e-08
probably O 0 1.0919475101900389e-08
results O 0 2.205044813408108e-09
from O 0 2.3708262020250004e-09
variation O 0 4.5819511740319285e-08
at O 0 9.438169001896313e-08
a O 0 1.3855262714912442e-08
locus O 0 3.731877384893778e-08
, O 0 3.6606997433352717e-09
or O 0 2.5967903383161683e-09
loci O 0 2.7764608390157264e-08
, O 0 7.513001776260353e-09
elsewhere O 0 3.9773464521886126e-08
in O 0 7.779142663366656e-09
the O 0 3.1656632870635804e-08
genome O 0 2.254942899071466e-07
. O 0 4.958723707204626e-07

Recently O 0 1.1303566679998767e-05
, O 0 1.3412653743216651e-07
however O 0 5.513958356573312e-08
, O 0 9.866880645859055e-09
a O 0 2.0654519872209676e-08
missense O 0 4.467192411539145e-07
variant O 0 3.5132924836034363e-07
of O 0 5.848518185302964e-07
APC B-Disease 0 1.5543646441074088e-05
( O 0 5.775387990070158e-07
I1307K O 0 3.2761949114501476e-05
) O 0 2.2043140646132997e-08
was O 0 1.5921497720228217e-07
described O 0 4.708875511738597e-09
that O 0 4.274321868669162e-11
confers O 0 1.0518551585292357e-09
an O 0 7.215508746050148e-11
increased O 0 6.594810919580141e-09
risk O 0 2.39412372593506e-07
of O 1 0.5066990852355957
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.922701358125778e-06
including O 0 3.276682036812417e-07
multiple O 0 2.3497341317124665e-05
adenomas B-Disease 1 0.9995154142379761
, O 0 5.556917699323094e-07
in O 0 1.0343360372644383e-06
Ashkenazim O 0 0.0015758391236886382
. O 0 1.7891230527311563e-05

We O 0 5.086677106191928e-07
have O 0 1.183526787684741e-08
studied O 0 9.887060770097378e-08
a O 0 2.7268844959849048e-09
set O 0 2.850596869663491e-09
of O 0 3.107002877200671e-09
164 O 0 1.530464288634903e-08
patients O 0 3.813923399320629e-09
with O 0 5.071967734693317e-09
multiple O 1 0.9996294975280762
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9925785660743713
/ I-Disease 1 1.0
or I-Disease 1 0.9998063445091248
carcinoma I-Disease 1 1.0
and O 0 3.7839936339878477e-07
analyzed O 0 1.1705146789608989e-06
codons O 0 9.860523277893662e-07
1263 O 0 2.3923805201775394e-05
- O 0 5.4648185141559225e-06
1377 O 0 4.872545468970202e-05
( O 0 2.483860157553863e-07
exon O 0 2.347823465242982e-05
15G O 0 1.1417475434427615e-05
) O 0 7.604956664408746e-09
of O 0 1.507993019345122e-08
the O 0 2.4358289607562256e-08
APC B-Disease 0 5.388723707255849e-07
gene O 0 1.407705383371649e-07
for O 0 2.4922147190409305e-07
germ O 1 0.9999537467956543
- O 0 0.00025657282094471157
line O 0 8.925162546802312e-06
variants O 0 6.153087269922253e-06
. O 0 2.0239115201547975e-06

Three O 0 2.2606861875829054e-06
patients O 0 2.2250510767207743e-07
with O 0 1.00898907007263e-08
the O 0 4.2890526685823716e-08
I1307K O 0 7.120744385247235e-07
allele O 0 2.4668603160193925e-08
were O 0 1.0808945738460807e-08
detected O 0 2.4463050252165885e-08
, O 0 4.0071615470260724e-10
each O 0 3.6142216996992715e-10
of O 0 7.050653838547305e-09
Ashkenazi O 0 1.5795457102285582e-06
descent O 0 5.782001608167775e-06
. O 0 3.985400326200761e-06

Four O 0 1.03877937362995e-05
patients O 0 7.122277111193398e-06
had O 0 1.5324702644647914e-06
a O 0 2.177799615310505e-06
germ O 1 0.9973224997520447
- O 0 4.813370651390869e-06
line O 0 6.650860768786515e-07
E1317Q O 0 1.743001689646917e-06
missense O 0 6.528812264150474e-07
variant O 0 1.4405715376142325e-07
of O 0 1.3566074130721972e-07
APC O 0 6.808932084823027e-07
that O 0 3.1525981825097915e-09
was O 0 3.718519536732856e-08
not O 0 2.16915235773385e-10
present O 0 7.698267023847905e-10
in O 0 1.3346241889422572e-09
controls O 0 4.992099178480203e-08
; O 0 7.268997626042051e-10
one O 0 3.9396522155676905e-10
of O 0 1.540467864380446e-09
these O 0 5.174171646693537e-10
individuals O 0 1.7331115431673538e-09
had O 0 1.0108595738245185e-08
an O 0 4.077172488514691e-10
unusually O 0 2.897547979330284e-09
large O 0 3.559477990133786e-10
number O 0 4.516092499962099e-10
of O 0 1.0918892456857066e-08
metaplastic B-Disease 0 1.2340186003712006e-05
polyps I-Disease 0 1.42749888709659e-06
of I-Disease 0 1.314708555355537e-07
the I-Disease 0 5.479208766701049e-07
colorectum I-Disease 0 0.0001506055996287614
. O 0 3.2600951271888334e-06

There O 0 5.21447532264574e-07
is O 0 1.1182431869372067e-08
increasing O 0 7.085895425973376e-09
evidence O 0 1.4940903625415558e-08
that O 0 4.0848865956455427e-10
there O 0 2.9657862832266346e-09
exist O 0 5.9004012342711576e-08
germ O 0 0.0025499174371361732
- O 0 2.0648619170060556e-07
line O 0 3.2050138543127105e-08
variants O 0 7.4253030390991626e-09
of O 0 6.45205178173569e-09
the O 0 1.0188675680922188e-08
APC B-Disease 0 1.4272863779751788e-07
gene O 0 1.2709042707115259e-08
that O 0 4.262917241426578e-10
predispose O 0 2.5768390088387605e-08
to O 0 1.4364546219169938e-09
the O 0 3.3029112778137915e-09
development O 0 1.5329300495636744e-08
of O 0 3.889059883022128e-07
multiple O 1 0.9999966621398926
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999998807907104
carcinoma I-Disease 1 1.0
, O 0 3.03260026157659e-06
but O 0 1.7468918755980667e-08
without O 0 1.541988403630512e-08
the O 0 6.335941105106713e-09
florid O 0 8.952082453106414e-07
phenotype O 0 3.689996930233974e-08
of O 0 2.8077693059458397e-08
classical O 0 1.1752902537409682e-05
FAP B-Disease 0 3.5783111798082246e-06
, O 0 2.0459962613017524e-08
and O 0 3.1547757739502913e-09
possibly O 0 1.727689813435518e-08
with O 0 9.796218281010738e-10
importance O 0 4.245380750944605e-06
for O 0 0.0129464790225029
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 0.0014815996401011944
in O 0 2.8995122747232926e-08
the O 0 1.5506831374523244e-08
general O 0 5.1459402072850935e-08
population O 0 3.959013561427582e-09
. O 0 4.129070774183674e-08
. O 0 5.820890578434046e-07

Genomic O 0 2.2595551854465157e-05
structure O 0 4.5826386667613406e-06
of O 0 3.228747118555475e-07
the O 0 7.374255233116855e-07
human O 0 0.20995277166366577
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999884366989136
CLD B-Disease 1 1.0
) O 0 2.5149034627247602e-05
gene O 0 1.4909533092577476e-05
. O 0 5.718020020140102e-06

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999678134918213
CLD B-Disease 1 1.0
) O 0 1.7550124766785302e-06
is O 0 2.7320240292283415e-08
caused O 0 1.4468272802048432e-08
by O 0 5.651326628886011e-10
mutations O 0 4.173018375297488e-09
in O 0 1.6969016192192043e-09
a O 0 8.479703161867747e-09
gene O 0 7.803677704032452e-09
which O 0 1.8381577371329172e-09
encodes O 0 2.087460515554085e-08
an O 0 2.6441579592528797e-08
intestinal O 0 0.08193883299827576
anion O 0 0.0006364352884702384
transporter O 0 0.3430764079093933
. O 0 2.2782978703617118e-05

We O 0 6.283771654125303e-07
report O 0 8.421648090006784e-08
here O 0 1.1050762083186783e-08
the O 0 1.3968345369264057e-09
complete O 0 9.035399095580487e-09
genomic O 0 2.7728409790483965e-08
organization O 0 1.587025844074219e-09
of O 0 5.853810769451684e-09
the O 0 1.6842975014697004e-08
human O 0 2.7816349756903946e-07
CLD B-Disease 0 0.008816140703856945
gene O 0 2.1761211144166737e-07
which O 0 1.0406327355383382e-08
spans O 0 1.8500725218473235e-07
approximately O 0 3.8617617548197813e-08
39kb O 0 3.103864855802385e-06
, O 0 1.0918392412406774e-08
and O 0 9.203471762475601e-09
comprises O 0 3.452792611824407e-07
21 O 0 5.0332291721133515e-06
exons O 0 3.096872751484625e-05
. O 0 3.924689735868014e-06

All O 0 1.0506331818760373e-05
exon O 0 0.0008124505984596908
/ O 0 8.002349932212383e-05
intron O 0 3.2864525564946234e-05
boundaries O 0 2.1254052740005136e-07
conform O 0 2.565711838542484e-07
to O 0 3.9739344259714926e-08
the O 0 2.6738962333183736e-07
GT O 0 0.00045941866119392216
/ O 0 0.401727557182312
AG O 1 0.9865297079086304
rule O 0 2.5828137950156815e-05
. O 0 1.0592368198558688e-05

An O 0 1.9764873115946102e-07
analysis O 0 2.1228224511560256e-07
of O 0 9.970119663194055e-08
the O 0 9.887004637221253e-08
putative O 0 2.1029154595453292e-06
promoter O 0 2.4276891053887084e-05
region O 0 4.208349935197475e-07
sequence O 0 6.885699832537284e-08
shows O 0 9.616870499939978e-08
a O 0 1.3723774827667512e-07
putative O 0 3.765493374885409e-06
TATA O 0 0.0001604764984222129
box O 0 3.516021479299525e-06
and O 0 1.7392718376640914e-08
predicts O 0 9.273819756572266e-08
multiple O 0 1.9921118976640173e-08
transcription O 0 4.660876129491953e-07
factor O 0 1.4011638427291473e-07
binding O 0 1.0226020208392583e-07
sites O 0 3.579191059088771e-07
. O 0 1.3268930842968985e-06

The O 0 9.97816300696286e-07
genomic O 0 4.394846655486617e-06
structure O 0 3.7448514831339708e-06
was O 0 5.636068181047449e-07
determined O 0 2.8438428500976443e-08
using O 0 7.22047133194792e-09
DNA O 0 1.225176227137581e-08
from O 0 6.071007585539689e-10
several O 0 2.8372029725609593e-10
sources O 0 2.1805484085035687e-09
including O 0 6.579404243645115e-10
multiple O 0 7.391728562566868e-09
large O 0 6.82324667877765e-08
- O 0 6.206122975527251e-07
insert O 0 2.287857370220081e-07
libaries O 0 1.3180847417970654e-06
and O 0 6.648119388330542e-09
genomic O 0 1.1843051339610611e-07
DNA O 0 1.8873268459174142e-07
from O 0 1.0924666327127852e-07
Finnish O 1 0.9900222420692444
CLD B-Disease 1 0.9999995231628418
patients O 0 2.655291245901026e-05
and O 0 5.22230379829125e-07
controls O 0 0.00014819201896898448
. O 0 7.423085662594531e-06

Exon O 0 0.00027678473270498216
- O 0 9.278982702198846e-07
specific O 0 2.718644154242611e-08
primers O 0 3.417158325191849e-07
developed O 0 3.149077798525468e-08
in O 0 6.858849599389316e-10
this O 0 5.82193737663772e-11
study O 0 2.0805064615547764e-10
will O 0 7.249802841391428e-11
facilitate O 0 2.277532384908909e-09
mutation O 0 1.069989763458068e-09
screening O 0 8.626359182528631e-09
studies O 0 5.816637393962765e-09
of O 0 1.3715539814995736e-08
patients O 0 2.236632390406612e-08
with O 0 1.4326876573989011e-08
the O 0 3.7579741274385015e-06
disease O 0 0.35398536920547485
. O 0 4.09405129175866e-06

Genomic O 0 4.831282694794936e-06
sequencing O 0 2.384174422331853e-06
of O 0 1.049828142640763e-06
a O 0 1.1808820090664085e-05
BAC O 1 0.9999958276748657
clone O 0 0.3133235573768616
H O 1 0.9999997615814209
_ O 0 9.41560927003593e-07
RG364P16 O 0 5.877649982721778e-06
revealed O 0 9.76190648316333e-08
the O 0 2.4245687679780303e-09
presence O 0 6.421089437935734e-09
of O 0 4.08540268281854e-09
another O 0 8.569061904495356e-09
, O 0 1.6245497169720124e-09
highly O 0 1.4677961956977015e-08
homologous O 0 1.220914214172808e-08
gene O 0 1.3508567597853016e-08
3 O 0 4.551013788045566e-08
of O 0 4.1342321566162354e-08
the O 0 2.5424893124181835e-07
CLD B-Disease 1 0.8587742447853088
gene O 0 1.8760572118026175e-07
, O 0 4.0923282540461514e-09
with O 0 8.461216172150898e-10
a O 0 3.234687406816761e-09
similar O 0 1.2498619916812004e-09
genomic O 0 5.342721820511542e-08
structure O 0 2.67187004965308e-07
, O 0 7.282823233367708e-09
recently O 0 1.9011512364386363e-08
identified O 0 6.771759153423318e-09
as O 0 6.009157615949334e-09
the O 0 2.1841174202563707e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 3.3701464417390525e-05
( O 0 5.136887466505868e-06
PDS B-Disease 0 0.05691218003630638
) O 0 3.738710177003668e-07
. O 0 3.494062639219919e-07
. O 0 2.4659063910803525e-06

The O 0 1.5798755157447886e-06
APCI1307K O 0 0.0010857840534299612
allele O 0 1.3449804328047321e-06
and O 0 2.23473350047243e-07
cancer B-Disease 0 3.9072183426469564e-05
risk O 0 6.910045158292633e-07
in O 0 1.3280303079454825e-08
a O 0 1.577791053364308e-08
community O 0 3.7134004760019934e-09
- O 0 2.516306452093886e-08
based O 0 1.386056824870252e-09
study O 0 3.5834375466947677e-09
of O 0 4.5812786453325316e-08
Ashkenazi O 0 1.3062930520391092e-05
Jews O 0 3.310155079816468e-06
. O 0 3.532910795911448e-06

Mutations O 0 1.0210257642029319e-05
in O 0 5.324704943632241e-07
APC O 0 3.3360884117428213e-06
are O 0 2.030705559263879e-08
classically O 0 8.327514478878584e-06
associated O 0 1.7454718772569322e-06
with O 0 7.321710199903464e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.3333761394023895
FAP B-Disease 0 0.002151904394850135
) O 0 2.393229010522191e-07
, O 0 2.597673720572402e-08
a O 0 5.1471577222628184e-08
highly O 0 1.0079822459374554e-05
penetrant O 1 0.9996442794799805
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.27185285091400146
by O 0 6.496422884083586e-07
multiple O 1 0.7926250100135803
intestinal O 1 0.9999998807907104
polyps B-Disease 0 0.04517947882413864
and O 0 8.925403705006829e-08
, O 0 1.7124049733752145e-08
without O 0 1.7726263479289628e-07
surgical O 0 0.0016985404072329402
intervention O 0 8.922541383071803e-06
, O 0 4.703776923520309e-09
the O 0 2.5121764668512014e-09
development O 0 5.030844931752654e-07
of O 1 0.9958177208900452
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.08954957127571106
CRC B-Disease 1 0.8839717507362366
) O 0 1.8853222627512878e-06
. O 0 3.950050540879602e-06

APC B-Disease 0 9.550175309414044e-05
is O 0 8.020319341994764e-07
a O 0 4.204733613732969e-06
tumour O 1 0.9999998807907104
- O 0 0.0007238730904646218
suppressor O 0 7.577927135571372e-06
gene O 0 1.3792804054446606e-07
, O 0 1.150674311389821e-08
and O 0 2.3829775486206017e-08
somatic O 0 8.391971277887933e-06
loss O 0 6.5971175899903756e-06
occurs O 0 2.8503186513262335e-06
in O 0 4.270479621482082e-06
tumours B-Disease 1 1.0
. O 0 7.744359027128667e-05

The O 0 1.54274093802087e-05
germline O 0 0.0004303855530451983
T O 0 0.00010512237349757925
- O 0 2.071073595288908e-06
to O 0 1.3051563385602094e-08
- O 0 3.31252863361442e-07
A O 0 1.5754221749375574e-07
transversion O 0 5.363858122109377e-07
responsible O 0 2.1659174009869275e-08
for O 0 4.370491968330725e-09
the O 0 2.1288107276973278e-08
APC O 0 4.2391567944832786e-07
I1307K O 0 1.3180344922147924e-06
allele O 0 3.634417566900083e-08
converts O 0 3.855359054227847e-08
the O 0 5.366525890337925e-09
wild O 0 6.65935129262607e-09
- O 0 5.0069917101325245e-09
type O 0 2.2580075587086412e-09
sequence O 0 8.071685542176965e-10
to O 0 1.1497106600089069e-09
a O 0 7.946068336650569e-08
homopolymer O 0 0.3000735640525818
tract O 0 0.4276679754257202
( O 0 7.865469342505094e-07
A8 O 0 3.012655724887736e-05
) O 0 1.0713135267792495e-08
that O 0 1.3395846654162824e-09
is O 0 7.670672097503939e-09
genetically O 0 1.5807134445822157e-07
unstable O 0 5.157268333277898e-06
and O 0 6.324412282765479e-08
prone O 0 5.983700702927308e-06
to O 0 6.887512427056208e-08
somatic O 0 3.065117562073283e-05
mutation O 0 3.060083145101089e-06
. O 0 3.3494263789179968e-06

The O 0 1.8806747448252281e-06
I1307K O 0 1.175283523480175e-05
allele O 0 5.230118631516234e-07
was O 0 6.616148766624974e-07
found O 0 4.070043857495875e-08
in O 0 5.0137028750896206e-08
6 O 0 4.0387126318819355e-06
. O 0 1.540063863103569e-06

1 O 0 9.950103958544787e-06
% O 0 1.854631932474149e-07
of O 0 3.58143751100215e-07
unselected O 0 0.00710766576230526
Ashkenazi O 0 5.237743607722223e-06
Jews O 0 3.1787806165084476e-08
and O 0 1.597019183563475e-09
higher O 0 5.2748600154473024e-08
proportions O 0 4.615774429339581e-08
of O 0 6.554721920792872e-08
Ashkenazim O 0 7.638564056833275e-06
with O 0 4.532691733061256e-08
family O 0 3.076194232676244e-08
or O 0 7.005947377791699e-09
personal O 0 1.1318179815589247e-07
histories O 0 4.344517776644352e-07
of O 0 4.4580015128303785e-06
CRC B-Disease 1 0.5961368083953857
( O 0 1.5265728734448203e-06
ref O 0 0.00021007086616009474
. O 0 1.503053113083297e-07
2 O 0 2.641021410454414e-06
) O 0 1.3150747690815479e-07
. O 0 8.719925403966045e-07

To O 0 2.0055553306974616e-07
evaluate O 0 1.420067519575241e-06
the O 0 7.377786914730677e-08
role O 0 2.7613361908152e-07
of O 0 1.6198850971704815e-07
I1307K O 0 1.8297872884431854e-05
in O 0 1.4212839971605717e-07
cancer B-Disease 0 4.593940957420273e-06
, O 0 1.5059953284435323e-08
we O 0 1.67646128090837e-08
genotyped O 0 3.676768528748653e-06
5 O 0 3.3727152981555264e-07
, O 0 3.0344981638563695e-08
081 O 0 1.8080367226502858e-05
Ashkenazi O 0 1.187607040264993e-06
volunteers O 0 9.426636893294926e-08
in O 0 1.434459484528361e-08
a O 0 2.1626396673468662e-08
community O 0 2.8504787863425918e-08
survey O 0 1.7252833117709088e-07
. O 0 5.647043508361094e-07

Risk O 0 2.4205228328355588e-05
of O 0 3.0356095521710813e-06
developing O 1 0.9973810315132141
colorectal B-Disease 1 1.0
, I-Disease 0 3.738208397408016e-05
breast I-Disease 0 0.11177215725183487
and I-Disease 0 1.1754619322346116e-07
other I-Disease 0 2.6665699692784983e-07
cancers I-Disease 1 0.6747532486915588
were O 0 1.006208592002622e-07
compared O 0 1.5290935095890745e-07
between O 0 2.830566359079967e-07
genotyped O 0 8.50405285746092e-06
I1307K O 0 4.6508188233929104e-07
carriers O 0 9.710666937223777e-09
and O 0 9.334236716895816e-10
non O 0 8.011675589614242e-08
- O 0 7.915195254781793e-08
carriers O 0 5.546125780853117e-09
and O 0 2.3769919366145587e-10
their O 0 9.747826851258523e-11
first O 0 6.183870748799336e-09
- O 0 1.0841469588740438e-07
degree O 0 2.065522949123988e-06
relatives O 0 6.140070354376803e-07
. O 0 8.596401244176377e-07

Sperm O 0 1.197169240185758e-06
DNA O 0 5.816517614221084e-07
analysis O 0 4.1330263655936506e-08
in O 0 2.9391962641511782e-08
a O 0 5.859834573129774e-07
Friedreich B-Disease 1 0.8367820382118225
ataxia I-Disease 1 0.9703301787376404
premutation O 0 0.04926200956106186
carrier O 0 3.1903156923362985e-05
suggests O 0 1.2971274827577872e-06
both O 0 8.922373240238812e-08
meiotic O 0 1.9241457266616635e-05
and O 0 4.202509984452263e-08
mitotic O 0 1.5826473145352793e-06
expansion O 0 2.8880768354611064e-07
in O 0 1.1080986794809178e-08
the O 0 4.813260190417168e-08
FRDA B-Disease 0 0.00034622190287336707
gene O 0 1.1961900554524618e-06
. O 0 1.7803190530685242e-06

Friedreich B-Disease 1 0.9999959468841553
ataxia I-Disease 1 0.9999908208847046
is O 0 3.635836492321687e-06
usually O 0 1.1005625566440358e-07
caused O 0 4.368227735085384e-08
by O 0 7.198617812953501e-10
an O 0 8.053324673795714e-10
expansion O 0 1.787630168337273e-07
of O 0 1.6920584755553136e-07
a O 0 5.737733204114193e-07
GAA O 0 0.00031534157460555434
trinucleotide O 0 0.0035996483638882637
repeat O 0 2.2082756458985386e-06
in O 0 1.5016448173810204e-07
intron O 0 2.8665233912761323e-05
1 O 0 1.3918694321546354e-06
of O 0 1.4052494634597679e-07
the O 0 5.662898843183939e-07
FRDA B-Disease 0 0.005309101659804583
gene O 0 4.742213604913559e-06
. O 0 4.387819444673369e-06

Occasionally O 0 4.107664608454797e-06
, O 0 6.616938463821498e-08
a O 0 1.3321147740441575e-08
fully O 0 1.7019557319031264e-08
expanded O 0 6.723676282405222e-09
allele O 0 2.1547785777897843e-09
has O 0 2.7214636100225675e-10
been O 0 4.955569843367869e-10
found O 0 3.3104216590196245e-10
to O 0 1.187944742575553e-10
arise O 0 4.934633146547185e-09
from O 0 1.9056738409517493e-09
a O 0 9.465928485496988e-09
premutation O 0 5.339172162166506e-07
of O 0 2.6601634672829277e-08
100 O 0 8.3731663380604e-08
or O 0 2.925035857970215e-08
less O 0 3.602271192448825e-07
triplet O 0 1.1493721103761345e-05
repeats O 0 3.948408448195551e-06
. O 0 9.502416560280835e-07

We O 0 1.2061802863172488e-06
have O 0 1.6783488376859168e-08
examined O 0 2.1170322384023166e-07
the O 0 1.1437423452775874e-08
sperm O 0 1.6674269076588644e-08
DNA O 0 3.471651766062678e-08
of O 0 2.4315674806985044e-08
a O 0 1.9325680966630898e-07
premutation O 0 3.677732456708327e-05
carrier O 0 1.246503961738199e-05
. O 0 2.8718220619339263e-06

This O 0 4.608569952324615e-07
mans O 0 1.3618443517771084e-05
leucocyte O 0 1.6839956515468657e-05
DNA O 0 9.532478202345374e-07
showed O 0 8.607379697878059e-08
one O 0 1.038542363218653e-09
normal O 0 7.420970504767865e-09
allele O 0 1.3348380178968e-09
and O 0 3.262052017394268e-10
one O 0 5.289917393014321e-10
allele O 0 1.0574432440790815e-09
of O 0 3.537712345291766e-09
approximately O 0 2.0863419436523145e-08
100 O 0 1.5159098154526873e-07
repeats O 0 8.488621574542776e-07
. O 0 4.225183545258915e-07

His O 0 2.944613697763998e-06
sperm O 0 4.227077567975357e-07
showed O 0 5.54884813652734e-08
an O 0 1.238520952462352e-09
expanded O 0 8.843298537897226e-09
allele O 0 4.1023002772533346e-09
in O 0 2.3637913848517655e-09
a O 0 3.415891569602536e-09
tight O 0 9.854828419975092e-08
range O 0 2.450222602590202e-08
centering O 0 5.0475541968353355e-08
on O 0 4.9593920081747456e-09
a O 0 1.3275307519933222e-09
size O 0 1.9706529741370105e-09
of O 0 1.0769763747475736e-08
approximately O 0 7.798815460091646e-08
320 O 0 6.152702098916052e-07
trinucleotide O 0 9.26853681448847e-05
repeats O 0 2.758735263341805e-06
. O 0 1.2503273865149822e-06

His O 0 1.3904743354942184e-05
affected O 0 2.5481504053459503e-06
son O 0 8.436626558250282e-06
has O 0 1.4246489321578792e-08
repeat O 0 5.3812780009820926e-08
sizes O 0 3.6613929665918477e-08
of O 0 4.134019349066875e-08
1040 O 0 2.340545279366779e-06
and O 0 1.6435033955986e-07
540 O 0 6.671807568636723e-06
. O 0 2.4378800844715443e-06

These O 0 1.2792209247436404e-07
data O 0 5.664573450303578e-07
suggest O 0 1.1828129231616913e-07
that O 0 3.8314884598378285e-09
expansion O 0 1.8841346616227383e-07
occurs O 0 1.2639156388161155e-08
in O 0 2.754416472683374e-09
two O 0 1.0097761515837078e-09
stages O 0 1.1058799032070965e-07
, O 0 2.7104414268563914e-09
the O 0 1.494240731148011e-09
first O 0 3.975600293415482e-09
during O 0 2.0524767663232524e-08
meiosis O 0 9.31320656150092e-08
followed O 0 3.863130260128855e-09
by O 0 5.290391458245836e-10
a O 0 7.87947751490492e-09
second O 0 1.497040642561842e-07
mitotic O 0 2.261693452965119e-06
expansion O 0 1.0294304047420155e-05
. O 0 3.84669237973867e-06

We O 0 1.6035907037803554e-06
also O 0 9.567472147864464e-08
show O 0 1.3202564375092152e-08
that O 0 2.36334840586494e-10
in O 0 2.2197114979416455e-10
all O 0 3.573852325189364e-10
informative O 0 9.645119369849908e-09
carrier O 0 3.219356514705396e-08
father O 0 1.0179778797692052e-08
to O 0 1.5965349042801336e-09
affected O 0 2.1052857235304145e-08
child O 0 2.6317309220758034e-07
transmissions O 0 5.070138513474376e-07
, O 0 3.3257829823440943e-09
with O 0 4.6328102465409415e-10
the O 0 1.8683372626782102e-09
notable O 0 6.670181740275893e-09
exception O 0 8.404089868463416e-09
of O 0 2.452799030550068e-08
the O 0 3.307086160475592e-08
premutation O 0 1.4867447134747636e-05
carrier O 0 2.3653537084555865e-07
, O 0 6.469278890364194e-09
the O 0 3.2796341198348955e-09
expansion O 0 6.112866657304039e-08
size O 0 2.7443077144084782e-08
decreases O 0 1.2625476131233881e-07
. O 0 3.8014849934597805e-08
. O 0 3.980026406225079e-07

The O 0 8.877353820935241e-07
R496H O 0 1.2057594176440034e-05
mutation O 0 1.1744278083369863e-07
of O 0 8.222592384754535e-08
arylsulfatase O 0 3.012075467268005e-05
A O 0 5.334545107871236e-07
does O 0 1.5264761898947654e-08
not O 0 3.577327234438599e-08
cause O 0 1.8489788999431767e-05
metachromatic B-Disease 1 0.9999994039535522
leukodystrophy I-Disease 1 0.9999998807907104
. O 0 4.975020056008361e-05

Deficiency B-Disease 1 0.999817430973053
of I-Disease 0 8.599393186159432e-05
arylsulfatase I-Disease 1 0.9365697503089905
A I-Disease 0 0.00015685876132920384
( O 0 9.246263630302565e-07
ARSA O 0 0.0009718654328025877
) O 0 1.8733409490323538e-08
enzyme O 0 6.1760694336499e-08
activity O 0 2.238803489262864e-07
causes O 0 4.5866040636610705e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 0.0002325464301975444
MLD B-Disease 1 0.9999998807907104
) O 0 4.825766609428683e-06
. O 0 5.412093287304742e-06

A O 0 7.867044473641727e-07
number O 0 4.636403971858272e-08
of O 0 3.176399161475274e-07
ARSA O 0 0.0055679259821772575
gene O 0 1.330921577391564e-07
mutations O 0 4.427193900369275e-08
responsible O 0 1.7083554837427073e-07
for O 0 5.717849944630871e-07
MLD B-Disease 1 1.0
have O 0 3.5353204452803766e-07
been O 0 1.706082599639558e-07
identified O 0 5.764949264630559e-07
. O 0 5.601964971901907e-07

Recently O 0 6.087959718570346e-06
, O 0 3.710095697329052e-08
the O 0 1.3279771060581425e-08
R496H O 0 4.993261200070265e-07
mutation O 0 7.859994433090378e-09
of O 0 4.1574885756290314e-08
ARSA O 0 0.007613925263285637
was O 0 2.491875079613237e-07
proposed O 0 1.0305315711889307e-08
to O 0 8.171912035948026e-10
be O 0 1.4313484841821378e-09
a O 0 4.65552485451326e-09
cause O 0 2.8594747902843665e-08
of O 0 3.3227448170691787e-07
MLD B-Disease 1 1.0
( O 0 5.412549626271357e-07
Draghia O 0 2.441992546664551e-05
et O 0 1.9802844235528028e-06
al O 0 1.073107114279992e-06
. O 0 7.356425246740628e-09
, O 0 8.375206306254768e-09
1997 O 0 8.426275854844789e-08
) O 0 6.653868211969893e-08
. O 0 1.0746248335635755e-06

We O 0 1.2810525049644639e-06
have O 0 1.4504523804248493e-08
investigated O 0 6.392789941855881e-08
the O 0 2.9442221993747353e-09
R496H O 0 1.363637807116902e-07
mutation O 0 2.5124542446519627e-09
and O 0 2.337945115282736e-10
found O 0 2.7724572637666256e-10
this O 0 4.97971906765482e-11
mutation O 0 1.830808976643894e-10
at O 0 3.5497709216514295e-09
a O 0 1.278018579853324e-09
relatively O 0 2.6068447400717787e-09
high O 0 1.2930441162239958e-09
frequency O 0 6.11757311475003e-10
in O 0 6.066062235854375e-11
an O 0 8.150612823554226e-11
African O 0 1.5169843159412721e-09
American O 0 2.409953347992655e-09
population O 0 5.042333772742325e-10
( O 0 1.6271792802058371e-09
f O 0 2.2666760912670725e-07
= O 0 9.898759856241668e-08
0 O 0 4.279475618318429e-08
. O 0 3.398799464093827e-09
09 O 0 2.764055295756407e-07
, O 0 1.4859226737939935e-08
n O 0 2.5757120170055714e-07
= O 0 4.783296390087344e-07
61 O 0 3.945846174246981e-07
subjects O 0 1.2342800346232252e-06
) O 0 2.77274637028313e-07
. O 0 1.1916607718376326e-06

The O 0 5.621516720566433e-06
ARSA O 0 0.0033558032009750605
enzyme O 0 4.030314926239953e-07
activity O 0 7.01143108017277e-08
in O 0 3.031193740454796e-09
subjects O 0 4.438676270979158e-08
with O 0 6.999225088399896e-10
and O 0 1.0509205727871063e-09
without O 0 4.999672231775776e-09
the O 0 3.393358261050139e-09
R496H O 0 1.4198954545463494e-07
mutation O 0 4.659122421202255e-09
was O 0 4.113506335556849e-08
determined O 0 2.8474845592540987e-08
and O 0 3.9248040373252024e-09
found O 0 7.866113094223692e-09
to O 0 3.006016102702347e-09
be O 0 2.953712474607073e-08
normal O 0 6.42603652067919e-07
. O 0 5.791018793388503e-07

It O 0 2.4601558834547177e-07
is O 0 1.9996571509750538e-08
therefore O 0 2.3696474116263744e-08
concluded O 0 5.5124019127106294e-08
that O 0 2.575470392507384e-10
the O 0 1.6344549047531132e-09
R496H O 0 2.5804916958804824e-07
mutation O 0 1.1614280204241823e-08
of O 0 5.875469710758807e-08
ARSA O 0 0.00023138178221415728
does O 0 6.732684632027031e-09
not O 0 9.573961623488003e-10
negatively O 0 5.609297470954289e-09
influence O 0 2.828290845968695e-08
the O 0 1.990329678847047e-09
activity O 0 1.2190247922205799e-08
of O 0 5.6727046171545226e-08
ARSA O 0 0.0987585186958313
and O 0 2.391610642860087e-08
is O 0 8.859878164457768e-09
not O 0 2.7583071382508706e-09
a O 0 6.859980317130976e-08
cause O 0 1.0895580544456607e-06
of O 0 4.6327484596986324e-05
MLD B-Disease 1 1.0

Down O 0 4.113085014978424e-05
- O 0 5.6348603720834944e-06
regulation O 0 9.20907439194707e-07
of O 0 1.7589876222245948e-07
transmembrane O 0 2.9083383196848445e-05
carbonic O 0 0.08123929053544998
anhydrases O 0 0.013715526089072227
in O 0 2.959680750791449e-05
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9730408787727356
lines O 0 4.50560065701211e-07
by O 0 1.1422250700832137e-08
wild O 0 9.492673314070998e-08
- O 0 3.76101098709114e-07
type O 0 4.9897753342520446e-06
von B-Disease 1 0.9169724583625793
Hippel I-Disease 1 0.998699426651001
- I-Disease 1 0.985283613204956
Lindau I-Disease 1 0.8860982656478882
transgenes O 0 0.001937865512445569
. O 0 2.2174803234520368e-05

To O 0 4.976076297680265e-07
discover O 0 7.267090609275328e-07
genes O 0 1.1858545434506595e-07
involved O 0 6.651203676710793e-08
in O 0 7.354955045002498e-08
von B-Disease 0 0.38352906703948975
Hippel I-Disease 1 0.999221682548523
- I-Disease 1 0.9996905326843262
Lindau I-Disease 1 0.9996222257614136
( O 0 5.190414867684012e-06
VHL B-Disease 1 0.9662919044494629
) O 0 2.331271844013827e-06
- O 0 0.00011403578537283465
mediated O 0 8.383639215026051e-05
carcinogenesis O 1 0.6356069445610046
, O 0 5.6891312993911924e-08
we O 0 1.899748447442562e-08
used O 0 3.5605146422312828e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999551773071289
lines O 0 1.6108180716400966e-05
stably O 0 5.10543686687015e-05
transfected O 0 1.3195461860959767e-06
with O 0 5.781067180521404e-09
wild O 0 1.3576843116425152e-07
- O 0 1.0637430705173756e-06
type O 0 4.56631005363306e-06
VHL O 1 0.8649677634239197
- O 0 3.932000618078746e-05
expressing O 0 2.1707062387577025e-06
transgenes O 0 0.00015144688950385898
. O 0 2.7442035843705526e-06

Large O 0 2.0471732113946928e-06
- O 0 1.1520070302140084e-06
scale O 0 4.0735005768510746e-07
RNA O 0 1.9511759319357225e-07
differential O 0 1.9079412538758334e-07
display O 0 3.369734358216192e-08
technology O 0 5.5695352330076275e-08
applied O 0 4.17790024798137e-09
to O 0 2.488207417883359e-10
these O 0 1.2220178202682064e-09
cell O 0 1.1660742416097492e-07
lines O 0 3.3976130797697124e-09
identified O 0 1.6895445043019208e-09
several O 0 1.0959615437400316e-09
differentially O 0 1.2518684400220081e-07
expressed O 0 2.0254937727059996e-09
genes O 0 2.946772603706904e-09
, O 0 6.717635336883632e-10
including O 0 1.5939455311198003e-09
an O 0 5.570105710006601e-09
alpha O 0 4.837234882870689e-06
carbonic O 0 0.002563042100518942
anhydrase O 0 0.0013081933138892055
gene O 0 1.3763518609266612e-06
, O 0 3.214313721855433e-07
termed O 0 1.6944393792073242e-05
CA12 O 0 0.031046390533447266
. O 0 1.2367883755359799e-05

The O 0 6.164584078760527e-07
deduced O 0 6.255418156797532e-07
protein O 0 5.944818326497625e-08
sequence O 0 1.3936843679118738e-08
was O 0 4.3872319110960234e-08
classified O 0 2.269805676746728e-08
as O 0 4.502849204612858e-09
a O 0 7.67212071650647e-09
one O 0 7.3267392153297806e-09
- O 0 5.542014491766167e-07
pass O 0 3.563503412351565e-07
transmembrane O 0 1.2139560567447916e-05
CA O 0 1.198936934088124e-05
possessing O 0 7.093251497281017e-06
an O 0 3.4370550849871506e-08
apparently O 0 2.911824878992775e-07
intact O 0 4.1804173633863684e-07
catalytic O 0 3.4680653016039287e-07
domain O 0 2.656543927059829e-07
in O 0 1.8399687107262253e-08
the O 0 4.088085958642296e-08
extracellular O 0 6.784810102544725e-05
CA O 0 0.0008723713108338416
module O 0 0.0010875053703784943
. O 0 1.0115403711097315e-05

Reintroduced O 0 3.4637127100722864e-05
wild O 0 2.768518470475101e-06
- O 0 9.155778570857365e-06
type O 0 8.528108082828112e-06
VHL B-Disease 0 0.0005217698635533452
strongly O 0 1.2732860454889305e-07
inhibited O 0 1.7317451295184583e-07
the O 0 1.6496267463139702e-08
overexpression O 0 2.429204073450819e-07
of O 0 3.3065628457507046e-08
the O 0 2.1542454931022803e-08
CA12 O 0 4.6509027015417814e-05
gene O 0 4.8428386634213894e-08
in O 0 5.272926095756247e-09
the O 0 3.788860425402163e-08
parental O 0 0.0005042051780037582
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999954700469971
lines O 0 0.000841691333334893
. O 0 1.1623847058217507e-05

Similar O 0 1.4359395095198124e-07
results O 0 5.0874533030764724e-08
were O 0 1.0305080344608086e-08
obtained O 0 2.2840939806201277e-08
with O 0 5.364714450450947e-09
CA9 O 0 0.00019510890706442297
, O 0 2.0762785268857442e-08
encoding O 0 1.6295071247895976e-07
another O 0 3.362685561114631e-07
transmembrane O 0 6.268894594541052e-06
CA O 0 1.7079578356060665e-06
with O 0 9.207387741128059e-09
an O 0 2.5392850488969998e-08
intact O 0 5.9435819821374025e-06
catalytic O 0 1.0526510777708609e-05
domain O 0 1.1114176231785677e-05
. O 0 3.2467103210365167e-06

Although O 0 6.271509960242838e-07
both O 0 1.0174133535656438e-07
domains O 0 1.4700790416100062e-06
of O 0 2.6047021606245835e-07
the O 0 3.65802549140426e-07
VHL B-Disease 0 0.003671040525659919
protein O 0 1.5832209498967131e-07
contribute O 0 7.703675919401576e-09
to O 0 1.797523241364729e-09
regulation O 0 3.543823652307765e-07
of O 0 6.148096787228496e-08
CA12 O 0 0.0006658435449935496
expression O 0 6.341650049535019e-08
, O 0 6.856026857349207e-09
the O 0 1.8572022808527322e-09
elongin O 0 1.1906957553264874e-07
binding O 0 9.795289024339127e-09
domain O 0 2.073940095215221e-07
alone O 0 3.664536762926218e-08
could O 0 6.475661340488159e-09
effectively O 0 2.264493872417006e-07
regulate O 0 8.94218487701437e-07
CA9 O 0 0.0025001121684908867
expression O 0 4.473127319215564e-06
. O 0 3.8811672311567236e-06

We O 0 4.345543402450858e-06
mapped O 0 1.1031408575945534e-05
CA12 O 0 0.000992625835351646
and O 0 8.920262075662322e-07
CA9 O 0 0.008993882685899734
loci O 0 1.028843485073594e-06
to O 0 7.371767196673318e-08
chromosome O 0 3.37279993800621e-06
bands O 0 2.3434736249328125e-06
15q22 O 0 2.2549036657437682e-05
and O 0 2.679854844700458e-07
17q21 O 0 7.69869948271662e-05
. O 0 3.5518223739927635e-06

2 O 0 2.378093449806329e-05
respectively O 0 2.273060772495228e-06
, O 0 8.99832315326421e-08
regions O 0 1.2365960344595806e-07
prone O 0 2.2863611093271174e-07
to O 0 3.742917531468493e-09
amplification O 0 7.181125170063751e-07
in O 0 9.96475435499633e-09
some O 0 1.132059335162694e-08
human O 0 6.551378533004026e-07
cancers B-Disease 1 0.6633194088935852
. O 0 1.0125566404894926e-05

Additional O 0 9.057857255356794e-07
experiments O 0 5.173881731934671e-07
are O 0 1.1007652567229798e-09
needed O 0 9.106281950721495e-09
to O 0 3.929813141567706e-10
define O 0 1.7616477165915967e-08
the O 0 8.529176476201883e-09
role O 0 1.5372816619674268e-07
of O 0 5.112238454785256e-07
CA O 0 0.0019409686792641878
IX O 1 0.9925549626350403
and O 0 7.626078399880498e-07
CA O 0 6.112187838880345e-05
XII O 0 0.009592898190021515
enzymes O 0 3.8199463148202994e-08
in O 0 2.343661265058472e-09
the O 0 2.11682049666706e-09
regulation O 0 2.5243053869417054e-08
of O 0 3.355999922405317e-09
pH O 0 3.210006980225444e-07
in O 0 3.639042400749304e-09
the O 0 3.1260065647131796e-09
extracellular O 0 5.806209628644865e-07
microenvironment O 0 8.377556923733209e-07
and O 0 1.7011598796301541e-09
its O 0 7.671809298948062e-10
potential O 0 1.6427819105047092e-08
impact O 0 6.199106650228714e-08
on O 0 9.378042591379199e-07
cancer B-Disease 0 0.00011230326344957575
cell O 0 1.1783069567172788e-05
growth O 0 2.703885456867283e-06
. O 0 1.2054016451656935e-06

A O 0 1.2492344012571266e-06
gene O 0 7.279604830046082e-08
encoding O 0 3.8433955751315807e-07
a O 0 1.4510035839521152e-07
transmembrane O 0 2.46144463744713e-06
protein O 0 9.483100171792103e-08
is O 0 1.4623798838542257e-09
mutated O 0 9.608799089733111e-09
in O 0 2.69431854604818e-09
patients O 0 1.094306085747121e-07
with O 0 2.8221611501066945e-05
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 1.0
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 0.00019294788944534957
. O 0 5.885995415155776e-05

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.35604092478752136
WFS B-Disease 1 0.9999905824661255
; O 0 1.4647774150944315e-05
OMIM O 1 0.9993854761123657
222300 O 0 0.000120219548989553
) O 0 2.0357509455948275e-08
is O 0 3.416347871265657e-09
an O 0 7.963543602329537e-09
autosomal B-Disease 1 0.99491947889328
recessive I-Disease 1 0.9999960660934448
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 0.9999409914016724
defined O 0 1.9398928543523652e-06
by O 0 5.715386208748896e-08
young O 0 3.3266842365264893e-06
- O 0 0.0009900403674691916
onset O 1 0.9907544851303101
non O 1 0.9863283038139343
- O 1 0.9994420409202576
immune O 1 0.9307337403297424
insulin B-Disease 1 0.9997788071632385
- I-Disease 1 0.9999778270721436
dependent I-Disease 1 0.9999963045120239
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9999622106552124
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
. O 1 0.9323211312294006

Linkage O 0 3.192351869074628e-05
to O 0 5.9510018246555774e-08
markers O 0 1.192665649796254e-06
on O 0 1.0662334943845053e-06
chromosome O 0 2.010954631259665e-05
4p O 0 0.12149888277053833
was O 0 1.0402457064628834e-06
confirmed O 0 5.049210471952392e-08
in O 0 7.661240530865143e-09
five O 0 1.7652904915621548e-08
families O 0 1.4549466520463739e-08
. O 0 3.7576160138996784e-07

On O 0 2.47328244995515e-07
the O 0 1.005565497536054e-08
basis O 0 4.6154227106853796e-08
of O 0 6.464816237894411e-08
meiotic O 0 0.00016062328359112144
recombinants O 0 0.006083245389163494
and O 0 8.40903055632225e-07
disease O 0 0.17830602824687958
- O 0 1.3059916454949416e-05
associated O 0 2.5538893169141375e-06
haplotypes O 0 6.1154019022069406e-06
, O 0 6.948738473511185e-08
the O 0 2.2186414128100296e-07
WFS B-Disease 0 0.04901711642742157
gene O 0 5.508470621862216e-07
was O 0 3.650651194675447e-07
localized O 0 2.0346296025763877e-07
to O 0 1.1169769109642402e-08
a O 0 1.3977540902487817e-06
BAC O 1 0.9986176490783691
/ O 0 0.0024865877348929644
P1 O 0 0.008585931733250618
contig O 0 2.5641327738412656e-05
of O 0 6.674969199593761e-08
less O 0 7.871294371852855e-08
than O 0 1.1937469679423884e-08
250 O 0 9.924829669216706e-08
kb O 0 1.9898614482372068e-05
. O 0 1.7231799347428023e-06

Mutations O 0 2.272449364681961e-06
in O 0 4.9303455540439245e-08
a O 0 1.018712438849434e-07
novel O 0 3.6982619633363356e-08
gene O 0 2.608188864883232e-08
( O 0 1.623850387488801e-08
WFS1 O 0 1.1320634257572237e-05
) O 0 1.0319163301630851e-08
encoding O 0 1.573053083347986e-07
a O 0 9.312228854696514e-08
putative O 0 1.8942054111903417e-06
transmembrane O 0 2.801377604555455e-06
protein O 0 2.7368074029254785e-07
were O 0 7.323385897706203e-09
found O 0 2.843618673864512e-09
in O 0 4.569108980057024e-10
all O 0 3.081905286528297e-10
affected O 0 2.218425887434705e-09
individuals O 0 2.785427444251809e-10
in O 0 4.359502536743776e-09
six O 0 8.629587711084241e-08
WFS B-Disease 0 0.0011810107389464974
families O 0 1.5233428962702078e-09
, O 0 1.2637149104932632e-09
and O 0 2.2766453999789604e-10
these O 0 3.093035272350164e-10
mutations O 0 3.2720364195881757e-09
were O 0 3.8657983481016345e-09
associated O 0 3.274135806918821e-08
with O 0 6.9538268476776466e-09
the O 0 5.60694616069668e-07
disease O 0 0.0017778532346710563
phenotype O 0 2.2699327928421553e-06
. O 0 2.030891437243554e-06

WFS1 O 0 0.016990438103675842
appears O 0 1.3932504998592776e-06
to O 0 3.634824663478753e-09
function O 0 3.8097667243164324e-08
in O 0 8.731207756795811e-09
survival O 0 4.288042703137762e-07
of O 0 5.2412431728043885e-08
islet O 0 9.921430319081992e-06
beta O 0 0.00010615894279908389
- O 0 9.34252529987134e-05
cells O 0 4.386771479403251e-08
and O 0 1.4364389677723466e-08
neurons O 0 6.292478929026402e-07
. O 0 7.844391802791506e-08
. O 0 6.445836788770976e-07

Stable O 0 0.0003924475167877972
interaction O 0 4.303981768316589e-06
between O 0 2.3807882598703145e-07
the O 0 1.5288305732497065e-08
products O 0 1.0970663488762966e-08
of O 0 4.14007761406765e-09
the O 0 9.730784178429985e-09
BRCA1 O 0 1.0589640453417815e-07
and O 0 2.320775749353743e-08
BRCA2 O 0 1.6800148614493082e-06
tumor B-Disease 0 1.729805808281526e-05
suppressor O 0 4.81586403111578e-06
genes O 0 7.740043628245985e-08
in O 0 3.708765916599077e-08
mitotic O 0 3.1162803679762874e-06
and O 0 6.666978151770309e-07
meiotic O 0 0.1787034571170807
cells O 0 1.2307912584219594e-05
. O 0 2.3800714643584797e-06

BRCA1 O 0 6.312382174655795e-05
and O 0 2.8481289859882963e-07
BRCA2 O 0 5.346233820091584e-07
account O 0 5.638839617461144e-09
for O 0 1.3114940244918216e-09
most O 0 6.878185243586188e-10
cases O 0 7.69022456825752e-10
of O 0 3.613155108439514e-09
familial O 0 3.439134559357626e-07
, O 0 1.8998823847482527e-08
early O 0 1.4945884458938963e-06
onset O 1 0.9882715344429016
breast B-Disease 0 0.200944185256958
and I-Disease 0 5.691616388503462e-05
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.7499050954938866e-06
encode O 0 2.50368032084225e-07
products O 0 6.773647953650652e-08
that O 0 6.004354236033294e-10
each O 0 8.806852469511739e-10
interact O 0 1.5369526096264963e-08
with O 0 1.6145019543500894e-08
hRAD51 O 0 1.4763909348403104e-05
. O 0 1.7435186236980371e-06

Results O 0 1.047446062329982e-06
presented O 0 9.89344357549271e-07
here O 0 2.196345008087519e-07
show O 0 3.79016142915134e-08
that O 0 2.3150050765252672e-09
BRCA1 O 0 8.200336765185057e-08
and O 0 1.2748251343452921e-08
BRCA2 O 0 2.5329103436888545e-07
coexist O 0 1.6293020621560572e-07
in O 0 9.385495935987365e-09
a O 0 1.2179371289278151e-08
biochemical O 0 2.736627493504784e-07
complex O 0 3.243143851250352e-07
and O 0 4.346218496209531e-09
colocalize O 0 5.834373496327316e-06
in O 0 5.844888661954428e-08
subnuclear O 0 2.770590435829945e-05
foci O 0 1.1772264770115726e-05
in O 0 6.486146730821929e-08
somatic O 0 8.262011306214845e-07
cells O 0 1.1970027635754832e-08
and O 0 1.7712288302718093e-09
on O 0 7.129439705266805e-09
the O 0 2.29164220932887e-09
axial O 0 2.780297592153147e-08
elements O 0 1.3086852845844987e-07
of O 0 1.407039746936789e-07
developing O 0 3.429418029554654e-06
synaptonemal O 0 0.00010274124360876158
complexes O 0 2.2557660486199893e-05
. O 0 3.1874312753643608e-06

Like O 0 2.7394255084800534e-05
BRCA1 O 0 2.2748847186448984e-05
and O 0 8.012177090677142e-07
RAD51 O 1 0.8140696287155151
, O 0 6.152484957056004e-07
BRCA2 O 0 9.592191645424464e-07
relocates O 0 5.571101269197243e-07
to O 0 7.004453550507606e-08
PCNA O 0 0.0001597374357515946
+ O 0 4.526924612946459e-07
replication O 0 7.483543384978475e-08
sites O 0 4.949149090549554e-09
following O 0 3.024142714025402e-09
exposure O 0 1.9442549614723248e-07
of O 0 5.3384233922315616e-08
S O 0 8.684125532454345e-06
phase O 0 5.411680376710137e-06
cells O 0 3.070959309070531e-08
to O 0 1.2344627542404396e-08
hydroxyurea O 0 6.07227457294357e-06
or O 0 3.1474030492972815e-07
UV O 0 0.00047826828085817397
irradiation O 0 3.5199343983549625e-05
. O 0 1.6417783399447217e-06

Thus O 0 6.48654486212763e-06
, O 0 5.928213226980006e-07
BRCA1 O 0 4.861746560891334e-07
and O 0 2.128230036646528e-08
BRCA2 O 0 1.5655118090762699e-07
participate O 0 4.7291930371784474e-08
, O 0 1.0317313225982616e-08
together O 0 4.969808564680989e-09
, O 0 1.4903127620868872e-09
in O 0 9.055010630198979e-10
a O 0 1.165942542513676e-08
pathway O 0 7.958111325478967e-08
( O 0 9.952616508712708e-09
s O 0 6.380876271805391e-08
) O 0 1.4117534918867136e-09
associated O 0 3.0624995872585714e-09
with O 0 2.672452537044734e-10
the O 0 5.523952961716816e-10
activation O 0 1.5955645693566112e-08
of O 0 1.9649002425126127e-08
double O 0 3.3115682640527666e-07
- O 0 6.962097359064501e-06
strand O 0 3.350572228555393e-07
break O 0 1.3095120721118292e-06
repair O 0 0.00014415687473956496
and O 0 9.222442258760566e-07
/ O 0 0.12351911514997482
or O 0 1.8688318732529297e-06
homologous O 0 1.722683919069823e-05
recombination O 0 2.1281675799400546e-05
. O 0 8.315023478644434e-06

Dysfunction O 1 0.9993007183074951
of O 0 5.553661594603909e-06
this O 0 8.85059208144412e-08
pathway O 0 3.020880967596895e-06
may O 0 2.4015664124021896e-08
be O 0 1.5795758034897744e-09
a O 0 1.0266231198485798e-09
general O 0 2.9525732969659657e-09
phenomenon O 0 9.46029743431609e-09
in O 0 4.923480512175615e-10
the O 0 8.432217146747689e-10
majority O 0 5.058961027870623e-10
of O 0 1.8556512992873309e-09
cases O 0 5.590669704957918e-09
of O 0 1.373389579839568e-07
hereditary B-Disease 1 0.9999997615814209
breast I-Disease 1 0.9999953508377075
and I-Disease 0 0.432944655418396
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0005619503790512681
. O 0 3.592555003706366e-05

A O 0 5.218885689828312e-06
novel O 0 7.226825573525275e-07
Arg362Ser O 0 6.235231467144331e-06
mutation O 0 3.0822846497358114e-08
in O 0 3.2974225572246496e-09
the O 0 1.1023394641540563e-08
sterol O 0 3.634473557667661e-07
27 O 0 5.173703812033636e-07
- O 0 6.342278311421978e-07
hydroxylase O 0 1.0730713029261096e-06
gene O 0 1.666143276679577e-07
( O 0 7.497029486103202e-08
CYP27 O 0 0.0001254860544577241
) O 0 7.537344970387494e-09
: O 0 1.1182895720551755e-09
its O 0 3.559396388741476e-10
effects O 0 2.330685688889389e-08
on O 0 7.214318475945447e-09
pre O 0 1.4047417096207937e-07
- O 0 2.3603911714076276e-08
mRNA O 0 1.5665490238347957e-08
splicing O 0 2.059873516202515e-08
and O 0 2.113568875472538e-09
enzyme O 0 5.212292819578579e-08
activity O 0 3.156237369239534e-07
. O 0 4.836561515730864e-07

A O 0 6.212948846950894e-06
novel O 0 5.281625590214389e-07
C O 0 2.343900632695295e-06
to O 0 6.629024884574619e-09
A O 0 5.627947174957626e-08
mutation O 0 1.6322554419190283e-09
in O 0 8.493522551944466e-10
the O 0 3.5916489782295002e-09
sterol O 0 2.279863906551327e-07
27 O 0 3.364224880897382e-07
- O 0 4.221888616484648e-07
hydroxylase O 0 4.827091970582842e-07
gene O 0 5.9102678306999223e-08
( O 0 3.8525289625113146e-08
CYP27 O 0 0.00040230416925624013
) O 0 2.33419559236836e-08
was O 0 4.138563625133429e-08
identified O 0 1.4706594830826702e-09
by O 0 2.20017032370734e-10
sequencing O 0 1.3737557758020102e-08
amplified O 0 1.0917563031398458e-07
CYP27 O 0 4.213874490233138e-06
gene O 0 1.888671263827746e-08
products O 0 9.886434781947173e-09
from O 0 4.0643093335290814e-09
a O 0 1.4864554920279716e-08
patient O 0 8.838193110705106e-08
with O 0 1.7381648831360508e-07
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 3.5715704143512994e-05
CTX B-Disease 1 0.9922243356704712
) O 0 1.7267645944230026e-06
. O 0 5.382928065955639e-06

The O 0 6.207117166923126e-07
mutation O 0 2.012018853747577e-07
changed O 0 2.285951268277131e-07
the O 0 3.721790520216928e-08
adrenodoxin O 0 1.096608230000129e-06
cofactor O 0 1.0813775475071452e-07
binding O 0 2.6016801157879854e-08
residue O 0 1.1119948339910479e-07
362Arg O 0 2.5980409645853797e-07
to O 0 1.0764937385943085e-08
362Ser O 0 3.232257995477994e-06
( O 0 1.4113429358530993e-07
CGT O 0 4.78688016301021e-05
362Arg O 0 4.333198830863694e-06
to O 0 1.2016859329833096e-07
AGT O 1 0.9846531748771667
362Ser O 0 1.004672230919823e-05
) O 0 3.325023456568488e-08
, O 0 6.307641076119808e-09
and O 0 2.3480282163035326e-09
was O 0 7.039396621166816e-08
responsible O 0 5.0252008776396906e-08
for O 0 3.4871014520376775e-08
deficiency O 0 0.0011255345307290554
in O 0 2.16444728806664e-08
the O 0 5.393793856001139e-08
sterol O 0 1.7182338751808857e-06
27 O 0 6.470799576163699e-07
- O 0 1.8883403640757024e-07
hydroxylase O 0 2.8191306000735494e-07
activity O 0 1.552935735560368e-08
, O 0 1.551472283978228e-09
as O 0 7.076841890274466e-10
confirmed O 0 7.232418552938213e-10
by O 0 9.112857690674048e-11
expression O 0 7.355089315375096e-10
of O 0 5.256638235806577e-09
mutant O 0 7.476552355001331e-08
cDNA O 0 3.612685191001219e-07
into O 0 2.059642270069162e-07
COS O 0 0.0064422027207911015
- O 0 4.949329741066322e-05
1 O 0 1.3494062841346022e-05
cells O 0 8.324992677444243e-07
. O 0 6.517751671708538e-07

Quantitative O 0 6.381657840393018e-06
analysis O 0 3.773808998630557e-07
showed O 0 9.932594480233092e-08
that O 0 6.993753909334544e-10
the O 0 1.2086152079149315e-09
expression O 0 5.72353231476086e-09
of O 0 1.83598611869229e-08
CYP27 O 0 4.5306060201255605e-06
gene O 0 1.396174731382871e-08
mRNA O 0 5.308337946985375e-08
in O 0 7.3629391472707084e-09
the O 0 7.423433867614904e-09
patient O 0 2.0482440277191927e-07
represented O 0 1.0116496014234144e-06
52 O 0 1.6291280189761892e-05
. O 0 7.639670911885332e-06

5 O 0 8.535634151485283e-06
% O 0 3.806937911576824e-07
of O 0 8.553095653951459e-08
the O 0 6.27098444283547e-08
normal O 0 5.588565841208037e-07
level O 0 6.163835223560454e-06
. O 0 8.529243018529087e-07

As O 0 7.590712698402058e-07
the O 0 1.0546765594199314e-07
mutation O 0 8.246292537705813e-08
occurred O 0 2.641446883444587e-07
at O 0 9.307754567089432e-08
the O 0 8.465288914294433e-09
penultimate O 0 1.6596887064679322e-07
nucleotide O 0 4.070672687817023e-08
of O 0 3.3043622948980556e-08
exon O 0 2.238343313365476e-06
6 O 0 7.079170245560817e-07
( O 0 1.0963467467206556e-08
- O 0 1.0404288275367435e-07
2 O 0 3.25853548588384e-08
position O 0 5.497324551129168e-08
of O 0 8.654676264541195e-08
exon O 0 6.485023277491564e-06
6 O 0 4.924875156575581e-06
- O 0 4.300391537981341e-06
intron O 0 1.3967726772534661e-05
6 O 0 5.62020204597502e-07
splice O 0 2.848990448001132e-07
site O 0 2.4336046067219286e-08
) O 0 1.0345447831738852e-09
of O 0 4.8943178398985765e-09
the O 0 5.162601013353196e-09
gene O 0 1.6913253020334196e-08
, O 0 3.67745367491068e-09
we O 0 5.127645419378268e-09
hypothesized O 0 1.2128603010808092e-08
that O 0 2.0307150405685093e-10
the O 0 2.953626454527125e-09
mutation O 0 9.528895894561629e-09
may O 0 8.360315995048495e-09
partially O 0 2.4550129040790125e-08
affect O 0 7.415254632547885e-09
the O 0 1.3585559344164722e-09
normal O 0 7.967067894298907e-09
splicing O 0 1.760035495124157e-08
efficiency O 0 2.5391639013605527e-08
in O 0 3.6093186217556195e-09
exon O 0 8.252655447904544e-07
6 O 0 8.617893598739101e-08
and O 0 1.886650391469402e-09
cause O 0 6.4433938185004536e-09
alternative O 0 1.2661981685369028e-08
splicing O 0 7.211184538391535e-08
elsewhere O 0 1.3133997001091302e-08
, O 0 6.604222724249098e-10
which O 0 1.7402920771125707e-10
resulted O 0 2.951289435060289e-09
in O 0 2.1796129345830195e-09
decreased O 0 1.6582838213707873e-07
transcript O 0 4.633703269973921e-07
in O 0 4.9931156986815495e-09
the O 0 2.5995323227334666e-08
patient O 0 7.462724624929251e-07
. O 0 1.5516262692472083e-06

Transfection O 0 0.000232358681387268
of O 0 1.918514271892491e-06
constructed O 0 3.5566532460507005e-05
minigenes O 0 0.00011910827743122354
, O 0 1.3601876958091452e-08
with O 0 1.3095993178779963e-09
or O 0 2.0025223701480854e-09
without O 0 4.234135708713893e-09
the O 0 1.8288379699527013e-09
mutation O 0 1.5354985061222237e-09
, O 0 2.3069213206383665e-09
into O 0 4.9581746708327046e-08
COS O 1 0.5504240393638611
- O 0 1.2826959391532e-05
1 O 0 8.638272674943437e-07
cells O 0 3.3166482893420834e-09
confirmed O 0 1.4449291763085625e-09
that O 0 4.3805025579102264e-11
the O 0 3.7998063029398566e-10
mutant O 0 1.1556804402346188e-08
minigene O 0 4.1469562006568594e-07
was O 0 4.798044628273601e-08
responsible O 0 7.592288575608563e-09
for O 0 1.3954392086290568e-09
a O 0 5.236524103224838e-09
mRNA O 0 1.5462411795397202e-08
species O 0 2.4672719423080025e-10
alternatively O 0 1.9021957342602036e-08
spliced O 0 8.90037981093883e-08
at O 0 2.1683602469124708e-08
an O 0 3.594540887164044e-09
activated O 0 5.794559569949342e-07
cryptic O 0 4.703218507984275e-07
5 O 0 1.4058969100005925e-07
splice O 0 2.9522013278437953e-07
site O 0 1.1118951448452208e-07
88 O 0 3.489137725409819e-07
bp O 0 6.707437023578677e-07
upstream O 0 2.743837512753089e-07
from O 0 2.2034649660440664e-08
the O 0 2.714260638470023e-08
3 O 0 2.050726237712297e-07
end O 0 1.405601892656705e-07
of O 0 4.1450979892942996e-07
exon O 0 2.2815853299107403e-05
6 O 0 7.569787157990504e-06
. O 0 2.519537247280823e-06

Our O 0 4.69569812366899e-07
data O 0 1.288785540509707e-07
suggest O 0 3.3845751090666454e-08
that O 0 3.3090011286596166e-10
the O 0 2.433064860696277e-09
C O 0 1.931225028783956e-07
to O 0 8.996650646686533e-10
A O 0 3.0983287047092745e-08
mutation O 0 2.198904391903511e-09
at O 0 1.9049950950034145e-08
the O 0 2.9773770116037213e-09
penultimate O 0 1.708047676629576e-07
nucleotide O 0 4.614014059711735e-08
of O 0 1.745572930644812e-08
exon O 0 1.735916612233268e-06
6 O 0 1.9791977479144407e-07
of O 0 4.049323010235639e-08
the O 0 2.5723014829281965e-08
CYP27 O 0 8.633878314867616e-05
gene O 0 4.385458041156198e-08
not O 0 3.7419254361736876e-09
only O 0 5.172723582802519e-09
causes O 0 4.774928541451118e-08
the O 0 5.949083714540393e-08
deficiency B-Disease 0 0.00151546741835773
in I-Disease 0 2.9366633569338774e-08
the I-Disease 0 4.497221084420744e-08
sterol I-Disease 0 4.3203553445891885e-07
27 I-Disease 0 2.6739346026261046e-07
- I-Disease 0 1.3111325358750037e-07
hydroxylase I-Disease 0 1.645458951315959e-07
activity I-Disease 0 2.5094095690292306e-08
, O 0 2.687974065551657e-09
but O 0 2.278992550230896e-09
also O 0 3.947130622350414e-09
partially O 0 5.1607432993705515e-08
leads O 0 5.895875343497892e-09
to O 0 6.769043658927387e-10
alternative O 0 2.355790051922213e-08
pre O 0 3.244838922000781e-07
- O 0 4.6592933955480476e-08
mRNA O 0 2.278376598496834e-08
splicing O 0 2.5662151514893594e-08
of O 0 6.026535714909187e-09
the O 0 1.8801779688715214e-08
gene O 0 4.844006866733253e-07
. O 0 1.407535137332161e-06

To O 0 4.349152220584074e-07
our O 0 2.3557231543236412e-07
knowledge O 0 2.030777068284806e-06
, O 0 1.4092120359521232e-08
this O 0 7.860260220482473e-10
is O 0 3.141030768816222e-10
the O 0 1.4374240686620965e-10
first O 0 1.086872258859728e-10
report O 0 1.1616217709953247e-10
regarding O 0 6.903788651868581e-10
effects O 0 1.1204422278865422e-08
on O 0 6.7033418815753976e-09
pre O 0 9.102464559873624e-08
- O 0 1.0317470433562903e-08
mRNA O 0 3.3502951524155833e-09
splicing O 0 1.4411921434032138e-08
of O 0 1.3753255201365278e-09
a O 0 1.226239332297041e-09
mutation O 0 8.809355467320756e-10
at O 0 3.017287752982156e-08
the O 0 1.880081157423774e-08
- O 0 2.482908314505039e-07
2 O 0 1.7586907574695942e-07
position O 0 1.3052189729023667e-07
of O 0 6.236797389647109e-08
a O 0 1.0843516662362163e-07
5 O 0 5.410908556768845e-07
splice O 0 3.883829322148813e-06
site O 0 1.6337970691893133e-06
. O 0 1.8945648889712174e-06

ATM O 0 0.0017788901459425688
germline O 0 6.275686610024422e-05
mutations O 0 4.137645248647459e-07
in O 0 1.4433892658871628e-07
classical O 1 0.9998645782470703
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 4.0818176785251126e-05
in O 0 4.637846018340497e-08
the O 0 5.428927707384901e-08
Dutch O 0 0.00012994171993341297
population O 0 5.945861758505089e-08
. O 0 1.524973754385428e-06

Germline O 0 0.0005210494273342192
mutations O 0 1.0968456081172917e-06
in O 0 3.4804230608642683e-08
the O 0 1.606049515601171e-08
ATM O 0 7.189305051724659e-06
gene O 0 1.5385012375190854e-08
are O 0 1.6029264027217494e-10
responsible O 0 5.946607650741953e-09
for O 0 2.466275628165704e-09
the O 0 1.5168164964052266e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999266862869263
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 0.9999998807907104
) O 0 8.61096032167552e-06
. O 0 5.708593562303577e-06

In O 0 3.321363521990861e-07
our O 0 9.432302050527142e-08
study O 0 1.9995312072751403e-08
, O 0 2.2026656054663363e-09
we O 0 7.273601720925171e-10
have O 0 1.2353519596164375e-10
determined O 0 1.110527003689299e-09
the O 0 6.906910599013827e-10
ATM O 0 1.2707701557701512e-07
mutation O 0 2.0850678961181757e-09
spectrum O 0 2.1860174115317932e-08
in O 0 2.0578696524609086e-09
19 O 0 4.062474445731823e-08
classical O 0 1.0919080523308367e-05
A B-Disease 1 0.9999974966049194
- I-Disease 1 0.9999980926513672
T I-Disease 1 0.9999998807907104
patients O 0 4.1683398421810125e-07
, O 0 2.2948876132744545e-09
including O 0 1.24798960055017e-09
some O 0 5.250403445344887e-10
immigrant O 0 8.036832532809512e-09
populations O 0 4.811795406567398e-10
, O 0 2.643797125667646e-10
as O 0 4.763416883157845e-10
well O 0 4.0524328337454563e-10
as O 0 4.865303715462233e-10
12 O 0 3.1769971098327687e-09
of O 0 3.1923039767178807e-09
Dutch O 0 1.53691075865936e-06
ethnic O 0 4.962915056694328e-08
origin O 0 1.4170964846016432e-07
. O 0 3.387882827610156e-07

Both O 0 6.711653668389772e-07
the O 0 1.9015941177258355e-07
protein O 0 1.4004211834617308e-07
truncation O 0 5.267983169687795e-07
test O 0 3.948834148559399e-08
( O 0 6.685835884923108e-09
PTT O 0 5.324481548996118e-07
) O 0 4.809247666770489e-09
and O 0 1.891961920463814e-09
the O 0 7.144195457442493e-09
restriction O 0 2.496791218220551e-08
endonuclease O 0 1.913177669621291e-07
fingerprinting O 0 8.050834026107623e-07
( O 0 5.039896677772049e-08
REF O 0 6.711283276672475e-06
) O 0 3.784142332818874e-09
method O 0 2.0302215020251424e-08
were O 0 2.9789275490799128e-09
used O 0 1.2115510816812503e-09
and O 0 2.379432484378441e-10
compared O 0 1.1891014839449099e-09
for O 0 9.057441602289273e-11
their O 0 5.840623124031552e-11
detection O 0 6.852575396010252e-09
efficiency O 0 3.2009557227041796e-09
, O 0 2.66293764816794e-10
identifying O 0 3.6372103107140674e-09
76 O 0 2.8558607922946067e-08
% O 0 5.286903803636278e-09
and O 0 1.334094834604116e-09
60 O 0 2.6169638900341852e-08
% O 0 6.9348859987883316e-09
of O 0 8.74228867075999e-09
the O 0 1.0241514303288568e-08
mutations O 0 2.0544664636190646e-08
, O 0 2.6761789229112765e-08
respectively O 0 1.1880001693498343e-06
. O 0 1.3143491059963708e-06

Most O 0 1.6450917428301182e-06
patients O 0 7.395855732283962e-07
were O 0 7.541503777019898e-08
found O 0 1.405483462946222e-08
to O 0 3.927155045602149e-09
be O 0 5.620717047349899e-08
compound O 0 4.823732979275519e-06
heterozygote O 0 0.00010272566578350961
. O 0 4.061854269821197e-06

Seventeen O 0 1.4777616343053523e-05
mutations O 0 3.1857035764915054e-07
were O 0 2.8508756244605138e-08
distinct O 0 1.5663609076455032e-08
, O 0 3.3780145347606094e-09
of O 0 5.1621680263735925e-09
which O 0 9.211897356031784e-10
10 O 0 1.0505964986862182e-08
were O 0 2.59327603835402e-09
not O 0 1.0685804463506088e-09
reported O 0 2.470160964662682e-08
previously O 0 1.7348560277241631e-07
. O 0 1.919607228728637e-07

Mutations O 0 3.3527408049849328e-06
are O 0 1.008204186803141e-08
small O 0 9.581950344283996e-09
deletions O 0 1.0036573883098754e-07
or O 0 2.0417198598465802e-08
point O 0 8.525462362740654e-07
mutations O 0 3.3544914401772985e-08
frequently O 0 1.5019221422107876e-08
affecting O 0 3.593027741999322e-08
splice O 0 5.987228632875485e-07
sites O 0 1.8147959224279475e-07
. O 0 8.03476552846405e-07

Moreover O 0 4.2393789044581354e-05
, O 0 8.914019531403028e-07
a O 0 1.6091287307062885e-06
16 O 0 7.40935774956597e-06
. O 0 3.9154929254436865e-06

7 O 0 0.00012060500012012199
- O 0 2.0393459635670297e-05
kb O 0 2.6428064302308485e-05
genomic O 0 1.3101841886964394e-06
deletion O 0 1.1643800235106028e-06
of O 0 1.4714014184846747e-07
the O 0 6.160633603258248e-08
3 O 0 1.0717207032939768e-07
end O 0 3.1239160591667314e-08
of O 0 7.708202964806787e-09
the O 0 4.055125568669382e-09
gene O 0 6.365084015413913e-09
, O 0 1.0161015362442072e-09
most O 0 7.136088386872075e-10
likely O 0 3.66245256344655e-09
a O 0 1.5104593131809452e-09
result O 0 2.701388668313598e-09
of O 0 7.806000290599968e-09
recombination O 0 2.7153481241271038e-08
between O 0 3.153742511585733e-08
two O 0 7.824185743743328e-09
LINE O 0 2.6165032522840193e-06
elements O 0 5.439592882794386e-07
, O 0 2.178338220915066e-08
was O 0 2.8000982865705737e-07
identified O 0 2.1281495321545663e-07
. O 0 7.894755640336371e-07

The O 0 3.082302839629847e-07
most O 0 2.7690830961546453e-08
frequently O 0 9.473406947790863e-09
found O 0 1.6531915836281996e-09
mutation O 0 1.0284889606637648e-09
, O 0 6.691624476751201e-10
identified O 0 4.813707654705013e-09
in O 0 1.4715404450527103e-09
three O 0 1.5705572398161394e-09
unrelated O 0 2.6293822230627484e-08
Turkish O 0 7.000933806011744e-07
A B-Disease 1 0.9997902512550354
- I-Disease 0 0.48106712102890015
T I-Disease 1 0.9810776114463806
individuals O 0 5.639850808591973e-09
, O 0 5.679944514724866e-09
was O 0 6.920380712926999e-08
previously O 0 1.0131159910997667e-08
described O 0 1.7183947598198301e-09
to O 0 1.1900673502207582e-10
be O 0 4.04680233767607e-10
a O 0 3.1910134534740564e-09
Turkish O 0 4.862006335315527e-07
A B-Disease 1 0.9997965693473816
- I-Disease 1 0.9992519021034241
T I-Disease 1 0.9999969005584717
founder O 0 0.00015385435835924
mutation O 0 1.0890626072068699e-06
. O 0 3.2224827464233385e-06

The O 0 3.1436863423550676e-07
presence O 0 2.3030190732242772e-07
of O 0 1.1840080560432398e-07
a O 0 1.5753440152366238e-07
founder O 0 9.972989118978148e-07
mutation O 0 1.63531002073114e-08
among O 0 1.6997036000887533e-09
relatively O 0 1.4852199470283267e-08
small O 0 1.3947739629927014e-09
ethnic O 0 1.946583783052347e-09
population O 0 1.8442604388102524e-10
groups O 0 2.2575241676037194e-10
in O 0 1.5667395159013608e-09
Western O 0 4.024414579362201e-08
Europe O 0 4.275526777064442e-08
could O 0 3.0468962908258845e-09
indicate O 0 7.625581943671023e-09
a O 0 1.2944628702271643e-09
high O 0 9.908634801547578e-09
carrier O 0 2.5929101088451034e-09
frequency O 0 7.855513572962991e-09
in O 0 7.036409788163667e-10
such O 0 1.7854137057682351e-09
communities O 0 1.8766023401894927e-08
. O 0 4.6068740289229027e-07

In O 0 5.668042604156653e-07
patients O 0 1.3267471388189733e-07
of O 0 3.6152663085431413e-08
Dutch O 0 1.735882142384071e-05
ethnic O 0 4.654026852790594e-08
origin O 0 1.3084888728087662e-08
, O 0 1.614008482420104e-09
however O 0 1.5067416203606854e-09
, O 0 2.704181600865496e-10
no O 0 6.62703669718212e-10
significant O 0 9.112119947474184e-09
founder O 0 1.2855326758653973e-07
effect O 0 5.1600739681134655e-08
could O 0 7.643551569458396e-09
be O 0 6.9514398681747025e-09
identified O 0 1.6814352932215115e-07
. O 0 2.81218376585457e-07

The O 0 5.542194685403956e-07
observed O 0 6.184592962199531e-07
genetic O 0 2.334960100824901e-07
heterogeneity O 0 3.685580054479942e-07
including O 0 1.146759043280099e-08
the O 0 6.77951339511651e-09
relative O 0 6.471712481470604e-07
high O 0 7.202854135357484e-07
percentage O 0 9.262983269309188e-08
of O 0 1.7297109522473875e-08
splice O 0 6.171195536808227e-07
- O 0 2.1066098554456403e-07
site O 0 5.01314829648436e-08
mutations O 0 9.516146093346833e-09
had O 0 2.6323879964706975e-08
no O 0 9.3339744822174e-09
reflection O 0 5.296656624409479e-08
on O 0 9.778752740885466e-08
the O 0 6.471354652148875e-08
phenotype O 0 1.1020808869943721e-06
. O 0 1.2594391591846943e-06

All O 0 1.9612969026638893e-07
patients O 0 1.8754329289549787e-07
manifested O 0 4.89936383019085e-07
classical O 0 0.00017948192544281483
A B-Disease 1 0.9999896287918091
- I-Disease 1 0.9994951486587524
T I-Disease 1 0.9926682114601135
and O 0 1.790447967664477e-08
increased O 0 4.2764077079482377e-07
cellular O 0 6.037023467797553e-06
radioresistant O 0 3.381712076588883e-06
DNA O 0 4.1545328599568165e-07
synthesis O 0 1.16345654532779e-06
. O 0 5.110576353217766e-07

Determination O 0 5.474708814290352e-06
of O 0 5.52889616756147e-07
the O 0 1.10131431085847e-07
genomic O 0 4.5958506689203205e-07
structure O 0 3.167865259001701e-07
of O 0 5.044166684342599e-08
the O 0 5.2719332899187066e-08
COL4A4 O 0 0.0014256698777899146
gene O 0 3.038367069052583e-08
and O 0 1.536260230139419e-09
of O 0 3.857124397654843e-08
novel O 0 3.5746953130910697e-07
mutations O 0 2.1498797195818042e-06
causing O 0 6.175039015943184e-05
autosomal B-Disease 1 0.9999856948852539
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.28304508328437805

Autosomal B-Disease 1 0.9999996423721313
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 3.2017685498431092e-06
a O 0 1.815872451516043e-06
progressive O 1 0.999230146408081
hematuric B-Disease 1 0.9999990463256836
glomerulonephritis I-Disease 1 1.0
characterized O 0 0.11814577132463455
by O 0 8.80622974364087e-06
glomerular B-Disease 1 1.0
basement I-Disease 1 1.0
membrane I-Disease 1 0.9999427795410156
abnormalities I-Disease 1 0.999580442905426
and O 0 7.487998487931691e-08
associated O 0 2.2501116347939387e-07
with O 0 1.2266703208752006e-08
mutations O 0 1.4833010197889962e-07
in O 0 1.9944957685424924e-08
either O 0 7.287231085228996e-08
the O 0 1.0651607595946189e-07
COL4A3 O 0 0.00906949769705534
or O 0 2.0000994638280645e-08
the O 0 1.8847451599413034e-08
COL4A4 O 0 8.1286059867125e-05
gene O 0 1.9710975962539123e-08
, O 0 2.738497206777879e-09
which O 0 1.8839022009053963e-10
encode O 0 1.9742232293396e-09
the O 0 4.670653641625222e-09
alpha3 O 0 2.27486498260987e-06
and O 0 2.5668418501822998e-08
alpha4 O 0 0.00010618445958243683
type O 0 0.032488808035850525
IV O 1 1.0
collagen O 1 0.9970120191574097
chains O 0 5.7229983212891966e-05
, O 0 2.0807551948109904e-07
respectively O 0 5.0277458285563625e-06
. O 0 3.147531060676556e-06

To O 0 1.0948676276711922e-07
date O 0 5.378896617003193e-07
, O 0 1.5722784851845972e-08
mutation O 0 3.313063379195569e-09
screening O 0 2.1200097677365193e-08
in O 0 1.7416743602893803e-09
the O 0 3.0172864207145267e-09
two O 0 2.9923101774187444e-09
genes O 0 9.002353529297125e-09
has O 0 1.8864956263797694e-09
been O 0 2.259498366186108e-09
hampered O 0 6.448683365078978e-08
by O 0 7.197738516317997e-10
the O 0 4.6673407361197405e-09
lack O 0 4.752893900672461e-08
of O 0 4.955281696084057e-08
genomic O 0 4.138698841416044e-07
structure O 0 6.377730983331276e-07
information O 0 6.181108460623363e-07
. O 0 1.499043605690531e-06

We O 0 7.994713655534724e-07
report O 0 4.14494678580013e-08
here O 0 1.4887680421793448e-08
the O 0 1.3147399835489182e-09
complete O 0 7.513274447035201e-09
characterization O 0 4.3698193508134864e-08
of O 0 5.3886295425797925e-09
the O 0 6.819288245196731e-09
48 O 0 9.11375721557306e-08
exons O 0 7.178879712910202e-08
of O 0 1.225442591845649e-08
the O 0 1.1155100843041055e-08
COL4A4 O 0 6.865869363537058e-05
gene O 0 4.1301184694475523e-08
, O 0 4.019119703713159e-09
a O 0 6.6697491973854994e-09
comprehensive O 0 5.339573760920757e-08
gene O 0 2.6336234526525004e-08
screen O 0 6.934134262337466e-07
, O 0 8.737471191011537e-09
and O 0 7.152781700270339e-10
the O 0 8.866060663414999e-10
subsequent O 0 1.3956148459115525e-09
detection O 0 1.69706417807447e-08
of O 0 1.140593952619895e-09
10 O 0 3.6187068896964547e-09
novel O 0 2.0263479783011462e-09
mutations O 0 1.5934987773746911e-09
in O 0 2.7411726222226207e-09
eight O 0 1.1916897335595422e-07
patients O 0 4.9230629883822985e-06
diagnosed O 0 0.03159664571285248
with O 0 2.538418266340159e-05
autosomal B-Disease 1 0.9999998807907104
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.22744952142238617

Furthermore O 0 9.637574294174556e-06
, O 0 1.3969837198146706e-07
we O 0 2.0563327041145385e-08
identified O 0 2.6165896116481235e-08
a O 0 4.9592410178433965e-09
glycine O 0 3.089317957005733e-08
to O 0 1.4377757873162977e-09
alanine O 0 6.504953375952027e-08
substitution O 0 8.220475677944705e-08
in O 0 9.884021601180848e-09
the O 0 2.817495392548608e-08
collagenous O 0 2.42484802583931e-05
domain O 0 1.7108500571794139e-07
that O 0 9.965566150071936e-10
is O 0 1.6793599844078244e-09
apparently O 0 9.252684840532766e-09
silent O 0 1.9855530553058998e-08
in O 0 7.057915918373681e-10
the O 0 1.8117941591455633e-09
heterozygous O 0 6.556569953630742e-09
carriers O 0 2.1718909337664627e-08
, O 0 5.719079876342903e-09
in O 0 2.9013156321866518e-08
11 O 0 1.9307531147205736e-06
. O 0 2.3507684545620577e-06

5 O 0 4.149988853896502e-06
% O 0 9.187970562152259e-08
of O 0 5.176042705556938e-08
all O 0 6.9169465710672284e-09
control O 0 3.7612906567119353e-07
individuals O 0 1.9325481215304308e-09
, O 0 2.7976430061471547e-09
and O 0 9.567792114140161e-10
in O 0 1.536969551629852e-09
one O 0 8.524098649154155e-10
control O 0 9.875391171476622e-09
individual O 0 2.0048297744157395e-10
homozygous O 0 4.871304692954936e-09
for O 0 9.606485606994397e-10
this O 0 2.192835690806305e-09
glycine O 0 5.997898711029848e-07
substitution O 0 1.2914644003103604e-06
. O 0 1.171953385892266e-06

There O 0 2.9729576453974005e-06
has O 0 6.879687219907282e-08
been O 0 1.4070391074483268e-08
no O 0 2.2964812274040014e-09
previous O 0 2.705132118308029e-09
finding O 0 7.587757977489673e-09
of O 0 3.860816999434746e-09
a O 0 5.895470778227718e-09
glycine O 0 5.800763602792358e-08
substitution O 0 6.997630208616101e-08
that O 0 1.1191985116454362e-09
is O 0 7.612353525310311e-10
not O 0 4.2074949080372903e-10
associated O 0 3.700037831677605e-09
with O 0 4.782981233297789e-10
any O 0 7.916883149050591e-09
obvious O 0 1.1822162804264735e-07
phenotype O 0 2.3479309163576545e-08
in O 0 1.1282181411331749e-08
homozygous O 0 1.7178426503505762e-07
individuals O 0 4.636138939417833e-08
. O 0 2.909681143137277e-06

Founder O 0 0.010985993780195713
BRCA1 O 0 1.9679851902765222e-05
and O 0 2.3802388682270248e-07
BRCA2 O 0 1.5868805576246814e-06
mutations O 0 5.324410423668269e-08
in O 0 6.168180188836914e-09
French O 0 2.6895736482401844e-06
Canadian O 0 0.0006066657369956374
breast B-Disease 1 0.9999996423721313
and I-Disease 1 0.9999872446060181
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.51415650988929e-05
. O 0 6.390039925463498e-05

We O 0 2.631560391819221e-07
have O 0 4.646812712394421e-09
identified O 0 8.544222218631603e-09
four O 0 9.440609405331202e-10
mutations O 0 5.38635580582536e-10
in O 0 1.0537783839970061e-10
each O 0 4.7516539314340633e-11
of O 0 1.969566953974322e-09
the O 0 9.811260781589226e-08
breast B-Disease 1 0.9993916749954224
cancer I-Disease 1 0.9644219875335693
- O 0 0.003641136223450303
susceptibility O 0 0.00025890959659591317
genes O 0 1.9081794278008601e-07
, O 0 6.12152390999654e-08
BRCA1 O 0 2.4919080487961764e-07
and O 0 1.7184971667916216e-08
BRCA2 O 0 2.4527014375053113e-07
, O 0 2.673876453584967e-09
in O 0 2.5095518996209876e-09
French O 0 2.125353603332769e-06
Canadian O 0 6.683375249849632e-05
breast B-Disease 1 0.9999662637710571
cancer I-Disease 1 0.9999419450759888
and O 1 0.9831624031066895
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.4481321310740896e-06
from O 0 7.263111456268234e-06
Quebec O 0 0.0004595868813339621
. O 0 8.399081707466394e-06

To O 0 7.438970328621508e-07
identify O 0 6.5368576542823575e-06
founder O 0 6.85770355630666e-05
effects O 0 0.00019666548178065568
, O 0 6.786786599377592e-08
we O 0 1.127228710373629e-08
examined O 0 3.5327786918060156e-08
independently O 0 7.2717472043848375e-09
ascertained O 0 1.4178709761836217e-07
French O 0 4.823148742616468e-07
Canadian O 0 1.6488047549501061e-06
cancer B-Disease 0 9.680810535428463e-07
families O 0 5.831942706535642e-10
for O 0 5.483976606157626e-10
the O 0 2.201212323527102e-09
distribution O 0 5.956415360941492e-09
of O 0 4.416295329434661e-09
these O 0 1.2578017516418072e-09
eight O 0 8.359522496448335e-08
mutations O 0 2.930129312517238e-07
. O 0 7.023148214102548e-07

Mutations O 0 2.637253601278644e-06
were O 0 1.452177542660138e-07
found O 0 2.1994509324940736e-08
in O 0 6.701207144743648e-09
41 O 0 1.3827653333464696e-07
of O 0 8.511840832170492e-08
97 O 0 4.250384336046409e-06
families O 0 2.388707400768908e-07
. O 0 2.2595459086005576e-06

Six O 0 4.223676626224915e-07
of O 0 2.1551727513724472e-07
eight O 0 5.515430601121807e-08
mutations O 0 1.3423705702564348e-08
were O 0 3.968600115200616e-09
observed O 0 8.610299140343614e-09
at O 0 8.045502397635573e-08
least O 0 2.4316372915222928e-08
twice O 0 3.2108638947647705e-07
. O 0 2.3741540644550696e-07

The O 0 8.059022547968198e-06
BRCA1 O 0 2.163640056096483e-05
C4446T O 0 2.7441476049716584e-05
mutation O 0 1.601092236569457e-07
was O 0 2.0336790385044878e-07
the O 0 6.5898566603550535e-09
most O 0 1.4179116769597044e-09
common O 0 3.911396984079829e-09
mutation O 0 4.608558867857937e-09
found O 0 2.994228198716087e-09
, O 0 1.0595025967674587e-09
followed O 0 2.9839775095297227e-09
by O 0 1.414945383082511e-09
the O 0 4.7123368318580106e-08
BRCA2 O 0 1.1602476206462597e-06
8765delAG O 0 1.0785781341837719e-05
mutation O 0 1.253635787179519e-06
. O 0 3.3137368973257253e-06

Together O 0 7.609311296619126e-07
, O 0 2.056603243261179e-08
these O 0 1.4553065419420363e-09
mutations O 0 3.571571260962969e-09
were O 0 2.825808920192685e-09
found O 0 6.432755994545403e-10
in O 0 6.655487272411165e-10
28 O 0 2.615951011364359e-08
of O 0 1.682316685958085e-08
41 O 0 2.1738561883921648e-07
families O 0 1.4807951531636832e-09
identified O 0 1.2133068771902344e-08
to O 0 1.527745263629754e-09
have O 0 3.89371157538676e-09
a O 0 5.884800913236177e-08
mutation O 0 1.3011774058213632e-07
. O 0 6.533708187816956e-07

The O 0 7.056441404529323e-07
odds O 0 3.0154178602970205e-06
of O 0 3.048200269972767e-08
detection O 0 4.523821814927942e-07
of O 0 7.989071626468558e-09
any O 0 2.5871695896739766e-09
of O 0 8.716514621198712e-09
the O 0 7.975963001172204e-09
four O 0 2.3793168324459657e-08
BRCA1 O 0 1.2738509269638598e-07
mutations O 0 5.93911799739999e-08
was O 0 1.8432585875416407e-06
18 O 0 8.22047240944812e-06
. O 0 6.944829237909289e-06

7x O 0 0.0029133055359125137
greater O 0 3.003564870596165e-06
if O 0 5.775713773914504e-08
one O 0 3.976282858531022e-09
or O 0 7.146890301790165e-10
more O 0 1.0160874919229457e-10
cases O 0 2.5156765559586347e-09
of O 0 6.8184917836333625e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 1.0369276424171403e-06
also O 0 7.445256411386936e-09
present O 0 8.337321943940879e-09
in O 0 8.947234064748955e-09
the O 0 5.17453244697208e-08
family O 0 3.421730241370824e-07
. O 0 5.640627591674274e-07

The O 0 1.181163156616094e-06
odds O 0 4.638448444893584e-06
of O 0 7.290859826980522e-08
detection O 0 5.448891329251637e-07
of O 0 1.726335874252527e-08
any O 0 6.102577554401023e-09
of O 0 1.3197655412966469e-08
the O 0 4.893076166467836e-09
four O 0 1.2381011771367412e-08
BRCA2 O 0 6.972555866013863e-08
mutations O 0 4.418858878807441e-08
was O 0 1.713155143079348e-06
5 O 0 2.2676997559756273e-06
. O 0 2.0218067220412195e-06

3x O 0 0.00029294606065377593
greater O 0 1.5668322248529876e-06
if O 0 5.95388556234866e-08
there O 0 9.427513880666538e-09
were O 0 4.310110046645832e-09
at O 0 3.873459775149968e-09
least O 0 1.2156939344087903e-10
five O 0 5.973498085065643e-11
cases O 0 3.362867484479892e-10
of O 0 1.3030718726270152e-08
breast B-Disease 0 0.06990932673215866
cancer I-Disease 0 0.0007843789062462747
in O 0 1.2770206581080856e-07
the O 0 5.220107937020657e-07
family O 0 8.379250857615261e-07
. O 0 2.064000909740571e-06

Interestingly O 0 6.1440805438905954e-06
, O 0 4.1907913583827394e-08
the O 0 6.387303130850341e-09
presence O 0 1.11424700577345e-08
of O 0 3.1372376696481297e-08
a O 0 4.583734494190139e-07
breast B-Disease 0 0.012810488231480122
cancer I-Disease 0 2.5855099011096172e-05
case O 0 3.4295121054128686e-07
< O 0 2.3994341518118745e-06
36 O 0 2.9553592639786075e-07
years O 0 1.3638479678945714e-08
of O 0 1.0334624711560991e-08
age O 0 1.6283715353893058e-07
was O 0 4.678564735627333e-08
strongly O 0 2.544961796857592e-09
predictive O 0 8.675066887064986e-09
of O 0 2.0088346541768942e-09
the O 0 7.379004629548547e-10
presence O 0 2.658584463688385e-09
of O 0 3.3777827201930677e-09
any O 0 3.2273106409519414e-09
of O 0 8.456686906299637e-09
the O 0 1.2243562608205139e-08
eight O 0 4.846720003115479e-08
mutations O 0 6.715834643955532e-08
screened O 0 1.9449055344011867e-06
. O 0 1.6398333855249803e-06

Carriers O 0 1.4219797321857186e-06
of O 0 8.34986551012662e-08
the O 0 3.912128399008452e-09
same O 0 2.8224584891489712e-09
mutation O 0 1.2950136518696809e-09
, O 0 2.775917828934382e-10
from O 0 2.9881222496364046e-10
different O 0 3.1826905000365e-10
families O 0 1.3188129754926337e-10
, O 0 2.6414181952816307e-10
shared O 0 1.2888975442493233e-09
similar O 0 1.53683465953236e-09
haplotypes O 0 2.8969083132324158e-08
, O 0 2.194559423074338e-09
indicating O 0 1.3779256846646604e-08
that O 0 2.315639902050748e-10
the O 0 1.2326175635735126e-09
mutant O 0 1.3869223103313288e-08
alleles O 0 2.918970620768846e-09
were O 0 1.4237280687723342e-08
likely O 0 3.6121834412483622e-09
to O 0 2.892014128175191e-10
be O 0 5.066203012660253e-10
identical O 0 1.2315389819050893e-09
by O 0 2.4525301234312735e-10
descent O 0 1.399165849846895e-08
for O 0 2.279922917125532e-09
a O 0 7.901118870279333e-09
mutation O 0 3.504041279356329e-09
in O 0 3.4318128339094756e-09
the O 0 3.346618271393709e-08
founder O 0 1.1956984735661536e-06
population O 0 4.920584828482788e-08
. O 0 2.5328622541564982e-06

The O 0 9.448868354411388e-08
identification O 0 1.0924312476845444e-07
of O 0 1.568216418945667e-07
common O 0 4.6820775878586574e-07
BRCA1 O 0 7.11194161340245e-07
and O 0 3.070326570764337e-08
BRCA2 O 0 3.442645777340658e-07
mutations O 0 4.473469594756807e-09
will O 0 4.027466971034954e-10
facilitate O 0 4.46010250954032e-09
carrier O 0 1.2151897266221567e-08
detection O 0 7.85622091825644e-08
in O 0 2.3700936768733527e-09
French O 0 9.045978686117451e-07
Canadian O 0 2.8392625608830713e-05
breast B-Disease 1 0.9999254941940308
cancer I-Disease 1 0.9996613264083862
and O 1 0.8703804016113281
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 0.00013476048479788005
. O 0 3.764548819162883e-05

Are O 0 9.127088560489938e-07
Dp71 O 0 0.00011983351578237489
and O 0 6.486573056463385e-07
Dp140 O 0 0.0005215760320425034
brain O 0 7.403775089187548e-05
dystrophin O 0 8.013163096620701e-06
isoforms O 0 2.7334843366588757e-07
related O 0 5.470255359796283e-08
to O 0 1.0522951399138947e-08
cognitive B-Disease 0 0.45414894819259644
impairment I-Disease 1 0.9999996423721313
in O 1 0.9999904632568359
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 1 0.9999183416366577

Molecular O 0 1.1520221960381605e-05
study O 0 1.6217771303672635e-07
and O 0 1.3412700283765844e-08
neuropsychological O 0 3.461113635694346e-07
analysis O 0 1.0389767268748074e-08
were O 0 1.0385442505977949e-09
performed O 0 4.36784208801555e-09
concurrently O 0 1.1883583006522258e-08
on O 0 3.762294653597564e-08
49 O 0 2.262092493765522e-06
patients O 0 4.980742232874036e-06
with O 1 0.7716277837753296
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999881982803345
DMD B-Disease 1 1.0
) O 0 2.4150028821168235e-07
in O 0 1.0433834241041495e-08
order O 0 3.1807561029495446e-09
to O 0 8.095368264626757e-10
find O 0 4.2583683246277815e-09
a O 0 2.824106060117515e-09
molecular O 0 3.0459393229875786e-08
explanation O 0 9.978962545176273e-09
for O 0 1.19817167298919e-09
the O 0 8.103899773459489e-09
cognitive B-Disease 0 1.0988485882990062e-05
impairment I-Disease 0 3.4486831282265484e-05
observed O 0 3.7638886851709685e-07
in O 0 8.841279708349248e-08
most O 0 8.59919737195014e-07
DMD B-Disease 1 0.9999998807907104
patients O 0 2.2256197553360835e-05
. O 0 3.4928643799503334e-06

Complete O 0 2.05435867428605e-06
analysis O 0 3.1173752290669654e-07
of O 0 1.5072518522174505e-07
the O 0 1.392619424223085e-07
dystrophin O 0 7.065760655677877e-06
gene O 0 1.6158813309630204e-07
was O 0 2.427101719604252e-07
performed O 0 2.9464425566061436e-08
to O 0 1.8069177265545022e-09
define O 0 9.233084341531139e-08
the O 0 3.4106591328963987e-08
localization O 0 7.130018275347538e-06
of O 0 1.3207909432821907e-07
deletions O 0 1.5553611376617482e-07
and O 0 1.2818521355484336e-08
duplications O 0 1.5498767425015103e-06
in O 0 1.1067552208032794e-08
relation O 0 6.768546256807895e-08
to O 0 2.7230433463643067e-09
the O 0 3.7905230954038416e-08
different O 0 8.717979653738439e-07
DMD B-Disease 1 0.9999997615814209
promoters O 0 0.0007821666076779366
. O 0 2.1834894141647965e-05

Qualitative O 0 1.1792367331509013e-05
analysis O 0 1.0313849543308606e-06
of O 0 1.588393132578858e-07
the O 0 1.2002004723399295e-07
Dp71 O 0 1.472218082199106e-05
transcript O 0 9.597828238838702e-07
and O 0 2.461106651807654e-09
testing O 0 2.7135449442994286e-09
for O 0 1.746703615079781e-10
the O 0 1.291530077329739e-10
specific O 0 2.7669053159762313e-10
first O 0 2.2813453348646817e-09
exon O 0 1.0205113198935578e-07
of O 0 1.2372701974072697e-08
Dp140 O 0 1.004455725706066e-06
were O 0 8.145678798143763e-09
also O 0 3.058775011055559e-09
carried O 0 8.416313868053749e-09
out O 0 1.8474025864634314e-08
. O 0 2.729295545123023e-07

Neuropsychological O 0 0.00012210659042466432
analysis O 0 1.6011731531762052e-06
assessed O 0 2.999356865984737e-06
verbal O 0 3.918033144145738e-06
and O 0 1.8971381621213368e-07
visuospatial O 0 0.00038832012796774507
intelligence O 0 1.7550091797602363e-06
, O 0 1.3083216288123367e-08
verbal O 0 2.9718194127781317e-07
memory O 0 9.713809413369745e-05
, O 0 1.4112204382854543e-07
and O 0 6.261517881966938e-08
reading O 0 1.506387343397364e-05
skills O 0 9.101087198359892e-05
. O 0 5.849951776326634e-06

Comparison O 0 6.210649644344812e-06
of O 0 6.077130478843173e-07
molecular O 0 3.310966576464125e-06
and O 0 2.5845670492685713e-08
psychometric O 0 3.775669938477222e-06
findings O 0 3.8987220563058145e-08
demonstrated O 0 2.3528173187514767e-08
that O 0 1.0325851285131193e-09
deletions O 0 2.6428674360090554e-08
and O 0 2.9840230286737324e-09
duplications O 0 7.801060064593912e-07
that O 0 1.4153016536511132e-09
were O 0 5.3438200531275015e-09
localized O 0 1.4915141832716472e-07
in O 0 3.884713439816778e-09
the O 0 9.024841318705512e-09
distal O 0 3.4942993920594745e-07
part O 0 3.500742806750168e-08
of O 0 5.1983235493935354e-08
the O 0 3.3330238125017786e-08
gene O 0 7.759214781799528e-08
seemed O 0 1.5981053991254157e-07
to O 0 1.26032573266599e-09
be O 0 2.4256974207048643e-09
preferentially O 0 2.6141304232396578e-08
associated O 0 4.981731294151359e-08
with O 0 6.902992311097478e-08
cognitive B-Disease 1 0.6113191246986389
impairment I-Disease 1 0.9994924068450928
. O 0 0.00016889510152395815

Two O 0 5.986150313219696e-07
altered O 0 1.315372401222703e-06
Dp71 O 0 1.5518629879807122e-05
transcripts O 0 7.977196219144389e-07
and O 0 4.76943728955348e-09
two O 0 2.264908927074316e-09
deleted O 0 2.3127423531832392e-08
Dp140 O 0 6.776568284294626e-08
DNA O 0 6.078020309274734e-09
sequences O 0 2.991648040406858e-09
were O 0 1.5156336186095132e-09
found O 0 9.371681208847349e-10
in O 0 8.03653754655187e-10
four O 0 3.897991263102085e-09
patients O 0 3.440019469280742e-08
with O 0 1.3091596429148922e-07
severe O 1 0.9999992847442627
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 0.9999998807907104
. O 0 0.005522713530808687

These O 0 1.4658635905107076e-07
findings O 0 7.739379270788049e-08
suggest O 0 1.4955217508827445e-08
that O 0 1.7569413979234838e-10
some O 0 1.2399953286390542e-10
sequences O 0 3.461533948367901e-09
located O 0 5.621143106537829e-09
in O 0 1.4054183372635976e-09
the O 0 6.7260743641384124e-09
distal O 0 1.4895242372858775e-07
part O 0 1.094959145575558e-08
of O 0 2.384709674174701e-08
the O 0 1.6003406599907066e-08
gene O 0 2.025116252468706e-08
and O 0 3.3089144757525446e-09
, O 0 2.2541004618403804e-09
in O 0 8.724128086612382e-10
particular O 0 4.519912444322927e-09
, O 0 1.0960743423993335e-09
some O 0 1.4080908661284752e-09
DMD B-Disease 1 0.9898097515106201
isoforms O 0 6.564543753029284e-08
expressed O 0 5.070400987960966e-09
in O 0 2.330670989536543e-09
the O 0 8.413103103066533e-09
brain O 0 3.7085649182699854e-06
may O 0 4.2005767753039436e-09
be O 0 3.042510410278254e-10
related O 0 1.0573223407916998e-09
to O 0 1.998911453027219e-10
the O 0 3.3806768495736605e-09
cognitive B-Disease 0 4.609911411534995e-05
impairment I-Disease 0 0.04465841129422188
associated O 0 5.4764521337347105e-05
with O 0 1.5278594219125807e-05
DMD B-Disease 1 1.0
. O 0 6.0284510254859924e-06
. O 0 5.743931524193613e-06

I1307K O 0 0.00039357010973617435
APC O 0 1.8469838323653676e-05
and O 0 1.1268347321902183e-07
hMLH1 O 0 2.7434762159828097e-06
mutations O 0 3.231858158869727e-08
in O 0 5.823708626451207e-09
a O 0 2.0491324193017135e-08
non O 0 5.924442803006968e-07
- O 0 6.224562412171508e-07
Jewish O 0 1.203463106946856e-08
family O 0 3.001306758676492e-09
with O 0 6.386718265360969e-09
hereditary B-Disease 1 0.9999982118606567
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9987881779670715

We O 0 2.656992421634641e-07
describe O 0 1.0544030715209374e-07
a O 0 2.8169097276986577e-08
French O 0 4.0597871020509047e-07
Canadian O 0 1.212872803080245e-06
hereditary B-Disease 1 0.9999898672103882
non I-Disease 1 0.9999996423721313
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 0.9999854564666748
HNPCC B-Disease 1 1.0
) O 0 1.707885166979395e-05
kindred O 0 0.0001781107421265915
which O 0 2.5051246410612293e-08
carries O 0 4.1265668215828555e-08
a O 0 7.567306781197658e-09
novel O 0 1.0377705805808546e-08
truncating O 0 2.5889713128890435e-07
mutation O 0 4.086877680720136e-08
in O 0 5.529281921212714e-08
hMLH1 O 0 1.5847293980186805e-05
. O 0 2.7804569526779233e-06

Interestingly O 0 1.0951389413094148e-05
, O 0 2.0439921399884042e-07
the O 0 9.086714669592766e-08
I1307K O 0 4.0046315916697495e-06
APC O 0 5.448709430311283e-07
polymorphism O 0 2.02024239115417e-07
, O 0 3.5823100041909584e-09
associated O 0 3.554920358084246e-09
with O 0 8.250276850585436e-11
an O 0 9.586839655462143e-11
increased O 0 1.5349019832910926e-08
risk O 0 1.521522108305362e-06
of O 0 0.4714917540550232
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 2.2793385596742155e-06
is O 0 2.0415912516114076e-08
also O 0 1.3152013922379524e-09
present O 0 7.423462289324334e-09
in O 0 6.433692689711279e-09
this O 0 7.085949160767768e-09
family O 0 1.423059501348689e-07
. O 0 6.053126639926631e-07

The O 0 1.7913757801579777e-06
I1307K O 0 1.9458630049484782e-05
polymorphism O 0 7.936787937978806e-07
has O 0 1.20495604605253e-08
previously O 0 1.5655395202429645e-08
only O 0 4.727645497304422e-10
been O 0 5.519297796574563e-10
identified O 0 4.5688647309916064e-10
in O 0 1.1419472312201862e-10
individuals O 0 1.1388280596325018e-10
of O 0 1.42737164310347e-08
self O 0 1.9393989987293025e-06
- O 0 8.842964234645478e-06
reported O 0 2.24519013158897e-07
Ashkenazi O 0 8.941997293732129e-07
Jewish O 0 2.6178210532634694e-07
origins O 0 2.0063944248249754e-06
. O 0 2.4035314254433615e-06

In O 0 3.869157296776393e-07
addition O 0 1.5844065615056024e-07
, O 0 1.4756251331959902e-08
in O 0 5.056165708339222e-09
this O 0 1.0637628555798528e-09
family O 0 4.273861264891821e-09
, O 0 1.7345201941409982e-09
there O 0 2.5340052278721714e-09
appears O 0 9.077564477877331e-09
to O 0 5.27338561706614e-10
be O 0 3.4344516119944046e-09
no O 0 7.389754586029085e-09
relationship O 0 1.60425237538675e-08
between O 0 1.2516852443411608e-08
the O 0 6.18137097063709e-09
I1307K O 0 2.005115362635479e-07
polymorphism O 0 1.0002343842074879e-08
and O 0 3.4658065306558683e-10
the O 0 6.865759627494583e-10
presence O 0 7.533076384902415e-09
or O 0 1.0180749576704784e-08
absence O 0 1.6748892903706292e-06
of O 0 4.277249900042079e-06
cancer B-Disease 0 0.012248201295733452
. O 0 3.484562114408618e-07
. O 0 2.402465725026559e-06

Identification O 0 8.990266451291973e-07
of O 0 1.983564601459875e-07
a O 0 3.616928623273452e-08
novel O 0 8.024012565499561e-09
mutation O 0 1.9761143832397465e-09
of O 0 7.557368952859633e-09
the O 0 1.546055372614319e-08
CPO O 0 4.191761945548933e-06
gene O 0 2.5807542769484826e-08
in O 0 9.410375589880005e-09
a O 0 4.2461561378104307e-08
Japanese O 0 1.5223730770230759e-05
hereditary B-Disease 1 0.9999961853027344
coproporphyria I-Disease 1 0.9999477863311768
family O 0 3.82039652322419e-05
. O 0 1.248490752914222e-05

Hereditary B-Disease 1 0.9999996423721313
coproporphyria I-Disease 1 0.9999988079071045
( O 0 0.005406315438449383
HCP B-Disease 1 0.9999972581863403
) O 0 2.941729633221257e-07
is O 0 1.9192295752645805e-08
an O 0 4.061513791953075e-08
autosomal B-Disease 1 0.9998371601104736
dominant I-Disease 1 1.0
disease I-Disease 1 0.9998137354850769
characterized O 0 2.170890638808487e-06
by O 0 4.4915204000517406e-08
a O 0 3.3379408250766573e-06
deficiency B-Disease 1 0.9990009665489197
of I-Disease 0 0.002443865640088916
coproporphyrinogen I-Disease 1 0.9998282194137573
oxidase I-Disease 0 8.062673259701114e-06
( O 0 5.997469543217449e-07
CPO O 0 4.2669675167417154e-05
) O 0 1.3854601910168185e-08
caused O 0 2.1692622809155182e-08
by O 0 8.665569373178528e-10
a O 0 7.44936157204279e-09
mutation O 0 3.4695384343308433e-09
in O 0 4.754369342663267e-09
the O 0 9.467395045703597e-08
CPO O 0 7.189261668827385e-05
gene O 0 1.5551994465567986e-06
. O 0 1.6789146002338384e-06

Only O 0 4.0443339344164997e-07
11 O 0 4.198368230845517e-07
mutations O 0 2.8392088680107008e-08
of O 0 1.2290215956056727e-08
the O 0 6.625220372313834e-09
gene O 0 1.5610906345386866e-08
have O 0 8.13871803284627e-10
been O 0 4.345173998387963e-09
reported O 0 2.5098213285446036e-08
in O 0 1.1718667991544862e-07
HCP B-Disease 1 0.9999040365219116
patients O 0 8.55542893987149e-05
. O 0 1.0701498467824422e-05

We O 0 2.9727857508987654e-07
report O 0 4.7053944740582665e-08
another O 0 1.7146371433796048e-08
mutation O 0 4.674084674860524e-09
in O 0 6.1078875290832e-09
a O 0 5.320552887155827e-08
Japanese O 0 7.019196345936507e-06
family O 0 9.434062349100714e-07
. O 0 1.4807613979428424e-06

Polymerase O 0 0.0001259286073036492
chain O 0 3.6800556699745357e-06
reaction O 0 1.6246565337496577e-07
- O 0 1.7224422776962456e-07
single O 0 5.549533277360297e-09
strand O 0 1.974152574746313e-08
conformational O 0 1.2525116055428498e-08
polymorphism O 0 1.2352352918298948e-08
and O 0 4.968896405443957e-10
direct O 0 1.7488646086860626e-09
sequence O 0 2.8841051769035175e-09
analyses O 0 1.0647093873217273e-08
demonstrated O 0 2.1219840107278287e-08
a O 0 6.7170109474545825e-09
C O 0 2.0759466679010075e-07
to O 0 2.17878159958218e-09
T O 0 1.7975486343857483e-07
substitution O 0 1.9722934396781966e-08
in O 0 6.793674511840209e-09
exon O 0 3.464948008513602e-07
1 O 0 6.875988134424915e-08
of O 0 1.154598638919424e-08
the O 0 1.368851609839794e-08
CPO O 0 4.6169014922270435e-07
gene O 0 7.359513443105925e-09
at O 0 1.6554073667407465e-08
nucleotide O 0 4.1321587929132875e-08
position O 0 1.1138882882733014e-07
85 O 0 2.3543260851965897e-07
, O 0 1.5517898077632708e-08
which O 0 1.5035550582354062e-09
lies O 0 2.0751107498995225e-08
in O 0 1.450681352821448e-09
the O 0 5.870516073258614e-09
putative O 0 1.169562366953869e-07
presequence O 0 4.96956488404976e-07
for O 0 1.669240745627576e-08
targeting O 0 1.2575246444157528e-07
to O 0 1.04776326281808e-07
mitochondria O 0 9.941320968209766e-06
. O 0 5.511158178705955e-06

This O 0 1.0470100875181743e-07
mutation O 0 1.5586897106345532e-08
changes O 0 9.997556560392695e-09
the O 0 3.885542998460778e-09
codon O 0 2.8252713946130825e-08
for O 0 5.071368214260019e-09
glutamine O 0 7.571915716653166e-08
to O 0 2.716828317872455e-09
a O 0 9.16594711242169e-09
termination O 0 5.618830556386456e-08
codon O 0 8.616315483322978e-08
at O 0 1.323254537055618e-07
amino O 0 1.3112175167862006e-07
acid O 0 2.418644555746141e-07
position O 0 1.6539767102585756e-06
29 O 0 1.295746915275231e-05
. O 0 2.6268842248100555e-06

MaeI O 0 3.297713919891976e-05
restriction O 0 3.652207567483856e-07
analysis O 0 7.720331041127793e-08
showed O 0 9.379504462003752e-08
two O 0 1.4791381452994301e-09
other O 0 1.3330265780098216e-09
carriers O 0 1.1496059215687637e-08
in O 0 5.134730862721426e-09
the O 0 2.248287778172653e-08
family O 0 1.9339067591772618e-07
. O 0 6.098094900153228e-07

The O 0 4.306506525608711e-06
C O 1 0.6483609676361084
- O 0 0.0005099681438878179
T O 0 1.0585006748442538e-05
mutation O 0 2.7001229696566043e-08
is O 0 4.895353900025157e-09
located O 0 5.3254027854166e-09
within O 0 6.671784902323452e-09
a O 0 4.510224194120838e-09
recently O 0 7.705851068351421e-09
proposed O 0 2.2871269322877197e-09
putative O 0 4.5766732625907025e-09
alternative O 0 2.2450641345983513e-09
translation O 0 3.641819734667706e-09
initiation O 0 3.533412140654946e-08
codon O 0 1.5550585885648616e-07
( O 0 6.028699317539576e-08
TIC O 0 1.8913455278379843e-05
- O 0 2.4241089704446495e-06
1 O 0 4.723918891613721e-07
) O 0 6.352143255838882e-09
, O 0 6.568598553968741e-09
supporting O 0 2.3691322681429483e-08
that O 0 6.753971160122774e-09
TIC O 0 7.790875679347664e-05
- O 0 2.9690959308936726e-06
1 O 0 2.0394649880017823e-07
is O 0 1.862707987854151e-09
the O 0 2.234299190106981e-09
real O 0 2.592857981653651e-07
TIC O 0 3.488722768452135e-06
rather O 0 3.3413495970080476e-08
than O 0 2.1100978742083498e-08
TIC O 0 0.00011646668281173334
- O 0 3.300669959571678e-06
2 O 0 5.414501060840848e-07
. O 0 2.541324839455683e-08
. O 0 3.080128578858421e-07

Human B-Disease 0 5.051609264228318e-07
complement I-Disease 0 5.139631412021117e-06
factor I-Disease 0 0.0008834456093609333
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999752044677734
associated O 0 0.00016810334636829793
with O 1 0.8020570278167725
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9999104738235474

This O 0 6.048036738093288e-08
study O 0 3.7118372375744e-08
reports O 0 4.5534345183284586e-09
on O 0 1.5508813788756015e-08
six O 0 4.438944767315434e-09
cases O 0 2.545320842983756e-09
of O 0 2.8859172829243107e-08
deficiency B-Disease 0 0.12305862456560135
in I-Disease 0 1.2355558354215646e-08
the I-Disease 0 7.286533154626795e-09
human I-Disease 0 2.336546511827464e-09
complement I-Disease 0 2.5403798176171222e-08
regulatory I-Disease 0 4.493169853958534e-07
protein I-Disease 0 4.186122168903239e-07
Factor I-Disease 0 1.5492693137275637e-06
H I-Disease 1 0.9997915625572205
( O 0 2.879320106785599e-07
FH O 0 9.542934094497468e-06
) O 0 3.934472747602058e-09
in O 0 9.282924984255203e-10
the O 0 8.09997069417534e-10
context O 0 8.3850046905809e-09
of O 0 1.0528672156340235e-08
an O 0 2.950616533325956e-07
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.01960059627890587

Five O 0 2.7575177341532253e-07
of O 0 4.0173283366584656e-08
the O 0 1.2286045070197815e-08
cases O 0 2.1695423235712497e-09
were O 0 9.705199977005918e-10
observed O 0 1.829874363146189e-09
in O 0 5.120566748395561e-10
children O 0 4.6392656383176245e-10
presenting O 0 2.166590995500428e-08
with O 0 2.4355207983717264e-07
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999997615814209
HUS B-Disease 1 1.0
) O 0 0.000597418169490993
. O 0 0.00010287967597832903

Two O 0 2.00047779230772e-07
of O 0 1.5607281511620386e-07
the O 0 7.69002710399036e-08
children O 0 1.5270440911763217e-08
exhibited O 0 3.450857093412196e-07
a O 0 1.7992311995840282e-07
homozygous O 0 9.91021533991443e-06
deficiency O 1 0.9253919720649719
characterized O 0 1.4349839716487622e-07
by O 0 3.0825655361610416e-09
the O 0 8.787610639160448e-09
absence O 0 2.5402886194569874e-07
of O 0 3.668718662197534e-08
the O 0 2.259740661259002e-08
150 O 0 4.532492781095243e-08
- O 0 9.482612028932635e-08
kD O 0 2.617690881834278e-07
form O 0 6.428650944911851e-09
of O 0 5.554957738240773e-08
Factor O 0 2.037125796050532e-06
H O 1 0.9994921684265137
and O 0 5.174509709604536e-09
the O 0 3.856607033725368e-09
presence O 0 7.93791521402909e-09
, O 0 7.3203515471576e-10
upon O 0 3.794991432215511e-09
immunoblotting O 0 1.821810258206824e-07
, O 0 7.59728335797405e-10
of O 0 2.0086736718383236e-09
the O 0 3.3500331397817718e-09
42 O 0 1.6335120278654358e-07
- O 0 3.01061419349935e-07
kD O 0 4.7788557822059374e-06
Factor O 0 2.016455482589663e-06
H O 1 0.9928956627845764
- O 0 2.9052973786747316e-06
like O 0 5.352288923177184e-08
protein O 0 1.708383194909402e-07
1 O 0 5.817627766191436e-07
( O 0 3.5671479992060995e-08
FHL O 0 1.5830240954528563e-05
- O 0 1.0179991249970044e-06
1 O 0 2.0528375443973346e-07
) O 0 2.093336393116374e-09
and O 0 1.687177730858025e-09
other O 0 5.349591880587923e-09
FH O 0 3.0287243134807795e-05
- O 0 1.1450965757831e-06
related O 0 2.6104240191671124e-07
protein O 0 3.462051267888455e-07
( O 0 1.6603497243750098e-08
FHR O 0 3.504520282149315e-05
) O 0 8.154605524168801e-08
bands O 0 5.001266345061595e-06
. O 0 4.993231414118782e-06

Southern O 0 1.0407167792436667e-05
blot O 0 1.7350922689729487e-06
and O 0 4.8506842986739684e-09
PCR O 0 4.900849859268419e-08
analysis O 0 4.089004246310424e-09
of O 0 2.2420816314649983e-09
DNA O 0 2.772602947231917e-08
of O 0 1.1972631774881393e-08
one O 0 6.269726071650439e-09
patient O 0 7.163450987945907e-08
with O 0 4.4003972021755544e-08
homozygous O 0 0.0010455631418153644
deficiency O 1 0.9999905824661255
ruled O 0 1.7881031453725882e-05
out O 0 4.363986505495632e-09
the O 0 1.6750733022874442e-09
presence O 0 6.507519856313593e-09
of O 0 6.4935585797343265e-09
a O 0 3.0096360958964397e-09
large O 0 3.1214189011308235e-09
deletion O 0 2.4508910456688682e-08
of O 0 1.5975682998714547e-08
the O 0 5.4064422272404045e-08
FH O 0 1.99594724108465e-05
gene O 0 2.783422736740704e-08
as O 0 9.235863629442065e-09
the O 0 3.076247168110058e-08
underlying O 0 0.00033767728018574417
defect O 0 3.609085251810029e-05
for O 0 2.8617481007131573e-07
the O 0 6.369555921992287e-05
deficiency O 1 0.9999985694885254
. O 0 0.00011479974637040868

The O 0 4.970010536453628e-07
other O 0 2.534257959041497e-08
four O 0 1.6138555380962316e-08
children O 0 2.5899149491692697e-09
presented O 0 3.348252519685957e-08
with O 0 3.2029667806909856e-08
heterozygous O 0 1.605980287422426e-05
deficiency O 1 0.9432064890861511
and O 0 7.575049920660604e-08
exhibited O 0 2.082525043078931e-06
a O 0 2.5701044847892263e-08
normal O 0 1.5827816923774662e-07
immunoblotting O 0 1.4119381148702814e-06
pattern O 0 5.0137984430875804e-08
of O 0 1.244913860887209e-08
proteins O 0 4.970121203484723e-09
of O 0 5.852418283325278e-08
the O 0 8.577623020755709e-07
FH O 0 0.12256275862455368
family O 0 3.341456704220036e-06
. O 0 3.888714218192035e-06

Factor B-Disease 1 0.9986302852630615
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999982118606567
is O 0 9.877881268494093e-08
the O 0 3.376856838599451e-08
only O 0 1.8127738599105214e-07
complement B-Disease 1 0.9999681711196899
deficiency I-Disease 1 1.0
associated O 0 0.0006508171209134161
with O 0 4.377584991743788e-05
HUS B-Disease 1 1.0
. O 0 0.000900191895198077

These O 0 6.491914206208094e-08
observations O 0 1.4548194826602412e-07
suggest O 0 9.074486229110335e-08
a O 0 2.4295788492167958e-08
role O 0 7.706663041062711e-08
for O 0 4.130315289785358e-08
FH O 0 0.05981499329209328
and O 0 8.070844614849193e-07
/ O 0 0.003984920680522919
or O 0 4.7435298711206997e-07
FH O 0 0.00017333096184302121
receptors O 0 8.452416722093403e-08
in O 0 8.11633693587055e-09
the O 0 2.490698136625724e-08
pathogenesis O 0 0.0007169784512370825
of O 0 5.8950295169779565e-06
idiopathic O 1 0.9999885559082031
HUS B-Disease 1 1.0
. O 0 1.8439232007949613e-05
. O 0 1.756935307639651e-05

Further O 0 7.007452609286702e-07
evidence O 0 1.5954907439663657e-07
for O 0 3.65279717584599e-09
a O 0 4.5952082139422146e-09
major O 0 2.3635671198007913e-08
ancient O 0 9.308124617746216e-07
mutation O 0 2.2417729269363917e-05
underlying O 1 0.9999890327453613
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 1.7861822925624438e-05
linkage O 0 0.037337128072977066
disequilibrium O 0 0.009403897449374199
studies O 0 1.689214315092613e-07
in O 0 7.470819518573535e-09
the O 0 1.2389610226648529e-08
Japanese O 0 8.176922392522101e-07
population O 0 2.074833638232576e-08
. O 0 6.894537705193216e-07

The O 1 0.9995120763778687
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.03153402358293533
DM B-Disease 1 1.0
) O 0 3.7877700265198655e-07
mutation O 0 5.2455934707040797e-08
is O 0 7.354236775114487e-09
an O 0 8.382606608847709e-09
unstable O 0 0.001627457677386701
( O 0 5.011857524550578e-07
CTG O 0 0.0021163669880479574
) O 0 4.7716326889712946e-08
n O 0 3.6072628972760867e-07
repeat O 0 1.8680142943594547e-07
, O 0 5.5002371546208906e-09
present O 0 2.7121944690122746e-09
at O 0 2.0336242911866975e-08
a O 0 9.561443858885355e-10
copy O 0 2.4078399274429785e-09
number O 0 4.334179404263949e-10
of O 0 5.304863659461034e-09
5 O 0 6.686756393037285e-08
- O 0 8.973796639111242e-08
37 O 0 3.173540719103585e-08
repeats O 0 1.0098170299954745e-08
on O 0 3.894565558937302e-09
normal O 0 5.490971233257369e-09
chromosomes O 0 1.0608635081510442e-09
but O 0 1.4996133501643527e-10
amplified O 0 2.683578914641771e-09
to O 0 2.780660701695581e-10
50 O 0 7.269916224572626e-09
- O 0 1.1999469862189471e-08
3000 O 0 6.9862915452745256e-09
copies O 0 4.60606264240937e-09
on O 0 2.5022742988767277e-07
DM B-Disease 1 0.9998980760574341
chromosomes O 0 3.500467300909804e-06
. O 0 7.98407711499749e-07

Previous O 0 8.699707905179821e-07
findings O 0 3.3432755230933253e-07
in O 0 3.555098260221712e-08
Caucasian O 0 5.388671979744686e-07
populations O 0 1.0911834102955709e-08
of O 0 9.874246131857944e-08
a O 0 1.1684597666317131e-05
DM B-Disease 1 1.0
founder O 1 0.997864305973053
chromosome O 0 1.2550733117677737e-05
raise O 0 1.5861741076150793e-07
a O 0 2.5445308082794327e-08
question O 0 2.7526533941113485e-08
about O 0 8.797618189504419e-10
the O 0 1.1488601181497415e-09
molecular O 0 1.7425124454462093e-08
events O 0 3.3041340774531136e-09
involved O 0 1.0389429760948588e-08
in O 0 2.7964799365065574e-09
the O 0 1.1045640846418792e-08
expansion O 0 2.05588753487973e-06
mutation O 0 7.920100983938028e-07
. O 0 1.9561819044611184e-06

To O 0 1.938938822831915e-07
investigate O 0 5.085901193524478e-07
whether O 0 2.1667608507414116e-07
a O 0 4.2944594724758645e-07
founder O 0 2.4845546704455046e-06
chromosome O 0 1.8504924526041577e-07
for O 0 9.909202347557766e-09
the O 0 9.718619509158088e-08
DM B-Disease 1 1.0
mutation O 0 5.7391240204651695e-08
exists O 0 1.2935849724726722e-08
in O 0 6.948864816891387e-10
the O 0 1.182812958688828e-09
Japanese O 0 4.6691152277844594e-08
population O 0 3.7731640034621705e-10
, O 0 5.892972221310799e-10
we O 0 1.9758958913485003e-09
genotyped O 0 1.1731269466963568e-07
families O 0 3.770286305382342e-10
using O 0 1.5325726243631266e-09
polymorphic O 0 3.471174991886983e-08
markers O 0 9.158960523336646e-08
near O 0 7.366270438069478e-07
the O 0 1.310737474113921e-07
( O 0 2.554334628257493e-07
CTG O 0 0.00013762143498752266
) O 0 3.176986496100653e-08
n O 0 4.862891955781379e-07
repeat O 0 4.0149464552996506e-07
region O 0 2.204916143000446e-07
and O 0 3.350980648519908e-08
constructed O 0 4.5614265218318906e-06
haplotypes O 0 1.6705533198546618e-05
. O 0 6.6599773163034115e-06

Six O 0 6.873981419630582e-07
different O 0 1.0132246330840644e-07
haplotypes O 0 2.4677956389496103e-06
were O 0 1.607795780955712e-07
found O 0 7.031318460803959e-08
and O 0 4.436085987435945e-08
DM B-Disease 1 0.9999966621398926
alleles O 0 4.108669315883162e-07
were O 0 2.5668865077932423e-07
always O 0 1.6582995954195212e-07
haplotype O 0 2.756449930529925e-06
A O 0 3.204921313226805e-06
. O 0 1.6089262544483063e-06

To O 0 1.7167648991289752e-07
find O 0 1.1924241505312239e-07
an O 0 3.7781782147305876e-09
origin O 0 1.9825181496457844e-08
of O 0 3.7324539903238474e-08
the O 0 5.7966605737647114e-08
( O 0 9.611625273464597e-08
CTG O 0 3.5837776522384956e-05
) O 0 2.303492863120482e-08
n O 0 1.9703162479345337e-07
repeat O 0 9.183187898997858e-08
mutation O 0 5.043307549357223e-09
and O 0 7.199866813856204e-10
to O 0 1.0128952121490897e-09
investigate O 0 1.74615895076613e-08
the O 0 3.037612161804759e-09
mechanism O 0 1.82294513706438e-07
of O 0 1.0952975415534638e-08
the O 0 2.2247268471886628e-09
expansion O 0 2.280254562947448e-08
mutation O 0 8.698590181488441e-10
in O 0 3.3907426866264245e-10
the O 0 5.750513953906022e-10
Japanese O 0 1.4748343879489312e-08
population O 0 1.0752429502325356e-10
we O 0 2.967374679307966e-10
have O 0 1.324959864046349e-10
studied O 0 1.8510920796188657e-08
90 O 0 1.8276672619776946e-08
Japanese O 0 7.392873158096336e-07
DM B-Disease 1 0.9996215105056763
families O 0 5.675526271176068e-09
comprising O 0 2.4759581052080648e-08
190 O 0 1.2287919126663382e-08
affected O 0 6.961789811299468e-09
and O 0 5.835973482248846e-09
130 O 0 1.1970283253504022e-07
unaffected O 0 1.3869403119315393e-06
members O 0 1.3128190801126038e-07
. O 0 1.0844526059372583e-06

The O 0 7.601738616358489e-07
results O 0 1.4932605552075984e-07
suggest O 0 6.137072716683178e-08
that O 0 4.784997953422021e-10
a O 0 3.101969792140835e-09
few O 0 1.8077485064438292e-09
common O 0 5.912677902841779e-09
ancestral O 0 5.191733976062096e-08
mutations O 0 1.0533733885154106e-08
in O 0 2.632155826631788e-09
both O 0 1.498259827314996e-08
Caucasian O 0 1.3991839296068065e-06
and O 0 1.7685492181840345e-08
Japanese O 0 9.015964224090567e-07
populations O 0 3.3137459443111084e-09
have O 0 4.39761616011225e-10
originated O 0 1.6446495276767337e-09
by O 0 1.6512745337760038e-10
expansion O 0 1.288686757305868e-08
of O 0 6.339144320577361e-09
an O 0 1.8837018611606027e-09
ancestral O 0 8.859172595521159e-08
n O 0 1.4731537589796062e-07
= O 0 1.3675264654011698e-07
5 O 0 3.688850114258457e-08
repeat O 0 1.630977131128475e-08
to O 0 2.1764223756548517e-09
n O 0 1.4416642102332844e-07
= O 0 3.5159604294676683e-07
19 O 0 8.232084383053007e-07
- O 0 4.800040187546983e-07
37 O 0 3.427550154810888e-07
copies O 0 1.8410784718980722e-07
. O 0 4.523247980614542e-07

These O 0 2.199064930152872e-08
data O 0 2.8601020218843587e-08
support O 0 6.330445057045608e-09
multistep O 0 2.984116065363196e-07
models O 0 3.874569642903225e-08
of O 0 9.094863884229198e-08
triplet O 0 3.2660607303114375e-06
repeat O 0 5.830985969623725e-07
expansion O 0 4.781203415404889e-07
that O 0 1.0633004476900965e-09
have O 0 1.6626044985201816e-10
been O 0 1.632995683120697e-10
proposed O 0 3.73576919399099e-10
for O 0 4.171941958563963e-10
both O 0 2.591789183270521e-08
DM B-Disease 1 0.9999997615814209
and O 0 3.4802988011506386e-06
Friedreichs B-Disease 1 0.9971304535865784
ataxia I-Disease 1 0.5988608598709106
. O 0 1.5410453215736197e-06
. O 0 6.23813957645325e-06

The O 0 4.3226921775385563e-07
molecular O 0 2.559263066359563e-06
basis O 0 3.942287094105268e-06
of O 0 0.0776076540350914
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 3.8844527239234594e-07
the O 0 6.618591896767612e-08
western O 0 3.0721167831870844e-07
Cape O 0 9.434404546482256e-07
, O 0 1.9408123108632935e-08
South O 0 3.2223798029917816e-07
Africa O 0 4.242719739977474e-07
. O 0 7.052108799143753e-07

Deficiency B-Disease 1 0.999984860420227
of I-Disease 0 7.0768746809335425e-06
the I-Disease 0 8.41239170767949e-07
sixth I-Disease 0 3.6614108012145152e-06
component I-Disease 0 2.274834741911036e-06
of I-Disease 0 7.458861972509112e-08
human I-Disease 0 2.871581017416247e-08
complement I-Disease 0 2.55029453910538e-06
( O 0 1.8424607333145104e-06
C6 O 1 0.6762925982475281
) O 0 4.899971273175652e-08
has O 0 5.908078914984571e-09
been O 0 2.5678050796784646e-09
reported O 0 1.1140699474054827e-09
in O 0 8.944904539287535e-11
a O 0 1.1318379566915837e-10
number O 0 1.4473473808340742e-10
of O 0 7.264174262111567e-10
families O 0 8.543171031716312e-11
from O 0 7.71214037076362e-10
the O 0 1.9063901568472374e-09
western O 0 4.672233089308975e-08
Cape O 0 1.8644583121840697e-07
, O 0 1.7905025018194465e-08
South O 0 2.6303084155188117e-07
Africa O 0 2.9016763392064604e-07
. O 0 5.84027475269977e-07

Meningococcal B-Disease 1 0.9999973773956299
disease I-Disease 1 0.9976615905761719
is O 0 2.507572958165838e-07
endemic O 0 6.703983501665789e-08
in O 0 5.928170843105818e-09
the O 0 1.0232884761762762e-08
Cape O 0 2.671044398994127e-07
and O 0 1.3252638986216425e-09
almost O 0 4.915451157216921e-09
all O 0 1.2431905505039254e-09
pedigrees O 0 6.50117044642684e-08
of O 0 5.7753503313051624e-08
total O 0 9.21591417863965e-05
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.3457756722345948e-05
C6Q0 O 1 0.9974352717399597
) O 0 4.325248781356095e-08
have O 0 2.1943209471686487e-09
been O 0 5.662032620534774e-09
ascertained O 0 1.1310583403201235e-07
because O 0 7.134717705525873e-09
of O 0 1.7130672347320797e-07
recurrent O 1 0.5714847445487976
disease O 1 0.552933931350708
. O 0 9.351524568046443e-06

We O 0 1.16056196475256e-06
have O 0 1.740658994719979e-08
sequenced O 0 3.28426814633076e-08
the O 0 4.9318384931495984e-09
expressed O 0 4.745083437285302e-09
exons O 0 5.3653106846240917e-08
of O 0 1.1165936619761396e-08
the O 0 3.019849970087307e-08
C6 O 0 3.9598086004843935e-05
gene O 0 2.1893095336622537e-08
from O 0 3.7273295561135456e-09
selected O 0 1.145849548578326e-08
cases O 0 2.606953986017402e-09
and O 0 9.746567997126476e-10
have O 0 6.254553541751307e-10
found O 0 1.4684898852479478e-09
three O 0 1.898954105072903e-09
molecular O 0 3.2156244742509443e-06
defects O 0 0.0015330190071836114
leading O 0 1.9919580154237337e-06
to O 0 2.1605329081353375e-08
total O 0 4.691652520705247e-06
deficiency O 1 0.9999996423721313
879delG O 0 0.07552367448806763
, O 0 1.8606871776682965e-07
which O 0 2.0626322871919456e-09
is O 0 8.402115114769515e-10
the O 0 3.009291704714201e-09
common O 0 3.7016562259850616e-08
defect O 0 9.102124067794648e-07
in O 0 1.2029856222284252e-08
the O 0 3.2665571580992037e-08
Cape O 0 5.904960289626615e-07
and O 0 9.411739831932664e-09
hitherto O 0 6.533041982947907e-07
unreported O 0 1.774415778754701e-07
, O 0 2.432906986982175e-09
and O 0 1.2379588465449842e-09
1195delC O 0 1.1334889649106117e-07
and O 0 3.774101475784164e-09
1936delG O 0 3.67645981214082e-07
, O 0 3.095421252652386e-09
which O 0 1.7341918179258897e-10
have O 0 8.821288838278818e-11
been O 0 3.796089831364924e-10
previously O 0 1.3769371198790736e-09
reported O 0 8.061054601604667e-10
in O 0 5.918925904957462e-10
African O 0 3.028946693461876e-08
- O 0 1.198396034851612e-06
Americans O 0 2.1776594394395943e-07
. O 0 9.73694000094838e-07

We O 0 2.3536622393294238e-06
also O 0 8.786575733665813e-08
show O 0 1.7968076804208977e-08
that O 0 1.7325091361541922e-10
the O 0 1.1174580150097313e-09
879delG O 0 6.417798203983693e-08
and O 0 3.2065898825095474e-09
1195delC O 0 2.5545859898556955e-06
defects O 0 2.5628119146858808e-06
are O 0 1.1085504736385587e-09
associated O 0 1.3714225133298896e-07
with O 0 8.50108392569382e-08
characteristic O 1 0.9999227523803711
C6 O 1 1.0
/ O 1 0.9999994039535522
C7 O 1 0.9998348951339722
region O 0 1.4229890439310111e-06
DNA O 0 4.351214499820344e-07
marker O 0 1.5230145322675526e-07
haplotypes O 0 4.359546608156961e-07
, O 0 6.7269598780228534e-09
although O 0 8.151585184634769e-09
small O 0 4.784023843740215e-09
variations O 0 5.7472959724691464e-08
were O 0 6.223559978479898e-08
observed O 0 2.93315451926901e-07
. O 0 5.561801117437426e-07

The O 0 3.6963763250241755e-06
1936delG O 0 0.00023325058282352984
defect O 0 7.899214688222855e-05
was O 0 1.0750819683380541e-06
observed O 0 5.927834578756119e-08
only O 0 3.2680447237254384e-09
once O 0 1.4931531566730882e-08
in O 0 1.1533478616598813e-09
the O 0 2.7317361706025167e-09
Cape O 0 8.557746866699745e-08
, O 0 8.576218624156695e-10
but O 0 2.1261020721752288e-10
its O 0 1.8139439950104475e-10
associated O 0 2.0556777613478516e-08
haplotype O 0 3.3705447322063264e-07
could O 0 4.348542503862518e-08
be O 0 5.060742225282411e-08
deduced O 0 1.3498660109689808e-06
. O 0 1.0854623724299017e-06

The O 0 2.3090316858542792e-07
data O 0 1.220219729702876e-07
from O 0 1.1198974192438982e-08
the O 0 1.1255980147950595e-08
haplotypes O 0 2.037161408452448e-07
indicate O 0 2.1098403024666368e-08
that O 0 4.608767256719659e-10
these O 0 3.367411627319683e-10
three O 0 3.090247613357633e-09
molecular O 0 7.198980824796308e-07
defects O 0 1.6728747596062021e-06
account O 0 5.958051829679789e-09
for O 0 6.6872511972349e-09
the O 0 7.195205853349762e-08
defects O 0 4.8475041694473475e-05
in O 0 1.1229561280856615e-08
all O 0 3.153073135919726e-09
the O 0 2.4111130869641784e-08
38 O 0 4.7397446678587585e-07
unrelated O 0 3.172681601881777e-07
C6Q0 O 0 1.8589220417197794e-05
individuals O 0 2.9153206515530883e-09
we O 0 7.642734445312271e-09
have O 0 1.427768347994629e-09
studied O 0 1.653074690466383e-07
from O 0 1.6503253874589063e-08
the O 0 5.109469469743999e-08
Cape O 0 3.226861963412375e-06
. O 0 8.69947541559668e-07

We O 0 7.705485813858104e-07
have O 0 7.699152426710043e-09
also O 0 1.7145087571890372e-09
observed O 0 2.2061890092572867e-09
the O 0 2.1387034365716318e-09
879delG O 0 2.6009911380242556e-07
defect O 0 2.291290002176538e-07
in O 0 8.065073053842298e-09
two O 0 1.2103336644031515e-07
Dutch O 1 0.9999932050704956
C6 B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
deficient I-Disease 1 0.9999998807907104
kindreds O 0 0.0019333390519022942
, O 0 6.909920813313875e-08
but O 0 7.862213102782789e-09
the O 0 1.5031286437761082e-08
879delG O 0 1.5393134162877686e-06
defect O 0 7.436672717631154e-07
in O 0 1.071146105147136e-08
the O 0 4.372645534544972e-08
Cape O 0 2.4103376290440792e-06
probably O 0 8.138228935195002e-08
did O 0 3.275021143167578e-09
not O 0 5.911253708745789e-10
come O 0 9.838273529183539e-10
from O 0 1.5231046424091232e-09
The O 0 5.874335240463324e-09
Netherlands O 0 1.2205484836158575e-06
. O 0 4.2338474059988584e-08
. O 0 4.056033162669337e-07

Complement B-Disease 1 0.9999905824661255
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.5771614698678604e-06
seven O 0 1.4531653391713917e-07
further O 0 1.8440287874454953e-07
molecular O 0 7.969813850650098e-06
defects O 0 1.3885516636946704e-05
and O 0 5.192434038292504e-09
their O 0 8.379329230479016e-09
associated O 0 1.1523520697664935e-06
marker O 0 4.382224233268062e-06
haplotypes O 0 5.308834442985244e-05
. O 0 9.250159564544447e-06

Seven O 0 6.772600613658142e-07
further O 0 1.254362445024526e-07
molecular O 0 7.094308784871828e-07
bases O 0 5.420127422439691e-07
of O 0 0.0006248924182727933
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.3651996368935215e-06
described O 0 1.2840558156312909e-05
. O 0 3.1852068786974996e-06

All O 0 4.701465172729513e-08
these O 0 1.1537268918004884e-08
new O 0 3.1233206243541645e-08
molecular O 0 7.5728820547738e-07
defects O 0 7.72296630202618e-07
involve O 0 4.242367523943358e-08
single O 0 3.86002412255948e-08
- O 0 1.3160457967842376e-07
nucleotide O 0 6.386829909388325e-08
events O 0 5.165023964082138e-09
, O 0 1.96792981910221e-09
deletions O 0 1.6697661919806706e-08
and O 0 1.8804353629775505e-09
substitutions O 0 4.941813003256357e-08
, O 0 2.5614899090697918e-09
some O 0 1.1940924915521123e-09
of O 0 5.79482284379651e-09
which O 0 9.200361028582904e-10
alter O 0 3.773671863882555e-08
splice O 0 2.2776863772833167e-07
sites O 0 2.8106253324722275e-08
, O 0 4.212194149033621e-09
and O 0 7.3194206251514515e-09
others O 0 9.475181173002056e-08
codons O 0 1.6222550129896263e-06
. O 0 2.4849198325682664e-06

They O 0 8.90129641106796e-08
are O 0 2.852234004535603e-09
distributed O 0 1.3536002319014528e-09
along O 0 4.6881920567898305e-09
the O 0 8.076495028319641e-09
C7 O 0 1.3536530786950607e-05
gene O 0 3.840856166448248e-08
, O 0 2.855107927857148e-09
but O 0 8.762049974464503e-10
predominantly O 0 2.2002806243648365e-09
towards O 0 2.285597489048996e-08
the O 0 2.578510560624636e-08
3 O 0 3.5038064538639446e-07
end O 0 1.1751138799809269e-06
. O 0 8.916026104088814e-07

All O 0 1.988623665738487e-07
were O 0 1.4214005261692364e-07
found O 0 1.6436468186498132e-08
in O 0 4.3619641232339745e-09
compound O 0 2.34096887652413e-07
heterozygous O 0 1.9213251789551578e-07
individuals O 0 2.9773161713819718e-08
. O 0 9.29688440010068e-07

The O 0 0.0002491327468305826
C6 O 1 0.9999978542327881
/ O 1 0.9995773434638977
C7 O 1 0.8628073334693909
marker O 0 2.7719856007024646e-05
haplotypes O 0 1.982739195227623e-05
associated O 0 1.2616728781722486e-06
with O 0 1.9038442644614406e-07
most O 0 2.026324364123866e-05
C7 B-Disease 1 0.9999990463256836
defects I-Disease 1 0.8885301947593689
are O 0 6.979155386943603e-08
tabulated O 0 5.961190254311077e-06
. O 0 2.74974439662401e-07
. O 0 9.66425204751431e-07

A O 0 2.2357051420840435e-05
genome O 0 9.54878260017722e-07
- O 0 2.1691676010959782e-07
wide O 0 1.751131861738031e-08
search O 0 1.065127808175248e-08
for O 0 5.4465778553947075e-09
chromosomal O 0 6.361254691000795e-06
loci O 0 4.2812882838916266e-07
linked O 0 1.5439565004271572e-06
to O 0 5.774359124188777e-08
mental O 1 0.9999661445617676
health O 0 0.00016310770297423005
wellness O 0 9.572348790243268e-05
in O 0 4.4229569340359376e-08
relatives O 0 4.639456108179729e-08
at O 0 1.488217833411909e-07
high O 0 1.3337668178792228e-06
risk O 0 7.885349759817473e-07
for O 0 1.452531023460324e-06
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 0.9999998807907104
among O 0 1.1001181974279461e-06
the O 0 5.578751824941719e-07
Old O 0 1.3856505574949551e-05
Order O 0 6.200632469699485e-07
Amish O 0 7.744038157397881e-06
. O 0 1.0187799261984765e-06

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.9975429773330688
BPAD B-Disease 1 1.0
; O 1 0.9990830421447754
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 9.841282917477656e-07
is O 0 2.700153700629926e-08
characterized O 0 4.0462271755359325e-08
by O 0 2.085107864147062e-09
episodes O 0 5.303419925439812e-08
of O 0 4.419849801706732e-07
mania B-Disease 1 0.8432433605194092
and O 0 6.367879450408509e-07
/ O 1 0.986090898513794
or O 0 1.3576777746493462e-05
hypomania B-Disease 1 0.9952229857444763
interspersed O 0 4.4241977548153955e-07
with O 0 5.639398725776346e-09
periods O 0 5.027904080634471e-06
of O 0 3.814038564087241e-06
depression B-Disease 1 0.9964146614074707
. O 0 1.5607947716489434e-05

Compelling O 0 1.2010677892249078e-05
evidence O 0 5.880509093003639e-07
supports O 0 3.791448222045801e-08
a O 0 7.020354075848445e-09
significant O 0 2.1680213180275132e-08
genetic O 0 5.433651750763602e-08
component O 0 3.1369302178063663e-07
in O 0 8.06882649584395e-09
the O 0 2.5557961080835412e-08
susceptibility O 0 5.866941705789941e-07
to O 0 6.405312547030917e-08
develop O 0 0.00011488232121337205
BPAD B-Disease 1 1.0
. O 0 8.160175639204681e-05

To O 0 9.458027960818072e-08
date O 0 4.750773143769038e-07
, O 0 1.0476069789433495e-08
however O 0 5.172950956477962e-09
, O 0 5.106154610245994e-09
linkage O 0 1.6378797340621531e-07
studies O 0 1.9850116217412506e-08
have O 0 1.585123032832314e-09
attempted O 0 3.7801477503762726e-08
only O 0 6.749241721060173e-10
to O 0 1.1613786599085074e-09
identify O 0 7.531728840604046e-08
chromosomal O 0 3.761441257665865e-05
loci O 0 6.563741408172064e-07
that O 0 1.3104269669383939e-08
cause O 0 2.247949595357568e-07
or O 0 6.872575841754269e-09
increase O 0 1.0308343512122065e-08
the O 0 8.091451064728972e-09
risk O 0 1.3048904179413512e-07
of O 0 1.6602744778992928e-07
developing O 0 9.567466622684151e-05
BPAD B-Disease 1 0.9999995231628418
. O 0 1.8612425265018828e-05

To O 0 9.382814170066922e-08
determine O 0 3.6533782576952945e-07
whether O 0 1.0410501261048921e-07
there O 0 1.9474757806392518e-08
could O 0 5.140581293971991e-09
be O 0 1.3344816363058953e-09
protective O 0 7.99922705851941e-09
alleles O 0 7.279903346812944e-10
that O 0 1.3652390329355057e-10
prevent O 0 3.7107876771358406e-09
or O 0 1.0925260696126315e-09
reduce O 0 5.752842202610964e-09
the O 0 1.0265839289758105e-09
risk O 0 2.5646690104963454e-08
of O 0 9.998700534197269e-09
developing O 0 6.625546120631043e-06
BPAD B-Disease 1 0.9999998807907104
, O 0 3.902097311936359e-09
similar O 0 4.5552298044704287e-10
to O 0 1.4028520012310253e-10
what O 0 4.113031581987059e-10
is O 0 1.5994844337896552e-10
observed O 0 1.1237161201549384e-09
in O 0 5.768749922197003e-10
other O 0 1.737650201505403e-08
genetic B-Disease 1 0.9999992847442627
disorders I-Disease 1 1.0
, O 0 3.4294728834538546e-07
we O 0 1.0695091390289235e-07
used O 0 1.073590169653471e-06
mental O 1 0.9916257262229919
health O 0 5.9531881561269984e-05
wellness O 0 0.0005086316377855837
( O 0 5.2659235194596477e-08
absence O 0 4.3738427280004544e-07
of O 0 1.1756884532587719e-07
any O 0 1.600938048795797e-06
psychiatric B-Disease 1 0.9999964237213135
disorder I-Disease 1 0.9789029359817505
) O 0 2.1523847593130085e-08
as O 0 2.404124010979558e-08
the O 0 1.3243624863434889e-08
phenotype O 0 1.925874215658041e-08
in O 0 4.827499289206116e-09
our O 0 9.515420451577938e-09
genome O 0 2.269589316483689e-08
- O 0 6.213501535512478e-08
wide O 0 3.735431164386682e-08
linkage O 0 1.9693939634635171e-07
scan O 0 1.7088622428218514e-07
of O 0 2.2908654528919214e-08
several O 0 5.392268853654514e-09
large O 0 4.976346446028401e-08
multigeneration O 0 4.091721166332718e-06
Old O 0 5.192630396777531e-07
Order O 0 4.572104117528397e-08
Amish O 0 7.241279149639013e-07
pedigrees O 0 1.2109953217986913e-07
exhibiting O 0 1.8351063602040085e-07
an O 0 9.963290636960664e-09
extremely O 0 4.3431131757643016e-07
high O 0 2.428808784316061e-06
incidence O 0 2.261247209389694e-05
of O 0 1.3582230167230591e-05
BPAD B-Disease 1 1.0
. O 0 8.338614861713722e-05

We O 0 1.2091896905985777e-06
have O 0 1.928498782888255e-08
found O 0 7.308664784488883e-09
strong O 0 3.4093303735716063e-09
evidence O 0 5.484397824773168e-09
for O 0 1.2608474264652614e-09
a O 0 5.509077638521376e-09
locus O 0 3.325962083522427e-08
on O 0 1.0133675942824993e-07
chromosome O 0 8.844060062074277e-07
4p O 0 0.00011446973803685978
at O 0 1.6746928395150462e-06
D4S2949 O 0 1.740856873766461e-06
( O 0 2.021858946932298e-08
maximum O 0 1.3271343846099626e-07
GENEHUNTER O 0 1.3678823961527087e-05
- O 0 3.3068943139369367e-07
PLUS O 0 1.634189885635351e-07
nonparametric O 0 6.681924702434117e-08
linkage O 0 4.15771843620405e-08
score O 0 2.8304279808821775e-08
= O 0 4.909700379585047e-08
4 O 0 6.880711111989513e-08
. O 0 4.146708310059921e-09
05 O 0 3.026233343916829e-07
, O 0 2.241060848007237e-08
P O 0 9.319102787230804e-07
= O 0 7.497072829210083e-08
5 O 0 3.047368934971928e-08
. O 0 1.0753501422655631e-09
22 O 0 1.6233393296261056e-08
x O 0 2.4250370600498172e-08
10 O 0 3.375092560986559e-08
( O 0 5.6638902456995766e-09
- O 0 2.8219591996503368e-08
4 O 0 2.55920582503677e-08
) O 0 1.0721572518690436e-09
; O 0 1.1516552156365378e-09
SIBPAL O 0 1.6410801890742732e-06
Pempirical O 0 3.908103565208876e-07
value O 0 3.764584732834919e-08
< O 0 2.62835499142966e-07
3 O 0 5.2247045800868364e-08
x O 0 4.676333986708414e-08
10 O 0 5.890977661238139e-08
( O 0 5.341914022238825e-09
- O 0 2.80323693147011e-08
5 O 0 1.766267132552457e-08
) O 0 8.714299837286887e-10
) O 0 5.536441860520824e-10
and O 0 5.89591764299513e-10
suggestive O 0 5.738029429380731e-08
evidence O 0 8.592810019081298e-09
for O 0 2.134648235951886e-09
a O 0 1.5132773256709697e-08
locus O 0 8.837300669028991e-08
on O 0 1.7307544908362615e-07
chromosome O 0 1.3936863751951023e-06
4q O 0 2.6100335617229575e-06
at O 0 9.202533988172945e-07
D4S397 O 0 1.4472088878392242e-06
( O 0 1.6623999954390456e-08
maximum O 0 1.623792229565879e-07
GENEHUNTER O 0 8.287671334983315e-06
- O 0 1.3071573334855202e-07
PLUS O 0 9.824331215213533e-08
nonparametric O 0 1.3369489693104697e-07
linkage O 0 2.1938534544574395e-08
score O 0 1.90173885528111e-08
= O 0 4.130890474129956e-08
3 O 0 1.8728799844325295e-08
. O 0 1.5310824830194747e-09
29 O 0 4.2549768153321565e-08
, O 0 4.652559670859091e-09
P O 0 5.132795308782079e-07
= O 0 5.745279452185059e-08
2 O 0 2.461539772014021e-08
. O 0 8.521400252092803e-10
57 O 0 2.140998311972453e-08
x O 0 3.7945955710938506e-08
10 O 0 4.278577847571796e-08
( O 0 6.435066701726555e-09
- O 0 3.4135357651621234e-08
3 O 0 1.2799123538798085e-08
) O 0 6.943193797681602e-10
; O 0 1.4878588361355582e-09
SIBPAL O 0 2.0791176211787388e-06
Pempirical O 0 5.093769459563191e-07
value O 0 3.9344598690149724e-08
< O 0 2.131415470785214e-07
1 O 0 7.202648077964113e-08
x O 0 5.986395024137892e-08
10 O 0 4.215105775529082e-08
( O 0 6.738158031538433e-09
- O 0 5.855488893757865e-08
3 O 0 1.662025894688668e-08
) O 0 5.332453922868297e-10
) O 0 3.478295984571389e-10
that O 0 2.3929361270269567e-10
are O 0 4.993408464493143e-10
linked O 0 4.432145317423419e-08
to O 0 1.2483044820044142e-08
mental O 1 0.9934060573577881
health O 0 0.0003753245691768825
wellness O 0 0.0012394026853144169
. O 0 1.132428315031575e-05

These O 0 6.45151345679551e-08
findings O 0 6.907693972380002e-08
are O 0 1.2481990996349168e-09
consistent O 0 1.2344816724407792e-08
with O 0 4.4336964655222744e-10
the O 0 1.2064271803780002e-09
hypothesis O 0 2.0798607280880788e-09
that O 0 2.944016905259694e-11
certain O 0 3.600391929037272e-10
alleles O 0 2.111175678720656e-09
could O 0 3.101744860956046e-09
prevent O 0 1.0449966225678509e-08
or O 0 1.0497968050415807e-09
modify O 0 4.004825360226505e-09
the O 0 2.227202200444367e-09
clinical O 0 7.468912599506439e-08
manifestations O 0 3.758902664685593e-07
of O 0 2.6005941435869318e-06
BPAD B-Disease 1 1.0
and O 0 9.17998335125958e-08
perhaps O 0 1.0987336196421893e-07
other O 0 2.7929898394063457e-08
related O 0 5.02930415677838e-05
affective B-Disease 1 0.999416708946228
disorders I-Disease 1 0.9999980926513672
. O 0 0.00017005341942422092

Segregation O 0 0.10301538556814194
distortion O 1 0.9992876648902893
in O 1 0.9788282513618469
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.002512554405257106

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.8811407685279846
DM B-Disease 1 1.0
) O 0 1.936558192028315e-06
is O 0 4.7810072345555454e-08
an O 0 4.373546502733916e-08
autosomal B-Disease 1 0.9870831966400146
dominant I-Disease 1 0.9999996423721313
disease I-Disease 1 0.9995119571685791
which O 0 2.3633598189576333e-08
, O 0 1.168533980688835e-08
in O 0 4.2099128627626214e-09
the O 0 7.987883243743e-09
typical O 0 2.1227799607004272e-07
pedigree O 0 1.9319544719564874e-07
, O 0 3.8168272986638385e-09
shows O 0 8.536793494329231e-09
a O 0 5.376309619720132e-09
three O 0 1.3937985876566472e-08
generation O 0 1.542314066682593e-06
anticipation O 0 3.23850940731063e-06
cascade O 0 2.768532795016654e-05
. O 0 4.340651685197372e-06

This O 0 1.2493525325396604e-08
results O 0 4.313006840561684e-08
in O 0 4.632991874586878e-07
infertility B-Disease 1 0.9999972581863403
and O 1 0.9999982118606567
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9987642765045166
CDM B-Disease 1 0.9999254941940308
) O 0 5.0016488728488184e-08
with O 0 2.8941455898490176e-09
the O 0 2.778256558144676e-08
disappearance O 0 8.800150226306869e-07
of O 0 1.7422022438040585e-06
DM B-Disease 1 1.0
in O 0 4.877852575191355e-07
that O 0 4.5149604943617305e-08
pedigree O 0 2.9160312351450557e-06
. O 0 1.2697602187472512e-06

The O 0 1.419393100832167e-07
concept O 0 1.360151884455263e-07
of O 0 8.860659761467105e-08
segregation O 0 2.6516729121794924e-05
distortion O 0 5.776490070275031e-05
, O 0 2.633020734776892e-08
where O 0 8.425565134473345e-09
there O 0 1.342293165507158e-09
is O 0 3.868259879080682e-10
preferential O 0 2.159358736264494e-08
transmission O 0 3.6400507497091894e-08
of O 0 9.790166455303506e-10
the O 0 7.843426463871594e-10
larger O 0 4.349079318899385e-09
allele O 0 2.77936806902801e-09
at O 0 5.012756432165588e-08
the O 0 3.9396336859454095e-08
DM B-Disease 1 0.9999756813049316
locus O 0 5.150388346919499e-07
, O 0 1.6834047045222178e-08
has O 0 3.4845930585447604e-09
been O 0 5.759099863666961e-09
put O 0 5.909724265507066e-09
forward O 0 5.020037363578922e-08
to O 0 2.842111435086281e-09
explain O 0 7.043936278705587e-08
partially O 0 1.276700487551352e-07
the O 0 1.773677382743699e-08
maintenance O 0 4.4038374653609935e-06
of O 0 1.7093983615268371e-06
DM B-Disease 1 1.0
in O 0 1.5715130530224997e-07
the O 0 9.351475682706223e-08
population O 0 3.4260462911106515e-08
. O 0 7.409029194604955e-07

In O 0 3.8855532125126047e-07
a O 0 1.4221693334093288e-07
survey O 0 9.124367039703429e-08
of O 0 3.488086406377988e-07
DM B-Disease 1 0.9999996423721313
in O 0 2.8596934953384334e-07
Northern O 0 5.144610781826486e-07
Ireland O 0 3.469600642347359e-07
, O 0 3.167680517890403e-08
59 O 0 8.723252449271968e-07
pedigrees O 0 1.7780657799448818e-06
were O 0 2.3400515658522636e-07
ascertained O 0 5.87851809541462e-06
. O 0 2.699636752367951e-06

Sibships O 0 0.00016067385149654
where O 0 8.300450105025448e-08
the O 0 6.339845093350505e-09
status O 0 3.208010568300779e-08
of O 0 9.091981389985904e-09
all O 0 8.182642341481028e-10
the O 0 1.834739027373189e-09
members O 0 1.101893243315999e-09
had O 0 5.546199943751162e-09
been O 0 1.580262920519715e-09
identified O 0 3.413533899987442e-09
were O 0 1.403136384858783e-09
examined O 0 3.506019918830816e-09
to O 0 2.2297767798828971e-10
determine O 0 8.565549158845442e-09
the O 0 7.131520263214952e-09
transmission O 0 2.0397314415276924e-07
of O 0 1.8076459440408144e-08
the O 0 8.227628711665602e-08
DM B-Disease 1 0.9999946355819702
expansion O 0 1.541993469800218e-06
from O 0 5.4619146538925634e-08
affected O 0 1.3785408370381447e-08
parents O 0 1.752858747039454e-09
to O 0 9.72398828125165e-10
their O 0 8.65470539679336e-09
offspring O 0 4.123798191812966e-07
. O 0 9.089346235668927e-07

Where O 0 4.943534008816641e-07
the O 0 1.6983635475753545e-07
transmitting O 0 4.852606070926413e-05
parent O 0 1.853314870459144e-07
was O 0 1.3766131132797454e-06
male O 0 4.0508999177291116e-07
, O 0 2.366736850945017e-07
58 O 0 7.765300324535929e-06
. O 0 4.61464878753759e-06

3 O 0 5.4084193834569305e-06
% O 0 1.1891852835788086e-07
of O 0 5.648508860645052e-08
the O 0 3.885018884375313e-08
offspring O 0 2.4940590037658694e-08
were O 0 8.021334707564165e-09
affected O 0 3.853835028877484e-09
, O 0 5.550885306959685e-10
and O 0 3.962063177542774e-10
in O 0 6.116838147107728e-10
the O 0 4.254291086080997e-10
case O 0 3.292652372977045e-09
of O 0 2.1948400874549634e-09
a O 0 6.283385811656217e-09
female O 0 1.0513004866652409e-07
transmitting O 0 6.336724618449807e-05
parent O 0 4.5038439111522166e-07
, O 0 2.0016858570670593e-07
68 O 0 1.4407694834517315e-05
. O 0 7.2082334554579575e-06

7 O 0 2.6452573365531862e-05
% O 0 1.225969526785775e-06
were O 0 4.933751256430696e-07
affected O 0 5.079692186882312e-07
. O 0 9.188432841256144e-07

Studies O 0 3.3758540212147636e-06
on O 0 1.0863685702133807e-06
meiotic O 0 8.167252963175997e-05
drive O 0 4.892873448625323e-07
in O 0 4.3383278125475044e-07
DM B-Disease 1 0.9999994039535522
have O 0 1.1178102887754449e-08
shown O 0 7.699768822533315e-09
increased O 0 6.572446586972092e-09
transmission O 0 1.0737007727357195e-08
of O 0 6.081160019988374e-10
the O 0 3.9893013892289275e-10
larger O 0 1.447941766485883e-09
allele O 0 8.619973068668685e-10
at O 0 1.1656312359775711e-08
the O 0 1.3631250794787775e-08
DM B-Disease 1 0.831121563911438
locus O 0 5.430678129414446e-08
in O 0 1.4967802997034596e-08
non O 0 4.9018590289051645e-06
- O 0 0.00023445169790647924
DM O 1 0.9999988079071045
heterozygotes O 0 3.0628503736807033e-05
for O 0 9.584966846887255e-07
CTGn O 0 0.000503014714922756
. O 0 4.548455308395205e-06

This O 0 4.767257166804484e-08
study O 0 9.881778062492685e-09
provides O 0 2.2666375443236575e-09
further O 0 2.991282999076361e-09
evidence O 0 1.1726466908612565e-08
that O 0 4.068184955574594e-10
the O 0 2.4263187015094445e-08
DM B-Disease 1 0.9999929666519165
expansion O 0 2.570923925304669e-06
tends O 0 8.104490234472905e-08
to O 0 2.581274749502427e-09
be O 0 1.5297871414077235e-08
transmitted O 0 1.2561808659938833e-07
preferentially O 0 3.005685584867024e-07
. O 0 7.742538059574144e-07

Diagnosis O 1 0.9968767166137695
of O 0 0.09685954451560974
hemochromatosis B-Disease 1 1.0
. O 0 0.004097870085388422

If O 0 9.781692642718554e-05
untreated O 1 0.9999943971633911
, O 0 0.0006619203486479819
hemochromatosis B-Disease 1 1.0
can O 0 7.112367711670231e-06
cause O 0 0.0143540408462286
serious O 0 0.36164745688438416
illness O 0 0.0047570280730724335
and O 0 9.585039428827713e-09
early B-Disease 0 1.946551861919943e-07
death I-Disease 0 5.0847660304498277e-08
, O 0 2.1010686523936783e-09
but O 0 1.4927196145819721e-09
the O 0 1.1961378554303792e-08
disease O 0 9.414918622496771e-07
is O 0 1.4938902337391369e-09
still O 0 4.48924852847199e-09
substantially O 0 1.8711665461523808e-07
under O 0 1.417887574461929e-06
- O 0 0.025140292942523956
diagnosed O 0 0.024760520085692406
. O 0 5.280364348436706e-06

The O 0 1.7660754565440584e-06
cornerstone O 0 0.00012087372306268662
of O 0 2.127682705577172e-07
screening O 0 4.0882704865907726e-07
and O 0 8.681968921564476e-09
case O 0 2.5771241141114842e-08
detection O 0 8.1438500387776e-08
is O 0 6.97765845103504e-10
the O 0 1.2156341488989142e-09
measurement O 0 7.325274964387063e-08
of O 0 5.139976266832491e-08
serum O 0 3.5419080290921556e-07
transferrin O 0 1.1370340189387207e-06
saturation O 0 4.6453089908027323e-07
and O 0 4.029345390677008e-08
the O 0 1.220988110617327e-07
serum O 0 2.825551746354904e-06
ferritin O 0 4.606703805620782e-05
level O 0 2.334810415050015e-05
. O 0 6.232175564946374e-06

Once O 0 3.0482256079267245e-06
the O 0 1.850234809808171e-07
diagnosis O 0 3.6004159483127296e-05
is O 0 3.8189629236740075e-08
suspected O 0 4.630394698779128e-07
, O 0 1.7205701752232017e-08
physicians O 0 5.6216283184085114e-08
must O 0 5.974848615863948e-09
use O 0 1.4568543704740478e-08
serum O 0 2.695142882203072e-07
ferritin O 0 8.695977157913148e-06
levels O 0 7.218807809294958e-07
and O 0 1.1617719053447217e-07
hepatic O 1 0.9978150129318237
iron O 1 0.9999563694000244
stores O 0 3.579767735573114e-07
on O 0 2.4650287855365605e-07
liver O 0 1.3512325267583947e-06
biopsy O 0 2.4136903675753274e-07
specimens O 0 6.26409546455875e-09
to O 0 1.9270929296766326e-09
assess O 0 5.044547037869052e-07
patients O 0 5.045330908615142e-08
for O 0 3.6941358860786977e-09
the O 0 2.6437495748155015e-08
presence O 0 7.756165700811835e-07
of O 0 9.387964382767677e-06
iron B-Disease 1 0.9999996423721313
overload I-Disease 1 0.9995439648628235
. O 0 3.2274376280838624e-05

Liver O 1 0.9807778000831604
biopsy O 0 0.0026463100221008062
is O 0 2.2880604433339613e-07
also O 0 1.5100797057243653e-08
used O 0 6.132073515630054e-09
to O 0 1.0231707703312054e-09
establish O 0 3.2554979156884656e-08
the O 0 3.8071719110632785e-09
presence O 0 8.89272211423986e-09
or O 0 4.599311598241229e-09
absence O 0 2.8264042839509784e-07
of O 0 2.4998489607241936e-06
cirrhosis B-Disease 1 1.0
, O 0 8.35727433923239e-08
which O 0 2.175501112589018e-09
can O 0 2.386542297116989e-09
affect O 0 1.0039465081490562e-07
prognosis O 0 1.8196245946455747e-05
and O 0 3.104280210664001e-07
management O 0 0.00011526484013302252
. O 0 1.2029019671899732e-05

A O 0 3.613809212765773e-06
DNA O 0 1.1246247595408931e-06
- O 0 8.781097449173103e-08
based O 0 1.4690838545661222e-09
test O 0 6.243195405097879e-10
for O 0 4.754448501564923e-10
the O 0 6.253423556756843e-09
HFE O 0 1.2046458323311526e-05
gene O 0 2.6863560265155684e-08
is O 0 8.791495864635124e-10
commercially O 0 9.006819290391377e-09
available O 0 1.134449423290107e-09
, O 0 2.834098233872595e-10
but O 0 7.898789955440577e-11
its O 0 3.528490347126656e-11
place O 0 1.1981304837149764e-09
in O 0 4.2510461817357736e-10
the O 0 1.3785033114999123e-09
diagnosis O 0 1.3972077113066916e-06
of O 0 3.619942162913503e-06
hemochromatosis B-Disease 1 1.0
is O 0 7.236936312438047e-07
still O 0 1.5603470160385768e-07
being O 0 9.691298430425377e-08
evaluated O 0 8.969583973339468e-07
. O 0 7.685919740652025e-07

Currently O 0 7.430181995005114e-06
, O 0 3.813132920527096e-08
the O 0 5.357147614404312e-09
most O 0 9.043308324407917e-10
useful O 0 9.649720134063955e-09
role O 0 6.253233042485817e-09
for O 0 6.34826358147933e-10
this O 0 2.3209947852542712e-10
test O 0 1.707186059185517e-09
is O 0 8.672427359579515e-11
in O 0 3.415445010146456e-11
the O 0 2.749617755704037e-10
detection O 0 2.0683937407284247e-07
of O 0 5.373175326894852e-07
hemochromatosis B-Disease 1 1.0
in O 0 2.6453642476553796e-07
the O 0 6.857285939076974e-08
family O 0 1.8721300065749347e-08
members O 0 1.3676062504686115e-09
of O 0 8.110305316222366e-08
patients O 0 2.6396179464427405e-08
with O 0 4.62368499043464e-09
a O 0 8.423094755016791e-08
proven O 0 1.4064768038224429e-05
case O 0 6.227620730214767e-08
of O 0 4.442800971560246e-08
the O 0 6.078771548345685e-07
disease O 0 0.0004875291488133371
. O 0 2.1422968075057724e-06

It O 0 1.1524956988751e-07
is O 0 2.5306158946136748e-08
crucial O 0 3.4940228488267167e-07
to O 0 8.07680606840222e-08
diagnose O 1 0.9999986886978149
hemochromatosis B-Disease 1 1.0
before O 1 0.9999864101409912
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 9.707161370897666e-05
because O 0 1.7114143702201545e-06
phlebotomy O 1 0.9998886585235596
therapy O 0 0.13805584609508514
can O 0 2.5530732727929717e-07
avert O 1 0.798844039440155
serious O 1 0.9999994039535522
chronic O 1 1.0
disease O 1 0.9996455907821655
and O 0 6.243391226234962e-08
can O 0 1.2646004243777043e-08
even O 0 1.503022595272796e-08
lead O 0 4.836294209553671e-08
to O 0 1.967802143454378e-09
normal O 0 2.9096847242726653e-07
life O 0 9.182469540292004e-08
expectancy O 0 2.9656047217940795e-07
. O 0 6.196872703867484e-08
. O 0 6.150085596345889e-07

Prevalence O 0 7.317469135159627e-05
of O 0 8.654591283629998e-07
the O 0 3.628329920957185e-07
I1307K O 0 1.3975987712910865e-05
APC B-Disease 0 3.977931442022964e-07
gene O 0 2.9773614684813765e-08
variant O 0 1.9138232332238658e-08
in O 0 7.176778615836099e-10
Israeli O 0 6.3138760886261025e-09
Jews O 0 1.8749199970358177e-09
of O 0 7.782566813219205e-10
differing O 0 3.873649734309481e-10
ethnic O 0 5.29031096707655e-10
origin O 0 5.702759930947821e-10
and O 0 1.2285054085126035e-09
risk O 0 2.1052782983588259e-07
for O 0 8.172391062544193e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.003010860178619623

BACKGROUND O 0 0.00016485089145135134
& O 0 3.13441087200772e-05
AIMS O 0 1.1397156640668982e-06
Israeli O 0 1.0702703434617433e-07
Jews O 0 3.288769079290432e-08
of O 0 9.69208890921891e-09
European O 0 2.7417335957125033e-08
birth O 0 4.098063399737839e-08
, O 0 4.377950890699367e-09
i O 0 1.2713527119956325e-08
. O 0 6.289353482458182e-10
e O 0 9.085809438147407e-09
. O 0 8.530962047892388e-10
, O 0 5.844807304811184e-09
Ashkenazim O 0 8.023401960599585e-07
, O 0 2.9470650364515905e-09
have O 0 3.176074403477003e-10
the O 0 6.3636997893468106e-09
highest O 0 0.13158929347991943
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 6.203641532920301e-05
of O 0 4.694959088169526e-08
any O 0 1.0769846348068768e-08
Israeli O 0 1.445039288228145e-07
ethnic O 0 3.486091202375974e-07
group O 0 4.300894147490908e-07
. O 0 1.083511847355112e-06

The O 0 7.78974026616197e-06
I1307K O 0 0.00015075472765602171
APC B-Disease 0 7.152607850002823e-06
gene O 0 1.0972001973641454e-06
variant O 0 4.1158873500535265e-06
was O 0 2.520929001548211e-06
found O 0 1.2391376458253944e-07
in O 0 1.1158616075590544e-07
6 O 0 1.1564427040866576e-05
. O 0 6.0457696235971525e-06

1 O 0 7.914522939245217e-06
% O 0 1.0157167906754694e-07
of O 0 5.7629048200169564e-08
American O 0 3.8451073436363004e-08
Jews O 0 3.120146629953524e-08
, O 0 2.8784008510029935e-09
28 O 0 2.825104594705863e-08
% O 0 2.4904451834117936e-09
of O 0 6.00274230322384e-09
their O 0 5.642134581762548e-08
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 3.0443125069723465e-06
, O 0 1.3164017431677166e-08
but O 0 6.30030361215006e-10
not O 0 3.8499614607445665e-10
in O 0 2.7379802869376135e-09
non O 0 3.6241246448298625e-07
- O 0 1.8610239749250468e-06
Jews O 0 3.1668290034758684e-07
. O 0 1.0471334235262475e-06

We O 0 2.8008915364807763e-07
assessed O 0 5.8831057003772e-07
the O 0 1.5417972676345926e-08
I1307K O 0 6.620573458349099e-07
prevalence O 0 3.615845400872786e-08
in O 0 3.7924571816283503e-10
Israeli O 0 1.8016009795118748e-09
Jews O 0 1.111858050073522e-09
of O 0 3.0122249139452606e-10
differing O 0 5.05444741616401e-10
ethnic O 0 7.946636682021335e-10
origin O 0 1.5800579733493691e-09
and O 0 1.1986700521049443e-09
risk O 0 4.570286193938955e-07
for O 0 1.378276738250861e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.002311877440661192

METHODS O 0 8.81576670508366e-06
DNA O 0 2.4547890120629745e-07
samples O 0 2.6392957153120733e-08
from O 0 4.7417270110372556e-09
500 O 0 3.746074561661317e-09
unrelated O 0 1.2547065608714547e-08
Jews O 0 2.2701596158469783e-09
of O 0 3.946513338348723e-09
European O 0 2.1590377485836143e-08
or O 0 4.302619149854081e-09
non O 0 5.420029935976345e-08
- O 0 1.1040607539314351e-08
European O 0 5.819100756809803e-09
origin O 0 1.3451533220631973e-09
, O 0 1.58203228295406e-10
with O 0 1.2512066382974751e-10
or O 0 1.1303629143810667e-09
without O 0 6.7831869010603896e-09
a O 0 8.208377089147234e-09
personal O 0 6.452867040707133e-08
and O 0 6.68995809860462e-08
/ O 0 0.0021165611688047647
or O 0 1.9201620204967185e-07
family O 0 2.2094242879688863e-08
history O 0 4.0966725123325887e-08
of O 0 2.2989199521816772e-07
neoplasia B-Disease 1 0.8266573548316956
, O 0 7.831295789628712e-08
were O 0 2.8152877362686013e-08
examined O 0 6.349008430106551e-08
for O 0 2.7662625523561246e-09
the O 0 5.963941340780821e-09
I1307K O 0 1.2488622758155543e-07
variant O 0 3.492644617963947e-09
by O 0 1.3627882156086457e-10
the O 0 7.902169474327536e-10
allele O 0 2.90109825051843e-09
- O 0 5.571062278164618e-09
specific O 0 2.4140476284628676e-09
oligonucleotide O 0 1.718001385597745e-06
( O 0 8.950582497391224e-08
ASO O 0 9.579690231475979e-05
) O 0 6.876014424506138e-08
method O 0 1.4204143781171297e-06
. O 0 1.8676452100407914e-06

RESULTS O 0 2.374068571953103e-06
In O 0 7.667588874937792e-08
persons O 0 1.9605352008511545e-08
at O 0 8.646377125387517e-08
average O 0 3.754774624553647e-08
risk O 0 2.9345616781029094e-07
for O 0 4.404723767947871e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 2.5190927317453315e-06
I1307K O 0 4.9925525672733784e-05
was O 0 7.520775398006663e-07
found O 0 1.2603623922302631e-08
in O 0 1.0629988445032268e-08
5 O 0 4.37736076719375e-07
. O 0 4.4674780497189204e-07

0 O 0 8.473120942653622e-06
% O 0 5.003061573916057e-07
of O 0 2.253889448411428e-07
120 O 0 2.456029903896706e-07
European O 0 3.934790697712742e-07
and O 0 9.885948060173178e-08
1 O 0 5.084599706606241e-06
. O 0 1.2586058346641948e-06

6 O 0 1.1453683327999897e-05
% O 0 2.5971368700083985e-07
of O 0 1.1109644759699222e-07
188 O 0 1.2934646065332345e-07
non O 0 2.0461804695059982e-07
- O 0 1.1898557517042718e-07
European O 0 2.9131321355180262e-08
Jews O 0 2.342455651671571e-08
( O 0 8.73660432887391e-09
P O 0 1.8510763766244054e-06
= O 0 1.794195298998602e-07
0 O 0 5.806353797765951e-08
. O 0 5.011462800297295e-09
08 O 0 4.1228506120205566e-07
) O 0 9.807799727923339e-08
. O 0 4.670130522299587e-07

It O 0 1.182890727591257e-07
occurred O 0 1.5772967572047492e-06
in O 0 6.049248213457759e-08
15 O 0 1.3149572168913437e-06
. O 0 8.026079854062118e-07

4 O 0 4.835574145545252e-06
% O 0 1.5130066799429187e-07
of O 0 1.318553302098735e-07
52 O 0 4.724405755496264e-07
Ashkenazi O 0 3.8222427178880025e-07
Israelis O 0 8.140945340073813e-08
with O 0 5.528301372237365e-08
familial O 0 0.00045838169171474874
cancer B-Disease 0 0.387973427772522
( O 0 6.117450652709522e-07
P O 0 0.0006408789195120335
= O 0 1.3221183507994283e-06
0 O 0 1.0652338744421286e-07
. O 0 3.287688565833946e-09
02 O 0 2.1765612245872035e-07
) O 0 3.613410015645968e-09
and O 0 1.1172981428941853e-09
was O 0 1.7788744699487324e-08
not O 0 1.3205447846331708e-10
detected O 0 2.2661752474562036e-09
in O 0 2.55963278350535e-10
51 O 0 1.3632705631039244e-08
non O 0 8.182665567346703e-08
- O 0 6.179109846016217e-08
European O 0 2.7268233893096294e-08
Jews O 0 2.0609029149909475e-08
at O 0 2.609602631764574e-07
increased O 0 1.0595575758998166e-06
cancer B-Disease 0 3.0003755455254577e-05
risk O 0 3.475824087217916e-06
. O 0 1.1565082331799204e-06

Colorectal B-Disease 1 0.9999997615814209
neoplasia I-Disease 1 0.9999790191650391
occurred O 0 0.008722851984202862
personally O 0 1.3804972695652395e-05
or O 0 4.3659948545382576e-08
in O 0 4.065146441689649e-09
the O 0 2.1514274806122557e-09
families O 0 2.2923446474365505e-10
of O 0 2.643697927240396e-09
13 O 0 2.7026631599369466e-08
of O 0 1.1219007056695318e-08
20 O 0 4.761532323982465e-08
Ashkenazi O 0 1.1716723946619823e-07
I1307K O 0 6.918294275237713e-07
carriers O 0 1.8434638704434292e-08
, O 0 2.318186309580028e-09
8 O 0 2.314661884383895e-08
of O 0 2.0581337523140064e-08
whom O 0 8.563625186752688e-08
also O 0 1.340438871011429e-08
had O 0 2.7774088806609143e-08
a O 0 9.936248268616055e-09
personal O 0 9.214822682679369e-08
or O 0 3.455539498986582e-08
family O 0 1.5791398411124646e-08
history O 0 9.675580514567628e-08
of O 0 1.6450712791993283e-06
noncolonic O 0 0.1856292337179184
neoplasia B-Disease 1 0.994778037071228
. O 0 7.339307194342837e-05

CONCLUSIONS O 0 7.239653768920107e-06
The O 0 1.2632114021471352e-06
I1307K O 0 3.532376285875216e-05
APC O 0 3.1329198009188985e-06
variant O 0 1.0011926860897802e-06
may O 0 3.9965101450434304e-08
represent O 0 2.7921842615796777e-09
a O 0 7.979720884065955e-09
susceptibility O 0 1.1620422668556785e-07
gene O 0 4.7471409914123797e-08
for O 0 1.9182931509931223e-07
colorectal B-Disease 1 1.0
, I-Disease 0 1.95728307517129e-06
or I-Disease 0 1.2924978420869593e-07
other I-Disease 0 4.273374543117825e-08
, I-Disease 0 2.543808648169943e-07
cancers I-Disease 0 0.0061706556007266045
in O 0 5.4831978957281535e-08
Ashkenazi O 0 3.2850248317117803e-06
Jews O 0 9.355294139368198e-08
, O 0 1.2354002265624331e-08
and O 0 4.21204937595121e-09
partially O 0 7.06643561443343e-08
explains O 0 7.435875915007273e-09
the O 0 1.987097819622363e-09
higher O 0 8.826317099419612e-08
incidence O 0 1.0699355698307045e-05
of O 0 0.0008340501226484776
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 6.832661370026472e-07
European O 0 1.2517087952801376e-06
Israelis O 0 2.6560651349427644e-06
. O 0 3.0085359412623802e-06

Systematic O 0 5.951659431957523e-07
analysis O 0 2.45069060156311e-07
of O 0 1.9148936303281516e-07
coproporphyrinogen O 0 9.800216503208503e-05
oxidase O 0 5.3227417993184645e-06
gene O 0 1.567498293297831e-05
defects O 0 0.0010587817523628473
in O 0 1.3922915513830958e-06
hereditary B-Disease 1 0.9999961853027344
coproporphyria I-Disease 1 0.9992296695709229
and O 0 1.4429821248995722e-06
mutation O 0 3.1049098652147222e-06
update O 0 1.1680721399898175e-05
. O 0 6.036827471689321e-06

Hereditary B-Disease 1 0.9999983310699463
coproporphyria I-Disease 1 0.999935507774353
( O 0 3.631443178164773e-05
HC B-Disease 1 1.0
) O 0 1.410386403222219e-06
is O 0 1.1570946867323073e-07
an O 0 1.5638299544207257e-07
acute O 1 1.0
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 0 0.0003568294341675937
autosomal O 1 0.9999910593032837
dominant O 1 0.9999864101409912
inheritance O 0 0.10450797528028488
caused O 0 8.774114576226566e-06
by O 0 2.097622164853874e-08
deficient B-Disease 0 1.2504640835686587e-05
activity I-Disease 0 1.833210205859359e-07
of I-Disease 0 5.40876271770685e-07
coproporphyrinogen I-Disease 0 0.007102458272129297
III I-Disease 1 0.9999984502792358
oxidase I-Disease 0 1.4915392057446297e-05
( O 0 2.1746450329374056e-06
CPO O 0 0.0001437435857951641
) O 0 9.360065860164468e-07
. O 0 5.463645720737986e-06

Clinical O 0 0.0008886072319000959
manifestations O 0 0.000417921895859763
of O 0 6.184814992593601e-06
the O 0 6.018594376655528e-06
disease O 0 0.009825929068028927
are O 0 7.607418583965853e-10
characterized O 0 2.1616088474729622e-08
by O 0 2.3753479183596937e-09
acute O 0 0.17394572496414185
attacks O 0 6.466370336966065e-07
of O 0 0.0004359483136795461
neurological B-Disease 1 1.0
dysfunction I-Disease 1 0.9999996423721313
often O 0 7.439310820700484e-07
precipitated O 0 1.2657582146857749e-06
by O 0 5.529626978528768e-09
drugs O 0 5.376753051677952e-07
, O 0 7.492038101020171e-09
fasting O 0 3.749221377802314e-08
, O 0 9.178456217284747e-09
cyclical O 0 7.070505944284378e-06
hormonal O 0 3.0396500733331777e-05
changes O 0 2.1120270332630753e-07
, O 0 2.0026271840833942e-07
or O 0 6.533367468364304e-06
infectious B-Disease 1 0.9999926090240479
diseases I-Disease 1 0.9997592568397522
. O 0 2.605208646855317e-05

Skin O 1 0.999913215637207
photosensitivity O 1 0.9999843835830688
may O 0 4.260161949787289e-05
also O 0 2.5504303380330384e-07
be O 0 3.720839458765113e-08
present O 0 2.407763588507805e-07
. O 0 1.1403244570828974e-06

The O 0 8.365757366846083e-07
seven O 0 2.8848199917774764e-07
exons O 0 3.6175464401821955e-07
, O 0 1.0660098581638522e-08
the O 0 4.0779930543521914e-08
exon O 0 9.34673698793631e-06
/ O 0 2.5593290047254413e-06
intron O 0 5.23200196766993e-06
boundaries O 0 2.0273926537583975e-08
and O 0 4.011790455393793e-09
part O 0 1.6939402769367007e-08
of O 0 4.7273619685483936e-08
3 O 0 3.736101064077957e-07
noncoding O 0 1.6580544297539745e-06
sequence O 0 2.5701192285509933e-08
of O 0 2.356171968642684e-08
the O 0 1.4281177129760181e-08
CPO O 0 8.086963134701364e-07
gene O 0 9.924106869618754e-09
were O 0 2.4959327937779108e-09
systematically O 0 3.823093397414823e-09
analyzed O 0 2.020493328203088e-09
by O 0 1.7846772670804256e-10
an O 0 1.2822475303764236e-09
exon O 0 6.423873628591537e-07
- O 0 1.1660953447290012e-07
by O 0 9.899530084567232e-09
- O 0 2.6143256945942994e-06
exon O 0 6.364021828630939e-06
denaturing O 0 1.4816266229900066e-05
gradient O 0 1.3662787750945427e-05
gel O 0 0.0001128000658354722
electrophoresis O 0 3.344992364873178e-05
( O 0 1.8552458413978457e-07
DGGE O 0 0.00012915888510178775
) O 0 7.73701458456344e-09
strategy O 0 2.0631684805039185e-08
followed O 0 7.975578530938776e-10
by O 0 5.341857858831567e-11
direct O 0 5.712644801647571e-10
sequencing O 0 3.0331541722716793e-09
in O 0 8.284088415244639e-10
seven O 0 9.728408301157287e-09
unrelated O 0 1.7913059480179072e-07
heterozygous O 0 2.0237617093243898e-07
HC B-Disease 1 0.9999921321868896
patients O 0 1.8413610405332292e-06
from O 0 1.1879010486381958e-07
France O 0 9.811594736675033e-07
, O 0 1.1007636580018243e-08
Holland O 0 2.0838372449816234e-07
, O 0 2.4747528470925317e-09
and O 0 4.728333280468178e-09
Czech O 0 1.2348638847470284e-05
Republic O 0 1.5059878933243454e-05
. O 0 5.476494607137283e-06

Seven O 0 1.1733535529856454e-06
novel O 0 3.0536648409906775e-07
mutations O 0 6.57013004001783e-08
and O 0 5.10181275004129e-09
two O 0 3.427129247057792e-09
new O 0 1.3940459453465337e-08
polymorphisms O 0 2.231257951734733e-07
were O 0 1.6363684096631914e-07
detected O 0 7.144918527046684e-06
. O 0 1.0919953865595744e-06

Among O 0 1.0363132219026738e-07
these O 0 6.779591110728234e-09
mutations O 0 1.282460981855138e-08
two O 0 2.074709959387633e-09
are O 0 1.3276116872518173e-09
missense O 0 1.6023800242237485e-07
( O 0 8.994320843669357e-09
G197W O 0 9.244138823305548e-07
, O 0 1.095631851910639e-08
W427R O 0 7.32396131297719e-07
) O 0 3.448196395083869e-09
, O 0 1.0412835038664525e-09
two O 0 2.889626871116491e-10
are O 0 2.5323465546733814e-10
nonsense O 0 4.938938857890207e-08
( O 0 3.5407230480899443e-09
Q306X O 0 2.429238747936324e-07
, O 0 4.857387825296655e-09
Q385X O 0 2.38005497976701e-07
) O 0 3.1582556569986764e-09
, O 0 1.9306323206791376e-09
two O 0 6.700551780092212e-10
are O 0 1.8476122021215957e-10
small O 0 2.5018476179639038e-09
deletions O 0 3.2730554266890977e-08
( O 0 1.3516195274121401e-08
662de14bp O 0 6.820793032602523e-07
; O 0 1.1855148862593978e-08
1168del3bp O 0 8.675539788782771e-07
removing O 0 2.406799524123926e-07
a O 0 2.002420451674425e-08
glycine O 0 9.412191559476923e-08
at O 0 1.0641981873504847e-07
position O 0 1.323159892763215e-07
390 O 0 4.6358117344880156e-08
) O 0 1.4645934465207233e-09
, O 0 8.336585866075552e-10
and O 0 5.869000840874605e-10
one O 0 3.936564962891964e-10
is O 0 1.5113288398538316e-10
a O 0 1.0343356171560458e-09
splicing O 0 1.6561715554530565e-08
mutation O 0 2.4839030832168874e-09
( O 0 7.591014927754713e-09
IVS1 O 0 1.4312395251181442e-05
- O 0 5.347535989130847e-06
15c O 0 1.2780574252246879e-05
- O 0 3.7787676774314605e-06
- O 0 2.146442056982778e-06
> O 0 7.24743472346745e-07
g O 0 4.0541846146879834e-07
) O 0 8.486661151607677e-09
which O 0 1.2444953956247673e-09
creates O 0 1.1719290426981388e-08
a O 0 3.7248566453484955e-09
new O 0 1.9889028202157988e-09
acceptor O 0 1.0969784192127463e-08
splice O 0 1.4158875956127304e-06
site O 0 6.415210123122961e-07
. O 0 1.121072727983119e-06

The O 0 1.051405320140475e-06
pathological O 0 4.64347904198803e-05
significance O 0 1.8839563153960626e-06
of O 0 1.29813827243197e-07
the O 0 5.523926915884658e-08
point O 0 7.457794026777265e-07
mutations O 0 4.452938995314071e-08
G197W O 0 1.3475429341269773e-06
, O 0 2.155330491859786e-08
W427R O 0 1.8752626829154906e-06
, O 0 8.276432872378336e-09
and O 0 2.961659584244103e-09
the O 0 8.43025915742146e-09
in O 0 1.480403355458293e-08
- O 0 2.2982207781296893e-07
frame O 0 6.544390771523467e-07
deletion O 0 3.6636743061535526e-07
390delGly O 0 5.940703431406291e-07
were O 0 6.70244704181755e-09
assessed O 0 1.7038429334093053e-08
by O 0 1.9216818414324877e-10
their O 0 2.944074706245914e-10
respective O 0 7.869385143521868e-09
expression O 0 4.241871742749481e-09
in O 0 1.2833976104076328e-09
a O 0 1.3861651826374555e-09
prokaryotic O 0 1.909945757105902e-09
system O 0 9.159900393740372e-09
using O 0 6.017323972429267e-09
site O 0 3.9654160843838326e-08
- O 0 3.2187554666052165e-07
directed O 0 1.048706934625443e-07
mutagenesis O 0 1.048150170390727e-05
. O 0 2.3926795620354824e-06

These O 0 9.14262372475605e-08
mutations O 0 1.2380320413285517e-07
resulted O 0 7.524075584797174e-08
in O 0 6.2005001133513815e-09
the O 0 6.009960085151533e-09
absence O 0 1.4297303607690992e-07
or O 0 3.2909133196312723e-09
a O 0 4.13430134571513e-09
dramatic O 0 3.4385568170591796e-08
decrease O 0 1.3478832272539876e-07
of O 0 3.506433756683691e-07
CPO O 0 0.00012469830107875168
activity O 0 4.769040060637053e-06
. O 0 1.4995840729170595e-06

The O 0 5.598381562776922e-07
two O 0 4.740617143283998e-08
polymorphisms O 0 1.38753406986325e-07
were O 0 1.6443680195266097e-08
localized O 0 1.1655605902660682e-07
in O 0 7.111105038148935e-09
noncoding O 0 1.1407616966607748e-06
part O 0 8.157962305688216e-09
of O 0 9.45384037720487e-09
the O 0 7.4041173192540555e-09
gene O 0 1.3907500928667105e-08
1 O 0 1.2074227129232895e-07
) O 0 3.920210378538513e-09
a O 0 3.713125806825701e-08
C O 0 3.502352410578169e-05
/ O 0 4.198710939817829e-06
G O 0 2.240228923255927e-06
polymorphism O 0 8.721091404595427e-08
in O 0 4.303341238909297e-09
the O 0 2.0740422712606232e-08
promotor O 0 9.13325566216372e-05
region O 0 5.706377237402194e-07
, O 0 3.9097283632827384e-08
142 O 0 1.6210798037263885e-07
bp O 0 2.786687787192932e-07
upstream O 0 9.225286135006172e-08
from O 0 6.1660156980281045e-09
the O 0 4.427723521160942e-09
transcriptional O 0 1.2548123606848094e-07
initiation O 0 9.576235271424594e-08
site O 0 2.0178433146611496e-07
( O 0 2.577596092123713e-08
- O 0 1.5360667475761147e-06
142C O 0 7.501301297452301e-06
/ O 0 7.032738722045906e-06
G O 0 9.05764136405196e-06
) O 0 1.9253674210517602e-08
, O 0 1.1367719210397809e-08
and O 0 7.550524649957424e-09
2 O 0 1.7124611417784763e-07
) O 0 2.459243919616938e-09
a O 0 8.261308082069263e-09
6 O 0 6.338856906040746e-08
bp O 0 3.3752598938008305e-08
deletion O 0 1.779305414117971e-08
polymorphism O 0 1.190386456073611e-08
in O 0 2.003462284960733e-09
the O 0 5.619063436768101e-09
3 O 0 9.641113507541377e-08
noncoding O 0 1.738545847729256e-06
part O 0 1.3919921215688191e-08
of O 0 1.2372868063437181e-08
the O 0 3.794783864918827e-08
CPO O 0 3.0850192160869483e-06
gene O 0 4.040974843633194e-08
, O 0 8.898355829956017e-09
574 O 0 2.057981305370049e-07
bp O 0 1.6146381653925346e-07
downstream O 0 1.057480503163788e-07
of O 0 1.9371583448446472e-08
the O 0 7.696216108854514e-09
last O 0 5.63959279276105e-09
base O 0 1.9039962495526197e-08
of O 0 5.554679827213249e-09
the O 0 2.97943913984966e-09
normal O 0 1.1235281149879484e-08
termination O 0 1.672928462426171e-08
codon O 0 3.1017645341080424e-08
( O 0 1.8236869792076504e-08
+ O 0 3.9600845980203303e-07
574 O 0 3.1832876175030833e-06
delATTCTT O 0 3.143711728625931e-05
) O 0 8.597762644058093e-07
. O 0 3.3015453482221346e-06

Five O 0 4.110599547857419e-06
intragenic O 0 0.0003775853256229311
dimorphisms O 0 0.000259396038018167
are O 0 2.0990869487036434e-08
now O 0 6.086814163808185e-09
well O 0 1.5602177327878053e-09
characterized O 0 6.9739765073961735e-09
and O 0 5.435086825045232e-10
the O 0 1.2230648716027304e-09
high O 0 3.5830087341537364e-08
degree O 0 7.648629463119505e-08
of O 0 9.10991282410123e-09
allelic O 0 3.021262102720357e-07
heterogeneity O 0 1.2015109405183466e-06
in O 0 1.0429421593016741e-07
HC B-Disease 1 0.9999997615814209
is O 0 2.348276240127234e-07
demonstrated O 0 4.6571081213642174e-08
with O 0 5.223114718511113e-10
seven O 0 1.1253419307521995e-09
new O 0 2.7632240939823305e-10
different O 0 1.2786080527682486e-10
mutations O 0 7.7010575694203e-10
making O 0 7.127002321638543e-10
a O 0 1.8992076800117275e-09
total O 0 3.5184937186016896e-09
of O 0 5.424818283472632e-08
nineteen O 0 2.6720176720118616e-06
CPO O 0 8.501858246745542e-05
gene B-Disease 0 3.586726052162703e-06
defects I-Disease 0 1.7476972061558627e-05
reported O 0 1.7936170593202405e-07
so O 0 1.6348142395372633e-08
far O 0 7.356681663850395e-08
. O 0 4.7050711771134957e-08
. O 0 7.444896255037747e-07

Coincidence O 0 2.5320379791082814e-05
of O 0 1.2687022490354138e-06
two O 0 8.075111423977432e-08
novel O 0 1.4014672444773169e-07
arylsulfatase O 0 9.625621260056505e-07
A O 0 9.575322224009142e-08
alleles O 0 7.3226877894683184e-09
and O 0 2.092853446100662e-09
mutation O 0 1.1306437563973759e-08
459 O 0 1.8305775029148208e-07
+ O 0 1.130920850300754e-06
1G O 0 2.604304791020695e-05
> O 0 1.6047428061938263e-06
A O 0 4.490882474783575e-07
within O 0 8.29415185421567e-08
a O 0 5.348451281861344e-08
family O 0 3.15124104588449e-08
with O 0 9.705930636982885e-08
metachromatic B-Disease 1 0.9999996423721313
leukodystrophy I-Disease 1 0.999998927116394
: O 0 4.0265337730716055e-08
molecular O 0 9.089765029557384e-08
basis O 0 6.98726694281504e-08
of O 0 1.160967784130662e-07
phenotypic O 0 3.0147135475999676e-05
heterogeneity O 0 0.00014863256365060806
. O 0 2.4212085918406956e-05

In O 0 1.4997514199421857e-06
a O 0 7.140104116842849e-07
family O 0 2.6660913476916903e-08
with O 0 8.788951788574195e-09
three O 0 6.814700981294664e-08
siblings O 0 2.267763790086974e-07
, O 0 2.6170574596307006e-09
one O 0 7.812848146215856e-10
developed O 0 1.2525831927234776e-08
classical O 0 1.8097551219398156e-05
late O 0 0.4072302281856537
infantile O 1 0.9999872446060181
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 0.0002416671923128888
MLD B-Disease 1 1.0
) O 0 3.743123500044021e-07
, O 0 3.1915995180042955e-08
fatal O 0 4.917094997836102e-07
at O 0 3.0231183245632565e-07
age O 0 5.093652930554526e-07
5 O 0 2.2656625731087843e-07
years O 0 2.0219166785295783e-08
, O 0 1.8209819208081512e-09
with O 0 3.1991429505495717e-09
deficient O 0 5.397186669142684e-06
arylsulfatase O 0 2.3681535822106525e-05
A O 0 3.001909590238938e-06
( O 0 1.1621674644857194e-07
ARSA O 0 7.667510362807661e-05
) O 0 6.067156110844962e-09
activity O 0 2.522428488305195e-08
and O 0 3.2237916780530895e-09
increased O 0 2.5386950142092246e-07
galactosylsulfatide O 0 6.255311745917425e-05
( O 0 6.614117751269077e-07
GS O 1 0.874167799949646
) O 0 2.636670046740619e-07
excretion O 0 2.948426754301181e-06
. O 0 2.991267137986142e-06

The O 0 4.952409540237568e-07
two O 0 4.6802782094346185e-08
other O 0 1.5338249781393642e-08
siblings O 0 6.188192287481797e-07
, O 0 4.174094669906481e-08
apparently O 0 3.1992519211598847e-07
healthy O 0 1.1625587603703025e-07
at O 0 3.885597266162222e-07
12 O 0 1.4157348005028325e-07
( O 0 8.605291590413344e-09
1 O 0 3.0263834105426213e-07
/ O 0 2.47831167143886e-07
2 O 0 8.017789809855458e-08
) O 0 1.0207653611260525e-09
and O 0 8.760028258336661e-10
15 O 0 1.1730560522948963e-08
years O 0 2.93946955665092e-09
, O 0 7.689109904340796e-10
respectively O 0 1.1430728363848175e-08
, O 0 1.1994979454144072e-09
and O 0 4.4311770919236437e-10
their O 0 7.969131465834778e-10
father O 0 6.820344822244806e-08
, O 0 1.285887751834025e-08
apparently O 0 7.366650578433109e-08
healthy O 0 7.161166770686123e-09
as O 0 5.902443533933877e-10
well O 0 1.0287125595809243e-09
, O 0 3.3256308817897207e-09
presented O 0 1.214450975339787e-07
ARSA O 0 0.005216056481003761
and O 0 6.039978472927032e-08
GS O 0 0.10655126720666885
values O 0 1.4530552761016224e-08
within O 0 6.030445032223497e-09
the O 0 1.1518551668032728e-09
range O 0 3.1916115972308035e-08
of O 0 2.5444634843552194e-07
MLD B-Disease 1 1.0
patients O 0 2.4224073058576323e-05
. O 0 2.5011961497511948e-06

Mutation O 0 2.161230128194802e-07
screening O 0 6.339026015211857e-08
and O 0 1.3065752924035223e-09
sequence O 0 7.79924302918289e-09
analysis O 0 7.832785975381285e-09
disclosed O 0 4.102646400383492e-08
the O 0 1.5172534340024413e-09
involvement O 0 3.960072803010917e-08
of O 0 5.377068568179766e-09
three O 0 1.9963291020275165e-09
different O 0 7.806506552299197e-09
ARSA O 0 0.0006108312518335879
mutations O 0 1.361862000948122e-08
being O 0 2.7257716084250205e-09
the O 0 9.405113354787886e-10
molecular O 0 2.4034820356177988e-08
basis O 0 1.7623332126959212e-08
of O 0 4.820380183900852e-08
intrafamilial O 0 1.3401699106907472e-05
phenotypic O 0 4.345992783783004e-05
heterogeneity O 0 0.00020192198280710727
. O 0 2.555227911216207e-05

The O 0 7.554315857305482e-07
late O 0 0.00020547265012282878
infantile O 1 0.8967729806900024
patient O 0 0.004750318359583616
inherited O 1 0.6761482954025269
from O 0 1.4023806897967006e-06
his O 0 4.326420821598731e-07
mother O 0 2.8766416448888776e-07
the O 0 3.265317261025302e-08
frequent O 0 5.563313365541944e-08
0 O 0 5.6877098586483044e-08
- O 0 5.5813920596392563e-08
type O 0 3.460935005250576e-08
mutation O 0 7.531380852299208e-09
459 O 0 6.855036360775557e-08
+ O 0 5.703406600332528e-07
1G O 0 8.390306902583688e-06
> O 0 2.6386297236058454e-07
A O 0 1.616761409195533e-07
, O 0 4.102010731088512e-09
and O 0 2.9477789098564244e-09
from O 0 1.2351504707908134e-08
his O 0 2.6828585575344732e-08
father O 0 1.0087682511539242e-07
a O 0 1.0017140006368663e-08
novel O 0 4.469844938626011e-09
, O 0 1.3217600347559255e-09
single O 0 2.1241737258037574e-09
basepair O 0 5.974270038677787e-07
microdeletion O 0 5.218410024099285e-07
of O 0 3.7371126637708585e-08
guanine O 0 3.465103191047092e-07
at O 0 1.3227499096046813e-07
nucleotide O 0 7.94906966916642e-08
7 O 0 1.478905460317037e-07
in O 0 2.0714685078360162e-08
exon O 0 2.1278278836689424e-06
1 O 0 1.1340474657117738e-06
( O 0 1.0328678712312467e-07
7delG O 0 2.6446327865414787e-06
) O 0 4.0654592226019304e-07
. O 0 2.5664949134807102e-06

The O 0 1.6115750440803822e-06
two O 0 6.417400868485856e-07
clinically O 0 0.0012213813606649637
unaffected O 0 1.0617764019116294e-05
siblings O 0 5.151341611053795e-07
carried O 0 2.0498399422308466e-08
the O 0 7.133084789501254e-09
maternal O 0 8.759167258176603e-08
mutation O 0 9.287197677565473e-09
459 O 0 8.061415712745656e-08
+ O 0 5.314163331604504e-07
1G O 0 1.1928491403523367e-05
> O 0 4.051610744681966e-07
A O 0 8.98314667097111e-08
and O 0 2.26787433277309e-09
, O 0 2.19157714198559e-09
on O 0 4.049182322773959e-09
their O 0 3.172441753740429e-10
paternal O 0 7.683323310914147e-09
allele O 0 4.902267924933312e-09
, O 0 1.5468598624224228e-09
a O 0 2.981843882920998e-09
novel O 0 2.979018587367932e-09
cytosine O 0 2.058031611795741e-08
to O 0 8.553935892940956e-10
thymidine O 0 4.6974943757049914e-07
transition O 0 7.39934819193877e-07
at O 0 7.021239980531391e-07
nucleotide O 0 1.0355125823480194e-06
2435 O 0 2.466812657075934e-05
in O 0 6.468059865483156e-08
exon O 0 4.1644839257060084e-06
8 O 0 1.2630172818717256e-07
, O 0 2.7722419915221508e-09
resulting O 0 2.537361654120218e-09
in O 0 5.212983378299896e-10
substitution O 0 3.057666564387773e-09
of O 0 4.267817210745761e-09
alanine O 0 3.102030277091217e-08
464 O 0 5.017232851400877e-08
by O 0 1.3718836733289663e-08
valine O 0 1.3823865629092325e-05
( O 0 3.542928084243613e-07
A464V O 0 3.6786761484108865e-05
) O 0 5.371325073610933e-07
. O 0 2.1855353224964347e-06

The O 0 3.0892381346347975e-06
fathers O 0 3.741984983207658e-06
genotype O 0 9.282496762352821e-07
thus O 0 3.7997057233951637e-07
was O 0 1.8168286715081194e-06
7delG O 0 2.706483610381838e-05
/ O 0 8.521963172825053e-05
A464V O 0 8.676085417391732e-05
. O 0 5.274440354696708e-06

Mutation O 0 4.2349643081252e-06
A464V O 0 2.3391230570268817e-05
was O 0 6.75676858463703e-07
not O 0 8.149284802527745e-09
found O 0 3.984178320592946e-09
in O 0 4.237529438455567e-09
18 O 0 3.3105231977970107e-07
unrelated O 0 8.597741725679953e-06
MLD B-Disease 1 0.9999998807907104
patients O 0 8.209880775211786e-07
and O 0 4.9821306191688564e-08
50 O 0 8.311093893098587e-07
controls O 0 1.0690665476431604e-05
. O 0 1.4546075135513092e-06

A464V O 0 0.00011679932504193857
, O 0 1.4454913355166354e-07
although O 0 5.8962612570212514e-08
clearly O 0 1.8710363747231895e-07
modifying O 0 2.4999658307933714e-06
ARSA O 1 0.8495005965232849
and O 0 5.082754341856344e-07
GS O 1 0.9999877214431763
levels O 0 1.6113252058858052e-05
, O 0 3.646576018923042e-08
apparently O 0 3.628578326697607e-08
bears O 0 1.5929918717461078e-08
little O 0 3.826368555337467e-09
significance O 0 7.155650738610575e-09
for O 0 2.07864303547467e-09
clinical O 0 1.7092519044581422e-07
manifestation O 0 1.2689528148257523e-06
of O 0 4.589238415064756e-06
MLD B-Disease 1 1.0
, O 0 1.0941490700133727e-06
mimicking O 0 1.6234605482168263e-06
the O 0 1.7592444123692985e-07
frequent O 0 2.635352984725614e-06
ARSA O 0 0.009549904614686966
pseudodeficiency O 0 0.000174910353962332
allele O 0 9.559666978020687e-06
. O 0 6.799576112825889e-06

Our O 0 6.957841947041743e-07
results O 0 1.2163914675511478e-07
demonstrate O 0 3.903871359511868e-08
that O 0 2.7862190332683667e-10
in O 0 2.5274682347031785e-10
certain O 0 7.29111715447317e-10
genetic O 0 2.3621655742545045e-08
conditions O 0 1.0448520697536878e-06
MLD B-Disease 1 1.0
- O 0 0.36383792757987976
like O 0 2.723634906942607e-06
ARSA O 1 0.9999734163284302
and O 0 6.584236871276516e-07
GS O 1 0.999982476234436
values O 0 1.7103671723361913e-07
need O 0 1.8012066504979884e-08
not O 0 2.4348512095428987e-10
be O 0 1.8699725101711806e-10
paralleled O 0 1.0574372488747485e-09
by O 0 4.3810979843961206e-10
clinical O 0 3.388927780179074e-06
disease O 0 2.86078943645407e-06
, O 0 4.66058880377318e-09
a O 0 8.689142738660394e-09
finding O 0 1.839038965556483e-08
with O 0 1.8141108615310486e-09
serious O 0 1.968882315850351e-06
diagnostic O 0 3.0056078230700223e-06
and O 0 1.8249490096877707e-07
prognostic O 0 0.04864218831062317
implications O 0 0.00012308901932556182
. O 0 1.8899463611887768e-05

Moreover O 0 1.3771730664302595e-05
, O 0 2.0772320397099975e-07
further O 0 2.816730386712152e-07
ARSA O 0 0.00010622700210660696
alleles O 0 9.012734381030896e-08
functionally O 0 4.991718469682382e-07
similar O 0 1.0669985783806624e-08
to O 0 1.1605776784051614e-08
A464V O 0 3.0300764137791703e-06
might O 0 3.054637076616018e-08
exist O 0 9.335789918907267e-09
which O 0 8.556252928393349e-10
, O 0 6.900840454626689e-10
together O 0 1.1558937140776493e-09
with O 0 3.3185467707141925e-09
0 O 0 1.6586727724643424e-07
- O 0 9.076546803044039e-08
type O 0 1.7763289861250087e-07
mutations O 0 5.059361996018197e-08
, O 0 3.040755558458841e-08
may O 0 1.291152500471071e-07
cause O 0 4.847495802096091e-06
pathological O 1 0.9959399700164795
ARSA O 1 0.9999855756759644
and O 0 5.747586783400038e-06
GS O 1 0.9999951124191284
levels O 0 6.456464234361192e-06
, O 0 4.6247081719741345e-09
but O 0 4.536588327219704e-10
not O 0 2.855367886578364e-10
clinical O 0 3.191471620311859e-08
outbreak O 0 1.1561853696662183e-08
of O 0 5.058635288435198e-09
the O 0 5.95788414159415e-08
disease O 0 6.315206974250032e-06
. O 0 4.251504748253865e-08
. O 0 9.847469755186467e-07

Human O 0 0.003627961268648505
MLH1 O 1 0.9999992847442627
deficiency O 1 0.9999988079071045
predisposes O 0 0.0009698498179204762
to O 0 7.67350138630718e-06
hematological B-Disease 1 0.9999997615814209
malignancy I-Disease 1 0.9999991655349731
and O 0 7.490663119824603e-05
neurofibromatosis B-Disease 1 0.9999998807907104
type I-Disease 1 0.9561785459518433
1 I-Disease 0 0.005420016590505838
. O 0 1.0765238585008774e-05

Heterozygous O 0 0.0003706409188453108
germ O 1 0.9998836517333984
- O 0 1.7256057617487386e-05
line O 0 2.323524626035578e-07
mutations O 0 7.1347447949676734e-09
in O 0 8.018867792003448e-10
the O 0 4.4897108253394435e-09
DNA O 0 1.794429522306018e-06
mismatch O 0 0.06044403091073036
repair O 0 0.0003032236418221146
genes O 0 1.9145923602081893e-07
lead O 0 6.041304345671961e-07
to O 0 6.204755891303648e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9381123185157776

The O 0 3.3195979085576255e-06
disease O 0 0.00036545025068335235
susceptibility O 0 2.6830537080968497e-06
of O 0 1.239239253436608e-07
individuals O 0 2.5390379576606392e-08
who O 0 7.528230980824446e-07
constitutionally O 0 3.998167358076898e-06
lack O 0 1.3744524949288461e-06
both O 0 5.2645678039198174e-08
wild O 0 9.406861778415987e-08
- O 0 1.0892125601458247e-07
type O 0 7.504268495495126e-08
alleles O 0 2.2200948635031637e-08
is O 0 1.8733659956637894e-08
unknown O 0 1.7123433053711778e-06
. O 0 1.228012706633308e-06

We O 0 1.141885036304302e-06
have O 0 1.566794161078633e-08
identified O 0 1.6202646335727877e-08
three O 0 1.5102576966796732e-09
offspring O 0 2.1508204106623907e-09
in O 0 8.650146710031947e-10
a O 0 5.144134718193527e-08
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.3261326849460602
who O 0 7.15166743248119e-06
developed O 1 0.6102261543273926
hematological B-Disease 1 0.9999997615814209
malignancy I-Disease 1 0.9999964237213135
at O 0 1.0362463399360422e-05
a O 0 2.678226529440053e-08
very O 0 4.075503046152562e-09
early O 0 3.155734162874069e-08
age O 0 1.5801347785782127e-07
, O 0 6.9175536410170935e-09
and O 0 3.3895157791619113e-09
at O 0 5.150035065071279e-08
least O 0 1.6782456535580081e-09
two O 0 2.994597902983287e-10
of O 0 8.894380787438649e-10
them O 0 5.528801860776866e-10
displayed O 0 4.2026947255635605e-08
signs O 0 5.23574783528602e-08
of O 0 1.5174704515175108e-07
neurofibromatosis B-Disease 1 0.9030293226242065
type I-Disease 0 5.2521532779792324e-05
1 I-Disease 0 0.00014816418115515262
( O 0 9.455932286073221e-07
NF1 B-Disease 0 0.0017459042137488723
) O 0 7.064838314363442e-07
. O 0 2.7637490802590037e-06

DNA O 0 1.5096700280992081e-06
sequence O 0 8.245616811564105e-08
analysis O 0 1.4284283089693872e-08
and O 0 1.1133265420681937e-09
allele O 0 8.46648351426893e-09
- O 0 9.889037144716895e-09
specific O 0 1.2182803654781083e-09
amplification O 0 1.1292411272734171e-07
in O 0 2.503508955697953e-09
two O 0 5.511252787471221e-09
siblings O 0 8.947613139298483e-08
revealed O 0 1.587377056466721e-07
a O 0 1.1013962364359031e-07
homozygous O 0 3.851706367186125e-07
MLH1 O 0 0.0001291329099331051
mutation O 0 1.8782537836159463e-07
( O 0 1.040928978568445e-07
C676T O 0 8.979436643130612e-06
- O 0 9.22809795156354e-06
- O 0 3.748038807316334e-06
> O 0 4.29633337262203e-06
Arg226Stop O 0 4.750645166495815e-05
) O 0 3.594148836327804e-07
. O 0 1.8690368506213417e-06

Thus O 0 4.411138888826827e-06
, O 0 2.88901873091163e-07
a O 0 4.0578828475190676e-07
homozygous O 0 9.892878551909234e-06
germ O 1 0.9949159622192383
- O 0 5.543143561226316e-05
line O 0 7.624168119946262e-06
MLH1 O 0 0.15883353352546692
mutation O 0 3.2447925946144096e-07
and O 0 8.790330952024306e-08
consequent O 1 0.7553082704544067
mismatch O 1 1.0
repair O 1 0.9999992847442627
deficiency O 1 0.9999887943267822
results O 0 3.5383698104851646e-07
in O 0 4.887575144607581e-08
a O 0 1.0543025297238273e-07
mutator O 0 4.18606105085928e-05
phenotype O 0 1.0603870492786882e-07
characterized O 0 5.5218411176838345e-08
by O 0 3.767386047570653e-08
leukemia B-Disease 1 0.9999998807907104
and O 0 0.0018197204917669296
/ O 1 1.0
or O 1 0.9999732971191406
lymphoma B-Disease 1 1.0
associated O 0 0.4713512659072876
with O 0 1.4207043932401575e-05
neurofibromatosis B-Disease 1 1.0
type I-Disease 1 0.9960875511169434
1 I-Disease 0 0.015275365673005581
. O 0 6.123083267084439e-07
. O 0 2.751103011178202e-06

Missense O 0 0.000342130457283929
mutations O 0 3.073554353250074e-06
in O 0 3.5202944559387106e-08
the O 0 1.8200175588845013e-08
most O 0 3.765185940807214e-09
ancient O 0 1.2017362394090014e-07
residues O 0 2.3826235917567828e-07
of O 0 7.649388322761297e-08
the O 0 1.767683386333374e-07
PAX6 O 0 0.0007913803565315902
paired O 0 2.4647474674566183e-06
domain O 0 1.9533929389581317e-06
underlie O 0 3.1436761673830915e-06
a O 0 8.467004164458558e-08
spectrum O 0 5.222764229984023e-06
of O 0 3.506902658045874e-06
human O 1 0.9794189929962158
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 1 0.9995157718658447

Mutations O 0 5.193831839278573e-06
of O 0 2.4043058033385023e-07
the O 0 9.357614061400454e-08
human O 0 2.992543102209311e-07
PAX6 O 1 0.5801031589508057
gene O 0 0.00012553810665849596
underlie O 1 0.9998568296432495
aniridia B-Disease 1 1.0
( O 1 0.997961163520813
congenital B-Disease 1 1.0
absence I-Disease 1 0.9444165229797363
of I-Disease 0 0.0003752900811377913
the I-Disease 0 7.1360518631991e-06
iris I-Disease 0 5.064104698249139e-05
) O 0 7.464355888942009e-08
, O 0 1.7767721516293022e-08
a O 0 3.258914915704736e-08
rare O 0 7.649095437045617e-07
dominant O 1 0.998508870601654
malformation B-Disease 1 0.9999997615814209
of I-Disease 0 0.0019629437010735273
the I-Disease 0 0.0015987250953912735
eye I-Disease 1 0.9964505434036255
. O 0 2.80560980172595e-05

The O 0 1.2067130228388123e-06
spectrum O 0 1.0394768651167396e-05
of O 0 1.4109971289144596e-06
PAX6 O 1 0.709726870059967
mutations O 0 2.055675622614217e-06
in O 0 2.930358391495247e-07
aniridia B-Disease 1 0.9999992847442627
patients O 0 5.483689164975658e-07
is O 0 5.882418996350225e-09
highly O 0 4.298798472746057e-08
biased O 0 2.9708662196981095e-08
, O 0 9.9758168392583e-10
with O 0 4.478829251919336e-10
92 O 0 1.504762821014083e-07
% O 0 1.8618919739310513e-08
of O 0 1.0688969709349294e-08
all O 0 3.4249469926805887e-09
reported O 0 2.789007957915146e-08
mutations O 0 6.352991466229696e-09
leading O 0 9.656623944920284e-09
to O 0 2.2154533763085738e-09
premature O 0 8.800530082453406e-08
truncation O 0 6.83848952576227e-07
of O 0 1.413376793379939e-07
the O 0 1.1200602045846608e-07
protein O 0 2.4149085220415145e-07
( O 0 1.0151238072353408e-08
nonsense O 0 1.5516128826220665e-07
, O 0 2.8136379892629293e-09
splicing O 0 4.7372548550583815e-08
, O 0 1.7370430649421564e-09
insertions O 0 1.594454168696302e-08
and O 0 2.0963051294842217e-09
deletions O 0 6.084309944753841e-08
) O 0 8.202303725113325e-09
and O 0 1.0621679535915973e-08
just O 0 1.2297044804654433e-07
2 O 0 2.52455663485307e-07
% O 0 8.735487888600346e-09
leading O 0 9.495657593561191e-09
to O 0 3.206698240276751e-10
substitution O 0 1.3847231805641513e-08
of O 0 1.0102929159927498e-08
one O 0 9.92228521567995e-10
amino O 0 2.3611148591839992e-09
acid O 0 4.525338326288875e-09
by O 0 1.580678921087042e-09
another O 0 4.9651497135982936e-08
( O 0 1.3338797089090804e-07
missense O 0 7.211072443169542e-06
) O 0 3.885708679263189e-07
. O 0 2.9513159915950382e-06

The O 0 2.921462964877719e-07
extraordinary O 0 6.114266284384939e-07
conservation O 0 9.563568426074198e-08
of O 0 8.701734088845114e-08
the O 0 1.1277334976966813e-07
PAX6 O 0 0.001308238017372787
protein O 0 2.0402140421538206e-07
at O 0 5.2612350032177346e-08
the O 0 4.487219484872185e-09
amino O 0 2.453655412182343e-08
acid O 0 8.992267197527326e-08
level O 0 1.4752220067748567e-06
amongst O 0 1.492750811848964e-06
vertebrates O 0 2.153692548745312e-06
predicts O 0 5.337649895409413e-07
that O 0 9.31039689788804e-09
pathological O 0 3.281147655798122e-05
missense O 0 8.416922355536371e-06
mutations O 0 1.3823381550537306e-07
should O 0 8.259164907542527e-09
in O 0 2.605949900313931e-09
fact O 0 3.608781495856306e-09
be O 0 1.3279510824304452e-09
common O 0 1.5586500978770346e-09
even O 0 1.0547902551394372e-09
though O 0 9.483417384714699e-10
they O 0 3.326377784329537e-10
are O 0 3.8031924831649633e-10
hardly O 0 2.5748343901454973e-08
ever O 0 1.2839074692294616e-08
seen O 0 3.3282848477256266e-08
in O 0 3.1424420399162045e-08
aniridia B-Disease 1 0.9999455213546753
patients O 0 4.417470336193219e-06
. O 0 1.90893638318812e-06

This O 0 1.7320357414973842e-07
indicates O 0 2.6657485818759596e-07
that O 0 2.3985988750752085e-09
there O 0 3.1668210276336595e-09
is O 0 6.106719574461295e-10
a O 0 1.489284140454572e-09
heavy O 0 4.6166638867362053e-07
ascertainment O 0 8.552980580134317e-05
bias O 0 9.407974488340187e-08
in O 0 1.6480786735328934e-09
the O 0 7.611162811116401e-10
selection O 0 5.627536214802831e-09
of O 0 7.530619683393525e-09
patients O 0 1.1291223067644296e-08
for O 0 9.488958951919813e-09
PAX6 O 0 7.443148933816701e-05
mutation O 0 2.6840307754127934e-08
analysis O 0 2.3611340438378647e-08
and O 0 4.146937460092204e-09
that O 0 1.689061335241604e-09
the O 0 2.4500124595761008e-08
missing O 0 4.472653927223291e-06
PAX6 O 1 0.838891863822937
missense O 0 0.00012368825264275074
mutations O 0 7.673330060242733e-07
frequently O 0 1.312771615857855e-07
may O 0 2.0230226027706522e-07
underlie O 0 1.7490241361883818e-06
phenotypes O 0 3.3015282951964764e-07
distinct O 0 1.294469171853052e-07
from O 0 5.878164870409819e-07
textbook O 0 9.267944551538676e-05
aniridia B-Disease 1 0.9999686479568481
. O 0 2.03162053367123e-05

Here O 0 7.760139851598069e-06
we O 0 8.743276680434064e-08
present O 0 3.032299744631928e-08
four O 0 2.0605925854511042e-08
novel O 0 9.121548316670669e-08
PAX6 O 0 6.620601925533265e-05
missense O 0 8.157207957992796e-06
mutations O 0 1.4947751481031446e-07
, O 0 9.478684503960721e-09
two O 0 3.653919389279281e-09
in O 0 8.506253479367842e-09
association O 0 1.555467399327881e-08
with O 0 1.0642099645963299e-08
atypical O 0 1.1359091331542004e-05
phenotypes O 0 8.83523443917511e-06
ectopia B-Disease 0 0.027238722890615463
pupillae I-Disease 0 0.005082194227725267
( O 0 1.152792492575827e-07
displaced B-Disease 0 1.3770697648851637e-07
pupils I-Disease 0 3.8733034557481005e-07
) O 0 1.114336640739566e-07
and O 0 2.110868308591307e-06
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.6312096118927002
( O 0 1.5236014405672904e-06
searching B-Disease 0 7.50097251511761e-06
gaze I-Disease 0 8.590302604716271e-05
) O 0 4.423479893489457e-08
, O 0 7.133492907485106e-09
and O 0 1.743003630316764e-09
two O 0 1.4890512156640057e-09
in O 0 3.4042360042008113e-09
association O 0 5.05717867582689e-09
with O 0 1.220312961791592e-09
more O 0 9.020917346447277e-09
recognizable O 0 1.1128005098726135e-05
aniridia B-Disease 1 0.9999877214431763
phenotypes O 0 6.376343662850559e-05
. O 0 9.561226761434227e-06

Strikingly O 0 3.4047665394609794e-05
, O 0 1.4464981745732075e-07
all O 0 8.54446646769702e-09
four O 0 9.703705394770168e-09
mutations O 0 1.4255187252842916e-08
are O 0 1.0564715768879296e-09
located O 0 8.52263948303289e-09
within O 0 1.0061968147567768e-08
the O 0 2.385014497008342e-08
PAX6 O 0 3.0568131478503346e-05
paired O 0 3.2436136621072365e-07
domain O 0 1.0139050488078283e-07
and O 0 3.063884257414884e-09
affect O 0 1.0442414932754218e-08
amino O 0 9.974927550615575e-09
acids O 0 5.392844837359689e-09
which O 0 4.6475553960867444e-10
are O 0 8.92077800518365e-11
highly O 0 7.181383043786127e-09
conserved O 0 2.493269413150756e-08
in O 0 1.4931011982355358e-09
all O 0 2.552944522449252e-09
known O 0 3.5977318901814215e-08
paired O 0 3.1425801694240363e-07
domain O 0 2.048536316578975e-06
proteins O 0 1.0376438694947865e-06
. O 0 2.1887558432354126e-06

Our O 0 7.905521783868608e-07
results O 0 8.746863500164181e-08
support O 0 2.2886466055638266e-08
the O 0 7.1427921355393664e-09
hypothesis O 0 9.144923041048969e-09
that O 0 3.74215693155211e-11
the O 0 3.113960478362543e-10
under O 0 3.672693926759507e-09
- O 0 7.507129140549296e-09
representation O 0 4.491714999943497e-09
of O 0 2.476845928356397e-08
missense O 0 1.7421573375031585e-06
mutations O 0 3.81990261644205e-08
is O 0 2.646896701818946e-09
caused O 0 6.957833420528914e-09
by O 0 2.5525452862495968e-09
ascertainment O 0 0.017822418361902237
bias O 0 2.9067855393805075e-06
and O 0 1.2895670309376328e-08
suggest O 0 1.8484954011910304e-08
that O 0 3.8006978120286306e-10
a O 0 2.5370472389596443e-09
substantial O 0 2.6565382782450797e-08
burden O 0 2.42360897573235e-07
of O 0 3.12641702748806e-07
PAX6 B-Disease 1 0.9998754262924194
- I-Disease 0 0.028979722410440445
related I-Disease 0 0.0005693063721992075
disease I-Disease 0 0.00021324449335224926
remains O 0 2.439463173686818e-07
to O 0 1.9618360269646473e-09
be O 0 1.1872799632328679e-08
uncovered O 0 1.364820832350233e-06
. O 0 2.0940964517990324e-08
. O 0 4.2862313875957625e-07

The O 0 6.911317314006737e-07
chromosomal O 0 1.1067657396779396e-05
order O 0 1.6424175441898115e-07
of O 0 2.634191957895382e-07
genes O 0 1.6491665633111552e-07
controlling O 0 5.075452918390511e-06
the O 0 5.623998688975007e-08
major O 0 5.368814072426176e-06
histocompatibility O 1 0.8993282318115234
complex O 0 2.0095551008125767e-05
, O 0 3.2651740866640466e-08
properdin O 0 2.827055823217961e-06
factor O 0 3.806796371463861e-07
B O 0 6.85198901919648e-05
, O 0 8.098402304312913e-08
and O 0 2.0165197156529757e-07
deficiency B-Disease 1 0.983982264995575
of I-Disease 0 7.323270097003842e-07
the I-Disease 0 4.954034693582798e-07
second I-Disease 0 7.693458314861346e-07
component I-Disease 0 3.69542453881877e-06
of I-Disease 0 4.957224746249267e-07
complement I-Disease 0 8.023180271266028e-06
. O 0 7.036227543721907e-06

The O 0 8.60732029650535e-07
relationship O 0 5.096801487525227e-07
of O 0 8.880760304919022e-08
the O 0 1.526412063412863e-08
genes O 0 7.1281069935480446e-09
coding O 0 9.619657959092365e-08
for O 0 1.1460810966923418e-08
HLA O 0 1.158601321549213e-06
to O 0 4.8387271966987555e-09
those O 0 4.465234848538557e-09
coding O 0 2.4844240442689625e-07
for O 0 1.6600331775862287e-08
properdin O 0 2.8406604997144314e-06
Factor O 0 3.4407025850669015e-07
B O 0 7.059867130010389e-06
allotypes O 0 1.493280478825909e-06
and O 0 7.182342276479403e-09
for O 0 4.896813265986566e-08
deficiency B-Disease 0 0.2082875519990921
of I-Disease 0 2.196864556935907e-07
the I-Disease 0 5.384717738365907e-08
second I-Disease 0 8.582249932942432e-08
component I-Disease 0 8.63054879118863e-07
of I-Disease 0 1.4058527142424282e-07
complement I-Disease 0 1.0574577800070983e-06
( O 0 2.7824574999613105e-07
C2 O 0 2.5535322492942214e-05
) O 0 1.1115489861879269e-08
was O 0 1.1991284054602147e-07
studied O 0 2.0994959015752102e-07
in O 0 5.056079110943301e-09
families O 0 1.5790818652661187e-09
of O 0 3.106459445234577e-08
patients O 0 6.549335580530169e-07
with O 0 2.2188135062606307e-06
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 1 0.7769792079925537

Patients O 0 4.677905053540599e-06
were O 0 7.48819815044044e-08
selected O 0 1.8900911058494785e-08
because O 0 2.3123927217483242e-09
they O 0 5.287486004590392e-10
were O 0 2.7990896267482412e-09
heterozygous O 0 8.713339383348284e-09
or O 0 6.598950275105153e-09
homozygous O 0 2.926551871951233e-07
for O 0 3.342425770824775e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.0004938308265991509

12 O 0 8.477768460579682e-06
families O 0 2.591566605758544e-08
with O 0 1.7662133089402232e-08
15 O 0 1.5723601620720729e-07
matings O 0 6.366670959323528e-07
informative O 0 4.328541933773522e-07
for O 0 1.874357963060902e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 7.439789897034643e-06
found O 0 1.7429267700208584e-06
. O 0 1.1764999499064288e-06

Of O 0 4.808172434422886e-06
57 O 0 5.8433051890460774e-06
informative O 0 1.1995851991741802e-06
meioses O 0 1.0116840712726116e-05
, O 0 1.6242994504978014e-08
two O 0 1.6633888710870792e-09
crossovers O 0 1.918182945814806e-08
were O 0 7.809097368749462e-09
noted O 0 2.4603805215406283e-08
between O 0 8.656822814145926e-08
the O 0 3.9591550375916995e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 2.5613161369619775e-07
and O 0 2.5535205949722695e-08
the O 0 1.968271021723922e-07
HLA O 1 0.5004008412361145
- O 0 0.01244927104562521
B O 0 0.0020823790691792965
gene O 0 2.2784634623462807e-08
, O 0 2.0162893576980423e-09
with O 0 5.880766984489583e-10
a O 0 1.623853407295428e-08
recombinant O 0 4.796141439555868e-08
fraction O 0 1.1670899624505182e-07
of O 0 1.79722121629311e-07
0 O 0 2.0166728518233867e-06
. O 0 1.2003382607872481e-06

035 O 0 0.0874585211277008
. O 0 0.00038559793028980494

A O 0 2.016483631450683e-05
lod O 0 8.446986612398177e-05
score O 0 7.10176891516312e-07
of O 0 8.362871284361972e-08
13 O 0 7.712486649325001e-08
was O 0 3.08405461169059e-08
calculated O 0 8.045176080884175e-09
for O 0 5.6864268849210475e-09
linkage O 0 1.5265484762494452e-05
between O 1 0.7284865975379944
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 7.097905472619459e-05
HLA O 1 0.9998183846473694
- O 0 0.052618641406297684
B O 0 0.0008683854248374701
at O 0 1.2153235218193004e-07
a O 0 1.5425525301537846e-09
maximum O 0 3.259255310084086e-09
likelihood O 0 1.544687044940929e-09
value O 0 1.4173925366733897e-09
of O 0 9.383128718454259e-10
the O 0 6.924890105786119e-10
recombinant O 0 5.433234306906343e-09
fraction O 0 1.90550029088854e-08
of O 0 4.6574456291637034e-08
0 O 0 1.1572882385735284e-06
. O 0 1.335526008006127e-06

04 O 0 0.014849921688437462
. O 0 0.0004794932610820979

18 O 0 1.165250432677567e-05
families O 0 3.791585712065171e-08
with O 0 1.7154876630343097e-08
21 O 0 3.334948246447311e-07
informative O 0 5.1911200671383995e-08
matings O 0 1.0429501173803146e-07
for O 0 4.618819549051523e-09
both O 0 9.450775273478484e-09
properdin O 0 2.7835426408273634e-06
Factor O 0 6.77367950174812e-07
B O 0 8.786842954577878e-06
allotype O 0 6.144619419501396e-06
and O 0 8.14844867136344e-08
HLA O 0 0.0015724233817309141
- O 0 0.0006603649817407131
B O 0 0.0038722739554941654
were O 0 2.4624421257612994e-07
found O 0 1.4518231239435408e-07
. O 0 2.71372300630901e-07

Of O 0 4.303763944335515e-06
72 O 0 7.995872692845296e-06
informative O 0 1.580965317771188e-06
meioses O 0 1.4893799743731506e-05
, O 0 3.978287566042127e-08
three O 0 1.520690240397471e-08
recombinants O 0 1.5672237623221008e-06
were O 0 2.042549596126264e-08
found O 0 3.2208660183385973e-09
, O 0 6.579177758148091e-10
giving O 0 1.1655284515299513e-09
a O 0 3.119906999415889e-09
recombinant O 0 1.8558857561856712e-08
fraction O 0 3.303795281794919e-08
of O 0 1.099788278224878e-07
0 O 0 2.305217094544787e-06
. O 0 2.019451812884654e-06

042 O 0 0.01037618424743414
. O 0 0.00018258912314195186

A O 0 1.5251136574079283e-05
lod O 0 7.649968028999865e-05
score O 0 1.5835335034353193e-06
of O 0 6.962229690543609e-07
16 O 0 2.1203024971327977e-06
between O 0 1.2445752872736193e-06
HLA O 0 0.0009215042809955776
- O 0 1.2513349247456063e-05
B O 0 5.894276000617538e-06
and O 0 5.248803613966402e-09
Factor O 0 1.1373145980542176e-07
B O 0 3.177706730639329e-06
allotypes O 0 1.6350189753211453e-06
was O 0 8.504473214543395e-08
calculated O 0 2.5710754414376424e-08
at O 0 9.167485437444611e-09
a O 0 1.4648644519610343e-09
maximum O 0 1.4962941996543577e-09
likelihood O 0 1.1943794842039779e-09
value O 0 7.660302392409335e-10
of O 0 3.8581285388694653e-10
the O 0 4.586983293197733e-10
recombinant O 0 2.6721176382693557e-09
fraction O 0 1.2799318049872e-08
of O 0 3.474242049605891e-08
0 O 0 9.363520803162828e-07
. O 0 1.2105073210477713e-06

04 O 0 0.01786179095506668
. O 0 0.000427405844675377

A O 0 8.800151590548921e-06
crossover O 0 2.07127709472843e-06
was O 0 1.5628446590199019e-06
shown O 0 2.550809163892609e-08
to O 0 1.7203952706879022e-09
have O 0 6.504835559084654e-10
occurred O 0 1.640389513113405e-08
between O 0 1.4340811871349501e-09
genes O 0 3.981016072351906e-10
for O 0 4.790367547080621e-10
Factor O 0 4.344571280512355e-08
B O 0 6.710687330269138e-07
and O 0 1.949148220603547e-08
HLA O 0 0.0025741641875356436
- O 0 0.0033984207548201084
D O 1 0.5047500729560852
, O 0 2.326062542579166e-08
in O 0 8.451043420620863e-09
which O 0 9.374653053839666e-09
HLA O 0 9.705995762487873e-05
- O 0 0.0005407620337791741
D O 0 0.04304833337664604
segregared O 0 4.973966861143708e-05
with O 0 1.7000910190745344e-07
HLA O 1 0.9377946853637695
- O 0 0.00247547822073102
A O 0 9.97636561805848e-06
and O 0 4.4091353856856585e-07
B O 0 0.019645551219582558
. O 0 3.552025873432285e-06

These O 0 7.695661707884938e-08
studies O 0 7.714295691130246e-08
suggest O 0 1.0626298951876834e-08
that O 0 7.07219699469519e-11
the O 0 1.51329018760471e-10
genes O 0 1.8974469218058232e-10
for O 0 3.425787986621742e-10
Factor O 0 6.946604713675697e-08
B O 0 0.000334624492097646
and O 0 9.883410712063778e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 7.865546081120556e-08
located O 0 8.212639812654743e-08
outside O 0 2.2424931245268453e-08
those O 0 1.7581558431345456e-09
for O 0 9.761698116506068e-09
HLA O 0 1.18518164526904e-05
, O 0 9.068115147670142e-09
that O 0 2.016384559322404e-10
the O 0 4.310140577779009e-10
order O 0 6.093025528564056e-10
of O 0 5.309196637881541e-09
genese O 0 7.812004128027183e-07
is O 0 9.602350026227668e-09
HLA O 0 1.533791987640143e-06
- O 0 6.583288723049918e-07
A O 0 3.114641344836855e-07
, O 0 8.223483227709494e-09
- O 0 1.0562670382796568e-07
B O 0 1.5442716403413215e-06
, O 0 5.426471716418746e-09
- O 0 9.85766774874719e-08
D O 0 1.540752805340162e-06
, O 0 5.5947229071762195e-09
Factor O 0 9.862218774969733e-08
B O 0 5.4447657021228224e-05
allotype O 0 0.05859493091702461
, O 0 6.315483915386721e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 3.632365874750576e-08
that O 0 5.26792720556557e-10
the O 0 1.0053617938154957e-09
genes O 0 2.7994684348442433e-09
coding O 0 5.607261641671357e-07
for O 0 7.676455311411701e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 2.0121878208101407e-07
Factor O 0 1.707514911686303e-06
B O 0 7.699867637711577e-06
allotypes O 0 6.530238465529692e-07
are O 0 8.897910186433933e-10
approximately O 0 3.74470277009209e-09
3 O 0 5.0861530098700314e-08
- O 0 4.627260352663143e-08
- O 0 4.9353417352904216e-08
5 O 0 1.970334473355706e-08
centimorgans O 0 1.0755336887768863e-07
from O 0 9.627658670297023e-09
the O 0 2.0967140912375726e-08
HLA O 0 1.3618183402286377e-05
- O 0 2.6534751214057906e-06
A O 0 5.402895340012037e-07
and O 0 2.9106606902473686e-08
HLA O 0 0.00032047880813479424
- O 0 3.73085422324948e-05
B O 0 9.73232599790208e-05
loci O 0 3.918836810612447e-08
, O 0 4.916201223892358e-09
and O 0 1.399928506451431e-09
that O 0 2.616571959102032e-10
the O 0 2.071637528189285e-09
apparent O 0 6.425992893355215e-08
lack O 0 2.8405196417224943e-08
of O 0 1.2637710433693883e-08
recombinants O 0 3.3371753715982777e-07
between O 0 6.094133198075724e-09
the O 0 2.949528177254024e-09
Factor O 0 2.7168402638722e-08
B O 0 3.77594346900878e-06
gene O 0 4.828744977203314e-07
and O 0 5.018763204134302e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 1.714168865873944e-05
suggests O 0 2.0413524737250555e-07
that O 0 4.300893530206906e-10
these O 0 6.417535391989304e-10
two O 0 3.0037579090702593e-09
genes O 0 7.512400479470216e-09
lie O 0 1.8599119755435822e-07
in O 0 9.992866090158259e-09
close O 0 1.5329833047417196e-07
proximity O 0 2.054512293625521e-07
to O 0 1.0154626473024564e-08
one O 0 4.476578752132809e-08
another O 0 5.410825565377309e-07
. O 0 2.893366399803199e-06

Distribution O 0 2.199523805757053e-06
of O 0 9.155473890132271e-07
emerin O 0 9.500245505478233e-05
and O 0 9.011255741597779e-08
lamins O 0 0.00017293657583650202
in O 0 8.126575856692853e-09
the O 0 9.414648616257182e-09
heart O 0 2.0239025388946175e-07
and O 0 2.989275271758629e-09
implications O 0 1.9944486950862483e-07
for O 0 1.6186682216812187e-07
Emery B-Disease 0 0.42407286167144775
- I-Disease 1 0.999995231628418
Dreifuss I-Disease 1 0.9999998807907104
muscular I-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
. O 0 0.18449394404888153

Emerin O 0 0.00037776504177600145
is O 0 4.4729600290338567e-07
a O 0 2.488391146471258e-07
nuclear O 0 6.111180937296012e-06
membrane O 0 1.4490053956706106e-07
protein O 0 1.7351762693351702e-08
which O 0 3.840800733012628e-10
is O 0 3.0166058540004315e-10
missing O 0 9.607626694219107e-09
or O 0 3.711594587230138e-09
defective O 0 1.3086082617519423e-06
in O 0 1.3008325083774253e-07
Emery B-Disease 0 0.2853691875934601
- I-Disease 1 0.9999996423721313
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9935163259506226
EDMD B-Disease 1 1.0
) O 0 4.8812798922881484e-05
. O 0 2.2361955416272394e-05

It O 0 1.146497012882719e-07
is O 0 2.7581506856222404e-08
one O 0 5.023089943989589e-09
member O 0 4.518087592941811e-08
of O 0 6.975429300837277e-08
a O 0 1.3657786723797471e-07
family O 0 3.42773240902261e-08
of O 0 2.649676957844349e-07
lamina O 0 0.08204997330904007
- O 0 2.042197411356028e-05
associated O 0 1.7587511536021339e-07
proteins O 0 7.543701663337288e-09
which O 0 8.906587134482891e-10
includes O 0 1.543347849519705e-08
LAP1 O 0 5.562863952945918e-05
, O 0 5.1324427374765946e-08
LAP2 O 0 9.244968532584608e-05
and O 0 1.7818686615100887e-07
lamin O 0 0.00019295045058242977
B O 0 0.0010773080866783857
receptor O 0 7.1260683398577385e-06
( O 0 2.3001357476459816e-06
LBR O 0 0.0011026269057765603
) O 0 1.3484365126714692e-06
. O 0 7.302365702344105e-06

A O 0 1.4035464118933305e-05
panel O 0 2.6491059088584734e-06
of O 0 2.1132278504865099e-07
16 O 0 5.056564305050415e-07
monoclonal O 0 1.474757738151311e-07
antibodies O 0 1.8400388768213816e-08
( O 0 1.3805090404162002e-08
mAbs O 0 4.4629004491980595e-07
) O 0 1.053064124789671e-08
has O 0 1.745149358356457e-09
been O 0 8.875163937105413e-10
mapped O 0 8.413709728927188e-10
to O 0 2.393899245500819e-10
six O 0 1.0099397984575376e-09
specific O 0 3.7199560098954976e-10
sites O 0 9.107771203886728e-10
throughout O 0 6.320379219992844e-10
the O 0 8.342884716405763e-10
emerin O 0 7.042109473331948e-08
molecule O 0 4.0640455445384305e-09
using O 0 3.4231313339461167e-09
phage O 0 2.5892346044997794e-08
- O 0 1.5314132184585105e-08
displayed O 0 1.896160917169709e-08
peptide O 0 1.7182218314815145e-08
libraries O 0 1.072227373555279e-08
and O 0 1.460122134311348e-09
has O 0 9.69687330432123e-10
been O 0 5.16561238228519e-10
used O 0 6.83406387036456e-10
to O 0 7.638882859595242e-10
localize O 0 1.4826365486442228e-06
emerin O 0 5.918624083278701e-05
in O 0 7.964899140233683e-08
human O 0 2.118969462117093e-07
and O 0 1.3019672451264341e-06
rabbit O 0 3.571246634237468e-05
heart O 0 0.0008656418649479747
. O 0 1.5069836081238464e-05

Several O 0 1.2925203236591187e-06
mAbs O 0 1.4370069038704969e-05
against O 0 2.610329374874709e-07
different O 0 3.061952114080668e-08
emerin O 0 4.243818239046959e-06
epitopes O 0 8.345302262569021e-07
did O 0 2.0464879568748984e-08
not O 0 1.5728834901196365e-09
recognize O 0 1.6896807508715028e-08
intercalated O 0 2.0484992546698777e-06
discs O 0 6.750187822035514e-06
in O 0 2.496391182660318e-08
the O 0 2.7288159287763847e-08
heart O 0 2.4920607302192366e-06
, O 0 3.754787147869365e-09
though O 0 3.937978831913824e-09
they O 0 2.5981267137709096e-10
recognized O 0 9.602533879160546e-09
cardiomyocyte O 0 1.3669857708009658e-06
nuclei O 0 1.034198433558231e-07
strongly O 0 1.6343996378509473e-08
, O 0 2.4668214138046096e-09
both O 0 1.8240757793108742e-09
at O 0 6.537778318715937e-08
the O 0 7.17802839389492e-09
rim O 0 1.6108930367408902e-07
and O 0 2.457194669958085e-09
in O 0 6.769279359275515e-09
intranuclear O 0 2.0885015601379564e-06
spots O 0 2.5153977389891224e-07
or O 0 8.461918099555987e-08
channels O 0 2.3464767764380667e-06
. O 0 9.689732678452856e-07

A O 0 4.777016511070542e-05
polyclonal O 0 3.010740147146862e-05
rabbit O 0 1.3867498864783556e-06
antiserum O 0 4.587802777678007e-06
against O 0 6.541108632518444e-07
emerin O 0 2.4575892894063145e-05
did O 0 5.455834184431296e-08
recognize O 0 7.419982495093791e-08
both O 0 6.612875580458422e-08
nuclear O 0 7.335547707043588e-06
membrane O 0 2.0602178096851276e-07
and O 0 4.393132968516511e-09
intercalated O 0 2.1252512283354008e-07
discs O 0 2.416007305328094e-07
but O 0 1.432634899600771e-09
, O 0 6.631791227285078e-10
after O 0 3.4129217230116637e-09
affinity O 0 9.358432251360682e-09
purification O 0 1.2512583680290845e-07
against O 0 3.4743742105547426e-08
a O 0 2.5339582876426903e-08
pure O 0 8.74916338489129e-07
- O 0 7.343460310949013e-07
emerin O 0 1.8091502624884015e-06
band O 0 1.7276970254442858e-07
on O 0 6.573326771786014e-08
a O 0 2.137366905685667e-08
western O 0 4.7887464660334444e-08
blot O 0 2.0946501422258734e-07
, O 0 8.061873835174538e-09
it O 0 1.1107261776999167e-09
stained O 0 3.7382611139946675e-07
only O 0 1.0429417329760327e-08
the O 0 7.581584071658654e-08
nuclear O 0 1.3896934433432762e-05
membrane O 0 2.1231739992799703e-06
. O 0 5.040747623752395e-07

These O 0 3.1053396298830194e-08
results O 0 4.7168153827215065e-08
would O 0 6.1822196251171135e-09
not O 0 9.173603543466413e-10
be O 0 4.717934931619538e-10
expected O 0 2.150360778330196e-09
if O 0 1.0864001920296573e-09
immunostaining O 0 1.4855633878596564e-07
at O 0 4.15210763549112e-08
intercalated O 0 1.4920192370482255e-07
discs O 0 1.5803487940502237e-07
were O 0 3.033391537954344e-09
due O 0 3.7272021025103186e-09
to O 0 2.0281989976389525e-10
a O 0 1.5521944840557467e-09
product O 0 1.2567465956792034e-09
of O 0 2.4149042765486683e-09
the O 0 3.905149981164868e-09
emerin O 0 7.089899440870795e-07
gene O 0 9.306988069113231e-09
and O 0 3.904748080429954e-09
, O 0 2.945547583621533e-09
therefore O 0 1.4572962392378486e-08
, O 0 1.4906795797742234e-09
cast O 0 4.273795983777973e-09
some O 0 4.128885566778706e-10
doubt O 0 6.076281700018171e-09
upon O 0 1.2076288857798545e-09
the O 0 1.0745833112224545e-09
hypothesis O 0 1.0689539919894742e-08
that O 0 2.7789546219736394e-09
cardiac B-Disease 1 0.9609110951423645
defects I-Disease 1 0.5112437009811401
in O 0 5.5384398365276866e-06
EDMD B-Disease 1 1.0
are O 0 3.312186791504246e-08
caused O 0 3.2606372712962184e-08
by O 0 1.9884627278088374e-09
absence O 0 1.1253622744789027e-07
of O 0 1.864362388914742e-07
emerin O 0 3.572023342712782e-05
from O 0 4.1511424342388636e-07
intercalated O 0 3.232134986319579e-05
discs O 0 0.00035540558747015893
. O 0 4.986331532563781e-06

Although O 0 5.774871169705875e-06
emerin O 0 0.00016759072605054826
was O 0 1.293327954954293e-06
abundant O 0 7.626734799259793e-08
in O 0 3.4904068524355125e-09
the O 0 5.018656157318446e-09
membranes O 0 4.14542107307625e-08
of O 0 2.4034179091358965e-08
cardiomyocyte O 0 5.395509560912615e-06
nuclei O 0 2.725992089835927e-07
, O 0 3.013640004212448e-09
it O 0 3.560523820222983e-10
was O 0 1.4042347729059657e-08
absent O 0 7.2301187259427024e-09
from O 0 5.170501804485639e-10
many O 0 4.0085526564759277e-10
non O 0 4.867699203714437e-07
- O 0 1.1015450581908226e-05
myocyte O 0 0.0005698739551007748
cells O 0 4.4061337689527136e-08
in O 0 1.2702693119592823e-08
the O 0 7.605917318187494e-08
heart O 0 2.5653778720879927e-05
. O 0 3.68755263480125e-06

This O 0 3.557621752747764e-08
distribution O 0 4.236529349554985e-08
of O 0 4.557763588763919e-08
emerin O 0 3.993160589743638e-06
was O 0 8.627810643702105e-08
similar O 0 5.360313304336728e-10
to O 0 1.6918075274041655e-10
that O 0 2.7232860411174897e-10
of O 0 3.5979926593654454e-08
lamin O 0 1.2115167919546366e-05
A O 0 3.39280404659803e-07
, O 0 4.928321750696796e-09
a O 0 7.328416540275384e-09
candidate O 0 1.4396261072135985e-08
gene O 0 3.105699253325156e-09
for O 0 1.7799188789524578e-09
an O 0 3.984216068175783e-09
autosomal O 0 9.154172744274547e-07
form O 0 1.2462512586353114e-06
of O 0 0.006715358234941959
EDMD B-Disease 1 1.0
. O 0 0.0014365679817274213

In O 0 1.1057561550842365e-06
contrast O 0 2.1745122467109468e-06
, O 0 1.3639516964758513e-06
lamin O 0 0.0023600244894623756
B1 O 1 0.8510507345199585
was O 0 6.264341209316626e-06
absent O 0 1.3211806617619004e-06
from O 0 5.307598982540185e-08
cardiomyocyte O 0 4.060362698510289e-06
nuclei O 0 2.82274868368404e-07
, O 0 1.080090861194094e-08
showing O 0 6.122854756540619e-08
that O 0 1.2142259642189401e-08
lamin O 0 5.108105324325152e-05
B1 O 0 0.0001318638096563518
is O 0 4.749855619934351e-09
not O 0 6.922143414023196e-10
essential O 0 7.307173088832997e-09
for O 0 2.9896172204502136e-09
localization O 0 1.5074401744641364e-06
of O 0 1.5561445820821973e-07
emerin O 0 3.6823023492615903e-06
to O 0 1.305447661081871e-08
the O 0 1.9690934038862906e-07
nuclear O 0 3.514419950079173e-05
lamina O 0 8.747696847422048e-05
. O 0 1.5688059420426725e-06

Lamin O 1 0.9960796236991882
B1 O 1 0.9971818923950195
is O 0 5.091355887998361e-07
also O 0 3.089500566488823e-08
almost O 0 8.230217929394712e-08
completely O 0 6.073416898288997e-07
absent O 0 3.5480309179547476e-06
from O 0 8.16948613646673e-07
skeletal O 1 0.8296589851379395
muscle O 0 0.0011709571117535233
nuclei O 0 0.0025897054001688957
. O 0 4.021473796456121e-05

In O 0 1.0292046681570355e-05
EDMD B-Disease 1 0.9999909400939941
, O 0 4.336929393389255e-08
the O 0 4.855812640869317e-09
additional O 0 6.001929619969815e-09
absence O 0 6.459664092517414e-08
of O 0 1.1825298429357645e-07
lamin O 0 0.048527464270591736
B1 O 1 0.9998219609260559
from O 0 4.751389496959746e-06
heart O 1 0.9963474869728088
and O 0 0.0001834571739891544
skeletal O 1 0.9999998807907104
muscle O 1 0.9630935192108154
nuclei O 0 0.08157368004322052
which O 0 2.597755894839793e-07
already O 0 1.208446889222614e-07
lack O 0 5.026624876336427e-07
emerin O 0 4.729202373709995e-06
may O 0 5.110198042501679e-09
offer O 0 9.667344702535274e-10
an O 0 1.0309355452653435e-10
alternative O 0 2.1875929956394202e-09
explanation O 0 3.559072592196344e-09
of O 0 4.608857739896166e-09
why O 0 3.746367216450608e-09
these O 0 7.116773281801159e-10
tissues O 0 1.6880830955301462e-08
are O 0 9.856304661326476e-10
particularly O 0 1.4949883109238726e-08
affected O 0 1.2472525234841214e-08
. O 0 1.7616544667475864e-08
. O 0 3.4406633631078876e-07

Genetic O 0 4.833269031223608e-06
mapping O 0 1.9358362806087825e-06
of O 0 8.416122341259324e-07
the O 0 1.4435354387387633e-06
copper B-Disease 1 0.9977182149887085
toxicosis I-Disease 1 0.9983322024345398
locus O 0 1.770373842191475e-06
in O 0 3.939724422252766e-07
Bedlington O 0 0.0014092078199610114
terriers O 0 2.0818179109483026e-05
to O 0 1.0789135274080763e-07
dog O 0 2.9028128665231634e-06
chromosome O 0 1.0279901516696555e-06
10 O 0 1.680976708939852e-07
, O 0 6.256298590301412e-09
in O 0 3.1701326008715114e-09
a O 0 1.7922143769055765e-08
region O 0 6.579384859151105e-08
syntenic O 0 9.601654937796411e-07
to O 0 5.066224773031536e-09
human O 0 7.96710182271454e-08
chromosome O 0 1.7453352256779908e-06
region O 0 2.3247289391292725e-06
2p13 O 0 7.72103521740064e-05
- O 0 2.479851355019491e-05
p16 O 0 2.1696279873140156e-05
. O 0 2.7422520361142233e-06

Abnormal O 1 0.9993945360183716
hepatic B-Disease 1 0.999996542930603
copper I-Disease 1 0.9979154467582703
accumulation I-Disease 0 0.00033113366225734353
is O 0 2.025865697419249e-08
recognized O 0 1.9810514118034916e-08
as O 0 1.7131693397232084e-08
an O 0 2.0056356220266025e-07
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 0.004728746134787798
man O 0 0.25765204429626465
, O 0 1.1044629673051531e-06
mouse O 0 1.0138523975911085e-05
, O 0 2.8094893878005678e-06
rat O 0 0.0014069860335439444
and O 0 1.9046718762183446e-06
dog O 0 0.00012767186854034662
. O 0 1.7828959244070575e-05

The O 0 2.29291708819801e-06
major O 0 1.2613403669092804e-05
cause O 0 9.8430491561885e-06
of O 0 2.126942308677826e-05
hepatic B-Disease 1 0.9999980926513672
copper I-Disease 1 0.9999980926513672
accumulation I-Disease 1 0.9999191761016846
in O 0 1.9279623302281834e-05
man O 0 9.373631655762438e-06
is O 0 1.765799062525275e-08
a O 0 4.300250111555215e-08
dysfunctional O 0 2.9640627872140612e-06
ATP7B O 0 0.003195680445060134
gene O 0 3.447468941430998e-07
, O 0 8.237772419761313e-08
causing O 0 3.2092531910166144e-05
Wilson B-Disease 1 0.6833572387695312
disease I-Disease 1 0.9727214574813843
( O 0 5.654918368236395e-06
WD B-Disease 1 0.994037389755249
) O 0 4.808232461073203e-06
. O 0 1.0219298019364942e-05

Mutations O 0 1.9491540115268435e-06
in O 0 5.136722336374078e-08
the O 0 1.1934832855331479e-07
ATP7B O 0 0.04988710209727287
genes O 0 5.421053472787207e-08
have O 0 1.2189497189396548e-09
also O 0 5.431304295200334e-10
been O 0 1.5355043903042542e-09
demonstrated O 0 1.411493055769597e-08
in O 0 1.0573268482971798e-08
mouse O 0 1.4196353959050612e-07
and O 0 1.4235439493859303e-07
rat O 0 2.7367565053282306e-05
. O 0 1.3813461237077718e-06

The O 0 2.9845250537618995e-06
ATP7B O 0 0.4688895046710968
gene O 0 5.668972562489216e-07
has O 0 1.5899807692676404e-08
been O 0 4.4148298350421555e-09
excluded O 0 8.155752517780002e-09
in O 0 3.4816016736272104e-10
the O 0 6.220112203081385e-10
much O 0 7.465719598087617e-09
rarer O 0 3.888918911343353e-07
human O 0 1.1926128706818417e-07
copper B-Disease 1 0.9995667338371277
overload I-Disease 1 0.9999752044677734
disease O 0 0.3104158043861389
non B-Disease 0 1.1977599569945596e-05
- I-Disease 0 5.018289812142029e-06
Indian I-Disease 0 4.2408308331687294e-07
childhood I-Disease 0 0.06715516000986099
cirrhosis I-Disease 1 0.9999980926513672
, O 0 3.92673825899692e-07
indicating O 0 5.753103778260993e-06
genetic O 0 4.988338332623243e-06
heterogeneity O 0 5.958912879577838e-05
. O 0 1.6616239008726552e-05

By O 0 3.607775624914211e-07
investigating O 0 5.526979293790646e-06
the O 0 4.2717121573332406e-07
common O 0 1.4548555554938503e-05
autosomal O 1 0.6525328755378723
recessive O 1 0.9992515444755554
copper B-Disease 1 0.9999998807907104
toxicosis I-Disease 1 1.0
( O 0 0.00012415050878189504
CT B-Disease 1 0.9998743534088135
) O 0 3.717520087320736e-07
in O 0 4.330602223490132e-07
Bedlington O 1 0.8168928623199463
terriers O 0 0.0002575232647359371
, O 0 2.7224684728821558e-08
we O 0 4.151654131590021e-09
have O 0 3.329043429811662e-10
identified O 0 1.1306561242818702e-09
a O 0 2.2390932163940391e-10
new O 0 1.7523764384019813e-10
locus O 0 2.1173376385519305e-09
involved O 0 5.435452532509544e-09
in O 0 5.274215908457336e-08
progressive O 1 0.9999982118606567
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.0005367412231862545

We O 0 1.374473413306987e-06
examined O 0 1.941525169968372e-06
whether O 0 1.0378699499824506e-07
the O 0 1.0522734328333172e-07
WD B-Disease 0 0.00024899665731936693
gene O 0 8.146558343469223e-07
ATP7B O 0 0.0008772647706791759
was O 0 1.7062598089978565e-06
also O 0 3.1572813696811863e-08
causative O 0 3.003181348049111e-07
for O 0 2.5316055030089046e-08
CT B-Disease 0 0.00013622168626170605
by O 0 1.1565073343433596e-08
investigating O 0 4.00939484279661e-07
the O 0 7.216537056820016e-08
chromosomal O 0 0.0005163448513485491
co O 0 0.0006046344642527401
- O 0 3.168394687236287e-05
localization O 0 0.00035234299139119685
of O 0 6.680299406980339e-07
ATP7B O 0 0.002828607801347971
and O 0 2.253787734218804e-08
C04107 O 0 4.3875667188331136e-07
, O 0 4.6560552635632746e-10
using O 0 6.250761575010699e-10
fluorescence O 0 6.079875713993488e-09
in O 0 2.3584638686457993e-09
situ O 0 4.6763344130340556e-07
hybridization O 0 6.064277613404556e-08
( O 0 3.084901933902984e-08
FISH O 0 8.040620969040901e-07
) O 0 4.241687889816603e-08
. O 0 3.3118618603111827e-07

C04107 O 0 8.102841820800677e-05
is O 0 1.0954943263641326e-07
an O 0 1.3584323887982919e-08
anonymous O 0 1.6873788410975976e-07
microsatellite O 0 4.617184458766133e-06
marker O 0 1.1294603154965444e-06
closely O 0 9.606170578990714e-07
linked O 0 2.9423147225315915e-06
to O 0 4.764566767789802e-07
CT B-Disease 1 0.9998273253440857
. O 0 2.8090176783734933e-05

However O 0 5.862758371222299e-06
, O 0 2.060008910120814e-06
BAC O 0 0.08067318052053452
clones O 0 1.2719175401798566e-06
containing O 0 2.2501266982999368e-07
ATP7B O 0 3.7640176742570475e-05
and O 0 2.2046757308658016e-08
C04107 O 0 7.901572303126159e-07
mapped O 0 2.8885219549579233e-08
to O 0 2.9099207488059164e-09
the O 0 4.6874074399738674e-08
canine O 0 9.387964382767677e-06
chromosome O 0 9.441856718694908e-07
regions O 0 8.833963960341862e-08
CFA22q11 O 0 7.275298685271991e-06
and O 0 1.685364559023128e-08
CFA10q26 O 0 9.41759117267793e-06
, O 0 1.5042155965261372e-08
respectively O 0 5.051734319749812e-08
, O 0 2.6061137692323655e-09
demonstrating O 0 3.762588818290169e-08
that O 0 3.892018707318812e-09
WD B-Disease 0 9.642144505050965e-06
cannot O 0 2.9541462609472546e-08
be O 0 8.434038356597284e-09
homologous O 0 5.952886183990813e-08
to O 0 6.720781442481893e-08
CT B-Disease 0 0.03301667049527168
. O 0 7.045507118164096e-06

The O 0 3.7269448966981145e-06
copper O 0 0.00013262408901937306
transport O 0 1.7982653162107454e-06
genes O 0 2.3117748071399546e-07
CTR1 O 0 9.739808592712507e-05
and O 0 3.528172598521451e-08
CTR2 O 0 0.005478108301758766
were O 0 3.940798620760688e-08
also O 0 2.027024326167748e-09
excluded O 0 5.68786973076385e-09
as O 0 1.0183229814941797e-09
candidate O 0 8.232239778749317e-09
genes O 0 1.158193208006253e-09
for O 0 3.279208904416464e-09
CT B-Disease 0 0.00018592715787235647
since O 0 4.49565149551745e-08
they O 0 2.0121249111326733e-09
both O 0 7.100290133621456e-09
mapped O 0 5.410321080034919e-08
to O 0 3.616307608922398e-08
canine O 0 4.673844887292944e-05
chromosome O 0 2.151196895283647e-05
region O 0 3.3497042750241235e-05
CFA11q22 O 0 0.003250968875363469
. O 0 2.1038738850620575e-05

2 O 0 0.0008764078957028687
- O 0 0.0003250262525398284
22 O 0 4.681293648900464e-05
. O 0 8.273662388091907e-06

5 O 0 0.00021903817832935601
. O 0 5.509473703568801e-05

A O 0 1.6199977608266636e-06
transcribed O 0 3.8552272485503636e-07
sequence O 0 3.7357089865963644e-08
identified O 0 1.8361998144200697e-08
from O 0 4.182429069743421e-09
the O 0 7.251220957016358e-09
C04107 O 0 1.057677650351252e-06
- O 0 2.2623763129558938e-07
containing O 0 1.0889363011301612e-07
BAC O 0 0.0007400896865874529
was O 0 3.9786218053450284e-07
found O 0 1.9665113981659488e-09
to O 0 4.707382261770476e-10
be O 0 1.0911225256649004e-09
homologous O 0 4.31713642612408e-09
to O 0 6.25325347058947e-10
a O 0 3.2353721923783496e-09
gene O 0 4.00886834839298e-09
expressed O 0 2.946491717281674e-09
from O 0 9.250815224959297e-09
human O 0 2.5505464407160616e-08
chromosome O 0 1.0125211247213883e-06
2p13 O 0 9.53954895521747e-06
- O 0 2.2160770640766714e-06
p16 O 0 9.256277166969085e-07
, O 0 8.551363173125992e-09
a O 0 1.0951596962627264e-08
region O 0 4.2488700557896664e-08
devoid O 0 1.9569230857996445e-07
of O 0 1.2628023071670214e-08
any O 0 2.6767096983348893e-08
positional O 0 6.282792128331494e-06
candidate O 0 1.191233423014637e-06
genes O 0 6.557360165970749e-07
. O 0 1.409213950864796e-06

Molecular O 0 3.7200384213065263e-06
analysis O 0 3.4830171102839813e-07
of O 0 1.5871954417434608e-07
the O 0 1.334800998620267e-07
APC B-Disease 0 1.3965682228445075e-06
gene O 0 1.6123607338158763e-07
in O 0 3.773772405679665e-08
205 O 0 7.620482023185104e-08
families O 0 3.774821344393331e-09
: O 0 2.8385249706275317e-09
extended O 0 3.426725925237406e-08
genotype O 0 3.338582530432177e-07
- O 0 2.7924019718739146e-07
phenotype O 0 1.547793360145988e-08
correlations O 0 9.924792010451711e-08
in O 0 9.346979190638649e-09
FAP B-Disease 0 2.2136261179639405e-07
and O 0 5.205414321807211e-09
evidence O 0 1.8316105965254792e-08
for O 0 8.07344135989041e-10
the O 0 1.3379325425333377e-09
role O 0 1.9725417743643447e-08
of O 0 2.992539904767e-08
APC B-Disease 0 3.0311090881696146e-07
amino O 0 3.898528788681688e-08
acid O 0 7.461451900780958e-08
changes O 0 1.7348378378301277e-07
in O 0 0.00041516454075463116
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9999867677688599
. O 0 0.0010567069984972477

BACKGROUND O 0 0.0009464261238463223
/ O 0 0.00015816603263374418
AIMS O 0 1.6366320778615773e-06
The O 0 3.6733123209842233e-08
development O 0 5.828251232742332e-07
of O 0 0.0433652438223362
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 7.971328130906841e-08
a O 0 1.0849761089559706e-08
variable O 0 1.117492764990402e-08
range O 0 2.3132717075213804e-08
of O 0 1.2489046241626056e-08
extracolonic O 0 9.728875738801435e-06
manifestations O 0 7.009484306763625e-06
in O 0 3.298740921309218e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.003793922020122409
FAP B-Disease 0 0.00021602807100862265
) O 0 7.862786333134864e-08
is O 0 5.55464785279014e-09
the O 0 2.0951300694349584e-09
result O 0 6.683387621109205e-09
of O 0 5.9307723176971194e-09
the O 0 1.2894760814674555e-08
dominant O 0 3.435663757045404e-06
inheritance O 0 3.940828264603624e-06
of O 0 0.00012180606427136809
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 0.9999878406524658
( O 0 6.577711701538647e-06
APC B-Disease 0 5.606502963928506e-05
) O 0 1.71131330262142e-06
gene O 0 1.681989488133695e-05
mutations O 0 2.6270314265275374e-05
. O 0 1.739499748509843e-05

In O 0 1.0086259294439515e-07
this O 0 2.5322899332991256e-09
study O 0 7.152634928786483e-09
, O 0 4.92705098942281e-10
direct O 0 2.8285265241123625e-09
mutation O 0 1.4611474252745893e-09
analysis O 0 4.098655637108095e-09
of O 0 9.82972636620616e-09
the O 0 2.795393605481422e-08
APC B-Disease 0 9.070262194654788e-07
gene O 0 1.886011489204975e-07
was O 0 4.814049816559418e-07
performed O 0 7.75862289970064e-08
to O 0 6.071393165996142e-09
determine O 0 1.6295521731990448e-07
genotype O 0 6.764647650925326e-07
- O 0 1.094234676202177e-06
phenotype O 0 5.916426104590755e-08
correlations O 0 1.018316098111427e-07
for O 0 2.6068907033049982e-08
nine O 0 5.325629786057107e-07
extracolonic O 0 3.0133998734527268e-05
manifestations O 0 1.174930048364331e-06
and O 0 6.6381224961276075e-09
to O 0 1.1873177996335471e-09
investigate O 0 1.4852708396517755e-08
the O 0 4.232884265320536e-09
incidence O 0 3.8080020203778986e-07
of O 0 4.3655539627707185e-08
APC B-Disease 0 7.257574452523841e-07
mutations O 0 4.033205414089025e-08
in O 0 5.284366011437669e-08
non O 0 0.006408935412764549
- O 1 0.9999939203262329
FAP O 1 0.9999997615814209
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0449892058968544

METHODS O 0 2.427381150482688e-05
The O 0 3.559047740964161e-07
APC B-Disease 0 1.1441982223914238e-06
gene O 0 9.702765169095073e-08
was O 0 1.0363665836621294e-07
analysed O 0 6.816209463522682e-08
in O 0 4.137362008549417e-09
190 O 0 1.3175924351571666e-08
unrelated O 0 3.1372795916695395e-08
FAP B-Disease 0 6.877653646597537e-08
and O 0 4.3331072063779175e-09
15 O 0 4.93919344535243e-07
non O 0 0.0008755940943956375
- O 1 0.9999421834945679
FAP O 1 0.9999996423721313
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 6.492994089057902e-06
using O 0 1.4344914234243333e-07
denaturing O 0 2.978526936203707e-05
gradient O 0 1.160619194706669e-05
gel O 0 3.308834129711613e-05
electrophoresis O 0 4.391662059788359e-06
, O 0 2.3629542766911982e-08
the O 0 8.719840849380489e-09
protein O 0 3.612660393059741e-08
truncation O 0 8.80771722222562e-08
test O 0 5.341109332590577e-09
, O 0 1.4708558815357264e-09
and O 0 2.885756078541135e-09
direct O 0 4.6094751127156997e-08
sequencing O 0 5.795145625597797e-07
. O 0 1.308752985096362e-06

RESULTS O 0 1.6217712982324883e-05
Chain O 0 4.745864771393826e-06
terminating O 0 4.512713474014163e-07
signals O 0 3.266513886046596e-07
were O 0 1.4734172992802996e-08
only O 0 8.248141614153326e-10
identified O 0 6.5670207050061435e-09
in O 0 3.127109904355052e-09
patients O 0 6.587029144355938e-09
belonging O 0 2.0392601385310627e-08
to O 0 9.649843146775083e-10
the O 0 2.4083369964955637e-08
FAP B-Disease 0 2.9021291538811056e-06
group O 0 2.0650411158840143e-07
( O 0 1.329461412069577e-07
105 O 0 5.065801360615296e-06
patients O 0 8.478832000946568e-07
) O 0 1.3464482151448465e-07
. O 0 1.6494526562382816e-06

Amino O 0 1.0920912245637737e-06
acid O 0 2.4884457161533646e-07
changes O 0 1.6753585185824704e-08
were O 0 9.841469861271435e-09
identified O 0 2.0020920032948197e-08
in O 0 2.3037112217849653e-09
four O 0 5.7224189831117656e-09
patients O 0 9.574076642593354e-09
, O 0 1.1890742834808066e-09
three O 0 2.380604824381294e-09
of O 0 8.967175091356694e-08
whom O 0 3.6219475418874936e-07
belonged O 0 6.947518613742432e-07
to O 0 1.1038706615451588e-09
the O 0 9.759482111348916e-09
non O 0 4.156381692155264e-06
- O 0 3.145727760056616e-06
FAP O 0 9.742112752064713e-07
group O 0 2.848346696282533e-07
of O 1 0.999826967716217
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9999067783355713
. O 0 0.00015339732635766268

Genotype O 0 0.00027487080660648644
- O 0 7.162294059526175e-05
phenotype O 0 9.16930616767786e-07
correlations O 0 1.16977264497109e-06
identified O 0 1.274244709748018e-07
significant O 0 1.069898871719488e-07
differences O 0 2.7811469749394746e-07
in O 0 6.383892525718693e-09
the O 0 2.267554366497393e-09
nature O 0 4.145988441450754e-09
of O 0 1.8446201233146553e-09
certain O 0 1.5397869645994433e-08
extracolonic O 0 3.4054667139571393e-06
manifestations O 0 8.812638725430588e-07
in O 0 7.918728783806728e-08
FAP B-Disease 0 5.569169388763839e-06
patients O 0 5.458581426864839e-07
belonging O 0 2.0550902490867884e-07
to O 0 8.010648144818333e-09
three O 0 9.93664883708334e-08
mutation O 0 9.225723260897212e-07
subgroups O 0 2.0103716451558284e-05
. O 0 4.646222350856988e-06

CONCLUSIONS O 0 6.547663815581473e-06
Extended O 0 2.7642975055641728e-06
genotype O 0 5.7984575505543035e-06
- O 0 3.714391368703218e-06
phenotype O 0 7.131196610998813e-08
correlations O 0 1.2378868063933623e-07
made O 0 1.4662347780358687e-08
in O 0 2.5112276702543568e-09
this O 0 4.3326917054109515e-10
study O 0 2.7992761442163783e-09
may O 0 4.441747858408007e-09
have O 0 2.062245790801498e-10
the O 0 6.758285042707257e-10
potential O 0 4.587790591870089e-09
to O 0 1.8730067496974812e-10
determine O 0 2.0627504149217657e-09
the O 0 3.708564011439819e-10
most O 0 1.7568409227397552e-10
appropriate O 0 2.857793779398321e-09
surveillance O 0 6.154256482204801e-08
and O 0 3.6116873936009597e-09
prophylactic O 0 2.2605611320614116e-06
treatment O 0 4.1567005837350735e-07
regimens O 0 4.0134383993972733e-07
for O 0 5.794203783437979e-09
those O 0 5.971066308063655e-09
patients O 0 5.621871856931193e-09
with O 0 1.2766760981719472e-09
mutations O 0 5.616666243213331e-08
associated O 0 1.1183225723243595e-07
with O 0 3.119468416912241e-08
life O 0 3.2162622574105626e-06
threatening O 0 5.21157471666811e-06
conditions O 0 1.296224036195781e-05
. O 0 4.799225280294195e-06

This O 0 1.7659040452144836e-07
study O 0 1.1381240483387955e-07
also O 0 6.601656998839189e-09
provided O 0 5.765364630150316e-09
evidence O 0 4.531539588015221e-09
for O 0 1.8264569856540902e-09
the O 0 5.385752288589174e-09
pathological O 0 4.0641903069627006e-06
nature O 0 1.8633627973940747e-08
of O 0 6.1200151613149956e-09
amino O 0 5.966125815604073e-09
acid O 0 9.93880711064321e-09
changes O 0 5.431545435641283e-09
in O 0 3.520071123475077e-09
APC O 0 4.601815106752838e-08
associated O 0 2.1278161455029476e-08
with O 0 1.7286909681502038e-09
both O 0 6.5204162069676386e-09
FAP B-Disease 0 3.180891781084938e-07
and O 0 4.149582366608229e-08
non O 1 0.998271107673645
- O 1 0.9999998807907104
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.963921308517456
. O 0 4.454669578990433e-06
. O 0 1.223190065502422e-05

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999998807907104
and O 0 0.0013689252082258463
cancer B-Disease 1 0.9998524188995361
risk O 0 1.0495716196601279e-05
of O 0 5.097078883409267e-07
the O 0 4.063683718413813e-07
APC O 0 2.485542972863186e-05
I1307K O 0 7.150739838834852e-05
polymorphism O 0 1.447283193556359e-05
. O 0 3.36626430907927e-06

Germ O 1 0.9999871253967285
- O 0 0.0007250260678119957
line O 0 1.1623541240624036e-06
and O 0 9.005874268552816e-09
somatic O 0 2.470364108830836e-07
truncating O 0 4.17854010947849e-07
mutations O 0 2.3503682555769956e-08
of O 0 1.939913119031189e-08
the O 0 3.103474810473017e-08
APC B-Disease 0 6.764390150237887e-07
gene O 0 5.7576972523065706e-08
are O 0 1.1121612519815471e-09
thought O 0 1.0140729145291516e-08
to O 0 2.620714090184606e-09
initiate O 0 1.2828586477553472e-05
colorectal B-Disease 1 1.0
tumor I-Disease 0 0.2137058973312378
formation O 0 0.00016200919344555587
in O 0 4.372069088276476e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.25510451197624207
sporadic O 1 1.0
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 6.152709102025256e-05
respectively O 0 0.00025910267140716314
. O 0 2.474734174029436e-05

Recently O 0 6.558381301147165e-06
, O 0 9.593620831083172e-08
an O 0 4.885394488951533e-08
isoleucine O 0 2.999803655256983e-05
- O 0 4.208475729683414e-05
- O 0 1.3105543075653259e-05
> O 0 1.8945864894703845e-06
lysine O 0 2.335688407129055e-07
polymorphism O 0 5.0480839064448446e-08
at O 0 1.0189165067231443e-07
codon O 0 9.979346771160635e-08
1307 O 0 3.944276159018045e-06
( O 0 3.730041342464574e-08
I1307K O 0 5.665924049935711e-07
) O 0 3.324844399799076e-09
of O 0 1.2913687896798365e-08
the O 0 2.3242353819341588e-08
APC B-Disease 0 2.603815403290355e-07
gene O 0 2.097826090619037e-08
has O 0 2.3842492424819284e-09
been O 0 1.10785081108844e-09
identified O 0 1.3027828815737053e-09
in O 0 1.157932527640071e-09
6 O 0 4.5756458177947934e-08
% O 0 1.3739418491809374e-08
- O 0 1.7977338018226874e-07
7 O 0 1.213955442835868e-07
% O 0 8.093643089068792e-09
of O 0 5.54377788120064e-09
the O 0 1.1055905524415266e-08
Ashkenazi O 0 2.2228920215638936e-07
Jewish O 0 4.419744215056198e-08
population O 0 1.1103709063320366e-08
. O 0 2.699734693578648e-07

To O 0 9.23201000091467e-08
assess O 0 2.48857617179965e-07
the O 0 1.3708714163840341e-08
risk O 0 6.51570672971502e-08
of O 0 7.960612613544527e-09
this O 0 4.5709480644973155e-10
common O 0 7.71340946670307e-09
APC B-Disease 0 9.500081432634033e-08
allelic O 0 1.0946082511509303e-06
variant O 0 1.8958082819153788e-06
in O 0 1.080286438082112e-06
colorectal O 1 1.0
carcinogenesis O 1 0.9999998807907104
, O 0 9.33505191369477e-07
we O 0 2.6519211715481106e-08
have O 0 1.13855724848122e-09
analyzed O 0 9.924220556456476e-09
a O 0 1.2885410516361162e-09
large O 0 1.3856946701196193e-09
cohort O 0 1.3056045133907901e-08
of O 0 5.464392049958633e-09
unselected O 0 2.713052526814863e-05
Ashkenazi O 0 2.1018959728280606e-07
Jewish O 0 1.9230954606541673e-08
subjects O 0 1.6499059540819871e-07
with O 0 1.4782195023599343e-08
adenomatous B-Disease 0 9.072622924577445e-05
polyps I-Disease 0 7.867322892707307e-06
and O 0 1.2888244249609215e-08
. O 0 5.051618856555251e-08
or O 1 0.9471707344055176
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 3.331207096834987e-07
for O 0 3.5944328402592873e-08
the O 0 4.3130032167937316e-07
APC O 0 2.7833231797558255e-05
I1307K O 0 0.00010203874990111217
polymorphism O 0 1.7401069271727465e-05
. O 0 4.538731900538551e-06

The O 0 1.9493174931994872e-06
APC O 0 5.587310170085402e-06
I1307K O 0 5.461854016175494e-06
allele O 0 1.369398034967162e-07
was O 0 1.7074499680802546e-07
identified O 0 4.816006082819513e-08
in O 0 6.853673628626211e-09
48 O 0 9.293137992472111e-08
( O 0 3.973826157022131e-09
10 O 0 6.992650458670369e-09
. O 0 6.547956066249583e-10
1 O 0 1.8239445509493635e-08
% O 0 6.849021794153032e-09
) O 0 3.1575808634443092e-09
of O 0 5.563133242958429e-08
476 O 0 5.228390818956541e-06
patients O 0 2.2916533453098964e-06
. O 0 2.335103317818721e-06

Compared O 0 1.345895270787878e-06
with O 0 1.1490929985313869e-08
the O 0 5.532074798253461e-09
frequency O 0 3.8725012529994274e-08
in O 0 7.484963759907259e-10
two O 0 1.7370686833384497e-10
separate O 0 3.2572275432407594e-10
population O 0 9.146308710406004e-11
control O 0 1.9693802144615802e-08
groups O 0 7.153054815134396e-10
, O 0 9.460942029804187e-10
the O 0 4.72788252992018e-09
APC O 0 2.9608372642542236e-07
I1307K O 0 8.207539963223098e-07
allele O 0 2.2723440906702308e-08
is O 0 3.308851415084746e-09
associated O 0 4.320390267764651e-09
with O 0 3.9061318068966955e-10
an O 0 5.397905455950536e-10
estimated O 0 4.966311806242629e-09
relative O 0 1.650817154086326e-07
risk O 0 2.4490341843375063e-07
of O 0 2.6500157446207595e-07
1 O 0 1.205504213430686e-05
. O 0 1.3801819704895024e-06

5 O 0 8.394367614528164e-05
- O 0 0.0001145625501521863
1 O 0 2.404221049800981e-05
. O 0 3.3835476642707363e-06

7 O 0 7.935522444313392e-05
for O 0 4.912646909360774e-05
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9999111890792847
( O 0 1.8405007722321898e-06
both O 0 1.03852289612405e-06
P O 0 0.000963941216468811
= O 0 3.3317198813165305e-06
. O 0 1.1519924214553612e-07
01 O 0 7.631238986505195e-06
) O 0 4.451962638540863e-07
. O 0 2.2255421754380222e-06

Furthermore O 0 1.1857775461976416e-05
, O 0 1.9645223403585987e-07
compared O 0 7.869928708714724e-08
with O 0 2.1812358141914956e-08
noncarriers O 0 2.4536599084967747e-05
, O 0 5.7710227707730155e-08
APC O 0 6.700353196720243e-07
I1307K O 0 1.8989279624292976e-06
carriers O 0 2.4966055889308336e-08
had O 0 2.262741327641038e-09
increased O 0 5.77106085142276e-10
numbers O 0 7.111495281542091e-10
of O 0 1.5771320249768905e-08
adenomas B-Disease 0 0.013536324724555016
and O 0 2.0337680325610563e-05
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9999808073043823
per O 0 5.3680255405197386e-06
patient O 0 1.0263346666761208e-05
( O 0 5.444856299163803e-08
P O 0 2.220991336798761e-05
= O 0 1.399826885517541e-07
. O 0 3.97898380910533e-09
03 O 0 1.976835903860774e-07
) O 0 1.635611868167075e-09
, O 0 6.501771343536689e-10
as O 0 1.0150226215088765e-09
well O 0 1.9475232537757847e-09
as O 0 3.943699145025903e-09
a O 0 2.082549066528827e-08
younger O 0 1.1342470429553941e-07
age O 0 6.767099876014981e-07
at O 0 1.614375287317671e-05
diagnosis O 0 0.00016751786461099982
. O 0 2.93412153951067e-06

We O 0 1.3910996585764224e-06
conclude O 0 2.261251211166382e-06
that O 0 9.751258467360913e-09
the O 0 3.4618722111190436e-08
APC O 0 9.884738574328367e-07
I1307K O 0 4.399362751428271e-06
variant O 0 1.0587918950477615e-06
leads O 0 1.177528687890117e-07
to O 0 1.256473947108816e-08
increased O 0 6.922413376742043e-06
adenoma B-Disease 1 0.9999998807907104
formation O 0 1.806292675610166e-05
and O 0 6.701937849129536e-08
directly O 0 3.28900746637828e-08
contributes O 0 6.4701306534686864e-09
to O 0 7.661003498249386e-10
3 O 0 4.982387125096466e-08
% O 0 1.620035838811873e-08
- O 0 6.980646816145963e-08
4 O 0 1.6044022999039953e-08
% O 0 1.1240205433082906e-09
of O 0 1.919645997716657e-09
all O 0 4.784982188255071e-09
Ashkenazi O 0 4.5355041038419586e-06
Jewish O 0 0.0001240716956090182
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.492062362260185e-05

The O 0 2.9917185884187347e-07
estimated O 0 1.1866113425185176e-07
relative O 0 8.325739031533885e-07
risk O 0 9.440923776082855e-08
for O 0 3.6874341358128504e-09
carriers O 0 3.764268896588874e-08
may O 0 3.759115685397774e-09
justify O 0 6.520876283389043e-09
specific O 0 4.198764391727394e-10
clinical O 0 8.118441918725239e-09
screening O 0 3.896987621487824e-09
for O 0 8.518962757442239e-10
the O 0 3.189723374319442e-09
360 O 0 2.0876834483374296e-08
, O 0 3.831027939327214e-09
000 O 0 1.13544142976707e-08
Americans O 0 1.2283226658027502e-09
expected O 0 2.5336088782523802e-09
to O 0 1.0345604373185324e-09
harbor O 0 1.6564993643441994e-07
this O 0 3.4681471583475343e-10
allele O 0 3.737780751578157e-09
, O 0 8.718987754008367e-10
and O 0 4.782288454130423e-10
genetic O 0 4.9565933579742705e-09
testing O 0 3.999604203386298e-09
in O 0 2.486072736562761e-10
the O 0 3.7891315085580857e-10
setting O 0 9.704612224936682e-09
of O 0 4.729379998735794e-09
long O 0 9.753081897656557e-09
- O 0 4.532570940796177e-08
term O 0 2.4119410468870228e-08
- O 0 1.2374661295666556e-08
outcome O 0 3.6815310799909184e-09
studies O 0 1.3923339148291802e-09
may O 0 6.253039197545718e-10
impact O 0 5.253190327181301e-09
significantly O 0 9.187953509126601e-08
on O 0 1.300640815316001e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 9.446666081203148e-05
in O 0 1.4141960491542704e-08
this O 0 7.001512258852927e-09
population O 0 2.1591652910046832e-08
. O 0 5.767880111307022e-07

Localization O 0 0.0005316041642799973
of O 0 2.1148237010493176e-06
human O 0 2.405856207587931e-07
BRCA1 O 0 1.6941123703873018e-07
and O 0 2.613525840189368e-09
its O 0 9.554442792492068e-10
loss O 0 4.275738874071067e-08
in O 0 4.0837355719247626e-09
high O 0 7.210166472759738e-07
- O 0 9.416734769729374e-08
grade O 0 1.9912552033929387e-06
, O 0 1.3657587061288723e-08
non B-Disease 0 0.0001311599335167557
- I-Disease 1 0.9997692704200745
inherited I-Disease 1 1.0
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.0632234662771225

Although O 0 6.732777251272637e-07
the O 0 6.602478208606044e-08
link O 0 1.8583358496471192e-07
between O 0 5.484568177394067e-08
the O 0 9.014659951844806e-08
BRCA1 O 0 1.0722256774897687e-05
tumour B-Disease 1 0.9999996423721313
- O 0 7.612191984662786e-05
suppressor O 0 9.5092473202385e-06
gene O 0 3.50477222355039e-07
and O 0 3.7796436913595244e-07
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 9.307454456575215e-05
established O 0 5.1453503147058655e-06
, O 0 8.884890156934944e-09
the O 0 5.629200217072139e-09
role O 0 1.3247115759895678e-07
, O 0 2.7268061142393663e-09
if O 0 9.587978189173896e-10
any O 0 1.129375926112175e-09
, O 0 1.2195124909908373e-09
of O 0 9.941556022852183e-09
BRCA1 O 0 3.027849615477862e-08
in O 0 9.292371316860226e-09
non B-Disease 0 0.00038967409636825323
- I-Disease 1 0.9526023864746094
familial I-Disease 1 0.9498607516288757
cancers I-Disease 1 0.9999912977218628
is O 0 7.674398148083128e-07
unclear O 0 6.807978934375569e-06
. O 0 3.1878660138318082e-06

BRCA1 O 0 7.40664909244515e-05
mutations O 0 5.739725565945264e-07
are O 0 8.054588107597738e-09
rare O 0 2.900114992598901e-08
in O 0 1.4899555367264838e-08
sporadic B-Disease 0 5.405122647061944e-05
cancers I-Disease 1 0.5025087594985962
, O 0 2.1287782203671668e-08
but O 0 8.575340437744217e-09
loss O 0 2.636370766140317e-07
of O 0 4.1803298245213227e-07
BRCA1 O 0 1.2211860678235098e-07
resulting O 0 1.8073080809699604e-08
from O 0 3.5265628195446652e-09
reduced O 0 1.9361648284643707e-08
expression O 0 4.98473173848879e-09
or O 0 1.4603255271694593e-09
incorrect O 0 2.3459611142584436e-08
subcellular O 0 5.216296017351851e-07
localization O 0 1.5370515029644594e-06
is O 0 4.029420797024841e-09
postulated O 0 2.076702365627625e-08
to O 0 5.51542533866467e-10
be O 0 4.80962103477367e-10
important O 0 2.3667237059044055e-09
in O 0 1.863418752634516e-09
non B-Disease 0 2.17757133214036e-06
- I-Disease 0 0.00348792620934546
familial I-Disease 1 0.995919406414032
breast I-Disease 1 1.0
and I-Disease 1 0.9999995231628418
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 1 0.9985931515693665

Epigenetic O 0 0.02295220084488392
loss O 0 0.0007132040918804705
, O 0 1.5824118690943578e-06
however O 0 4.619416813511634e-07
, O 0 1.8835951465234757e-08
has O 0 1.4074303944511257e-09
not O 0 1.1922234033345802e-10
received O 0 6.048158085469879e-10
general O 0 3.5199838599453415e-09
acceptance O 0 3.1985449844285085e-09
due O 0 5.188049101434444e-09
to O 0 5.430786931270859e-10
controversy O 0 6.6133023501890875e-09
regarding O 0 6.293748633368068e-09
the O 0 4.378051254860793e-09
subcellular O 0 1.287598024646286e-06
localization O 0 5.237558525550412e-06
of O 0 2.5597924491194135e-07
BRCA1 O 0 3.6082815313420724e-07
proteins O 0 1.1861346571606646e-08
, O 0 3.767067990878559e-09
reports O 0 2.411042920869022e-09
of O 0 4.982365631178709e-09
which O 0 4.953283339048653e-10
have O 0 4.933934372175486e-10
ranged O 0 4.9044501793105155e-08
from O 0 1.1222895945905975e-09
exclusively O 0 5.632132538124779e-09
nuclear O 0 7.267188095738675e-08
, O 0 1.4722892349716687e-10
to O 0 7.501910898044528e-11
conditionally O 0 2.9645660148958086e-08
nuclear O 0 1.7586974365713104e-07
, O 0 4.0836481418615733e-10
to O 0 6.285156284313587e-10
the O 0 4.8685855347230245e-08
ER O 0 0.494569331407547
/ O 0 5.347117985365912e-05
golgi O 0 3.0093395253061317e-05
, O 0 9.887981100575871e-09
to O 0 1.0436820296888527e-08
cytoplasmic O 0 6.173514748297748e-07
invaginations O 0 3.3737328521965537e-06
into O 0 5.423225601930426e-08
the O 0 1.3065042026028095e-07
nucleus O 0 8.590995093982201e-06
. O 0 2.7912221867154585e-06

In O 0 4.7104543909881613e-07
an O 0 2.349893080122456e-08
attempt O 0 8.046269073247458e-08
to O 0 4.609332027172286e-09
resolve O 0 1.8089986042468809e-07
this O 0 1.3071885796023253e-09
issue O 0 5.3960755863613485e-09
, O 0 9.243895648936018e-10
we O 0 5.389921842180456e-10
have O 0 1.6341672459674328e-10
comprehensively O 0 5.147353832057888e-08
characterized O 0 7.14730532536123e-08
19 O 0 4.827027737519529e-07
anti O 0 5.5970381254155654e-06
- O 0 2.4989931262098253e-05
BRCA1 O 0 1.7179668247990776e-06
antibodies O 0 3.1083357043826254e-07
. O 0 8.428677347183111e-07

These O 0 5.3020645651713494e-08
reagents O 0 6.47052161184547e-07
detect O 0 7.066063858474081e-07
a O 0 2.0076392104328988e-07
220 O 0 9.014898409986927e-07
- O 0 2.699212018342223e-06
kD O 0 6.162871159176575e-06
protein O 0 3.987486962842013e-08
localized O 0 3.317978780614794e-08
in O 0 1.3002582344157076e-09
discrete O 0 5.869365438115892e-08
nuclear O 0 1.7413982504876913e-06
foci O 0 4.980230414730613e-07
in O 0 4.992743996012905e-09
all O 0 6.729757640044909e-09
epithelial O 0 1.303642329730792e-05
cell O 0 9.519610102870502e-06
lines O 0 3.534059089815855e-08
, O 0 5.852579532117375e-10
including O 0 2.8158000930922356e-10
those O 0 4.696638633561179e-10
derived O 0 1.0887323043107244e-08
from O 0 1.5727155755485e-07
breast B-Disease 0 0.06834636628627777
malignancies I-Disease 0 0.21821026504039764
. O 0 2.694608519959729e-05

Immunohistochemical O 0 0.00024442689027637243
staining O 0 1.540256562293507e-05
of O 0 2.4971423044917174e-06
human O 0 7.394777412628173e-07
breast O 0 2.1380235921242274e-05
specimens O 0 9.526173982976616e-08
also O 0 1.1535772337367689e-08
revealed O 0 5.784406198472425e-07
BRCA1 O 0 1.2012886827506009e-06
nuclear O 0 7.962831659824587e-06
foci O 0 4.295456619729521e-06
in O 0 3.608301568647221e-08
benign O 0 0.003216412616893649
breast O 0 0.015202755108475685
, O 0 1.0453045433678199e-06
invasive B-Disease 1 0.9999076128005981
lobular I-Disease 1 1.0
cancers I-Disease 1 0.9999865293502808
and O 0 4.308461939217523e-06
low B-Disease 1 0.9999557733535767
- I-Disease 1 0.9999738931655884
grade I-Disease 1 0.9999997615814209
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.0004539431829471141

Conversely O 0 4.971306407242082e-05
, O 0 6.661760494353075e-07
BRCA1 O 0 3.789229765516211e-07
expression O 0 6.77367353318914e-08
was O 0 1.2120004555526975e-07
reduced O 0 2.2071075633789405e-08
or O 0 1.1441105840503951e-09
undetectable O 0 7.586530870185015e-08
in O 0 3.3275199262661204e-10
the O 0 2.367837870220768e-10
majority O 0 4.3274225869360805e-10
of O 0 6.429373922145487e-09
high O 0 1.0632167004587245e-06
- O 0 1.2496918770921184e-06
grade O 0 0.009786431677639484
, O 0 4.247847300575813e-06
ductal B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 0 4.0974623516376596e-07
suggesting O 0 1.3480118354891601e-07
that O 0 1.5019441246266751e-09
absence O 0 3.967084865053039e-07
of O 0 3.307105771455099e-07
BRCA1 O 0 1.6723372482374543e-06
may O 0 5.1772374831671186e-08
contribute O 0 2.336200211061623e-08
to O 0 3.7223710780409647e-09
the O 0 4.361101346717078e-08
pathogenesis O 0 2.9286891731317155e-05
of O 0 2.5284448312845598e-08
a O 0 5.814507542112324e-09
significant O 0 2.428707723822754e-08
percentage O 0 1.198407062474871e-07
of O 0 9.124280353489667e-08
sporadic B-Disease 0 0.08555343747138977
breast I-Disease 1 0.9996117949485779
cancers I-Disease 1 0.9911400675773621
. O 0 1.2550796100185835e-06
. O 0 5.5097498261602595e-06

